Use these links to rapidly review the document
TABLE OF CONTENTS
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Table of Contents

As filed with the Securities and Exchange Commission on September 30, 2011

Registration No. 333-175877

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



AMENDMENT NO. 2
TO
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933



INTERMOLECULAR, INC.
(Exact name of registrant as specified in its charter)



Delaware
(State or other jurisdiction of
incorporation or organization)
  3674
(Primary Standard Industrial
Classification Code Number)
  20-1616267
(I.R.S. Employer
Identification Number)

3011 N. First Street
San Jose, CA 95134
(408) 582-5700
(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)



David Lazovsky
President and Chief Executive Officer
Intermolecular, Inc.
3011 N. First Street
San Jose, CA 95134
(408) 582-5700
(Name, address, including zip code, and telephone number, including area code, of agent for service)



Copies to:

Patrick A. Pohlen
Latham & Watkins LLP

140 Scott Drive
Menlo Park, CA 94025
Telephone: (650) 328-4600
Facsimile: (650) 463-2600

 

Alan F. Denenberg
Davis Polk & Wardwell LLP

1600 El Camino Real
Menlo Park, CA 94025
Telephone: (650) 752-2000
Facsimile: (650) 752-2111



Approximate date of commencement of proposed sale to the public:
As soon as practicable after the effective date of this Registration Statement.

         If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.  o

         If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o

         If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o

         If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o

         Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer o   Accelerated filer o   Non-accelerated filer ý
(Do not check if a
smaller reporting company)
  Smaller reporting company o

          The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.


Table of Contents

The information in this prospectus is not complete and may be changed. We and the selling stockholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we and the selling stockholders are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED SEPTEMBER 30, 2011

                  Shares

GRAPHIC

Common Stock

        Intermolecular, Inc. is offering                        shares of its common stock, and the selling stockholders identified in this prospectus are offering an additional                        shares. We will not receive any proceeds from the sale of the shares of common stock to be offered by the selling stockholders. This is our initial public offering and no public market currently exists for our shares. We anticipate that the initial public offering price of our common stock will be between $            and $            per share.

        We have applied to have our common stock listed on The NASDAQ Global Market under the trading symbol "IMI."



         Investing in our common stock involves risks. See "Risk Factors" beginning on page 11.



PRICE $            A SHARE



 
  Price to Public   Underwriting
Discounts and
Commissions
  Proceeds to
Intermolecular
  Proceeds to
the Selling
Stockholders
 

Per Share

  $                $                $                $               

Total

  $                $                $                $               

        We have granted the underwriters the right to purchase up to an additional                        shares of common stock to cover over-allotments.

        The Securities and Exchange Commission and state securities regulators have not approved or disapproved these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

        The underwriters expect to deliver the shares of common stock to purchasers on                        , 2011.



Morgan Stanley   J.P. Morgan

Barclays Capital



Pacific Crest Securities   Needham & Company, LLC



The date of this prospectus is                        , 2011.


Table of Contents




TABLE OF CONTENTS

 
  Page

Prospectus Summary

  1

Risk Factors

  11

Forward-Looking Statements

  34

Use of Proceeds

  35

Dividend Policy

  35

Capitalization

  36

Dilution

  39

Selected Consolidated Financial Data

  42

Management's Discussion and Analysis of Financial Condition and Results of Operations

  46

Business

  74

Customer and Collaborative Agreements

  90

Management

  94

Executive Compensation

  105

Certain Relationships and Related Party Transactions

  127

Principal and Selling Stockholders

  131

Description of Capital Stock

  134

Shares Eligible for Future Sale

  139

Material United States Federal Income Tax Consequences to Non-U.S. Holders

  142

Underwriting

  146

Legal Matters

  154

Experts

  154

Where You Can Find Additional Information

  154

Index to Consolidated Financial Statements

  F-1

        Neither we, the selling stockholders nor the underwriters have authorized anyone to provide you with information different from that contained in this prospectus. We take no responsibility for, and can provide no assurance as to the reliability of, any information that others may give you. We, the underwriters and the selling stockholders are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date on the front cover of this prospectus, or such other dates as are stated in this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock.


Dealer Prospectus Delivery Obligation

        Until                            , 2011 (25 days after commencement of this offering), all dealers that buy, sell, or trade shares of our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

i


Table of Contents


PROSPECTUS SUMMARY

         This summary highlights information contained elsewhere in this prospectus and does not contain all of the information you should consider in making your investment decision. You should read the following summary together with the more detailed information appearing elsewhere in this prospectus, including "Selected Consolidated Financial Data," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Risk Factors," "Business" and our consolidated financial statements and related notes, before deciding whether to purchase shares of our capital stock. Unless otherwise indicated herein, "Intermolecular, Inc.," "Intermolecular," "the Company," "we," "us" and "our" refer to Intermolecular, Inc. and its subsidiaries.

Our Company

        We have pioneered a proprietary approach to accelerate research and development, innovation and time-to-market for the semiconductor and clean-energy industries. Our approach consists of our proprietary high productivity combinatorial (HPC) platform, coupled with our multi-disciplinary team. Through paid collaborative development programs (CDPs) with our customers, we develop proprietary technology and intellectual property (IP) for our customers focused on advanced materials, processes, integration and device architectures. This developed technology enables our customers to bring optimized, high-volume manufacturing-ready integrated devices to market faster and with less risk than traditional approaches to R&D. We provide our customers with the developed proprietary technology through various fee arrangements and grant them rights to associated IP, primarily through royalty-bearing licenses.

        We currently target large, high-volume semiconductor and high-growth emerging clean-energy markets, including DRAM, flash memory, complex logic, flat glass, solar cells, LEDs and other energy-efficient technologies with our HPC platform. Within these broad markets, we have engaged in paid programs for 18 customers, including ATMI, Elpida Memory, GLOBALFOUNDRIES, Guardian Industries, SanDisk, Taiwan Semiconductor Manufacturing Company (TSMC) and Toshiba. ATMI and Elpida have commenced shipping products incorporating technology developed through our CDPs and pay us licensing and royalty fees. To date, we have received the majority of our revenue from customers in DRAM, flash memory, complex logic and energy-efficient applications in flat glass, and have not yet received a material amount of revenue from customers in solar cells, LEDs and other energy-efficient technologies.

        Our HPC platform consists of our Tempus HPC processing tools, automated characterization and informatics and analysis software. Our platform is purpose-built for R&D using combinatorial process systems. Combinatorial processing is a methodology for discovery and development that employs parallel and other high-throughput experimentation, which allows R&D experimentation to be performed at speeds up to 100 times faster than traditional methods. Our processing tools allow us to perform up to 192 experiments on a single substrate as compared to traditional methods, which typically allow only a single experiment at a time. Our multi-disciplinary team of approximately 135 scientists and engineers, of whom approximately 55 have Ph.D.s, designs customized workflows for our customers' specific applications using the HPC platform and applies the workflows in collaboration with our customers.

        Our business model aligns our interests with those of our customers as we collaborate to develop differentiated proprietary technology and IP for high-volume integrated devices through CDPs. Customers pay us development service fees during multi-year CDPs, which typically last for two years and may range from one to three years. Our customers also receive rights to the technology and IP developed during the CDPs, and once our customers commercialize products using this technology and IP, they pay us primarily through royalty fees. In certain cases, we sell HPC processing tools to our customers who pay a recurring license fee to operate those tools with our combinatorial processing capabilities. By aligning our interests with those of our customers, we facilitate collaboration and open

1


Table of Contents


communication that is more likely to result in innovative, differentiated products and future CDPs with those customers.

        We were founded in 2004 and are headquartered in San Jose, California. Our total revenue increased to $23.8 million for the six months ended June 30, 2011 from $16.5 million for the six months ended June 30, 2010. Our total revenue increased to $42.7 million for the year ended December 31, 2010 from $26.9 million for the year ended December 31, 2009. Our backlog as of June 30, 2011 was $108.8 million, of which $28.3 million is scheduled to be recognized as revenue during the remainder of the year ending December 31, 2011. Our adjusted EBITDA for the six months ended June 30, 2011 was $2.0 million, and our adjusted EBITDA for the year ended December 31, 2010 was $4.6 million. Our net loss decreased to $3.2 million for the six months ended June 30, 2011 from $3.3 million for the six months ended June 30, 2010. Our net loss decreased to $1.8 million for the year ended December 31, 2010 from $5.3 million for the year ended December 31, 2009. Since inception, we have incurred net losses leading to an accumulated deficit of $73.2 million as of June 30, 2011.

Industry

        High-volume integrated devices serve large and growing markets, including the markets for semiconductors, clean energy (which includes flat glass, solar cells, LEDs, advanced batteries and other energy-efficient technologies) and flat-panel displays. According to IHS iSuppli, the semiconductor market had $304 billion in sales in 2010 and is expected to grow at a compound annual growth rate (CAGR) of 5.7% from 2010 to 2015. Also, based on data from Freedonia Group, GlobalData, IHS iSuppli and MarketsandMarkets, the clean-energy markets had $166 billion in sales in 2010 and are collectively expected to grow at a CAGR of 10.8% from 2010 to 2015.

        Success in these markets requires rapid and cost-effective product innovation, fast time-to-market, competitive pricing, production scalability and the ability to achieve specific requirements. Devices in these markets are typically manufactured using thin-film deposition of advanced materials through customized processes that create a specific device architecture. To deliver performance and cost improvements, it is increasingly necessary to evaluate elements in the periodic table that have previously not been used in high-volume manufacturing, and to develop advanced device structures capable of addressing particular application requirements. These device structures must then be scaled and integrated into cost-effective manufacturing processes. In addition, innovation in these markets and control of the resulting IP are critical to enable competitive differentiation.

        Existing approaches used to explore new materials, processes, integration and device architectures are complex and time-consuming. Traditionally, device manufacturers have conducted R&D using expensive high-volume manufacturing tools that are not specifically built for that purpose. Production tools can typically only run one process at a time and are required to be taken off high-volume manufacturing lines to perform and evaluate experiments. These high-volume manufacturing environments are not conducive to R&D because these environments require stability to minimize risk and to reduce contamination that the research-based introduction of new materials, tools or processes may cause. In addition to some of the challenges above, certain clean-energy device manufacturers use laboratory-scale tools for R&D, which do not address the scale-up requirements critical to high-volume manufacturing. These factors combine to increase development risks due to long learning cycles, limited data sets, narrow exploration capabilities and slow time-to-market. Moreover, third-party approaches to complement internal R&D typically are not tailored for customer-specific applications, do not offer proprietary IP or competitive differentiation and do not provide high-volume manufacturing-ready technology.

        Traditional R&D approaches are increasingly challenged by the market need to accelerate innovation and time-to-market for the semiconductor and clean-energy industries. Substantially improved methodologies are required to generate the learning cycles necessary to accelerate innovation, improve product development and ensure manufacturing scalability of high-volume integrated devices in these markets. Further, companies require new ways to develop proprietary technology and obtain IP rights to support competitive advantage for their new products.

2


Table of Contents

Our Solution and Benefits to Our Customers

        We develop technology and IP rights focused on advanced materials, processes, integration and device architectures in collaboration with our customers. This technology enables our customers to bring optimized, high-volume manufacturing-ready integrated devices to market faster and with less risk than traditional approaches to R&D. Our HPC platform increases R&D productivity because it is purpose-built for R&D and utilizes advanced combinatorial processing systems, which allow experiments to be performed at speeds up to 100 times faster than traditional methods.

        The key elements of our HPC platform include the following:

        Our differentiated platform solution and approach to collaborative engagements are designed to deliver the following significant benefits to our customers:

Strengths

        We have pioneered, developed and patented a proprietary platform and methodology for accelerating R&D in the semiconductor and clean-energy markets. Our strengths include:

3


Table of Contents

Our Strategy

        Our mission is to drive our customers' success by transforming R&D and accelerating innovation in markets that derive competitive advantage from the interaction of materials science, processes, integration and device architecture. To accomplish this, we intend to continue to execute on our strategy, the key elements of which are:

Risks Related to Our Financial Condition and Business

        Our business is subject to a number of risks and uncertainties that you should understand before making an investment decision. These risks are discussed more fully in the section of this prospectus entitled "Risk Factors" and include:

4


Table of Contents

Corporate Information

        We were originally incorporated as The BEP Group, Inc. in Delaware in June 2004. In November 2004, we changed our name to Intermolecular, Inc. Our principal executive offices are located at 3011 N. First Street, San Jose, California 95134, and our telephone number is (408) 582-5700. Our website address is www.intermolecular.com. Information contained on or accessible through our website is not incorporated by reference into this prospectus, and you should not consider information contained on or accessible through our website to be part of this prospectus.

        Our logo, "Intermolecular," "Tempus" and other trademarks or service marks of Intermolecular, Inc. appearing in this prospectus are the property of Intermolecular, Inc. This prospectus contains additional trade names, trademarks and service marks of other companies. We do not intend our use or display of other companies' trade names, trademarks or service marks to imply relationships with, or endorsement or sponsorship of us by, these other companies. Use of such trademarks and service marks in this prospectus may occur without their respective superscript symbols ( TM or SM ) to facilitate readability only and does not constitute a waiver of any rights that might be associated with the respective trademarks or service marks.

5


Table of Contents


The Offering

Common stock offered by us

              shares (or            shares if the underwriters exercise their over-allotment option in full).

Common stock offered by the selling stockholders

 

            shares.

Common stock to be outstanding after this offering

 

            shares (or            shares if the underwriters exercise their over-allotment option in full).

Proposed                    symbol

 

"IMI"

Use of proceeds

 

We intend to use the net proceeds received by us from this offering for working capital and other general corporate purposes, including the costs associated with being a public company. If and to the extent the gross proceeds from the sale by Symyx Technologies, Inc. (Symyx) of shares in this offering are less than $67 million, we will use a portion of our net proceeds to satisfy an obligation to Symyx in connection with an agreement for the purchase of IP from Symyx and the termination of related royalty obligations. We have also agreed to reimburse Symyx for 50% of their underwriting discounts and commissions. We may also use a portion of the net proceeds to expand our current business through acquisitions of other businesses, products, intellectual property or technologies. Other than as set forth above, we do not have agreements or commitments for any specific acquisitions at this time. We will not receive any proceeds from the sale of the shares of common stock to be offered by the selling stockholders. Please see "Use of Proceeds."

Risk factors

 

See "Risk Factors" starting on page 11 of this prospectus for a discussion of factors you should carefully consider before deciding to invest in our common stock.

        The number of shares of common stock to be outstanding after this offering is based on 72,639,388 shares outstanding as of June 30, 2011 and excludes:

6


Table of Contents

        Except as otherwise indicated, all information in this prospectus assumes:

7


Table of Contents


Summary Consolidated Financial Data

        The following table sets forth a summary of our historical consolidated financial data for the periods ended or as of the dates indicated. You should read this table together with our consolidated financial statements and the accompanying notes, "Selected Consolidated Financial Data" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" appearing elsewhere in this prospectus. The summary consolidated financial data in this section is not intended to replace our consolidated financial statements and the accompanying notes. Our historical results are not necessarily indicative of our future results.

 
  Years Ended December 31,   Six Months Ended
June 30,
 
 
  2008   2009   2010   2010   2011  
 
   
   
   
  (unaudited)
 
 
  (in thousands, except share and per share amounts)
 

Consolidated Statement of Operations Data:

                               

Revenue:

                               
 

CDP and services revenue

  $ 14,647   $ 14,182   $ 27,705   $ 9,806   $ 15,820  
 

Product revenue

    6,206     9,065     6,959     3,300     1,360  
 

Licensing and royalty revenue

    2,276     3,663     8,010     3,386     6,644  
                       
   

Total revenue

    23,129     26,910     42,674     16,492     23,824  

Cost of revenue

    12,625     13,018     20,926     8,752     11,323  
                       
     

Gross profit

    10,504     13,892     21,748     7,740     12,501  

Operating expenses:

                               
 

Research and development

    11,849     10,983     13,917     6,353     9,488  
 

Sales and marketing

    3,849     3,211     4,074     1,926     1,980  
 

General and administrative

    4,300     4,867     5,761     2,877     3,925  
                       
   

Total operating expenses

    19,998     19,061     23,752     11,156     15,393  
                       

Loss from operations

    (9,494 )   (5,169 )   (2,004 )   (3,416 )   (2,892 )

Other income (expense):

                               
 

Interest income, net

    174     (6 )   43     17     10  
 

Other income (expense), net

    6     (62 )   202     55     (335 )
                       
   

Total other income (expense), net

    180     (68 )   245     72     (325 )

Loss before provision for income taxes

    (9,314 )   (5,237 )   (1,759 )   (3,344 )   (3,217 )

Provision for income taxes

    186     17     19     2     13  
                       

Net loss

    (9,500 )   (5,254 )   (1,778 )   (3,346 )   (3,230 )

Accretion on redeemable convertible preferred stock

    (5,436 )   (9,170 )   (14,162 )   (6,340 )   (7,095 )
                       

Net loss attributable to common stockholders

  $ (14,936 ) $ (14,424 ) $ (15,940 ) $ (9,686 ) $ (10,325 )
                       

Net loss per share of common stock, basic and diluted

  $ (1.39 ) $ (1.31 ) $ (1.43 ) $ (0.87 ) $ (0.91 )
                       

Weighted-average number of shares used in computing net loss per share of common stock, basic and diluted(1)

    10,716,462     11,023,779     11,134,573     11,115,486     11,296,902  
                       

Pro forma net loss per share of common stock, basic and diluted(1)

              $ (0.03 )       $ (0.04 )
                             

Weighted-average number of shares used in computing pro forma net loss per share of common stock, basic and diluted(1)

                65,376,321           68,243,300  
                             

Other Data:

                               

Adjusted EBITDA(2)(unaudited)

  $ (5,062 ) $ 272   $ 4,589   $ (274 ) $ 2,026  
                       

8


Table of Contents

 

 
  As of June 30, 2011  
 
  Actual   Pro Forma(3)   Pro Forma as
Adjusted(4)
 
 
  (unaudited)
 
 
  (in thousands)
 

Consolidated Balance Sheet Data:

                   

Cash, cash equivalents and short-term investments

  $ 35,630   $ 42,006   $               

Working capital

    23,927     30,973                   

Total assets

    69,299     75,675                   

Preferred stock warrant liability

    670                       

Redeemable convertible preferred stock

    80,515                       

Accumulated accretion of redeemable convertible preferred stock to redemption values

    41,521                       

Total stockholders' (deficit) equity

    (73,175 )   55,907                   

(1)
Please see Note 9 to our audited consolidated financial statements for an explanation of the calculations of our basic and diluted net loss per share of common stock and pro forma net loss per share of common stock.

(2)
The following table presents a reconciliation of adjusted EBITDA to our net loss, the most comparable GAAP measure, for each of the periods indicated:

 
  Years Ended December 31,   Six Months Ended June 30,  
 
  2008   2009   2010   2010   2011  
 
   
   
   
  (unaudited)
 
 
  (in thousands)
 

Net loss

  $ (9,500 ) $ (5,254 ) $ (1,778 ) $ (3,346 ) $ (3,230 )

Non-GAAP adjustments:

                               

Revenue(a)

                    312  

Interest, net

    (94 )   48     13     (17 )   445  

Provision for taxes

    186     17     19     2     13  

Depreciation and amortization

    3,430     4,380     4,971     2,412     3,504  

Stock-based compensation expense(b)

    916     1,081     1,364     675     982  
                       
 

Adjusted EBITDA (unaudited)

  $ (5,062 ) $ 272   $ 4,589   $ (274 ) $ 2,026  
                       

(a)
Reduction in revenue as a result of common stock warrants issued in connection with a customer agreement

(b)
Includes stock-based compensation as follows:

 
  Years Ended December 31,   Six Months
Ended June 30,
 
 
  2008   2009   2010   2010   2011  
 
   
   
   
  (unaudited)
 
 
  (in thousands)
 

Cost of revenue

  $ 71   $ 134   $ 285   $ 118   $ 233  

Research and development

    170     222     204     118     191  

Sales and marketing

    408     378     422     231     303  

General and administrative

    267     347     453     208     255  
                       
 

Total stock-based compensation

  $ 916   $ 1,081   $ 1,364   $ 675   $ 982  
                       
(3)
The pro forma column in the consolidated balance sheet data table above reflects (i) the conversion of all outstanding shares of our redeemable convertible preferred stock into 58,461,447 shares of common stock immediately before the completion of this offering, (ii) the resulting reclassification of accumulated accretion of redeemable convertible preferred stock and preferred stock warrant liability to additional paid-in capital, (iii) the conversion of a warrant for redeemable convertible preferred stock into a warrant to purchase 168,747 shares of our common stock at an exercise price of $0.44 per share immediately before the completion of this offering and the resulting reclassification of the preferred stock warrant liability to additional paid-in capital and (iv) the cash exercise of certain warrants outstanding to purchase shares of our common stock as of June 30, 2011, which will expire upon completion of this offering if unexercised, and the resulting receipt of approximately $6.4 million in net proceeds and issuance of 2,621,985 shares of common stock.

9


Table of Contents

(4)
The pro forma as adjusted column in the consolidated balance sheet data table above reflects (i) the conversion of all outstanding shares of our redeemable convertible preferred stock into 58,461,447 shares of common stock immediately before the completion of this offering, (ii) the resulting reclassification of accumulated accretion of redeemable convertible preferred stock and preferred stock warrant liability to additional paid-in capital, (iii) the conversion of a warrant for redeemable convertible preferred stock into a warrant to purchase 168,747 shares of our common stock at an exercise price of $0.44 per share immediately before the completion of this offering and the resulting reclassification of the preferred stock warrant liability to additional paid-in capital, (iv) the cash exercise of certain warrants outstanding to purchase shares of our common stock as of June 30, 2011, which will expire upon completion of this offering if unexercised, and the resulting receipt of approximately $6.4 million in net proceeds and issuance of 2,621,985 shares of common stock, and (v) the issuance of the shares offered by us in this offering and the net proceeds therefrom at an assumed initial public offering price of $          (the midpoint of the price range set forth on the cover page of this prospectus).

10


Table of Contents


RISK FACTORS

         Investing in our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information in this prospectus, before deciding whether to invest in shares of our common stock. The occurrence of any of the events or circumstances described below or other adverse events could harm our business, financial condition, results of operations and growth prospects. If such an event or circumstance were to occur, the trading price of our common stock may decline and you may lose all or part of your investment. Additional risks or uncertainties not presently known to us or that we currently deem immaterial may also harm our business.

Risks Related to Our Financial Condition and Business

We have a limited operating history, which makes it difficult for investors to evaluate our current business and future prospects.

        We were incorporated in June 2004 and do not have a long history of operating results on which you can base your evaluation of our business. We are still proving our business model, and we have not yet demonstrated our ability to generate significant revenue, particularly licensing and royalty revenue. As a result, it may be difficult for public market analysts and investors to evaluate our future prospects. If we do not generate significant licensing and royalty revenue, we may never be profitable. Furthermore, because of our limited operating history and because the semiconductor and clean-energy industries are rapidly evolving, we have limited experience in analyzing and understanding the trends that may emerge and affect our business. If we are unable to obtain significant licensing and royalty revenue from products that incorporate technology developed through our collaborative development programs (CDPs), we will have expended a significant amount of time and resources without obtaining the benefits we anticipated, and our financial condition and results of operations would be materially and adversely affected.

Our operating results may fluctuate from quarter to quarter, which may make it difficult to predict our future performance and may result in volatility in the market price of our common stock if we fail to meet the expectations of public market analysts and investors in these periods.

        Our revenue, expenses and operating results have fluctuated, and may in the future fluctuate significantly from quarter to quarter due to a number of factors, many of which are outside our control. Factors that may contribute to these fluctuations include the following, as well as other factors described elsewhere in this prospectus:

11


Table of Contents

        Due to these factors and other risks discussed in this section, you should not rely on quarter-to-quarter comparisons to predict our future performance. Our revenue mix may also vary from quarter to quarter as we enter into new CDPs and related customer arrangements, existing CDPs are completed or expanded and licensing and royalty arrangements take effect. Unfavorable changes in any of these factors may adversely affect our business and operating results. Additionally, our common stock could be subject to significant price volatility should our actual or projected revenue or earnings fail to meet the expectations of the investment community. Furthermore, stocks of high technology companies are subject to extreme price and volume fluctuations that are often unrelated or disproportionate to the operating performance of those companies.

We have incurred operating losses since our inception and may not be able to achieve or maintain profitability.

        We have generated net losses each year since our inception, including $3.2 million for the six months ended June 30, 2011 and $1.8 million and $5.3 million for the years ended December 31, 2010 and 2009, respectively. Our accumulated deficit as of June 30, 2011 was $73.2 million. We will need to significantly increase revenue to achieve profitability and we may not achieve or subsequently maintain

12


Table of Contents


profitability if our revenue increases more slowly than we expect or not at all. Our ability to achieve our objectives and achieve or maintain the profitability of our business will depend, in large part, on potential customers accepting our HPC platform and methodology as effective tools in the development of new products; and on our success in helping our customers develop products that are successful in the marketplace. Historically, semiconductor companies have conducted R&D activities internally using traditional research methods. In order for us to achieve our business objectives, we must convince these companies that our technology and capabilities justify collaborating with us on their basic R&D programs. We must also convince potential customers in the clean-energy industry that our HPC platform and approach are useful tools in an emerging industry. We cannot assure you we will achieve the levels of customer acceptance necessary for us to maintain and grow a profitable business. Our ability to achieve profitability also depends upon many other factors, including many that are beyond our control. These factors include, without limitation:

In addition, we expect to continue to incur significant expenses or revenue adjustments in connection with, among other things:

        We cannot assure you we will achieve the levels of customer acceptance necessary for us to maintain and grow a profitable business, or that any of these other factors will be satisfactory. Also, we cannot assure you that customers, even those that accept our HPC platform as a valid tool for R&D, will be satisfied with the integrated devices developed through our CDPs or will be able to successfully commercialize end products incorporating the developed technology. Failure to achieve the necessary customer acceptance or extend or add current or new customer relationships, as well as difficulty with any of these other factors would adversely affect our revenue and profitability and our financial condition and results of operations would be materially and adversely affected.

We depend on a limited number of customers, which have historically been in the semiconductor industry, and a loss of any of them would adversely affect our business and operating results.

        Our customer base is highly concentrated. Revenue has historically come from a few customers, and we expect that revenue from a small number of customers will continue to account for a high

13


Table of Contents


percentage of our revenue for the foreseeable future. Due to the concentrated nature of manufacturers in the DRAM, flash memory and complex logic markets, our revenue is and may continue to be concentrated among and reliant upon key high-volume customers. For example, our four largest customers in the six months ended June 30, 2011, all of which are in the semiconductor industry, accounted for 75% of our revenue, and our two largest customers for the years ended December 31, 2010 and 2009, both of which are in the semiconductor industry, accounted for 72% and 88% of our revenue, respectively. Our largest customer accounted for 33%, 52% and 59% of our revenue in each of these periods, respectively. The loss of any of these customers or a decrease in the manufacturing or sales volumes of their products, or their failure to pay amounts due to us, and the related impact on our future anticipated licensing and royalty revenue, would materially and adversely affect our business, financial condition or results of operations, and we may not be able to replace the business from these customers. In addition, this type of loss could cause significant fluctuations in our results of operations because our expenses are fixed in the short term and our sales and development cycle to obtain new customers is long.

Our rapid growth has presented significant challenges to our management and administrative systems and resources, and we may experience difficulties managing our growth, particularly as we handle the additional responsibilities of becoming a public company, which could adversely affect our business and operating results.

        We will need to continue to grow in all operational areas and to successfully integrate and support our existing and new employees, which may make it difficult to implement our business strategy in the time frame we anticipate, if at all. Our business has grown rapidly, and we expect this growth to continue as we expand our R&D capacity for current and additional CDPs. For example, we had 190 full-time employees as of June 30, 2011 and 107 employees at the end of 2008. The rapid expansion of our business and addition of new personnel has placed a strain on our management, operational systems and facilities and may continue to do so. To effectively manage our operations and growth as well as our new obligations as a public company, we must continue to expend funds to enhance our operational, financial and management controls, reporting systems and procedures and to attract and retain sufficient numbers of talented employees. If we are unable to expand our R&D capacity and implement improvements to our control systems efficiently and quickly, or if we encounter deficiencies in existing systems and controls, then we will not be able to successfully grow our business as planned. Our future operating results will also depend on our management's ability to:

We may not manage our expansion successfully, which could adversely affect our business, financial condition or results of operations.

Our business prospects and future growth depend on royalties, which may be difficult to structure and enforce.

        We believe that our royalty-bearing licenses with our customers lay the framework for ongoing royalty revenue from our customers' products that incorporate technology developed through our CDPs with these customers, and that this revenue stream will increase as revenue from products developed using our platform increases. We are dependent upon our ability to structure, negotiate and enforce agreements for the determination and payment of royalties. Unless we adequately demonstrate the value of our platform to our potential customers we may face resistance to structuring royalty

14


Table of Contents


arrangements in the future that are acceptable to us, or our customers may not agree to enter into royalty-bearing licenses with us at all. If we are unable to maintain the royalty-bearing license aspect of our business model, our operating results would suffer and we may not achieve profitability.

Our sales cycles are long, and we commit significant resources to a project before we have any commitment that a potential customer may agree to use our platform or service. One or more failures to enter into a CDP after we have devoted significant resources to a project could adversely affect our business and operating results.

        Our sales efforts require us to educate our potential customers about the benefits of our solutions, which often requires significant time and expense, including a significant amount of our senior management's time and effort. Our sales cycles to date have typically ranged from 9 to 24 months and may be even longer in the future. Furthermore, we need to target those individuals within a customer's organization who have overall responsibility for the profitability of their products. These individuals tend to be senior management or executive officers. We may face difficulty identifying and establishing contact with these individuals. In addition, our customers' technology and product pipeline are highly confidential and they may choose to withhold certain information from us during the sales cycle to protect their own proprietary technology. Our ability to implement our HPC platform and methodology is heavily dependent upon the information provided to us by our customers. If our customers reveal the complexities of their specifications after we enter into a CDP with them, that complexity may cause delays unanticipated at the time we entered into the program. During our sales cycles, we incur significant expenses and, in many cases, may begin to build, configure or expand new systems, develop software and design workflows to meet our customers' requirements prior to obtaining contractual commitments, without any assurance of resulting revenue. Where a potential customer engagement requires a new dedicated HPC platform, we may invest in new HPC capacity ahead of a customer commitment. Our HPC platform build, configuration and customization cycles to date have ranged from three to nine months and may be even longer in the future. Investment of time and expense in a particular customer engagement that does not ultimately result in material revenue will adversely affect our revenue and results of operations. Other factors impacting sales and the length of our sales and development cycles include, but are not limited to, the following:

The semiconductor industry is rapidly changing and an inability to evolve existing products in a timely manner, anticipate trends in technology development and introduce new technologies could adversely affect our business and operating results.

        We must continually devote significant engineering resources to keep up with the rapidly evolving technologies, materials and equipment used in semiconductor design and manufacturing processes.

15


Table of Contents


These innovations are inherently complex and require long development cycles. The semiconductor industry is subject to a number of evolving trends, including:

        These and other changes could have a material impact on our business. Not only do we need the technical expertise to implement the changes necessary to keep our technologies current, but we also rely heavily on the judgment of our management and advisors to anticipate future market trends. Our customers expect us to stay ahead of the technology curve in their sectors and expect that the technology developed through our CDPs will help them develop new products that keep pace with or push the limits of technological innovation. If we are not able to accurately predict industry changes, or if we are unable to apply our HPC platform to our customers' needs on a timely basis, our existing solutions will be rendered obsolete and we may lose customers. If we do not keep pace with technology, our existing and potential customers may choose to develop their own solutions internally as an alternative to ours, and we could lose market share to competitors, which could adversely affect our operating results.

The clean-energy industry is in a very early stage of development, and we may not earn significant revenue from our initiatives in this industry for an extended period, if ever.

        Most sectors of the clean-energy industry are in the very early stages of development. Many of the associated technologies have not yet achieved commercial viability in comparison to available alternatives, and may never achieve market adoption. Many of the associated technologies will require substantial investments of capital to achieve scale, which may not be available on attractive terms, if at all. Companies within the clean-energy industry may also be hesitant to enter into CDPs with us given our recent entry into the clean-energy industry. Certain technologies may depend on government subsidies to be commercially viable, and those subsidies may not be available from federal and state governments facing increasing financial constraints. If sectors of the clean-energy industry take an extended period to achieve market acceptance and to garner significant revenue, we may not earn material revenue from our initiatives in this area until such time, if ever. Furthermore, it may be difficult for us to predict which clean-energy companies may become market leaders, and we may invest time and resources in collaborations with companies who are ultimately unsuccessful in the clean-energy industry, which could adversely affect our operating results.

If a project to which we have devoted technology and significant resources fails to produce any measurable success or value to our customers in the form of differentiated technology and intellectual property, we may not earn licensing and royalty revenue sufficient to recover the upfront costs and cash invested in the CDP, which could adversely affect our results of operations.

        In some cases, the revenue we receive from our customers during the development stage is not sufficient for us to fully recover our costs and cash invested in HPC platforms dedicated to customer engagement, and our business model relies on licensing and royalty revenue based on the sales by our

16


Table of Contents


customers in the end-markets of products incorporating the technology developed through our CDPs. Our CDPs involve complex R&D, and our ability to develop the differentiated technology and intellectual property sought by our customers is inherently uncertain and difficult to predict. In addition, there are a limited number of CDPs to which we can commit our resources at any given time. If a project to which we have devoted technology and significant resources fails to produce any measurable success or value to our customers in the form of differentiated technology and intellectual property that they may use in their products, we may not receive meaningful amounts of, or any, licensing and royalty revenue. In this case, we may not recover the upfront costs and cash invested in the CDP, which could adversely affect our results of operations. In addition, even if we successfully develop differentiated technology and intellectual property through a CDP that our customer is able to commercialize, there may be a significant delay before we receive any licensing or royalty revenue due to the complexities inherent in production and manufacturing in our target markets.

A decline in sales in the end markets for products incorporating technology developed through our CDPs could adversely affect our business and results of operations.

        Our success is tied to our customers' ability to successfully commercialize the products that incorporate technology developed through our CDPs. The markets for our customers' products are intensely competitive and are characterized by rapid technological change. These changes result in frequent product introductions, short product life cycles and increased product capabilities. Competition is based on a variety of factors including price, performance, product quality, software availability, marketing and distribution capability, customer support, name recognition and financial strength. Products incorporating the technology developed through our CDPs may not achieve market success or may become obsolete. We cannot assure you that our customers will dedicate the resources necessary to promote and commercialize products developed through our CDPs, successfully execute their business strategies for such products, be able to manufacture such products in quantities sufficient to meet demand or cost-effectively manufacture products at high volume. Our customers are not contractually obliged to manufacture, distribute or sell any products incorporating our CDP-developed technology. Our customers may develop internally or in collaboration with others technology that they might utilize instead of technology developed through our CDPs. Any of these factors, as well as more general market or industry issues, could result in a decline in sales of the products incorporating our technology, which would result in a decrease in any associated licensing and royalty revenue or the failure of any licensing and royalty revenue to materialize at all, and could adversely affect our business and results of operations. Any failure of a customer to achieve market success for products developed through our CDPs could also negatively affect such customer's willingness to work with us on other collaborations and could more generally harm our reputation and business prospects.

If we are unable to scale our development services and secure new CDPs, our growth prospects would be limited and our business and operating results could be adversely affected.

        Our customers require a significant amount of individualized attention as well as dedicated lab space for CDPs. We have limited space and internal capacity, both in terms of personnel as well as capital equipment resources, to meet these types of demands for our customers. In addition, because of the significant confidentiality concerns associated with the projects and products we work on and the restrictions on resource and information sharing we have implemented in response, we are not able to fully capitalize upon economies of scale. If the demand for our services and products exceeds our capacity to meet such demand, we may be required to turn down potential opportunities, which would cause us to lose potential revenue, and our potential customers may take their business to a competitor or decide to develop or expand internal R&D capabilities. If we are unable to scale our development services to meet demand, our growth may be hindered and our business and operating results could be adversely affected.

17


Table of Contents


We may not be successful in maintaining and managing CDPs, which would adversely affect our ability to develop successful products and our financial condition and operating results.

        CDPs are complex and time-consuming to implement and they may require substantial resources to maintain. We may not be successful in all of our collaboration efforts and may fail to achieve the technological innovations sought by our customers in a reasonable amount of time or at all. When we collaborate with a customer, we rely to some degree on the efforts and resources of that customer. Our customers may not devote sufficient resources to collaborations or may otherwise fail in the aspects of the collaboration for which they are responsible. Disagreements over the implementation and management of the program may occur, which could lead to material delays and/or a failure to achieve the successful development of technology through the CDP. If we fail to achieve successful collaborations, or if our customers are dissatisfied with the results of or the way we design and manage a CDP, our operating results and financial condition would be materially and adversely affected.

Our strategy includes conducting proprietary R&D efforts in collaboration with and on behalf of multiple customers. Failure to adequately protect against potential conflicts of interest and breaches of confidentiality would harm our reputation and our relationships with our customers, and our business prospects and operating results would be adversely affected. Moreover, some potential customers may hesitate to grant us access to their proprietary information, which could impair our ability to provide value for such customers.

        Our strategy includes conducting proprietary R&D efforts in collaboration with and on behalf of customers who in some cases may have overlapping interests and technologies. We seek to structure our collaborative agreements and business practices to minimize any potential conflicts and the possibility of any breaches of confidentiality. We may need access to some of our customers' proprietary information, and they may be reluctant to share it with us because of the risk of a potential conflict between us and/or our customers and other potential customers and the risk of a breach of confidentiality. Our failure to do so could result in our inability to attract new customers or retain existing customers, or lead to our having incomplete information with respect to existing customers that could impair our ability to fully address the customers' needs and demonstrate the value of our technology to the customers. Even if we make significant efforts to isolate each development activity, we may fail to meet the contractual confidentiality commitments as to one or more customers. Moreover, even if we meet these commitments, conflicts between a customer and us, or between or among customers, could nevertheless arise. In either event, we may become involved in a dispute with our customers regarding the solutions developed during the collaboration or the rights to these solutions, including possible litigation. Disputes of this nature could harm the relationship between us and our customers, and could adversely affect our ability to enter into new CDPs and cause our revenue and operating results to decline.

We may be unable to make the substantial R&D investments required to remain competitive in our business.

        The semiconductor and clean-energy industries require substantial investment in R&D to develop and bring to market new and enhanced technologies and products. To remain competitive, we anticipate that we will need to maintain or increase our levels of R&D expenditures to keep pace with the development efforts of our customers. We expect R&D expenses to increase in absolute dollars for the foreseeable future, due to the increasing complexity and number of solutions we plan to develop both for our customers and internally, the expansion of our customer base and any associated increase in upfront R&D costs. In addition, the ultimate success of products incorporating our technology will depend in part on significant continued investment in R&D by our customers. We do not know whether we or our customers will have sufficient resources to maintain or increase the level of investment in R&D required to remain competitive. In addition, we cannot assure you that the technologies, products and applications on which we and our customers have focused our R&D expenditures will become commercially successful. If we are required to invest significantly greater

18


Table of Contents


resources than anticipated in our R&D efforts without a corresponding increase in revenue, our operating results could be materially and adversely affected.

If we are unable to develop our platform and expertise to support our future growth plans, our business and operating results could be adversely affected.

        We intend to further develop and broaden our HPC platform, including our software and informatics capabilities, to address a wider range of markets and customers for multiple applications within semiconductors, flat glass, solar cells, light emitting diodes (LEDs), flat-panel displays, advanced batteries and other energy-efficient technologies. However, we have limited expertise and experience in certain of these fields, and if we are unable to develop our platform and expertise to support these fields our business growth might be limited, and our business and operating results could be adversely affected.

If we lose one or more of our key personnel without obtaining adequate replacements in a timely manner or if we are unable to retain and recruit skilled personnel, our operations could become disrupted and the growth of our business could be delayed or restricted.

        Our success depends, in large part, on the continued contributions of our senior management team, in particular, the services of Mr. David Lazovsky, our President and Chief Executive Officer, and Dr. Tony Chiang, our Chief Technology Officer. If we lose the services of Mr. Lazovsky or Dr. Chiang, it could slow the execution of our business plan, hinder our development processes and impair our sales efforts, and searching for a replacement could divert our other senior management's time and increase our operating expenses. In addition, our customers could become concerned about our future operations, which could harm our reputation.

        None of our senior management is bound by written employment contracts to remain with us for a specified period. The loss of any of our senior management could harm our ability to implement our business strategy and respond to the rapidly changing market conditions in which we operate. Upon hiring or promotion, new senior management personnel must spend a significant amount of time learning our technology, business model and management systems and their new roles, in addition to performing their regular duties. Accordingly, until new senior personnel become familiar with our technology, business model and systems or with their new roles, we may experience some disruption to our ongoing operations. Moreover, the loss of a member of our senior management or our professional staff would require the remaining management to divert attention to seeking a replacement.

        Our future success and competitiveness depends on our ability to retain and motivate our unique team of highly skilled scientists and engineers, who have expertise across various disciplines, fields and technologies, including engineering, materials science, process development and integration, equipment, device process technologies and device integration. In addition, as we grow, we will have to continue to retain, attract and motivate qualified and talented personnel, including our scientists and engineers, management, sales and marketing and legal and finance personnel. Because our CDPs are customer-specific and project-specific and last for a significant period of time, the loss of key scientists or engineers or other personnel could have an adverse effect on a particular development program and on our ability to deliver results to a customer in a timely manner or at all. We do not know whether we will be able to retain all of these employees as we continue to pursue our business strategy. Competition for personnel is intense in the semiconductor and clean-energy industries.

        We may encounter difficulties in hiring qualified scientists and engineers because there is a limited pool of scientists and engineers with the specialized expertise required to understand and implement our platform in conjunction with our customers. Further, we may have difficulty in obtaining visas permitting entry for some of our employees who are foreign nationals into the United States, and delays in obtaining visas permitting entry into other key countries for several of our key personnel,

19


Table of Contents


which could disrupt our ability to strategically locate our personnel. The loss of the services of key employees or our inability to retain, attract and motivate qualified scientists and engineers could have a material adverse effect on our business, financial condition and results of operations.

Following the completion of this offering, we may have a financial obligation to Symyx Technologies, Inc.

        In connection with an agreement for the purchase of intellectual property and the termination of our royalty obligations under an existing license agreement, we have an obligation to issue a promissory note to Symyx Technologies, Inc. (Symyx), a wholly-owned subsidiary of Accelrys, Inc., upon the consummation of this offering to the extent the gross proceeds from Symyx's sale of                        shares in this offering (before deducting underwriting discounts and commissions and estimated offering expenses) are less than $67 million. At an assumed initial public offering price of $        per share (the midpoint of the price range set forth on the cover page of this prospectus) the gross proceeds from the sale of Symyx's shares would be $             million, and we would have a $            obligation to Symyx. A $1.00 increase (decrease) in the assumed initial public offering price of $        per share would increase (decrease) the gross proceeds to Symyx by $             million. Such note, if issued, would have a term of 24 months and an interest rate equal to 4%. Such note would be payable in an amount equal to the lesser of the principal amount and the greater of $500,000 per quarter or the amount of accrued interest, with a balloon payment at maturity if applicable. Such note would also be pre-payable by us at any time without penalty or premium, and would be secured by tangible personal property, excluding intellectual property. If we issue such note, a portion of the net proceeds of this offering received by us would be used to make payments of scheduled interest and payment of principal at any time at or prior to maturity. Such financial obligation would limit our ability to use the net proceeds of this offering for other purposes.

We may be unable to effectively protect our intellectual property, which would negatively affect our ability to compete.

        We depend on our proprietary HPC platform for our success and ability to compete. If others are able to reproduce our technology, our business will suffer significantly unless we can prevent them from competing with us. As of September 1, 2011, we owned 106 U.S. patents and patent applications (most of which also have foreign counterparts), which we believe protect our rights in our HPC platform, and we continue to file patent applications to seek protection for the further evolution of our HPC platform. Patent laws provide only limited protection, however. We cannot assure you that all maintenance fees have been paid or that all filings have been made with the appropriate regulatory or governmental authorities with respect to any IP registered or applied for outside of the U.S. that we purchase. Also, patent protection in foreign countries may be limited or unavailable where we need this type of protection. A more detailed description of how we protect our IP is set forth in the section entitled "Business—Intellectual Property."

        The patent positions of technology companies, including ours, are often uncertain and involve complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We apply for patents covering our HPC platform and further advancements of our HPC platform as we deem appropriate. However, we may not obtain patents on all inventions for which we seek patents, and any patents we obtain may be challenged (both before and after any such patents issue) and may be narrowed in scope or extinguished as a result of these challenges. Additional uncertainty may result from potential passage of patent reform legislation by the United States Congress, legal precedent as handed down by the United States Federal Circuit and Supreme Court as they determine legal issues concerning the scope and construction of patent claims and inconsistent interpretation of patent laws by the lower courts. For these reasons, among others, our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing similar or superior products. In that case, our revenue and operating results could decline.

20


Table of Contents

        Our strategy includes obtaining patent protection for technology developed in collaboration with our customers. A portion of our revenue from our customers derives from the licenses granted to our customers under these patents. If we are unable to obtain this type of protection, we would not be able to enforce exclusive rights to the technologies in question, and our revenue and operating results could decline.

        We have in the past, and may in the future, develop patented technology with U.S. federal government funding. When new technologies are developed with U.S. government funding, the government obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise "march-in" rights to use or allow third parties to use our patented technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the U.S. government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, U.S. government-funded technology may be subject to restrictions on transfer to foreign entities, and some U.S. government-funded data may be subject to public disclosure under the Freedom of Information Act.

        Many of our customers and competitors have significant operations outside the United States. Foreign laws may not afford us sufficient protections for our intellectual property, however, and we may not always seek patent protection outside the United States. We believe that our success depends, in part, upon our ability to obtain international protection for our IP. However, the laws of some foreign countries may not be as comprehensive as those of the United States and may not be sufficient to protect our proprietary rights abroad. Accordingly, our international competitors could obtain foreign patent protection for, and market overseas, products and technologies for which we are seeking patent protection in the United States.

Confidentiality agreements with employees and others may not adequately prevent disclosures of trade secrets and other proprietary information.

        We rely in part on trade secret protection to protect our confidential and proprietary information and processes. However, trade secrets are difficult to protect. We have taken measures to protect our trade secrets and proprietary information, but these measures may not be effective. We require new employees and consultants to execute confidentiality agreements upon the commencement of an employment or consulting arrangement with us. These agreements generally require that all confidential information developed by the individual or made known to the individual by us during the course of the individual's relationship with us be kept confidential and not disclosed to third parties. These agreements also generally provide that inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. Nevertheless, employees, collaborators or consultants may still disclose or misuse our confidential information, and we may not be able to meaningfully protect our trade secrets. In addition, others may independently develop substantially equivalent information or techniques or otherwise lawfully gain access to our trade secrets, and thereafter communicate this information to others without maintaining its confidentiality. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.

21


Table of Contents


Significant litigation over intellectual property in the industry may cause us to become involved in costly and lengthy litigation, which could subject us to liability, require us to stop licensing our developed technology or force us to develop new technology.

        Whether or not patents are granted to us, litigation may be necessary to enforce our IP rights, to defend against a claim of infringement of IP rights of others or to determine the validity and scope of the proprietary rights of others. Because infringement is a fact-intensive inquiry, and because patent applications in the United States and many foreign jurisdictions are typically not published until eighteen months after filing (or, in some cases, are not published until they issue as patents), we cannot be certain that we do not now, and will not in the future, infringe a third party's patent rights. We may also become party to claims by our customers to IP rights developed by us in connection with a CDP. If our customers become involved in disputes with third parties over allegations that our customers' practice of our IP rights infringes the IP rights of such third parties, it may also become necessary for us to become involved in such disputes.

        Any claim, even if without merit, could be time consuming to defend, result in costly litigation, or require us to enter into licensing agreements, resulting in unexpected operating costs. Moreover, our opponents in any litigation may have significantly more resources with which to defend against or assert claims in the litigation. A successful claim of infringement against us in connection with the use of our technologies could force us to stop using our technologies that incorporate the infringed IP; pay substantial monetary damages or royalties; grant cross-licenses to third parties relating to our own IP; obtain a license from the owner of the infringed IP, which may not be available to us on acceptable terms or at all; or re-engineer our platform or products to avoid further IP infringement, which may be technically impossible or commercially infeasible. The occurrence of any of these eventualities could adversely affect our business Even if we are successful in defending such a claim, litigation could also divert our resources, including our managerial and engineering resources. Any infringement claim or other litigation against or by us could have a material negative effect on our business.

Our intellectual property indemnification policies and obligations may adversely impact our business and operating results.

        Any assertion by a third party asserting ownership or other rights to technology developed through our CDPs could result in our customers becoming the target of litigation and we may be bound to indemnify our customers under the terms of our license agreements. These obligations could result in substantial expenses to us, which could have a material adverse effect on our business, financial condition and results of operations. In addition to the time and expense required for us to satisfy our support and indemnification obligations to our customers, any litigation could severely disrupt or shut down the business of our customers, which in turn could damage our relations with them and have a material adverse effect on our reputation, business, financial condition and results of operations.

We will need to rely on our customers to deliver timely and accurate information to accurately report our financial results from licensing and royalty revenue in the time frame and manner required by law.

        We will need to receive timely, accurate and complete information from our customers to accurately report our financial results on a timely basis. Licensing and royalty revenue we may receive in the future may be based on the revenue from the sale of our customers' products that incorporate technology developed through our CDPs, and we will need to rely on our customers to provide us with complete and accurate information regarding revenue and payments owed to us on a timely basis. If the information that we receive is not accurate, we may not receive the full amount of revenue that we are entitled to under these arrangements on a timely basis, which could result in adjustments to our financial results in a future period. Although we typically have audit rights with these parties, performing this type of audit could be harmful to our collaborative relationships, expensive and

22


Table of Contents


time-consuming and may not be sufficient to reveal any discrepancies in a timeframe consistent with our reporting requirements.

We may need additional capital in the future to finance our business.

        Our future capital requirements may be substantial, particularly as we continue to develop our business and expand our collaborative development efforts. Although we believe that, based on our current level of operations and anticipated growth, our existing cash, cash equivalents and marketable securities, combined with the net proceeds from this offering, will provide adequate funds for ongoing operations, planned capital expenditures and working capital requirements for at least the next 12 months, we may need additional capital if our current plans and assumptions change. Our need for additional capital will depend on many factors, including the financial success of our business, whether we are successful in obtaining payments from customers, whether we can enter into additional collaborations, the progress and scope of collaborative R&D projects performed by us and our customers, the effect of any acquisitions of other businesses or technologies that we may make in the future, the filing, prosecution and enforcement of patent claims, how quickly we expand, how much we need to develop or enhance our solutions or HPC platform and any necessary responses to competitive pressures.

        If our capital resources are insufficient to meet our capital requirements, and our revenue is insufficient to support any of these activities, then we will have to raise additional funds. If future financings involve the issuance of equity securities, our then-existing stockholders would suffer dilution. If we raised additional debt financing, we may be subject to restrictive covenants that limit our ability to conduct our business. We may not be able to raise sufficient additional funds on terms that are favorable to us, if at all. If we fail to raise sufficient funds and continue to incur losses, our ability to fund our operations, take advantage of strategic opportunities, develop products or technologies or otherwise respond to competitive pressures could be significantly limited. If this happens, we may be forced to delay or terminate R&D programs, curtail or cease operations, obtain funds through collaborative and licensing arrangements that may require us to relinquish commercial rights, or grant licenses on terms that are not favorable to us. If adequate funds are not available, we may not be able to successfully execute our business plan or continue our business.

Failure of suppliers to timely deliver sufficient quantities of the components, materials or software used in our collaborations, may result in delays or other disruptions in executing our CDPs, which could adversely affect our business and operating results.

        We have historically relied on a small number of contract manufacturing companies for the manufacture and assembly of a majority of our HPC tools. While we are not dependent on any single contract manufacturing company, key parts of our tools are currently available only from a limited number of sources. In addition, components of our capital equipment are available from only a few suppliers. If supplies from these vendors are delayed or interrupted for any reason, we may not be able to get equipment or components for our tools or our own research efforts in a timely fashion or in sufficient quantities or under acceptable terms, if at all. Even though alternative sources of supply would be available, it could be time-consuming and expensive for us to qualify new vendors and work with them to integrate our designs into the tools they manufacture for us. In addition, we depend upon our vendors to provide components of appropriate quality and reliability. Consequently, if supplies from these vendors were delayed or interrupted for any reason, it could materially and adversely affect our business.

23


Table of Contents


Our business strategy requires us to evaluate, integrate and develop elements of our customers' value chains, including development and manufacturing processes. Our ability to evaluate these effectively may sometimes depend on the cooperation from our customers' materials suppliers and equipment manufacturers as well as access to their data and tools. If these third parties do not cooperate with us or provide us access to the necessary materials, tools or equipment we may not be able to deliver effective solutions to our customers, which would adversely affect our business and results of operations.

        We have to evaluate multiple elements of our customers' value chains to help them test and develop end products that meet their specifications, including the materials, tools and equipment used by them during the manufacturing process. Our ability to evaluate a customer's value chain effectively may sometimes depend on cooperation from such customer's materials suppliers and equipment manufacturers and on access to their data and tools. Our evaluation of the materials and equipment in the value chain must be unbiased to maintain credibility with our customers, and our evaluation sometimes results in recommendations that our customers change materials, tools or equipment. Our recommendations may negatively impact our relationships with materials and tool providers and equipment manufacturers. Tensions in our relationships with these providers and manufacturers may cause these parties to limit or deny our access to their newest materials and equipment, which would in turn limit our ability to complete our development activities with our customers or control the quality of the combinatorial methods applied to their development efforts, which would adversely affect our business and operations.

If we cannot compete successfully in our industry, our results of operations and financial condition would be adversely affected.

        Competition in our market may intensify in the future, which could slow our ability to grow or execute our strategy and could lead to increased pricing pressure, negatively impacting our revenue. Our current and potential customers may choose to develop their own combinatorial development methods internally, particularly if we are slow in deploying our solutions or improving them to meet market needs. We currently face indirect competition from the internal R&D groups at integrated circuit (IC) companies, particularly those of our customers who work with us to develop knowledge of combinatorial methods and who may then use our methods independently. Our customers do not license our technology exclusively, and several of them also design, develop, manufacture and market semiconductor projects based on their own or other architectures and develop their own intellectual property internally. They often compete with each other and with us in various applications. Our customers are generally much larger and have significantly greater resources than us. We also face indirect competition from university collaborations, consortia and alliance partnerships. In addition, there may be other providers of high-throughput empirical solutions for the design of and R&D relating to integrated devices of which we are not aware and there may be new entrants to the industry in the future, particularly if acceptance of these solutions grows. In addition, we believe that the demand for solutions that address the need for better integration between the design and manufacturing processes may encourage direct competitors to enter into our market. Other potential competitors include fabrication facilities that may decide to offer solutions competitive with ours as part of their value proposition to their customers. If these potential competitors change the pricing environment or are able to attract industry partners or customers faster than we can, we may not be able to grow and execute our strategy as quickly or at all.

The semiconductor industry is highly cyclical, subject to price volatility, difficult to predict and subject to significant downturns.

        Currently, the substantial majority of our revenue is dependent upon the overall condition of the semiconductor industry, especially in light of the licensing component of our revenue. The semiconductor industry is highly cyclical and subject to rapid technological change and has been subject

24


Table of Contents


to significant economic downturns at various times, such as the recent economic downturn, characterized by diminished product demand, accelerated erosion of average selling prices and production overcapacity. The semiconductor industry also periodically experiences increased demand and production capacity constraints. In addition, the semiconductor industry has historically experienced price volatility. As a result, we may experience significant fluctuations in operating results due to general semiconductor industry conditions and overall economic conditions.

        In 2008 and 2009, the semiconductor industry experienced significant challenges as a result of the severe tightening of the credit markets, turmoil in the financial markets, and weakened global economy. While the semiconductor market recovered somewhat in 2010 and the first part of 2011, the recovery may not continue, which limits our ability to forecast our business. There may be sudden changes in our customers' manufacturing capacity requirements and spending, which depend in part on capacity utilization, demand for our customers' IC products by consumers, inventory levels relative to demand, and access to affordable capital. In addition, the semiconductor industry has experienced significant consolidation in the past and may continue to see high levels of consolidation in the future. If any of our customers are acquired, the acquiror may not continue to engage in a CDP with us. Alternatively, our customers may opt to acquire companies or technologies that decrease their need for our services or otherwise divert their R&D resources. As a result of these and other potential changes, the timing and length of any cycles can be difficult to predict. Further, uncertainty about future global economic conditions and any effect on the semiconductor industry could make it challenging for us to forecast our operating results, make business decisions and identify the risks that may affect our business, financial condition and results of operations. If we are not able to timely and appropriately adapt to changes resulting from the difficult macroeconomic environment, our business, financial condition and results of operations may be significantly negatively affected.

A substantial portion of our revenue is derived from business arrangements with related parties, and such arrangements could create conflicts of interest that could adversely affect our business and results of operations.

        Some of our customers and other business partners hold a significant stake in our capital stock. Related party transactions disclosed in our financial statements accounted for $10.4 million and $26.0 million, or 43.5% and 61.0%, respectively, of our revenue for the six months ended June 30, 2011 and the year ended December 31, 2010. ATMI, which beneficially owns approximately 10.6% of our capital stock as of September 1, 2011, accounted for $7.8 million and $22.1 million, or 32.7% and 51.8%, respectively, of our revenue for the six months ended June 30, 2011 and the year ended December 31, 2010. For more information about these transactions, see "Certain Relationships and Related Party Transactions" and Note 11 to our consolidated financial statements. We have also entered into CDPs with GLOBALFOUNDRIES, whose majority stockholder, Advanced Technology Investment Company, LLC, beneficially owns approximately 4.4% of our capital stock (assuming exercise of an outstanding warrant held by them) as of September 1, 2011, and SanDisk Corporation and Toshiba Corporation, which collectively hold warrants exercisable for an aggregate of 1,644,736 shares of our common stock.

        We believe that the transactions and agreements that we have entered into with related parties are on terms that are at least as favorable as could reasonably have been obtained at such time from third parties. However, these relationships could create, or appear to create, potential conflicts of interest when our board of directors is faced with decisions that could have different implications for us and our related parties or their affiliates. In addition, conflicts of interest may arise between us and our related parties and their affiliates. The appearance of conflicts, even if such conflicts do not materialize, might adversely affect the public's perception of us, as well as our relationship with other companies and our ability to enter into new relationships in the future, including new CDPs with competitors of such related parties, which could have a material adverse effect on our ability to do business.

25


Table of Contents


We are subject to warranty claims, product recalls and product liability.

        We may, from time to time, be subject to warranty or product liability claims for our HPC tools that may in the future lead to expenses as we compensate affected customers for costs incurred related to product quality issues. Although we maintain product liability insurance, such insurance is subject to significant deductibles and there is no guarantee that such insurance will be available or adequate to protect against all such claims. Alternatively, we may elect to self-insure with respect to certain matters. We may incur costs and expenses in the event of any recall of a HPC tool sold to our customers. We may incur replacement costs, contract damage claims from our customers and reputational harm. Costs or payments made in connection with warranty and product liability claims and product recalls could materially affect our financial condition and results of operations.

Compliance with environmental, health and safety laws and regulations could increase costs or cause us to incur substantial liabilities.

        We are subject to various foreign, federal, state and local environmental laws and regulations governing, among other matters, emissions and discharges of hazardous materials into the air and water, the use, generation, storage, handling, transportation and disposal of, and exposure to, hazardous materials and wastes, remediation of contamination and employee health and safety. In addition, under certain of these environmental laws, liability can be joint and several and without regard to comparative fault. Our operations involve the use of hazardous materials and produce hazardous waste, and we could become liable for any injury or contamination that could arise due to such use or disposal of these materials. Failure to comply with environmental laws and regulations could result in the imposition of substantial civil and criminal fines and sanctions, could require operational changes or limits or the installation of costly equipment or otherwise lead to third party claims. Future environmental laws and regulations, stricter enforcement of existing laws and regulations, or the discovery of previously unknown contamination or violations of such laws and regulations could require us to incur costs or become the basis for new or increased liabilities, which could impair our operations and adversely affect our business and results of operations.

Acquisitions may harm our business and operating results, cause us to incur debt or assume contingent liabilities or dilute our shareholders.

        We have made and may in the future make strategic investments or acquisitions where there is an opportunity to expand the potential applications and reach of our HPC platform. Exploring and implementing any investments or acquisitions may place strain upon our ability to manage our future growth and may divert management attention from our core development and licensing business. There are also other risks associated with this strategy. We cannot assure you that we will be able to make investments or acquire businesses on satisfactory terms, that any business acquired by us or in which we invest will be integrated successfully into our operations or be able to operate profitably, or that we will be able to realize any expected synergies or benefits from such investments or acquisitions. Our relative inexperience in effecting such transactions heightens these risks. In addition, to finance any acquisitions or investments, we may utilize our existing funds, or might need to raise additional funds through public or private equity or debt financings. Prolonged tightening of the financial markets may impact our ability to obtain financing to fund future acquisitions and we could be forced to obtain financing on less than favorable terms. Additionally, equity financings may result in dilution to our stockholders. We cannot predict the number, timing or size of investments or acquisitions, or the effect that any such transactions might have on our operating results.

26


Table of Contents


Global or regional economic, political and social conditions could adversely affect our business and operating results.

        We operate in multiple jurisdictions throughout the world and are subject to foreign business, political and economic risks. In particular, we are subject to risks arising from adverse changes in global economic conditions. Global economic uncertainties in the key markets of many of our customers may cause our customers to delay or reduce technology purchases and investments. The impact of this on us is difficult to predict, but if businesses defer licensing our technology, require fewer CDPs or development tools, or if consumers defer purchases of new products that incorporate technology developed through our CDPs, our revenue could decline. A decline in revenue would have an adverse effect on our results of operations and our financial condition.

        In addition, some of our largest customers are located outside of the United States, primarily in Asia, which further exposes us to foreign risks. Also, a substantial portion of the consumer products market that serves as the end-market for the products we help our customers to develop is located in Asia. As a result, our operations are subject to substantial influence by political and economic conditions in Asia, as well as natural disasters such as the recent earthquake and tsunami and related nuclear power plant crisis in Japan. Reduced end user demand as well as disruptions to the supply chain for our customers resulting from these events could lead to a reduction in our revenue and an adverse impact on our financial condition.

        We are also subject to general geopolitical risks in connection with international operations, such as political, social and economic instability, terrorism, interference with information or communication of networks or systems, potential hostilities, changes in diplomatic and trade relationships, and disease outbreaks, and any disruptive effect these events would have on our business operations. Although to date we have not experienced any material adverse effect on our operations as a result of these types of regulatory, geopolitical, and other factors, we cannot assure investors that these factors will not have a material adverse effect on our business, financial condition, and operating results or require us to modify our current business practices. Inconsistencies among, and unexpected changes in, a wide variety of foreign laws and regulatory environments with which we are not familiar, including, among other issues, with respect to employees, protection of our intellectual property, and a wide variety of operational regulations and trade and export controls under domestic, foreign, and international law may also have unexpected, adverse impacts on our operations and financial condition.

In the future, exchange rate fluctuations could affect our revenue, which could adversely affect our business and operating results.

        Our licensing and royalty revenue is derived from sales of our customers' products that incorporate technology developed through our CDPs. To the extent that sales for these customer products are denominated in a foreign currency, an increase in the value of the U.S. dollar relative to such foreign currencies could adversely affect our licensing and royalty revenue irrespective of the volume of such products sold, which could adversely affect our business and operating results.

        In addition, we derive a significant portion of our revenue from customers in foreign countries, particularly those based in Japan. Revenue generated from customers in Japan accounted for 29%, 30% and 27% of total revenue for the years ended December 31, 2010, 2009 and 2008, respectively. We expect that a significant portion of our total future revenue will continue to be derived from companies based in Japan and other foreign countries. If the U.S. dollar increases in value relative to the currencies in any of these countries, the cost of our CDPs, which have historically been billed in U.S. dollars, will be more expensive to existing and potential customers in those countries, which could adversely affect our ability to generate new or expand existing CDPs.

27


Table of Contents


Business interruptions could delay us in the process of developing our products and could disrupt our sales.

        Our headquarters are located in the San Francisco Bay Area near known earthquake fault zones and are vulnerable to significant damage from earthquakes. We are also vulnerable to other types of natural disasters and other events that could disrupt our operations, such as terrorist acts and other events beyond our control. We do not carry insurance for earthquakes and we may not carry sufficient business interruption insurance to compensate us for losses that may occur. Any losses or damages we incur could have a material adverse effect on our cash flows and success as an overall business.

Our ability to use our net operating loss carryforwards to offset future taxable income, and our ability to use our tax credit carryforwards, may be subject to certain limitations.

        In general, a corporation that undergoes an "ownership change" under Section 382 of the Internal Revenue Code is subject to limitations on its ability to utilize its pre-change net operating loss carryforwards (NOLs) to offset future taxable income and its ability to utilize tax credit carryforwards. As of December 31, 2010, we reported U.S. federal NOLs of approximately $17.4 million. In general, an "ownership change" occurs if the aggregate stock ownership of certain stockholders (generally, 5% shareholders, applying certain aggregation and look-through rules) increases by more than 50 percentage points over such stockholders' lowest percentage ownership during the testing period (generally, three years). We have not determined whether an ownership change has occurred in the past. If we have experienced an ownership change in the past, or if we undergo an ownership change in connection with this offering, our ability to utilize NOLs and tax credit carryforwards could be limited. Furthermore, future changes in our stock ownership, such as certain stock issuances and transfers between stockholders, some of which changes are outside of our control, could result in ownership changes under Section 382 of the Internal Revenue Code. For these reasons, we may not be able to utilize a material portion of our NOLs and tax credit carryforwards, even if we attain profitability.

Risks Relating to this Offering and Ownership of Our Common Stock

An active trading market for our common stock may not develop, and you may not be able to resell your shares at or above the initial public offering price.

        Prior to this offering, there has been no public market for shares of our common stock. Although we will apply to have our common stock approved for quotation on a stock exchange, an active trading market for our shares may never develop or be sustained following this offering. The initial public offering price of our common stock will be determined through negotiations between us and the underwriters. This initial public offering price may not be indicative of the market price of our common stock after this offering. In the absence of an active trading market for our common stock, investors may not be able to sell their common stock at or above the initial public offering price or at the time that they would like to sell.

Our stock price may be volatile, and the market price of our common stock after this offering may drop below the price you pay.

        The market price of our common stock could be subject to significant fluctuations after this offering and it may decline below the initial public offering price. Market prices for securities of early stage companies have historically been particularly volatile. As a result of this volatility, you may not be able to sell your common stock at or above the initial public offering price. These fluctuations could be in response to, among other things, the factors described in this "Risk Factors" section or elsewhere in this registration statement, or other factors, some of which are beyond our control, such as:

28


Table of Contents

        Furthermore, the stock markets have experienced price and volume fluctuations that have affected, and continue to affect, the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market fluctuations, as well as general economic, political and market conditions, such as recessions, interest rate changes and international currency fluctuations, may negatively affect the market price of our common stock.

        In the past, many companies that have experienced volatility in the market price of their stock have become subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management's attention from other business concerns, which could seriously harm our business.

We will incur increased costs and demands upon management as a result of complying with the laws and regulations affecting public companies, which could harm our results of operations.

        As a public company, we will incur significant additional accounting, legal and other expenses that we did not incur as a private company, including costs associated with public company reporting requirements. We have incurred and will continue to incur costs associated with corporate governance requirements, including requirements under Section 404 and other provisions of the Sarbanes-Oxley Act, as well as rules implemented by the Securities Exchange Commission, or SEC, and the exchange on which we list our common stock. The expenses incurred by public companies for reporting and corporate governance purposes have increased dramatically in recent years. We expect these rules and regulations to substantially increase our financial and legal compliance costs. In addition, these rules and regulations are subject to change from time to time, and we may incur additional financial and legal compliance costs as we seek to understand and comply with changes in these rules and regulations. We also expect that as we become a public company it will be more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage previously available. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as our executive officers.

If we experience material weaknesses or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately report our financial condition or results of operations, which may adversely affect investor confidence in our company and, as a result, the value of our common stock.

        As a result of becoming a public company, we will be required, under Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting for the first fiscal year beginning after the effective date of this

29


Table of Contents


offering. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting, as well as an opinion from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. A material weakness is a control deficiency or combination of control deficiencies that results in more than a remote likelihood that a material misstatement of annual or interim financial statements will not be prevented or detected.

        We are in the very early stages of the costly and challenging process of hiring personnel and compiling the system and processing documentation necessary to perform the evaluation needed to comply with Section 404. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal controls are effective. We cannot assure you that there will not be material weaknesses and significant deficiencies in our internal controls in the future. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm were to issue an adverse opinion on the effectiveness of our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, which would cause the price of our common stock to decline.

        We have not completed a testing cycle under Section 404 of the Sarbanes-Oxley Act and cannot assure you that we will be able to implement and maintain an effective internal control over financial reporting in the future. Any failure to maintain such controls could severely inhibit our ability to accurately report our financial condition or results of operations.

The concentration of our capital stock ownership with insiders upon the completion of this offering will limit your ability to influence corporate matters.

        We anticipate that our executive officers, directors, current five percent or greater stockholders and entities affiliated with them will together beneficially own approximately        % of our common stock outstanding after this offering. Entities affiliated with Redpoint Ventures, entities affiliated with CMEA Ventures and entities affiliated with U.S. Venture Partners will beneficially own approximately      %,      % and      % of our common stock outstanding after this offering. This significant concentration of share ownership may adversely affect the trading price for our common stock because investors often perceive disadvantages in owning stock in companies with concentrated stock ownership. Also, these stockholders, acting together, will be able to influence our management and affairs and matters requiring stockholder approval, including the election of directors and the approval of significant corporate transactions, such as mergers, consolidations or the sale of substantially all of our assets. Consequently, this concentration of ownership may have the effect of delaying or preventing a change of control, including a merger, consolidation or other business combination involving us, or discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control, even if that change of control would benefit our other stockholders.

A significant portion of our total outstanding shares may be sold into the public market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well.

        Sales of a substantial number of shares of our common stock in the public market could occur at any time after the expiration of the lock-up agreements described in the "Underwriting" and "Shares Eligible for Future Sale—Lock-up Agreements" sections of this prospectus. These sales, or the market perception that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. After this offering, we will have          shares of common stock outstanding based on the number of shares outstanding as of June 30, 2011 and assuming the conversion of all shares of preferred stock into shares of our common stock and no exercise of outstanding options or

30


Table of Contents


warrants after June 30, 2011. This includes the          shares that we are selling in this offering, which may be resold in the public market immediately after this offering. The remaining                        shares, or      % of our outstanding shares after this offering, are currently restricted as a result of securities laws or lock-up agreements but will be able to be sold, subject to any applicable volume limitations under federal securities laws, in the near future as set forth below:

        The lock-up agreements expire 180 days after the date of this prospectus, except that the 180-day period may be extended in certain cases for up to 34 additional days under certain circumstances where we announce or pre-announce earnings or a material event occurs within approximately 17 days prior to, or approximately 16 days after, the termination of the 180-day period. The representatives of the underwriters may, in their sole discretion and at any time without notice, release all or any portion of the securities subject to lock-up agreements.

        Following this offering, holders of              shares of our common stock (including shares issuable upon exercise of certain stock options) not sold in this offering will be entitled to rights with respect to the registration of these shares under the Securities Act. See "Description of Capital Stock—Registration Rights." If we register their shares of common stock following the expiration of the lock-up agreements, these stockholders could sell those shares in the public market without being subject to the volume and other restrictions of Rule 144 and Rule 701.

        After the closing of this offering, we intend to register approximately              shares of common stock that have been reserved for issuance under our stock incentive plans. Of these shares, approximately              shares will be eligible for sale upon the exercise of outstanding options after the expiration of the lock-up agreements.

Purchasers in this offering will experience immediate and substantial dilution in the book value of their investment.

        The initial public offering price of our common stock is substantially higher than the net tangible book value per share of our outstanding common stock immediately after this offering. Therefore, if you purchase our common stock in this offering, you will incur immediate dilution of approximately $      in net tangible book value per share from the price you paid, based on an assumed initial offering price of $      per share, the midpoint of the range set forth on the cover of this prospectus. In addition, investors purchasing common stock in this offering will own only approximately      % of our shares outstanding after this offering even though they will have contributed       % of the total consideration received by us in connection with our sales of common stock. Moreover, we issued options and warrants in the past to acquire our stock at prices significantly below the initial public offering price. As of June 30, 2011, 16,403,610 shares of common stock were issuable upon exercise of outstanding stock options with a weighted average exercise price of $1.09 per share. As of June 30, 2011, warrants to purchase 4,446,721 shares of common stock (assuming conversion of all shares of preferred stock into common stock as of June 30, 2011) were issuable upon exercise of outstanding warrants with a weighted average exercise price of $2.60 per share. To the extent that these outstanding options and warrants are ultimately exercised, you will incur further dilution. For a further description of the dilution that you will experience immediately after this offering, see the "Dilution" section of this prospectus.

31


Table of Contents


If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.

        The trading market for our common stock will be influenced by the research and reports that industry or securities analysts may publish about us, our business, our market or our competitors. If any of the analysts who may cover us change their recommendation regarding our stock adversely, or provide more favorable relative recommendations about our competitors, our stock price would likely decline. If any analyst who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

Our management will have broad discretion over the use of the proceeds we receive in this offering and might not apply the proceeds in ways that increase the value of your investment.

        Our management will have broad discretion in the application of the net proceeds from this offering, and you will be relying on the judgment of our management regarding the application of these proceeds. Our management might not apply our net proceeds of this offering in ways that increase the value of your investment. We expect to use the net proceeds to us from this offering for working capital and other general corporate purposes, which may in the future include expansion of production facilities and HPC platform and equipment, investments in, or acquisitions of, complementary businesses, joint ventures, partnerships, services, intellectual property or technologies. Our management might not be able to yield a significant return, if any, on any investment of these net proceeds. You will not have the opportunity to influence our decisions on how to use our net proceeds from this offering.

After the completion of this offering, we do not expect to declare any dividends in the foreseeable future.

        After the completion of this offering, we do not anticipate declaring any cash dividends to holders of our common stock in the foreseeable future. Consequently, investors may need to rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investment. Investors seeking cash dividends should not purchase our common stock.

Anti-takeover provisions contained in our certificate of incorporation and bylaws, as well as provisions of Delaware law, could impair a takeover attempt.

        Our amended and restated certificate of incorporation and our amended and restated bylaws to be effective upon the completion of this offering will contain provisions that could delay or prevent a change in control of our company. These provisions could also make it more difficult for stockholders to elect directors and take other corporate actions. These provisions include:

32


Table of Contents

        Section 203 of the Delaware General Corporation Law prohibits, subject to some exceptions, "business combinations" between a Delaware corporation and an "interested stockholder," which is generally defined as a stockholder who becomes a beneficial owner of 15% or more of a Delaware corporation's voting stock, for a three-year period following the date that the stockholder became an interested stockholder.

        These and other provisions in our amended and restated certificate of incorporation and our amended and restated bylaws to be effective upon the completion of this offering under Delaware law could discourage potential takeover attempts, reduce the price that investors might be willing to pay in the future for shares of our common stock and result in the market price of our common stock being lower than it would be without these provisions. See "Description of Capital Stock—Preferred Stock" and "Description of Capital Stock—Anti-Takeover Provisions."

33


Table of Contents


FORWARD-LOOKING STATEMENTS

        This prospectus contains forward-looking statements that involve risks and uncertainties. The forward-looking statements are contained principally in the sections entitled "Prospectus Summary," "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Business." These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties are contained principally in the section entitled "Risk Factors."

        Forward-looking statements include all statements that are not historical facts. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential," or the negative of those terms, and similar expressions and comparable terminology intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this prospectus and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this prospectus.


MARKET, INDUSTRY AND OTHER DATA

        Unless otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate, including our general expectations and market position, market opportunity and market size, is based on information from various sources, on assumptions that we have made that are based on those data and other similar sources and on our knowledge of the markets for our services. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified any third party information and cannot assure you of its accuracy or completeness. While we believe the market position, market opportunity and market size information included in this prospectus is generally reliable, such information is inherently imprecise. In addition, projections, assumptions and estimates of our future performance and the future performance of the industry in which we operate is necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in "Risk Factors" and elsewhere in this prospectus. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.

34


Table of Contents


USE OF PROCEEDS

        We estimate that we will receive net proceeds of approximately $           million from the sale of                shares of common stock offered by us in this offering, based on an assumed initial public offering price of $          per share (the midpoint of the price range set forth on the cover page of this prospectus) and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. A $1.00 increase (decrease) in the assumed initial public offering price of $          per share would increase (decrease) the net proceeds to us from this offering by $           million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters' over-allotment option to purchase additional shares from us is exercised in full, we estimate that we will receive additional net proceeds of $           million. We will not receive any proceeds from the sale of the shares of common stock to be offered by the selling stockholders.

        We intend to use the net proceeds received by us from this offering for working capital and other general corporate purposes.

        In connection with an agreement for the purchase of intellectual property and the termination of our royalty obligations under an existing license agreement, we have an obligation to issue a promissory note to Symyx Technologies, Inc. (Symyx), a wholly-owned subsidiary of Accelrys, Inc., upon the consummation of this offering to the extent the gross proceeds from Symyx's sale of                    shares in this offering (before deducting underwriting discounts and commissions and estimated offering expenses) are less than $67 million. At an assumed initial public offering price of $          per share (the midpoint of the price range set forth on the cover page of this prospectus), the gross proceeds from the sale of Symyx's shares would be $             million, and we would have a $                obligation to Symyx. A $1.00 increase (decrease) in the assumed initial public offering price of $          per share would increase (decrease) the gross proceeds to Symyx by $                 million. Such note, if issued, would have a term of 24 months and an interest rate equal to 4%. Such note would be payable in an amount equal to the lesser of the principal amount and the greater of $500,000 per quarter or the amount of accrued interest, with a balloon payment at maturity if applicable. Such note would also be pre-payable by us at any time without penalty or premium, and would be secured by tangible personal property, excluding intellectual property. If we issue such note, a portion of the net proceeds of this offering would be used to make payments of scheduled interest and payment of principal at any time at or prior to maturity. We have also agreed to reimburse Symyx for 50% of their underwriting discounts and commissions.

        We may also use a portion of the net proceeds to expand our current business through acquisitions of other businesses, products, intellectual property or technologies. Other than as set forth above, we do not have agreements or commitments for any specific acquisitions at this time.

        Pending the use of the net proceeds from this offering, we plan to invest the net proceeds in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or director or guaranteed obligations of the U.S. government. We cannot predict whether the proceeds invested will yield a favorable return, if any.


DIVIDEND POLICY

        We have never declared or paid any cash dividends on our common stock. We currently intend to retain any future earnings for use in the operation and expansion of our business, and currently do not plan to declare or pay any dividends on shares of our common stock in the foreseeable future. Subject to the foregoing, the payment of cash dividends in the future, if any, will be at the discretion of our board of directors and will depend upon a number of factors, including our earnings, capital requirements, requirements under the Delaware General Corporation Law, restrictions and covenants pursuant to any credit facilities we may enter into, our overall financial condition and any other factors deemed relevant by our board of directors.

35


Table of Contents


CAPITALIZATION

        The following table sets forth our capitalization as of June 30, 2011 as follows:

        The pro forma and pro forma as adjusted information below is illustrative only and our capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this table in conjunction with the sections titled "Selected Consolidated Financial Data" and "Management's

36


Table of Contents


Discussion and Analysis of Financial Condition and Results of Operations" and our consolidated financial statements and related notes included elsewhere in this prospectus.

 
  As of June 30, 2011  
 
  Actual   Pro Forma   Pro Forma as
Adjusted
 
 
  (unaudited)
 
 
  (in thousands, except share and
per share amounts)

 

Preferred stock warrant liability

    670            

Redeemable convertible preferred stock, par value $0.001 per share: 59,230,199 shares authorized, 58,461,447 shares issued and outstanding, actual; no shares authorized, no shares issued and outstanding, pro forma and pro forma as adjusted

    80,515                       

Accumulated accretion of redeemable convertible preferred stock to redemption values

    41,521                       

Stockholders' equity (deficit):

                   
 

Common stock, par value $0.001 per share: 105,000,000 shares authorized, 11,555,956 shares issued and outstanding, actual; 105,000,000 shares authorized, 72,639,388 shares issued and outstanding, pro forma;                    shares issued and outstanding, pro forma as adjusted

    12     73                   
 

Additional paid-in capital

        129,021                   
 

Accumulated deficit

    (73,187 )   (73,187 )                 
               
   

Total stockholders' equity (deficit)

    (73,175 )   55,907                   
               
     

Total capitalization

  $ 49,531   $ 55,907   $               
               

        If the underwriters' over-allotment option were exercised in full, pro forma as adjusted cash and cash equivalents, common stock and additional paid-in capital, stockholders' equity (deficit) and shares issued and outstanding as of June 30, 2011 would be $           million, $           million, $           million and                    shares, respectively.

        A $1.00 increase (decrease) in the assumed initial public offering price of $          per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase (decrease) each of pro forma as adjusted additional paid-in capital, stockholders' equity (deficit) and total capitalization by approximately $           million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. We may also increase or decrease the number of shares we are offering. An increase (decrease) of 1,000,000 in the number of shares we are offering would increase (decrease) each of pro forma as adjusted additional paid-in capital, stockholders' equity (deficit) and total capitalization by approximately $           million, assuming the assumed initial public offering price per share (the midpoint of the price range set forth on the cover page of this prospectus) remains the same. An increase of 1,000,000 in the number of shares we are offering, together with a $1.00 increase in the assumed initial public offering price per share, would increase each of pro forma as adjusted additional paid-in capital, stockholders' equity (deficit) and total capitalization by approximately $           million. A decrease of 1,000,000 in the number of shares we are offering, together with a $1.00 decrease in the assumed initial public offering price per share, would decrease each of pro forma as adjusted additional paid-in capital, stockholders' equity (deficit) and total capitalization by approximately $           million. The pro forma as adjusted information is illustrative only, and we will adjust this information based on the actual initial public offering price and other terms of this offering determined at pricing.

37


Table of Contents

        The number of actual, pro forma and pro forma as adjusted shares of common stock issued and outstanding in the table above each excludes the following shares as of June 30, 2011:

38


Table of Contents


DILUTION

        If you invest in our common stock in this offering, your interest will be diluted to the extent of the difference between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering.

        Net tangible book value per share is determined by dividing our total tangible assets less our total liabilities by the number of shares of common stock outstanding. Our historical net tangible book value (deficit) as of June 30, 2011 was $(75.8) million, or $(6.56) per share.

        Our pro forma net tangible book value (deficit) as of June 30, 2011 was $53.3 million, or $0.73 per share, after giving effect to the following:

        After further giving effect to the filing of our amended and restated certificate of incorporation, which will occur in connection with the consummation of this offering, and our receipt of the net proceeds from the sale of                    shares of common stock offered by us in this offering at an assumed initial public offering price of $          per share (the midpoint of the price range set forth on the cover page of this prospectus), after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June 30, 2011 would have been $           million, or $          per share. This represents an immediate increase in net tangible book value of $          per share to existing stockholders and an immediate dilution in net tangible book value of $          per share to purchasers of common stock in this offering, as illustrated in the following table:

Assumed initial public offering price per share, based on the midpoint of the price range set forth on the cover page of this prospectus. 

                   $               
 

Pro forma net tangible book value (deficit) per share as of June 30, 2011

  $                                
 

Increase in pro forma net tangible book value (deficit) per share attributable to new investors

             
             

Pro forma as adjusted net tangible book value per share after this offering

                                   
             

Dilution per share to investors in this offering

                   $               
             

        If the underwriters' over-allotment option to purchase additional shares from us is exercised in full, the pro forma as adjusted net tangible book value per share after this offering would be $          per

39


Table of Contents


share, the increase in pro forma as adjusted net tangible book value per share to existing stockholders would be $          per share and the dilution to new investors purchasing shares in this offering would be $          per share.

        A $1.00 increase (decrease) in the assumed initial public offering price of $          per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase (decrease) our pro forma as adjusted net tangible book value by $           million, the pro forma as adjusted net tangible book value per share by $          per share and the dilution in the pro forma net tangible book value to new investors in this offering by $          per share and the dilution in the pro forma net tangible book value to new investors purchasing shares in this offering by $          per share, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.

        The following table presents on a pro forma as adjusted basis as of June 30, 2011, after giving effect to the pro forma adjustments described above, the differences between the existing stockholders and the new investors purchasing shares in this offering with respect to the number of shares purchased from us, the total consideration paid, which includes net proceeds received from the issuance of common and redeemable convertible preferred stock, cash received from the exercise of stock options and the value of any stock issued for services and the average price paid per share:

 
   
   
  Total
Consideration
   
 
 
  Shares Purchased    
 
 
  Average Price
per Share
 
 
  Number   Percent   Amount   Percent  
 
   
   
  (in
thousands)

   
   
 

Existing stockholders

                   % $                    % $               

New investors

                               
                         
 

Totals

                 100.0 % $                  100.0 %                 
                         

        The sale by the selling stockholders in this offering will cause the number of shares held by existing stockholders to be reduced to            shares or        % of the total number of shares of our common stock outstanding after this offering. If the underwriters exercise their over-allotment option in full, our existing stockholders would own         % and our new investors would own        % of the total number of shares of our common stock outstanding after this offering.

        The foregoing calculations are based on 72,639,388 shares of common stock outstanding as of June 30, 2011, assuming the conversion of all outstanding shares of our redeemable convertible preferred stock into 58,461,447 shares of common stock in connection with the consummation of this offering and the cash exercise of certain warrants outstanding to purchase shares of our common stock as of June 30, 2011, which will expire upon completion of this offering if unexercised, resulting in the issuance of 2,621,985 shares of common stock for an aggregate exercise price of approximately $6.4 million, and exclude the following:

40


Table of Contents

                       shares of common stock that will be reserved for future issuance under our 2011 Incentive Award Plan, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this benefit plan, which will become effective immediately prior to the consummation of this offering.

        To the extent that outstanding options or warrants are exercised, you will experience further dilution. If all of our outstanding options and warrants were exercised, our pro forma net tangible book value as of June 30, 2011 would have been $         million, or $        per share, and the pro forma, as adjusted net tangible book value after this offering would have been $         million, or $        per share, causing dilution to new investors of $        per share.

        In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.

41


Table of Contents


SELECTED CONSOLIDATED FINANCIAL DATA

        The selected consolidated statement of operations data for the years ended December 31, 2008, 2009 and 2010 and the consolidated balance sheet data as of December 31, 2009 and 2010 are derived from our audited consolidated financial statements included elsewhere in this prospectus. The selected consolidated statement of operations data for the six months ended June 30, 2010 and 2011 and the consolidated balance sheet data as of June 30, 2011 are derived from our unaudited consolidated financial statements included elsewhere in this prospectus. The selected consolidated statement of operations data for the years ended December 31, 2006 and 2007 and the consolidated balance sheet data as of December 31, 2006, 2007 and 2008 are derived from our audited consolidated financial statements which are not included in this prospectus. The unaudited interim consolidated financial statements include, in the opinion of management, all adjustments, which consist only of normal recurring adjustments, that management considers necessary for the fair statement of the financial information set forth in those statements. Our historical results are not necessarily indicative of the results that may be expected in the future. You should read the following selected consolidated historical financial data below in conjunction with the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the consolidated financial statements and related notes included elsewhere in this prospectus.

42


Table of Contents

 
  Years Ended December 31,   Six Months Ended June 30,  
 
  2006   2007   2008   2009   2010   2010   2011  
 
   
   
   
   
   
  (unaudited)
 
 
  (in thousands, except share and per share amounts)
 

Consolidated Statement of Operations Data:

                                           

Revenue:

                                           
 

CDP and services revenue

  $ 3,628   $ 8,594   $ 14,647   $ 14,182   $ 27,705   $ 9,806   $ 15,820  
 

Product revenue

            6,206     9,065     6,959     3,300     1,360  
 

Licensing and royalty revenue

            2,276     3,663     8,010     3,386     6,644  
                               
   

Total revenue

    3,628     8,594     23,129     26,910     42,674     16,492     23,824  

Cost of revenue

    1,992     4,873     12,625     13,018     20,926     8,752     11,323  
                               
     

Gross profit

    1,636     3,721     10,504     13,892     21,748     7,740     12,501  

Operating expenses:

                                           
 

Research and development

    5,175     9,415     11,849     10,983     13,917     6,353     9,488  
 

Sales and marketing

    773     1,541     3,849     3,211     4,074     1,926     1,980  
 

General and administrative

    3,647     3,837     4,300     4,867     5,761     2,877     3,925  
                               
   

Total operating expenses

    9,595     14,793     19,998     19,061     23,752     11,156     15,393  
                               

Loss from operations

    (7,959 )   (11,072 )   (9,494 )   (5,169 )   (2,004 )   (3,416 )   (2,892 )

Other income (expense):

                                           
 

Interest income, net

    448     850     174     (6 )   43     17     10  
 

Other income (expense), net

            6     (62 )   202     55     (335 )
                               
   

Total other income (expense), net

    448     850     180     (68 )   245     72     (325 )

Loss before provision for income taxes

    (7,511 )   (10,222 )   (9,314 )   (5,237 )   (1,759 )   (3,344 )   (3,217 )

Provision for income taxes

    1     1     186     17     19     2     13  
                               

Net loss

    (7,512 )   (10,223 )   (9,500 )   (5,254 )   (1,778 )   (3,346 )   (3,230 )

Accretion on redeemable convertible preferred stock

    (1,351 )   (4,168 )   (5,436 )   (9,170 )   (14,162 )   (6,340 )   (7,095 )
                               

Net loss attributable to common stockholders

  $ (8,863 ) $ (14,391 ) $ (14,936 ) $ (14,424 ) $ (15,940 ) $ (9,686 ) $ (10,325 )
                               

Net loss per share of common stock, basic and diluted

  $ (0.91 ) $ (1.40 ) $ (1.39 ) $ (1.31 ) $ (1.43 ) $ (0.87 ) $ (0.91 )
                               

Weighted-average number of shares used in computing net loss per share of common stock, basic and diluted(1)

    9,730,679     10,246,738     10,716,462     11,023,779     11,134,573     11,115,486     11,296,902  
                               

Pro forma net loss per share of common stock, basic and diluted(1)

                          $ (0.03 )       $ (0.04 )
                                         

Weighted-average number of shares used in computing pro forma net loss per share of common stock, basic and diluted(1)

                            65,376,321           68,243,300  
                                         

Other Data:

                                           

Adjusted EBITDA (unaudited)

  $ (5,238 ) $ (7,737 ) $ (5,062 ) $ 272   $ 4,589   $ (274 ) $ 2,026  

 

 
  Years Ended December 31,    
 
 
  As of June 30,
2011
 
 
  2006   2007   2008   2009   2010  
 
   
   
   
   
   
  (unaudited)
 
 
  (in thousands)
 

Consolidated Balance Sheet Data:

                                     

Cash, cash equivalents and short-term investments

  $ 20,698   $ 26,744   $ 40,902   $ 32,620   $ 23,064   $ 35,630  

Working capital

    22,519     18,552     26,663     16,389     4,825     23,927  

Total assets

    28,906     40,877     62,190     54,469     55,571     69,299  

Long-term debt, including current portion

        3,194     4,445              

Preferred stock warrant liability

                159     215     670  

Redeemable convertible preferred stock

    35,738     35,738     55,633     55,633     55,633     80,515  

Accumulated accretion of redeemable convertible preferred stock to redemption values

    1,490     5,658     11,094     20,264     34,426     41,521  

Total stockholders' deficit

    (9,629 )   (22,706 )   (36,579 )   (49,889 )   (64,356 )   (73,175 )

(1)
Please see Note 9 to our audited consolidated financial statements for an explanation of the calculations of our basic and diluted net loss per share of common stock and pro forma net loss per share of common stock.

43


Table of Contents

Non-GAAP Financial Measure

        We believe that the use of adjusted EBITDA, a non-GAAP financial measure, is helpful for an investor in determining whether to invest in our common stock. We include adjusted EBITDA in this prospectus because (i) we seek to manage our business to a consistent level of adjusted EBITDA, (ii) it is a key basis upon which our management assesses our operating performance, (iii) it is one of the primary metrics investors use in evaluating companies' performance in our industry and (iv) it is a factor in the evaluation of the performance of our management in determining compensation. We define adjusted EBITDA as net income (loss) less interest, provision for income taxes, depreciation and amortization expense, non-cash revenue adjustments as a result of common stock warrants issued to customers and stock-based compensation expense.

        We use adjusted EBITDA as a key performance measure because we believe it facilitates operating performance comparisons from period to period by excluding potential differences caused by variations in capital structures, tax positions (such as the impact of changes in effective tax rates or fluctuations in permanent differences or discrete quarterly items), the impact of depreciation and amortization expense, the non-cash impact of common stock warrants issued to customers and the impact of stock-based compensation expense.

        In addition, we believe adjusted EBITDA and similar measures are widely used by investors, securities analysts, ratings agencies and other interested parties in our industry as a measure of financial performance and debt-service capabilities. Our use of adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

        Because of these limitations, adjusted EBITDA should not be considered as a measure of discretionary cash available to us to invest in the growth of our business. When evaluating our performance, you should consider adjusted EBITDA alongside other financial performance measures, including our net loss and other GAAP results.

44


Table of Contents

        The following table presents a reconciliation of adjusted EBITDA to our net income (loss), the most comparable GAAP measure, for each of the periods indicated:

 
  Years Ended December 31,   Six Months
Ended June 30,
 
 
  2006   2007   2008   2009   2010   2010   2011  
 
   
   
   
   
   
  (unaudited)
 
 
  (in thousands)
 

Net loss

  $ (7,512 ) $ (10,223 ) $ (9,500 ) $ (5,254 ) $ (1,778 ) $ (3,346 ) $ (3,230 )

Non-GAAP adjustments:

                                           

Revenue(1)

        519                     312  

Interest, net

    (448 )   (850 )   (94 )   48     13     (17 )   445  

Provision for taxes

    1     1     186     17     19     2     13  

Depreciation and amortization

    872     2,105     3,430     4,380     4,971     2,412     3,504  

Stock-based compensation expense(2)

    1,849     711     916     1,081     1,364     675     982  
                               
 

Adjusted EBITDA (unaudited)

  $ (5,238 ) $ (7,737 ) $ (5,062 ) $ 272   $ 4,589   $ (274 ) $ 2,026  
                               

(1)
Reduction in revenue as a result of common stock warrants issued in connection with a customer agreement

(2)
Includes stock-based compensation as follows:

 
  Years Ended December 31,   Six Months Ended June 30,  
 
  2006   2007   2008   2009   2010   2010   2011  
 
   
   
   
   
   
  (unaudited)
 
 
  (in thousands)
 

Cost of revenue

  $ 19   $ 81   $ 71   $ 134   $ 285   $ 118   $ 233  

Research and development

    179     192     170     222     204     118     191  

Sales and marketing

    108     256     408     378     422     231     303  

General and administrative

    1,543     182     267     347     453     208     255  
                               
 

Total stock-based compensation

  $ 1,849   $ 711   $ 916   $ 1,081   $ 1,364   $ 675   $ 982  
                               

45


Table of Contents


MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS

         The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this prospectus. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section entitled "Risk Factors" included elsewhere in this prospectus.

Overview

        We have pioneered a proprietary approach to accelerate research and development, innovation and time-to-market for the semiconductor and clean-energy industries. Using our approach, we develop technology and intellectual property (IP) focused on advanced materials, processes, integration and device architectures in collaboration with our customers. This technology enables our customers to bring optimized, high-volume manufacturing-ready integrated devices to market faster and with less risk than traditional approaches to research and development (R&D). We provide our customers with proprietary technology through various fee arrangements and grant them rights to associated IP, primarily through royalty-bearing licenses. Our proprietary approach is broadly applicable to high-volume integrated device markets, which include semiconductors, flat glass, solar cells, light-emitting diodes (LEDs), flat-panel displays, advanced batteries and other energy-efficient technologies.

        We currently target large, high-volume semiconductor and high-growth emerging clean-energy markets, including DRAM, flash memory, complex logic, flat glass, solar cells, LEDs and energy-efficient technologies. Within these broad markets, we target customers that have track records of technological innovation, deploy significant resources and are pursuing technical advancements that are critical to their success and strategy. We have engaged in paid programs with 18 customers, including ATMI, Elpida Memory, GLOBALFOUNDRIES, Guardian Industries, SanDisk, Taiwan Semiconductor Manufacturing Company (TSMC) and Toshiba. ATMI and Elpida have commenced shipping products incorporating technology developed through our collaborative development programs (CDPs) and pay us licensing and royalty fees. To date, we have received the majority of our revenue from customers in DRAM, flash memory, complex logic and energy-efficient applications in flat glass, and have not yet received a material amount of revenue from customers in solar cells, LEDs and other energy-efficient technologies.

        We were founded in 2004 and are headquartered in San Jose, California. Our total revenue increased to $23.8 million for the six months ended June 30, 2011 from $16.5 million for the six months ended June 30, 2010. Our total revenue increased to $42.7 million for the year ended December 31, 2010 from $26.9 million for the year ended December 31, 2009. Our backlog as of June 30, 2011 was $108.8 million, of which $28.3 million is scheduled to be recognized as revenue during the remainder of the year ending December 31, 2011. Our adjusted EBITDA for the six months ended June 30, 2011 was $2.0 million, and our adjusted EBITDA for the year ended December 31, 2010 was $4.6 million. Our net loss decreased to $3.2 million for the six months ended June 30, 2011 from $3.3 million for the six months ended June 30, 2010. Our net loss decreased to $1.8 million for the year ended December 31, 2010 from $5.3 million from the year ended December 31, 2009. Since inception, we have incurred net losses leading to an accumulated deficit of $73.2 million as of June 30, 2011.

How We Generate Revenue

        Our business model aligns our interests with those of our customers as we collaborate to develop proprietary technology and IP for high-volume integrated devices through CDPs. As such, our customer engagement process generates revenue in three ways: CDP and services revenue; product revenue; and licensing and royalty revenue. CDPs are our primary engagement model with customers and are

46


Table of Contents


structured to result in licensing and royalty revenue. When we initially engage with a customer, we generate revenue from micro-CDPs, CDPs and licensing of our HPC platform. When technology developed through CDPs is incorporated in our customers' commercialized products, we generate licensing and royalty revenue. In certain cases, we sell HPC processing tools to our customers who pay a recurring license fee to operate those tools with our combinatorial processing capabilities.

 
  Years Ended December 31,   Six Months
Ended June 30,
 
 
  2008   2009   2010   2010   2011  
 
   
   
   
  (unaudited)
 
 
  (in thousands)
 

Revenue:

                               
 

CDP and services revenue

  $ 14,647   $ 14,182   $ 27,705   $ 9,806   $ 15,820  
 

Product revenue

    6,206     9,065     6,959     3,300     1,360  
 

Licensing and royalty revenue

    2,276     3,663     8,010     3,386     6,644  
                       
   

Total revenue

  $ 23,129   $ 26,910   $ 42,674   $ 16,492   $ 23,824  
                       

        Our revenue growth has been primarily driven by the adoption of our collaboration model and HPC platform leading to both new CDPs and the ramp of licensing and royalty revenue from products commercialized by our customers that incorporate technology developed through our CDPs. Successful CDPs result in the commercialization of products whereby we receive licensing fees and royalties over the course of the respective product cycles. Certain of our semiconductor customers have already commenced shipping products incorporating technology developed through our CDPs, which generate associated licensing and royalty revenue. Our revenue mix may vary from quarter to quarter as we enter into new CDPs and related customer arrangements, existing CDPs are completed or expanded and licensing and royalty arrangements generate revenue.

        Prior to entering into a new CDP, we negotiate licensing fees and royalty rates for technology to be developed in CDPs. The fees and rates are negotiated with each customer on the basis of multiple

47


Table of Contents


factors including the size of the servable market of the technology to be developed, the value contribution of the technology to the customer's product, and the anticipated overall margin structure of the customer's product. Licensing fees and royalty rates are set for each CDP-developed technology. While royalty rates vary, when working with device manufacturers, we typically target 1-2% of their projected end-product revenue for each CDP-developed technology. When working with suppliers to device manufacturers, we typically target higher royalty rates depending on the anticipated value contribution of the technology to their product. Licensing fees and royalty rates are structured in a variety of ways including fixed quarterly fees, percentage of revenue and fee per product.

        Our proprietary platform was initially created to address critical development challenges in the semiconductor industry and we began generating revenue in 2006. The applicability of our platform to address similar challenges in adjacent vertical markets such as clean-energy markets has created, and we believe will continue to create, new market opportunities for us. During the year ended December 31, 2010, we began generating revenue from customers in the clean-energy industry. We believe collaborating with companies in the clean-energy industry will accelerate the long-term growth of our business. The following table sets forth our revenue by customer end market:

 
  Years Ended December 31,   Six Months
Ended June 30,
 
 
  2008   2009   2010   2010   2011  
 
   
   
   
  (unaudited)
 
 
  (in thousands)
 

Semiconductor

  $ 23,129   $ 26,910   $ 40,678   $ 16,216   $ 21,810  

Clean energy

            1,996     276     2,014  
                       
 

Total

  $ 23,129   $ 26,910   $ 42,674   $ 16,492   $ 23,824  
                       

Key Financial Metrics

        We monitor the key financial metrics set forth below to help us evaluate growth trends, establish budgets, measure the effectiveness of our sales and marketing efforts, manage our human resources and assess operational efficiencies.

        Revenue growth and mix.     We monitor revenue from CDPs for existing and new customers, applications and the resulting licensing fees and royalties. As our customer engagements progress, we expect licensing and royalty revenue to be an increasing and significant component of our revenue. We are broadening our development and sales efforts by expanding CDPs in the semiconductor industry resulting from the adoption of our HPC platform for technology development and engaging in CDPs with companies in the clean-energy industry as we believe this will accelerate the future growth of our business.

        Backlog.     We monitor our backlog as it represents the aggregate value of contracted business not yet recognized. Our backlog consists of future revenue that our customers are contractually committed to pay in our CDPs and guaranteed licensing and royalty revenue for our developed technology and intellectual property. Our backlog as of June 30, 2011, December 31, 2010 and 2009 was $108.8 million, $78.2 million and $34.5 million, respectively. As of June 30, 2011, our backlog for customers in the semiconductor industry was $105.7 million, of which $26.5 million is scheduled to be recognized as revenue during the remainder of the year ending December 31, 2011 and $79.2 million in future periods beyond this year. As of June 30, 2011, our backlog for customers in the clean-energy industry was $3.1 million, of which $1.8 million is scheduled to be recognized as revenue during the remainder of the year ending December 31, 2011 and $1.3 million in future periods beyond this period.

        Adjusted EBITDA.     We monitor our adjusted EBITDA to measure the profitability of our business. We use adjusted EBITDA as a key performance measure because we believe it facilitates operating

48


Table of Contents


performance comparisons from period to period by excluding potential differences caused by variations in capital structures, tax positions (such as the impact of changes in effective tax rates or fluctuations in permanent differences or discrete quarterly items), the impact of depreciation and amortization expense, the non-cash impact of common stock warrants issued to customers and the impact of stock-based compensation expense. See "Selected Consolidated Financial Data—Non-GAAP Financial Measure" for a reconciliation of adjusted EBITDA to our net income (loss), the most comparable GAAP measure.

Factors Affecting our Performance

        Reliance on our customers' success.     Our success is tied to our customers' ability to successfully commercialize the products that incorporate technology developed through CDPs. We believe that we significantly improve our customers' ability to succeed in their end markets, but if they are unable to do so, the longer-term licensing and royalty revenue that we expect may be delayed or may not materialize. We attempt to manage this risk by carefully selecting projects and only participating in opportunities that we deem to have significant potential for long-term success.

        Exposure to semiconductor memory and solar power end markets.     Our performance is linked to the end markets in which our customers operate. Certain of these markets, such as the semiconductor memory markets and the solar panel market, have historically shown significant price volatility as a result of imbalances in supply and demand. As such, these markets have been traditionally challenging for participants. We believe that we manage this end market risk by participating in multiple end markets and by selecting customers that we believe will be successful in those markets.

        Revenue mix and royalty rates.     Our revenue from CDPs and product sales vary from contract to contract depending on the customer's requirements and the scope of the collaboration. The gross profit from CDPs and product sales may vary based on the size and scope of the contract. Our royalty rates vary from contract to contract depending on multiple factors, including the industry, the scope of our collaboration, and the degree to which our IP is central to the development of a given product. Individual royalty opportunities vary depending on the end market size and the duration of the specific end product life cycle. The gross profit from licensing and royalty revenue may vary based on the size and scope of the contract. We target an average gross margin contribution that is consistent across the industries and end markets we serve.

        Long sales cycles.     Our sales cycles are long, and we commit significant resources to and incur significant expenses for a project before a potential customer commits to use our HPC platform or CDPs. To be successful, we must establish contact with potential customers, often with senior management or executive officers, and educate them about the benefits of our HPC platform. Our sales cycles to date have typically ranged from 9 to 24 months and may be even longer in the future. Investment of time and resources in a particular customer engagement that does not ultimately result in material revenue will adversely affect our revenue and results of operations.

        Customer concentration.     Due to the concentrated nature of manufacturers in the DRAM, flash memory and complex logic markets, our revenue is and may continue to be concentrated to key high-volume customers. For example, our four largest customers in the six months ended June 30, 2011, all of which are in the semiconductor industry, accounted for 75% of our revenue. These customers collectively reported $25 billion of semiconductor revenue in 2010, and we believe there is an opportunity to expand our engagements with these customers into new applications over time. In addition, because our platform is broadly applicable to semiconductors, flat glass, solar cells, LEDs, flat-panel displays, advanced batteries and other energy-efficient technologies, we believe we have significant opportunities to engage with a broad range of customers.

        Related Party Transactions.     Some of our customers and other business partners hold a significant stake in our capital stock. Related party transactions disclosed in our financial statements accounted for

49


Table of Contents


$10.4 million and $26.0 million, or 43.5% and 61.0%, respectively, of our revenue for the six months ended June 30, 2011 and the year ended December 31, 2010. ATMI, which beneficially owns approximately 10.6% of our capital stock as of September 1, 2011, accounted for $7.8 million and $22.1 million, or 32.7% and 51.8%, respectively, of our revenue for the six months ended June 30, 2011 and the year ended December 31, 2010. We believe that the transactions and agreements that we have entered into with related parties are on terms that are at least as favorable as could reasonably have been obtained at such time from third parties. However, these relationships could create, or appear to create, potential conflicts of interest when our board of directors is faced with decisions that could have different implications for us and our related parties or their affiliates. In addition, conflicts of interest may arise between us and our related parties and their affiliates. The appearance of conflicts, even if such conflicts do not materialize, might adversely affect the public's perception of us, as well as our relationship with other companies and our ability to enter into new relationships in the future, including new CDPs with competitors of such related parties, which could have a material adverse effect on our ability to do business.

Warrants Issued in Connection with a CDP

        In March 2010, in connection with a CDP, we issued contingent warrants to two customers to purchase an aggregate of up to 1,644,736 shares of our common stock at a cash exercise price of $3.04144 per share. The exercise price was equal to the price of the then-most recent sale of preferred stock. These warrants become exercisable for four months after an election by the holders to license technology developed through the associated CDP. If either of the customers elect to license this technology, we will record a one-time, non-cash charge based on the fair value of these warrants as measured on the date of election against any revenue derived from these agreements. The fair value will be determined using the Black-Scholes option pricing model and may be significant. This election is available to the customers through May 2012 and may be extended for up to an additional two years if the customers extend the CDP.

        In June 2011, in connection with a CDP, we issued a fully vested and exercisable warrant to a customer to purchase 822,000 shares of our common stock at a cash exercise price of $4.15412 per share. The exercise price was equal to the price of the then-most recent sale of preferred stock. The fair value of the warrant as measured on the date of grant using the Black-Scholes options pricing model was $312,000 and was recognized as a reduction of revenue derived from the agreement during the six month period ended June 30, 2011.

Cost of Revenue and Operating Expenses

Cost of Revenue

        The following table sets forth our cost of revenue by revenue category:

 
  Years Ended December 31,   Six Months
Ended June 30,
 
 
  2008   2009   2010   2010   2011  
 
   
   
   
  (unaudited)
 
 
  (in thousands)
 

Cost of revenue:

                               
 

Cost of CDP and services revenue

  $ 9,141   $ 8,849   $ 16,855   $ 6,932   $ 10,533  
 

Cost of product revenue

    3,370     3,972     3,665     1,652     469  
 

Cost of licensing and royalty revenue

    114     197     406     168     321  
                       
   

Total cost of revenue

  $ 12,625   $ 13,018   $ 20,926   $ 8,752   $ 11,323  
                       

        Our cost of revenue is variable and depends on the product mix and type of revenue earned in each period relating to our customer programs. As customers commercialize products that incorporate

50


Table of Contents


technology developed through our CDPs, we expect our cost of revenue to decrease as a percentage of total revenue as licensing and royalty revenue become an increasing component of our revenue.

    Cost of CDP and services revenue.   Our cost of CDP and services revenue is primarily comprised of salaries and other personnel-related expenses (including stock-based compensation) for our collaborative research and development scientists, engineers and development fab process operations employees. Additionally, our cost of revenue includes costs of wafers, targets, materials, program-related supplies and depreciation of equipment used in CDPs.

    Cost of product revenue.   Our cost of product revenue primarily includes our cost of products sold. Our cost of product revenue will fluctuate based on the type of product and configuration sold. Historically, we have not sold a significant number of our workflow products and we do not anticipate selling a significant number in the future. Our cost of product revenue is recognized in a similar manner as the corresponding product revenue and is generally recognized on a straight-line basis over the maintenance period. The variability in cost of product revenue as a percentage of revenue is related to the quantity and configuration of products sold during the period and the corresponding maintenance period that product revenue and cost of product revenue is being recognized.

    Cost of licensing and royalty revenue.   Our cost of licensing and royalty revenue includes license fees paid to Symyx.

Research and Development

        Our R&D expenses consist of costs incurred for development and continuous improvement of our HPC platform, expansion of software capabilities and application research and development that are not associated with customer programs. R&D costs include personnel-related expenses (including stock-based compensation expenses), for our technical staff as well as consultant costs, parts and prototypes, wafers, chemicals, supply costs, facilities costs, utilities costs related to laboratories and offices occupied by technical staff, depreciation on equipment used by technical staff, and outside services, such as machining and third-party R&D costs. Overhead costs that are not allocated to a customer program are recognized as expenses within R&D. We expect our R&D expenses will continue to increase for the foreseeable future as we continue to devote substantial internal resources to develop and improve our HPC platform and extend the applicability of our platform to a broader set of applications within the industries we serve.

Sales and Marketing

        Our sales and marketing expenses consist primarily of personnel-related costs (including stock-based compensation) for our sales and marketing employees, as well as payments of commissions to our sales employees, facility costs and professional expenses. Professional expenses consist of external website and marketing communication consulting costs and market research. We expect that our sales and marketing expenses will continue to increase for the foreseeable future as we increase the number of our sales and marketing employees to support the growth in our business and as we incur external marketing communication costs.

General and Administrative

        General and administrative expenses consist primarily of personnel-related costs (including stock-based compensation) as well as professional services and facilities costs related to our executive, finance, legal, human resources, management information systems and information technology functions. Professional services consist of outside accounting, information technology, consulting and legal costs.

51


Table of Contents

        Following the completion of this offering, we expect to incur significant additional accounting and legal costs related to compliance with rules and regulations enacted by the Securities and Exchange Commission, including the additional costs of achieving and maintaining compliance with Section 404 of the Sarbanes-Oxley Act, as well as additional insurance, investor relations and other costs associated with being a public company. In addition to these expenses, we expect that our general and administrative expenses will continue to increase for the foreseeable future.

Interest Income, net

        Interest income represents interest earned on our cash, cash equivalents and short-term investments. We expect interest income will vary each reporting period depending on our average investment balances during the period and market interest rates.

        Interest expense consists of interest accrued or paid on lines of credit outstanding. We expect interest expense to fluctuate in the future with changes in obligations and market interest rates.

Other Income (Expense), net

        Other income consists of municipal economic development grant proceeds received during the year ended December 31, 2010. Other income (expense), net also consists of the change in fair value of our preferred stock warrants and other income. Our outstanding preferred stock warrant, which was issued in connection with a line of credit, is classified as a liability and is remeasured to fair value at each balance sheet date with the corresponding gain or loss from the adjustment recorded as other income (expense), net. We will continue to record adjustments to the fair value of the preferred stock warrant until it is exercised, automatically converted into a warrant to purchase common stock or expires, at which time the warrant will no longer be remeasured at each balance sheet date.

Provision for Income Taxes

        We are subject to taxes in the United States as well as other tax jurisdictions or countries in which we conduct business. Earnings from our non-U.S. activities are subject to local country income tax and may be subject to current U.S. income tax. To date, we have incurred net losses and have not recorded any U.S. federal income tax benefits as these losses have been offset by valuation allowances. As of December 31, 2010, we had net operating loss carryforwards for federal and state income tax purposes of approximately $17.4 million and $18.5 million, respectively, to offset future taxable income. In addition, we had $2.5 million in U.S. federal R&D credit and $2.5 million in California R&D credit carryforwards to offset future income tax liabilities. Our ability to use our net operating loss carryforwards to offset future taxable income and our ability to use our tax credit carryforwards to offset future income tax liabilities may be subject to certain limitations arising from "ownership changes" within the meaning of Section 382 of the Internal Revenue Code.

52


Table of Contents

Results of Operations

Comparison of the Six Months Ended June 30, 2010 and 2011

 
  Six Months Ended June 30,    
   
 
 
  2010   2011   $ Change   % Change  
 
  (unaudited)
   
   
 
 
  (in thousands)
   
 

Revenue:

                         
 

CDP and services revenue

  $ 9,806   $ 15,820   $ 6,014     61 %
 

Product revenue

    3,300     1,360     (1,940 )   (59 )%
 

Licensing and royalty revenue

    3,386     6,644     3,258     96 %
                     
   

Total revenue

    16,492     23,824     7,332     44 %

Cost of revenue

    8,752     11,323     2,571     29 %
                     
     

Gross profit

    7,740     12,501     4,761     62 %

Operating expenses:

                         
 

Research and development

    6,353     9,488     3,135     49 %
 

Sales and marketing

    1,926     1,980     54     3 %
 

General and administrative

    2,877     3,925     1,048     36 %
                     
   

Total operating expenses

    11,156     15,393     4,237     38 %
                     

Loss from operations

    (3,416 )   (2,892 )   524        

Other income (expense):

                         
 

Interest income, net

    17     10     (7 )      
 

Other income (expense), net

    55     (335 )   (390 )      
                     
   

Total other income (expense), net

    72     (325 )   (397 )      

Loss before provision for income taxes

    (3,344 )   (3,217 )   127        

Provision for income taxes

    2     13     11        
                     

Net loss

  $ (3,346 ) $ (3,230 ) $ 116        
                     

    Revenue

        Our revenue increased by $7.3 million, or 44%, to $23.8 million during the six months ended June 30, 2011 from $16.5 million during the six months ended June 30, 2010. This increase was due to increases in CDP and services revenue and licensing and royalty revenue of $9.2 million which were partially offset by decreases in product revenue of $1.9 million.

        CDP and services revenue increased by $6.0 million, or 61%, to $15.8 million during the six months ended June 30, 2011 from $9.8 million during the six months ended June 30, 2010. This increase was primarily attributable to $3.8 million in revenue derived from new customer engagements, combined with $3.4 million from the expansion of existing customer engagements, offset by a $1.2 million decrease in revenue from the scheduled completion of CDPs. Of the new customer engagements, $2.6 million in revenue was derived from three new CDPs.

        Product revenue decreased by $1.9 million, or 59%, to $1.4 million during the six months ended June 30, 2011 from $3.3 million during the six months ended June 30, 2010. The decrease in product revenue is due to differences in both the type of product sold during each period as well as the length of the corresponding maintenance periods for the respective products for which the revenue was recognized. We have not had any product sales of our workflow hardware that were initiated during 2011.

        Licensing and royalty revenue increased by $3.2 million, or 96%, to $6.6 million during the six months ended June 30, 2011 from $3.4 million during the six months ended June 30, 2010. This

53


Table of Contents


increase was primarily attributable to an increase in sales of products subject to licensing fees and royalties.

        The following table presents revenue by geographic region (based on invoiced locations) during the six months ended June 30, 2011 and 2010 in dollars (in thousands) and as a percentage of revenue for the periods presented:

 
  Six Months Ended June 30,  
 
  2010   2011  
 
  Revenue   % of Revenue   Revenue   % of Revenue  
 
  (unaudited)
 
 
  (in thousands)
   
  (in thousands)
   
 

United States

  $ 11,699     71 % $ 14,886     63 %

Japan

    4,583     28 %   7,468     31 %

Taiwan

        0 %   1,470     6 %

Europe

    210     1 %       0 %
                   
 

Total

  $ 16,492     100 % $ 23,824     100 %
                   

    Cost of Revenue

        Cost of revenue increased by $2.6 million, or 29%, to $11.3 million during the six months ended June 30, 2011 from $8.7 million during the six months ended June 30, 2010. This change is directly attributable to the increased CDP and services revenue we recognized from our new and ongoing customer engagements, which resulted in a $3.6 million increase in direct labor, materials and other costs associated with these programs. Additionally, cost of licensing and royalty revenue increased by $0.2 million directly attributable to increased licensing and royalty revenue. This increase was partially offset by a $1.2 million decrease in cost of product revenue associated with the decrease in product revenue recognized during the period.

        Cost of revenue as a percentage of revenue decreased to 48% during the six months ended June 30, 2011 from 53% during the six months ended June 30, 2010. The decrease in cost of revenue as a percentage of revenue is primarily attributable to the increase in licensing and royalty revenue as a percentage of total revenue and the fact that cost of sales associated with licensing and royalty revenue is lower than cost of sales for CDP and product revenue. To the extent we are successful in growing our revenue and increasing licensing and royalty revenue as a percentage of revenue we expect our cost of revenue as a percentage of total revenue to decline.

    Research and Development

        R&D expenses increased by $3.1 million, or 49%, to $9.5 million during the six months ended June 30, 2011 from $6.4 million during the six months ended June 30, 2010. The change is attributable to $1.1 million in higher personnel costs as a result of increased headcount, $0.8 million increase in facility and occupancy-related costs due to clean room expansion, $0.1 million in parts costs for internal R&D projects, $1.0 million increase in depreciation expense and $0.1 million of higher consulting and professional service fees.

    Sales and Marketing

        Sales and marketing expenses were essentially flat for the six months ended June 30, 2011 compared to the six months ended June 30, 2010.

    General and Administrative

        General and administrative expenses increased by $1.0 million, or 36%, to $3.9 million during the six months ended June 30, 2011 from $2.9 million during the six months ended June 30, 2010. The

54


Table of Contents

increase is primarily attributable to $0.4 million in higher professional fees associated with legal and accounting services and $0.3 million in higher personnel costs as a result of increased headcount.

    Interest Income, net

        Interest income, net was essentially flat for the six months ended June 30, 2011 compared to the six months ended June 30, 2010.

    Loss from Operations

        Our operating loss decreased by $0.5 million, to an operating loss of $2.9 million during the six months ended June 30, 2011 from an operating loss of $3.4 million during the six months ended June 30, 2010. To the extent we are successful in growing our revenue and increasing licensing and royalty revenue as a percentage of our total revenue, and if our expenses increase at a slower rate than our revenue, we expect that our net loss will decrease in the future. Our operating expenses increased by $4.2 million to $15.4 million during the six months ended June 30, 2011 from $11.2 million during the six months ended June 30, 2010. We expect our operating expenses to continue to increase as we expand and invest in our business, making investments in both personnel and capital resources leading to increased depreciation expense.

    Other Income (Expense), net

        Other income (expense) decreased by $0.4 million to $(0.3) million during the six months ended June 30, 2011 from an expense of $0.1 million during the six months ended June 30, 2010. This increase was due to the remeasurement of our preferred stock warrant liability to its current fair value.

    Provision for Income Taxes

        Provision for income taxes as of June 30, 2011 and 2010 consisted of income taxes on our foreign entities and were not significant during either period.

    Net Loss

        Our net loss decreased by $0.1 million, to a net loss of $3.2 million during the six months ended June 30, 2011 from a net loss of $3.3 million during the six months ended June 30, 2010. The increase in net loss from our operating loss during the six months ended June 30, 2011 was primarily attributed to the remeasurement of our preferred stock warrant liability to its current fair value that resulted in an expense of $0.5 million.

55


Table of Contents

Comparison of the Years Ended December 31, 2009 and 2010

 
  Years Ended
December 31,
   
   
 
 
  2009   2010   $ Change   % Change  
 
  (in thousands)
   
 

Revenue:

                         
 

CDP and services revenue

  $ 14,182   $ 27,705   $ 13,523     95 %
 

Product revenue

    9,065     6,959     (2,106 )   (23 )%
 

Licensing and royalty revenue

    3,663     8,010     4,347     119 %
                     
   

Total revenue

    26,910     42,674     15,764     59 %

Cost of revenue

    13,018     20,926     7,908     61 %
                     
     

Gross profit

    13,892     21,748     7,856     57 %

Operating expenses:

                         
 

Research and development

    10,983     13,917     2,934     27 %
 

Sales and marketing

    3,211     4,074     863     27 %
 

General and administrative

    4,867     5,761     894     18 %
                     
   

Total operating expenses

    19,061     23,752     4,691     25 %
                     

Loss from operations

    (5,169 )   (2,004 )   3,165        

Other income (expense):

                         
 

Interest income, net

    (6 )   43     49        
 

Other income (expense), net

    (62 )   202     264        
                     
   

Total other income (expense), net

    (68 )   245     313        

Loss before provision for income taxes

    (5,237 )   (1,759 )   3,478        

Provision for income taxes

    17     19     2        
                     

Net loss

  $ (5,254 ) $ (1,778 ) $ 3,476        
                     

    Revenue

        Our revenue increased by $15.8 million, or 59%, to $42.7 million during the year ended December 31, 2010 from $26.9 million during the year ended December 31, 2009, primarily due to increases in revenue from CDPs and licensing arrangements partially offset by reductions in revenue from product revenue.

        CDP and services revenue increased by $13.5 million, or 95%, to $27.7 million during the year ended December 31, 2010 from $14.2 million during the year ended December 31, 2009. This change is attributable to $10.2 million in revenue derived from three customer engagements, including one for a customer in the clean-energy industry, that commenced during the year ended December 31, 2010. The remaining $3.3 million increase is due to the net effect of expansions of existing CDPs, partially offset by reductions from the scheduled completion of two CDPs.

        Product revenue decreased by $2.1 million, or 23%, to $7.0 million during the year ended December 31, 2010 from $9.1 million during the year ended December 31, 2009. This decrease is primarily attributable to the recognition of revenue during the year ended December 31, 2009 from four workflow platform sales as compared to recognition of revenue during the year ended December 31, 2010 from two workflow platform sales.

        Licensing and royalty revenue increased by $4.3 million, or 119%, to $8.0 million during the year ended December 31, 2010 from $3.7 million during the year ended December 31, 2009. This change is primarily attributable to a $2.5 million increase in licensing fees and royalties from commercialized products and a $1.8 million increase in licensing fees from licenses to the HPC capabilities of our workflows and other technology.

56


Table of Contents

        Revenue to customers in the various geographic regions remained relatively unchanged. The following table presents revenue by geographic region (based on invoiced locations) during the years ended December 31, 2010 and 2009 in dollars and as a percentage of revenue for the periods presented:

 
  Years Ended December 31,  
 
  2009   2010  
 
  Revenue   % of Revenue   Revenue   % of Revenue  
 
  (in thousands)
   
  (in thousands)
   
 

United States

  $ 18,894     70 % $ 29,526     70 %

Japan

    7,906     30 %   12,449     29 %

Taiwan

        0 %   489     1 %

Europe

    110     0 %   210     0 %
                   
 

Total

  $ 26,910     100 % $ 42,674     100 %
                   

    Cost of Revenue

        Cost of revenue increased by $7.9 million, or 61%, to $20.9 million during the year ended December 31, 2010 from $13.0 million during the year ended December 31, 2009. This change is directly attributable to the increased CDP and services revenue during the year ended December 31, 2010 that we recognized from our new and ongoing CDPs, which resulted in a $8.0 million increase in direct labor, materials and other costs associated with these programs, including an increase in licensing fees payable to Symyx in the amount of $0.9 million. Additionally, cost of licensing and royalty revenue increased by $0.2 million directly attributable to increased licensing and royalty revenue. These increases were partially offset by a $0.3 million decrease in direct workflow platform costs due to fewer workflow platform sales during the year ended December 31, 2010.

        Cost of revenue as a percentage of revenue remained consistent with the prior year and was 49% and 48% during the years ended December 31, 2010 and 2009, respectively. To the extent we are successful in growing our revenue and increasing licensing and royalty revenue as a percentage of revenue we expect our cost of revenue as a percentage of total revenue to decline.

    Research and Development

        R&D expenses increased by $2.9 million, or 27%, to $13.9 million during the year ended December 31, 2010 from $11.0 million during the year ended December 31, 2009. The change is attributable to $2.1 million in higher personnel costs as a result of increased headcount, a $1.6 million increase in facility and occupancy-related costs due to clean room expansion, $0.8 million in parts costs for internal R&D projects and $0.3 million of higher consulting and professional service fees. These increases were partially offset by a decrease in R&D expenses due to an increase in the use of equipment for CDPs resulting in an increase in the allocation of expenses to cost of revenue during the year ended December 31, 2010 as compared to the year ended December 31, 2009.

    Sales and Marketing

        Sales and marketing expenses increased by $0.9 million, or 27%, to $4.1 million during the year ended December 31, 2010 from $3.2 million during the year ended December 31, 2009. The change is primarily attributable to $0.5 million in higher personnel costs related to commissions earned on 2010 bookings and collections combined with $0.2 million in higher travel, entertainment and marketing expenses attributable to increased sales and marketing efforts during the year ended December 31, 2010.

57


Table of Contents

    General and Administrative

        General and administrative expenses increased by $0.9 million, or 18%, to $5.8 million during the year ended December 31, 2010 from $4.9 million during the year ended December 31, 2009. The increase is primarily attributable to $0.5 million in higher personnel costs as a result of increased headcount, $0.2 million in higher professional fees, $0.1 million in higher facility and occupancy-related costs and $0.1 million in higher travel and entertainment costs.

    Interest Income, net

        Interest income, net changed by $49,000 to income of $43,000 during the year ended December 31, 2010 from an expense of $6,000 during the year ended December 31, 2009. The change is due primarily to the $0.1 million reduction in interest expense during the year ended December 31, 2010 due to the repayment of our obligations under our amended loan and security agreement which were partially offset by $44,000 of interest income earned on our cash, cash equivalents and short-term investments.

    Loss from Operations

        Our operating loss decreased by $3.2 million, to an operating loss of $2.0 million during the year ended December 31, 2010 from an operating loss of $5.2 million during the year ended December 31, 2009. The decrease in operating loss is related to increased revenue and the composition of that revenue. The increase in licensing and royalty revenue as a percentage of our total revenue and the increase in our operating expenses growing at a slower rate than revenue have resulted in a decrease in our operating loss.

    Other Income (Expense), net

        Other income (expense) increased by $0.3 million to income of $0.2 million during the year ended December 31, 2010 from an expense of $0.1 million during the year ended December 31, 2009. The change was directly attributable to municipal economic development grant proceeds we received during the year ended December 31, 2010.

    Provision for Income Taxes

        The income tax provision for the year ended December 31, 2010 was $19,000 compared to $17,000 for the year ended December 31, 2009. Both amounts consisted of income taxes on our foreign entities and were not significant in either period.

    Net Loss

        Our net loss decreased by $3.5 million, to a net loss of $1.8 million during the year ended December 31, 2010 from a net loss of $5.3 million during the year ended December 31, 2009. The decrease in net loss from our operating loss during the year ended December 31, 2010 was primarily attributed to municipal economic development grant proceeds and interest income we received during the year.

58


Table of Contents

Comparison of the Years Ended December 31, 2008 and 2009

 
  Years Ended
December 31,
   
   
 
 
  2008   2009   $ Change   % Change  
 
  (in thousands)
   
 

Revenue:

                         
 

CDP and services revenue

  $ 14,647   $ 14,182   $ (465 )   (3 )%
 

Product revenue

    6,206     9,065     2,859     46 %
 

Licensing and royalty revenue

    2,276     3,663     1,387     61 %
                     
   

Total revenue

    23,129     26,910     3,781     16 %

Cost of revenue

    12,625     13,018     393     3 %
                     
     

Gross profit

    10,504     13,892     3,388     32 %

Operating expenses:

                         
 

Research and development

    11,849     10,983     (866 )   (7 )%
 

Sales and marketing

    3,849     3,211     (638 )   (17 )%
 

General and administrative

    4,300     4,867     567     13 %
                     
   

Total operating expenses

    19,998     19,061     (937 )   (5 )%
                     

Loss from operations

    (9,494 )   (5,169 )   4,325        

Other income (expense):

                         
 

Interest income, net

    174     (6 )   (180 )      
 

Other income (expense), net

    6     (62 )   (68 )      
                     
   

Total other income (expense), net

    180     (68 )   (248 )      

Loss before provision for income taxes

    (9,314 )   (5,237 )   4,077        

Provision for income taxes

    186     17     (169 )      
                     

Net loss

  $ (9,500 ) $ (5,254 ) $ 4,246        
                     

    Revenue

        Our revenue increased by $3.8 million, or 16%, to $26.9 million during the year ended December 31, 2009 from $23.1 million during the year ended December 31, 2008 primarily due to increases in product revenue and licensing and royalty revenue offset by a reduction in revenue from ongoing CDPs.

        CDP and services revenue decreased by $0.5 million, or 3%, to $14.2 million during the year ended December 31, 2009 from $14.6 million during the year ended December 31, 2008. The change is primarily due to a decrease in revenue of $4.0 million from the scheduled completion of CDPs, offset by a $3.5 million increase in revenue from the expansion of existing CDPs.

        Product revenue increased by $2.9 million, or 46%, to $9.1 million during the year ended December 31, 2009 from $6.2 million during the year ended December 31, 2008. The increase in revenue during the year ended December 31, 2009 is primarily attributable to the recognition of revenue during the year ended December 31, 2008 from two workflow platform sales as compared to the recognition of revenue during the year ended December 31, 2009 from two previous and two additional workflow platform sales.

        Licensing and royalty revenue increased by $1.4 million, or 61%, to $3.7 million during the year ended December 31, 2009 from $2.3 million during the year ended December 31, 2008. This change is primarily attributable to a $0.5 million increase in licensing and royalty fees from commercialized products and a $0.9 million increase in licensing fees from licenses to the HPC capabilities of our workflows.

59


Table of Contents

        Revenue from customers in the various geographic regions (based on invoiced locations) remained relatively unchanged. The following table presents revenue by geographic region during the years ended December 31, 2008 and 2009 in dollars and as a percentage of revenue for the periods presented:

 
  Years Ended December 31,  
 
  2008   2009  
 
  Revenue   % of Revenue   Revenue   % of Revenue  
 
  (in thousands)
   
  (in thousands)
   
 

United States

  $ 16,522     72 % $ 18,894     70 %

Japan

    6,267     27 %   7,906     30 %

Taiwan

    90     0 %       0 %

Europe

    250     1 %   110     0 %
                   
 

Total

  $ 23,129     100 % $ 26,910     100 %
                   

    Cost of Revenue

        Cost of revenue increased by $0.4 million, or 3%, to $13.0 million during the year ended December 31, 2009 from $12.6 million during the year ended December 31, 2008. The increase is directly attributable to the increase in product revenue during the year ended December 31, 2009, which resulted in a $0.6 million increase in direct workflow platform costs, including an increase in licensing fees payable to Symyx in the amount of $0.1 million. Additionally, cost of licensing and royalty revenue increased by $0.1 million directly attributable to increased licensing and royalty revenue. These increases were partially offset by a $0.3 million reduction in direct labor, materials and other costs associated with our ongoing CDPs due to the reduction in services revenue during the year ended December 31, 2009.

    Research and Development

        R&D expenses decreased by $0.9 million, or 7%, to $11.0 million during the year ended December 31, 2009 from $11.8 million during the year ended December 31, 2008. The decrease is attributable to a $1.1 million decrease in personnel costs, $0.7 million reduction in parts costs for internal R&D programs and $0.3 million reduction in consulting and professional service fees due to R&D personnel being used for ongoing CDPs during the year ended December 31, 2009 as compared to being used during the year ended December 31, 2008 for internal R&D projects. These decreases were partially offset by an increase in facility and occupancy-related expenses and an increase in R&D expenses due to a reduction in the use of equipment for CDPs resulting in a decrease in the allocation of expenses to cost of revenue during the year ended December 31, 2009 as compared to the year ended December 31, 2008.

    Sales and Marketing

        Sales and marketing expenses decreased by $0.6 million, or 17%, to $3.2 million during the year ended December 31, 2009 from $3.8 million during the year ended December 31, 2008. The decrease is attributable to a $0.3 million decrease in personnel costs related to staff turnover and reduced commission expense and $0.3 million decrease in travel, entertainment and marketing expenses.

    General and Administrative

        General and administrative expenses increased by $0.6 million, or 13%, to $4.9 million during the year ended December 31, 2009 from $4.3 million during the year ended December 31, 2008. The increase is attributable to $0.3 million in higher facility and occupancy-related costs, $0.2 million in higher personnel costs due to changes in headcount and $0.1 million in higher consulting and professional services costs.

60


Table of Contents

    Interest Income, net

        Interest income, net decreased by $0.2 million to an expense of $6,000 during the year ended December 31, 2009 from $0.2 million during the year ended December 31, 2008. The change is attributable to a $0.5 million reduction in interest income combined with a $0.3 million reduction in interest expense. The decrease in interest income is attributable to lower average cash, cash equivalents and short-term investments on hand during the year ended December 31, 2009 compared to the year ended December 31, 2008 as we used the proceeds received from our Series D convertible preferred stock financing during the year ended December 31, 2008 for capital expenditures and principal repayments on our debt obligations during the year ended December 31, 2009. The decrease in interest expense is attributable to the repayment of our obligations under our amended loan and security agreement in February 2009.

    Loss from Operations

        Our operating loss decreased by $4.3 million, to an operating loss of $5.2 million during the year ended December 31, 2009 from an operating loss of $9.5 million during the year ended December 31, 2008. The decrease in operating loss is related to increased product and licensing and royalty revenue. The increase in revenue combined with the overall decline in operating expense has resulted in a decrease in our operating loss during the year ended December 31, 2009.

    Other Income (Expense), net

        Other income (expense) decreased by $0.1 million to an expense of $0.1 million during the year ended December 31, 2009 from income of $6,000 during the year ended December 31, 2008. The change is not significant.

    Provision for Income Taxes

        The tax provision for the year ended December 31, 2009 of $17,000 consisted of $13,000 in foreign income taxes on our foreign entities and $4,000 in state income taxes. The tax provision for the year ended December 31, 2008 of $186,000 consisted of $11,000 in income taxes on our foreign entities and $175,000 in state income taxes.

    Net Loss

        Our net loss was essentially the same as our loss from operations for the years ended December 31, 2009 and December 31, 2008.

Liquidity and Capital Resources

        To date, we have substantially satisfied our capital and liquidity needs through private placements of redeemable convertible preferred stock and, to a lesser extent, cash flow from operations. As of June 30, 2011, we had $35.6 million of cash, cash equivalents and short-term investments and $23.9 million of net working capital. During the six months ended June 30, 2011, we closed a private placement of our Series E redeemable convertible preferred stock for $24.9 million in net proceeds. As of June 30, 2011, we had no debt outstanding under our amended loan and security agreement or any other debt instruments and had access to advances of $10.0 million under the amended loan and security agreement.

        To date, we have incurred significant losses. During the six months ended June 30, 2011 and 2010 and the years ended December 31, 2010, 2009 and 2008, we incurred net losses of $3.2 million, $3.3 million, $1.8 million, $5.3 million and $9.5 million. As of June 30, 2011, our accumulated deficit was $73.2 million.

        We have experienced positive cash flows from operations during the years ended December 31, 2010, 2009 and 2008. We may continue to generate positive cash flows from operations on an annual

61


Table of Contents


basis, although this may fluctuate significantly on a quarterly basis. As such, we believe that our existing sources of liquidity will be sufficient to fund our operations for at least the next 12 months. Our future capital requirements will depend on many factors, including our rate of revenue growth, the expansion of our sales and marketing activities, the timing and extent of our spending to support our R&D efforts and our ability to expand CDPs in the semiconductor industry, resulting from the adoption of our HPC platform for technology development, and our ability to engage in CDPs with companies in the clean-energy industry. To the extent that existing cash and cash equivalents and cash from operations are insufficient to fund our future activities, we may need to raise additional funds through public or private equity or debt financing. We may also seek to invest in or acquire complementary businesses, applications or technologies, any of which could also require us to seek additional equity or debt financing. Additional funds may not be available on terms favorable to us or at all.

Cash Flows

        The following summary of our cash flows for the periods indicated has been derived from our consolidated financial statements included elsewhere in this prospectus:

 
  Years Ended December 31,   Six Months Ended
June 30,
 
 
  2008   2009   2010   2010   2011  
 
   
   
   
  (unaudited)
 
 
  (in thousands)
 

Net cash provided by (used in) operating activities

  $ 981   $ 1,088   $ 1,175   $ (4,977 ) $ (5,985 )

Net cash (used in) provided by investing activities

  $ (8,162 ) $ (16,708 ) $ 924   $ 3,302   $ (7,282 )

Net cash provided by (used in) financing activities

  $ 21,339   $ (4,426 ) $ 109   $ 56   $ 25,083  

Cash Flows from Operating Activities

        We have experienced positive cash flows from operating activities during each of the years ended December 31, 2010, 2009 and 2008 including the receipt of advance payments from CDPs, product sales and licensing and royalty fees.

        Net cash used in operating activities during the six months ended June 30, 2011 was primarily attributable to our net loss of $3.2 million and non-cash charges of $3.5 million of depreciation and amortization and $1.0 million in stock-based compensation, and $0.8 million related to both common and preferred stock warrant charges. The net decline in cash flow from our operating assets and liabilities of $(8.0) million was primarily as a result of a $8.3 million reduction in deferred revenue, and a $0.7 million decrease in accounts payable, offset by an increase in accrued and other liabilities of $1.1 million.

        Net cash provided by operating activities during the year ended December 31, 2010 of $1.2 million reflects the net loss of $1.8 million and non-cash charges of $5.0 million for depreciation and amortization and $1.4 million for stock-based compensation. The net change in our operating assets and liabilities of $(3.4) million was primarily a result of a $0.8 million increase in inventory, a $2.9 million increase in accounts receivable and a $4.5 million decrease in deferred revenue which were partially offset by a $3.3 million increase in accounts payable and accrued expenses.

        Net cash provided by operating activities during the year ended December 31, 2009 of $1.1 million reflects the net loss of $5.3 million and non-cash charges of $4.4 million for depreciation and amortization and $1.1 million for stock-based compensation. The net change in our operating assets and liabilities of $0.8 million was primarily the result of a $0.5 million decrease in deferred revenue which was partially offset by $1.6 million in our prepaid expenses and other assets, inventory and accounts receivable balances.

62


Table of Contents

        Net cash provided by operating activities during the year ended December 31, 2008 of $1.0 million reflects the net loss of $9.5 million and non-cash charges which consist of $3.4 million for depreciation and amortization and $0.9 million for stock-based compensation. The net change in our operating assets and liabilities of $6.1 million was primarily due to an advance royalty payment in the amount of $10.0 million that will be earned through 2012 that resulted in a net increase in deferred revenue of $9.5 million, which was partially offset by a $3.9 million increase in prepaid expenses and other assets, inventory and accounts receivable balances.

Cash Flows from Investing Activities

        Our investing activities consist primarily of purchases and sales of short-term investments, capital expenditures to purchase property and equipment and our investments in intangible assets relating to our patents and trademarks. In the future, we expect we will continue to make significant capital expenditures to support our expanding operations and incur costs to protect our investment in our developed technology and IP.

        During the six months ended June 30, 2011, cash used in investing activities was $7.3 million as a result of $6.2 million in capital expenditures, $0.8 million in the purchase of short-term investments and $0.3 million in capitalized patent and trademark costs.

        During the year ended December 31, 2010, cash provided by investing activities of $0.9 million was primarily attributable to the $11.8 million in net proceeds received from the sale of our investments which were partially offset by $10.5 million of capital expenditures and $0.3 million in capitalized intangible asset costs. These capital expenditures were incurred as a result of us relocating our operations during the year ended December 31, 2010 to a new facility to support our expanding operations, as well as to prepare for new business programs requiring additional equipment.

        During the year ended December 31, 2009, cash used in investing activities of $16.7 million was due to $11.8 million for the purchase of investments, $4.8 million in capital expenditures relating to the acquisition of lab equipment and machinery and $0.1 million in capitalized intangible asset costs.

        During the year ended December 31, 2008, cash used in investing activities of $8.2 million was attributable to $7.6 million in capital expenditures and $0.5 million in capitalized intangible asset costs.

Cash Flows from Financing Activities

        To date, we have financed our operations primarily with proceeds from the sale of our redeemable convertible preferred stock.

        During the six months ended June 30, 2011, cash provided by financing activities was $25.1 million, primarily as a result of the receipt of $24.9 million in net proceeds from the sale of our Series E redeemable convertible preferred stock in March and June 2011.

        During the year ended December 31, 2010, cash provided by financing activities was $0.1 million which consisted of proceeds received from the exercise of stock options.

        During the year ended December 31, 2009, cash used in financing activities was $4.4 million, primarily as a result of us paying off our outstanding loan balances under our amended loan and security agreement.

        During the year ended December 31, 2008, cash provided by financing activities was $21.3 million primarily due to the receipt of $19.9 million in net proceeds from the sale of our Series D redeemable convertible preferred stock combined with $3.0 million in proceeds from borrowings under our amended loan and security agreement in May 2008 which were partially offset by principal repayments on our debt obligations of $1.7 million.

63


Table of Contents

Contractual Obligations

        The following summarizes our contractual obligations as of December 31, 2010:

 
  Payments Due by Period  
 
  2011   2012   2013   2014   2015   Total  
 
  (in thousands)
 

Contractual Obligations:

                                     

Operating lease obligations

  $ 1,550   $ 1,573   $ 1,657   $ 1,707   $ 728   $ 7,215  
                           

Total

  $ 1,550   $ 1,573   $ 1,657   $ 1,707   $ 728   $ 7,215  
                           

        Operating lease agreements represent our obligations to make payments under our non-cancelable lease agreements for our facilities in San Jose, California. During the six months ended June 30, 2011, we made regular lease payments of $681,000 under the operating lease agreements.

Off-Balance Sheet Arrangements

        Through June 30, 2011, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

Segment Information

        We have one business activity, which is to develop and apply high productivity combinatorial R&D technologies. Although we track revenue earned from customers in the semiconductor and clean-energy industries, we do not currently track and maintain discrete financial information, including operating margins for these industry sectors. As such, we are a single reporting and operating unit structure.

Quantitative and Qualitative Disclosures about Market Risk

        We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in interest rates and foreign currency exchange rates. We do not hold or issue financial instruments for trading purposes.

Interest Rate Sensitivity

        Our exposure to market risk for changes in interest rates relates primarily to our investment portfolio and our outstanding debt obligations. Our cash, cash equivalents and investment accounts as of June 30, 2011 total $35.6 million, consisting primarily of cash, money market funds and certificates of deposit with maturities of less than one year from the date of purchase. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of the interest rates in the United States. However, because of the short-term nature of the instruments in our portfolio, a sudden change in market interest rates would not be expected to have a material impact on our consolidated financial condition or our results of operation.

        We have no long-term debt outstanding as of June 30, 2011 under our amended loan and security agreement. Our obligations under this debt agreement carry interest rates that are fixed and are not subject to fluctuations. However, in the future, to the extent we enter into other long-term debt arrangements, we would be subject to fluctuations in interest rates which could have a material impact on our future financial condition and results of operation.

Foreign Currency Exchange Risk

        As we expand internationally, our consolidated results of operations and cash flows will become increasingly subject to fluctuations due to changes in foreign currency exchange rates. Our revenue is

64


Table of Contents


denominated in U.S. dollars. Our expenses are generally denominated in the currencies in which our operations are located, which is primarily in the United States, with an insignificant portion of expenses incurred in our wholly-owned subsidiaries in Hong Kong and Japan and our wholly-owned branch in Taiwan in their local currencies. The effect of a hypothetical 10% change in foreign currency exchanges rates applicable to our business would not have a material impact on our consolidated financial statements. To date, we have not entered into any material foreign currency hedging contracts although we may do so in the future.

Critical Accounting Policies and Estimates

        Our consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States and include our accounts and the accounts of our wholly-owned subsidiaries. The preparation of our consolidated financial statements requires our management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosures for contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the applicable periods. Management bases its estimates, assumptions and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances. Different assumptions and judgments would change the estimates used in the preparation of our consolidated financial statements which, in turn, could change the results from those reported. Our management evaluates its estimates, assumptions and judgments on an ongoing basis.

        The critical accounting policies requiring estimates, assumptions and judgments that we believe have the most significant impact on our consolidated financial statements are described below.

Revenue Recognition

        We generate revenue from three principal sources: CDPs and other services, which also includes other R&D services and product maintenance and support; product sales; and technology licensing and royalty fees. It is possible for our customers to work with us across multiple areas of our business, and certain of our customer arrangements involve the delivery or performance of multiple products, services or licenses. For example, product sale arrangements include product maintenance and support, and CDPs and other R&D services include licensing of technology and may also include sales of products. When there are multiple elements of deliverables in a contract entered into or modified on or prior to December 31, 2010, we identify all deliverables and allocate revenue among all of the undelivered elements, which might include CDP and other services revenue, product revenue and licensing and royalty revenue, based on objective and reliable evidence of fair value for any such element. In the event that vendor-specific objective evidence does not exist, revenue will be recognized over the term of the agreement and will be allocated among the deliverables based on the relative stated invoice price for the elements. In an arrangement that includes software that is more than incidental to the products or services as a whole, we recognize revenue from the software and software-related elements, as well as any non-software deliverable(s) for which a software deliverable is essential to its functionality, in accordance with the authoritative guidance on software revenue recognition.

        CDP and services revenue.     We enter into CDPs with customers under which we conduct R&D activities jointly with the customer. These agreements specify minimum levels of research effort required to be performed by us. Payments received under the agreements are not refundable if the research effort is not successful. Historically, we have not provided any refunds under these arrangements.

        We retain rights to certain elements of technology developed during the course of performance, which the customer has an option to license in the future under the terms defined in the agreement. We typically recognize revenue from these arrangements on a time and materials basis. Most arrangements with customers have fixed monthly fees and requirements to provide regular reporting of

65


Table of Contents


R&D activities performed. Payments received prior to performance are deferred and recognized as revenue when earned over future performance periods.

        Product maintenance and support services revenue is included in CDP and services revenue. These services entitle customers to receive product updates and enhancements or technical support and maintenance, depending on the offering. The related revenue is recognized ratably over the period the services are delivered. We do not have vendor-specific objective evidence of selling price for our product maintenance and support services.

        Product revenue.     We recognize revenue from the sale of products generally on a straight line basis over the maintenance period once delivery has occurred (title and risk of loss have passed to the customer), and customer acceptance, if required, has been achieved. We have determined that the software included with its equipment products is more than incidental to the product as a whole. We do not have vendor-specific objective evidence of selling price for our products.

        Licensing and royalty revenue.     We recognize revenue for licenses to IP when earned pursuant to the terms of the agreements. Time-based license revenue is recognized ratably over the license term. License and royalty revenue that becomes triggered by specific customer actions, such as exercise of a license option or by sales volume, is recognized when they occur based on royalty reports or other information received from the licensee, generally one quarter in arrears. Minimum and prepaid royalties and license fees are recognized ratably over the related periods.

        In October 2009, the Financial Accounting Standards Board (FASB) issued a new accounting standard which excludes from the scope of software revenue guidance the revenue arrangements which include tangible products that contain software components and non-software components that function together to deliver the tangible product's essential functionality. At the same time, the FASB also issued another accounting standard which changes the requirements for establishing separate units of accounting in a multiple-element arrangement and requires the allocation of arrangement consideration to each deliverable to be based on its relative selling price. The new standards are effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010. We adopted the new standards commencing on January 1, 2011 and therefore will apply such standards against all arrangements entered into or modified on or after January 1, 2011. The adoption did not have an impact on our consolidated financial condition, operating revenue, results of operations or cash flows for the six month period ended June 30, 2011 as there were no multiple-element arrangements that originated during the period. The adoption of this standard may impact future revenue recognition for multiple-element arrangements where product maintenance and support and time-based licenses are the only undelivered elements. The impact of adopting these provisions will result in more product revenue recognized in earlier periods than would otherwise have been the case prior to adoption, as we allocate revenue using the relative selling price method as opposed to recognizing all revenue from the arrangement ratably over the longer of the product maintenance and support term or license period.

Stock-Based Compensation

        We recognize compensation costs related to stock options and shares of restricted stock granted to employees based on the estimated fair value of the awards on the date of grant, net of estimated forfeitures. We estimate the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards.

66


Table of Contents

        The fair value of the awards granted during the six months ended June 30, 2011 and 2010 and the years ended December 31, 2010, 2009 and 2008 was calculated using the Black-Scholes option valuation model with the following weighted-average assumptions:

 
  Years Ended
December 31,
  Six Months
Ended
June 30,
 
 
  2008   2009   2010   2010   2011  
 
   
   
   
  (unaudited)
 

Expected term (in years)

    6.0     6.0     6.0     6.0     6.0  

Risk-free interest rate

    3.3 %   2.5 %   2.2 %   2.7 %   2.4 %

Expected volatility

    55 %   55 %   55 %   55 %   57 %

Expected dividend rate

    0 %   0 %   0 %   0 %   0 %

        The Black-Scholes model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the expected term and the price volatility of the underlying stock. These assumptions include:

    Expected Term.     The expected term represents the period that the stock-based awards are expected to be outstanding. For option grants that are considered to be "plain vanilla," we used the simplified method to determine the expected term as provided by the SEC. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.

    Expected Volatility.     The expected volatility is derived from historical volatilities of several unrelated, publicly listed peer companies over a period approximately equal to the expected term of the award because we have limited information on the volatility of our common stock since we have no trading history. When making the selections of our industry peer companies to be used in the volatility calculation, we considered the size, operational and economic similarities to our principal business operations.

    Expected Dividend Rate.     The expected dividend rate was assumed to be zero as we have never paid dividends and have no current plans to do so.

    Risk-Free Interest Rate.     The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term of the awards.

        In addition to the assumptions used in the Black-Scholes option-pricing model, we must also estimate a forfeiture rate to calculate the stock-based compensation for our awards. Our forfeiture rate is based on an analysis of our actual forfeitures. We will continue to evaluate the appropriateness of the forfeiture rate based on actual forfeiture experience, analysis of employee turnover and other factors. Quarterly changes in the estimated forfeiture rate can have a significant impact on our stock-based compensation expense as the cumulative effect of adjusting the rate is recognized in the period the forfeiture estimate is changed. If a revised forfeiture rate is higher than the previously estimated forfeiture rate, an adjustment is made that will result in a decrease to the stock-based compensation expense recognized in the financial statements. If a revised forfeiture rate is lower than the previously estimated forfeiture rate, an adjustment is made that will result in an increase to the stock-based compensation expense recognized in the financial statements.

        We will continue to use judgment in evaluating the expected volatility, expected terms and forfeiture rates utilized for our stock-based compensation calculations on a prospective basis. As we continue to accumulate additional data related to our common stock and stock option exercises, we may have refinements to the estimates of our expected volatility, expected terms and forfeiture rates, which could materially impact our future stock-based compensation expense.

67


Table of Contents

        We are also required to estimate the fair value of the common stock underlying our stock-based awards when performing the fair value calculations with the Black-Scholes option-pricing model. The fair value of the common stock underlying our stock-based awards was estimated on each grant date by our board of directors, with input from management. Our board of directors is comprised of a majority of non-employee directors with significant experience in the semiconductor industry. We believe that our board of directors has the relevant experience and expertise to determine a fair value of our common stock on each respective grant date. Given the absence of a public trading market of our common stock, and in accordance with the American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation , our board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of our common stock including:

    contemporaneous valuations performed by unrelated third party specialists;

    prices for our convertible preferred stock sold to outside investors in arm's-length transactions;

    the rights, preferences and privileges of our convertible preferred stock relative to those of our common stock;

    actual operating and financial performance;

    the likelihood of achieving a liquidity event, such as an initial public offering or a sale of our company given prevailing market conditions and the nature and history of our business;

    illiquidity of stock-based awards involving securities in a private company;

    industry information such as market size and growth; and

    macroeconomic conditions.

        In valuing our common stock, the board of directors considered contemporaneous valuations, which determined the equity value of our business by taking a weighted combination of the value indications under two valuation approaches, an income approach and a market approach. The income approach estimates the present value of future estimated cash flows, based upon forecasted revenue and costs. These future cash flows are discounted to their present values using a discount rate which is derived from an analysis of the cost of capital of comparable publicly traded companies in the same industry or similar lines of business as of each valuation date and is adjusted to reflect the risks inherent in the projected cash flows. The market approach estimates the fair value of a company by applying market multiples of comparable publicly traded companies in the same industry or similar lines of business which are based on key metrics implied by the enterprise values or acquisition values of the comparable publicly traded companies.

        The results of the income approach and the market approach were then weighted evenly to determine the fair value of our business. This fair value was then allocated to each of our classes of stock using the Probability Weighted Expected Return Method (PWERM).

        The PWERM involves a forward-looking analysis of the possible future outcomes of the business. This method is particularly useful when discrete future outcomes can be predicted at a high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM included non-initial public offering (IPO) market-based outcomes as well as IPO scenarios. In the non-IPO scenarios, a large portion of the equity value is allocated to the convertible preferred stock to incorporate higher aggregate liquidation preferences. In the IPO scenarios, the equity value is allocated pro rata among the shares of common stock and each series of convertible preferred stock, which causes the common stock to have a higher relative value per share than under the non-IPO scenario. The fair value of the enterprise determined using the IPO and non-IPO scenarios will be weighted according to the board of directors' estimate of the probability of each scenario. The Black-Scholes option-pricing model incorporates various subjective assumptions, including expected volatility, expected term, and the risk-free interest rates, as well as the fair value of the common stock on the grant date as

68


Table of Contents


determined by management. These input factors are subjective and are determined using management's judgment. If a difference arises between the assumptions used in determining stock-based compensation expense and the actual factors that become known over time, we may change the input factors used in determining future stock-based compensation expense. Any such changes could materially impact our results of operations in the period in which the changes are made and in periods thereafter.

        Information regarding stock option grants to our employees since January 1, 2010 is summarized as follows:

Grant Date
  Number of
Options Granted
  Exercise Price   Fair Value Per
Share of Common
Stock
  Intrinsic Value
Per Share
 

February 4, 2010

    1,986,250   $ 1.33   $ 1.33      

March 2, 2010

    52,000     1.33     1.33      

May 4, 2010

    67,500     1.33     1.33      

June 25, 2010

    43,500     1.33     1.33      

August 19, 2010

    594,000     1.33     1.33      

December 14, 2010

    416,500     1.70     1.70      

March 31, 2011

    1,236,500     3.10     3.10      

April 27, 2011

    261,000     3.10     3.10      

May 20, 2011

    282,000     3.10     3.10      

June 6, 2011

    662,500     3.10     3.36 * $ 0.26  

June 24, 2011

    58,000     3.10     4.15 *   1.05  

*
We reassessed the fair value of our common stock subsequent to the grant date of these options. The intrinsic value per share represents the difference between the exercise price, which was the original fair value determination made by our board on the date of option grant, and the assessed fair value applied retrospectively for accounting purposes.

        Other than as discussed in the section entitled "Grants Made on June 6, 2011 and June 24, 2011," no single event caused the valuation of our common stock to increase or decrease through June 30, 2011. Instead, a combination of the factors described below in each period led to the changes in the fair value of the underlying common stock.

    Grants Made between February 4, 2010 and August 19, 2010

        On February 4, 2010, the board determined the fair value of the common stock to be between $1.30 and $1.35 per share based on a number of factors, including its review of a contemporaneous valuation analysis conducted as of December 31, 2009. This contemporaneous valuation was prepared on a minority, non-marketable interest basis assuming we were in the Expansion stage of our development. The contemporaneous valuation weighted the income approach and market approach equally to determine the fair value of our business.

        The weightings assigned to each scenario in the PWERM analysis contained in the contemporaneous valuation analysis as of December 31, 2009 were as follows:

IPO

  25.0 - 30.0%

Strategic Merger or Sale

  25.0 - 30.0%

Remain Private Company

  45.0 - 37.5%

Liquidation

  5.0 -    2.5%

        The IPO, Sale and Remaining Private scenarios were discounted to present value using a discount rate of 30% and a holding period between two and four years. The liquidation scenario assumes the business was dissolved and, therefore, no value was assigned to this scenario.

69


Table of Contents

        During the period between the February 2010 and August 2010 valuations, we granted 1,986,250 options on February 4, 2010, 52,000 options on March 2, 2010, 67,500 options on May 4, 2010, 43,500 options on June 25, 2010 and 594,000 options on August 19, 2010. All of the options granted during this period were assigned an exercise price of $1.33 per share, which the board determined to be the fair value based on many factors, including its review of the contemporaneous valuation conducted as of December 31, 2009, which valued the common stock at a range of fair values of $1.30 to $1.35 per share, and based on its determination that there were no events in the period between the date of each of the option grants and the date of the contemporaneous valuation that would result in a change to the fair value of the underlying common stock.

    Grants Made on December 14, 2010

        On December 14, 2010, the board determined a fair value of the common stock to be between $1.65 and $1.75 per share based on a number of factors, including its review of a contemporaneous valuation analysis conducted as of October 31, 2010. This contemporaneous valuation was prepared on a minority, non-marketable interest basis assuming we were in the Expansion stage of our development. The contemporaneous valuation weighted the income approach and market approach equally to determine the fair value of our business.

        The weightings assigned to each scenario in the PWERM analysis contained in the contemporaneous valuation analysis as of October 31, 2010 were as follows:

IPO

  30.0 - 35.0%

Strategic Merger or Sale

  30.0 - 35.0%

Remain Private Company

  35.0 - 27.5%

Liquidation

  5.0 -    2.5%

        The IPO, Sale and Remaining Private scenarios were discounted to present value using a discount rate of 28% and a holding period between two and three years. The liquidation scenario assumes the business was dissolved and, therefore, no value was assigned to this scenario.

        We granted 416,500 options on December 14, 2010 with an exercise price of $1.70, which the board determined to be the fair value based on many factors, including its review of the contemporaneous valuation conducted as of October 31, 2010, which valued the common stock at a range of fair values of $1.65 to $1.75 per share, and based on its determination that there were no events in the period between the date of the option grant and the date of the contemporaneous valuation that would result in a change to the fair value of the underlying common stock.

        No single event caused the valuation of the common stock to increase from August 2010 to December 2010; rather it was a combination of factors. This increase in value reflects a number of milestones attained between valuation dates related to new CDPs entered into during the period or the extension of existing CDPs. The increase is also consistent with the stock price movement associated with the guideline companies as well as various market indices from December 31, 2009 to October 31, 2010.

    Grants Made between March 31, 2011 and May 20, 2011

        On March 31, 2011, the board determined a fair value of the common stock to be between $3.00 and $3.20 per share based on a number of factors, including its review of a contemporaneous valuation analysis conducted as of March 4, 2011. This contemporaneous valuation was prepared on a minority, non-marketable interest basis assuming we were in the Expansion stage of our development. The contemporaneous valuation weighted the income approach and market approach equally to determine the fair value of our business.

70


Table of Contents

        The weightings assigned to each scenario in the PWERM analysis contained in the contemporaneous valuation as of March 4, 2011 were as follows:

IPO

  50.0 - 55.0%

Strategic Merger or Sale

  25.0 - 30.0%

Remain Private Company

  22.5 - 15.0%

Liquidation

  2.5 -    0.0%

        The IPO, Sale and Remaining Private scenarios were discounted to present value using a discount rate of 40% and an 18-month holding period. The liquidation scenario assumes the business was dissolved and, therefore, no value was assigned to this scenario. The discount rate is derived from an analysis of the cost of capital of comparable publicly-traded companies in the same industry or similar lines of business and is adjusted to reflect the risks inherent in the projected cash flows. The increase in the discount rate from the October 2010 valuation to the March 2011 valuation reflects the increased risk of achieving our updated projected financial results which, in the March 2011 valuation, assumed a much greater success rate for certain developed technology to move into customer manufacturing on existing and prospective projects, thereby, increasing the projected financial results and the related risk of achieving the higher results. Accordingly, the discount rate was increased to reflect these increased risks.

        We granted 1,779,500 options between March 31, 2011 and May 20, 2011 with an exercise price of $3.10 per share, which the board determined to be the fair value based on many factors, including its review of the contemporaneous valuation conducted as of March 4, 2011, which valued the common stock at a range of fair values of $3.00 to $3.20 per share, and based on its determination that there were no events in the period between the date of the contemporaneous valuation and May 20, 2011 that would result in a change to the fair value of the underlying common stock on each grant date.

        Similar to the change in fair value between the August 2010 and December 2010 valuations, no single event caused the valuation of the common stock to increase for this period; rather it was a combination of factors. This increase in value reflects the much higher growth and profit potential of our business. In addition, our board substantially increased the probability of an IPO exit from 30-35% to 50-55%, which assumes a conversion of the preferred stock and minimizes the value of the preferred stock liquidation preferences, and thus, increases the common stock value and its relative value to the preferred stock. The IPO probability was increased given higher revenue forecast and greater visibility of future earnings. As of the date of this valuation, and continuing through May 20, 2011, we had not yet had any formal meetings with potential underwriters about an IPO but were beginning to have preliminary and other informal discussions on the matter.

        The value increase also reflects the newly extended CDPs, the raising of the Series E preferred stock financing in March 2011 in which we raised $15.0 million through the sale of 3,610,873 preferred shares for $4.15 per share, as well as our boards' optimism with respect to the royalty element with each customer engagement. As a result, our board increased its projected net cash flows, revenue and operating profits during the later years of our projections. In addition, the revenue multiples used in the market approach were increased from 3.5x to 4.0x. The increase in value is also consistent with the stock price movement associated with the guideline companies as well as various market indices from October 31, 2010 to March 4, 2011.

    Grants Made on June 6, 2011 and June 24, 2011

        On June 6, 2011 and June 24, 2011, we granted 662,500 and 58,000 options, respectively, with an exercise price of $3.10 per share. All options granted by our board were intended to be exercisable at the fair value of our stock at the time of grant, based on information known at that time.

        On August 25, 2011, our board determined a fair value of our common stock to be between $5.90 and $6.05 per share based on a number of factors, including its review of a contemporaneous valuation

71


Table of Contents


analysis conducted as of August 5, 2011. This contemporaneous valuation was prepared on a minority, non-marketable interest basis assuming we were in the Expansion stage of our development. The contemporaneous valuation weighted the income approach and market approach equally to determine the fair value of our business.

        The weightings assigned to each scenario in the PWERM analysis contained in the contemporaneous valuation as of August 5, 2011 were as follows:

IPO

  70.0 - 75.0%

Strategic Merger or Sale

  10.0 - 15.0%

Remain Private Company

  20.0 - 10.0%

Liquidation

  0.0 - 0.0%

        The IPO, Sale and Remaining Private scenarios were discounted to present value using a discount rate of 18% and a 9-month holding period. The liquidation scenario assumes the business was dissolved and, therefore, no value was assigned to this scenario. The increase in probability weighting for an IPO is related to the filing of our registration statement on July 29, 2011, increasing the likelihood of the IPO outcome and increasing the corresponding value of a Strategic Merger or Sale as the value ascribed to a Strategic Merger or Sale scenario assumes a premium over the estimated IPO value. The discount rate is derived from an analysis of the cost of capital of comparable publicly-traded companies in the same industry or similar lines of business and is adjusted to reflect the risks inherent in the projected cash flows. The decrease in the discount rate from the March 2011 valuation is related to a reduction in the risk of our achieving our estimated future cash flows primarily as a result of our entering a multi-year CDP with a key strategic customer on June 1, 2011. This effectiveness of a multi-year CDP on June 1, 2011 increased backlog as of June 30, 2011 by approximately 90%.

        For the purposes of recording stock-based compensation expense as part of our quarter-end close process, we reassessed the fair value of our common stock. We considered the results and underlying assumptions included in the valuation of the common stock as determined by our board on August 25, 2011 that have been summarized above. This assessment led us to conclude that the fair value of our common stock for financial reporting purposes increased on a straight-line basis from May 31, 2011 through the effective date of the valuation. The May 31, 2011 date, which was the last date preceding the effectiveness of a multi-year CDP agreement, was selected as this was the first initial material event that occurred since the prior valuation date. Following May 31, 2011, additional events leading to an increased likelihood of an IPO outcome occurred that were considered in the August 5, 2011 contemporaneous valuation. As a result, we reassessed the fair value of our common stock as of June 6, 2011 and June 24, 2011 as $3.36 and $4.15, respectively.

        Our board substantially increased the probability of an IPO exit from 50-55% to 70-75%, which assumes a conversion of the preferred stock and minimizes the value of the preferred stock liquidation preferences, and thus, increases the common stock value and its relative value to the preferred stock. The IPO probability was increased given our IPO organizational meeting that was held on June 20, 2011 and the filing of our registration statement that occurred on July 29, 2011.

        The value increase reflects the newly signed CDP with a strategic customer and the second closing of our Series E preferred stock financing in June 2011 in which we raised $10.0 million through the sale of 2,407,249 preferred shares for $4.15 per share.

        As of June 30, 2011 we had $5.1 million of unrecognized stock-based compensation expense, net of estimated forfeitures, that is expected to be recognized over a weighted average period of 3.2 years. In future periods, our stock-based compensation expense is expected to increase as a result of our existing unrecognized stock-based compensation to be recognized as these awards vest and as we issue additional stock-based awards to attract and retain employees.

        The intrinsic value of all outstanding options as of June 30, 2011 was $54.4 million based on the estimated fair value for our common stock of $4.41 per share.

72


Table of Contents

        Determining the fair value of our common stock requires making complex and subjective judgments. Our approach to valuation is based on a discounted future cash flow approach that uses our estimates of revenue, driven by assumed market growth rates and estimated costs, as well as appropriate discount rates. These estimates are consistent with the plans and estimates that we use to manage the business. There is inherent uncertainty in making these estimates.

        Although it is reasonable to expect that the completion of the IPO will add value to the shares because they will have increased liquidity and marketability, the amount of additional value cannot be measured with precision or certainty.

Recent Accounting Pronouncements

        In January 2010, the FASB issued an amendment to an accounting standard which requires new disclosures for fair value measurements and provides clarification for existing fair value disclosure requirements. The amendment will require an entity to disclose separately the amounts of significant transfers in and out of Levels I and II fair value measurements and to describe the reasons for the transfers; and to disclose information about purchases, sales, issuances and settlements separately in the reconciliation for fair value measurements using significant unobservable inputs, or Level III inputs. This amendment clarifies existing disclosure requirements for the level of disaggregation used for classes of assets and liabilities measured at fair value and requires disclosures about the valuation techniques and inputs used to measure fair value for both recurring and nonrecurring fair value measurements using Level II and Level III inputs. This guidance is effective for interim and annual reporting periods beginning after December 15, 2009, except for certain Level III activity disclosure requirements that will be effective for reporting periods beginning after December 15, 2010. Accordingly, we have adopted this amendment as of January 1, 2010, except for the additional Level III requirements which we will adopt during the year ending December 31, 2011.

73


Table of Contents


BUSINESS

Overview

        We have pioneered a proprietary approach to accelerate research and development, innovation and time-to-market for the semiconductor and clean-energy industries. Through paid collaborative development programs (CDPs) with our customers, we develop proprietary technology and intellectual property (IP) for our customers focused on advanced materials, processes, integration and device architectures. This technology enables our customers to bring optimized, high-volume manufacturing-ready integrated devices to market faster and with less risk than traditional approaches to research and development (R&D). We provide our customers with proprietary technology through various fee arrangements and grant them rights to associated IP, primarily through royalty-bearing licenses. Our proprietary approach is broadly applicable to high-volume integrated device markets, which include the markets for semiconductors, flat glass, solar cells, light-emitting diodes (LEDs), flat-panel displays, advanced batteries and other energy-efficient technologies.

        Our approach consists of our proprietary high productivity combinatorial (HPC) platform, coupled with our multi-disciplinary team. Our HPC platform consists of our Tempus HPC processing tools, automated characterization and informatics and analysis software. Our platform is purpose-built for R&D using combinatorial process systems. Combinatorial processing is a methodology for discovery and development that employs parallel and other high-throughput experimentation, which allows R&D experimentation to be performed at speeds up to 100 times faster than traditional methods. Our processing tools allow us to perform up to 192 experiments on a single substrate as compared to traditional methods, which typically allow only a single experiment at a time. Our automated characterization systems and proprietary informatics and analytics match the high throughput of our processing tools. Our multi-disciplinary team of approximately 135 scientists and engineers, of whom approximately 55 have Ph.D.s, designs customized workflows for our customers' specific applications using the HPC platform and applies the workflows in collaboration with our customers. The combination of the HPC platform and our team generates significant competitive advantages for our customers. By accelerating innovation and enabling our customers to commercialize higher-performance and lower-cost integrated devices faster than through traditional methods of R&D, we provide them an opportunity to gain market share and generate higher margins, often through a first-mover advantage.

        Our business model aligns our interests with those of our customers as we collaborate to develop differentiated proprietary technology and IP for high-volume integrated devices through collaborative development programs. Customers pay us development services fees during multi-year CDPs, which typically last for two years and may range from one to three years. Our customers receive rights to the technology and IP developed during the CDPs, and once our customers commercialize products using this technology and IP, they pay us primarily through royalties. In certain cases, we sell HPC processing tools to our customers who pay a recurring license to operate those tools with our combinatorial processing capabilities. By aligning our interests with those of our customers, we facilitate collaboration and open communication that is more likely to result in innovative, differentiated products and future CDPs with those customers.

        We currently target large, high-volume semiconductor and high-growth emerging clean-energy markets, including DRAM, flash memory, complex logic, flat glass, solar cells, LEDs and other energy-efficient technologies. According to IHS iSuppli, the semiconductor market had $304 billion in sales in 2010 and is expected to grow at a compound annual growth rate (CAGR) of 5.7% from 2010 to 2015. Based on data from Freedonia Group, GlobalData, IHS iSuppli and MarketsandMarkets, the clean-energy markets had $166 billion in sales in 2010 and are collectively expected to grow at a CAGR of 10.8% from 2010 to 2015. Within these broad markets, we target customers that have track records of technological innovation, deploy significant resources and are pursuing technical advancements that are critical to their success and strategy. We have engaged in paid programs with 18 customers. Our largest

74


Table of Contents


customers are ATMI, Elpida Memory, GLOBALFOUNDRIES, Guardian Industries, SanDisk, Taiwan Semiconductor Manufacturing Company (TSMC) and Toshiba, which collectively recorded $46 billion in revenue in 2010 associated with the semiconductor and clean-energy markets. ATMI and Elpida have commenced shipping products incorporating technology developed through our CDPs and pay us licensing and royalty fees. To date, we have received the majority of our revenue from customers in DRAM, flash memory, complex logic and energy-efficient applications in flat glass, and have not yet received a material amount of revenue from customers in solar cells, LEDs and other energy-efficient technologies.

        We were founded in 2004 and are headquartered in San Jose, California. Our total revenue increased to $42.7 million for the year ended December 31, 2010 from $26.9 million for the year ended December 31, 2009. Our total revenue increased to $23.8 million for the six months ended June 30, 2011 from $16.5 million for the six months ended June 30, 2010. Our backlog as of June 30, 2011 was $108.8 million, of which $28.3 million is scheduled to be recognized as revenue during the remainder of the year ending December 31, 2011. Our adjusted EBITDA for the six months ended June 30, 2011 was $2.0 million, and our adjusted EBITDA for the year ended December 31, 2010 was $4.6 million. Our net loss decreased to $1.8 million for the year ended December 31, 2010 from $5.3 million for the year ended December 31, 2009. Our net loss decreased to $3.2 million for the six months ended June 30, 2011 from $3.3 million for the six months ended June 30, 2010. Since inception, we have incurred net losses leading to an accumulated deficit of $73.2 million as of June 30, 2011.

Industry Background

        High-volume integrated devices serve large and growing markets, including the markets for semiconductors, flat glass, solar cells, LEDs, flat-panel displays, advanced batteries and other energy-efficient technologies. Success in these markets requires rapid and cost-effective product innovation, fast time-to-market, competitive pricing, production scalability and the ability to achieve specific requirements. These devices are typically manufactured using thin-film deposition of advanced materials through customized processes that create a specific device architecture. It is increasingly necessary to evaluate elements in the periodic table that have previously not been used in high-volume manufacturing to deliver performance and cost improvements, and to develop advanced device structures capable of addressing particular application requirements. These device structures must then be scaled and integrated into cost-effective manufacturing processes to serve high-volume integrated device markets. Traditional R&D approaches are increasingly challenged by the market need to accelerate innovation and time-to-market for the semiconductor and clean-energy industries.

Semiconductor Industry

        Since the inception of the semiconductor industry more than 50 years ago, innovation has been continually driven by consumer demands for smaller, higher-performance, more power-efficient and less expensive electronic products. Recently, this innovation has been driven by broad end-market demand for smartphones, PCs, tablet computers, cloud computing, high-definition media, and advanced aerospace and industrial applications. The semiconductor industry is characterized by intense competition, with many semiconductor companies seeking to gain market advantage over competitors by expanding their broad product portfolios, using their deep design and/or process capabilities and leveraging their IP libraries. Increasingly, these companies are relying on combinations of advanced materials, processes, integration and device architectures to compete and differentiate their products.

        Historically, the pace of semiconductor innovation has been enabled by device scaling, in which, according to Moore's Law, the number of transistors in a design generally doubles every two years. This increasing density has reduced costs and improved capabilities over time, thereby driving market demand and growth. However, semiconductors are approaching the limitations of device scaling with the current set of materials and manufacturing processes. Consequently, semiconductor manufacturers

75


Table of Contents


are turning to advanced materials, processes, integration and new device architectures to enable continued device scaling and to deliver improved product performance and cost competitiveness. The reliance on advanced materials, processes, integration and new device architectures has in turn made advancements in semiconductor technology increasingly complex and expensive. Each new process node requires experimentation with more elements in the periodic table and more material combinations to deliver the desired physical and electrical characteristics for device performance and manufacturability. For example, the broad adoption of copper interconnects enabled the industry to continue device scaling in the microprocessor field, but as this advancement required changes not only in materials, but also in processes, integration and device architectures to achieve high-volume, cost-effective manufacturing, the transition was challenging and slow.

        Semiconductor manufacturing companies have used device scaling to shrink transistors and develop new process technology nodes to address customer requirements for lower cost and higher performance ICs. However, advanced R&D and new fabrication facility costs have increased significantly over time, especially as the use of advanced materials and processes have become increasingly important to the development and introduction of the latest generation process technology nodes. According to data compiled by a leading manufacturer in the semiconductor industry and presented at a 2009 industry conference, the industry average for logic process R&D has reached between $600 million and $900 million for nodes between 45nm and 32nm. This represents more than an 80% increase from 65nm and older nodes, and expectations are for process R&D to reach $1.3 billion for 22nm and 12nm nodes, an additional 70% increase in process R&D costs. In addition, according to IC Knowledge, costs of semiconductor fabrication facilities have increased from approximately $50 million in 1975 to the approximately $3.5 billion required to open a new 32nm facility currently, with the expectation that costs for a leading edge facility will reach $8 billion by 2015. The greater expertise and higher costs required to explore advanced materials, processes, integration and new device architectures have led to increased specialization among materials, capital equipment, semiconductor manufacturing and IC design companies. However, this specialization has left gaps in the industry knowledge base with respect to the complexities of the interaction between materials science, process technology, device integration and the scale-up to high-volume IC production.

        To succeed in the market and deliver an appropriate financial return, semiconductor companies are under intense pressure to rapidly develop optimized ICs and efficiently scale them to cost-effective production. Using advanced semiconductor materials, processes, integration and new device architectures requires intensive, time-consuming experimentation because advanced materials are not well understood and accurate, robust models do not exist. As a result, semiconductor companies must increasingly rely on time and resource-intensive, empirical R&D to develop innovative solutions and enable manufacturability at lower costs.

Clean-Energy Industry

        The emerging clean-energy markets also depend on improvements in advanced materials, processes, integration and new device architectures. Clean-energy markets, which include the markets for flat glass, solar, LEDs, advanced batteries and other energy-efficient technologies, remain in early stages of technological evolution. Companies in the fast-evolving clean-energy markets are in the early stages of understanding materials, processes, integration, device architectures and manufacturing methodologies. As a result, those companies that successfully develop relevant, scalable proprietary materials and device technologies will likely have a competitive advantage over their peers in both time-to-market and price.

        Decreasing prices, government policies and social awareness are driving growth in the clean-energy markets and certain sectors have entered high-volume production. Reduced prices and improved performance relative to traditional alternatives generally catalyze widespread adoption of new technologies. For example, LEDs are currently more expensive to purchase than incandescent and

76


Table of Contents


fluorescent lighting. To increase penetration of the general lighting market, price reductions and improvements in performance, such as brightness, color, form factor and features like dimming, will be critical. New advanced materials, improved process technologies and new device architectures will enable larger wafer sizes, higher-volume production and improved yields for lower-cost and higher-performing LEDs.

        Because of the early stages of technology development in the clean-energy markets, there are significant opportunities for cost savings and potential competitive advantage. Market participants who resolve the price-performance challenges ahead of their competitors through advanced materials, processes, integration and new device architectures may greatly accelerate market adoption and establish themselves as market leaders. These opportunities amplify the importance of empirical R&D to develop low-cost, high-performance solutions in these early-stage markets.

Current Challenges with Innovation in High-Volume Integrated Device Markets

        Advanced materials and device integration are driving forces behind technology advancement in the high-volume integrated device markets. In addition, innovation in these markets and control of the resulting IP are critical to enable competitive differentiation. However, the existing approach used to explore new materials, processes, integration and device architectures is complex, time-consuming and requires empirical R&D. For example, Intel, an industry leader, has stated at technology conferences that while the Tri-Gate advanced transistor technology was invented in 2002, it was not optimized for high-volume manufacturing until 2011.

        Traditionally, device manufacturers have conducted R&D using expensive high-volume manufacturing tools that are not specifically built for that purpose. Production tools typically can only run one process at a time, which leads to limited cycles of learning. Furthermore, using tools deployed in a production environment for R&D requires reserving tool time on high-volume manufacturing lines to evaluate each experiment, resulting in substantial opportunity costs for existing product manufacturing. High-volume manufacturing environments are also not conducive to R&D because these environments require stability to minimize risk and to reduce contamination that the research-based introduction of new materials, tools or processes may cause. Additionally, high-volume manufacturing is conducted by operators focused on repetitive, mistake-free processing, not on many cycles of trial and error. In addition to some of the challenges above, certain clean-energy device manufacturers use laboratory-scale tools for R&D, which do not address the scale-up requirements critical to high-volume manufacturing. These factors combine to increase development risks due to long learning cycles, limited data sets, narrow exploration capabilities and slow time-to-market.

        Successful R&D programs require flexibility around experimentation and the introduction of new materials, chemicals, processes and tools to derive the most efficient high-volume integrated device solutions. Furthermore, we believe they are best administered by scientists and engineers with experience across various disciplines of equipment, materials, device architectures and processes to conduct successful experiments and derive optimized solutions.

        The following existing approaches have been used to complement internal R&D, but each has specific limitations:

77


Table of Contents

        Substantially improved methodologies are required to generate the learning cycles necessary to accelerate innovation, improve product development and ensure manufacturing scalability of high-volume integrated devices. Further, companies require new ways to develop proprietary technology and obtain IP rights to support competitive advantage for their new products.

Our Solution

        We have pioneered a proprietary approach to accelerate research and development, innovation and time-to-market for the semiconductor and clean-energy industries. Using our approach, we develop technology and IP rights focused on advanced materials, processes, integration and device architectures in collaboration with our customers. This technology enables our customers to bring optimized, high-volume manufacturing-ready integrated devices to market faster and with less risk than traditional approaches to R&D. Our proprietary HPC platform consists of our Tempus HPC processing tools, automated characterization and informatics and analysis software. Our HPC platform increases R&D productivity because it is purpose-built for R&D and utilizes advanced combinatorial processing systems, which allow for experiments to be performed at speeds up to 100 times faster than traditional methods. We provide our customers with proprietary technology through various fee arrangements and grant them rights to IP developed during the collaboration, primarily through royalty-bearing licenses. Our multi-disciplinary team of approximately 135 scientists and engineers, of whom approximately 55 have Ph.D.s, designs customized workflows for our customers' specific applications using our HPC platform and applies the workflows in collaboration with our customers to develop proprietary technology for them.

        The key elements of our HPC platform include the following:

78


Table of Contents

        The following graphic illustrates how these elements combine to form our HPC platform:

GRAPHIC

Benefits to Our Customers

        Our business model aligns our interests with those of our customers as we collaborate to develop optimized, manufacturing-ready IP for high-volume integrated devices. We provide our customers with proprietary technology through various fee arrangements and grant them rights to IP developed during our CDPs, primarily through royalty-bearing licenses. Our differentiated platform solution and approach to collaborative engagements are designed to deliver the following significant benefits to our customers:

79


Table of Contents

Strengths

        We have pioneered, developed and patented a proprietary platform and methodology for accelerating R&D in the semiconductor and clean-energy markets. Our strengths include:

80


Table of Contents

Our Strategy

        Our mission is to drive our customers' success by transforming R&D and accelerating innovation in markets that derive competitive advantage from the interaction of materials science, processes, integration and device architecture. To accomplish this, we:

Our Platform

HPC Workflows

        We begin the development and discovery process by working with our customers to define the specific requirements a new solution should have to meet the needs of a given application. Generally, these criteria are well beyond the performance attributes of currently available solution sets. We then apply the components of our HPC platform to develop and discover solution sets that match these criteria.

        Once an experiment is processed, the data sets of each experiment are stored in a secure database and analyzed for desired properties. As with processing, our clean room labs include a broad array of characterization and metrology instruments and software to evaluate different properties under a wide variety of process conditions. These properties include physical, electrical, mechanical, thermal, chemical, and optical properties. In general, we are able to design, process and characterize tens to hundreds of experiments in a single day.

81


Table of Contents

        To reach the point of commercialization or transfer to our customers' manufacturing process qualification, a solution set must progress through an extensive series of screening stages. Below is an illustration of the screening process of the HPC platform for use in evaluating materials, unit processes, and process sequences.

GRAPHIC

        Secondary screening begins while primary screening is still ongoing, and while we are still generating additional primary screening candidates. Tertiary screening begins once we have identified a

82


Table of Contents


reasonable set of options from secondary screening, and while we are still generating additional secondary screening candidates. As these stages overlap, there may be feedback from later stages that is then incorporated back into an earlier stage to further optimize the selection of materials, unit processes and process sequences.

Wet Processing Tools

        We offer a series of wet processing tools which apply HPC methods to fluids-based applications such as cleans, deposition and wet etch, self-assembly, and surface treatment processes. These tools, which can be used alone or in combination, include:

Dry Processing Tools

        In addition, we offer dry processing tools which apply HPC methods to vapor-based applications. Each of these tools can be used in primary, secondary and tertiary screening. These tools, which can be used alone or in combination, include:

Automated Characterization

        Immediately after processing substrates on our Tempus HPC processing tools, we use automated and customized characterization instruments to rapidly generate physical and electrical data from the experiments. The aggregated data is automatically loaded into our informatics data warehouse. As with processing, our clean room labs include a broad array of characterization and metrology instruments and software to evaluate different properties under a wide variety of process conditions. Our characterization instruments match the throughput of our processing tools to maximize experimental learning cycles.

83


Table of Contents

Informatics Software, Analysis and Services

        Our informatics software has the ability to automate the capture, entry and storage of HPC processing and automated characterization and metrology data and then to evaluate, summarize and securely distribute in real time this data to the appropriate parties. Additionally, we use our informatics software to leverage experiments processed and characterized in the past for a customer to increase the speed and effectiveness of the engagement. The key components of our informatics software include:

Our Technology

        Embedded throughout our hardware and software, our technology is based upon the parallel and/or rapid serial experimentation capabilities of combinatorial methods. High-productivity combinatorial methods generally refer to techniques that vary materials, unit processes, process, and device integration sequences across multiple regions of one or more substrates, the output of which can then be evaluated in parallel. Our informatics software and analytical methods characterize and analyze these combinations of materials, unit processes, process, and device integration sequences for the most promising solutions in a structured, automated and throughput-matched fashion. The relationship between materials, processes, integration and device output are established earlier in the development process, so that performance and manufacturability considerations are taken into account from the outset, instead of late in the R&D process.

        Although our approach is unique in the semiconductor and clean-energy industries, combinatorial technology has been widely used in other industries, especially where new materials function as primary enablers of product innovation. Examples include the pharmaceutical, biotechnology, and energy sectors, where combinatorial techniques have been accelerating development since the early 1990s.

        We are able to deploy and benefit from our proprietary combinatorial methods because of our multi-disciplinary team of approximately 135 scientists and engineers, of whom approximately 55 have

84


Table of Contents


Ph.D.s. Our team has expertise in a wide range of disciplines, fields and technologies, including the following:

Disciplines   Applications   Equipment
(Hardware & Process)
  Devices
(Processes and Integration)
Chemistry
Physics
Materials science
Engineering

•        Chemical

•        Electrical

•        Mechanical

•        Software

•        Controls

•        Systems

  Equipment development

•        Systems engineering

•        Semiconductor tools

•        Flat panel display tools

•        Software
Design, qualification, manufacturing

•        Modeling / TCAD

•        Development / integration

•        Yield management

•        Statistical methods

•        Test structures

•        Inspection, review & characterization

•        Electrical test

  Deposition

•        ALD

•        PVD

•        PECVD

•        CVD (metals/dielectrics)

•        ECD / electroless

•        CBD / curtain coating
Wet processing
Laser annealing
Defect detection

•        Optical, e-beam, laser

•        High-speed voltage contrast

  Process, equipment, integration

•        DRAM / Non-Volatile Memory

•        Microprocessors

•        Solar cells (CIGS, thin film Si, cSi)

•        Low e glass coatings

•        LED
Process technologies

•        Selenization / absorber formation

•        Shallow trench isolation gapfill

•        High-k / metal gate

•        Contact & advanced silicide

•        Advanced Cu—interconnect (Cu, Al)

•        Advanced packaging

Our Collaborative Development Programs

        Our CDPs allow our customers to collaborate with our multi-disciplinary team on specific technical problems. We establish processes and procedures to protect our customers' confidential information during these CDPs. Our CDP work is primarily carried out at our facility in close collaboration with our customers. In addition, we support device qualification for pilot manufacturing at our customers' manufacturing and development sites. Customer teams and our teams collaborate on development of new materials, unit processes, process modules and integration sequences, and qualify the supply chain for high-volume manufacturing. Our multi-disciplinary team can rapidly adapt our Tempus HPC platform to meet customer application requirements and develop and optimize device and product technologies to ensure success with customer programs.

        We typically initiate new customer engagements with smaller, customer-paid programs called micro-CDPs. Our micro-CDPs precede the full CDP. These are smaller programs that require significantly less investment from our team but allow us to demonstrate the capabilities of our HPC platform to a customer without requiring a customer to commit to a multi-year agreement. We use these micro-CDPs to demonstrate the capabilities and value of our HPC platform to these new customers, with the objective of engaging with these customers in a full CDP.

        Our CDPs are designed to result in the development of proprietary technology and IP for new devices, manufacturing process technology and materials, which we license to our customers for use in volume production. We provide our customers with proprietary technology through various fee arrangements and grant them rights to associated IP primarily through royalty-bearing licenses.

        In the early stages of developing our business, we structured engagements with customers to allow us to continue to grow while also giving customers an opportunity to invest in our business and success. We do not expect to continue to provide our customers and partners with opportunities to invest in our company after the completion of this offering independent of their ability to do so in the open market.

85


Table of Contents

Our Customers

        Our customers include semiconductor device, semiconductor materials and equipment and clean-energy market leaders, including ATMI, Elpida, GLOBALFOUNDRIES, Guardian, SanDisk, Toshiba and TSMC. Typically, our customers engage in CDPs with our team leveraging our HPC platform to develop and commercialize high-volume integrated devices using collaboratively developed technology. To date, ATMI and Elpida have already successfully developed products through their CDPs and we have granted them rights to the associated technology and IP rights through royalty-bearing licenses. Successes in our initial CDPs have led to expanded relationships and follow-on programs with existing customers for new products and applications.

        One example of a customer who has successfully developed and commercialized products through a CDP and expanded upon initial CDPs through follow-on programs is Elpida. We initially began working with Elpida through a micro-CDP in November 2007, resulting in a full CDP in May 2008. In this resulting CDP, we were able to accelerate time-to-market by reducing experimentation cycle times from weeks to hours, thereby increasing learning cycles for them by over 100 times per month. The increased volume of experimental data evaluated during the collaboration enabled the development of a lower-cost and more power-efficient solution through innovations in materials, processes and integration. As a result of our engagement success, Elpida subsequently engaged us in follow-on programs for new products. Elpida incorporated technology developed through this CDP in their next generation DRAM products which entered high-volume manufacturing in the fourth quarter of 2010.

        The majority of our revenue comes from ATMI and Elpida, which represented a combined 53%, 72%, 88% and 81% of our total revenue for the six months ended June 30, 2011 and the fiscal years ended December 31, 2010, 2009 and 2008, respectively. We believe that the revenue concentration associated with these two customers will likely continue to decline as our other customers begin to transition technology developed through CDPs into licensing and royalty revenue and as we continue to enter into new CDPs with new and existing customers in the semiconductor and clean-energy markets.

Intellectual Property

        Our success depends in large part on our IP. We have patented and continue to seek patent protection for combinatorial methods and systems included in our HPC platform. We have also patented and continue to seek patent protection of innovations that result from applying our HPC platform to design, develop and manufacture ICs, photovoltaic cells, glass coatings, LEDs, organic light-emitting diodes (OLEDs) and thin films for electronics, optical and energy applications (Fields). As of September 1, 2011, we owned 216 U.S. patents and patent applications (most of which also have foreign counterparts), of which 106 are related to the HPC platform and 110 are related to innovations in the Fields. We also have a license to approximately 384 U.S. patents and patent applications granted to us by Symyx Technologies, Inc. (Symyx), a wholly-owned subsidiary of Accelrys, Inc., that exclusively provides us the right to use combinatorial methods and systems in the Fields.

        As of September 1, 2011, we owned 12 patents and 94 patent applications related to our HPC platform in the United States, and two patents and 41 patent applications in other jurisdictions. The expiration dates of these patent rights range from May 2025 to September 2031. We continue to file patent applications to seek protection for further advancements of our HPC platform. We own all rights to such patents and generally do not grant licenses to third parties under these patents other than in connection with the use of our HPC platform. Our patents and patent applications cover the following aspects of the HPC platform:

86


Table of Contents

        In addition to the patents we own, we have rights to approximately 384 U.S. patents and patent applications pursuant to licenses and sublicenses granted to us by Symyx to use combinatorial methods and to make, use and sell combinatorial systems. These rights are exclusive to us in the Fields. The expiration dates of the rights arising from the 384 U.S. patents and patent applications that exclusively provide us the right to use combinatorial methods and systems in the fields of ICs, photovoltaic cells, glass coatings, LEDs, organic light emitting diodes (OLEDs) and thin films for electronics, optical and energy applications range from October 2014 to November 2028. On July 28, 2011, we entered an asset purchase agreement with Symyx, pursuant to which Symyx will transfer to us all the patents for combinatorial methods and systems owned by them, effective upon the consummation of this offering. See "Certain Relationships and Related Party Transactions—Symyx" for further details about this transaction.

        We also have and seek patent protection for innovations developed using our HPC Platform (applications IP). Such innovations cover advancements in new materials, processes, process conditions, process sequences and device architectures in applications such as semiconductor memory, semiconductor complex logic, glass coatings, solar cells and LEDs. As of September 1, 2011, we owned 21 patents and 89 patent applications in the U.S. covering applications IP, as well as one patent and 27 patent applications in other countries. We may develop applications IP either on our own or in collaboration with our customers through CDPs.

        In most cases, we maintain an ownership interest in the applications IP that results from CDPs and we grant licenses under this applications IP to the CDP customer. Such licenses generally allow the CDP customer to have exclusivity for a limited term in a particular field. We keep the right to grant licenses under the CDP patents outside that field. Furthermore, if the CDP customer elects to not extend the term of exclusivity beyond the limited term, we have the right to grant licenses to third parties within the field. If required we assign separate teams for each CDP, maintain separate databases of experimental data and limit access to such databases only to the specific team that assists the CDP customer.

        We may also develop applications IP internally where we believe such IP may have broad applicability in the relevant market. We are able to leverage this IP to begin CDPs with new customers. In addition, our ability to own the applications IP in these situations allows us to leverage learning and patent protection across industries and applications while providing our existing customers with the IP rights they desire to gain competitive advantage in their fields for the markets they serve.

Sales and Marketing

        We sell and market our solutions worldwide through our own sales force by developing direct relationships with our customers. We have sales personnel located in Japan, Taiwan, Europe and the United States, including account managers, who are responsible for specific customer accounts, and product marketing personnel, who provide business development support and application and workflow platform expertise. We often base customer support personnel at or near the offices of our major customers to improve our level of service and expand our sales.

        Our business development and product marketing group focuses on our strategy, platform and technology roadmap, new platform introduction process, demand assessment and competitive analysis. The group coordinates new application evaluation and development both internally with our engineering teams and externally with new and existing customers. We intend to increase our sales and marketing efforts and further expand our business development and product marketing organization.

87


Table of Contents

Manufacturing

        We manufacture our HPC tools through partnerships with experienced contract manufacturers that manufacture and assemble sub assemblies incorporating our designs. We believe that our third party manufacturers have adequate sources and supplies of the raw materials needed to manufacture our products. We believe that partnering with contract manufacturers provides us with access to the most current facilities and processes without significant capital outlay on our part, allowing us to focus our resources on R&D, product design and collaboration program support. Although we have historically relied on a small number of contract manufacturers for the manufacture and assembly of a majority of our workflow platforms, we have relationships with a variety of contract manufacturers and are not dependent on any single contract manufacturer.

Research and Development

        We conduct R&D activities for CDPs and for internal research and development on both workflow platform development and application R&D. We employ a research and development team of approximately 157 full-time employees. This R&D team includes many experienced semiconductor engineers with advanced degrees from leading universities around the world and managers with experience from leading chip manufacturers, solar PV companies and equipment suppliers. We believe these R&D professionals on our team have enabled us to develop our HPC platform, support customer CDPs, implement our technology roadmap rapidly and provide us with the foundation for our technology advancement in the future.

        Our customer-sponsored R&D expenses included in cost of revenue were $9.1 million in 2008, $8.8 million in 2009 and $16.9 million in 2010, which represented approximately 39%, 33% and 40%, respectively, of our revenue in those years.

        We devote a substantial portion of our resources to engineering next generation platforms by integrating future generations of technology and developing a standardized software and informatics platform. We work closely with multiple vendors during the development of new workflows or workflow modifications for use in our future platforms. We work with our software and component vendors to establish integration standards. To that end, we are developing scalable software architectures that will allow us to integrate new processes requested by our customers to further expand the opportunities with new and existing customers, accelerate time-to-market, and allow our workflow platforms to operate with adjacent vertical technologies such as clean-energy markets. Our internal R&D expenses were $11.8 million, $11.0 million and $13.9 million for the fiscal years ended December 31, 2008, 2009 and 2010, respectively, which represented approximately 51%, 41% and 33%, respectively, of our revenue in those years.

Competition

        The principal capabilities required to be competitive in our market include technical expertise, processes and integration capabilities, diversity of platform offerings, development speed and performance, quality and reliability of field engineers, depth of collaboration with customers and technical support. We believe we compete favorably with respect to these factors because of the breadth of capabilities of our HPC platform, the depth of multi-disciplinary expertise of our internal research team and external engineering teams who collaborate with customers and our use of combinatorial processing and throughput matched characterization and analysis. These differentiating factors allow us to explore more comprehensive solution sets and provide faster solutions to our customers. We are not aware of any companies that currently compete or have to date competed with us in the use of combinatorial methods in research and development applications; however, we do believe that we compete for the R&D resources of our customers with equipment suppliers, industry consortia, alliance partnership, university research and third-party IP licensing. In addition, many of our

88


Table of Contents


customers design, develop, manufacture and market solutions based on their own unique device architectures and develop their own intellectual property in-house.

        A portion of our revenue is generated from the sales of end products by our customers, and our competitive position therefore is dependent on their competitive positions. The markets for our customers' products that incorporate technology developed through our CDPs are intensely competitive and characterized by rapid technological change. These changes result in frequent product introductions, short product development cycles and increased product capabilities typically representing significant price and performance improvements.

Environmental Regulation

        We are subject to various foreign, federal, state and local environmental laws and regulations governing, among other matters, emissions and discharges of hazardous materials into the air and water, the use, generation, storage, handling, transportation and disposal of, and exposure to, hazardous materials and wastes, remediation of contamination and employee health and safety. In addition, under certain of these environmental laws, liability can be joint and several and without regard to comparative fault. Our operations involve the use of hazardous materials and produce hazardous waste, and we could become liable for any injury or contamination that could arise due to such use or disposal of these materials. Failure to comply with environmental laws and regulations or to obtain or maintain required environmental permits could result in the imposition of substantial civil and criminal fines and sanctions, could require operational changes or limits or the installation of costly equipment or otherwise lead to third party claims. Future environmental laws and regulations, stricter enforcement of existing laws and regulations, or the discovery of previously unknown contamination or violations of such laws and regulations could require us to incur costs, or become the basis for new or increased liabilities or subject us to fines or other sanctions.

Employees

        As of June 30, 2011, we had a total of 190 full-time employees, consisting of 157 people engaged in CDPs and R&D activities and 33 people in sales and marketing, legal and general and administrative roles. None of our employees are represented by a labor union, and we consider our employee relations to be good.

        Our CDPs are labor-intensive, and as we engage in additional CDPs, we will need to hire enough highly-skilled engineers and other technical staff to support the CDPs. We evaluate our hiring needs on a project by project basis, taking into account current and anticipated CDP timelines and lifecycles. We believe our location in San Jose, California provides us with access to a large population of highly-skilled engineers who will be able to meet the technical requirements of our new CDPs.

Facilities

        Our facilities currently consist of an aggregate of approximately 146,000 square feet of office, research and development clean room space in San Jose, California, pursuant to a lease that expires in 2015. For our CDP engagements, as of September 1, 2011 we are using approximately 35% of the capacity of our clean room space in San Jose. We have historically expanded and invested in our facilities to support the growth of our CDPs and we expect to be able to continue to do so on commercially reasonable terms as we engage in new CDPs in the future. We have no reason to believe that additional space that we may need in the future will not be available on commercially reasonable terms.

Legal Proceedings

        We are not currently a party to any material pending legal proceedings.

89


Table of Contents


CUSTOMER AND COLLABORATIVE AGREEMENTS

        The descriptions below contain only a summary of the material terms of the agreements and do not purport to be complete. These descriptions are qualified in their entirety by reference to the respective agreements that are filed as exhibits to the registration statement of which this prospectus is a part.

Collaborative Development Program Agreement with GLOBALFOUNDRIES (GF)

        In June 2011, we entered into a CDP agreement with GF to develop and improve certain semiconductor products.

        Under the agreement, we will provide development services to GF and grant GF non-exclusive use of our proprietary HPC platform (which includes a subscription to the platform and a license to the associated software) for the purpose of developing and improving certain semiconductor products.

        Each party will own the rights arising out of the CDP created by its inventors ("GF CDP IP"). We agreed that we would not grant a license under our rights in the GF CDP IP to any third party outside a certain field without the prior written consent of GF.

        GF has agreed to pay us (i) royalties on sales of products that incorporate the GF CDP IP, (ii) fees for providing development services to GF, (iii) subscription and license fees for use of the HPC platform, and (iv) certain pre-approved expenses and material costs. GF may grant sublicenses to use the GF CDP IP to third parties, but must share with us the royalties it receives from certain third party sublicenses. We also granted GF an option to purchase certain HPC processing tools.

        We are required to supply a certain number of full-time employees or contractors dedicated to supporting the development activities under the CDP.

        The initial period for development activities and use of the HPC platform is three years, and will automatically renew for additional one-year periods unless either party elects to terminate. The initial term of the agreement is five years from the date of the last sale of a product that incorporates GF CDP IP.

Collaborative Development Program Agreement with Toshiba and SanDisk

        In March 2010, we entered into a CDP agreement with Toshiba and SanDisk to develop certain memory technologies and related materials.

        Under the agreement, we will provide development services to Toshiba and SanDisk and grant Toshiba and SanDisk non-exclusive use of our proprietary HPC platform (which includes a subscription to the platform and a license to the associated software).

        Toshiba and SanDisk will own the rights to the technology and IP arising out of the CDP that is based on Toshiba or SanDisk background technology or that is solely developed by Toshiba or SanDisk. We will own the rights to the technology and IP arising out of the CDP that is solely developed by us and that is based on our background technology. Jointly developed technology and IP arising out of the CDP that is based on our background technology will be jointly owned. Patent rights based on technology solely developed by us that is based on Toshiba or SanDisk background technology will be jointly owned.

        We granted Toshiba and SanDisk an exclusive license under our rights in the technology and IP arising out of the CDP (Toshiba-SanDisk CDP IP) during the term of the CDP. After the conclusion of the CDP term, Toshiba and SanDisk each shall have the option (i) to continue to maintain an exclusive license to certain or all of the Toshiba-SanDisk CDP IP, (ii) to convert the exclusive license to non-exclusive, or (iii) to terminate the exclusive license.

90


Table of Contents

        Toshiba and SanDisk have agreed to pay us (i) volume-based royalties on sales of products that incorporate the Toshiba-SanDisk CDP IP subject to certain minimum and maximum levels, (ii) fees for providing development services to Toshiba and SanDisk, (iii) subscription and license fees for use of the HPC platform, and (iv) certain pre-approved expenses and material costs. Toshiba or SanDisk may request that we grant to other third parties a royalty-bearing license to the Toshiba-SanDisk CDP IP.

        The initial period for the development activities is two years, and may be extended for up to two additional one-year periods. The obligations of Toshiba and SanDisk to pay royalties under the licenses granted by us shall continue for the duration of such licenses.

Advanced Memory Development Program Agreement with Elpida Memory, Inc. (Elpida)

        In May 2008, we entered into an Advanced Memory Development Program Agreement with Elpida relating to a CDP to develop and improve certain advanced memory products. The Elpida agreement was supplemented and/or amended in August 2008, January 2009, May 2009 and July 2010.

        Under the agreement, we will provide development services to Elpida and grant Elpida non-exclusive use of our proprietary HPC platform (which includes a subscription to the platform and a license to the associated software) for the purpose of developing and improving certain advanced memory products.

        We own the rights for certain technology and IP arising out of the CDP (our CDP IP). Elpida owns the rights for certain other technology and IP arising out of the CDP (Elpida CDP IP). All other technology and IP arising out of the CDP will be jointly owned by Elpida and us (joint CDP IP). We have also granted Elpida an exclusive license to use our CDP IP and the joint CDP IP in certain fields during the term of the agreement.

        Elpida has agreed to pay us (i) royalties on sales of products that incorporate our technology, our CDP IP, Elpida CDP IP or joint CDP IP subject to certain minimum and maximum levels; (ii) fees for providing development services to Elpida, (iii) subscription and license fees for use of the HPC platform, and (iv) certain pre-approved expenses and material costs.

        The current period for development activities and use of the HPC platform is through April 1, 2013, after which the exclusive license converts to a non-exclusive license unless Elpida meets certain minimum quarterly sales thresholds from high-volume manufacturing of royalty-bearing products. Elpida's obligation to pay royalties under the licenses granted by us shall continue for the duration of such licenses.

ATMI Engagement

        In November 2006, we entered into an alliance agreement with ATMI to develop advanced materials for semiconductor products under one or more individual CDPs as agreed between the parties from time to time. Each CDP would provide payments from ATMI to us (i) for providing development services to ATMI, (ii) for subscription and license fees for use of the HPC platform, and (iii) for certain pre-approved expenses and material costs. ATMI owns any technology and IP that it independently creates during the alliance agreement. We own the technology and IP we independently create. Unless modified by the terms of a CDP, we also own the Alliance Technology arising out of the CDP and the HPC technology. The initial term of the alliance activities is ten years.

        The parties have had one CDP under the alliance agreement. Under that CDP, ATMI owns any technology and IP that it independently creates during the alliance agreement, as well as any materials manufacturing technology and associated IP rights that are created during the course of the alliance agreement (the Alliance Materials Manufacturing Technology). We own the technology and IP we independently create and, other than the Alliance Materials Manufacturing Technology, any other technology and IP that is created during the course of the alliance agreement (the Alliance IP). We

91


Table of Contents


granted to ATMI a limited, field-restricted, exclusive license to use the Alliance IP, with the right to sublicense, and ATMI has agreed to pay us royalties or share revenues on the sales or licenses of ATMI products that incorporate the Alliance IP. We retained the right to be the sole licensor of any Alliance IP to any IC manufacturers or original equipment manufacturers.

        In July 2007, we entered into a Wets Workflow Purchase Agreement with ATMI, which was extended through amendments in December 2007, December 2008, March 2009, August 2010 and March 2011 (as amended, the ATMI Wets Workflow Agreement), pursuant to which we agreed to sell to ATMI certain HPC processing tools and license informatics software related to liquid or fluids-based materials (wets) used in semiconductor processing and manufacturing (collectively, the wets workflow). The wets workflow may only be used at certain designated sites and solely for the purpose of developing and commercializing materials, wets processing processes, products and materials manufacturing technologies in a certain field. ATMI is obligated to pay us royalties on products that incorporate any material identified, first synthesized, or discovered through use of any wets workflow (the ATMI products). During the term of the agreement, we have agreed not to enter into any joint marketing, sales or development agreements in certain fields with certain competitors of ATMI. During the term of the agreement and subject to economic terms, we also agreed not to ship certain elements of the wets workflow and certain other proprietary HPC processing tools to certain ATMI competitors for use in certain defined fields. We have agreed to evaluate ATMI materials for CDPs between us and integrated device manufacturers for an IC or solar application. We have agreed to recommend ATMI materials to our customers in these CDPs, provided that the ATMI materials are timely available, meet our customer's requirements and are cost competitive. If we identify an opportunity for ATMI and us to work in a joint development program or if ATMI introduces us to such an opportunity with an integrated device manufacturer, we and ATMI will enter into good faith negotiations to agree on an economic arrangement, unless ATMI does not have HPC-related resources available to contribute to such an opportunity. We are required to supply a certain number of full-time employees or contractors dedicated to supporting ATMI's use of the wets workflow. The agreement will continue in effect as long as any license granted under any applicable purchase order under the agreement remains in effect, which will be at least through December 31, 2013.

        In December 2008, we entered into a Dry Workflow Purchase Agreement with ATMI, which was extended thru amendments in August 2010 and March 2011 (as amended, the ATMI Dry Workflow Agreement), pursuant to which we agreed to sell to ATMI certain HPC processing tools and license informatics software related to vapor-based applications (dry) used in semiconductor processing and manufacturing (collectively, the dry workflow). For sales of compounds or materials (or composition of compounds or materials) identified, first synthesized, or discovered in whole or in part through the use of the dry workflow, and any derivative thereof (the ATMI dry products), ATMI would pay us a royalty on these ATMI dry products. We are required to supply a certain number of full-time employees or contractors dedicated to supporting ATMI's use of the dry workflow. The agreement will continue in effect as long as any license granted under any applicable purchase order under the agreement remains in effect, which will be at least through December 31, 2013.

Symyx Agreements and Asset Purchase

        In March 2005, we entered into a Collaborative Development and License Agreement with Symyx Technologies, Inc. (Symyx). In addition, in December 2005, we entered into an Alliance Agreement (Symyx Alliance Agreement) with Symyx, and we amended the Symyx Alliance Agreement in August 2006, June 2007, August 2007, November 2007 and September 2009.

        Under the Symyx agreements, Symyx granted us a license to certain high-throughput combinatorial patents held or licensed by them and related software to design, develop and manufacture integrated circuits, photovoltaic cells, glass coatings, light emitting diodes, organic light-emitting diodes and thin films for electronics, optical and energy applications (Fields), and we agreed to pay Symyx royalties in

92


Table of Contents


connection with such license. During the three months ended March 31, 2011 and 2010 and the years ended December 31, 2010, 2009 and 2008, we recorded $421,000, $279,000, $2.0 million, $1.2 million and $1.0 million in royalty expense, respectively, and had accrued liabilities due to Symyx of $375,000, $795,000 and $502,000 as of March 31, 2011 and December 31, 2010 and 2009, respectively. In addition, during the three months ended March 31, 2011 and 2010 and the years ended December 31, 2010, 2009 and 2008, we purchased $0, $0, $6,000, $14,000 and $286,000, respectively, of fixed assets, maintenance and consumables from Symyx.

        On July 28, 2011, we entered into an agreement with Symyx, pursuant to which we agreed to use commercially reasonable efforts to allow Symyx to sell in this offering             shares of our common stock held by them. Pursuant to the agreement, Symyx agreed to sell such shares and, upon consummation of this offering, including the sale of such shares, to terminate our future royalty obligations under the Symyx agreements to the extent they would have accrued after December 31, 2011. Additionally, upon consummation of this offering and such sale, Symyx would transfer to us all the patents held by them that relate to combinatorial processing. For a more detailed description of the asset purchase, see "Certain Relationships and Related Party Transactions—Symyx."

93


Table of Contents


MANAGEMENT

Executive Officers, Directors and Key Employees

        The following table sets forth certain information about our executive officers, key employees and directors, as of September 1, 2011.

Name
  Age   Position

Executive Officers

         

David E. Lazovsky

    39   President, Chief Executive Officer and Director

Peter L. Eidelman

    45   Chief Financial Officer

Tony P. Chiang, Ph.D. 

    41   Chief Technology Officer

John R. Behnke

    50   Senior Vice President and General Manager, Semiconductor Group

James Craig Hunter

    42   Senior Vice President and General Manager, Clean Energy Group

Sandeep Jaggi, J.D., Ph.D. 

    48   General Counsel and Senior Vice President of Intellectual Property

Zia Malik

    59   Senior Vice President, Global Sales and Marketing

Directors

         

Thomas R. Baruch(1)(3)

    72   Chairman of the Board

Marvin D. Burkett(2)

    69   Director

Irwin B. Federman(1)

    76   Director

Isy Goldwasser

    41   Director

Bruce M. McWilliams(2)(3)

    55   Director

George M. Scalise(2)(3)

    77   Director

John L. Walecka(1)

    51   Director

(1)
Member of the Compensation Committee.

(2)
Member of the Audit Committee.

(3)
Member of the Nominating and Corporate Governance Committee.

Executive Officers

         David E. Lazovsky is our founder and has served as our President and Chief Executive Officer and as a member of our board of directors since September 2004. Mr. Lazovsky brings an in-depth knowledge of semiconductor manufacturing operations and our business and operations to our board of directors. He previously held several senior management positions at Applied Materials Inc. (Applied Materials). From 1996 through August 2004, Mr. Lazovsky held management positions in the Metal Deposition and Thin Films Product Business Group where he was responsible for managing more than $1 billion in Applied Materials' semiconductor manufacturing equipment business. From 2003 until 2004, Mr. Lazovsky managed key strategic accounts in Business Management where he worked closely with leading integrated circuit manufacturers to ensure Applied Materials was developing and providing cutting-edge technology solutions. From 2002 until 2003, Mr. Lazovsky served as the Technology Program Manager for the Endura 2 Platform, Applied Materials' flagship 300mm metallization platform. From 2000 until 2002, Mr. Lazovsky served as Director of Business Management for the European region in the Metal Deposition Product Business Group. Previously, Mr. Lazovsky served as a Business Manager from 1997 to 2000, Account Product Manager from 1996 to 1997 and Total Product Support Engineer from 1995 to 1996. Mr. Lazovsky holds a B.S. in mechanical engineering from Ohio University and, as of September 1, 2011, held 23 pending or issued U.S. patents.

94


Table of Contents

         Peter L. Eidelman has served as our Chief Financial Officer since February 2006. Prior to joining Intermolecular, Mr. Eidelman served as Senior Vice President and Chief Financial Officer at Cellon International from October 2002 to February 2006, where he led the company through several financings, acquisitions, restructurings and divestitures. Mr. Eidelman also served as Chief Financial Officer and Treasurer of Sunrise Telecom Inc. from July 1997 to October 2002, which he helped guide through an initial public offering. Earlier in his career he was the manager of tax, accounting and compliance for Amdahl Corporation from 1994 to July 1997 and a manager at the public accounting firm of Coopers & Lybrand (now part of PricewaterhouseCoopers) from 1988 to 1993. Mr. Eidelman holds a B.S. in accounting from the University of Massachusetts at Amherst and studied business and taxation at Bentley College in Waltham, Massachusetts. He also completed an executive management program at the Wharton School, University of Pennsylvania. Mr. Eidelman is a certified public accountant and a member of the American Institute of Certified Public Accountants, Financial Executives International and the Tax Executives Institute.

         Tony P. Chiang, Ph.D. has served as our Chief Technology Officer since May 2005 and is responsible for our technology strategy and direction, HPC platform development, core technology and applications development and informatics and operations. Prior to joining Intermolecular, in August 2000, Dr. Chiang founded Angstron Systems Inc. (Angstron), a venture-backed atomic layer deposition start-up company that was acquired by Novellus Systems Inc. (Novellus) in April 2004. Following the acquisition, Dr. Chiang then served as Director of Technology for Novellus until April 2005. From February 1996 until he founded Angstron, Dr. Chiang worked in technology development, product, program and account management roles at Applied Materials, where he led the development, productization and qualification of several generations of enabling thin film deposition technologies used in high-volume manufacturing. Dr. Chiang holds a B.S. in materials science and engineering from Cornell University and a Ph.D. in materials science and engineering from the Massachusetts Institute of Technology. As of September 1, 2011, he held 151 pending or issued U.S. patents spanning advanced materials, process, device and device integration technologies, as well as combinatorial systems and methods.

         John R. Behnke has served as our Senior Vice President and General Manager of our Semiconductor Group since July 2011 and had previously served as our Vice President, Worldwide Sales and Marketing since October 2009. Mr. Behnke has more than 27 years of semiconductor industry experience. Most recently he served as Corporate Vice President, Initial Manufacturing Operations & Silicon Technology at Spansion, Inc. (Spansion), with responsibility for all wafer fabrication and its Submicron Development Center. His responsibilities included development of Spansion's proprietary Charge Trapping NOR and NAND process technologies. Mr. Behnke's previous responsibilities at Spansion included product deployment for its Wireless Business Unit. Mr. Behnke worked at Spansion from the time of its initial public offering and spin-off from Advanced Micro Devices, Inc. (AMD)/ Fujitsu in December 2005 until August 2009. Prior to Spansion's spin-off from AMD/Fujitsu, he held various positions in AMD, including as Director of Operations and Technology in its Fab 25 wafer fabrication facility in Austin, Texas from 2000 to 2005, where he was involved in the development of AMD's APC/APM technologies. Prior to Spansion and AMD, Mr. Behnke worked at the Hughes Research Lab in Malibu, California from 1985 to 1992 on the development of InP/GaAs HEMT low noise amplifiers and radiation-hardened SOS. Mr. Behnke holds a B.S. in mechanical engineering with an industrial engineering minor from Marquette University and completed a Clean Energy program at the University of Texas at Austin. As of September 1, 2011, he held five pending or issued U.S. patents.

         J. Craig Hunter has served as Senior Vice President and General Manager of our Clean Energy Group since July 2011 and had previously served as Vice President and General Manager of our Clean Energy Technologies Group since January 2009. From June 2008 to December 2008, he was an Entrepreneur in Residence at Sequoia Capital, with a focus on the photovoltaic industry. Mr. Hunter

95


Table of Contents


previously held several management positions at Applied Materials, including the Managing Director of Channel Development from March 2008 to May 2008, the General Manager of their thin-film solar business from 2005 through March 2008, during which time he oversaw the development of that business from conception of the SunFab Thin Film Line to manufacturing the first solar panels, and Senior Manager of product management of the PVD and e-beam inspection tools used in LCD manufacturing from 2003 through 2005. Prior to joining Applied Materials, Mr. Hunter served in a variety of senior management roles, including Chief Financial Officer of Evercare Corporation, a manufacturer of consumer products, from 1999 to 2001, and Director of Mergers and Acquisitions at The Beacon Group in New York from 1997 to 1999. Mr. Hunter holds a B.A. in East Asian Studies from Harvard College and graduated with high distinction from Harvard Business School. As of September 1, 2011, he held six pending or issued U.S. patents.

         Sandeep Jaggi, J.D., Ph.D. has served as our General Counsel and Senior Vice President of Intellectual Property since July 2011, and had previously served as our Vice President, Legal Affairs, Licensing and Intellectual Property since July 2010. Prior to joining Intermolecular, he was General Counsel and Senior Vice President of Intellectual Property at Robert Bosch Healthcare Inc. (formerly known as Health Hero Network Inc.) from January 2006 to July 2010. Prior to Robert Bosch Healthcare Inc., he held several senior management positions at LSI Logic, Inc. from August 1995 to January 2006, including Vice President, Chief IP Counsel, Assistant Corporate Secretary and Assistant General Counsel. From October 1989 to August 1995, Dr. Jaggi worked for Lockheed Martin at NASA's Stennis Space Center in Mississippi and NASA's Johnson Space Center in Houston, Texas, where he held several positions including Project Leader, Principal Engineer and Senior Scientist. During his time in Houston, he founded ETS Inc., which commercialized space based-technologies for NASA and the U.S. Navy. He obtained a J.D. with a specialization in intellectual property law from Santa Clara University and also holds a B.Tech. in Electrical Engineering from the Indian Institute of Technology, New Delhi, and an M.S. and Ph.D. in Electrical Engineering from Tulane University. As of September 1, 2011, he held 13 pending or issued U.S. patents and is licensed to practice law in the state of California and before the United States Patent and Trademark Office.

         Zia Malik has served as our Senior Vice President, Global Sales and Marketing since May 2011. Prior to joining Intermolecular, he was the founder and Chief Executive Officer of Princely Solar LLC (Princely Solar) from July 2007 to May 2011, and remains a member of Princely Solar's board of directors. Prior to Princely Solar, Mr. Malik held the position of Vice President of Worldwide Sales at PDF Solutions, Inc. from December 2003 to June 2007, where he executed that company's strategy to expand sales into Singapore, Korea and China. Mr. Malik also served as Vice President of Operations at Ishoni Networks from September 2003 to December 2003, and as the Director, Foundry and Contracts Management Group at National Semiconductor Corporation from February 1997 to September 2000. While at National Semiconductor Corporation, Mr. Malik managed the company's diverse contract manufacturing portfolio and was responsible for all technical functions associated with the technology transfer agreements for the company's domestic and international foundries. Mr. Malik obtained a M.S. in Chemistry from the University of Karachi and a master's degree in business administration from the University of Phoenix.

Directors

         Thomas R. Baruch has served as a member of our board of directors since November 2004. Mr. Baruch is the founder and a partner emeritus of CMEA Ventures, a venture capital firm that was established in 1989 as an affiliated fund of New Enterprise Associates. Mr. Baruch brings to our board of directors an extensive knowledge of the clean technology industry and experience he has gained working closely with entrepreneurs to build industry-leading companies in the clean-energy industry, as well as years of public company governance experience. Mr. Baruch currently works with various clean technology companies, including serving as a member of the board of directors for FORO Energy, a

96


Table of Contents


company developing a new hybrid thermal mechanical drilling technology for geothermal energy wells, as the Chairman of the board of directors of Cnano Technology Limited, a leading nanomaterial company that manufactures and develops carbon nanotubes for advanced energy and other applications, and as the Chairman of the board of directors of Wildcat Discovery Technologies, Inc., a company focused on the discovery of advanced materials for clean-energy technology applications. In addition, Mr. Baruch is currently on the board of directors of Codexis, Inc., where he is Chairman and also serves on the audit, compensation and nominating and corporate governance committees of the board of directors, and Entropic Communications, Inc., where he serves on the compensation and nominating and corporate governance committees of the board of directors. Before starting CMEA Ventures, Mr. Baruch was a founder and Chief Executive Officer of Microwave Technology, Inc., a supplier of gallium arsenide integrated circuits. Prior to his employment with Microwave Technology, Inc., Mr. Baruch managed a dedicated venture fund at Exxon Corporation, and was president of the Exxon Materials Division. Earlier in his career, Mr. Baruch worked as a patent attorney and remains a registered patent attorney. He is also both a member of the Executive Committee of the Council of Competitiveness and a member of the Steering Committee of the ESIS Initiative (Energy, Security, Innovation and Sustainability) of the Council of Competitiveness. Mr. Baruch is a member of the board of trustees of Rensselaer Polytechnic Institute, the National Advisory Council on Innovation and Entrepreneurship and the Sierra's Club Climate Recovery Cabinet. Mr. Baruch holds a B.S. in engineering from Rensselaer Polytechnic Institute and a J.D. from Capital University.

         Marvin D. Burkett has served as a member of our board of directors since June 2011. A 40-year veteran of the semiconductor industry, Mr. Burkett brings to our board of directors years of experience with global semiconductor and personal computing companies, as well as in-depth knowledge of public company financial and accounting principles. Mr. Burkett served as Senior Advisor to NVIDIA Corporation (NVIDIA) from February 2009 until January 2011. Previously, he began at NVIDIA in August 2002 and served as its Chief Financial Officer from September 2002 to February 2009. Prior to NVIDIA, Mr. Burkett served as the Chief Financial Officer of Arcot Systems, Inc., and also as its Financial Consultant from February 2000 to September 2002. Mr. Burkett also served as an Executive Vice President and Chief Financial Officer of Packard Bell NEC (PBNEC) from 1998 to 1999. Prior to PBNEC, he spent 26 years at AMD from 1972 to 1998, where he served in a variety of positions, including Chief Financial Officer, Senior Vice President, Chief Administrative Officer and Corporate Controller. Mr. Burkett also worked in the Semiconductor Division of Raytheon Company. Mr. Burkett has served as a member of the board of directors and the chair for the audit committee of the board of directors for each of Audience, Inc., since September 2010, G2 Holdings Corporation since January 2011 and NetLogic Microsystems, Inc., since December 2010. Mr. Burket has also served as a member of the board of directors for Entegris, Inc., since May 2010, where he is also the chair for the audit committee and a member of the compensation committee. Mr. Burkett holds a master's degree in business administration and a BS degree in applied mathematics and business administration, both from the University of Arizona.

         Irwin B. Federman has served as a member of our board of directors since June 2005. Mr. Federman brings to our board of directors an extensive knowledge of the semiconductor industry as well as public company governance experience. Mr. Federman has been a managing member at U.S. Venture Partners, a venture capital firm, since April 1990. Mr. Federman was President and Chief Executive Officer of Monolithic Memories, Inc., a semiconductor company, from 1979 to 1987, where he also served as the Chief Financial Officer from 1970 to 1979. Mr. Federman also serves on the board of directors and as a member of the audit and compensation committees of the board of directors for each of SanDisk Corporation, Check Point Software Technologies Ltd., a security software company, and Mellanox Technologies, Ltd., a semiconductor company. Mr. Federman also serves on the board of directors for various private corporations, including Neoconix, Inc., ON24, Inc., Silego Technology, Inc. and Supply Frame, Inc., as well as charitable trusts, including the San Francisco Ballet,

97


Table of Contents


the Brooklyn College Foundation and the San Francisco Museum of Modern Art. Previously, Mr. Federman served as a director of Centillium Communications, Inc., a developer and supplier of communications integrated circuits, and Nuance Communications, Inc., a speech recognition software company. Mr. Federman holds a B.S. in Economics from Brooklyn College and was awarded an Honorary Doctorate of Engineering from Santa Clara University.

         Isy Goldwasser has served as a member of our board of directors since August 2008. Mr. Goldwasser has been an entrepreneur-in-residence at Khosla Ventures since April 2011 and is an investor in the life sciences and energy industries. Mr. Goldwasser has also been an independent consultant providing technical and business advisory services for Accelyrs, Inc. (Accelrys) since April 2011. Mr. Goldwasser brings to our board of directors an in-depth knowledge of and years of investment experience in the life sciences and energy industries. Mr. Goldwasser served as advisor to the Chief Executive Officer of Accelrys from July 2010 to April 2011, following the merger of Symyx Technologies, Inc. (Symyx) and Accelrys. He was the first employee of Symyx at its founding in 1995, and became its President in 1998 and its Chief Executive Officer in June 2007. Mr. Goldwasser also serves on the board of directors of Kalypsys, Inc. Mr. Goldwasser holds a B.S. in chemical engineering from the Massachusetts Institute of Technology and an M.S. degree in chemical engineering from Stanford University.

         Bruce M. McWilliams has served as a member of our board of directors since March 2005. Dr. McWilliams brings to our board of directors broad experience in the electronics manufacturing and clean technology sectors as well as extensive management experience. Dr. McWilliams has served as Chief Executive Officer of SuVolta, Inc., a developer of low-power, high-performance integrated circuit technology, since June 2009. Dr. McWilliams also served as a director of Tessera Technologies, Inc. from 1999 to January 2011, where he previously served as its Chief Executive Officer from June 1999 to September 2008 and Chief Strategic Officer from September 2008 to March 2009. Dr. McWilliams also founded and served as Chief Executive Officer of SVision LLC, a silicon chip-based display company, from 1996 to 1999. His management experience also includes serving as Senior Vice President at Flextronics International, or Flextronics, from 1995 to 1996, a position he assumed upon Flextronics' acquisition of nCHIP, Inc., a multi-chip module packaging company that he co-founded and led as Chief Executive Officer from 1989 to 1995. He currently serves on the board of directors of NemoTEK Technologies, a mobile phone camera manufacturing company, REEL Solar, Inc., a solar heating technology company, and NovaTorque, Inc., a magnet motor design company, and is also a trustee of Carnegie Mellon University and a member of its advisory boards for Physics and Human and Computer Interaction. He holds B.S., M.S. and Ph.D. degrees in physics from Carnegie Mellon University.

         George M. Scalise has served as a member of our board of directors since December 2004. Mr. Scalise brings to our board of directors extensive knowledge of the semiconductor industry and market analysis. Mr. Scalise served as President Emeritus of the Semiconductor Industry Association, or SIA, an association of semiconductor manufacturers and suppliers, from July 2010 to December 2010. Mr. Scalise previously worked at Apple Computer, Inc., where he served as Executive Vice President and Chief Administrative Officer from March 1997 to May 1998, and has also held executive management positions at National Semiconductor Corporation, Maxtor Corporation, AMD, Fairchild Semiconductor Corporation and Motorola Semiconductor. Mr. Scalise was Chairman of the Board of the Federal Reserve Bank of San Francisco from May 2003 to December 2005, and also served on President George W. Bush's Council of Advisors on Science and Technology. He currently serves on the boards of directors of ATMI, Inc., MindTree Limited and Cadence Design Systems, Inc. He served on the California Council on Science and Technology and was a member of the Joint High-Level Advisory Panel of the United States-Israel Science and Technology Commission, and chaired the Secretary of Energy Advisory Board at the US Department of Energy. Mr. Scalise holds a B.S. in mechanical engineering from Purdue University.

98


Table of Contents

         John L. Walecka has served as a member of our board of directors since January 2005. Mr. Walecka is a founding partner and has served as a general partner of Redpoint Ventures since its founding in 1999, and brings to our board of directors the extensive experience he has gained working closely with entrepreneurs to build industry-leading companies in emerging cleantech and technology sectors. Prior to founding Redpoint, he was a general partner with Brentwood Venture Capital from 1984 to 1999. Mr. Walecka currently works with Entropic Communications, Inc., where he serves as a member of the board of directors, as well as Fortinet, Inc., where he serves as a member of the board of directors as well as a member of the audit, compensation and nominating and corporate governance committees. Mr. Walecka also serves as a member of the boards of directors of Avnera Corporation, Envia Systems, Inc., Schooner Information Technology, Inc., and Datameer Inc. Mr. Walecka also works with software infrastructure and security products for the enterprise market as well as enabling products for the cable, consumer and broadband markets. Mr. Walecka served as director of the Western Association of Venture Capitalists and is currently a director of the Stanford Business School Venture Capital Trust and an advisor to the Stanford Engineering School. Earlier in his career, he worked for Hewlett Packard Corporation and the Stanford University Smart Product Design Laboratory. He holds B.S. and M.S. degrees in engineering from Stanford, and an MBA from Stanford's Graduate School of Business.

Scientific Advisory Board

        We maintain a scientific advisory board consisting of members with experience and expertise in the field of molecular engineering electronics who provide us with consulting services. Our scientific advisory board consists of the following members:

         Georges Belfort, Ph.D., is the Russell Sage Endowed Professor of Chemical Engineering in the Howard P. Isermann Department of Chemical and Biological Engineering at Rensselaer Polytechnic Institute. Prior to joining Rensselaer, he spent four years on the faculty of the School of Applied Science at Hebrew University in Jerusalem. Dr. Belfort received his B.S. degree in chemical engineering from the University of Cape Town, and his M.S. and Ph.D. in engineering from the University of California, Irvine. He has won several major awards in separation science, and has made important contributions to the field of surface and interfacial science. He was elected to the National Academy of Engineering in 2003.

         James R. Engstrom, Ph.D., is currently the BP Amoco/H. Laurance Fuller Professor in the School of Chemical and Biomolecular Engineering at Cornell University. Since 2002 he has also been a member of the Graduate Field of Chemistry and Chemical Biology. Dr. Engstrom is the recipient of numerous awards, including a 1991 NSF Presidential Young Investigator Award, the Lilly Endowment Teaching Fellowship in 1995, and two College of Engineering Teaching Awards. In 2005 he was made a Fellow of the American Vacuum Society. From 1998 to 2001, he worked for Symyx Technologies, Inc., where he was vice president of high-throughput screening and electronic materials. Presently, Dr. Engstrom's research is focused on inorganic-organic interfaces, and organic thin-film electronics. He earned a B.S. in chemical engineering from the University of Minnesota, and a Ph.D. in chemical engineering from the California Institute of Technology.

         J.M.J. Fréchet, Ph.D., is currently Vice President for Research at King Abdullah University of Science and Technology, where he has served since June 2010. Previously, Dr. Fréchet served as the Henry Rapoport Endowed Chair in Organic Chemistry at the Department of Chemistry, University of California, Berkeley. He also serves as scientific director for the Molecular Foundry at Lawrence Berkeley National Laboratory. His research, reported in nearly 1,000 scientific publications and patents, focuses mainly on organic and polymer chemistry applied to nanoscience and nanotechnology, with emphasis on the design, synthesis, fundamental understanding and applications of functional macromolecules. Dr. Fréchet is a member of the National Academy of Sciences and the National Academy of Engineering. In addition to a B.S. in chemical engineering from the Institut de Chimie et

99


Table of Contents


Physique Industrielles in Lyon, France, he holds M.S. and Ph.D. degrees in chemistry from Syracuse University and the State University of New York, respectively.

         Craig J. Hawker, Ph.D., is director of the Materials Research Laboratory and professor of Materials and Chemistry at the University of California, Santa Barbara. Prior to joining the university, he was a research staff member at the IBM Almaden Research Center in San Jose. Dr. Hawker is editor of the Journal of Polymer Science-Polymer Chemistry, and is an honorary Professor of Chemistry at the University of Queensland. He serves on the scientific advisory boards of Relypsa, Inc., and Warwick Effect Polymers Ltd. He is the recipient of numerous awards, most notably election to the Royal Society, the 2010 MacroUK Award for Outstanding Achievement, and the 2008 DSM International Performance Materials Award. Dr. Hawker's research has focused on the interface between organic and polymer chemistry, with emphasis on the design, synthesis and application of well-defined macromolecular structures in biotechnology, microelectronics, and surface science.

         Yoshio Nishi, Ph.D., has been professor of electrical engineering at Stanford University since 2002, and serves as director of research at the Center for Integrated Systems and director of Stanford Site at National Nanotechnology Infrastructure Network. With a Ph.D. in electronics engineering from the University of Tokyo, Dr. Nishi has worked at the senior level with Toshiba R&D for VLSI memory technology and Si-SiO2 interface physics, Hewlett-Packard Laboratories ULSI Research Lab, and Texas Instruments, Inc. R&D. He has contributed to more than 250 publications, co-authored or edited 11 books, and has been responsible for over 70 Japan and U.S. patents. A fellow of the Institute of Electrical and Electronics Engineers (IEEE) and a member of the Japan Society of Applied Physics and The Electrochemical Society, he has received numerous awards over the past 15 years.

         Ralph G. Nuzzo, Ph.D., a recognized leader in the chemistry of materials, is director of the Frederick Seitz Materials Research Laboratory and the Center for Microanalysis of Materials at the University of Illinois Urbana-Champaign. He also serves as the William H. and Janet Lycan Professor of Chemistry and a Professor of Materials Science and Engineering at the university. Dr. Nuzzo received his B.S. in chemistry from Rutgers University and his Ph.D. in organic chemistry from MIT. After completing his graduate studies, he was a distinguished member of the technical staff in materials research at Bell Laboratories.

         J. George Shanthikumar, Ph.D., is Professor of Industrial Engineering and Operations Research at the University of California, Berkeley. He has authored or coauthored more than 250 papers and has coauthored three books, "Stochastic Models of Manufacturing Systems," "Stochastic Orders And Their Applications" and "Stochastic Orders." He is a co-editor of Flexible Services and Manufacturing Journal, and has served on numerous technical journal editorial boards. As a consultant for KLA-Tencor Corp., he worked on joint development projects with semiconductor companies such as AMD, IBM, Intel, LSI Logic, Motorola, Texas Instruments, Toshiba, Fujitsu, TSMC and UMC. He received a B.S. in mechanical engineering from the University of Sri Lanka, and an M.S. and Ph.D. in industrial engineering from the University of Toronto.

         Anthony J. Tether, Ph.D., was director of the Defense Advanced Research Projects Agency (DARPA) from 2001 to 2009. Prior to this, Dr. Tether founded The Sequoia Group and served as its Chief Executive Officer and President; he also served as Chief Executive Officer of Dynamics Technology Inc. and in top-level management roles at Science Applications International Corporation and Ford Aerospace Corp. He has also held other positions in the Department of Defense, serving as Director of DARPA's Strategic Technology Office, and as the Director of National Intelligence in the Office of the Secretary of Defense. Dr. Tether has served on Army, Navy and Defense Science Boards, and on the Office of National Drug Control Policy Research and Development Committee. He is a Life Member of IEEE. Dr. Tether received his B.S. in electrical engineering from Rensselaer Polytechnic Institute, and his M.S. and Ph.D. in electrical engineering from Stanford University.

100


Table of Contents

         W. Henry Weinberg, Ph.D., is an award-winning scientist and advisor to start-ups and venture firms in the chemical space. He currently serves as general editor of the prestigious review journal Surface Science Reports. Previously, he was Chief Technical Officer at Draths Corporation and Chief Technology Officer at Symyx. For more than 24 years, he was on the faculty of both the California Institute of Technology and the University of California, Santa Barbara. Dr. Weinberg was also principal investigator in the US-USSR Exchange Program in Chemical Catalysis between 1974 and 1980, and has served on many review panels for industrial, academic and governmental organizations. He holds a B.S. degree in chemical engineering from the University of South Carolina, and a Ph.D. in chemical engineering from the University of California, Berkeley.

Board Composition

        In accordance with our amended and restated certificate of incorporation to take effect following the completion of this offering, our board of directors will be divided into three classes with staggered three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following their election. After the completion of this offering, our directors will be divided among the three classes as follows:

    the Class I directors will be            ,             and            , and their terms will expire at the annual meeting of stockholders to be held in                        2012;

    the Class II directors will be            ,             and            , and their terms will expire at the annual meeting of stockholders to be held in                        2013; and

    the Class III directors will be            ,             and            , and their terms will expire at the annual meeting of stockholders to be held in                        2014.

        Our amended and restated certificate of incorporation will provide that the authorized number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change of control at our company.

Voting Arrangements

        Pursuant to a voting agreement that we entered into with certain holders of our common stock and certain holders of our redeemable convertible preferred stock:

    CMEA Ventures VI, L.P. (or its affiliates) has the right to nominate a director to our board of directors;

    Redpoint Ventures II, L.P. (or its affiliates) has the right to nominate a director to our board of directors;

    U.S. Venture Partners IX, L.P. (or its affiliates) has the right to nominate a director to our board of directors;

    Symyx Technologies, Inc. (or its affiliates) (Symyx) has the right to nominate a director to our board of directors, subject to approval by our board of directors in the event such nominee is not the then-current Chairman, Chief Executive Officer, President or Chief Operating Officer of Symyx;

    our then-incumbent Chief Executive Officer has the right to be nominated to serve on our board of directors; and

101


Table of Contents

    the holders of a majority of our common stock and the holders of a majority of our redeemable convertible preferred stock, in each case voting as a separate class, have the right to nominate two directors to our board of directors,

and the holders of our common stock and redeemable convertible preferred stock who are parties to the voting agreement are obligated to vote for such nominee. The provisions of this voting agreement will terminate upon the completion of this offering and there will be no further contractual obligations regarding the election of our directors. Our directors hold office until their successors have been elected and qualified or appointed, or the earlier of their death, resignation or removal.

Director Independence

        Upon the completion of this offering, our common stock will be listed on either the Nasdaq Global Market or the New York Stock Exchange. Under the rules of The Nasdaq Stock Market and the New York Stock Exchange, independent directors must comprise a majority of a listed company's board of directors within a specified period of the completion of this offering. In addition, the rules of The Nasdaq Stock Market and the New York Stock Exchange require that, subject to specified exceptions, each member of a listed company's audit, compensation and nominating and governance committees be independent. Audit committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended. Under the rules of The Nasdaq Stock Market and the New York Stock Exchange, a director will only qualify as an "independent director" if, in the opinion of that company's board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

        To be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee: (1) accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries; or (2) be an affiliated person of the listed company or any of its subsidiaries.

        In                        , our board of directors undertook a review of its composition, the composition of its committees and the independence of each director. Based upon information requested from and provided by each director concerning his background, employment and affiliations, including family relationships, our board of directors has determined that none of Messrs. Baruch, Burkett, Federman, Scalise and Walecka or Dr. McWilliams, representing six of our eight directors, has a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is "independent" as that term is defined under the rules of The Nasdaq Stock Market or the New York Stock Exchange. Our board of directors also determined that Messrs. Burkett and Scalise and Dr. McWilliams, who comprise our audit committee, Messrs. Baruch, Federman and Walecka, who comprise our compensation committee, and Messrs. Baruch and Scalise and Dr. McWilliams, who comprise our nominating and governance committee, satisfy the independence standards for those committees established by applicable SEC rules and the rules of The Nasdaq Stock Market and the New York Stock Exchange. In making this determination, our board of directors considered the relationships that each non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director.

Board Committees

        Our board of directors has the following committees: an audit committee, a compensation committee and a nominating and corporate governance committee. The composition and

102


Table of Contents


responsibilities of each committee are described below. Members serve on these committees until their resignation or until otherwise determined by our board of directors.

Audit Committee

        Our audit committee oversees our corporate accounting and financial reporting process. Among other matters, the audit committee: appoints the independent registered public accounting firm; evaluates the independent registered public accounting firm's qualifications, independence and performance; determines the engagement of the independent registered public accounting firm; reviews and approves the scope of the annual audit and the audit fee; discusses with management and the independent registered public accounting firm the results of the annual audit and the review of our quarterly consolidated financial statements; approves the retention of the independent registered public accounting firm to perform any proposed permissible non-audit services; monitors the rotation of partners of the independent registered public accounting firm on our engagement team as required by law; reviews our consolidated financial statements and our management's discussion and analysis of financial condition and results of operations to be included in our annual and quarterly reports to be filed with the SEC; reviews our critical accounting policies and estimates; and annually reviews the audit committee charter and the committee's performance. The current members of our audit committee are Messrs. Burkett and Scalise and Dr. McWilliams. Mr. Burkett serves as the chairman of the committee. All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC, The Nasdaq Stock Market and the New York Stock Exchange. Our board of directors has determined that Mr. Burkett is an audit committee financial expert as defined under the applicable rules of the SEC and has the requisite financial sophistication as defined under the applicable rules and regulations of The Nasdaq Stock Market and the New York Stock Exchange. Each of the members of our audit committee qualifies as an independent director under the applicable rules and regulations of the SEC, The Nasdaq Stock Market and the New York Stock Exchange relating to audit committee independence. The audit committee operates under a written charter that satisfies the applicable standards of the SEC, The Nasdaq Stock Market and the New York Stock Exchange.

Compensation Committee

        Our compensation committee reviews and recommends policies relating to compensation and benefits of our officers and employees. The compensation committee reviews and approves corporate goals and objectives relevant to compensation of our Chief Executive Officer and other executive officers, evaluates the performance of these officers in light of those goals and objectives, and sets the compensation of these officers based on such evaluations. The compensation committee also approves grants of stock options and other awards under our stock plans. The compensation committee will review and evaluate, at least annually, the performance of the compensation committee and its members, including compliance of the compensation committee with its charter. The current members of our compensation committee are Messrs. Baruch, Federman and Walecka. Mr. Baruch serves as the chairman of the committee. Each of the members of our compensation committee is an independent or outside director under the applicable rules and regulations of the SEC, The Nasdaq Stock Market, the New York Stock Exchange and the Internal Revenue Code of 1986, as amended relating to compensation committee independence. The compensation committee operates under a written charter.

Nominating and Corporate Governance Committee

        The nominating and corporate governance committee is responsible for making recommendations to our board of directors regarding candidates for directorships and the size and composition of our board of directors. In addition, the nominating and corporate governance committee is responsible for overseeing our corporate governance policies and reporting and making recommendations to our board

103


Table of Contents


of directors concerning governance matters. The current members of our nominating and corporate governance committee are Messrs. Baruch and Scalise and Dr. McWilliams. Mr. Baruch serves as the chairman of the committee. Each of the members of our nominating and corporate governance committee is an independent director under the applicable rules and regulations of the SEC, The Nasdaq Stock Market and the New York Stock Exchange relating to nominating and corporate governance committee independence. The nominating and corporate governance committee operates under a written charter.

        There are no family relationships among any of our directors or executive officers.

Compensation Committee Interlocks and Insider Participation

        None of the members of our compensation committee has at any time during the prior three years been an officer or employee of ours. None of our executive officers currently serves or in the prior three years has served as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our board of directors or compensation committee.

Code of Business Conduct and Ethics

        We will adopt a code of business conduct and ethics that applies to all of our employees, officers and directors, including those officers responsible for financial reporting. The code of business conduct and ethics will be available on our website at www.intermolecular.com. Any amendments to the code, or any waivers of its requirements, will be disclosed on our website. Information contained on or accessible through our website is not incorporated by reference into this prospectus, and you should not consider information contained on or accessible through our website to be part of this prospectus.

104


Table of Contents


EXECUTIVE COMPENSATION

Compensation Discussion and Analysis

        This section discusses the principles underlying our policies and decisions with respect to the compensation of our executive officers who are named in the "2010 Summary Compensation Table" and the most important factors relevant to an analysis of these policies and decisions. In 2010, our "named executive officers" were as follows:

        The titles above reflect promotions received by Mr. Hunter and Dr. Jaggi in July 2011. In 2010, Mr. Hunter's principal position was Vice President and General Manager, Clean Energy Technologies, and Dr. Jaggi's position was Vice President, Legal Affairs, Licensing and Intellectual Property.

        The following discussion and analysis of compensation arrangements of our named executive officers should be read together with the compensation tables and related disclosures set forth below. This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt following the completion of this offering may differ materially from the currently-planned programs summarized in this discussion.

Determination of Compensation

        Our compensation committee is responsible for overseeing our executive compensation program, as well as determining and approving the ongoing compensation arrangements for our Chief Executive Officer and other named executive officers. The compensation committee meets periodically throughout the year to review and determine adjustments, if any, to the compensation, including base salary, annual bonus and long-term equity awards, for our named executive officers, including our Chief Executive Officer. For 2010, the compensation committee determined each individual component of compensation for our named executive officers. Following the completion of this offering, the compensation committee will continue to oversee the review process for all named executive officers.

        Our Chief Executive Officer evaluates the individual performance and contributions of each other named executive officer and, at least annually, reports to the compensation committee his recommendations regarding each element of the other named executive officers' compensation. Our Chief Executive Officer does not participate in any formal discussion with the compensation committee regarding decisions on his own compensation and recuses himself from meetings when his compensation is discussed.

        We do not generally rely on formulaic guidelines for determining the mix or levels of cash and equity-based compensation, but rather maintain a flexible compensation program that allows us to adapt components and levels of compensation to motivate and reward individual named executive officers within the context of our desire to attain financial and operational goals. Subjective factors considered in compensation determinations include a named executive officer's skills and capabilities, contributions as a member of the executive management team, contributions to our overall performance and whether the total compensation potential and structure is sufficient to ensure the

105


Table of Contents


retention of a named executive officer when considering the compensation potential that may be available elsewhere.

        The market for experienced management is highly competitive in our industry. Our goal is to attract and retain the most highly qualified executives to manage each of our business functions. In doing so, we draw upon a pool of talent that is highly sought after both by large and established technology companies in our geographic area and by other competitive companies in development or early stage phases. Established organizations in our industry seek to recruit top talent from emerging companies in the sector just as smaller organizations look to attract and retain the best talent from the industry as a whole. The competition for technical and non-technical skills is aggressive across the sector and we expect it to remain aggressive for the foreseeable future.

        Our compensation committee determines compensation for our named executive officers, in large part based upon our financial resources, but also considering competitive market data. Prior to 2010, in making compensation determinations the compensation committee relied on the recommendations from our Chief Executive Officer and the experience of its members in similar companies. In setting both cash and equity compensation for 2010, our compensation committee conducted a review of our named executive officer compensation, as well as the mix of elements used to compensate our named executive officers, and compared this compensation information with data contained in third-party surveys produced by Thelander and Radford. The surveys compiled executive compensation data primarily from private technology and life sciences companies and reported such data on an aggregate basis. The surveys reported compensation, position and responsibilities of executives. While our compensation committee reviewed compensation levels and elements derived from this supplemental industry data, our compensation committee was not aware of the identity of any of the surveyed companies and, as such, did not rely on data for any single company.

        Historically, our compensation committee has not engaged the services of a compensation consultant; however, in connection with this offering, our compensation committee has engaged a compensation consultant directly to assist the committee in designing programs and setting compensation levels that are appropriate for a public company.

Executive Compensation Philosophy and Objectives

        We operate in the highly competitive and dynamic technology industry, which is characterized by frequent technological advances and rapidly changing market requirements. To succeed in this environment, we must continuously develop and refine new and existing products and services, and to achieve these objectives, we need a highly talented and seasoned team of technical, sales, marketing, operations, financial and other business professionals. Our executive compensation philosophy recognizes that, given that the market for experienced management is highly competitive in our industry, key and core to our success is our ability to attract and retain the most highly-qualified executives to manage each of our business functions. We regard as fundamental that executive officer compensation be structured to provide competitive base salaries and benefits to attract and retain superior employees, and to provide incentive compensation to motivate executive officers to attain, and to reward executive officers for attaining, established financial, operational and other goals that are consistent with increasing stockholder value.

        In determining the form and amount of compensation payable to the named executive officers, we are guided by the following objectives and principles:

106


Table of Contents

        We design the principal components of our executive compensation program to fulfill one or more of the principles and objectives described above. Compensation for our named executive officers consists of the elements identified in the following table:

Compensation Element                                  
  Primary Objective

Base salary

  To recognize ongoing performance of job responsibilities and as a necessary tool in attracting and retaining employees

Annual performance-based cash compensation (bonuses)

 

To emphasize corporate and individual objectives and provide reward opportunities for our named executive officers (and employees generally) when key business and individual objectives are met

Long-term equity incentive compensation

 

To incentivize and reward increases in stockholder value, to emphasize and reinforce our focus on team success and to attract and retain key employees

Retirement savings (401(k)) plan

 

To provide retirement savings in a tax-efficient manner

Health and welfare benefits

 

To provide a basic level of protection from health, dental, life and disability risks

        We view the components of our executive compensation program as related but distinct, and we regularly reassess the total compensation of our named executive officers to ensure that our overall compensation objectives are met. Historically, not all components have been provided to our named executive officers. We have considered, but not relied exclusively upon, the following factors in determining the appropriate level for each compensation component: our understanding of the competitive market based on the collective experience of members of our compensation committee and their review of compensation surveys; our recruiting and retention goals; our view of internal equity

107


Table of Contents


and consistency; the length of service of our executive officers; our overall performance and other considerations our compensation committee determines are relevant.

        Each of the primary elements of our executive compensation program is discussed in more detail below. While we have identified particular compensation objectives that each element of executive compensation serves, our compensation programs are designed to be flexible and complementary and to collectively serve all of the executive compensation objectives described above. Accordingly, whether or not specifically mentioned below, we believe that, as a part of our overall executive compensation policy, each individual element, to a greater or lesser extent, serves each of our compensation objectives and that, collectively, they are effective in achieving our overall objectives.

Elements of Executive Compensation Program

        The following describes the primary components of our executive compensation program for each of our named executive officers, the rationale for that component and how compensation amounts are determined.

        We provide our executive officers, including our named executive officers, with a base salary to compensate them for services rendered to our company during the fiscal year. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive's skill set, experience, role and responsibilities. Generally, initial base salary amounts were established based on consideration of, among other factors, the scope of the named executive officer's responsibilities, years of service and the compensation committee's general knowledge of the competitive market based on, among other things, experience with other companies and our industry.

        Thereafter, the base salaries of our named executive officers have been reviewed annually by the compensation committee and merit salary increases have been made as deemed appropriate based on such factors as the scope of an executive officer's responsibilities, individual contribution, prior experience and sustained performance.

        In February 2010, the compensation committee approved a base salary increase of 3.5% for each of our named executive officers other than Dr. Chiang, who received an increase of 8%. The base salary increases were partially merit-based and also reflected a cost of living adjustment for each of our named executive officers. Dr. Chiang received a larger salary increase based on his significant contributions to us in 2009, reflecting his increased responsibilities with respect to managing our engineering and technology divisions. The actual base salaries paid to the named executive officers during 2010 are set forth in the "2010 Summary Compensation Table" below.

        In February 2011, the compensation committee approved base salary increases of 22.3%, 8.5%, 8.2% and 8.7%, for Messrs. Lazovsky, Eidelman and Hunter and Dr. Chiang, respectively. The base salary increases reflected the compensation committee's review of compensation survey data and the experience of its members with similar companies.

        We use cash bonuses to motivate our named executive officers to achieve our short-term financial and strategic objectives while making progress towards our longer-term growth and other goals.

        We provide cash bonuses to incentivize named executive officers to achieve annual corporate performance goals. All of our named executive officers are eligible for annual cash bonuses, which are determined annually at the discretion of the compensation committee. Determination of the bonus payouts for the named executive officers is based on funding of our company-wide bonus pool. For 2010, the bonus pool was funded based on our achievement of pre-established targets. A base bonus

108


Table of Contents


pool was established at a level of 8% of our base salary accrual. Our compensation committee established the target size of the bonus pool based upon the experience of its members with similar companies and after reviewing the compensation surveys. The achievement of each corporate performance objective target was weighted, such that the available bonus pool would be determined by multiplying the percentage of corporate performance objectives actually achieved (as determined based on the respective weighting of each objective) by the base bonus pool. The table below sets forth the 2010 pre-established corporate performance targets and relevant weighting:

2010 Corporate Performance Objectives
  Weighting of Corporate
Performance Objectives
 

Positive pro forma profit

    6.66 %

EBITDA profit greater than 10%

    6.67 %

2010 year-end cash greater than $20 million

    6.67 %

Bookings greater than $50 million

    30 %

Revenue greater than $40 million

    15 %

Customer production qualification milestone

    10 %

Customer qualification milestone

    10 %

Customer HPC-derived product revenue greater than $10 million

    7.5 %

HPC WF and Informatics license renewals greater than $5.3 million

    7.5 %

        In order to be considered in determining the size of the bonus pool, we must achieve at least 80% of the goal of certain performance objectives, such as bookings greater than $50 million and revenue greater than $40 million; other performance objectives, such as positive pro forma profit, require achievement of the stated goal in order to be considered in determining the size of the bonus pool. Based on our achievement of each performance objective, the weighting of the performance objective may be increased or decreased as determined by the compensation committee in its discretion. Based on our actual achievement in 2010 of 98% of the corporate performance objectives, in early 2011, the compensation committee established a bonus pool equal to 8% of our base salary accrual, or approximately $1.2 million, of which 40% was reserved for executive management, including named executive officers. The compensation committee in its discretion determines the size of our Chief Executive Officer's cash bonus award. Except with respect to himself, our Chief Executive Officer recommends the size of the cash bonus award for each named executive officer, but each award is ultimately determined by the compensation committee in its discretion. One factor considered in making bonus determinations was the compensation committee's performance review of our executive officers, which accounts for, among other things, the executive's initiative, teamwork, management skills and communications. The cash bonuses paid to our named executive officers for the 2010 fiscal year are set forth in the "2010 Summary Compensation Table" below.

        In addition, in the first quarter of 2010, we awarded a $110,000 discretionary cash bonus to Mr. Lazovsky based on the successful execution of a multi-year customer contract. As he was eligible to receive a cash bonus upon execution of the contract, we did not award Mr. Lazovsky a separate discretionary annual cash bonus under our 2009 bonus pool for services rendered in 2009.

        The goals of our long-term equity-based awards are to reward and encourage long-term corporate performance based on the value of our common stock and, thereby, to align the interests of our executive officers, including our named executive officers, with those of our stockholders. Our board of directors adopted the 2004 Equity Incentive Plan (amended and restated on September 5, 2007), or the 2004 Plan, in order to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentives to our employees, consultants and non-employee

109


Table of Contents

directors and to promote the success of our business. The 2004 Plan provides for the grant of stock options and restricted stock.

        We intend to adopt a 2011 Incentive Award Plan, or the 2011 Plan, which will be effective upon the consummation of this offering. Upon the effectiveness of the 2011 Plan, no further grants will be made under the 2004 Plan. For additional information regarding the 2004 Plan and the 2011 Plan, see the section entitled "—Equity Incentive Plans" below. We do not currently have any formal stock ownership requirements or guidelines for our named executive officers, given the limited market for our securities. Our compensation committee will continue to periodically review best practices and re-evaluate our position with respect to such requirements or guidelines.

        Equity Award Features.     Historically we have granted stock options to our named executive officers. Since our named executive officers are able to benefit from stock options only if the market price of our common stock increases relative to the stock option's exercise price, we believe stock options provide meaningful incentives to our named executive officers to achieve increases in the value of our stock over time and are an effective tool for meeting our compensation goal of increasing long-term stockholder value by tying the value of these stock options to our future performance. We also believe stock option grants encourage the retention of our named executive officers because the vesting of equity awards is largely based on continued employment.

        We generally use stock options to compensate our named executive officers in the form of both initial grants in connection with the commencement of employment and additional "incentive" grants. The compensation committee, based on recommendations from our Chief Executive Officer and its review of compensation survey data, approves a pool of shares to be awarded to employees as an annual incentive grant and reserves 25 - 30% of the pool for stock options to be granted to the executive management team. To date, there has been no set program for the award of incentive grants, and our compensation committee retains discretion to make stock option awards to employees at any time, including in connection with the promotion of an employee, to reward an employee, for retention purposes or in other circumstances recommended by management.

        The exercise price of each stock option grant is equal to the fair market value of our common stock on the grant date. Since 2007, the determination of the appropriate fair market value of our common stock has been made by our compensation committee. In the absence of a public trading market, our compensation committee has reviewed a common stock valuation analysis prepared by an independent third-party appraiser in determining the fair market value of our common stock. It is our policy that stock options granted after the completion of this offering will have a per share exercise price that is not less than the closing price of a share of our common stock on the grant date. Stock options typically vest over a four-year period as follows: 25% of the shares underlying an option vest on the first anniversary of the vesting commencement date, and the remainder of the shares underlying an option vest in substantially equal monthly installments over the next 36 months. Stock options granted to our named executive officers in 2007 and prior years may be exercised prior to fully vesting but are subject to a right of repurchase by us at the exercise price paid by the named executive officer that lapses pursuant to the vesting schedule of the option. We believe the vesting schedule of our stock options appropriately encourages long-term employment with our company while allowing our executives to realize compensation in line with the value they have created for our stockholders.

        In February 2010, each of our named executive officers, other than Mr. Jaggi, was granted an option to purchase shares of our common stock as part of our annual incentive grant program. These options are subject to the vesting terms described in the paragraph immediately above and were granted at an exercise price of $1.33 per share, which was equal to the fair market value of our common stock on the grant date. In August 2010, in connection with the commencement of his employment, Mr. Jaggi was granted an option to purchase 500,000 shares of our common stock at an

110


Table of Contents


exercise price of $1.33 per share, which was equal to the fair market value of our common stock on the grant date.

        In March 2011, each of our named executive officers was granted an option to purchase shares of our common stock as part of our annual incentive grant program. These options are subject to the vesting terms described above and were granted at an exercise price of $3.10 per share, which was equal to the fair market value of our common stock on the grant date. In determining the size of the incentive grants, the compensation committee approved a pool of 1.2 million shares, of which 30% were reserved for executives. In determining the size of the stock option pool and the allocation to named executive officers, the compensation committee reviewed the compensation survey data and drew upon the experience of its members with similar companies.

Name
  2010 Stock
Option Grants
  March 2011 Stock
Option Grants
 

David E. Lazovsky

    375,000     105,000  

Peter L. Eidelman

    200,000     50,000  

Tony P. Chiang

    375,000     75,000  

J. Craig Hunter

    130,000     50,000  

Sandeep Jaggi

    500,000     50,000  

        We maintain a retirement savings plan under section 401(k) of the Internal Revenue Code, or the Code, to provide retirement benefits to our eligible employees. The Code allows eligible employees to defer a portion of their compensation, within prescribed limits, which may be on a pre-tax basis through contributions to the 401(k) plan. Historically, the 401(k) plan has been funded entirely with employee contributions; however, in the future, we may match a portion of our employees' annual contributions, within prescribed limits.

        All of our full-time employees, including our named executive officers, are eligible to participate in our health and welfare plans, including:

Changes to Compensation Approach for 2011

        In connection with the preparation of this offering, our compensation committee retained Compensia to further advise on compensation matters for 2011. The following is a discussion of the key changes to certain primary elements of compensation following the completion of this offering for each of our named executive officers.

        We intend to enter into a Change in Control Severance Agreement with each of our named executive officers that will become effective upon the closing of this offering. Under the terms of this agreement, each named executive officer would be entitled to the payments and benefits described below upon a qualifying termination of employment.

111


Table of Contents

        Change in Control and Involuntary Termination.     Upon a termination of employment by us other than for "cause" or by the named executive officer for "good reason" (each, as defined in the Change in Control Severance Agreement) on or within the one-month period preceding, or the one-year period following, a "change in control," the named executive officer will be entitled to:

        Involuntary Termination.     Upon a termination of employment by us other than for "cause" or by the named executive officer for "good reason" at any time other than the period beginning one month preceding and ending one year following a "change in control," the named executive officer will be entitled to:

        The named executive officer's right to receive the severance payments described above is subject to continued compliance with certain restrictive covenants and his delivery of an effective general release of claims in favor of the company.

Tax and Accounting Considerations

        Internal Revenue Code Section 162(m).     Generally, Section 162(m) of the Code, or Section 162(m), disallows a tax deduction for any publicly-held corporation for individual compensation exceeding $1.0 million in any taxable year to its chief executive officer and each of its other named executive officers, other than its chief financial officer, unless compensation qualifies as "performance-based compensation" within the meaning of the Code. As we are not currently publicly traded, our compensation committee has not previously taken the deductibility limit imposed by Section 162(m) into consideration in setting compensation. Following this offering, we expect that our compensation committee will seek to qualify the variable compensation paid to our named executive officers for an exemption from the deductibility limitations of Section 162(m). As such, in approving the amount and form of compensation for our named executive officers in the future, our compensation committee will consider all elements of the cost to us of providing such compensation, including the potential impact of Section 162(m). However, our compensation committee may, in its judgment, authorize compensation payments that do not comply with the exemptions in Section 162(m) when it believes that such payments are appropriate to attract and retain executive talent.

        Furthermore, we do not expect Section 162(m) to apply to awards under the 2011 Plan until the earliest to occur of our annual stockholders' meeting in 2015, a material modification of the 2011 Plan or exhaustion of the shares reserved for issuance under the 2011 Plan.

        Internal Revenue Code Section 409A.     Section 409A of the Code requires that "nonqualified deferred compensation" be deferred and paid under plans or arrangements that satisfy the requirements of the Code with respect to the timing of deferral elections, timing of payments and

112


Table of Contents


certain other matters. Failure to satisfy these requirements can expose employees and other service providers to accelerated income tax liabilities, penalty taxes and interest on their vested compensation under such plans. Accordingly, as a general matter, it is our intention to design and administer our compensation and benefits plans and arrangements for all of our employees and other service providers, including our named executive officers, so that they are either exempt from, or satisfy the requirements of, Section 409A of the Code.

        Internal Revenue Code Section 280G.     Section 280G of the Code, or Section 280G, disallows a tax deduction with respect to excess parachute payments to certain executives of companies which undergo a change in control. In addition, Section 4999 of the Code, or Section 4999, imposes a 20% excise tax on the individual with respect to the excess parachute payment. Parachute payments are compensation linked to or triggered by a change in control and may include, but are not limited to, bonus payments, severance payments, certain fringe benefits, and payments and acceleration of vesting from long-term incentive plans including stock options and other equity-based compensation. Excess parachute payments are parachute payments that exceed a threshold determined under Section 280G based on the executive's prior compensation. In approving the compensation arrangements for our named executive officers in the future, our compensation committee will consider all elements of the cost to the company of providing such compensation, including the potential impact of Section 280G. However, our compensation committee may, in its judgment, authorize compensation arrangements that could give rise to loss of deductibility under Section 280G and the imposition of excise taxes under Section 4999 when it believes that such arrangements are appropriate to attract and retain executive talent.

        Accounting for Stock-Based Compensation.     We follow Financial Accounting Standards Board Accounting Standards Codification Topic 718, or ASC Topic 718, for our stock-based compensation awards. ASC Topic 718 requires companies to calculate the grant date "fair value" of their stock-based awards using a variety of assumptions. ASC Topic 718 also requires companies to recognize the compensation cost of their stock-based awards in their income statements over the period that an employee is required to render service in exchange for the award. Grants of stock options, restricted stock, restricted stock units and other equity-based awards under our equity incentive award plans will be accounted for under ASC Topic 718. Our compensation committee will regularly consider the accounting implications of significant compensation decisions, especially in connection with decisions that relate to our equity incentive award plans and programs. As accounting standards change, we may revise certain programs to appropriately align accounting expenses of our equity awards with our overall executive compensation philosophy and objectives.

113


Table of Contents

Compensation Tables

2010 Summary Compensation Table

        The following table sets forth information concerning the compensation of our named executive officers for the year ended December 31, 2010.

Name and Principal Position
  Year   Salary($)   Bonus($)(3)   Option
Awards($)(5)
  Total($)  

David E. Lazovsky

    2010     256,875     235,000 (4)   498,750     990,625  
 

Chief Executive Officer and President

                               

Peter L. Eidelman

    2010     234,945     72,000     266,000     572,945  
 

Chief Financial Officer

                               

Tony P. Chiang

    2010     252,240     100,200     498,750     851,190  
 

Chief Technology Officer

                               

J. Craig Hunter(1)

    2010     206,417     50,100     172,900     429,417  
 

Senior Vice President and General Manager,
Clean Energy Group

                               

Sandeep Jaggi(1)(2)

    2010     106,534     24,200     665,000     795,734  
 

General Counsel and Senior Vice President of
Intellectual Property

                               

(1)
In 2010, Mr. Hunter's principal position was Vice President and General Manager, Clean Energy Technologies, and Dr. Jaggi's position was Vice President, Legal Affairs, Licensing and Intellectual Property. Mr. Hunter and Dr. Jaggi were promoted to their current positions in July 2011.

(2)
Dr. Jaggi's 2010 salary and bonus reflect his partial-year employment, which commenced on July 12, 2010.

(3)
Amounts represent discretionary annual cash bonuses awarded from our 2010 bonus pool, which was funded based on our achievement of pre-established corporate performance objectives.

(4)
Amount represents (i) $125,000 attributable to the discretionary annual cash bonus awarded to Mr. Lazovsky for performance of services rendered in 2010; and (ii) a cash bonus of $110,000 awarded to Mr. Lazovsky based on the successful execution of a multi-year customer contract in the first quarter of 2010. As Mr. Lazovsky was eligible to receive a cash bonus upon execution of this contract, he was not awarded a separate discretionary annual cash bonus under our 2009 bonus pool for services rendered in 2009.

(5)
Amounts reflect the full grant-date fair value of stock options granted, computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of all stock option awards made to named executive officers in "Management's Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates—Stock-Based Compensation."

114


Table of Contents


Grants of Plan-Based Awards in 2010

        The following table sets forth information regarding grants of plan-based awards made to our named executive officers for the year ended December 31, 2010.

Name
  Grant Date   All Other
Option
Awards:
Number of
Securities
Underlying
Options
(# shares)(1)
  Exercise
or Base
Price of
Option
Awards Per
Share($)
  Grant Date
Fair Value
of Stock and
Options Awards
($)(2)
 

David E. Lazovsky

  February 4, 2010     375,000     1.33     498,750  

Peter L. Eidelman

 
February 4, 2010
   
200,000
   
1.33
   
266,000
 

Tony P. Chiang

 
February 4, 2010
   
375,000
   
1.33
   
498,750
 

J. Craig Hunter

 
February 4, 2010
   
130,000
   
1.33
   
172,900
 

Sandeep Jaggi

 
August 19, 2010
   
500,000
   
1.33
   
665,000
 

(1)
Represents incentive stock options granted pursuant to our 2004 Plan. In August 2010, in connection with the commencement of his employment, Dr. Jaggi was granted a stock option to purchase 500,000 shares of our common stock.

(2)
Amounts reflect the full grant-date fair value of stock options granted during 2010 computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of all stock option awards made to executive officers in "Management's Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates—Stock-Based Compensation."

115


Table of Contents


Outstanding Equity Awards at 2010 Fiscal Year-End

        The following table summarizes the number of shares of common stock underlying outstanding equity incentive plan awards for each named executive officer as of December 31, 2010.

 
  Option Awards(1)(2)  
Name
  Vesting
Commencement
Date
  Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
  Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
  Option
Exercise
Price
($)
  Option
Expiration
Date
 

David E. Lazovsky

   
July 9, 2007

(3)
 
600,000
   
0
   
0.83
   
September 4, 2017
 

    January 20, 2009     191,666     208,334     1.00     January 19, 2019  

    February 1, 2010     0     375,000     1.33     February 3, 2020  

Peter L. Eidelman

   
February 27, 2006

(3)
 
625,000
   
0
   
0.10
   
May 4, 2016
 

    July 9, 2007 (3)   115,000     0     0.83     September 4, 2017  

    January 20, 2009     100,625     109,375     1.00     January 19, 2019  

    February 1, 2010     0     200,000     1.33     February 3, 2020  

Tony P. Chiang

   
May 9, 2005

(3)
 
2,250,000
   
0
   
0.05
   
June 14, 2015
 

    July 9, 2007 (3)   200,000     0     0.83     September 4, 2017  

    January 20, 2009     191,666     208,334     1.00     January 19, 2019  

    February 1, 2010     0     375,000     1.33     February 3, 2020  

J. Craig Hunter

   
January 30, 2009
   
335,416
   
364,584
   
1.00
   
February 24, 2019
 

    February 1, 2010     0     130,000     1.33     February 3, 2020  

Sandeep Jaggi

   
July 12, 2010
   
0
   
500,000
   
1.33
   
August 18, 2020
 

(1)
Each stock option was granted pursuant to our 2004 Plan.

(2)
Unless otherwise noted, these options vest as to 1 / 4 th of the total number of shares subject to the option on the first anniversary of the vesting commencement date, and as to 1 / 48 th of the total number of shares subject to the option in monthly installments over the three-year period thereafter, subject to continued service with our company through the applicable vesting dates and accelerated vesting under certain circumstances, as described under the section entitled "Potential Payments Upon Termination or Change in Control" below.

(3)
Contains an early exercise provision permitting the executive to exercise the option prior to vesting, with any unvested shares subject to repurchase by us at the exercise price paid until the shares vest in accordance with the vesting schedule of the option.

2010 Option Exercises and Stock Vested

        The Company has not granted any stock awards to its named executive officers. Additionally, our named executive officers did not exercise any stock options during 2010.

Potential Payments Upon Termination or Change in Control

Employment Letters

        The employment letters for Mr. Hunter and Dr. Jaggi provide that the 50% of the shares subject to the stock options granted to each executive in connection with entering into their employment letters will accelerate immediately upon a termination of employment without "cause" or for "good reason" within twelve months of a "change in control" (each as defined in the relevant employment letter). Our compensation committee determined to provide these change in control severance arrangements in

116


Table of Contents


order to mitigate some of the risk that exists for executives working in a small technology company. These arrangements are intended to attract and retain qualified executives that have alternatives that may appear to them to be less risky absent these arrangements, and to mitigate a potential disincentive to consider and execute any acquisition, particularly where the services of these executives may not be required by the acquirer.

Summary of Potential Payments

        The following table summarizes the payments that would be made to certain of our named executive officers upon the occurrence of certain qualifying terminations of employment in connection with a change in control, assuming such named executive officer's termination of employment with us occurred on December 31, 2010 and, where relevant, that a change in control of Intermolecular occurred on December 31, 2010. Amounts shown in the table below do not include (i) accrued but unpaid salary, and (ii) other benefits earned or accrued by the named executive officer during his employment that are available to all salaried employees, such as accrued vacation.

Name
  Benefit(1)   Termination without Cause
or for Good Reason($)
 

J. Craig Hunter

  Value of Accelerated Option Awards     127,604  

Sandeep Jaggi

  Value of Accelerated Option Awards     92,500  

(1)
Represents the aggregate value of the named executive officer's unvested stock options that would have vested on an accelerated basis, determined by multiplying the number of accelerating option shares by the fair market value of our common stock ($1.70) on December 31, 2010 (as determined by our board of directors) and subtracting the applicable exercise prices.

2010 Director Compensation

2010 Non-Employee Director Compensation Program

        In 2010, none of our non-employee directors received cash or equity compensation for their services as a director. In connection with this offering, we intend to approve and implement a compensation program for our non-employee directors that consists of annual retainer fees and long-term equity awards.

Equity Incentive Plans

2011 Incentive Award Plan

        We intend to adopt the 2011 Plan, which will be effective on the date of adoption. The principal purpose of the 2011 Plan is to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards. The 2011 Plan is also designed to permit us to make cash-based awards and equity-based awards intended to qualify as "performance-based compensation" under Section 162(m).

        The principal features of the 2011 Plan are summarized below. This summary is qualified in its entirety by reference to the text of the 2011 Plan, which is filed as an exhibit to the registration statement of which this prospectus is a part.

        Share Reserve.     Under the 2011 Plan, shares of our common stock will be initially reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, or SARs, restricted stock awards, restricted stock unit awards, deferred stock awards, dividend equivalent awards, stock payment awards, performance shares and other incentive awards. The number of shares initially reserved for issuance or transfer pursuant to awards under the

117


Table of Contents


2011 Plan will equal the sum of (i)             shares, (ii) any shares of our common stock which, as of the effective date of this offering, are (A) available for issuance under the 2004 Plan or (B) underlying awards outstanding under the 2004 Plan that, on or after the effective date of this offering, terminate, expire or lapse for any reason without delivery of shares to the holder thereof, up to a maximum of            shares and (iii) an annual increase on the first day of each fiscal year beginning in 2012 and ending in 2021, equal to the lesser of (A)             shares, (B)          percent (      %) of the shares of stock outstanding on the last day of the immediately preceding fiscal year and (C) such smaller number of shares of stock as determined by our board of directors, all of which may be issued as incentive stock options; provided, however, that shares shall be available for issuance as incentive stock options only to the extent that such shares will not cease to qualify as incentive stock options. Shares granted under the 2011 Plan may be treasury shares, authorized but unissued shares, or shares purchased in the open market.

        The following counting provisions will be in effect for the share reserve under the 2011 Plan:

        However, the following shares may not be added back to the share reserve under the 2011 Plan:

        After a transition period that may apply following the effective date of this offering, the maximum number of shares of our common stock that may be subject to one or more awards granted to any one participant pursuant to the 2011 Plan during any calendar year will be            and the maximum amount that may be paid in cash pursuant to the 2011 Plan to any one participant during any calendar year will be            dollars ($            ).

        Administration.     The compensation committee of our board of directors will administer the 2011 Plan unless our board of directors assumes authority for administration. The compensation committee must consist solely of two or more members of our board of directors, each of whom is intended to qualify as an "outside director," within the meaning of Section 162(m), a "non-employee director" for purposes of Rule 16b-3 under the Exchange Act and an "independent director" within the meaning of the rules of The Nasdaq Global Market and the New York Stock Exchange, or other principal securities market on which shares of our common stock are traded. The 2011 Plan provides that the compensation committee may delegate its authority to grant awards to employees other than our executive officers and certain of our senior executives to a committee consisting of one or more

118


Table of Contents


members of our board of directors or one or more of our officers and the equity awards policy we expect to adopt in 2011 calls for the compensation committee to approve all equity awards, other than awards made to our non-employee directors, which must be approved by our full board of directors.

        Subject to the terms and conditions of the 2011 Plan, the administrator has the authority to select the persons to whom awards are to be made, to determine the number of shares to be subject to awards and the terms and conditions of awards, and to make all other determinations and to take all other actions necessary or advisable for the administration of the 2011 Plan. The administrator is also authorized to make all determinations and interpretations under, and adopt or revise rules relating to administration of, the 2011 Plan. Our board of directors may at any time remove the compensation committee as the administrator and revest in itself the authority to administer the 2011 Plan. The full board of directors will administer the 2011 Plan with respect to awards to non-employee directors.

        Eligibility.     Awards under the 2011 Plan may be granted to individuals who are then our officers, employees or consultants or are the officers, employees or consultants of our affiliates. Such awards also may be granted to our directors. Only employees of our company or certain of our affiliates may be granted incentive stock options, or ISOs.

        Awards.     The 2011 Plan provides that the administrator may grant or issue stock options, SARs, restricted stock, restricted stock units, deferred stock, dividend equivalents, performance awards, stock payments, performance shares and other incentive awards, or any combination thereof. Each award will be set forth in a separate agreement with the person receiving the award and will indicate the type, terms and conditions of the award.

        Nonstatutory Stock Options, or NSOs, will provide for the right to purchase shares of our common stock at a specified exercise price which may not be less than fair market value on the date of grant, and usually will vest and become exercisable (at the discretion of the administrator) in one or more installments after the grant date, subject to the participant's continued employment or service with us or our affiliates and/or subject to the satisfaction of corporate performance targets and individual performance targets established by the administrator. NSOs may be granted for any term specified by the administrator that does not exceed ten years.

        Incentive Stock Options, or ISOs, will be designed in a manner intended to comply with the provisions of Section 422 of the Code and will be subject to specified restrictions contained in the Code. Among such restrictions, ISOs must have an exercise price of not less than the fair market value of a share of common stock on the date of grant, may only be granted to employees, and must not be exercisable after a period of ten years measured from the date of grant. In the case of an ISO granted to an individual who owns (or is deemed to own) more than 10% of the total combined voting power of all classes of our capital stock, the 2011 Plan provides that the exercise price must be at least 110% of the fair market value of a share of common stock on the date of grant and the term of the ISO must not exceed five years.

        Restricted Stock may be granted to any eligible individual and made subject to such restrictions as may be determined by the administrator. Restricted stock, typically, may be forfeited for no consideration or repurchased by us at the original purchase price if the conditions or restrictions on vesting are not met. In general, restricted stock may not be sold or otherwise transferred until restrictions are removed or expire or certain conditions are met. Recipients of restricted stock, unlike recipients of options, will have voting rights and will have the right to receive dividends, if any, prior to the time when the restrictions lapse, however, extraordinary dividends will generally be subject to the conditions or restrictions on vesting applicable to the underlying shares.

        Restricted Stock Units may be awarded to any eligible individual, typically without payment of consideration, but subject to vesting conditions based on continued employment or service or on performance or other criteria established by the administrator. Like restricted stock, restricted stock

119


Table of Contents


units may not be sold, or otherwise transferred or hypothecated, until vesting conditions are removed or expire. Unlike restricted stock, stock underlying restricted stock units will not be issued until the restricted stock units have vested, and recipients of restricted stock units generally will have no voting or dividend rights prior to the time when vesting conditions are satisfied.

        Deferred Stock Awards represent the right to receive shares of our common stock on a future date. Deferred stock may not be sold or otherwise hypothecated or transferred until issued. Deferred stock will not be issued until the deferred stock award has vested, and recipients of deferred stock generally will have no voting or dividend rights prior to the time when the vesting conditions are satisfied and the shares are issued. Deferred stock awards generally will be forfeited, and the underlying shares of deferred stock will not be issued, if the applicable vesting conditions and other restrictions are not met.

        Stock Appreciation Rights typically will provide for payments to the holder based upon increases in the price of our common stock over a set exercise price. The exercise price of any SAR granted under the 2011 Plan must be at least 100% of the fair market value of a share of our common stock on the date of grant. Vesting conditions and restrictions, including continued employment or service with us or our affiliates and/or performance and other conditions, may be imposed by the administrator in the SAR agreements. SARs under the 2011 Plan will be settled in cash or shares of our common stock, or in a combination of both, at the election of the administrator.

        Dividend Equivalents represent the value of the dividends, if any, per share paid by us, calculated with reference to the number of shares covered by the award. Dividend equivalents may be settled in cash or shares, at such times and subject to such limitations as determined by the administrator.

        Performance Awards will be based upon specific performance targets and may be paid in cash or in common stock or in a combination of both. Performance awards may include cash bonuses.

        Stock Payments may be authorized by the administrator in the form of common stock as part of a deferred compensation or other arrangement in lieu of all or any part of compensation, including bonuses, that would otherwise be payable in cash to the employee, consultant or non-employee director.

        Performance Shares are contractual rights to receive a range of shares of our common stock in the future based on the attainment of specified performance goals, in addition to other conditions which may apply to these awards. Conditions applicable to performance shares may be based on continuing service with us or our affiliates, the attainment of performance goals and/or such other conditions as the administrator may determine.

        Other Incentive Awards are awards other than those enumerated in this summary that are denominated in, linked to or derived from shares of our common stock or value metrics related to our shares, and may remain forfeitable unless or until specified conditions are met.

        Non-Employee Director Awards.     Our board of directors may grant awards under the 2011 Plan to our non-employee directors pursuant to a written non-discretionary formula established by the administrator. The program will specify the type or types of awards to be granted, the number of shares subject to each award, and the terms and conditions applicable to each award, as determined by the administrator in its discretion.

        Change in Control.     In the event of a change in control where the acquiror does not assume or replace awards granted, prior to the consummation of such transaction, awards issued under the 2011 Plan will be subject to accelerated vesting such that 100% of such awards will become vested and exercisable or payable, as applicable. In addition, the administrator will also have complete discretion to structure one or more awards under the 2011 Plan to provide that such awards will become vested and exercisable or payable on an accelerated basis in the event such awards are assumed or replaced

120


Table of Contents


with equivalent awards but the individual's service with us or the acquiring entity is subsequently terminated within a designated period following the change in control event. The administrator may also make appropriate adjustments to awards under the 2011 Plan and is authorized to provide for the acceleration, cash-out, termination, assumption, substitution or conversion of such awards in the event of a change in control or certain other unusual or nonrecurring events or transactions. Under the 2011 Plan, a change in control is generally defined as:

        Adjustments of Awards.     In the event of any stock dividend, stock split, combination or exchange of shares, merger, consolidation, spin-off, recapitalization, distribution of our assets to stockholders (other than normal cash dividends) or any other corporate event affecting the number of outstanding shares of our common stock or the share price of our common stock that would require adjustments to the 2011 Plan or any awards under the 2011 Plan in order to prevent the dilution or enlargement of the potential benefits intended to be made available thereunder, the administrator will make equitable adjustments to:

        Repricing and Participant Payments.     Subject to applicable limitations of the Code and other applicable law, the administrator is able to increase or reduce the applicable price per share of an award, or cancel and replace an award with another award and/or cash. With regard to tax withholding, exercise price and purchase price obligations arising in connection with awards under the 2011 Plan, the administrator may, in its discretion, accept cash or check, shares of our common stock that meet specified conditions, a "market sell order" or such other consideration as it deems acceptable.

        Amendment and Termination.     Our board of directors may suspend, amend or modify the 2011 Plan at any time and from time to time. However, we must generally obtain stockholder approval to increase the number of shares available under the 2011 Plan (other than in connection with certain corporate events, as described above).

        Our board of directors may terminate the 2011 Plan at any time. No incentive stock options may be granted pursuant to the 2011 Plan after the tenth anniversary of the effective date of the 2011 Plan, and no additional annual share increases to the 2011 Plan's aggregate share limit will occur from and after such anniversary; however, the 2011 Plan does not have a specified expiration date and will otherwise continue in effect until terminated by us. Any award that is outstanding on the termination

121


Table of Contents


date of the 2011 Plan will remain in force according to the terms of the 2011 Plan and the applicable award agreement.

        Securities Laws and U.S. Federal Income Taxes.     The 2011 Plan is designed to comply with various securities and U.S. federal tax laws as follows:

        Securities Laws.    The 2011 Plan is intended to conform to all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the SEC thereunder, including without limitation, Rule 16b-3. The 2011 Plan will be administered, and options will be granted and may be exercised, only in such a manner as to conform to such laws, rules and regulations.

        Section 409A of the Code.    Certain awards under the 2011 Plan may be considered "nonqualified deferred compensation" for purposes of Section 409A of the Code (Section 409A) which imposes certain additional requirements regarding the payment of deferred compensation. Generally, if at any time during a taxable year a nonqualified deferred compensation plan fails to meet the requirements of Section 409A, or is not operated in accordance with those requirements, all amounts deferred under the 2011 Plan and all other equity incentive plans for the taxable year and all preceding taxable years by any participant with respect to whom the failure relates are includible in gross income for the taxable year to the extent not subject to a substantial risk of forfeiture and not previously included in gross income. If a deferred amount is required to be included in income under Section 409A, the amount also is subject to interest and an additional income tax. The interest imposed is equal to the interest at the underpayment rate plus one percentage point, imposed on the underpayments that would have occurred had the compensation been includible in income for the taxable year when first deferred, or if later, when not subject to a substantial risk of forfeiture. The additional U.S. federal income tax is equal to 20% of the compensation required to be included in gross income. In addition, certain states, including California, have laws similar to Section 409A, which impose additional state penalty taxes on such compensation.

        Section 162(m) of the Code.    In general, under Section 162(m), income tax deductions of publicly held corporations may be limited to the extent total compensation (including, but not limited to, base salary, annual bonus, and income attributable to stock option exercises and other non-qualified benefits) for certain executive officers exceeds $1,000,000 (less the amount of any "excess parachute payments" as defined in Section 280G) in any taxable year of the corporation. However, under Section 162(m), the deduction limit does not apply to certain "performance-based compensation" established by an independent compensation committee that is adequately disclosed to and approved by stockholders. In particular, stock options and SARs will satisfy the "performance-based compensation" exception if the awards are made by a qualifying compensation committee, the 2011 Plan sets the maximum number of shares that can be granted to any person within a specified period and the compensation is based solely on an increase in the stock price after the grant date. Specifically, the option exercise price must be equal to or greater than the fair market value of the stock subject to the award on the grant date. Under a Code Section 162(m) transition rule for compensation plans of corporations which are privately held and which become publicly held in an initial public offering, certain awards under the 2011 Plan will not be subject to Section 162(m) until a specified transition date, which is the earlier of:

122


Table of Contents

        After the transition date, rights or awards granted under the 2011 Plan, other than options and SARs, will not qualify as "performance-based compensation" for purposes of Section 162(m) unless such rights or awards are granted or vest upon pre-established objective performance goals, the material terms of which are disclosed to and approved by our stockholders. Thus, after the transition date, we expect that such other rights or awards under the plan will not constitute performance-based compensation for purposes of Section 162(m).

        We intend to file with the SEC a registration statement on Form S-8 covering the shares of our common stock issuable under the 2011 Plan.

2004 Equity Incentive Plan (Amended and Restated September 5, 2007)

        Our board of directors adopted, and our stockholders approved, the 2004 Plan in September 2004. The 2004 Plan provides for the grant of stock options and stock purchase rights to our employees, directors and consultants of our company. As a result of our adoption of the 2011 Plan (discussed above), we will not make any further awards under the 2004 Plan following the completion of this offering; all outstanding awards will continue to be governed by their existing terms. The material terms of the 2004 Plan are summarized below.

        Administration.     Our compensation committee has been delegated the authority to administer the 2004 Plan and the awards granted thereunder. After the closing of this offering, certain limitations as to the composition of the plan administrator may be imposed under Section 162(m), Section 16 of the Exchange Act, and/or stock exchange rules, as applicable. Our board of directors administers the 2004 Plan with respect to awards to independent directors.

        Limitations on Awards.     The aggregate number of shares of our common stock that is authorized pursuant to the 2004 Plan is 20,514,693 shares, which shares may be authorized but unissued shares or shares of reacquired common stock. Shares tendered or withheld to satisfy grant or exercise price or tax withholding obligations associated with an award granted under the 2004 Plan, shares subject to an award that is granted under the 2004 Plan that is forfeited or expires and shares of restricted stock that are repurchased by us at their original purchase price may be used again for new grants under the 2004 Plan.

        Stock Options.     The 2004 Plan provides for the grant of stock options, including ISOs and NSOs. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other Code requirements are satisfied. The exercise price of a stock option may not be less than 100% of the fair market value of the underlying share on the date of grant (or 110% in the case of ISOs granted to an optionee who owns stock representing more than 10% of the voting power of all classes of our common stock). A stock option may provide for "early exercise" prior to vesting in exchange for shares of restricted stock that vest on the option's vesting schedule.

        In general, the maximum term of options granted is ten years. The maximum term of options granted to an optionee who owns stock representing more than 10% of the voting power of all classes of our common stock is five years. If an optionee's service relationship with us terminates other than by disability or death, the optionee may exercise the vested portion of any option in such period of time as specified in the optionee's option agreement, but prior to the date of this offering, to the extent required by applicable law, in no event will such period be less than 30 days following the termination of service. In the absence of a specified time in such option agreement, the option shall remain exercisable for three months following the optionee's termination of service with us. Shares of common stock representing any unvested portion of the option on the date of termination shall immediately cease to be issuable and shall become available for issuance under the 2004 Plan. If, after termination, the optionee does not exercise the option within the time period specified, the option shall terminate

123


Table of Contents


and the shares of common stock covered by such option will become available for issuance under the 2004 Plan. If an optionee's service relationship with us terminates by disability or death, the optionee may exercise the vested portion of any option in such period of time as specified in the optionee's option agreement, but prior to the date of this offering, to the extent required by applicable law, in no event will such period be less than six months following the termination of service. In the absence of a specified time in such option agreement, the option shall remain exercisable for 12 months following the optionee's termination of service with us.

        Stock Purchase Rights.     The 2004 Plan provides that we may issue stock purchase rights alone, in addition to or in tandem with options granted under the 2004 Plan and/or cash awards made outside the 2004 Plan. Any stock purchase rights will be governed by a restricted stock purchase agreement. We will have the right to repurchase shares of common stock acquired by the purchaser upon exercise of a stock purchase right upon the termination of the purchaser's status as an employee, director or consultant for any reason. Once the stock purchase right is exercised, the purchaser shall have rights equivalent to those of our other stockholders.

        Corporate Transactions.     In the event of certain significant corporate transactions, the plan administrator has the discretion to take one or more of the following actions: (a) provide for the purchase or any option, stock purchase right or restricted stock for an amount of cash equal to the amount that could have been obtained upon the exercise of such option or stock purchase right; (b) provide that any option or stock purchase right be made exercisable; (c) provide for the assumption of any option, stock purchase right or restricted stock; (d) provide adjustments in the number and type of shares of common stock subject to outstanding options and stock purchase rights; and (e) provide for the termination of any option or stock purchase right. In addition, in the event of certain non-reciprocal transactions with our shareholders known as "equity restructurings," the plan administrator may make equitable adjustments to the 2004 Plan and outstanding awards.

        Change in Control.     In the event we undergo a change in control, and any surviving corporation does not assume or substitute similar awards for options, stock purchase rights or restricted stock under the 2004 Plan, the vesting of options, stock purchase rights or restricted stock held by participants in the 2004 Plan whose status as an employee, director or consultant has not terminated prior to such event shall be accelerated and made fully exercisable at least ten days prior to the closing of the event of change in control, and any options or stock purchase rights outstanding under the 2004 Plan shall terminate if not exercised prior to the closing of the event of change in control.

        Plan Amendment and Termination.     Our board of directors may amend or terminate the 2004 Plan at any time; however, (i) no amendment or termination may adversely affect an outstanding award without the affected participant's consent, and (ii) except in connection with certain changes in our capital structure, stockholder approval will be required for any amendment that increases the number of shares available under the 2004 Plan or extends the term of the 2004 Plan. No award may be granted pursuant to the 2004 Plan after September 7, 2014, however, we will cease granting awards under the 2004 Plan upon effectiveness of the 2011 Plan.

        We intend to file with the SEC a registration statement on Form S-8 covering the shares of our common stock issuable under the 2004 Plan.

Confidentiality Information, Secrecy and Invention Agreements

        Each of our named executive officers has entered into a standard form agreement with respect to confidential information, secrecy and inventions. Among other things, this agreement obligates each named executive officer to refrain from disclosing any of our proprietary information received during the course of employment and, with some exceptions, to assign to us any inventions conceived or developed during the course of employment.

124


Table of Contents

Limitation on Liability and Indemnification Matters

        Our amended and restated certificate of incorporation and amended and restated bylaws, each to be effective upon the completion of this offering, will provide that we will indemnify our directors, officers, employees and agents to the fullest extent permitted by the Delaware General Corporation Law, which prohibits our amended and restated certificate of incorporation from limiting the liability of our directors for the following:

        If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated certificate of incorporation does not eliminate a director's duty of care and, in appropriate circumstances, equitable remedies, such as injunctive or other forms of non-monetary relief, remain available under Delaware law. This provision also does not affect a director's responsibilities under any other laws, such as the federal securities laws or other state or federal laws. Under our amended and restated bylaws, we will also be empowered to enter into indemnification agreements with our directors, officers, employees and other agents and to purchase insurance on behalf of any person whom we are required or permitted to indemnify.

        In addition to the indemnification required in our amended and restated certificate of incorporation and amended and restated bylaws, we have entered into indemnification agreements with each of our directors, and will enter into new indemnification agreements with each of our current directors, officers and certain employees before the completion of this offering. These agreements provide for the indemnification of our directors, officers and certain employees for all reasonable expenses and liabilities incurred in connection with any action or proceeding brought against them by reason of the fact that they are or were our agents. We believe that these provisions in our amended and restated certificate of incorporation and amended and restated bylaws and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. Furthermore, we have obtained director and officer liability insurance to cover liabilities our directors and officers may incur in connection with their services to us. This description of the indemnification provisions of our amended and restated certificate of incorporation, our amended and restated bylaws and our indemnification agreements is qualified in its entirety by reference to these documents, each of which is attached as an exhibit to this registration statement.

        The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit us and our stockholders. A stockholder's investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer.

125


Table of Contents

Rule 10b5-1 Sales Plans

        Our directors and executive officers may adopt written plans, known as Rule 10b5-1 plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the director or officer when entering into the plan, without further direction from them. The director or officer may amend or terminate the plan in some circumstances. Our directors and executive officers may also buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of material, nonpublic information.

126


Table of Contents


CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

        We describe below each transaction, since January 1, 2008, to which we were a party or will be a party, in which:

Preferred Stock Issuances

Issuance of Series E Preferred Stock

        On March 4, 2011 and June 14, 2011, we sold 3,610,873 shares and 2,407,249 shares of Series E preferred stock, respectively, at a price of $4.15412 per share for aggregate gross proceeds of approximately $25.0 million. The table below sets forth the number of shares of Series E preferred stock sold to our directors, executive officers and 5% stockholders and their affiliates.

Name
  Number of Shares of
Series E
Preferred Stock
  Aggregate
Purchase Price
 

ATMI, Inc.(1)

    1,623,838   $ 6,745,617.92  

CMEA Ventures VI, L.P.(2)(3)

    601,811   $ 2,499,995.12  

Redpoint Ventures II, L.P.(4)(5)

    695,003   $ 2,887,125.87  

Symyx Technologies, Inc. 

    198,211   $ 823,392.28  

U.S. Venture Partners IX, L.P.(6)

    492,010   $ 2,043,868.59  

(1)
George M. Scalise is one of our directors and is a member of the board of directors of ATMI, Inc.

(2)
Includes 13,788 shares purchased by CMEA Ventures VI GmbH & Co. KG.

(3)
Thomas R. Baruch is one of our directors and is a general partner of CMEA Ventures Management, L.P., which is the general partner of each of CMEA Venture Partners VI, L.P. and CMEA Ventures VI GmbH & Co. KG.

(4)
Includes 15,708 shares purchased by Redpoint Associates II, LLC.

(5)
John L. Walecka is one of our directors and is a managing member of each of Redpoint Ventures II, L.P. and Redpoint Associates II, LLC.

(6)
Irwin B. Federman is one of our directors and is a managing member of Presidio Management Group IX, LLC, which is the general partner of U.S. Venture Partners IX, L.P.

Issuance of Series D Preferred Stock

        On December 16, 2008, we sold 6,575,832 shares of Series D preferred stock at a price of $3.04144 per share for gross proceeds of approximately $20.0 million. The table below sets forth the number of

127


Table of Contents


shares of Series D preferred stock sold to our directors, executive officers and 5% stockholders and their affiliates.

Name
  Number of Shares of
Series D
Preferred Stock
  Aggregate
Purchase Price
 

ATMI, Inc. 

    3,287,916   $ 9,999,999.24  

CMEA Ventures VI, L.P.(1)(2)

    1,014,233   $ 3,084,728.82  

Redpoint Ventures II, L.P.(3)(4)

    1,014,233   $ 3,084,728.82  

Symyx Technologies, Inc.(5)

    541,448   $ 1,646,781.61  

U.S. Venture Partners IX, L.P.(6)

    718,002   $ 2,183,760.01  

(1)
Includes 23,226 shares purchased by CMEA Ventures VI GmbH & Co. KG.

(2)
Thomas R. Baruch is one of our directors and is a general partner of CMEA Ventures Management, L.P., which is the general partner of each of CMEA Ventures VI, L.P. and CMEA Ventures VI GmbH & Co. KG.

(3)
Includes 22,922 shares purchased by Redpoint Associates II, LLC.

(4)
John L. Walecka is one of our directors and is a managing member of each of Redpoint Ventures II, L.P. and Redpoint Associates II, LLC.

(5)
Isy Goldwasser is one of our directors and, at the time of the transaction, was an executive officer of Symyx Technologies, Inc.

(6)
Irwin B. Federman is one of our directors and is a managing member of Presidio Management Group IX, LLC, which is the general partner of U.S. Venture Partners IX, L.P.

Symyx

        In March 2005, we entered into a Collaborative Development and License Agreement with Symyx Technologies, Inc. (Symyx). In addition, in December 2005, we entered into an Alliance Agreement (Symyx Alliance Agreement) with Symyx, and we amended the Symyx Alliance Agreement in August 2006, June 2007, August 2007, November 2007 and September 2009. Prior to the completion of this offering, Symyx is a beneficial owner of approximately 10.9% of our common stock. Isy Goldwasser is one of our directors and, at the time of these transactions, was an executive officer of Symyx.

        Under the Symyx agreements, Symyx granted us a license to certain high-throughput combinatorial patents held or licensed by them and related software to design, develop and manufacture integrated circuits, photovoltaic cells, glass coatings, light emitting diodes, organic light-emitting diodes and thin films for electronics, optical and energy applications (Fields), and we agreed to pay Symyx royalties in connection with such license. During the six months ended June 30, 2011 and 2010 and the years ended December 31, 2010, 2009 and 2008, we recorded $0.9 million, $0.8 million, $2.0 million, $1.2 million and $1.0 million in royalty expense, respectively, and had accrued liabilities due to Symyx of $405,000, $795,000 and $502,000 as of June 30, 2011 and December 31, 2010 and 2009, respectively. In addition, during the six months ended June 30, 2011 and 2010 and the years ended December 31, 2010, 2009 and 2008, we purchased $0, $0, $6,000, $14,000 and $286,000, respectively, of fixed assets, maintenance and consumables from Symyx.

        On July 28, 2011, we entered into an agreement with Symyx, pursuant to which we agreed to use commercially reasonable efforts to allow Symyx to sell in this offering             shares of our common stock held by them. Pursuant to the agreement, Symyx agreed to sell such shares and, upon consummation of this offering, including the sale of such shares, to terminate our future royalty

128


Table of Contents


obligations under the Symyx agreements to the extent they would have accrued after December 31, 2011. Additionally, upon consummation of this offering and such sale, Symyx would transfer to us all the patents held by them that relate to combinatorial processing. To the extent the gross proceeds (before deducting underwriting discounts and commissions and offering expenses) to Symyx from the sale of their shares in this offering are less than $67 million, we would issue Symyx a secured promissory note that would have a term of 24 months and an interest rate equal to 4%. Such note would be payable in an amount equal to the greater of $500,000 per quarter or the amount of accrued interest, with a balloon payment at maturity, if applicable. Such note would also be pre-payable by us at any time without penalty or premium, and would be secured by tangible personal property, excluding intellectual property. In addition, we have agreed to reimburse Symyx for 50% of the underwriting discounts and commissions payable by them in connection with this offering, which amount is equal to $            , based on an assumed initial public offering price of $            (the midpoint of the price range set forth on the cover page of this prospectus). In addition, we agreed to continue to license from them the rights they have to certain patents held by Lawrence Berkeley National Laboratory and for which we have an exclusive sub-license in the Fields and to assume certain royalty and license fee obligations to Berkeley in connection with such sub-license, not to exceed $300,000 per year.

ATMI, Inc.

        In November 2006, we entered into an Alliance Agreement with ATMI, which is the beneficial owner of approximately 10.6% of our common stock outstanding as of June 30, 2011. In July 2007, we entered into a Wets Workflow Purchase Agreement with ATMI, and then in December 2008 entered into a Dry Workflow Purchase Agreement with ATMI, pursuant to which we sold to ATMI certain high productivity development tools. Under the Alliance Agreement and related ancillary agreements, we agreed to work with ATMI to conduct R&D and other activities with respect to materials and HPC technology for use in semiconductor applications. Under the agreements, ATMI pays us fees for services and both parties may provide royalties to the other for licensed technology sold to third parties. During the six months ended June 30, 2011 and 2010 and the years ended December 31, 2010, 2009 and 2008, we recorded revenue in the amount of $7.8 million, $10.3 million, $22.1 million, $16.0 million and $13.4 million, respectively, in equipment sales, license fees and service fees and had accounts receivable in the amount of $447,000, $461,000 and $1.2 million as of June 30, 2011 and December 31, 2010 and 2009, respectively, related to these agreements. We recorded a deferred revenue balance in the amount of $8.2 million, $13.3 million and $22.8 million related to these agreements as of June 30, 2011 and December 31, 2010 and 2009, respectively.

Investor Rights Agreement

        We have entered into an amended and restated investor rights agreement with certain holders of our preferred stock and warrants, including entities with which certain of our directors are affiliated. As of June 30, 2011, the holders of 60,922,194 million shares of our common stock issuable upon the conversion of our preferred stock or exercise of warrants, are entitled to rights with respect to the registration of their shares under the Securities Act. For a more detailed description of these registration rights, see "Description of Capital Stock—Registration Rights." The investor rights agreement also provides for rights of first refusal. We have obtained waivers so that the rights of first refusal will not apply to, and will terminate upon completion of, this offering.

Voting Agreement

        We have entered into an amended and restated voting agreement with certain holders of our common stock and preferred stock. Upon the closing of this offering, the amended and restated voting agreement will terminate. For a description of the amended and restated voting agreement, see the section titled "Management—Voting Arrangements."

129


Table of Contents

Right of First Refusal and Co-Sale Agreement

        We have entered into an amended and restated right of first refusal and co-sale agreement with certain holders of our common stock and preferred stock. This agreement provides for rights of first refusal and co-sale relating to certain shares of our common stock in favor of the holders of certain shares of our preferred stock. Upon the closing of this offering, the amended and restated right of first refusal and co-sale agreement will terminate.

Indemnification Agreements

        We have entered into indemnification agreements with each of our directors and will enter into new indemnification agreements with each of our current directors, officers and certain employees before the completion of this offering. These agreements, among other things, will require us to indemnify each director and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys' fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person's services as a director or executive officer. See "Executive Compensation—Limitation on Liability and Indemnification Matters."

Stock Options

        We have granted stock options to our executive officers and certain of our directors. For more information regarding these stock options, see the section titled "Executive Compensation—Compensation Discussion and Analysis."

Policies and Procedures for Related Party Transactions

        Our board of directors intends to adopt a written related person transaction policy to set forth the policies and procedures for the review and approval or ratification of related person transactions. This policy will cover, with certain exceptions set forth in Item 404 of Regulation S-K under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount involved exceeds $120,000 and a related person had or will have a direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person.

        As provided by our audit committee charter to be effective upon completion of this offering, our audit committee will be responsible for reviewing and approving in advance any related party transaction.

130


Table of Contents


PRINCIPAL AND SELLING STOCKHOLDERS

        The following table sets forth information known to us about the beneficial ownership of our common stock at September 1, 2011, as adjusted to reflect the sale of the shares of common stock in this offering, by:

        The information in the table below is calculated based on 72,876,287 shares of common stock outstanding before this offering and                        shares of common stock outstanding after this offering. The number of shares outstanding before and after this offering is based on the number of shares of common stock outstanding on September 1, 2011, as adjusted to give effect to:

        In computing the number of shares of common stock beneficially owned by a person, entity or group and the corresponding percentage ownership of that person, entity or group, shares of common stock underlying common stock or preferred stock options and warrants that are held by that person, entity or group and that are currently exercisable or exercisable within 60 days of September 1, 2011 are considered to be outstanding. We did not deem these shares to be outstanding, however, for the purpose of computing the percentage ownership of any other person, entity or group.

        Unless otherwise noted below, the address of each beneficial owner listed on the table is c/o Intermolecular, Inc., 3011 N. First Street, San Jose, California 95134. We have determined beneficial ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the

131


Table of Contents


tables below have sole voting and investment power with respect to all shares of common stock that they beneficially own, subject to applicable community property laws where applicable.

 
   
   
   
   
   
   
   
  Beneficial
Ownership
After this
Offering
(Over-allotment
Option
Exercised
in Full)
 
 
  Beneficially Owned Prior to this Offering   Beneficial Ownership After
this Offering
 
 
   
  Number of
Shares
Exercisable
within 60
Days
   
   
 
 
  Common
Stock
  Number of
Shares
Beneficially
Owned
  Percentage
of
Beneficial
Ownership
  Shares
Being
Offered
  Number of
Shares
Beneficially
Owned
  Percentage
of
Beneficial
Ownership
  Percentage
of
Beneficial
Ownership
 

5% Stockholders

                                                 

ATMI, Inc.(1)

    7,714,485         7,714,485     10.59 %                        

Entities affiliated with CMEA Ventures(2)

    15,096,892         15,096,892     20.72 %                        

Entities affiliated with Redpoint Ventures(3)

    15,190,084         15,190,084     20.84 %                        

Symyx Technologies, Inc.(4)

    7,936,409         7,936,409     10.89 %                        

U.S. Venture Partners(5)

    10,753,439         10,753,439     14.76 %                        

Named Executive Officers and Directors

                                                 

David E. Lazovsky(6)

    7,587,268     1,031,250     8,618,518     11.66 %                        

Peter L. Eidelman(7)

        967,708     967,708     1.31 %                        

Tony P. Chiang, Ph.D.(8)

        2,881,250     2,881,250     3.80 %                        

J. Craig Hunter(9)

        535,416     535,416     *                          

Sandeep Jaggi, J.D., Ph.D.(10)

        156,250     156,250     *                          

Thomas R. Baruch(11)

    15,096,892     250,000     15,346,892     20.99 %                        

Marvin D. Burkett(12)

        25,000     25,000     *                          

Irwin B. Federman(13)

    10,753,439         10,753,439     14.76 %                        

Isy Goldwasser(14)

                                         

Bruce M. McWilliams(15)

    440,000     210,000     650,000     *                          

George M. Scalise(16)

    380,000         380,000     *                          

John L. Walecka(17)

    15,190,084         15,190,084     20.84 %                        

All executive officers and directors as a
group (14 persons)(18)

    49,447,683     6,306,874     55,754,557     70.41 %                        

*
Represents beneficial ownership of less than 1%.

(1)
Includes 1,470,000 shares to be issued upon the cash exercise of a warrant upon the consummation of this offering. The address of ATMI, Inc. is 7 Commerce Drive, Danbury, Connecticut 06810.

(2)
Includes: (i) 14,751,005 shares held prior to this offering by CMEA Ventures VI, L.P. (CMEA VI) and (ii) 345,887 shares held prior to this offering by CMEA Ventures VI GmbH & Co. KG (CMEA VI GmbH). CMEA Ventures VI Management, L.P. (CMEA VI Mgmt) is the general partner of each of CMEA VI and CMEA VI GmbH. Thomas R. Baruch, David J. Collier, Karl D. Handelsman, Faysal A. Sohail and James F. Watson are the general partners of CMEA VI Mgmt and, as such, have voting and dispositive power over these shares. Each disclaims beneficial ownership of the shares held by these entities, except to the extent of any pecuniary interest therein. The address of each of the entities affiliated with CMEA Ventures is One Embarcadero Center, Suite 3250, San Francisco, California 94111.

(3)
Includes: (i) 14,846,786 shares held prior to this offering by Redpoint Ventures II, L.P. (RV II) and (ii) 343,298 shares held prior to this offering by Redpoint Associates II, LLC (RA II). Redpoint Ventures II, LLC (RV II LLC), a Delaware limited liability company, is the sole general partner of RV II. Voting and dispositive decisions with respect to shares held by RV II and RA II are shared by Jeffery D. Brody, R. Thomas Dyal, Timothy M. Haley, G. Bradford Jones, John L. Walecka and Geoffrey Y. Yang in their capacities as managing members of each of RV II and RA II. Each disclaims beneficial ownership of the shares held by these entities, except to the extent of any pecuniary interest therein. The address of each of the entities affiliated with Redpoint Ventures is 3000 Sand Hill Road, Building Two, Suite 290, Menlo Park, California 94025.

(4)
Includes 7,936,409 shares held prior to this offering. The address of Symyx Technologies, Inc. is c/o Accelrys, Inc., 10188 Telesis Court, Suite 100, San Diego, California 92121.

(5)
Includes 10,753,439 shares held prior to this offering by U.S. Venture Partners IX, L.P. (USVP IX). Presidio Management Group IX, LLC (PMG IX) is the general partner of USVP IX. Each of Irwin B. Federman, Winston S. Fu, Steven M. Kransz, David E. Liddle, Paul Matteucci, Jonathan D. Root, Christopher Rust, Casey M. Tansey and Philip M. Young are the managing members of PMG IX and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons disclaim beneficial ownership of the shares held by USVP IX, except to the extent of any pecuniary interest therein. The address of U.S. Venture Partners is 2735 Sand Hill Road, Menlo Park, California 94025.

(6)
Consists of: (i) 6,595,504 shares held by David E. Lazovsky, (ii) 450,000 shares held by The David E. Lazovsky 2010 Annuity Trust, (iii) 450,000 shares held by The Juel D. Lazovsky 2010 Annuity Trust, (iv) 91,764 shares held by The Lazovsky 2010 Irrevocable Children's Trust and (v) 1,031,250 shares that may be acquired pursuant to the exercise of stock options within 60 days of September 1, 2011 by Mr. Lazovsky.

(7)
Consists of 967,708 shares that may be acquired pursuant to the exercise of stock options within 60 days of September 1, 2011.

(8)
Consists of 2,881,250 shares that may be acquired pursuant to the exercise of stock options within 60 days of September 1, 2011.

(9)
Consists of 535,416 shares that may be acquired pursuant to the exercise of stock options within 60 days of September 1, 2011.

132


Table of Contents

(10)
Consists of 156,250 shares that may be acquired pursuant to the exercise of stock options within 60 days of September 1, 2011.

(11)
Consists of the shares described in Note (2) above. Mr. Baruch disclaims beneficial ownership of the shares held by the entities affiliated with CMEA Ventures as descibed in Note (2) above, except to the extent of his pecuniary interest therein. Also includes 250,000 shares that may be acquired pursuant to the exercise of stock options within 60 days of September 1, 2011.

(12)
Consists of 25,000 shares that may be acquired pursuant to the exercise of stock options within 60 days of September 1, 2011.

(13)
Consists of the shares described in Note (5) above. Mr. Federman disclaims beneficial ownership of the shares held by the entities affiliated with U.S. Ventures as descibed in Note (5) above, except to the extent of his pecuniary interest therein.

(14)
Excludes shares held by Symyx Technologies, Inc.

(15)
Consists of: (i) 440,000 shares held by Bruce and Astrid McWilliams 1997 Trust UAD 11/06/97 and (ii) 210,000 shares that may be acquired pursuant to the exercise of stock options within 60 days of September 1, 2011.

(16)
Consists of 380,000 shares held by George M. Scalise and Dorothea Scalise TR Family Trust UA 12/28/88. Includes 30,000 shares subject to our right of repurchase, which right lapses as to 15,000 shares annually on February 25, 2012 and February 25, 2013.

(17)
Consists of the shares described in Note (3) above. Mr. Walecka disclaims beneficial ownership of the shares held by the entities affiliated with Redpoint Ventures as descibed in Note (3) above, except to the extent of his pecuniary interest therein.

(18)
Includes: (i) 41,040,415 shares held by entities affiliated with certain of our directors and (ii) 49,447,683 shares beneficially owned by our executive officers and directors, which includes the 41,040,415 shares held by such entities and 6,306,874 shares that may be acquired pursuant the exercise of stock options within 60 days of September 1, 2011.

133


Table of Contents


DESCRIPTION OF CAPITAL STOCK

General

        Upon the completion of this offering, we will have authorized under our amended and restated certificate of incorporation             shares of common stock, $0.001 par value per share, and            shares of preferred stock, $            par value per share. The following information assumes the filing of our amended and restated certificate of incorporation and the conversion of all outstanding shares of our preferred stock into shares of common stock upon the completion of this offering.

        As of June 30, 2011, there were outstanding:

        The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and restated bylaws to be in effect upon the completion of this offering is a summary and is qualified in its entirety by reference to the full copies of these documents, which have been filed with the SEC as exhibits to our registration statement, of which this prospectus forms a part. The descriptions of the common stock and preferred stock reflect changes to our capital structure that will occur upon the closing of this offering. Currently, there is no established public trading market for our common stock.

Common Stock

Voting Rights

        Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors.

Dividends

        Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.

Liquidation

        In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.

Rights and Preferences

        Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate in the future.

134


Table of Contents

Preferred Stock

        Upon the completion of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up to                shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change of control of our company or other corporate action. Upon completion of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock.

Warrants

        The following table sets forth information about outstanding warrants to purchase shares of our stock as of June 30, 2011. In connection with the consummation of this offering, the warrant to purchase shares of our Series B redeemable convertible preferred stock will convert into a warrant to purchase shares of our common stock. Certain of the warrants below (as indicated), which will expire upon completion of this offering if unexercised, will be exercised on a cash basis in connection with the consummation of this offering, resulting in the issuance of 2,621,985 shares of common stock.

Class of Stock
  Number of
Shares
  Exercise
Price/Share
  Expiration
Date

Common

    150,000   $ 0.75   (1)(2)

Common

    11,238   $ 0.83   (2)(3)

Common

    1,470,000   $ 1.88   12/1/2012(2)

Common

    180,000   $ 1.02   (4)

Common

    1,644,736   $ 3.04144   (5)

Common

    822,000   $ 4.15412   12/1/2012(2)

Series B preferred stock

    168,747   $ 0.44445   11/4/2012(2)

(1)
Expires ten days following the termination of a Campaign Proposal Agreement, dated April 26, 2007, by and between Loomis Group, Inc. and us.

(2)
Warrants will be exercised on a cash basis in connection with the consummation of this offering.

(3)
Expires ten days following the termination of a Standard Production Agreement, dated April 19, 2007, by and between Compass Rose Media, LLC and us.

(4)
Expires on the earlier of (i) three months after Timane S.a r.l. (Timane), the holder of the warrant, ceases to be a service provider to us or the death or disability of Dr. Rabinzohn if he becomes a service provider after Timane ceases to be a service provider or (ii) June 15, 2018.

(5)
Expires 120 days from the end of the Collaborative Development Program under the Collaborative Development Program Agreement by and among Toshiba Corporation, SanDisk Corporation and us, dated March 15, 2010.

135


Table of Contents

Registration Rights

        We are party to an investor rights agreement, which provides that holders of our preferred stock have the right to demand that we file a registration statement or request that their shares be covered by a registration statement that we are otherwise filing. In the event that we propose to register any of our securities under the Securities Act, either for our own account or for the account of other security holders, these holders are entitled to notice of such registration and are entitled to certain "piggyback" registration rights allowing the holder to include their common stock in such registration, subject to certain marketing and other limitations. Pursuant to the investor rights agreement, the holders of common stock issuable upon conversion of our preferred stock have the right upon the earlier of six months after the completion of this offering and March 4, 2014 to require us, on not more than two occasions, to file a registration statement under the Securities Act to register the resale of their shares of common stock with an anticipated aggregate offering price, net of underwriting discounts and commissions, of at least $5 million. We may, in certain circumstances, defer such registrations and any underwriters will have the right, subject to certain limitations, to limit the number of shares included in such registrations. Further, these holders may require us to register the resale of all or a portion of their shares on a registration statement on Form S-3 once we are eligible to use Form S-3, subject to certain conditions and limitations. In an underwritten offering, the underwriter has the right, subject to specified conditions, to limit the number of registrable securities such holders may include. Additionally, the holders of registration rights have waived their rights to include any of their shares in this offering prior to the completion of this offering.

Anti-Takeover Provisions

Certificate of Incorporation and Bylaws to be in Effect Upon the Completion of this Offering

        Our amended and restated certificate of incorporation to be in effect upon the completion of this offering will provide for our board of directors to be divided into three classes, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of common stock outstanding will be able to elect all of our directors. Our amended and restated certificate of incorporation and amended and restated bylaws to be effective upon the completion of this offering will provide that all stockholder action must be effected at a duly called meeting of stockholders and not by a consent in writing, and that only our board of directors, chairman of the board, Chief Executive Officer or President (in the absence of a Chief Executive Officer) may call a special meeting of stockholders.

        Our amended and restated certificate of incorporation will require a        % stockholder vote for the amendment, repeal or modification of certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws relating to the classification of our board of directors, the requirement that stockholder actions be effected at a duly called meeting, and the designated parties entitled to call a special meeting of the stockholders. The combination of the classification of our board of directors, the lack of cumulative voting and the         % stockholder voting requirements will make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Because our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control.

136


Table of Contents

        These provisions may have the effect of deterring hostile takeovers or delaying changes in our control or management. These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of us. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts. Such provisions may also have the effect of preventing changes in our management.

Section 203 of the Delaware General Corporation Law

        We are subject to Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:

    if, before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested holder;

    if, upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

    if, on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2 / 3 % of the outstanding voting stock that is not owned by the interested stockholder.

        In general, Section 203 defines business combination to include the following:

    any merger or consolidation involving the corporation and the interested stockholder;

    any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;

    subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

    any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or

    the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation.

        In general, Section 203 defines an "interested stockholder" as an entity or person who, together with the person's affiliates and associates, beneficially owns, or is an affiliate or associate of the corporation and within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.

137


Table of Contents

Limitations of Liability and Indemnification Matters

        For an in depth discussion of liability and indemnification, please see "Executive Compensation—Limitation on Liability and Indemnification Matters."

NASDAQ Global Market Listing

        We have applied to have our common stock listed on The NASDAQ Global Market under the trading symbol "IMI."

Transfer Agent and Registrar

        The transfer agent and registrar for our common stock is                                    .

138


Table of Contents


SHARES ELIGIBLE FOR FUTURE SALE

        Prior to this offering, there has been no public market for our common stock. Future sales of our common stock in the public market, or the availability of such shares for sale in the public market, could adversely affect market prices of our common stock prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal restrictions on resale. Nevertheless, sales of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price of our common stock and our ability to raise equity capital in the future.

        Based on the number of shares of common stock outstanding as of June 30, 2011, upon completion of this offering, we will have an aggregate of                  shares of common stock outstanding. All of the shares sold by us in this offering will be freely tradable unless purchased by our affiliates.

        The remaining                      shares of common stock outstanding after this offering will be restricted as a result of securities laws or lock-up agreements as described below. Following the expiration of the lock-up period, all shares will be eligible for resale in compliance with Rule 144 or Rule 701 promulgated under the Securities Act to the extent such shares have been released from any repurchase option that we may hold. "Restricted securities" as defined under Rule 144 were issued and sold by us in reliance on exemptions from the registration requirements of the Securities Act. These shares may be sold in the public market only if registered or pursuant to an exemption from registration, such as Rule 144 or Rule 701 under the Securities Act. Subject to the lock-up agreements as described below and the provisions of Rule 144 or Rule 701, the shares of common stock outstanding after this offering (excluding the shares sold by us in this offering) will generally become available for sale in the public market as follows:

Approximate
Number of Shares
  Date
    Immediately

 

 

Beginning 90 days after the date of this prospectus

 

 

Beginning 180 days after the date of this prospectus

Rule 144

        Rule 144 provides an exemption from the registration and prospectus-delivery requirements of the Securities Act. This exemption is available to affiliates of ours that sell our restricted or non-restricted securities and also to non-affiliates that sell our restricted securities. Restricted securities include securities acquired from the issuer of those securities, or from an affiliate of the issuer, in a transaction or chain of transactions not involving any public offering. The shares we are selling in this offering are not restricted securities. However, all the shares we have issued before this offering are restricted securities, and they will continue to be restricted securities until they are resold pursuant to Rule 144 or pursuant to an effective registration statement.

        In general, under Rule 144, as in effect on the date of this prospectus, a person who is, or at any time during the 90 days preceding the sale was, an affiliate of ours generally may sell, within any three-month period, a number of shares that does not exceed the greater of:

139


Table of Contents

        In addition, sales by these persons must also satisfy requirements relating to the manner of sale, public notice, the availability of current public information about us and, in the case of restricted securities, a minimum holding period for those securities. All other persons may rely on Rule 144 to freely sell our restricted securities, so long as they satisfy both the minimum holding period requirement and, until a one-year holding period has elapsed, the current public information requirement.

        Rule 144 does not supersede our security holders' contractual obligations under the lock-up agreements described below.

Rule 701

        Generally, an employee, officer, director or qualified consultant of ours who purchased shares of our common stock before the effective date of the registration statement relating to this prospectus, or who holds options as of that date, pursuant to a written compensatory plan or contract may rely on the resale provisions of Rule 701 under the Securities Act. Under Rule 701, of these persons:

        Rule 701 does not supersede our security holders' contractual obligations under the lock-up agreements described below.

Lock-up Agreements

        We, along with our directors, executive officers, the selling stockholders and substantially all of our other security holders, have agreed with the underwriters that, subject to certain exceptions, for a period of 180 days following the date of this prospectus, we or they will not offer, sell, contract to sell, pledge, or otherwise dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, whether any of these transactions are to be settled by delivery of our common stock or other securities, in cash or otherwise, or publicly disclose the intention to effect any of these transactions. Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC may, in their sole discretion, at any time without prior notice, release all or any portion of the shares from the restrictions in any such agreement.

        If:

140


Table of Contents

Registration Rights

        We are party to an investor rights agreement that provides that holders of our preferred stock have the right to demand that we file a registration statement or request that their shares be covered by a registration statement that we are otherwise filing. See "Description of Capital Stock—Registration Rights." Except for shares purchased by affiliates, registration of their shares under the Securities Act would result in these shares becoming freely tradable without restriction under the Securities Act immediately upon effectiveness of the registration, subject to the expiration of the lock-up period and to the extent such shares have been released from any repurchase option that we may hold.

Stock Plans

        As soon as practicable after the completion of this offering, we intend to file a Form S-8 registration statement under the Securities Act to register shares of our common stock subject to options outstanding or reserved for issuance under our 2004 Equity Incentive Plan and our 2011 Incentive Award Plan. This registration statement will become effective immediately upon filing, and shares covered by this registration statement will thereupon be eligible for sale in the public markets, subject to Rule 144 limitations applicable to affiliates and any lock-up agreements. For a more complete discussion of our stock plans, see "Executive Compensation—Equity Incentive Plans."

141


Table of Contents


MATERIAL UNITED STATES FEDERAL INCOME TAX
CONSEQUENCES TO NON-U.S. HOLDERS

        The following is a summary of the material United States federal income tax consequences to non-U.S. holders (as defined below) of the acquisition, ownership and disposition of our common stock issued pursuant to this offering. This discussion is not a complete analysis of all of the potential United States federal income tax consequences relating thereto, nor does it address any estate and gift tax consequences or any tax consequences arising under any state, local or foreign tax laws, or any other United States federal tax laws. This discussion is based on the Internal Revenue Code of 1986, as amended, or the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the Internal Revenue Service, or IRS, all as in effect as of the date of this offering. These authorities may change, possibly retroactively, resulting in United States federal income tax consequences different from those discussed below. No ruling has been or will be sought from the IRS with respect to the matters discussed below, and there can be no assurance that the IRS will not take a contrary position regarding the tax consequences of the acquisition, ownership or disposition of our common stock, or that any such contrary position would not be sustained by a court.

        This discussion is limited to non-U.S. holders who purchase our common stock issued pursuant to this offering and who hold our common stock as a "capital asset" within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all of the United States federal income tax consequences that may be relevant to a particular holder in light of such holder's particular circumstances. This discussion also does not consider any specific facts or circumstances that may be relevant to holders subject to special rules under the United States federal income tax laws, including, without limitation:

    U.S. expatriates or former long-term residents of the United States;

    partnerships or other pass-through entities;

    "controlled foreign corporations," "passive foreign investment companies" or corporations that accumulate earnings to avoid United States federal income tax;

    banks, insurance companies, or other financial institutions;

    brokers, dealers, or traders in securities, commodities or currencies;

    tax-exempt organizations;

    tax-qualified retirement plans; or

    persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment.

        PROSPECTIVE INVESTORS ARE URGED TO CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR UNITED STATES FEDERAL INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL OR FOREIGN TAX LAWS AND ANY OTHER UNITED STATES FEDERAL TAX LAWS.

Definition of Non-U.S. Holder

        For purposes of this discussion, a non-U.S. holder is any beneficial owner of our common stock that is not a "U.S. person" or a partnership (or other entity treated as a partnership) for United States federal income tax purposes. A U.S. person is any of the following:

    an individual citizen or resident of the United States;

142


Table of Contents

    a corporation (or other entity treated as a corporation for United States federal income tax purposes) created or organized under the laws of the United States, any state therein or the District of Columbia;

    an estate the income of which is subject to United States federal income tax regardless of its source; or

    a trust (1) the administration of which is subject to the primary supervision of a United States court and all substantial decisions of which are controlled by one or more United States persons or (2) that has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.

Distributions on Our Common Stock

        If we make cash or other property distributions on our common stock, such distributions will constitute dividends for United States federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under United States federal income tax principles. Amounts not treated as dividends for United States federal income tax purposes will constitute a return of capital and will first be applied against and reduce a holder's adjusted tax basis in the common stock, but not below zero. Distributions in excess of our current and accumulated earnings and profits and in excess of a non-U.S. holder's tax basis in its shares will be treated as gain realized on the sale or other disposition of the common stock and will be treated as described under "Gain on Disposition of Our Common Stock" below.

        Dividends paid to a non-U.S. holder of our common stock will be subject to United States federal withholding tax at a rate of 30% of the gross amount of the dividends, or such lower rate specified by an applicable income tax treaty. To receive the benefit of a reduced treaty rate, a non-U.S. holder must furnish to us or our paying agent a valid IRS Form W-8BEN (or applicable successor form) certifying such holder's qualification for the reduced rate. This certification must be provided to us or our paying agent prior to the payment of dividends and must be updated periodically. Non-U.S. holders that do not timely provide us or our paying agent with the required certification, but who qualify for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS.

        If a non-U.S. holder holds our common stock in connection with the conduct of a trade or business in the United States, and dividends paid on the common stock are effectively connected with such holder's United States trade or business (and if required by an applicable income tax treaty, attributable to a permanent establishment maintained by the non-U.S. holder in the United States), the non-U.S. holder will be exempt from United States federal withholding tax. To claim the exemption, the non-U.S. holder must furnish to us or our paying agent a properly executed IRS Form W-8ECI (or applicable successor form).

        Any dividends paid on our common stock that are effectively connected with a non-U.S. holder's United States trade or business (and if required by an applicable income tax treaty, attributable to a permanent establishment maintained by the non-U.S. holder in the United States) will be subject to United States federal income tax on a net income basis at the regular graduated United States federal income tax rates in much the same manner as if such holder were a resident of the United States. A non-U.S. holder that is a foreign corporation also may be subject to a branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of a portion of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. Non-U.S. holders are urged to consult any applicable income tax treaties that may provide for different rules.

143


Table of Contents

        A non-U.S. holder who claims the benefit of an applicable income tax treaty will be required to satisfy applicable certification and other requirements prior to the distribution date. Non-U.S. holders should consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty.

Gain on Disposition of Our Common Stock

        A non-U.S. holder will not be subject to United States federal income tax on any gain realized upon the sale or other disposition of our common stock, unless:

    the gain is effectively connected with the non-U.S. holder's conduct of a trade or business in the United States, and if required by an applicable income tax treaty, attributable to a permanent establishment maintained by the non-U.S. holder in the United States;

    the non-U.S. holder is a nonresident alien individual present in the United States for 183 days or more during the calendar year of the disposition, and certain other requirements are met; or

    our common stock constitutes a "United States real property interest" by reason of our status as a United States real property holding corporation, or USRPHC, for United States federal income tax purposes at any time within the shorter of the five-year period preceding the disposition or the non-U.S. holder's holding period for our common stock. The determination of whether we are a USRPHC depends on the fair market value of our United States real property interests relative to the fair market value of our other trade or business assets and our foreign real property interests.

        We believe we are not currently and do not anticipate becoming a USRPHC for United States federal income tax purposes. Even if we become a USRPHC, however, so long as our common stock is regularly traded on an established securities market, such common stock will be treated as U.S. real property interests only if the non-U.S. holder actually or constructively holds more than 5% of our common stock.

        Gain described in the first bullet point above will be subject to United States federal income tax on a net income basis at the regular graduated United States federal income tax rates in much the same manner as if such holder were a resident of the United States. Further, non-U.S. holders that are foreign corporations also may be subject to a branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of a portion of its effectively connected earnings and profits for the taxable year, as adjusted for certain items.

        Gain described in the second bullet point above will be subject to United States federal income tax at a flat 30% rate (or such lower rate specified by an applicable income tax treaty), but may be offset by United States source capital losses (even though the individual is not considered a resident of the United States).

        Non-U.S. holders are urged to consult any applicable income tax treaties that may provide for different rules.

Information Reporting and Backup Withholding

        We must report annually to the IRS and to each non-U.S. holder the amount of distributions on our common stock paid to such holder and the amount of any tax withheld with respect to those distributions. These information reporting requirements apply even if no withholding was required because the distributions were effectively connected with the holder's conduct of a United States trade or business, or withholding was reduced or eliminated by an applicable income tax treaty. This information also may be made available under a specific treaty or agreement with the tax authorities in the country in which the non-U.S. holder resides or is established. Backup withholding may apply to

144


Table of Contents


distribution payments to a non-U.S. holder of our common stock and information reporting and backup withholding may apply to the payments of the proceeds of a sale of our common stock within the United States or through certain United States-related financial intermediaries, unless the non-U.S. holder furnishes to us or our paying agent the required certification as to its non-U.S. status, such as by providing a valid IRS Form W-8BEN or IRS Form W-8ECI, or certain other requirements are met. Notwithstanding the foregoing, backup withholding may apply if either we have or our paying agent has actual knowledge, or reason to know, that the holder is a U.S. person who is not an exempt recipient.

        Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a non-U.S. holder's United States federal income tax liability, provided the required information is timely furnished to the IRS.

New Legislation Relating to Foreign Accounts

        Newly enacted legislation may impose withholding taxes on certain types of payments made to "foreign financial institutions" (as specially defined for the purposes of these rules) and certain other non-United States entities. Under this legislation, the failure to comply with additional certification, information reporting and other specified requirements could result in withholding tax being imposed on payments of dividends and sales proceeds to foreign intermediaries and certain non-United States holders. The legislation imposes a 30% withholding tax on dividends on, or gross proceeds from the sale or other disposition of, our common stock paid to a foreign financial institution or to a foreign non-financial entity, unless (i) the foreign financial institution undertakes certain diligence and reporting obligations or (ii) the foreign non-financial entity either certifies it does not have any substantial United States owners or furnishes identifying information regarding each substantial United States owner. If the payee is a foreign financial institution, it must enter into an agreement with the United States Treasury requiring, among other things, that it undertake to identify accounts held by certain United States persons or United States-owned foreign entities, annually report certain information about such accounts and withhold 30% on payments to account holders whose actions prevent it from complying with these reporting and other requirements. The legislation will apply to payments made after December 31, 2012 (subject to certain transition rules). Prospective investors should consult their tax advisors regarding this legislation.

145


Table of Contents


UNDERWRITING

        Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters named below, for whom Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC and Barclays Capital Inc. are acting as representatives, have severally agreed to purchase, and we and the selling stockholders have agreed to sell to them, severally, the number of shares indicated below:

Name
  Number of Shares

Morgan Stanley & Co. LLC

        

J.P. Morgan Securities LLC

        

Barclays Capital Inc. 

        

Pacific Crest Securities LLC

        

Needham & Company, LLC

        
     
 

Total

        

        The underwriters and the representatives are collectively referred to as the "underwriters" and the "representatives," respectively. The underwriters are offering the shares of common stock subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several underwriters to pay for and accept delivery of the shares of common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered by the underwriters' option to purchase additional shares described below.

        The underwriters initially propose to offer part of the shares of common stock directly to the public at the offering price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $        per share. After the initial offering of the shares of common stock, the offering price and other selling terms may from time to time be varied by the representatives.

        We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to               additional shares of common stock at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. The underwriters may exercise this option solely for the purpose of covering over-allotments, if any, made in connection with the offering of the shares of common stock offered by this prospectus. To the extent the option is exercised, each underwriter will become obligated, subject to certain conditions, to purchase about the same percentage of the additional shares of common stock as the number listed next to the underwriter's name in the preceding table bears to the total number of shares of common stock listed next to the names of all underwriters in the preceding table.

        The following table shows the per share and total public offering price, underwriting discounts and commissions, and proceeds before expenses to us and the selling stockholders. These amounts are

146


Table of Contents


shown assuming both no exercise and full exercise of the underwriters' option to purchase up to an additional              shares of common stock.

 
   
  Total  
 
  Per Share   No Exercise   Full Exercise  

Public offering price

  $          $          $         

Underwriting discounts and commissions to be paid by:

                   
 

Us

  $          $          $         
 

The selling stockholders

  $          $          $         

Proceeds, before expenses, to us

  $            $            $           

Proceeds, before expenses, to selling stockholders

  $          $          $         

        The estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions but inclusive of our obligation to reimburse Symyx for 50% of their underwriting discounts and commissions, are approximately $        .

        The underwriters have informed us that they do not intend sales to discretionary accounts to exceed 5% of the total number of shares of common stock offered by them.

        We have applied to have our common stock listed on The NASDAQ Global Market under the trading symbol "IMI."

        We and all directors and officers and the holders of substantially all of our outstanding stock and stock options have agreed that, without the prior written consent of Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC on behalf of the underwriters, we and they will not, during the period ending 180 days after the date of this prospectus:

whether any such transaction described in the first two bullet points above is to be settled by delivery of common stock or such other securities, in cash or otherwise. In addition, each such person agrees that, without the prior written consent of Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC on behalf of the underwriters, it will not, during the period ending 180 days after the date of this prospectus, make any demand for, or exercise any right with respect to, the registration of any shares of common stock or any security convertible into or exercisable or exchangeable for common stock.

        The restrictions described in the immediately preceding paragraph do not apply to:

147


Table of Contents

        The 180 day restricted period described in the immediately preceding paragraph will be extended if:

148


Table of Contents

in which case the restrictions described in the immediately preceding paragraph will continue to apply until the expiration of the 18 day period beginning on the issuance of the earnings release or the occurrence of the material news or material event.

        Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC, in their sole discretion, may release the common stock and other securities subject to the lock-up agreements described above in whole or in part at any time with or without notice. When determining whether or not to release common stock and other securities from lock-up agreements, Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC will consider, among other factors, the holder's reasons for requesting the release, the number of shares of common stock and other securities for which the release is being requested and market conditions at the time. At least two business days before the effectiveness of any written consent of Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC during the 180 day period, (1) Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC will notify the Company of the impending release or waiver of any restriction and (2) the Company has agreed to announce the impending release or waiver by press release through a major news service at least two business days before the effective date of the release or waiver, except where the release or waiver is effected solely to permit a transfer of common stock that is not for consideration and where the transferee has agreed in writing to be bound by the terms of this agreement.

        In order to facilitate the offering of the common stock, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the common stock. Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no greater than the number of shares available for purchase by the underwriters under the option to purchase additional shares of common stock. The underwriters can close out a covered short sale by exercising the option to purchase additional shares of common stock or purchasing shares in the open market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available under the option to purchase additional shares of common stock. The underwriters may also sell shares in excess of the option to purchase additional shares of common stock, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating the offering, the underwriters may bid for, and purchase, shares of common stock in the open market to stabilize the price of the common stock. These activities may raise or maintain the market price of the common stock above independent market levels or prevent or retard a decline in the market price of the common stock. The underwriters are not required to engage in these activities and may end any of these activities at any time.

        The estimated offering expenses payable by us, in addition to the underwriting discounts and commissions, are approximately $         million, which includes legal, accounting and printing costs and various other fees associated with registering and listing our common stock. The underwriters have agreed to reimburse us and the selling stockholders for certain of these expenses.

        We, the selling stockholders and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act.

149


Table of Contents

        A prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any, participating in this offering. The representatives may agree to allocate a number of shares of common stock to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters that may make Internet distributions on the same basis as other allocations.

        Other than the prospectus in electronic format, the information on any underwriter's or selling group member's website and any information contained in any other website maintained by an underwriter or selling group member is not part of the prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or any underwriter or selling group member in its capacity as underwriter or selling group member and should not be relied upon by investors.

Pricing of the Offering

        Prior to this offering, there has been no public market for our common stock. The initial public offering price will be determined by negotiations between us and the representatives. Among the factors to be considered in determining the initial public offering price will be our future prospects and those of our industry in general, our sales, earnings and certain other financial and operating information in recent periods, and the price-earnings ratios, price-sales ratios, market prices of securities, and certain financial and operating information of companies engaged in activities similar to ours.

Selling Restrictions

        In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a "Relevant Member State") an offer to the public of any shares of our common stock may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of any shares of our common stock may be made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State:

        For the purposes of this provision, the expression an "offer to the public" in relation to any shares of our common stock in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares of our common stock to be offered so as to enable an investor to decide to purchase any shares of our common stock, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State, and the expression "2010 PD Amending Directive" means Directive 2010/73/EU.

150


Table of Contents

        Each underwriter has represented and agreed that:

        No prospectus or other disclosure document (as defined in the Corporations Act 2001 (Cth) of Australia (Corporations Act)) in relation to the shares of our common stock has been or will be lodged with the Australian Securities & Investments Commission (ASIC). This document has not been lodged with ASIC and is only directed to certain categories of exempt persons. Accordingly, if you receive this document in Australia:

        Each underwriter has represented and agreed that:

151


Table of Contents

        This prospectus has not been and will not be registered as a prospectus with the Registrar of Companies in India or with the Securities and Exchange Board of India. This prospectus or any other material relating to these securities is for information purposes only and may not be circulated or distributed, directly or indirectly, to the public or any members of the public in India and in any event to not more than 50 persons in India. Further, persons into whose possession this prospectus comes are required to inform themselves about and to observe any such restrictions. Each prospective investor is advised to consult its advisors about the particular consequences to it of an investment in these securities. Each prospective investor is also advised that any investment in these securities by it is subject to the regulations prescribed by the Reserve Bank of India and the Foreign Exchange Management Act and any regulations framed thereunder.

        No securities registration statement (SRS) has been filed under Article 4, Paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948, as amended) (FIEL) in relation to the shares of our common stock. The shares of our common stock are being offered in a private placement to "qualified institutional investors" (tekikaku-kikan-toshika) under Article 10 of the Cabinet Office Ordinance concerning Definitions provided in Article 2 of the FIEL (the Ministry of Finance Ordinance No. 14, as amended) (QIIs), under Article 2, Paragraph 3, Item 2 i of the FIEL.

        The shares of our common stock may not be offered, sold and delivered directly or indirectly, or offered or sold to any person for reoffering or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the Korea Securities and Exchange Act and the Foreign Exchange Transaction Law and the decrees and regulations thereunder. The shares of our common stock have not been registered with the Financial Services Commission of Korea for public offering in Korea. Furthermore, the shares of our common stock may not be resold to Korean residents unless the purchaser of the shares of our common stock complies with all applicable regulatory requirements (including but not limited to government approval requirements under the Foreign Exchange Transaction Law and its subordinate decrees and regulations) in connection with the purchase of the shares of our common stock.

        This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares of our common stock may not be circulated or distributed, nor may the of our common stock be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Future Act, Chapter 289 of Singapore (the SFA), (ii) to a "relevant person" as defined in Section 275(2) of the SFA, or any person

152


Table of Contents

pursuant to Section 275 (1A), and in accordance with the conditions, specified in Section 275 of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

        Where the shares of our common stock are subscribed and purchased under Section 275 of the SFA by a relevant person which is:

        shares, debentures and units of shares and debentures of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferable within six months after that corporation or that trust has acquired the shares of our common stock under Section 275 of the SFA except:

        By accepting this prospectus, the recipient hereof represents and warrants that he is entitled to receive it in accordance with the restrictions set forth above and agrees to be bound by limitations contained herein. Any failure to comply with these limitations may constitute a violation of law.

153


Table of Contents


LEGAL MATTERS

        The validity of our common stock offered by this prospectus will be passed upon for us by Latham & Watkins LLP, Menlo Park, California. Certain attorneys and investment funds affiliated with Latham & Watkins LLP collectively own shares of preferred stock, which will convert into shares of common stock upon the completion of this offering, as well as options to purchase shares of our common stock pursuant to our 2004 Equity Incentive Plan, altogether comprising less than 1% of our shares of common stock upon the completion of this offering. Certain legal matters in connection with this offering will be passed upon for the selling stockholders by                                                 . Certain legal matters in connection with this offering will be passed upon for the underwriters by Davis Polk & Wardwell LLP, Menlo Park, California.


EXPERTS

        The consolidated financial statements of Intermolecular, Inc. and subsidiaries as of December 31, 2010 and 2009, and for each of the years in the three-year period ended December 31, 2010, have been included herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. The audit report covering the December 31, 2010 financial statements refers to the change in the manner in which the Company accounted for convertible preferred stock.


WHERE YOU CAN FIND ADDITIONAL INFORMATION

        We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of our common stock offered hereby. This prospectus does not contain all of the information set forth in the registration statement and the exhibits and schedules thereto. Some items are omitted in accordance with the rules and regulations of the SEC. For further information with respect to us and the common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed therewith. Statements contained in this prospectus as to the contents of any contract, agreement or any other document are summaries of the material terms of this contract, agreement or other document. A copy of the registration statement, and the exhibits and schedules thereto, may be inspected without charge at the public reference facilities maintained by the SEC at 100 F Street, N.E., Washington, D.C. 20549. Copies of these materials may be obtained by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facility. The SEC maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the SEC's website is http://www.sec.gov.

        Upon completion of this offering, we will become subject to the information and periodic reporting requirements of the Exchange Act and, in accordance therewith, will file periodic reports, proxy statements and other information with the SEC. Such periodic reports, proxy statements and other information will be available for inspection and copying at the public reference room and web site of the SEC referred to above. We maintain a website at www.intermolecular.com. You may access our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The reference to our website address does not constitute incorporation by reference of the information contained on or accessible through our website.

154


Table of Contents


INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

INTERMOLECULAR, INC. AND SUBSIDIARIES

Consolidated Financial Statements

Years Ended December 31, 2008, 2009 and 2010 and the
Six Months Ended June 30, 2010 and 2011

 
  Page  

Report of Independent Registered Public Accounting Firm

    F-2  

Consolidated Balance Sheets

    F-3  

Consolidated Statements of Operations

    F-4  

Consolidated Statements of Redeemable Convertible Preferred Stock and of Stockholders' Deficit

    F-5  

Consolidated Statements of Cash Flows

    F-6  

Notes to Consolidated Financial Statements

    F-7  

F-1


Table of Contents


Report of Independent Registered Public Accounting Firm

The Board of Directors
Intermolecular, Inc.:

        We have audited the accompanying consolidated balance sheets of Intermolecular, Inc. and subsidiaries (the Company) as of December 31, 2009 and 2010, and the related consolidated statements of operations, redeemable convertible preferred stock and of stockholders' deficit and cash flows for each of the years in the three-year period ended December 31, 2010. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

        We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

        In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Intermolecular, Inc. and subsidiaries as of December 31, 2009 and 2010, and the results of their operations and their cash flows for each of the years in the three-year period ended December 31, 2010, in conformity with U.S. generally accepted accounting principles.

        As discussed in note 6(a) to the consolidated financial statements, effective for all periods presented, the Company changed the manner in which it accounted for redeemable convertible preferred stock.

/s/ KPMG LLP

Mountain View, California
June 30, 2011, except as related
to note 6(a) to the consolidated
financial statements which is as
of July 28, 2011

F-2


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

(In thousands, except share and per share data)

 
  December 31,
2009
  December 31,
2010
  June 30,
2011
  Pro Forma
Stockholders'
Equity as of
June 30,
2011
 
 
   
   
  (unaudited)
 

ASSETS

                         

Current assets:

                         
 

Cash and cash equivalents

  $ 20,856   $ 23,064   $ 34,880        
 

Short-term investments

    11,764         750        
 

Accounts receivable, net of allowance for doubtful accounts of zero as of December 31, 2009 and 2010 and June 30, 2011 (unaudited)

        3,296     3,298        
 

Accounts receivable, due from related parties

    1,189     836     972        
 

Prepaid expenses and other current assets

    3,442     1,868     2,029        
                     
   

Total current assets

    37,251     29,064     41,929        
 

Inventory

    1,379     2,189     2,055        
 

Property and equipment, net

    13,874     21,728     22,278        
 

Intangible assets, net

    1,664     2,238     2,638        
 

Restricted cash

    173     173     173        
 

Other assets

    128     179     226        
                     

Total assets

  $ 54,469   $ 55,571   $ 69,299        
                     

LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)

                         

Current liabilities:

                         
 

Accounts payable

  $ 426   $ 2,806   $ 839        
 

Accrued payable, due to related parties

    502     795            
 

Accrued liabilities

    1,428     2,720     3,854        
 

Accrued compensation and employee benefits

    1,219     2,243     2,025        
 

Deferred revenue, current portion

    1,876     5,233     3,289        
 

Related party deferred revenue, current portion

    15,252     10,227     7,325        
 

Preferred stock warrant liability

    159     215     670        
                     
   

Total current liabilities

    20,862     24,239     18,002        
                     
 

Deferred revenue, net of current portion

        1,470            
 

Related party deferred revenue, net of current portion

    7,500     3,216     1,250        
 

Deferred rent, net of current portion

    99     808     1,071        
 

Other long-term liabilities

        135     115        
                     
   

Total liabilities

    28,461     29,868     20,438        

Commitments and contingencies (note 5)

                         
 

Redeemable convertible preferred stock, par value $0.001 per share—56,000,000, 56,000,000 and 59,230,199 shares authorized as of December 31, 2009 and 2010 and June 30, 2011 (unaudited); 52,443,325, 52,443,325 and 58,461,447 shares issued and outstanding as of December 31, 2009 and 2010 and June 30, 2011 (unaudited); liquidation preference of $80,975 as of June 30, 2011 (unaudited), actual; no shares issued and outstanding, pro forma (unaudited)

    55,633     55,633     80,515        
 

Accumulated accretion of redeemable convertible preferred stock to redemption values

    20,264     34,426     41,521        
                     
     

Total redeemable convertible preferred stock

    75,897     90,059     122,036        

Stockholders' equity (deficit):

                         
 

Common stock, par value $0.001 per share—85,000,000, 85,000,000 and 105,000,000 shares authorized as of December 31, 2009 and 2010 and June 30, 2011 (unaudited); 11,065,607, 11,239,439 and 11,555,956 shares issued and outstanding as of December 31, 2009 and 2010 and June 30, 2011 (unaudited), actual; 72,639,388 shares issued and outstanding, pro forma (unaudited)

    11     11     12   $ 73  
 

Additional paid-in capital

                129,021  
 

Accumulated deficit

    (49,900 )   (64,367 )   (73,187 )   (73,187 )
                   

Total stockholders' (deficit) equity

    (49,889 )   (64,356 )   (73,175 ) $ 55,907  
                   

Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)

  $ 54,469   $ 55,571   $ 69,299        
                     

See accompanying notes to consolidated financial statements.

F-3


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Consolidated Statement of Operations

(In thousands, except share and per share data)

 
  Years Ended December 31,   Six Months Ended
June 30,
 
 
  2008   2009   2010   2010   2011  
 
   
   
   
  (unaudited)
 

Revenue:

                               
 

Collaborative development program and services revenue

  $ 14,647   $ 14,182   $ 27,705   $ 9,806   $ 15,820  
 

Product revenue

    6,206     9,065     6,959     3,300     1,360  
 

Licensing and royalty revenue

    2,276     3,663     8,010     3,386     6,644  
                       
   

Total revenue

    23,129     26,910     42,674     16,492     23,824  

Cost of revenue:

                               
 

Cost of collaborative development program and services revenue

    9,141     8,849     16,855     6,932     10,533  
 

Cost of product revenue

    3,370     3,972     3,665     1,652     469  
 

Cost of licensing and royalty revenue

    114     197     406     168     321  
                       
   

Total cost of revenue

    12,625     13,018     20,926     8,752     11,323  
                       
     

Gross profit

    10,504     13,892     21,748     7,740     12,501  

Operating expenses:

                               
 

Research and development

    11,849     10,983     13,917     6,353     9,488  
 

Sales and marketing

    3,849     3,211     4,074     1,926     1,980  
 

General and administrative

    4,300     4,867     5,761     2,877     3,925  
                       
   

Total operating expenses

    19,998     19,061     23,752     11,156     15,393  
                       

Loss from operations

    (9,494 )   (5,169 )   (2,004 )   (3,416 )   (2,892 )

Other income (expense):

                               
 

Interest income, net

    174     (6 )   43     17     10  
 

Other income (expense), net

    6     (62 )   202     55     (335 )
                       
   

Total other income (expense), net

    180     (68 )   245     72     (325 )

Loss before provision for income taxes

   
(9,314

)
 
(5,237

)
 
(1,759

)
 
(3,344

)
 
(3,217

)

Provision for income taxes

    186     17     19     2     13  
                       

Net loss

    (9,500 )   (5,254 )   (1,778 )   (3,346 ) $ (3,230 )

Accretion on redeemable convertible preferred stock

   
(5,436

)
 
(9,170

)
 
(14,162

)
 
(6,340

)
 
(7,095

)
                       

Net loss attributable to common stockholders

  $ (14,936 ) $ (14,424 ) $ (15,940 ) $ (9,686 ) $ (10,325 )
                       

Net loss per share of common stock, basic and diluted

  $ (1.39 ) $ (1.31 ) $ (1.43 ) $ (0.87 ) $ (0.91 )
                       

Weighted-average number of shares used in computing net loss per share of common stock, basic and diluted

    10,716,462     11,023,779     11,134,573     11,115,486     11,296,902  
                       

Pro forma net loss per share of common stock, basic and diluted

              $ (0.03 )       $ (0.04 )
                             

Weighted-average number of shares used in computing pro forma net loss per share of common stock, basic and diluted

                65,376,321           68,243,300  
                             

Related Party Transactions

         The Consolidated Statements of Operations shown above include the following related party transactions:

 
  Years Ended December 31,   Six Months
Ended June 30,
 
 
  2008   2009   2010   2010   2011  
 
   
   
   
  (unaudited)
 

Revenue:

                               
 

Collaborative development program and services revenue

  $ 6,625   $ 3,263   $ 13,382   $ 4,883   $ 5,511  
 

Product revenue

    6,206     9,065     6,047     3,300     4  
 

Licensing and royalty revenue

    2,276     3,663     6,584     3,261     4,844  
                       
   

Total revenue

  $ 15,107   $ 15,991   $ 26,013   $ 11,444   $ 10,359  
                       

Cost of Revenue:

                               
 

Cost of collaborative development program and services revenue

    625     597     1,250     443     299  
 

Cost of product revenue

    310     429     322     164     45  
 

Cost of licensing and royalty revenue

    114     197     406     168     220  
                       
   

Total cost of revenue

  $ 1,049   $ 1,223   $ 1,978   $ 775   $ 564  
                       

See accompanying notes to consolidated financial statements.

F-4


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Consolidated Statements of Redeemable Convertible Preferred Stock and of Stockholders' Deficit

(In thousands, except share data)

 
   
   
   
  Stockholders' Deficit  
 
  Redeemable Convertible
Preferred Stock
   
 
 
   
  Common stock    
   
   
 
 
 

  Additional
paid-in
capital
  Accumulated
deficit
  Total
stockholders'
deficit
 
 
  Shares   Amount   Shares   Amount  
 
   
 

Balances as of December 31, 2007

    45,867,493   $ 41,394         10,517,487   $ 11   $   $ (22,717 ) $ (22,706 )
 

Issuance of common stock from option exercises

                489,270         147         147  
 

Issuance of Series D redeemable convertible preferred stock (net of issuance costs of $90)

    6,575,832     19,910                          
 

Stock-based compensation

                        916         916  
 

Accretion of preferred stock to redemption amount

        5,436                 (1,063 )   (4,373 )   (5,436 )
 

Net loss (restated)

                            (9,500 )   (9,500 )
                                   

Balances as of December 31, 2008

    52,443,325     66,740         11,006,757     11         (36,590 )   (36,579 )
 

Issuance of common stock from option exercises

                58,850         33         33  
 

Issuance cost increase of Series D redeemable convertible preferred stock increase to $103

        (13 )                        
 

Stock-based compensation

                        1,081         1,081  
 

Accretion of preferred stock to redemption amount

        9,170                 (1,114 )   (8,056 )   (9,170 )
 

Net loss (restated)

                            (5,254 )   (5,254 )
                                   

Balances as of December 31, 2009

    52,443,325     75,897         11,065,607     11         (49,900 )   (49,889 )
 

Issuance of common stock from option exercises

                173,832         109         109  
 

Stock-based compensation

                        1,364         1,364  
 

Accretion of preferred stock to redemption amount

        14,162                 (1,473 )   (12,689 )   (14,162 )
 

Net loss

                            (1,778 )   (1,778 )
                                   

Balances as of December 31, 2010

    52,443,325     90,059         11,239,439     11         (64,367 )   (64,356 )
 

Issuance of Series E redeemable convertible preferred stock (net of issuance costs of $118) (unaudited)

    6,018,122     24,882                          
 

Issuance of common stock from option exercises (unaudited)

                306,517     1     170         171  
 

Stock-based compensation (unaudited)

                        982         982  
 

Issuance of common stock warrants (unaudited)

                        312         312  
 

Non-cash issuance of common stock for services (unaudited)

                10,000         41         41  
 

Accretion of preferred stock to redemption amount (unaudited)

        7,095                 (1,505 )   (5,590 )   (7,095 )
 

Net loss (unaudited)

                            (3,230 )   (3,230 )
                                   

Balances as of June 30, 2011 (unaudited)

    58,461,447   $ 122,036         11,555,956   $ 12   $   $ (73,187 ) $ (73,175 )
                                   

See accompanying notes to consolidated financial statements.

F-5


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(In thousands)

 
  Years Ended December 31,   Six Months
Ended June 30,
 
 
  2008   2009   2010   2010   2011  
 
   
   
   
  (unaudited)
 

Cash flows from operating activities:

                               
 

Net loss

  $ (9,500 ) $ (5,254 ) $ (1,778 ) $ (3,346 ) $ (3,230 )
 

Adjustments to reconcile net loss to net cash used in operating activities:

                               
   

Depreciation and amortization

    3,430     4,380     4,971     2,412     3,504  
   

Stock-based compensation

    916     1,081     1,364     675     982  
   

Revaluation of preferred stock warrant liability

    80     42     56         455  
   

Common stock warrant charge (contra revenue)

                    312  
   

Changes in operating assets and liabilities:

                               
     

Prepaid expenses and other assets

    (2,683 )   279     1,523     1,209     (167 )
     

Inventory

    (354 )   778     (810 )   (729 )   134  
     

Accounts receivable

    (831 )   567     (2,943 )   (1,776 )   (138 )
     

Accounts payable

    960     (561 )   1,000     198     (668 )
     

Accrued and other liabilities

    (554 )   293     2,274     391     1,113  
     

Deferred revenue

    1,368     476     4,827     1,188     (3,414 )
     

Related party deferred revenue

    8,149     (993 )   (9,309 )   (5,199 )   (4,868 )
                       
       

Net cash provided by (used in) operating activities

    981     1,088     1,175     (4,977 )   (5,985 )
                       

Cash flows from investing activities:

                               
 

Purchase of short-term investments

        (11,764 )       1,133     (750 )
 

Redemption of short-term investments

            11,764     5,016      
 

Purchase of property and equipment

    (7,631 )   (4,810 )   (10,517 )   (2,691 )   (6,190 )
 

Capitalized intangible assets

    (531 )   (134 )   (323 )   (156 )   (342 )
                       
       

Net cash (used in) provided by investing activities

    (8,162 )   (16,708 )   924     3,302     (7,282 )
                       

Cash flows from financing activities:

                               
 

Proceeds from long-term debt

    3,000                  
 

Payment of long-term debt

    (1,749 )   (4,446 )            
 

Proceeds from issuance of common stock

    178     33     109     56     201  
 

Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

    19,910     (13 )           24,882  
                       
       

Net cash provided by (used in) financing activities

    21,339     (4,426 )   109     56     25,083  
                       

Net increase in cash and cash equivalents

    14,158     (20,046 )   2,208     (1,619 )   11,816  

Cash and cash equivalents at beginning of period

    26,744     40,902     20,856     20,856     23,064  
                       

Cash and cash equivalents at end of period

  $ 40,902   $ 20,856   $ 23,064   $ 19,237   $ 34,880  
                       

Supplemental disclosure of cash flow information:

                               
 

Cash paid for interest

  $ 295   $ 113   $   $   $  
                       
 

Cash paid for income taxes, net of refunds received

  $ 3   $ 279   $ (73 ) $ 10   $ 11  
                       

Noncash investing and financing activities

                               
 

Accretion of redeemable convertible preferred stock

  $ 5,436   $ 9,170   $ 14,162   $ 6,340   $ 7,095  
                       

See accompanying notes to consolidated financial statements.

F-6


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

1. The Company and Summary of Significant Accounting Policies

Business

        Intermolecular, Inc. and subsidiaries (the Company) is headquartered in San Jose, California and has wholly-owned subsidiaries in Hong Kong and Japan and a wholly-owned branch in Taiwan.

        The Company develops and applies high productivity combinatorial research and development technologies to accelerate research and development, innovation and time to market for the semiconductor and clean-energy industries. The Company creates high productivity combinational systems and methods, which allow the Company to perform collaborative research and development services, sell high productivity combinatorial systems, and license intellectual property to customers.

        The Company's consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Since inception, the Company has incurred net losses and has accumulated a deficit of $64.4 million and $73.2 million as of December 31, 2010 and June 30, 2011, respectively.

Basis of Presentation

        The Company's consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its consolidated subsidiaries. All intercompany transactions and balances have been eliminated during consolidation. Certain prior-year balances have been reclassified to conform to current financial statement presentation.

        The Company has evaluated subsequent events through June 30, 2011, which is the date the annual financial statements were issued. For the issuance of financial statements for the six months ended June 30, 2011, the unaudited interim period presented herein, such evaluation was performed through September 8, 2011.

Use of Estimates

        The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenue and expenses. Such estimates include the valuations of accounts receivable, inventories, intangible assets, capital stock and warrants and assumptions used in the calculation of income taxes and stock-based compensation, among others. These estimates and assumptions are based on management's best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts such estimates and assumptions when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates.

Unaudited Interim Financial Information

        The accompanying interim consolidated balance sheet as of June 30, 2011, the consolidated interim statements of operations and cash flows during the six months ended June 30, 2010 and 2011 and the interim consolidated statement of redeemable convertible preferred stock and of stockholders' deficit during the six months ended June 30, 2011 are unaudited. The unaudited interim consolidated financial

F-7


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

1. The Company and Summary of Significant Accounting Policies (Continued)


statements have been prepared on a basis consistent with the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's consolidated financial position as of June 30, 2011 and its consolidated results of operations and cash flows during the six months ended June 30, 2010 and 2011. The financial data and the other financial information disclosed in these notes to the consolidated financial statements related to the six month periods are also unaudited. The consolidated results of operations during the six months ended June 30, 2011 are not necessarily indicative of the results to be expected during the year ending December 31, 2011 or for any other future annual or interim period.

Unaudited Pro Forma Stockholders' Equity

        The Company's Restated Certificate of Incorporation as in effect immediately prior to the consummation of this offering provides that the Company's redeemable convertible preferred stock will automatically convert to common stock in the event of an underwritten initial public offering at a price that exceeds $5.40 per share and with aggregate minimum proceeds to the Company of at least $30.0 million. Since the Company expects to raise more than $30.0 million in the offering, as well as sell its shares of common stock at a per share offering price in excess of $5.40, the Company has included the automatic conversion of its redeemable convertible preferred stock in the presentation of pro forma disclosures and balances.

        The unaudited pro forma stockholders' equity as of June 30, 2011 has been prepared assuming the automatic conversion of all outstanding shares of the Company's redeemable convertible preferred stock into shares of common stock immediately before the completion of an initial public offering and the resulting reclassification of accumulated accretion of redeemable convertible preferred stock and preferred stock warrant liability to additional paid-in capital. The pro forma shares of common stock outstanding as of June 30, 2011 reflect the conversion of the redeemable convertible preferred stock into 58,461,447 shares of common stock and the conversion of 2,621,985 preferred and common stock warrants that expire upon an initial public offering if unexercised.

Concentration of Credit Risk

        Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and short-term investments. The Company's cash, cash equivalents and short-term investments consist of demand deposits, money market accounts and certificates of deposit maintained with high quality financial institutions.

Cash and Cash Equivalents

        The Company considers all highly liquid investments purchased with a maturity of three months or less to be cash equivalents. The Company's cash equivalents are comprised of money market funds and are maintained with high quality financial institutions.

Short-Term Investments

        The Company considers all high quality investments purchased with a maturity between three and twelve months to be short-term investments. The Company has short-term investments consisting of

F-8


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

1. The Company and Summary of Significant Accounting Policies (Continued)


certificates of deposit maintained with high quality credit institutions. The carrying value of these investments approximates their fair value due to the short term of their maturities.

Restricted Cash

        In connection with a lease transaction, the Company has restricted cash pledged as collateral representing a security deposit required by the lease agreement for its headquarters.

Inventory

        Inventories are stated at the lower of cost or market value, with cost determined on an average cost basis. Inventories consist only of raw materials. Inventories in excess of salable amounts and spare parts inventories that are considered obsolete are recorded as a cost in the period in which they occur. The Company did not experience any significant inventory impairments during the three-year-period ended December 31, 2010 and the six months ended June 30, 2011.

Property and Equipment

        Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of equipment is recognized on a straight-line basis over the estimated useful lives of the equipment, ranging from three to five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Maintenance and repairs that do not extend the life of or improve an asset are expensed in the period incurred.

Intangible Assets

        Intangible assets consist of issued and pending patents and trademarks as a result of third-party legal fees incurred in the patent and trademark application processes. Intangible assets with finite lives are amortized on a straight-line basis over their useful lives, while intangible assets without finite lives are not amortized. Upon the issuance of pending patent and trademark applications, the period of benefit will be determined. Patents, upon issuance, have a maximum life of 20 years from their application filing date. Trademarks, upon issuance, have an indefinite life and will not be amortized.

Impairment of Long-Lived Assets

        The Company evaluates its long-lived assets, which consist of property and equipment and intangible assets, for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Impairment exists if the carrying amounts of such assets exceed the estimates of future net undiscounted cash flows expected to be generated by such assets. Should impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the estimated fair value of the asset. As of December 31, 2009 and 2010 and June 30, 2011, the Company has not recorded an impairment on any of its long-lived assets.

F-9


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

1. The Company and Summary of Significant Accounting Policies (Continued)

Revenue Recognition

        The Company derives its revenue from three principal sources: collaborative development programs and other services; product sales; and technology licensing and royalty fees. Revenue is recognized when all of the following criteria are met:

    Persuasive evidence of an arrangement exists;

    Delivery has occurred;

    The vendor's fee is fixed or determinable; and

    Collectability of the fee is probable.

        Persuasive evidence of the arrangement represents a written contract signed by both the Company and the customer, or a customer purchase order. The Company assesses whether a price is fixed or determinable by, among other things, reviewing contractual terms and conditions related to payment terms. The Company assesses collectability based on factors such as the customer's creditworthiness and past collection history, if applicable. If collection is not probable, revenue recognition is deferred until receipt of payment.

        Collaborative development programs and other services —The Company enters into collaborative development programs and other research and development service agreements with customers under which the Company conducts research and development activities jointly with the customer. The agreements specify minimum levels of research effort required to be performed by the Company. Payments received under the agreements are not refundable if the research effort is not successful. The Company retains rights to certain elements of technology developed in the course of its performance, which the customer has an option to license in the future under the terms defined in the agreement. Most arrangements with customers have fixed monthly fees and requirements to provide regular reporting of research and development activities performed and revenue is recognized in a manner consistent with the fixed monthly fee. Payments received prior to performance are deferred and recognized as revenue when earned over future performance periods.

        The Company considers arrangements that include specifically identified, dedicated equipment to contain a lease provision, as these arrangements convey the right to the customer to use specific equipment and provide the ability to the customer to direct the use of the equipment as well as control more than a minor amount of the output of the equipment. To date the Company has determined these arrangements to contain operating leases, with a lease term that corresponds to the term of the CDP arrangement. The amount of revenue allocated for the lease element is based on its relative fair value, but the impact of the allocation does not change the amount of revenue recognized for the total arrangement as the lease term is consistent with the CDP term.

        Future minimum operating lease payments associated with CDP arrangements that contain operating leases were $5.2 million and $11.3 million as of December 31, 2010 and 2011, respectively.

        Product maintenance and support services —Included in collaborative development programs and other services revenue, these services entitle customers to receive product updates and enhancements or technical support and maintenance, depending on the offering. The related revenue is recognized ratably over the period the services are delivered.

F-10


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

1. The Company and Summary of Significant Accounting Policies (Continued)

        Product revenue —The Company recognizes revenue from the sale of products once delivery has occurred (title and risk of loss have passed to the customer), and customer acceptance, if required, has been achieved. The Company has determined that the software included with its equipment products is more than incidental to the product as a whole.

        Licensing and royalty revenue —The Company recognizes revenue for licenses to intellectual property when earned pursuant to the terms of the agreements. Time-based license revenue is recognized ratably over the license term. Licensing and royalty revenue that becomes triggered by specific customer actions, such as exercise of a license option or by sales volume, is recognized when it occurs based on royalty reports or other information received from the licensee. Minimum and prepaid royalties and license fees are recognized ratably over the related periods.

        Multiple-element arrangements —Certain of the Company's customer arrangements involve the delivery or performance of multiple products, services or licenses. Product sale arrangements include product maintenance and support. Collaborative development programs and other research and development services include licenses of technology and may also include sales of products.

        The Company evaluates whether a delivered element has value to the customer without the remaining undelivered elements by determining whether the delivered element could be sold by the Company, or resold by the customer, on a stand-alone basis. The Company concluded that all of its products and services deliverables have value to the customers on a stand-alone basis, as all these deliverables have been or could be sold and used by customers on a stand-alone basis. Intellectual property license arrangements have value on a stand-alone basis if the customer could purchase and use them without the remaining elements of the arrangement. In addition, the Company assesses whether there is objective and reliable evidence of fair values of all undelivered elements. Fair values of such elements are determined by reference to the Company-specific objective evidence, such as pricing of these elements when sold separately, substantive renewal prices for product maintenance and support and time-based licenses, or other available evidence. If the fair value of any undelivered elements in a multiple-element arrangement cannot be objectively determined, revenue is deferred until all elements are delivered, or until fair value can objectively be determined for any remaining undelivered elements. However, in situations where the undelivered elements are software-related hardware elements, the Company will recognize revenue under a proportional performance model when fair value for the hardware elements is not available, if the undelivered hardware elements are substantially similar products. If product maintenance and support and time-based licenses are the only undelivered elements without objective and reliable evidence of fair value, all revenue from the arrangement is amortized over the longer of the product maintenance and support term or license period. For purposes of classification in the consolidated statements of operations, revenue is allocated between collaborative development programs and services revenue, product revenue and licensing and royalty revenue based on objective and reliable evidence of fair value for any elements for which it exists or based on the relative stated invoice amount for elements for which objective and reliable evidence of fair value does not exist.

        In 2009, the Financial Accounting Standards Board (FASB) issued ASU 2009-13 Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements—a consensus of the FASB Emerging Issues Task Force (ASU 2009-13) and ASU 2009-14 Software (Topic 985): Certain Revenue Arrangements That Include Software Elements—a consensus of the FASB Emerging Issues Task Force (ASU 2009-14). ASU 2009-13 and 14 are amendments to the accounting standards for revenue recognition to remove

F-11


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

1. The Company and Summary of Significant Accounting Policies (Continued)


tangible products containing software components and nonsoftware components that function together to deliver the product's essential functionality from the scope of industry-specific software revenue recognition guidance, and also:

    provide updated guidance on whether multiple deliverables exist, how the deliverables in an arrangement should be separated, and how the consideration should be allocated;

    require an entity to allocate revenue in an arrangement using estimated selling prices (ESP) of deliverables if the Company does not have vendor-specific objective evidence of selling price (VSOE) or third-party evidence of selling price (TPE); and

    eliminate the use of the residual method and require an entity to allocate revenue using the relative selling price method.

        For all transactions entered into after December 31, 2010, the Company recognizes revenue using estimated selling prices of the delivered goods and services based on a hierarchy of methods contained in ASU 2009-13. The Company uses VSOE for determination of estimated selling price of elements in each arrangement if available, and since third-party evidence is not available for those elements where vendor-specific objective evidence of selling price cannot be determined, the Company evaluates factors to determine its ESP for all other elements. In multiple-element arrangements where hardware and software are sold as part of the solution, revenue is allocated to the hardware and software as a group using the relative selling prices of each of the deliverables in the arrangement based upon the aforementioned selling price hierarchy.

        The adoption of ASU 2009-13 and 14 did not have any impact on the Company's consolidated financial condition, operating revenue, results of operations or cash flows for the six month period ended June 30, 2011 as there were no multiple-element arrangements that included the sale of products originating during the period. The adoption of this standard may impact future revenue recognition for multiple-element product arrangements where product maintenance and support and time-based licenses are the only undelivered elements. The impact of adopting these provisions will result in more product revenue being recognized in earlier periods as the Company allocates revenue using the relative selling price method as opposed to recognizing all revenue from the arrangement ratably over the longer of the product maintenance and support term or license period.

Deferred Revenue

        Deferred revenue represents amounts collected from customers for which the related revenue has not been recognized, because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount that is expected to be recognized as revenue within one year from the balance sheet date.

Accounts Receivable and Allowance for Doubtful Accounts

        Trade accounts receivable are recorded at invoiced amounts, which include unbilled contractually obligated amounts, net of allowances for doubtful accounts if applicable, and do not bear interest.

        The allowance for doubtful accounts is based on the Company's assessment of the collectability of its customer accounts. The Company reviews the allowance by considering certain factors such as historical experience, industry data, credit quality, age of balances and current economic conditions that

F-12


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

1. The Company and Summary of Significant Accounting Policies (Continued)


may affect a customers' ability to pay. The Company determined that an allowance for doubtful accounts was not required as of December 31, 2009 and 2010 or June 30, 2011 and did not recognize any charges to bad debt during the years ended December 31, 2008, 2009 and 2010 and the six months ended June 30, 2010 and 2011.

Concentration of Revenue and Accounts Receivable

        Significant customers are those that represent more than 10% of the Company's total revenue or accounts receivable. For each significant customer, including related parties, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:

 
  Revenue   Accounts Receivable  
 
  Years Ended
December 31,
  Six Months
Ended
June 30,
  As of
December 31,
   
 
 
  As of
June 30,
2011
 
 
  2008   2009   2010   2010   2011   2009   2010  
 
   
   
   
  (unaudited)
   
   
  (unaudited)
 

Customer A

    58 %   59 %   52 %   62 %   33 %   100 %   11 %   10 %

Customer B

    *         *     *     11 %       20 %   12 %

Customer C

    *         *         *         12 %    

Customer D

    23 %   29 %   20 %   21 %   20 %       *     *  

Customer E

            *     *     11 %       11 %   22 %

Customer F

            *     *     *         19 %   14 %

Customer G

            *         *         24 %   28 %

*
less than 10%

Cost of Revenue

        Cost of revenue is primarily comprised of salaries and other personnel-related expenses for collaborative research and development scientists, engineers and development fab process operations employees. Additionally, cost of revenue includes wafers, targets, materials, program-related supplies, depreciation on equipment used in collaborative development programs and allocated facility-related costs. Product cost of revenue primarily includes cost of products sold. Cost of licensing and royalty includes related party license fees paid to Symyx.

Research and Development

        Research and development expenses, including direct and allocated expenses, are expensed as incurred. Research and development costs include salaries of technical staff, consultant costs, research and development parts and prototypes, wafers, chemicals, research and development supply costs, facilities rental, utilities costs related to laboratories and offices occupied by technical staff, depreciation on equipment used by technical staff, and outside services, such as machining and third-party research and development costs.

F-13


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

1. The Company and Summary of Significant Accounting Policies (Continued)

Software Development Costs

        The costs to develop software have not been capitalized as the technological feasibility of the related software is not established until substantially all product development is complete.

Income Taxes

        Income taxes have been accounted for under the asset and liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. Accordingly, realization of any deferred tax assets is dependent on future taxable income against which these deductions, losses and credits can be utilized.

        The Company assesses the likelihood that the deferred tax assets will be recovered and establishes a valuation allowance to the extent the Company believes that it is more likely than not that all or some portion of the asset will not be realized due to the inability to generate sufficient taxable income in the period and/or of the character necessary to utilize the benefit of the deferred tax asset. The Company recorded a full valuation allowance against its deferred tax assets as of December 31, 2009 and 2010 and June 30, 2011. Based on the available evidence, the Company believed it was more likely than not that it would not be able to utilize its deferred tax assets in the future. The Company intends to maintain a full valuation allowance until and if sufficient evidence exists to support all or a portion of its reversal.

        The Company regularly reviews its tax positions for benefits to be realized. A tax position must be more likely than not to be sustained upon examination. The amount recognized is measured as the largest amount of benefit that is more likely than not to be realized upon settlement. The Company's policy is to recognize interest and penalties related to income tax matters as income tax expense. Through June 30, 2011, the Company did not have any interest or penalties associated with unrecognized tax benefits.

Share-Based Compensation

        Compensation costs related to employee stock options granted during the years ended December 31, 2008, 2009 and 2010 and the six months ended June 30, 2010 and 2011 are based on the fair value of the options on the date of grant, net of estimated forfeitures. The Company determines the grant date fair value of the options using the Black-Scholes option-pricing model and the related stock-based compensation expense is generally recognized on a straight-line basis over the period in which an employee is required to provide service in exchange for the options, or the vesting period of the respective options.

        The Company accounts for stock options issued to nonemployees based on the fair value of the options determined using the Black-Scholes option-pricing model. The fair value of stock options granted to nonemployees is remeasured each reporting period as the stock options vest and the resulting change in value, if any, is recognized in the Company's consolidated statements of operations during the period the related services are rendered.

F-14


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

1. The Company and Summary of Significant Accounting Policies (Continued)

Comprehensive Loss

        Comprehensive loss consists of the same components as net loss and therefore the Company does not separately disclose a statement of comprehensive loss.

Employee Savings Plan

        The Company has a savings plan in the United States that qualifies under Section 401(k) of the Internal Revenue Code. Participating employees may contribute up to the statutory limits. The Company has not made employer contributions to the plan to date.

Segment Information

        The Company operates in one reportable segment. The Company's chief operating decision-maker, its chief executive officer, reviews its operating results on an aggregate basis and manages its operations as a single operating segment.

Deferred Offering Costs

        Deferred offering costs, consisting of legal, accounting and filing fees relating to the initial public offering, are capitalized. The deferred offering costs will be offset against initial public offering proceeds upon the effectiveness of the offering. In the event the offering is terminated, deferred offering costs will be expensed. As of June 30, 2011, the Company had capitalized $0.7 million of deferred offering costs in prepaid expenses and other current assets on the consolidated balance sheet. No amounts were deferred as of December 31, 2009 and 2010.

Fair Value of Financial Instruments

        The Company measures and reports its cash equivalents, short-term investments and preferred stock warrant liabilities at fair value. Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:

    Level I—Unadjusted quoted prices in active markets for identical assets or liabilities;

    Level II—Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and

    Level III—Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.

        The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

F-15


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

1. The Company and Summary of Significant Accounting Policies (Continued)

        The Company's financial instruments consist of Level I and Level III liabilities. Level I securities include highly liquid money market funds and short-term investments. The Company does not hold any Level II instruments. Level III liabilities that are measured at fair value on a recurring basis consist of preferred stock warrant liabilities. The fair values of the outstanding preferred stock warrants are measured using the Black-Scholes option-pricing model. Inputs used to determine estimated fair value include the estimated fair value of the underlying stock at the valuation measurement date, the remaining contractual term of the warrants, risk-free interest rates, expected dividends and the expected volatility of the underlying stock.

Foreign Currency

        The functional currency of foreign subsidiaries is the U.S. dollar and foreign currency transaction gains and losses are recorded in other income (expense), net.

Net Loss per Share of Common Stock

        The Company's basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the if-converted method. For purposes of this calculation, redeemable convertible preferred stock, options to purchase common stock, common stock subject to repurchase, warrants to purchase redeemable convertible preferred stock and warrants to purchase common stock are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share of common stock as their effect is antidilutive.

Unaudited Pro Forma Net Loss per Share of Common Stock

        The Company's Restated Certificate of Incorporation as in effect immediately prior to the consummation of this offering provides that the Company's redeemable convertible preferred stock will automatically convert to common stock in the event of an underwritten initial public offering at a price that exceeds $5.40 per share and with aggregate minimum proceeds to the Company of at least $30.0 million. Since the Company expects to raise more than $30.0 million in the offering, as well as sell its shares of common stock at a per share offering price in excess of $5.40, the Company has included the automatic conversion of its redeemable convertible preferred stock in the presentation of pro forma disclosures and balances.

        In contemplation of the Company's initial public offering, the Company has presented the unaudited pro forma basic and diluted net loss per share of common stock which has been computed to give effect to the automatic conversion of the redeemable convertible preferred stock into shares of common stock on a weighted average basis and the conversion of certain preferred and common stock warrants that expire upon an initial public offering if unexercised. Also, the numerator in the pro forma basic and diluted net loss per share calculation has been adjusted to remove gains and losses resulting from the accretion of redeemable convertible preferred stock and the remeasurement of the preferred stock warrant liability as if the conversion had occurred as of the beginning of the period.

F-16


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

1. The Company and Summary of Significant Accounting Policies (Continued)

Recent Accounting Pronouncements

        In January 2010, the FASB issued an amendment to an accounting standard that requires new disclosures for fair value measurements and provides clarification for existing fair value disclosure requirements. The amendment will require an entity to disclose separately the amounts of significant transfers in and out of Levels I and II fair value measurements and to describe the reasons for the transfers; and to disclose information about purchases, sales, issuances and settlements separately in the reconciliation for fair value measurements using significant unobservable inputs, or Level III inputs. This amendment clarifies existing disclosure requirements for the level of disaggregation used for classes of assets and liabilities measured at fair value and requires disclosures about the valuation techniques and inputs used to measure fair value for both recurring and nonrecurring fair value measurements using Level II and Level III inputs. This guidance is effective for interim and annual reporting periods beginning after December 15, 2009, except for certain Level III activity disclosure requirements that will be effective for reporting periods beginning after December 15, 2010. Accordingly, the Company adopted this amendment as of January 1, 2010, except for the additional Level III requirements, which will be adopted during the year ending December 31, 2011. The Company did not hold any Level II investments during any of the years presented and has disclosed in note 7 the underlying inputs used to value its Level III preferred stock warrant liability.

2. Fair Value of Financial Instruments

        The Company measures and reports its cash equivalents, short-term investments and preferred stock warrant liability at fair value. The following table sets forth the fair value of the Company's financial assets and liabilities by level within the fair value hierarchy (in thousands):

 
  As of December 31, 2009  
 
  Fair Value   Level I   Level II   Level III  

Assets:

                         
 

Money market funds

  $ 20,285   $ 20,285   $   $  
 

Short-term investments

    11,764     11,764          
                   

Total assets measured at fair value

  $ 32,049   $ 32,049   $   $  
                   

Liabilities:

                         
 

Preferred stock warrant liability

  $ 159   $   $   $ 159  
                   

Total liabilities measured at fair value

  $ 159   $   $   $ 159  
                   

F-17


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

2. Fair Value of Financial Instruments (Continued)

 

 
  As of December 31, 2010  
 
  Fair Value   Level I   Level II   Level III  

Assets:

                         
 

Money market funds

  $ 20,659   $ 20,659   $   $  
                   

Total assets measured at fair value

  $ 20,659   $ 20,659   $   $  
                   

Liabilities:

                         
 

Preferred stock warrant liability

  $ 215   $   $   $ 215  
                   

Total liabilities measured at fair value

  $ 215   $   $   $ 215  
                   

 

 
  As of June 30, 2011  
 
  Fair Value   Level I   Level II   Level III  
 
  (unaudited)
 

Assets:

                         
 

Money market funds

  $ 23,667   $ 23,667   $   $  
 

Short-term investments

    750     750              
                   

Total assets measured at fair value

  $ 24,417   $ 24,417   $   $  
                   

Liabilities:

                         
 

Preferred stock warrant liability

  $ 670   $   $   $ 670  
                   

Total liabilities measured at fair value

  $ 670   $   $   $ 670  
                   

        The following table sets forth a summary of the changes in the fair value of the Company's Level III financial liabilities (in thousands):

 
  Years Ended
December 31,
  Six Months
Ended
June 30,
 
 
  2008   2009   2010   2010   2011  
 
   
   
   
  (unaudited)
 

Fair value—beginning of period

  $ 37   $ 117   $ 159   $ 159   $ 215  

Change in fair value of warrant liabilities

    80     42     56         455  
                       

Fair value—end of period

  $ 117   $ 159   $ 215   $ 159   $ 670  
                       

F-18


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

3. Property and Equipment

        Property and equipment consist of the following (in thousands):

 
  As of December 31,   As of June 30,  
 
  2009   2010   2011  
 
   
   
  (unaudited)
 

Lab equipment and machinery

  $ 16,128   $ 24,766   $ 30,208  

Leasehold improvements

    3,488     5,055     5,782  

Computer equipment and software

    1,842     2,314     2,551  

Furniture and fixtures

    79     108     122  

Construction in progress

    3,280     5,252     2,870  
               
 

Total property and equipment

    24,817     37,495     41,533  

Less accumulated depreciation

    (10,943 )   (15,767 )   (19,255 )
               
 

Property and equipment, net

  $ 13,874   $ 21,728   $ 22,278  
               

        As of December 31, 2009 and 2010 and June 30, 2011, no property and equipment were pledged as collateral against borrowings. Amortization of leasehold improvements is included in depreciation expense. Depreciation expense was $3.4 million, $4.4 million, $5.0 million, $2.4 million and $3.5 million during the years ended December 31, 2008, 2009 and 2010 and the six months ended June 30, 2010 and 2011, respectively.

        The Company maintained dedicated equipment to support contractual customer capacity requirements as part of certain collaborative development programs that are classified as lab equipment and machinery that have a net book value of $2.1 million and $6.4 million as of December 31, 2010 and June 30, 2011, respectively.

4. Intangible Assets

        Intangible assets consist of the following (in thousands):

 
  As of December 31,    
 
 
  As of June 30,
2011
 
 
  2009   2010  
 
   
   
  (unaudited)
 

Patents issued

  $ 121   $ 209   $ 424  

Patents pending

    1,514     2,009     2,204  

Trademarks

    38     38     38  
               
 

Total intangible assets

    1,673     2,256     2,666  

Less patent amortization

    (9 )   (18 )   (28 )
               
 

Intangible assets, net

  $ 1,664   $ 2,238   $ 2,638  
               

        Amortization commences upon patent issuance. The useful life of the patents, once approved, will not exceed 20 years, and will depend on the nature of the patent. The average estimated amortization period of our current portfolio is 17 years. Amortization expense during the years ended December 31, 2008, 2009, 2010 and the six months ended June 30, 2010 and 2011 was $4,000, $5,000, $9,000, $3,000 and $10,000, respectively.

F-19


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

4. Intangible Assets (Continued)

        Estimated future aggregate annual amortization expense for both issued and pending intangible assets is as follows (in thousands):

 
   
 

As of December 31:

       
 

2011

 
$

73
 
 

2012

    123  
 

2013

    123  
 

2014

    123  
 

2015

    123  
 

Thereafter

    1,635  
       
   

Total

  $ 2,200  
       

5. Commitments and Contingencies

Leases

        The Company entered into an operating lease agreement in July 2005 for its facility in California with a lease term that expires on October 31, 2011. During the year ended December 31, 2008, the space under the operating lease was expanded to support the Company's operating needs. During the year ended December 31, 2010, the Company relocated its operations to a new facility and, accordingly, entered into an operating lease agreement in May 2010 that expires in May 2015. Rent expense for both facilities, which is being recognized on a straight-line basis over the lease term, was approximately $725,000, $797,000, $1.6 million, $581,000 and $1.1 million during the years ended December 31, 2008, 2009 and 2010 and the six months ended June 30, 2010 and 2011, respectively. Future commitments and obligations under the operating leases to be satisfied as they become due over the term are as follows (in thousands):

 
   
 

As of December 31:

       
 

The years ending December 31,

       
 

2011

  $ 1,550  
 

2012

    1,573  
 

2013

    1,657  
 

2014

    1,707  
 

2015

    728  
       
   

Total

  $ 7,215  
       

F-20


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

5. Commitments and Contingencies (Continued)

 

 
   
 

As of June 30 (unaudited):

       
 

Six month period ending December 31, 2011

 
$

869
 
 

The years ending December 31,

       
 

2012

    1,573  
 

2013

    1,657  
 

2014

    1,707  
 

2015

    728  
       
   

Total

  $ 6,534  
       

        During 2010 and the six months ended June 30, 2011, the Company made regular payments of $874,000 and $681,000, respectively, on the operating leases.

Equipment Loan

        On June 1, 2007, the Company borrowed $3.8 million pursuant to the terms of a loan and security agreement with a bank that was signed in 2005. In May 2008, the Company borrowed an additional $3.0 million under this loan and security agreement. The loan amounts were payable over a 36-month term ending June 1, 2010 and May 1, 2011, respectively. The outstanding loan balances under this loan and security agreement were paid off in February 2009. Effective January 27, 2010 and March 26, 2010, the Company amended the terms of the loan and security agreement to extend the availability of additional loan advances through December 31, 2011. Any additional borrowing will be payable in 36 monthly installments ending no later than December 1, 2013. These loans are secured by all company assets, excluding intellectual property. The amount borrowed must be requested in no less than $500,000 increments. The loan amount must be 100% first position secured by eligible equipment purchased within 270 days before the equipment advance. The loan advance allows for a look back for eligible equipment purchased, as long as the loan request is made within 90 days of the execution of the loan and security agreement. Equipment advances will accrue interest at a 5.50% annual rate.

        In connection with the original loan and security agreement, the Company issued a warrant to purchase Series B redeemable convertible preferred stock for 2.5% of the value of the loan facility. As of December 31, 2009 and 2010 and June 30, 2011, there were no outstanding balances under the equipment loans and the Company was compliant with all loan covenants, which primarily consist of monthly and annual financial statement reporting and the maintenance of certain minimum financial ratios. Also as of December 31, 2009 and 2010 and June 30, 2011, there was $10.0 million available for advances under this loan and security agreement.

Litigation

        The Company is subject to various claims arising in the ordinary course of business. Although no assurance may be given, the Company believes that it is not presently a party to any litigation of which the outcome, if determined adversely, would individually or in the aggregate be reasonably expected to have a material adverse effect on the business, operating results, cash flows or financial position of the Company.

        Third parties and others may claim in the future that the Company has infringed their past, current or future intellectual property rights. These claims, whether meritorious or not, could be

F-21


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

5. Commitments and Contingencies (Continued)


time-consuming, result in costly litigation, require expensive changes in the Company's methods of doing business or require the Company to enter into costly royalty or licensing agreements, if available. As a result, these claims could harm the Company's business, operating results, cash flows and financial position.

Indemnification

        From time to time, the Company agrees to indemnify certain customers against certain third-party liabilities, including liability if its products infringe a third party's intellectual property rights. The indemnification is typically limited to no more than the amount paid by the customer. As of December 31, 2010 and June 30, 2011, the Company was not subject to any material pending intellectual property-related litigation for which it is indemnifying a customer.

6. Redeemable Convertible Preferred Stock and Stockholders' Deficit

        (a)    Redeemable Convertible Preferred Stock     

    During the year ended December 31, 2008, the Company issued 6,575,832 shares of Series D at $3.04 per share, resulting in net cash proceeds of $19.9 million.

    During the six months ended June 30, 2011, the Company issued 6,018,122 shares of Series E at $4.15 per share, resulting in net cash proceeds of $24.9 million.

    The following tables are in thousands, except share data:

 
  As of December 31, 2009  
 
  Shares
Authorized
  Shares Issued
and
Outstanding
  Aggregate
Liquidation
Preference
 
 
   
   
   
 

Series A

    8,399,831     8,399,831   $ 800  

Series B

    22,949,711     22,780,964     10,125  

Series C

    14,686,698     14,686,698     25,050  

Series D

    9,963,760     6,575,832     20,000  
               

Total

    56,000,000     52,443,325   $ 55,975  
               

 

 
  As of December 31, 2010  
 
  Shares
Authorized
  Shares Issued
and
Outstanding
  Aggregate
Liquidation
Preference
 
 
   
   
   
 

Series A

    8,399,831     8,399,831   $ 800  

Series B

    22,949,711     22,780,964     10,125  

Series C

    14,686,698     14,686,698     25,050  

Series D

    9,963,760     6,575,832     20,000  
               

Total

    56,000,000     52,443,325   $ 55,975  
               

F-22


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

6. Redeemable Convertible Preferred Stock and Stockholders' Deficit (Continued)

 

 
  As of June 30, 2011  
 
  Shares
Authorized
  Shares Issued
and
Outstanding
  Aggregate Liquidation Preference  
 
  (unaudited)

 

Series A

    8,399,831     8,399,831   $ 800  

Series B

    22,949,711     22,780,964     10,125  

Series C

    14,686,698     14,686,698     25,050  

Series D

    6,575,832     6,575,832     20,000  

Series E

    6,618,127     6,018,122     25,000  
               

Total

    59,230,199     58,461,447   $ 80,975  
               

    Significant terms of Series A, B, C, D and E redeemable convertible preferred stock are as follows:

        Conversion Features     

    Holders of Series A, B, C, D and E redeemable convertible preferred stock have the option to convert each share into one share of common stock at any time. The preferred stock will automatically convert into shares of common stock upon an affirmative vote of more than 60% of the preferred stock voting together or an initial public offering with a share price of not less than $5.40 and with net proceeds of not less than $30.0 million.

        Voting Rights     

    Each share of Series A, B, C, D and E redeemable convertible preferred stock has voting rights equivalent to the number of shares of common stock into which it is convertible. In regards to the selection of the Company's board of directors, the Series A holders will elect two directors, the Series B holders will elect one director, the Series C holders will elect one director and the common stock holders will elect one director. Any remaining directors will be elected by the common and preferred stock holders voting together.

        Dividend Rights     

    The holders of Series A, B, C, D and E redeemable convertible preferred stock are entitled to receive annual noncumulative dividends at a rate of $0.01, $0.04, $0.15, $0.24 and $0.33 per share, respectively, as adjusted for stock splits, stock dividends, reverse stock splits, stock combinations, reorganizations, and the like, out of any assets available when and if declared by the board of directors. No dividends have been declared to date.

    Annual noncumulative cash dividends of $0.01, $0.04, $0.15, $0.24 and $0.33 per share of Series A, B, C, D and E redeemable convertible preferred stock, respectively, multiplied by the number of years that dividends were not declared and paid since issuance, must be paid prior to the payment of any dividends on the common stock, if and when declared by the board of directors.

        Liquidation Preferences     

    In the event of liquidation, dissolution or winding up of the affairs of the Company, the holders of Series A, B, C, D and E redeemable convertible preferred stock are entitled to receive $0.10, $0.44, $1.88, $3.04 and $4.15 per share, respectively, and any declared but unpaid dividends prior

F-23


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

6. Redeemable Convertible Preferred Stock and Stockholders' Deficit (Continued)

    to any other distributions. In the event of insufficient assets to pay the holders of Series A, B, C, D and E, the remaining assets will be distributed proportionally to all holders of redeemable convertible preferred stock. Any remaining assets after distribution to the holders of Series A, B, C, D and E redeemable convertible preferred stock will be distributed pro rata among all stockholders on an as converted basis until the holders of the redeemable convertible preferred stock receive a return of three times their original purchase price. Any remaining assets will be distributed pro rata among the common stockholders.

        Redemption Rights     

    Series A, B, C, D and E redeemable convertible preferred stock are redeemable at any time after June 14, 2016 upon the affirmative vote or written consent of the holders of greater than 60% of the then-outstanding shares of redeemable convertible preferred stock (the Redemption Request). Upon receiving a Redemption Request, the Company will redeem these shares from any source of funds legally available on each of the respective Redemption Dates (as defined below) in three equal annual installments of one-third of the outstanding shares of redeemable convertible preferred stock to be redeemed. The redemption date for each annual redemption of shares (the Redemption Date) will be (i) for the first such installment, a date determined by the Company falling not later than 60 days after the date the Company received a Redemption Request and (ii) for the second and third installments, on the first and second anniversary of the first Redemption Date. The shares of preferred stock not redeemed as of a certain Redemption Date will remain outstanding and will be entitled to all the rights and preferences provided to holders of the redeemable convertible preferred stock.

    The redemption price of the redeemable convertible preferred stock will be the greater of the original purchase price as adjusted for any stock splits, stock dividends, reverse stock splits, stock combinations, recapitalizations, and similar events, plus any declared but unpaid dividends, or the fair market value of each respective Series as determined by the board of directors with the approval of at least 60% of the directors then serving on the board on the date of Redemption Request. The original purchase price was $800,000, $10.1 million, $25.1 million, $20.0 million and $25.0 million for Series A, B, C, D and E, respectively.

    Adoption of Classification and Measurement of Redeemable Securities Accounting Standard

    In connection with the Company's decision to file a registration statement with the Securities Exchange Commission for an initial public offering of the Company's common stock, the Company adopted the provisions of ASC Topic 480-10-S99-3A, Classification and Measurement of Redeemable Securities

    The shares contain redemption features that are not solely within the Company's control. Accordingly, all shares of redeemable convertible preferred stock, previously classified in stockholders' (deficit) equity, have been classified as temporary equity rather than as a component of stockholders' (deficit) equity in the Company's consolidated balance sheets for all periods presented.

    The carrying value of redeemable convertible preferred stock was recorded at its fair value at the date of issue. In accordance with the standard, the Company has accounted for changes in the redemption value over the period from the date of issuance to the earliest redemption date using

F-24


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

6. Redeemable Convertible Preferred Stock and Stockholders' Deficit (Continued)


    the interest method to a value equal to the fair value, as determined by the Company using the most recent round of redeemable convertible preferred stock financing as an estimate for the fair value, of its redeemable convertible preferred stock over the period from the date of issuance to the earliest redemption date on June 14, 2016. As the Company did not have a round of redeemable preferred stock financing around December 31, 2009 or December 31, 2010, the Company determined the fair value by selecting a value that approximated an increase in value on a consistent basis between the Series D round (December 31, 2008) and the Series E round (June 14, 2011). The increases in the redemption value increases the value of the redeemable convertible preferred stock and decreases the additional paid-in capital and accumulated deficit balances. There was no impact of adopting this accounting principle on the consolidated statements of cash flows and the impact on the consolidated statement of operations was an increase in the net loss attributable to common stockholders as a result of the accounting for the change in the redemption value.

        Estimated Redemption Values     

    The redemption values by security that the Company is using to accrete to are as follows (in thousands):

 
  December 31,   June 30,  
 
  2009   2010   2011  
 
   
   
  (unaudited)
 

Redeemable convertible preferred stock series:

                   

A

  $ 28,765   $ 33,067   $ 34,894  

B

    78,013     89,680     94,635  

C

    50,295     57,816     61,010  

D

    22,519     25,887     27,317  

E

            25,000  

    In evaluating the fair value of preferred stock and the related preferred stock accretion for the three and six months ended June 30, 2011 the Company considered the potential impact of the appreciation on the fair value of common stock between the June 14, 2011 Series E second closing and June 30, 2011, as well as the convergence of the preferred stock and common stock prices as the likelihood of an IPO increases and determined that no changes in the estimated redemption value was needed.

F-25


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

6. Redeemable Convertible Preferred Stock and Stockholders' Deficit (Continued)

    (b)    Common Stock

    As of December 31, 2009 and 2010 and June 30, 2011, the Company had reserved shares of common stock, on an as if converted basis, for issuance as follows:

 
  As of December 31,    
 
 
  As of June 30,
2011
 
 
  2009   2010  
 
   
   
  (unaudited)
 

Issuances under stock option plan

    15,065,146     14,891,314     16,639,767  

Conversion of redeemable convertible preferred stock

    52,443,325     52,443,325     58,461,447  

Issuances upon exercise of warrants

    1,979,985     3,624,721     4,446,721  
               

    69,488,456     70,959,360     79,547,935  
               

7. Warrants

Preferred Stock Warrants

        In connection with the loan and security agreement obtained in November 2005, the Company issued a warrant to purchase 168,747 shares of Series B redeemable convertible preferred stock at a price of $0.44 per share. The Series B warrants are exercisable immediately and expire in November 2012. The fair value of the warrant on the date of issuance was $37,000 which is being recognized as interest expense over the term of the loan and security agreement. The fair value of the warrant was determined using the Black-Scholes option-pricing model and is remeasured at each reporting period. As of December 31, 2009, 2010 and June 30, 2011, the Company recorded a warrant liability of $159,000, $215,000 and $670,000 on the consolidated balance sheets. During the years ended December 31, 2008, 2009 and 2010 and the six months ended June 30, 2010 and 2011, the remeasurement of the warrant liability resulted in the recognition of remeasurement gains and losses of $80,000, $42,000, $56,000, $0 and $455,000, respectively, which was recorded as other income (expense), net on the consolidated statement of operations.

        The Company determined the fair value of the Series B warrants at the end of each reporting period using the Black-Scholes option-pricing model with the following assumptions:

 
  Years Ended
December 31,
  Six Months
Ended
June 30,
 
 
  2008   2009   2010   2010   2011  
 
   
   
   
  (unaudited)
 

Contractual term (in years)

    4.0     3.0     2.0     2.5     1.5  

Risk-free interest rate

    1.3 %   1.7 %   0.6 %   0.8 %   0.3 %

Expected volatility

    65 %   60 %   55 %   71 %   44 %

Expected dividend rate

    0 %   0 %   0 %   0 %   0 %

Common Stock Warrants

        During the year ended December 31, 2007, the Company issued warrants to purchase 1,635,000 shares of common stock in connection with certain collaboration agreements with exercise prices

F-26


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

7. Warrants (Continued)


ranging from $0.75 to $1.88 per share and five year terms. Of these warrants, 1,470,000 were granted to a related party and were exercisable immediately while the remaining warrants vest over periods ranging from two to four years. During the years ended December 31, 2008, 2009 and 2010 and the six months ended June 30, 2010 and 2011, the Company recognized expenses related to the issuances and vesting of these warrants in the amount of $43,000, $7,000, $1,000, $1,000 and $0, respectively. As of December 31, 2009 and 2010 and June 30, 2011, 1,631,238 of these warrants to purchase shares of common stock were still outstanding.

        During the year ended December 31, 2008, the Company issued warrants to purchase 180,000 shares of common stock for consulting services with an exercise price of $1.02 per share and a 10 year term. These warrants vest over four years. During the years ended December 31, 2008, 2009 and 2010 and the six months ended June 30, 2010 and 2011, the Company recognized expenses related to the issuances and vesting of these warrants in the amount of $41,000, $51,000, $35,000, $21,000 and $27,000 , respectively. As of December 31, 2009 and 2010 and June 30, 2011, these warrants to purchase shares of common stock were still outstanding.

        During the year ended December 31, 2010, the Company issued warrants to purchase 1,644,736 shares of common stock in connection with certain collaboration agreements with an exercise price of $3.04 per share and approximately two year terms, of which 822,368 were granted to a related party. These warrants will become exercisable upon election of specified licenses by the holders prior to the expiration of the warrants. These warrants, if they become exercisable, do not contain a net exercise provision and therefore can only be exercised on a cash basis upon surrender of the warrants. Upon a license election by the holders, the Company will record the fair value of these warrants as measured on the date of election against any related revenue derived from these agreements. As of June 30, 2011, the holders have not elected the license option.

        During the six months ended June 30, 2011, the Company issued a warrant to purchase 822,000 shares of common stock in connection with a collaboration agreement with an exercise price of $4.15 per share and a term of 18 months. The warrant was exercisable immediately. The warrant does not contain a net exercise provision and therefore can only be exercised on a cash basis upon surrender of the warrants. The fair value of the warrant as measured on the date of grant was $312,000 and was recognized as a reduction of revenue derived from the agreement.

        In total, the Company had 1,811,238, 3,455,974 and 4,277,974 outstanding warrants to purchase shares of common stock as of December 31, 2009 and 2010 and June 30, 2011, respectively. Of these outstanding warrants, 1,693,426, 1,742,176 and 2,588,238 were exercisable as of December 31, 2009 and 2010 and June 30, 2011, respectively. During the years ended December 31, 2008, 2009, 2010 and the six months ended June 30, 2010 and 2011, the Company recognized expenses related to the issuances and vesting of these warrants in the amount of $84,000, $58,000, $36,000, $22,000 and $27,000, respectively. Additionally, during the six months ended June 30, 2011, the Company recognized a reduction to revenue in the amount of $312,000 related to the issuance and vesting of a warrant granted to a customer in connection with a collaboration agreement.

8. Stock-Based Compensation

        During the year ended December 31, 2004, the Company adopted the 2004 Equity Incentive Plan (the 2004 Plan) which includes both incentive and nonstatutory stock options. As of June 30, 2011, under the 2004 Plan, the Company may grant options to purchase up to 20,514,693 shares of common

F-27


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

8. Stock-Based Compensation (Continued)


stock to employees, directors and service providers with exercise prices not less than the fair market value of the underlying common stock at date of grant for incentive stock options and not less than 85% of fair market value for nonstatutory options. Options granted to persons who, at the time of the grant, own more than 10% of the voting power of all classes of stock will have exercise prices equal to at least 110% of the fair market value of the underlying common stock. These options generally expire 10 years from the date of grant and are generally exercisable at any time after the date of grant when the shares are vested. Incentive and nonstatutory stock options granted generally vest at a rate of 25% on the first anniversary of the commencement or grant date and 1/48 th  each month thereafter.

        Option activity for the periods presented are as follows:

 
   
  Options Outstanding  
 
  Shares
Available For
Grant
  Number of
Stock Options
Outstanding
  Weighted-
Average
Exercise Price
  Weighted-
Average
Remaining
Contractual
Life (Years)
  Aggregate
Intrinsic
Value
(in thousands)
 

Balance as of January 1, 2008

    4,998,266     10,611,238   $ 0.37     8.5   $ 6,856  
 

Granted

    (1,626,000 )   1,626,000     1.09              
 

Exercised

        (485,508 )   0.36           119  
 

Cancelled

    1,129,981     (1,129,981 )   0.71              
                             

Balance as of December 31, 2008

    4,502,247     10,621,749     0.45     7.7     5,989  
 

Granted

    (3,450,500 )   3,450,500     1.00              
 

Exercised

        (152,600 )   0.09           142  
 

Repurchased

    93,750                      
 

Cancelled

    1,724,775     (1,724,775 )   0.59              
                             

Balance as of December 31, 2009

    2,870,272     12,194,874     0.59     7.3     9,047  
 

Granted

    (3,159,750 )   3,159,750     1.38              
 

Exercised

        (173,832 )   0.59           141  
 

Cancelled

    642,960     (642,960 )   1.03              
                             

Balance as of December 31, 2010

    353,482     14,537,832     0.74     6.9     13,937  

Exercisable as of December 31, 2010

          9,302,319   $ 0.49     5.9   $ 11,375  

Vested and expected to vest as of December 31, 2010

          13,339,011   $ 0.70         $ 13,309  
 

Additional shares authorized (unaudited)

    2,054,970                      
 

Granted (unaudited)

    (2,500,000 )   2,500,000     3.10              
 

Exercised (unaudited)

        (306,517 )   0.62           833  
 

Cancelled (unaudited)

    327,705     (327,705 )   1.20              
                             

Balance as of June 30, 2011 (unaudited)

    236,157     16,403,610     1.09     6.9     54,408  
                             

Exercisable as of June 30, 2011 (unaudited)

          10,277,781   $ 0.56     5.7   $ 39,217  

Vested and expected to vest as of June 30, 2011 (unaudited)

          15,022,393   $ 1.02         $ 50,882  

F-28


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

8. Stock-Based Compensation (Continued)

        The options exercisable as of December 31, 2010 include options that are exercisable prior to vesting. The weighted average grant date fair value of options granted during the years ended December 31, 2008, 2009 and 2010 and the six months ended June 30, 2011 was $0.60, $0.53, $0.74 and $1.77, respectively.

        The Company recognized stock-based compensation expense for awards granted to its employees and nonemployees as follows (in thousands):

 
  Years Ended December 31,   Six Months Ended
June 30,
 
 
  2008   2009   2010   2010   2011  
 
   
   
   
  (unaudited)
 

Cost of revenue

  $ 71   $ 134   $ 285   $ 118   $ 233  

Research and development

    170     222     204     118     191  

Sales and marketing

    408     378     422     231     303  

General and administrative

    267     347     453     208     255  
                       

Total stock-based compensation

  $ 916   $ 1,081   $ 1,364   $ 675   $ 982  
                       

        As of December 31, 2009 and 2010 and June 30, 2011, there was $2.5 million, $3.4 million and $5.1 million, respectively, of unrecognized compensation cost related to stock option compensation arrangements which is primarily recognized on a straight-line basis over a weighted average period of 2.6, 2.8 and 3.2 years, respectively. There were no capitalized stock-based compensation costs or recognized stock-based compensation tax benefits during the years ended December 31, 2008, 2009 and 2010 and the six months ended June 30, 2010 and 2011.

        Additional information regarding options outstanding as of December 31, 2010 is as follows:

 
  Options Outstanding   Options Exercisable  
Exercise Price
  Options
Outstanding
  Weighted-Average
Remaining
Contractual Life
(Years)
  Weighted-Average
Exercise Price per
Share
  Exercisable   Weighted-Average
Exercise Price per
Share
 

$0.01

    440,000     4.1   $ 0.01     440,000   $ 0.01  

  0.05

    2,754,792     4.5     0.05     2,754,792     0.05  

  0.10

    1,457,000     5.4     0.10     1,457,000     0.10  

  0.75

    978,000     5.9     0.75     977,530     0.75  

  0.83

    2,002,395     6.7     0.83     1,723,759     0.83  

  1.00

    3,140,645     8.2     1.00     1,388,462     1.00  

  1.02

    714,000     7.2     1.02     497,771     1.02  

  1.33

    2,525,500     9.2     1.33          

  1.45

    109,000     7.8     1.45     63,005     1.45  

  1.70

    416,500     10.0     1.70          
                             

  

    14,537,832     6.9     0.74     9,302,319     0.49  
                             

F-29


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

8. Stock-Based Compensation (Continued)

        Additional information regarding options outstanding as of June 30, 2011 is as follows (unaudited):

 
  Options Outstanding   Options Exercisable  
Exercise Price
  Options
Outstanding
  Weighted-Average
Remaining
Contractual Life
(Years)
  Weighted-Average
Exercise Price per
Share
  Exercisable   Weighted-Average
Exercise Price per
Share
 

$0.01

    440,000     3.6   $ 0.01     440,000   $ 0.01  

  0.05

    2,700,000     4.0     0.05     2,700,000     0.05  

  0.10

    1,442,000     4.9     0.10     1,442,000     0.10  

  0.75

    828,000     5.4     0.75     828,000     0.75  

  0.83

    1,835,187     6.2     0.83     1,801,980     0.83  

  1.00

    3,016,393     7.7     1.00     1,778,495     1.00  

  1.02

    684,000     6.7     1.02     562,855     1.02  

  1.33

    2,488,030     8.7     1.33     636,987     1.33  

  1.45

    89,000     7.3     1.45     62,464     1.45  

  1.70

    413,500     9.5     1.70          

  3.10

    2,467,500     9.8     3.10     25,000     3.08  
                             

  

    16,403,610     6.9     1.09     10,277,781     0.56  
                             

Determining Fair Value of Stock Options

        The fair value of each grant of stock options was determined by the Company and its board of directors using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.

        Valuation Method —The Company estimates the fair value of its stock options using the Black-Scholes option-pricing model.

        Expected Term —The expected term represents the period that the stock-based awards are expected to be outstanding. For option grants that are considered to be "plain vanilla," the Company used the simplified method to determine the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.

        Expected Volatility —The expected volatility was based on the historical stock volatilities of several of the Company's publicly listed peers over a period approximately equal to the expected term of the options as the Company did not have a sufficient trading history to use the volatility of its own common stock.

        Fair Value of Common Stock —The fair value of the common stock underlying the stock options has historically been determined by the Company's board of directors. Because there has been no public market for the Company's common stock, the board of directors has determined the fair value of the common stock at the time of the option grant by considering a number of objective and subjective factors including valuations of comparable companies, sales of redeemable convertible preferred stock to unrelated third parties, operating and financial performance, lack of liquidity of capital stock and general and industry-specific economic outlook, amongst other factors. The fair value of the underlying

F-30


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

8. Stock-Based Compensation (Continued)


common stock shall be determined by the board of directors until such time that the Company's common stock is listed on an established stock exchange or national market system.

        Risk-Free Interest Rate —The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term of the options.

        Expected Dividend —The expected dividend has been zero as the Company has never paid dividends and does not expect to pay dividends.

        Summary of Assumptions —The fair value of the employee stock options were estimated on the grant dates using a Black-Scholes option-pricing model with the following weighted average assumptions:

 
  Years Ended
December 31,
  Six Months
Ended
June 30,
 
 
  2008   2009   2010   2010   2011  
 
   
   
   
  (unaudited)
 

Expected term (in years)

    6.0     6.0     6.0     6.0     6.0  

Risk-free interest rate

    3.3 %   2.5 %   2.2 %   2.7 %   2.4 %

Expected volatility

    55 %   55 %   55 %   55 %   57 %

Expected dividend rate

    0 %   0 %   0 %   0 %   0 %

9. Net Loss per Share of Common Stock

        The following table sets forth the computation of the Company's basic and diluted net loss per share of common stock during the years ended December 31, 2008, 2009 and 2010 and the six months ended June 30, 2010 and 2011 (in thousands, except for share and per share amounts):

 
  Years Ended December 31,   Six Months Ended
June 30,
 
 
  2008   2009   2010   2010   2011  
 
   
   
   
  (unaudited)
 

Net loss attributable to common stockholders

  $ (14,936 ) $ (14,424 ) $ (15,940 ) $ (9,686 ) $ (10,325 )
                       

Shares used in computing net loss per share of common stock, basic and diluted

    10,716,462     11,023,779     11,134,573     11,115,486     11,296,902  
                       

Net loss per share of common stock, basic and diluted

  $ (1.39 ) $ (1.31 ) $ (1.43 ) $ (0.87 ) $ (0.91 )
                       

F-31


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

9. Net Loss per Share of Common Stock (Continued)

        The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive:

 
  Years Ended December 31,   Six Months Ended
June 30,
 
 
  2008   2009   2010   2010   2011  
 
   
   
   
  (unaudited)
 

Redeemable convertible preferred stock

    52,443,325     52,443,325     52,443,325     52,443,325     58,461,447  

Stock options to purchase common stock

    10,621,749     12,194,874     14,537,832     13,981,041     16,403,610  

Common stock subject to repurchase

    482,709     52,084             30,000  

Common and preferred stock warrants

    1,979,985     1,979,985     3,624,721     3,624,721     4,446,721  

        The following table sets forth the computation of the Company's pro forma basic and diluted net loss per share, which are computed to give effect to the conversion of all currently outstanding redeemable convertible preferred stock, as if conversion had occurred at January 1, 2010. The table below further assumes the conversion and subsequent exercise of preferred and certain common stock warrants that expire upon an initial public offering if not exercised (in thousands, except for share and per share amounts):

 
  Year Ended
December 31, 2010
  Six Months Ended
June 30, 2011
 
 
   
  (unaudited)
 

Net loss attributable to common stockholders

  $ (15,940 ) $ (10,325 )

Accretion of redeemable convertible preferred stock

    14,162     7,095  

Change in fair value of redeemable convertible preferred stock warrant liabilities

    56     455  
           

Net loss used in computing pro forma net loss per share of common stock, basic and diluted

    (1,722 )   (2,775 )
           

Weighted-average number of shares used in computing net loss per share of common stock, basic and diluted

    11,134,573     11,296,902  

Weighted-average number of pro forma adjustments to reflect assumed conversion of redeemable convertible preferred stock and certain warrants

    54,241,748     56,946,398  
           

Weighted-average number of shares used in computing pro forma net loss per share of common stock, basic and diluted

    65,376,321     68,243,300  
           

Pro forma net loss per share of common stock, basic and diluted

  $ (0.03 ) $ (0.04 )
           

F-32


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

10. Income Taxes

        The Company follows FASB ASC 740-270, Income Taxes—Interim Reporting , for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income, net of US book loss on which a full valuation allowance has been placed, to determine the interim provision for income taxes. For the six months ended June 30, 2011, the income tax provision of $13,000 represents a provision for income taxes of $12,000 related to foreign income taxes and state minimum income taxes of $1,000.

        The provision for annual income taxes consisted of the following (in thousands):

 
  As of December 31,  
 
  2008   2009   2010  

Current:

                   
 

U.S. Federal

  $   $   $  
 

State

    175     4     1  
 

Foreign

    11     13     18  
               
   

Total current

  $ 186   $ 17   $ 19  

Deferred:

                   
 

U.S. Federal

  $   $   $  
 

State

             
 

Foreign

             
               
   

Total deferred

             
               

Total provision for income taxes

  $ 186   $ 17   $ 19  
               

        The reconciliation of federal statutory income tax to the Company's provision for income taxes is as follows (in thousands):

 
  As of December 31,  
 
  2008   2009   2010  

Expected provision at statutory federal rate

  $ (3,167 ) $ (1,781 ) $ (616 )

State tax—net of federal benefit

    116     4     1  

U.S. federal research credit

    (490 )   (444 )   (626 )

Non deductible expenses

    318     399     486  

Change in statutory tax rate

            (264 )

Others

    26     93     164  

Change in valuation allowance

    3,383     1,746     874  
               

Provision for income taxes

  $ 186   $ 17   $ 19  
               

        As of December 31, 2010, the Company's foreign subsidiaries had accumulated approximately $0.2 million of earnings that have been reinvested in their operations. The Company has not provided U.S. tax on these earnings as the reinvestment is considered permanent in duration.

        Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax

F-33


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

10. Income Taxes (Continued)


purposes. Significant components of the Company's deferred tax assets and liabilities are as follows (in thousands):

 
  As of December 31,  
 
  2009   2010  

Deferred tax assets:

             
 

Net operating loss federal and state

  $ 7,925   $ 8,426  
 

Research credits

    2,231     3,271  
 

Accrued compensation and vacation

    287     324  
 

Deferred revenue, other accruals and reserves

    4,027     3,705  
 

Stock compensation

    239     242  
           
 

Gross deferred tax assets

    14,709     15,968  
 

Valuation allowance

    (13,917 )   (15,818 )
           
   

Total deferred tax asset

    792     150  

Deferred tax liabilities:

             
 

Patents

    649      
 

Property and equipment

    143     150  
           
 

Total deferred tax liabilities

    792     150  
           

Net deferred tax assets

  $   $  
           

        The Company established valuation allowances for U.S. federal and state deferred tax assets. The valuation allowances require an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction by jurisdiction basis. During the year ended December 31, 2010, the Company continued to maintain the valuation allowances for U.S. federal and state deferred tax assets. The Company intends to maintain a full valuation allowance until sufficient positive evidence exists to support reversal. The valuation allowance for deferred tax assets was $13.9 million and $15.8 million as of December 31, 2009 and 2010, respectively. The increase in the valuation allowance during the years ended December 31, 2009 and 2010 was $1.8 million and $1.9 million, respectively.

        As of December 31, 2010, the Company has net operating loss carryforwards for U.S. federal and state income tax purposes of approximately $17.4 million and $18.5 million, respectively, to offset future taxable income. The U.S. federal net operating loss carryforwards will start to expire in 2026 while for state purposes, the net operating loss carryforwards will start to expire in 2018. Utilization of the Company's net operating loss carryforwards and tax credits may be subject to substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. Such an annual limitation could result in the expiration of the net operating loss before utilization. The Company has not determined whether an ownership change has occurred.

        In addition, the Company has $2.5 million U.S. federal R&D credit and $2.5 million California R&D credit carryforwards to offset future income tax liabilities. U.S. federal R&D tax credits can be carried forward for 20 years and will start to expire in 2025. California R&D credits can be carried forward indefinitely.

F-34


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

10. Income Taxes (Continued)

Uncertain Tax Positions

        As of both December 31, 2010 and June 30, 2011, the total amount of unrecognized tax benefits excluding interest thereon was $1.1 million, none of which would impact the effective tax rate if realized during the year. The Company has not accrued interest and penalties related to the unrecognized tax benefits reflected in the financial statements for the year ended December 31, 2010 and six months ended June 30, 2011. Although the timing and outcome of income tax audits is highly uncertain, unrecognized tax benefits are not expected to decrease in the next twelve months.

        The following table summarizes the activity related to unrecognized tax benefits (in thousands):

 
  As of December 31,  
 
  2008   2009   2010  

Unrecognized benefit—beginning of period

  $ 222   $ 518   $ 746  

Gross increases—prior period tax positions

             

Gross increases—current period tax positions

    296     228     321  
               

Unrecognized benefit—end of period

  $ 518   $ 746   $ 1,067  
               

        The Company's U.S. federal, state and local and foreign income tax returns are subject to audit by relevant tax authorities. The Company's income tax reporting periods beginning with tax year ended December 31, 2007 for the U.S., and tax year ended December 31, 2006 for the Company's major state and local jurisdictions remain generally open to audit by relevant tax authorities.

11. Related Party Transactions

        The Company entered into a Collaborative Development and License Agreement in March 2005 and an Alliance Agreement in December 2005 with a technology company under which the two companies will work together to conduct research and development and other activities with respect to materials and high throughput technology for use in semiconductor applications. Depending on the output of the research and development, the primary rightholder could be either company. However, the party that is not the primary rightholder will be assigned the right to use the output property. Each party is bearing its own expenses with respect to patents and the patent application process. The Company is required to pay royalties based on a percentage of revenue derived, directly or indirectly, from the use of this technology. The Company is not generating revenue from the other party. In August 2006, the Company received $13.5 million from the other party in exchange for shares of Series C representing 9.8% of the Company's fully diluted shares. In December 2008, the Company received $1.6 million from the other party in exchange for shares of Series D. As of December 31, 2010, the other party's stock holdings represent 9.4% of the Company's fully diluted shares. The other party's chief executive officer, who is a member of their board of directors, is also a director of the Company. During the years ended December 31, 2008, 2009 and 2010 and the six months ended June 30, 2010 and through April 30, 2011, the Company expensed $1.0 million, $1.2 million, $2.0 million, $0.8 million and $0.6 million, respectively, in royalties and had accrued liabilities in the amount of $502,000 and $795,000 due to the other party as of December 31, 2009 and 2010, respectively. During the years ended December 31, 2008, 2009 and 2010 and the six months ended June 30, 2010 and through April 30, 2011, the Company purchased $286,000, $14,000, $6,000, $0 and $0, respectively, of fixed assets, maintenance and consumables from the other party. Effective May 2011

F-35


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

11. Related Party Transactions (Continued)


this entity is no longer considered a related party due to the change in status of the Company's director and such director's relationship with the other party.

        The Company entered into a Collaborative Development and License Agreement in August 2006 and a second Collaborative Development and License Agreement in March 2010 with another related party. Under the agreements, the two companies will work together to conduct research and development and other activities. Depending on the output of the research and development, the primary rightholder will be the Company or the other party. However, if the other party is not the primary rightholder, it will be able to license the developed technology from the Company. The other party's vice chairman of the board of directors is a director of the Company and is also a managing member of a significant shareholder of the Company. As of December 31, 2010 and June 30, 2011, this shareholder held a 12.5% and 11.8% interest, respectively, in the Company on a fully diluted share basis. During the years ended December 31, 2008, 2009 and 2010 and the six months ended June 30, 2010 and 2011, the Company recorded revenue in the amount of $1.7 million, $0, $3.9 million, $1.2 million and $2.6 million, respectively, from these agreements.

        In November 2006, the Company entered into an Alliance Agreement with a related party that holds a 7.4% and 8.5% interest in the Company on a fully diluted share basis as of December 31, 2010 and June 30, 2011, respectively. Under the agreement, the two companies will work together to conduct research and development and other activities with respect to materials and high productivity combinatorial technology for use in semiconductor applications. Depending on the output of the research and development, the primary rightholder could be either company. However, the party that is not the primary rightholder will be assigned the right to use the output property. Under the agreement, the other party will pay the Company fees for services and both parties may provide royalties to the other for licensed technology sold to third parties. In July 2007, the Company and the other party entered into a Workflow Purchase Agreement whereby the other party agreed to purchase from the Company a fluids-based workflow including services and licensing of intellectual property. In December 2007, the Company and the other party added an addendum to the Workflow Purchase Agreement. As part of this addendum, the other party increased the number of fluids-based workflows for purchase, contracted with the Company for additional services and provided for a $10.0 million prepayment of minimum royalties. The $10.0 million minimum royalty prepayment is nonrefundable. The minimum royalty prepayment began revenue recognition during the year ended December 31, 2009 and should be fully earned no later than the year ended December 31, 2012. The agreement committed the other party to purchase three additional workflows in addition to the initial workflow order. In December 2008, the Company and the other party added an additional addendum to the Workflow Purchase Agreement and entered into a Dry Workflow Agreement. As part of this 2008 addendum, the third Wet Workflow was canceled and the deposit applied to the Dry Workflow purchase. In March 2009, the Company and the other party entered into a supplement to the Workflow Purchase Agreement which adjusted the timing and delivery of services to be performed. Effective August 2010, the Company and the other party entered into a Modification to the Wets Workflow Purchase Agreement and Dry Workflow Purchase Agreement which further extended and adjusted the timing and services to be performed. During the years ended December 31, 2008, 2009 and 2010 and the six months ended June 30, 2010 and 2011, the Company recorded revenue in the amount of $13.4 million, $16.0 million, $22.1 million, $10.3 million and $7.8 million, respectively, in equipment sales, license fees and service fees and had accounts receivable in the amount of $1.2 million, $461,000 and $447,000 as of December 31, 2009, 2010 and June 30, 2011, respectively, related to these agreements. The Company recorded a deferred revenue balance in the amount of $22.8 million, $13.3 million and $8.2 million

F-36


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

11. Related Party Transactions (Continued)


related to these agreements as of December 31, 2009, 2010 and June 30, 2011, respectively. The deferred revenue balance includes the unrecognized portion of the prepayment of the $10.0 million minimum royalty, of which $7.5 million and $5.0 million remains as of December 31, 2010 and June 30, 2011, respectively, as well as payments for elements of the workflow purchases.

12. Information about Geographic Areas

Revenue

        Revenue by geography is based on the billing address of the customer. The following table sets forth revenue by geographic area (in thousands):

 
  Years Ended December 31,   Six Months Ended
June 30,
 
 
  2008   2009   2010   2010   2011  
 
   
   
   
  (unaudited)
 

United States

  $ 16,522   $ 18,894   $ 29,526   $ 11,699   $ 14,886  

Japan

    6,267     7,906     12,449     4,583     7,468  

Taiwan

    90         489         1,470  

Europe

    250     110     210     210      
                       

Total

  $ 23,129   $ 26,910   $ 42,674   $ 16,492   $ 23,824  
                       

Long-Lived Assets

        Substantially all of the Company's long-lived assets are located in the U.S. An insignificant amount of long-lived assets reside in the Company's foreign subsidiaries and branches in Hong Kong, Japan and Taiwan.

13. Subsequent Events (unaudited)

        On July 28, 2011, the Company entered into an agreement with Symyx Technologies, Inc., a related party (Symyx), pursuant to which the Company agreed to use commercially reasonable efforts to allow Symyx to sell in an initial public offering shares of the Company's common stock held by them. Pursuant to the agreement, Symyx agreed to sell such shares and, upon consummation of the initial public offering and such sale, to terminate the Company's future royalty obligations under an existing license agreement. Future royalty obligations will continue to accrue, if earned, until the later of an initial public offering or December 31, 2011. Additionally, upon consummation of the initial public offering and such sale, Symyx would transfer to the Company all patents held by them that relate to combinatorial processing. To the extent the gross proceeds (before deducting underwriting discounts and commissions and offering expenses) to Symyx from the sale of their shares in an initial public offering are less than $67 million, the Company would issue Symyx a secured promissory note that would have a term of 24 months and an interest rate equal to 4%. Such note would be payable in an amount equal to the greater of $500,000 per quarter or the amount of accrued interest, with a balloon payment at maturity, if applicable. Such note would also be pre-payable by the Company at any time without penalty or premium, and would be secured by tangible personal property, excluding intellectual property. In addition, the Company has agreed to reimburse Symyx for 50% of the underwriting discounts and commissions payable by them in connection with this offering. In the event that an initial

F-37


Table of Contents


INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)

13. Subsequent Events (unaudited) (Continued)


public offering does not occur by July 1, 2012 the purchase agreement with Symyx expires and the royalty obligation continues under its original terms.

        On September 15, 2011 the Company terminated its loan and security agreement discussed in Note 5. There were no balances outstanding under the loan and security agreement and the Company was compliant with all covenants.

F-38


Table of Contents

GRAPHIC


Table of Contents


PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 13.    Other Expenses of Issuance and Distribution

        The following table sets forth the fees and expenses, other than underwriting discounts and commissions, payable in connection with the registration of the common stock hereunder. All amounts are estimates except the SEC registration fee, the FINRA filing fee and The Nasdaq Global Market or the New York Stock Exchange listing fee.

 
  Amount to
be Paid
 

Securities and Exchange Commission registration fee

  $ 23,220  

FINRA filing fee

    20,500  

NASDAQ Global Market or the New York Stock Exchange listing fee

    *  

Symyx transaction expenses

    *  

Blue Sky fees and expenses

    *  

Printing and engraving expenses

    *  

Legal fees and expenses

    *  

Accounting fees and expenses

    *  

Transfer Agent and Registrar fees

    *  

Miscellaneous expenses

    *  
       

Total

  $ *  
       

*
to be filed by amendment.

Item 14.    Indemnification of Directors and Officers

        Section 145 of the Delaware General Corporation Law provides that a corporation may indemnify its directors and officers from certain expenses in connection with legal proceedings and permits a corporation to include in its charter documents, and in agreements between the corporation and its directors and officers, provisions expanding the scope of indemnification beyond that specifically provided by this section.

        The Registrant's restated certificate of incorporation provides for the indemnification of directors to the fullest extent permissible under Delaware law.

        The Registrant's amended and restated bylaws provide for the indemnification of officers, directors and third parties acting on the Registrant's behalf if such persons act in good faith and in a manner reasonably believed to be in and not opposed to the Registrant's best interest, and, with respect to any criminal action or proceeding, such indemnified party had no reason to believe his or her conduct was unlawful.

        The Registrant is entering into indemnification agreements with each of its directors and executive officers, in addition to the indemnification provisions provided for in its charter documents, and the Registrant intends to enter into indemnification agreements with any new directors and executive officers in the future.

        The underwriting agreement (a form of which is filed as Exhibit 1.1 hereto) will provide for indemnification by the underwriters of the Registrant and the Registrant's executive officers and directors, and indemnification of the underwriters by the Registrant, for certain liabilities, including liabilities arising under the Securities Act of 1933, as amended, in connection with certain matters.

II-1


Table of Contents

        The Registrant intends to purchase and maintain insurance on behalf of any person who is or was a director or officer against any loss arising from any claim asserted against him or her and incurred by him or her in that capacity, subject to certain exclusions and limits of the amount of coverage.

Item 15.    Recent Sales of Unregistered Securities

        The following sets forth information regarding all unregistered securities sold by the Registrant since January 1, 2008:

    1.
    On June 20, 2008, the Registrant issued a warrant to purchase 180,000 shares of its common stock at an exercise price of $1.02 per share to a French company owned exclusively by one of the Registrant's consultants. One-fourth of the shares subject to the warrant became exercisable on the first anniversary of the date of issuance, with the remaining shares vesting monthly thereafter such that all shares subject to the warrant may be exercisable by the holder four years after the date of issuance. The vested portion of the warrant may be exercised at any time prior to the warrant's termination, which in any event would occur, if at all, no later than ten years from the date of issuance.

    2.
    On December 16, 2008, the Registrant issued and sold an aggregate of 6,575,832 shares of its Series D preferred stock at a price of $3.04144 per share, for aggregate gross consideration of $19,999,998.49, to seven accredited investors.

    3.
    On March 15, 2010, the Registrant issued warrants to purchase an aggregate of 1,644,736 shares of its common stock at an exercise price of $3.04144 per share to Toshiba Corporation and SanDisk Corporation, which may become exercisable pursuant to the terms of that certain Collaborative Development Program Agreement, by and among the Registrant, Toshiba Corporation and SanDisk Corporation. Upon becoming exercisable, the warrants may be exercised no later than 120 days following the end of the activities conducted by Toshiba, SanDisk and the Registrant pursuant to the Collaborative Development Program Agreement.

    4.
    On March 4, 2011, the Registrant issued and sold an aggregate of 3,610,873 shares of its Series E preferred stock at a price of $4.15412 per share, for aggregate gross consideration of $14,999,999.78, to seven accredited investors.

    5.
    On June 1, 2011, the Registrant issued a warrant to purchase 822,000 shares of its common stock at an exercise price of $4.15412 per share to Advanced Technology Investment Company LLC. The warrant may be exercised at any time prior to its termination date, which is the eighteen month anniversary of its issue date.

    6.
    On June 14, 2011, the Registrant issued and sold an aggregate of 2,407,249 shares of its Series E preferred stock at a price of $4.15412 per share, for aggregate gross consideration of $10,000,001.21, to one accredited investor.

    7.
    On August 25, 2011, the Registrant issued a warrant to purchase 5,000 shares of its common stock at an exercise price of $0.10 per share to The Enterprise Network. The warrant may be exercised at any time prior to the warrant's termination, which in any event would occur, if at all, no later than eighteen months from the date of issuance.

    8.
    Between January 1, 2008 and September 1, 2011, the Registrant granted stock options to purchase 11,024,250 shares of its common stock at exercise prices ranging from $1.00 to $5.98 per share to a total of 250 employees, consultants and directors under its 2004 Equity Incentive Plan.

    9.
    Between January 1, 2008 and September 1, 2011, the Registrant issued and sold an aggregate of 1,350,356 shares of its common stock to employees and consultants at prices ranging from $0.01 to $1.33 per share pursuant to the exercise of options granted under its 2004 Equity Incentive Plan.

II-2


Table of Contents

        The issuance of securities described above in Item 15 paragraphs 2 - 6 was exempt from registration under the Securities Act of 1933, as amended, in reliance on Section 4(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder, as transactions by an issuer not involving any public offering. The purchasers of the securities in these transactions represented that they were accredited investors and that they were acquiring the securities for investment only and not with a view toward the public sale or distribution thereof. Such purchasers received written disclosures that the securities had not been registered under the Securities Act of 1933, as amended, and that any resale must be made pursuant to a registration statement or an available exemption from registration. All purchasers either received adequate financial statement or non-financial statement information about the Registrant or had adequate access, through their relationship with the Registrant, to financial statement or non-financial statement information about the Registrant. The sale of these securities was made without general solicitation or advertising.

        The issuance of securities described above in Item 15 paragraphs 1, 7 and 8 was exempt from registration under the Securities Act of 1933, as amended, in reliance on Rule 701, Section 4(2) and Regulation S of the Securities Act of 1933, as amended, pursuant to compensatory benefit plans or agreements approved by the Registrant's board of directors.

        All certificates representing the securities issued in these transactions described in this Item 15 included appropriate legends setting forth that the securities had not been offered or sold pursuant to a registration statement and describing the applicable restrictions on transfer of the securities. There were no underwriters employed in connection with any of the transactions set forth in this Item 15.

Item 16.    Exhibits and Financial Statement Schedules

    (a)
    Exhibits

Exhibit No.   Description of Exhibits
  1.1 * Form of Underwriting Agreement.
 
   
  2.1 # Asset Purchase Agreement by and between Intermolecular, Inc. and Symyx Technologies, Inc. dated as of July 28, 2011.(1)
 
   
  3.1 # Fifth Restated Certificate of Incorporation of Intermolecular, Inc., currently in effect.
 
   
  3.2 * Form of Restated Certificate of Incorporation of Intermolecular, Inc., to be in effect immediately prior to the consummation of this offering.
 
   
  3.3 # Bylaws of Intermolecular, Inc., as amended, currently in effect.
 
   
  3.4 * Form of Amended and Restated Bylaws of Intermolecular, Inc., to be in effect immediately prior to the consummation of this offering.
 
   
  4.1 * Specimen Common Stock Certificate.
 
   
  4.2 # Warrant to purchase shares of common stock issued to Timane S.a.r.l. dated June 20, 2008.
 
   
  4.3 * Form of warrant to purchase shares of common stock issued to Toshiba Corporation and SanDisk Corporation dated March 15, 2010.
 
   
  5.1 * Opinion of Latham & Watkins LLP.
 
   
  10.1 # Fourth Amended and Restated Investor Rights Agreement dated as of March 4, 2011, by and among Intermolecular, Inc. and certain stockholders named therein, as amended by Amendment No. 1 to Fourth Amended and Restated Investor Rights Agreement dated as of June 14, 2011.
 
   

II-3


Table of Contents

Exhibit No.   Description of Exhibits
  10.2 # Lease Agreement by and between Intermolecular, Inc. and Novellus Systems, Inc. dated as of May 10, 2010, as amended by the Confirmation of Commencement Date of the Lease Agreement dated as of June 10, 2010.
 
   
  10.3 Collaborative Development Program Agreement by and among SanDisk Corporation, Toshiba Corporation and Intermolecular, Inc. dated March 15, 2010.
 
   
  10.4 Alliance Agreement by and between Intermolecular, Inc. and Advanced Technology Materials, Inc. dated as of November 17, 2006.
 
   
  10.5 Wets Workflow Purchase Agreement by and between Intermolecular, Inc. and Advanced Technology Materials, Inc. dated as of July 13, 2007, as amended by the Addendum to Wets Workflow Purchase Agreement dated as of December 21, 2007, the Amendment to Addendum to Wets Workflow Purchase Agreement dated as of December 16, 2008 and the Supplemental Agreement to the Amendment to the Addendum to Wets Workflow Purchase Agreement dated as of March 16, 2009.
 
   
  10.6 Dry Workflow Purchase Agreement by and between Intermolecular, Inc. and Advanced Technology Materials, Inc. dated as of December 16, 2008.
 
   
  10.7 Modification to the Wets Workflow Purchase Agreement and Dry Workflow Purchase Agreement by and between Intermolecular, Inc. and Advanced Technology Materials, Inc. dated as of August 27, 2010.
 
   
  10.8 Amendment Number 5 to the Wets Workflow Purchase Agreement and Dry Workflow Purchase Agreement by and between Intermolecular, Inc. and Advanced Technology Materials, Inc. dated as of March 3, 2011.
 
   
  10.9 Advanced Memory Development Program Agreement by and between Intermolecular, Inc. and Elpida Memory, Inc. dated as of May 22, 2008, as amended by Exhibit C—Royalty Terms dated as of August 18, 2008, the Supplemental Joint Development Agreement dated as of January 27, 2009, the Amendment to the Supplemental Joint Development Agreement dated as of May 25, 2009 and the Amendment to the Advanced Memory Agreement dated July 29, 2010.
 
   
  10.10 Collaborative Development Program Agreement by and between Intermolecular, Inc. and GLOBALFOUNDRIES Inc. dated as of June 1, 2011.
 
   
  10.11 # Form of Indemnification Agreement between Intermolecular, Inc. and each of its directors, as currently in effect.
 
   
  10.12 * Form of Indemnification Agreement between Intermolecular, Inc. and each of its directors, officers and certain employees, to be in effect before the completion of the offering.
 
   
  10.13 a+# Intermolecular, Inc. 2004 Equity Incentive Plan, as amended.
 
   
  10.13 b+# Form of Early Exercise Stock Option Agreement under the 2004 Equity Incentive Plan.
 
   
  10.13 c+# Form of Stock Option Agreement under the 2004 Equity Incentive Plan.
 
   
  10.14 a+* Intermolecular, Inc. 2011 Incentive Award Plan.
 
   
  10.14 b+* Form of Stock Option Grant Notice and Stock Option Agreement under the 2011 Incentive Award Plan.
 
   
  10.14 c+* Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2011 Incentive Award Plan.
 
   

II-4


Table of Contents

Exhibit No.   Description of Exhibits
  10.14 d+* Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2011 Incentive Award Plan.
 
   
  23.1   Consent of KPMG LLP, Independent Registered Public Accounting Firm.
 
   
  23.2 * Consent of Latham & Watkins LLP (included in Exhibit 5.1).
 
   
  24.1 # Power of Attorney.

*
To be filed by amendment.

+
Indicates a management contract or compensatory plan.

Certain portions have been omitted pursuant to a confidential treatment request. Omitted information has been filed separately with the SEC.

#
Previously filed.

(1)
All exhibits, schedules and similar attachments to this exhibit have been omitted. Copies of such exhibits, schedules and similar attachments will be furnished supplementally to the SEC upon request.
    (b)
    Financial Statement Schedules

        Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.

Item 17.    Undertakings

        Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933, as amended, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933, as amended, and will be governed by the final adjudication of such issue.

        The undersigned Registrant hereby undertakes that:

        (a)   The Registrant will provide to the underwriters at the closing, as specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.

        (b)   For purposes of determining any liability under the Securities Act of 1933, as amended, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in the form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act of 1933, as amended, shall be deemed to be part of this registration statement as of the time it was declared effective.

        (c)   For the purpose of determining any liability under the Securities Act of 1933, as amended, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

II-5


Table of Contents


SIGNATURES

        Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this amendment to this Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Jose, State of California, on the 30 th day of September, 2011.

    INTERMOLECULAR, INC.

 

 

By:

 

/s/ DAVID E. LAZOVSKY

David E. Lazovsky
President and Chief Executive Officer

        Pursuant to the requirements of the Securities Act of 1933, as amended, this amendment to this Registration Statement has been signed by the following persons in the capacities indicated below on the dates indicated.

Signature
 
Title
 
Date

 

 

 

 

 
/s/ DAVID E. LAZOVSKY

DAVID E. LAZOVSKY
  President, Chief Executive Officer and Director (Principal Executive Officer)   September 30, 2011

/s/ PETER L. EIDELMAN

PETER L. EIDELMAN

 

Chief Financial Officer (Principal Financial and Accounting Officer)

 

September 30, 2011

*

THOMAS R. BARUCH

 

Director

 

September 30, 2011

*

MARVIN D. BURKETT

 

Director

 

September 30, 2011

*

IRWIN FEDERMAN

 

Director

 

September 30, 2011

*

ISY GOLDWASSER

 

Director

 

September 30, 2011

*

BRUCE M. MCWILLIAMS

 

Director

 

September 30, 2011

II-6


Table of Contents

Signature
 
Title
 
Date

 

 

 

 

 
*

GEORGE M. SCALISE
  Director   September 30, 2011

*

JOHN L. WALECKA

 

Director

 

September 30, 2011

*By:   /s/ PETER L. EIDELMAN

   
    PETER L. EIDELMAN,
Attorney-in-Fact
   

II-7


Table of Contents


EXHIBIT INDEX

Exhibit No.   Description of Exhibits
  1.1 * Form of Underwriting Agreement.
 
   
  2.1 # Asset Purchase Agreement by and between Intermolecular, Inc. and Symyx Technologies, Inc. dated as of July 28, 2011.(1)
 
   
  3.1 # Fifth Restated Certificate of Incorporation of Intermolecular, Inc., currently in effect.
 
   
  3.2 * Form of Restated Certificate of Incorporation of Intermolecular, Inc., to be in effect immediately prior to the consummation of this offering.
 
   
  3.3 # Bylaws of Intermolecular, Inc., as amended, currently in effect.
 
   
  3.4 * Form of Amended and Restated Bylaws of Intermolecular, Inc., to be in effect immediately prior to the consummation of this offering.
 
   
  4.1 * Specimen Common Stock Certificate.
 
   
  4.2 # Warrant to purchase shares of common stock issued to Timane S.a.r.l. dated June 20, 2008.
 
   
  4.3 * Form of warrant to purchase shares of common stock issued to Toshiba Corporation and SanDisk Corporation dated March 15, 2010.
 
   
  5.1 * Opinion of Latham & Watkins LLP.
 
   
  10.1 # Fourth Amended and Restated Investor Rights Agreement dated as of March 4, 2011, by and among Intermolecular, Inc. and certain stockholders named therein, as amended by Amendment No. 1 to Fourth Amended and Restated Investor Rights Agreement dated as of June 14, 2011.
 
   
  10.2 # Lease Agreement by and between Intermolecular, Inc. and Novellus Systems, Inc. dated as of May 10, 2010, as amended by the Confirmation of Commencement Date of the Lease Agreement dated as of June 10, 2010.
 
   
  10.3 Collaborative Development Program Agreement by and among SanDisk Corporation, Toshiba Corporation and Intermolecular, Inc. dated March 15, 2010.
 
   
  10.4 Alliance Agreement by and between Intermolecular, Inc. and Advanced Technology Materials, Inc. dated as of November 17, 2006.
 
   
  10.5 Wets Workflow Purchase Agreement by and between Intermolecular, Inc. and Advanced Technology Materials, Inc. dated as of July 13, 2007, as amended by the Addendum to Wets Workflow Purchase Agreement dated as of December 21, 2007, the Amendment to Addendum to Wets Workflow Purchase Agreement dated as of December 16, 2008 and the Supplemental Agreement to the Amendment to the Addendum to Wets Workflow Purchase Agreement dated as of March 16, 2009.
 
   
  10.6 Dry Workflow Purchase Agreement by and between Intermolecular, Inc. and Advanced Technology Materials, Inc. dated as of December 16, 2008.
 
   
  10.7 Modification to the Wets Workflow Purchase Agreement and Dry Workflow Purchase Agreement by and between Intermolecular, Inc. and Advanced Technology Materials, Inc. dated as of August 27, 2010.
 
   
  10.8 Amendment Number 5 to the Wets Workflow Purchase Agreement and Dry Workflow Purchase Agreement by and between Intermolecular, Inc. and Advanced Technology Materials, Inc. dated as of March 3, 2011.
 
   

Table of Contents

Exhibit No.   Description of Exhibits
  10.9 Advanced Memory Development Program Agreement by and between Intermolecular, Inc. and Elpida Memory, Inc. dated as of May 22, 2008, as amended by Exhibit C—Royalty Terms dated as of August 18, 2008, the Supplemental Joint Development Agreement dated as of January 27, 2009, the Amendment to the Supplemental Joint Development Agreement dated as of May 25, 2009 and the Amendment to the Advanced Memory Agreement dated July 29, 2010.
 
   
  10.10 Collaborative Development Program Agreement by and between Intermolecular, Inc. and GLOBALFOUNDRIES Inc. dated as of June 1, 2011.
 
   
  10.11 # Form of Indemnification Agreement between Intermolecular, Inc. and each of its directors, as currently in effect.
 
   
  10.12 * Form of Indemnification Agreement between Intermolecular, Inc. and each of its directors, officers and certain employees, to be in effect before the completion of the offering.
 
   
  10.13a +# Intermolecular, Inc. 2004 Equity Incentive Plan, as amended.
 
   
  10.13b +# Form of Early Exercise Stock Option Agreement under the 2004 Equity Incentive Plan.
 
   
  10.13c +# Form of Stock Option Agreement under the 2004 Equity Incentive Plan.
 
   
  10.14a +* Intermolecular, Inc. 2011 Incentive Award Plan.
 
   
  10.14b +* Form of Stock Option Grant Notice and Stock Option Agreement under the 2011 Incentive Award Plan.
 
   
  10.14c +* Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2011 Incentive Award Plan.
 
   
  10.14d +* Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2011 Incentive Award Plan.
 
   
  23.1   Consent of KPMG LLP, Independent Registered Public Accounting Firm.
 
   
  23.2 * Consent of Latham & Watkins LLP (included in Exhibit 5.1).
 
   
  24.1 # Power of Attorney.

*
To be filed by amendment.

+
Indicates a management contract or compensatory plan.

Certain portions have been omitted pursuant to a confidential treatment request. Omitted information has been filed separately with the SEC.

#
Previously filed.

(1)
All exhibits, schedules and similar attachments to this exhibit have been omitted. Copies of such exhibits, schedules and similar attachments will be furnished supplementally to the SEC upon request.



Exhibit 10.3

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

[*] COLLABORATIVE DEVELOPMENT PROGRAM AGREEMENT

 

This [*] COLLABORATIVE DEVELOPMENT PROGRAM AGREEMENT (“ Agreement ”) is made as of March 15, 2010 (“ Effective Date ”) by and among TOSHIBA CORPORATION doing business at 1-1, Shibaura 1-chome, Minato-ku, Tokyo 105-8001, Japan (together with its Affiliates, “ Toshiba ”), SANDISK CORPORATION doing business at 601 McCarthy Boulevard, Milpitas, CA 95035 USA (together with its Affiliates, “ SanDisk ”), and INTERMOLECULAR, INC .  doing business at 2865 Zanker Road, San Jose, CA 95134 USA (together with its Affiliates, “ Intermolecular ”).  Toshiba, SanDisk and Intermolecular shall be referred to herein individually as a party or collectively as the parties.

 

BACKGROUND

 

WHEREAS , Toshiba, SanDisk and Intermolecular desire to enter into a collaborative development program for the further development of certain [*] (“[*]”) technology as specified in this Agreement, and based on (a) the prior work between SanDisk and Intermolecular to develop [*] from [*] through [*], (b) subsequent [*] development work conducted independently by Intermolecular from [*] through [*], (c) work provided by Toshiba and SanDisk, and (d) the collaborative efforts of the parties under this Agreement;

 

NOW THEREFORE , in consideration of the mutual promises and covenants contains herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, intending to be legally bound, the parties agree as follows:

 

1.              DEFINITIONS

 

1.1            Affiliate ” shall mean any entity controlling, controlled by or under common control with, a party to this Agreement.  For purposes of this Agreement, the direct or indirect ownership of more than fifty percent (50%) of the outstanding securities of, or voting interest in, an entity shall be deemed to constitute control.

 

1.2            Category One IP ” shall mean the patents and patent applications owned by [*] covering [*] including that listed in Exhibit A.  Exhibit A may be updated and/or amended from time to time as approved in writing by [*].

 

1.3            Category Two IP ” shall mean (a) [*] specifically designated by [*] for [*] in a Collaborative Development Program, or (b) [*] agreed upon by [*] for [*] in the CDP.

 

1.4            Category Three IP ” shall mean [*], as among the parties hereto, [*] by [*] and based [*] on [*] or other [*] or [*]; provided that any [*] activities that may result in Technology or Intellectual Property Rights in this category shall be pre-approved in writing by the parties in accordance with Section 2.1.2.

 

1.5            Category Four IP ” shall mean [*], as among the parties hereto, [*] by [*] and based [*] on [*] (or other [*] or [*] as determined and confirmed by the IP Committee)..

 

Intermolecular Confidential

 



 

1.6            Category Five IP ” shall mean [*], as among the parties hereto, [*] by [*] and based [*] on [*] (or other [*] or [*] as determined and confirmed by the IP Committee).

 

1.7            Category Six IP ” shall mean [*], as among the parties hereto, [*] by [*] and based [*] on [*] (or other [*] or [*] as determined and confirmed by the IP Committee).

 

1.8            Category Seven IP ” shall mean [*] on the one hand and [*] on the other hand, and based [*] on [*] (or other [*] or [*] as determined and confirmed by the IP Committee).

 

1.9            Category Eight IP ” shall mean [*] by [*] on the one hand and [*]on the other hand, and based [*] on [*] (or other [*] or [*] as determined and confirmed by the IP Committee)..

 

1.10          CDP IP ” shall mean collectively or separately [*] and [*].

 

1.11          CDP Chip ” shall mean [*].

 

1.12          Non-CDP Chip ” shall mean one or more Die packaged or otherwise connected together, utilizing CDP IP outside the CDP Field.

 

1.13          Collaborative Development Program ” or “CDP” shall mean the activities that are conducted by Toshiba, SanDisk and Intermolecular under this Agreement in accordance with the Development Plan.

 

1.14          CDP Field ” shall mean [*] semiconductor integrated circuit [*] chips.

 

1.15          Confidential Information ” shall mean any information disclosed by one party to any other party in connection with this Agreement, whether in electronic, written, graphic, oral, machine readable or other tangible or intangible form, that is marked or identified at the time of disclosure as “confidential” or “proprietary” or in some other manner so as to clearly indicate its confidential nature.  Except as specifically provided in Section 6 below, the terms and conditions of this Agreement shall constitute Confidential Information of each of the parties.

 

1.16          Development Plan ” shall mean the written plan describing the activities to be conducted by each party and the target specifications to be met for deliverables during the CDP that is attached hereto as Exhibit B.

 

1.17          Die ” shall mean a semiconductor integrated circuit in die form.

 

1.18          Foreground IP ” shall mean the [*] and [*] developed under the CDP as [*] and [*]; provided however , that Foreground IP excludes HPC Technology, HPC Derivatives, Non [*] Foreground IP and [*] Design IP.  For purposes of categorization, conventional inventorship rules apply (except for [*] and [*], which shall be subject to Sections 3.2.2 and 3.2.3).

 

1.19          FTE ” shall mean an Intermolecular employee assigned to the CDP, based on approximately one hundred sixty-six (166) hours of professional services performed by one

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2



 

qualified person during a one month period, or the same number of hours in aggregate performed by two or more qualified persons during a one month period

 

1.20          HPC Derivatives ” shall mean all improvements, derivatives and modifications to any HPC Technology, developed by any party during the course of the CDP based on access to or use of Intermolecular-provided tools, software or information enabling the use of HPC Technology.

 

1.21          HPC Technology ” shall mean all Technology, including the Workflow Infrastructure, and without reference to any Toshiba or SanDisk Confidential Information or any Toshiba and SanDisk Contributed Background IP, used for the simultaneous, parallel, or rapid serial:  (i) design, (ii) synthesis, (iii) processing, (iv) process sequencing, (v) process integration, (vi) device integration, (vii) analysis, or (viii) characterization of more than two (2) compounds, compositions, mixtures, processes, or synthesis conditions, or the structures derived from such on a single wafer.  It is understood that any such test vehicles include physical and/or electrical characterization devices such as test structures or chips used in the design, process development, manufacturing process qualification, and manufacturing process control of integrated circuit devices to the extent that such devices are used in simultaneous, parallel, and rapid serial processing.  Nothing in this Agreement shall limit the use of test wafers used in research and development using nominally uniform processing.  It is also understood that HPC Technology does not include the use of commercially available equipment in commercial manufacturing for nominally uniform processing of one or more identical integrated circuits on a single substrate, or the use of such equipment in research and development for nominally uniform processing of one or more integrated circuits on a single substrate.  Toshiba and/or SanDisk existing or practiced technology or methodologies, and/or publicly known tools and methods, are excluded from the definition of HPC Technology.  HPC Technology excludes [*] Design IP.

 

1.22          IM [*] Developed Technology ” mean the [*] Technology developed independently by Intermolecular subsequent to [*] and prior to [*] that is attached hereto as Exhibit C.  Such exhibit shall not restrict or modify Toshiba’s and SanDisk’s rights with respect to their respective independent ownership rights of intellectual property rights and technology independently developed by them respectively.

 

1.23          Informatics Software ” shall mean the Intermolecular-proprietary software platform enabling the operation of Dry and Wet Workflows and the gathering and sharing of CDP information through a web-based interface.

 

1.24          Initial Term ” means the two (2) year period from the Effective Date.

 

1.25          Intellectual Property Rights ” shall mean all U.S.  and foreign rights in and to all (i) patents and patent applications, including all divisions, substitutions, continuations, continuation-in-part applications, and reissues, re-examinations and extensions thereof, (ii) copyrights and other rights in works of authorship, (iii) unpatented information, trade secrets, know-how, invention disclosures, engineering notebooks, confidential information, data, or materials, (iv) mask work rights, and (v) any other intellectual or other proprietary rights of any kind now known or hereafter recognized in any jurisdiction.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

3



 

1.26          Intermolecular Background IP ” shall mean (i) the Original CDP Developed Technology; (ii) the IM [*] Developed Technology; (iii) all Intellectual Property Rights in subsections (i) and (ii); and (iv) Technology and Intellectual Property Rights created, conceived or developed by or for Intermolecular outside of or independently from the Collaborative Development Program, provided that each of (i), (ii), (iii) and (iv) are to the extent unanimously preapproved in writing by the IP Committee for submission to the CDP.  If Toshiba and/or SanDisk do not approve for submission any Technology or Intellectual Property Rights proposed for inclusion by Intermolecular under categories (i), (ii) and (iii) above, such Technology or Intellectual Property Rights shall not be deemed licensed under Section 4 below and shall be excluded from the covenant set forth in Section [*] and, if a patent or patent application, shall not be subject to the provisions of Section [*].  Intermolecular Background IP excludes HPC Technology.

 

1.27          Intermolecular Customer ” shall mean a Third Party that engages in a development program with Intermolecular where Intermolecular performs development services in the field of semiconductors, including but not limited to semiconductor materials, semiconductor device technology, and/or semiconductor manufacturing equipment, process and characterization technology on behalf of and/or in collaboration with such Third Party, in a manner similar to the development program described in this Agreement.

 

1.28          Licensed IP ” shall mean [*] and [*].

 

1.29          “[*]” shall mean [*].

 

1.30          “[*] Foreground IP ” shall mean the materials, process, structure and other Technology included in [*] developed pursuant to the CDP, but not [*] Design IP, and all Intellectual Property Rights therein or thereto.

 

1.31          Non [*] Foreground IP ” shall mean the materials, process, structure and other Technology included in [*] that are not [*] based and all Intellectual Property Rights therein or thereto.  The parties agree that no such Non [*] Foreground IP are intended to be developed pursuant to the CDP.

 

1.32          “[*] Technology ” means [*] derived from CDP IP, that [*]  per physical [*]; provided that such [*] Technology-based devices (i) provide similar functional capabilities as the [*] -based [*] technology produced by SanDisk and Toshiba as of the Effective Date and (ii) are used for [*]  per physical [*] at the time of shipment by SanDisk or Toshiba.

 

1.33          New [*] Concepts ” shall mean Intellectual Property Rights and Technology that is contributed by Toshiba and/or SanDisk that the parties agree to develop pursuant to the CDP that does not contain, and is not a derivative, modification, improvement and enhancement of, the Intermolecular Background IP or the Toshiba and SanDisk Contributed Background IP.

 

1.34          Original CDP Developed Technology ” shall mean the [*] and [*] Documentation as agreed upon by SanDisk and Intermolecular on [*], and attached hereto as Exhibit D.  Such exhibit shall not restrict or modify Toshiba’s and SanDisk’s rights with respect

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

4



 

to their respective independent ownership rights of intellectual property rights and technology independently developed by them respectively.

 

1.35          CDP Product ” shall mean a product containing one or more CDP Chips manufactured and offered for sale by or for Toshiba or SanDisk.  CDP Products may be delivered to customers in any form including wafer form, packaged and unpackaged [*] Die, and finished goods.

 

1.36          Non-CDP Product ” shall mean a product containing one or more Non-CDP Chips manufactured and offered for sale by or for Toshiba or SanDisk.  Non-CDP Products may be delivered to customers in any form including wafer form, packaged and unpackaged Die, and finished goods.

 

1.37          “[*]” shall mean a [*], including the [*], and [*] if any are needed, and the [*].

 

1.38          “[*] Design IP ” shall mean any of the following arising or resulting from the Development Program, including any Intellectual Property Rights or Technology therein:  (i) [*] Technology device designs; (ii) [*] Technology circuit designs; (iii) [*] Technology chip architectures; (iv) [*] process integration technology; (v) [*] steering elements (e.g.  [*]); (vi) device and chip operation and testing; and (vii) any and all [*].

 

1.39          [ intentionally left blank ]

 

1.40          Technology ” shall mean tangible embodiments of Intellectual Property Rights, whether in electronic, written or other media, including techniques, methodologies, processes, designs, test vehicles, synthetic procedures, systems, or any of combinations of the foregoing, as well as any directories, source code, object code, firmware, technical documentation, specifications, requirements, designs, design drawings, design files, and quality control data, schemes, schematics, diagrams, bills of material, netlists, build instructions, test reports, mask works, data sheets, reference designs, net lists, RTL, algorithms, formulae, photomasks, databases, lab notebooks, manuscripts, records, prototypes, samples, studies, and invention disclosure forms.

 

1.41          Term ” shall mean the Initial Term and any renewals thereof pursuant to Section 11.1.

 

1.42          Toshiba and SanDisk Contributed Background IP ” shall mean Intellectual Property Rights and Technology related [*] owned by Toshiba and/or SanDisk that is provided by Toshiba and/or SanDisk to Intermolecular at any time under the CDP.  All such Technology or Intellectual Property Rights shall be specified in the Development Plan or specified by Toshiba or SanDisk during the CDP under Section 2.2.

 

1.43          Third Party ” shall mean any person or entity other than Toshiba, SanDisk and Intermolecular, and any permitted assigns.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

5



 

1.44          Third Party Licensee ” shall mean an entity other than Toshiba, any Toshiba Affiliate, SanDisk or any SanDisk Affiliate to whom a license to all or a portion of the Licensed IP or a license to any Joint IP, as applicable, is granted under Section 5.10.

 

1.45          Third Party CDP Product ” shall mean a product (which is neither a CDP Product nor a Non-CDP Product) containing one or more CDP Chips manufactured and offered for sale by or for a Third Party Licensee to a customer other than SanDisk and/or Toshiba. Third Party CDP Products may be delivered to customers in any form including [*].

 

1.46          Third Party Non-CDP Product ” shall mean a product (which is neither a CDP Product nor a Non-CDP Product) containing one or more Non-CDP Chips manufactured and offered for sale by or for a Third Party Licensee to a customer other than SanDisk and/or Toshiba.  [*].

 

1.47          Workflow Infrastructure ” shall mean the HPC processing tools implemented by Intermolecular ([*]), characterization infrastructure (including physical metrology and electrical test equipment), and the Informatics Software designed or optimized by Intermolecular and installed at Intermolecular’s facilities for use by the parties to perform the development activities specified in the Development Plan, as more fully described in Exhibit E attached hereto.

 

2.              COLLABORATIVE DEVELOPMENT PROGRAM

 

2.1            CDP .

 

2.1.1         Pre-CDP Workshop .  Immediately after the Effective Date of this Agreement, Intermolecular, Toshiba and SanDisk shall set up a technical workshop in a manner and schedule to be agreed by the parties for informing Toshiba and SanDisk of the Technology which are described in Exhibits C and D attached hereto.  Exhibits C and D are to be provided to Toshiba and SanDisk on the Effective Date.  Promptly but no later than [*] days following such technical workshop, the Operating Committee will determine which items will be listed on Exhibit H (which shall be the Intermolecular Background IP for the CDP).  The parties confirm and agree that items not initially included in Exhibit H (but listed in Exhibit C or D) may at any time prior to the licensing election described in Section 4.2.2, upon Toshiba’s and SanDisk’s approval, be added to and included in Exhibit H.  In addition, at any time prior to the licensing election described in Section 4.2.2, Exhibit H may be updated in accordance with Section 1.26(iv).

 

2.1.2         Development Plan .  Subject to the terms and conditions set forth herein, Toshiba, SanDisk and Intermolecular will conduct this Collaborative Development Program in accordance with the Development Plan within the scope of the CDP Field.  The Development Plan shall contain the activities to be conducted by each party, the information sharing processes to be used during the CDP, the deliverables to be produced in the CDP, the target specifications to be met for such deliverables and metrics to be met by each party.  For the avoidance of doubt, no Toshiba and SanDisk Contributed Background IP shall be considered part of the CDP unless expressly identified as “Toshiba and SanDisk Contributed Background IP” in the Development Plan, or otherwise pre-approved by Toshiba and SanDisk in writing.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

6



 

2.1.3         Intermolecular .  Intermolecular agrees to provide [*] Intermolecular FTEs and use of its Workflow Infrastructure for Intermolecular to perform the specified activities at Intermolecular facilities under the Development Plan.  The fees to support these resources are set forth in Section 5.  In return for the services to be performed by Intermolecular and for the Workflow Infrastructure provided by Intermolecular for use in the CDP, Toshiba and SanDisk agree to pay the fees as set forth in Sections 5.1 and 5.2 in accordance with the terms of this Agreement.

 

2.1.4         Change Orders .  Any of the parties may propose to the other parties from time to time to change the Development Plan, provided the change is within the CDP Field.  As part of such change process, Intermolecular, Toshiba and/or SanDisk may propose the introduction of new [*] concepts and materials that are not part of the initial Development Plan, including without limitation New [*] Concepts.  Any such party suggesting a change shall provide a written proposal to the other parties detailing the proposed change and the anticipated effect on scheduling and cost.  The parties agree to promptly discuss and decide upon any proposed changes to the Development Plan, including introduction of New [*] Concepts.  All changes to the Development Plan, including new forms of experiments, must be approved by Toshiba and SanDisk in writing; provided that Toshiba and SanDisk agree to consider Intermolecular’s requested changes in good faith.  Any such decision to amend the Development Plan shall include any changes to pricing, cost allocations, licensing terms, activities, responsibilities, development schedule or other provisions related to implementation of any such change.  If the proposed change by SanDisk and/or Toshiba requires additional capital expenditures or substantial additional resources by Intermolecular beyond the then-current CDP for the then-current Development Plan, the amended Development Plan will be subject to Intermolecular’s approval.  If Toshiba and SanDisk do not agree in writing to a change to the Development Plan, the Development Plan in existence prior to the proposed change shall continue in full force and effect.

 

2.2            Committees .

 

2.2.1         Operating Committee .  The parties will establish an operating committee (the “ Operating Committee ”) to oversee the performance of the Collaborative Development Program, monitor progress of the CDP, resolve any disputes or disagreements between the Project Managers (as defined below) and escalate any remaining disputes, as necessary, and ensure open communications among the parties.  The Operating Committee will initially be comprised of at least one (1) representative from each party, including the Project Manager of each party, or such other equal number of representatives as the parties may from time to time agree in writing, with each party’s representatives selected by that party, provided that the Project Manager of such party remains on the Operating Committee.  Any party may replace any of its Operating Committee members at any time, upon written notice to the other party.  The Operating Committee will meet on a quarterly basis or as otherwise agreed by the parties, at locations or in a manner agreed by the parties.  All decisions of the Operating Committee shall be made by SanDisk and Toshiba, subject to Section 2.1.4.

 

2.2.2         IP Committee .  The parties will also establish a committee (the “ IP Committee ”), reporting to the Operating Committee, that will be responsible for reviewing invention disclosures, patent filing decisions and Intellectual Property Rights ownership

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

7



 

decisions resulting from activities under the CDP, including without limitation, determination of the Intellectual Property Rights, if any, in all Technology developed in the CDP.  The IP Committee will meet on at least a calendar quarterly basis or as otherwise agreed to by the parties.  The IP Committee shall consist of two (2) members from each party, one from its technical employee and the other one from its patent attorney, agent or IP staff member.  All decisions of the IP Committee must be made by unanimous vote of the parties, with each party having a single vote.  If there is disagreement among the parties regarding the existence or ownership of Intellectual Property Rights or Technology, the parties will escalate the dispute as appropriate within their respective organizations as promptly as possible for resolution; provided, however, that no party shall publicly disclose or otherwise publish any information, or otherwise jeopardize the opportunity to file a patent application, regarding an invention claimed by another party hereunder resulting from or relating to CDP activities during any period where the ownership of such claimed invention has not yet been determined.  Each party agrees that it will not unreasonably delay or prolong resolution of any ownership, inventorship or other claim regarding the Technology or Intellectual Property Rights.

 

2.3            Access to Information .  The parties acknowledge and agree that each party shall provide the other parties timely and sufficient access to information reasonably necessary to carry out their obligations under all phases of the Collaborative Development Program.  Further, Intermolecular agrees that it shall immediately provide both Toshiba and SanDisk with any information made available to it during the course of its activities in the CDP as set forth in Section 2.1.2.  The parties agree to comply with all information sharing processes set forth in the Development Plan.

 

2.4            Project Managers .  Each party hereby appoints the initial principal point of contact set forth in the Development Plan to be its project manager for the CDP, who shall coordinate and act as a liaison with the other parties with respect to the Development Plan (each a “ Project Manager ”).  A party may from time to time change its Project Manager upon written notice to the other parties.

 

2.5            Development Records .  Each party agrees to maintain reasonable records of the activities it performs under the Development Plan, and cause such records to be maintained in sufficient detail and in good scientific manner as will properly reflect all material work done and results achieved, including information sufficient to establish dates of conception and reduction to practice of inventions.

 

3.              IP OWNERSHIP

 

3.1            Prior and Independent Technology .  Each party shall retain all right, title and interest in and to all materials, Technology, concepts, know-how, inventions, discoveries, works of authorship, and all related Intellectual Property Rights created, conceived or developed by or for that party prior to the Effective Date.  For Toshiba and SanDisk, this includes all Toshiba and SanDisk Contributed Background IP, and for Intermolecular this includes all Intermolecular Background IP, including [*].  In addition, each party shall retain all right, title and interest in and to all materials, Technology, concepts, know-how, inventions, discoveries, works of authorship, and all related Intellectual Property Rights created, conceived or developed by or for that party outside of or independently from the Collaborative Development Program without use or incorporation of any Confidential Information,

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

8



 

Technology or Intellectual Property Rights of or received from any other party pursuant to the Agreement.

 

3.2            Foreground IP .

 

3.2.1         Intermolecular Sole Ownership of Foreground IP .  Intermolecular shall be the sole owner of [*].

 

3.2.2         Toshiba and SanDisk Sole Ownership of Foreground IP .  Toshiba and SanDisk shall be the sole owners of (a) all [*] and [*], and (b) all Technology and Intellectual Property Rights (other than patents and patent applications) in and to [*].  The actual division of ownership of such Technology and Intellectual Property Rights shall be determined between Toshiba and SanDisk based on separate agreements between Toshiba and SanDisk.

 

3.2.3         Joint Ownership Among the Parties .  Intermolecular, Toshiba and SanDisk shall jointly own (a) all Technology and Intellectual Property Rights in [*] and (b) any patents and patent applications resulting solely from inventions under [*] (collectively, all of the foregoing constitute “Joint IP”).  Except as expressly provided elsewhere in this Agreement, each party has the right to use, fully exploit, disclose or otherwise dispose of such Joint IP for any purpose without consent of or accounting to the other party.

 

3.2.4         [*] Design IP and [*]Foreground IP .  Notwithstanding anything to the contrary in this Agreement, as among the parties and regardless of creator, Toshiba and SanDisk based on existing agreements between Toshiba and SanDisk, shall own all right, title and interest, including Intellectual Property Rights, in and to the [*] Design IP and Non [*] Foreground IP and any derivatives, modifications, improvements to and enhancements thereto and any Intellectual Property Rights in any of the foregoing.  Intermolecular hereby assigns, and agrees to assign to Toshiba and SanDisk, as applicable, in the future when they are first fixed in a tangible medium or reduced to practice, as applicable, all Intellectual Property Rights in and to any [*] Design IP and [*] Foreground IP that Intermolecular may obtain as a result of Intermolecular’s activities under the CDP.

 

3.3            HPC Technology and Derivatives .  Notwithstanding any other provision to the contrary, as among the parties and regardless of creator, Intermolecular shall own all right, title and interest, including Intellectual Property Rights, in and to HPC Technology and any HPC Derivatives, and all Intellectual Property Rights in any of the foregoing. [*].

 

3.4            Cooperation .  Each party agrees to execute all papers, including patent applications and invention assignments, and otherwise agrees to assist the other party, as reasonably required and at the other party’s reasonable expense, to perfect in the applicable party the rights, title and other interests in their respective inventions which this Agreement designates such party to own.  Without limiting the foregoing, the parties agree to use reasonable efforts to keep the other parties informed as to the status of patent matters with respect to any Joint IP, [*] and [*].

 

3.5            Patent Prosecution .  Intermolecular shall have the first right to prepare, file, prosecute and maintain, at its own expense and in consultation with the other parties, any patent applications claiming inventions in the Foreground IP owned solely by Intermolecular.  The IP Committee will determine on a case-by-case basis which party shall be responsible for preparing,

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

9


 

filing, prosecuting and maintaining, in consultation with the other parties, any patent applications claiming inventions in the Foreground IP that constitute Joint IP, and the cost allocation will be determined at such time by the parties.  In the event that Intermolecular makes a decision (and in such event Intermolecular shall promptly inform the applicable parties) that Intermolecular will not file, prosecute or maintain any such patent or patent application in a Joint IP, [*] or [*]  invention, or undertake such other activities described above, then the applicable party that jointly owns (or desires to further prosecute) such invention shall have the right to assume such activities at its own expense but without affecting the ownership and license provisions set forth in Sections 3 and 4 hereof.  Nothing in this Agreement shall limit or restrict a party’s rights to file or prosecute any solely-owned invention unless that party has agreed to assign such invention and Intellectual Property Rights therein to another party pursuant to the terms and conditions of this Agreement.

 

3.6            Enforcement .

 

3.6.1         Joint IP .  With prior consultation to Toshiba and SanDisk, Intermolecular shall have the initial right, but not the obligation, to take reasonable legal action to enforce Intellectual Property Rights in any Joint IP against commercially material infringements.  If Intermolecular does not take action sufficient to halt such infringement within [*] following receipt of notice of such infringement, then either Toshiba or SanDisk, as applicable, shall have the right, but not the obligation, to take action to stop such infringement at its sole expense.  Notwithstanding the foregoing, if Toshiba and SanDisk elect to receive [*] license under Section 4.2 below, then either Toshiba or SanDisk, as applicable based on inventorship or upon written agreement between Toshiba and SanDisk, shall have the initial right, but not the obligation, to take reasonable legal action to enforce any Intellectual Property Rights in Joint IP against commercially material infringements.

 

3.6.2         [*] Licensed Intellectual Property Rights . During the Initial Term, and after the Initial Term if Toshiba and SanDisk both exercise their option to take [*] license in accordance with Section 4.2, Toshiba and/or SanDisk shall have the right, but not the obligation, to take reasonable legal action to enforce the Licensed IP without consultation with Intermolecular.  If one or both of such parties decides to take legal action to enforce such Licensed IP against a Third Party, then the enforcing party may request that Intermolecular participate (and Intermolecular shall participate) in such action as may be reasonably necessary to enforce such rights; provided, however, that Intermolecular’s participation shall be conditioned upon the enforcing party bearing Intermolecular’s reasonable costs to participate in such enforcement action and indemnifying Intermolecular against any liabilities, losses, damages, costs and expenses, including reasonable attorneys’ fees, incurred by Intermolecular as a result of participating in any such action.

 

3.6.3         Cooperation; Costs . Each party agrees to render such reasonable assistance in connection with enforcement activities described in this Section 3.6 as the enforcing party may request.  Costs of maintaining any such action shall be paid by and shall be the responsibility of the party bringing the action.

 

3.6.4         Recoveries . Subject to the payment obligations set forth in Section 5, any damages or settlement recovered from any action under this Section 3.6 shall belong to the party bringing the action.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

10



 

4.              LICENSES

 

4.1            Collaboration Licenses .

 

4.1.1         Intermolecular License to Toshiba and SanDisk . Subject to the terms and conditions of this Agreement, including payment of applicable license fees, Intermolecular grants to Toshiba and SanDisk for the Term [*] non-transferable [*] license under and to the Intermolecular Background IP (including the [*]), HPC Technology, HPC Derivatives and any other Technology and/or Intellectual Property Rights Intermolecular contributes to the development efforts under the CDP (including the [*]), to engage in the CDP and perform the activities set forth in the Development Plan.  Notwithstanding the foregoing [*] license, Intermolecular reserves the right to use the Technology and Intellectual Property Rights licensed in this Section 4.1.1 solely for the purpose of Intermolecular performing its duties under the CDP, and not for the benefit of any Third Party.

 

4.1.2         Toshiba and/or SanDisk License to Intermolecular . Subject to the terms and conditions of this Agreement, Toshiba and SanDisk each grant to Intermolecular for the Term [*] non-transferable [*] license under and to the Toshiba and SanDisk Contributed Background IP and to and any other Technology and/or Intellectual Property Rights either party contributes to the development efforts under the CDP, solely to engage in the CDP and perform the activities set forth in the Development Plan, and not for the benefit of any Third Party.

 

4.2            Technology License .

 

4.2.1         Technology License .

 

A.     Within CDP Field . Subject to the terms and conditions of this Agreement, including but not limited to Section 4.2.2 and Section 6 below, Intermolecular grants Toshiba and SanDisk a worldwide, [*] (except as to Intermolecular for purposes of performing its activities related to this Agreement), [*], non-transferable license within the CDP Field, without right of sublicense, under and to Intermolecular Background IP, the Licensed IP and any other Technology and/or Intellectual Property Rights Intermolecular contributes to the development efforts under the CDP to (i) use and modify such Technology and/or applicable Intellectual Property Rights including know-how; and (ii) use, make, have made, import, offer to sell, sell, lease, copy, modify, distribute, and otherwise dispose of, and exploit, the CDP Products.

 

B.     Outside CDP Field . In addition to Section 4.2.1(A), and subject to the terms and conditions of this Agreement, including but not limited to Section 4.2.2 and Section 6 below, Toshiba’s and/or SanDisk’s license shall be extended at its respective discretion to activities outside the CDP Field, without right of sublicense, under this Section 4.2.1(B) for Non-CDP Products in fields to be agreed upon by

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

11



 

Intermolecular and the applicable party in advance as set forth in this Section 4.2.1(B).  On a case-by-case basis, Toshiba and SanDisk shall (i) notify Intermolecular in writing in advance for each instance where Toshiba or SanDisk, as applicable, desires to extend the use of the Technology licensed under Section 4.2.1(A) into a new field of use on [*] basis and the license under Section 4.2.1(A) will be extended to that field and apply to the specified Non-CDP Products unless Intermolecular notifies Toshiba or SanDisk promptly in writing that such proposed Non-CDP Product or field of use is subject to a pre-existing obligation of Intermolecular to grant [*] license to such Non-CDP Product or field to a Third Party; and (ii) obtain Intermolecular’s prior written approval to extend the use of the Technology licensed under Section 4.2.1(A) into a new field of use or new Non-CDP Product on [*] basis, as applicable.  If extended, Toshiba and SanDisk shall be granted a worldwide, [*] non-transferable license under and to the applicable Intermolecular Background IP and to the Licensed IP Intermolecular contributes to the development efforts under the CDP to (i) use and modify such Technology; and (ii) use, make, have made, import, offer to sell, sell, lease, copy, modify, distribute, and otherwise dispose of, and exploit, the specified Non-CDP Products outside the CDP Field in the applicable field; provided however , that Non-CDP Product Fee [*] and [*] under this Section 4.2.1(B) shall be [*] percent ([*]%) of the [*] and [*] applicable to Section 4.2.1(A), and the fees payable to Intermolecular for Third Party CDP Products and Third Party Non-CDP Products for such extensions shall be subject to Section 5.10 below.  Such [*], and [*] applicable to this Section 4.2.1(B) shall be separately accounted from [*], and [*]  applicable within the CDP Field.

 

4.2.2         License Election .  Each of Toshiba and SanDisk shall have the right to elect during or within [*] days after [*] to either:

 

A.     receive [*] license under Section 4.2.1 after the Term to (i) the Intermolecular Background IP, and (ii) the Licensed IP, and (iii) any other Technology and/or Intellectual Property Rights Intermolecular contributes to the development efforts under the CDP in accordance with Section 1.26(iv) above.  If Toshiba and/or SanDisk make an election under this subsection (a), then the license in Section 4.2.1 shall convert to [*] license at the end of the Term;

 

B.     terminate the license to the Licensed IP, provided that if such election is made, (a) SanDisk shall

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

12



 

continue to have a license to the Original CDP Developed Technology under all the terms and conditions (including without limitation the economic terms) of the Collaborative Development and License Agreement by and between Intermolecular, Inc.  and SanDisk Corporation effective as of August 25, 2006 as amended (the “2006 Agreement”), and (b) Toshiba and SanDisk shall continue to have the right to license Joint IP to Third Party Licensees;

 

C.     retain [*] license under Section 4.2.1 in the CDP Field after the Term to (i) Intermolecular Background IP, and (ii) the Licensed IP and (iii) any other Technology and/or Intellectual Property Rights Intermolecular contributes to the development efforts under the CDP in accordance with Section 1.26(iv) above, in which case Intermolecular shall not exercise any ownership rights in any Joint IP in the CDP Field (including not granting licenses to any third parties under such Joint IP).  In the event only Toshiba or SanDisk but not both, make an election under this subsection (c), the party electing to retain the [*] license shall ensure that Intermolecular is properly compensated under Intermolecular’s rights as [*] licensor under this Agreement, to the same extent as if both Toshiba and SanDisk had elected to retain the [*] license and the party not electing to retain the exclusive license will retain [*] license; or

 

D.             retain [*] license under Section 4.2.1 only to (i) the Intermolecular Background IP (other than the [*]) and (ii) the [*] and (iii) any other Technology and/or Intellectual Property Rights Intermolecular contributes to the development efforts under the CDP in accordance with Section 1.26(iv) above, and to have Intermolecular not exercise its ownership rights in Joint IP (including not granting licenses to any third parties under such Joint IP), but not take [*]  license under or to [*].  In the event Toshiba and SanDisk make an election under this subsection (D), then upon such election, Toshiba and SanDisk will retain [*] license to all Intellectual Property Rights licensed under Section 4.2.1 for which Toshiba and SanDisk did not elect to retain [*] license.

 

4.2.3         Option .  Notwithstanding anything to the contrary in this Agreement, after Toshiba and/or SanDisk has elected a license pursuant to Section 4.2.2 and has identified whether such license is [*] or [*], Toshiba and SanDisk shall each have the one time option at any point after the Term, to [*] such license as applicable, from [*] to [*], or from [*] to [*], as long as (1) Toshiba and/or SanDisk continues to make any payments due and payable to Intermolecular under this Agreement, (2) the applicable [*] and [*] under Section 5.4 below associated with the license so elected by Toshiba and/or SanDisk, shall replace the [*] and [*] previously applicable prior to such election (for example, if SanDisk and/or Toshiba elected to [*] to [*], the [*] for [*] SanDisk and Toshiba shall be [*] from [*], as applicable, to [*] and no further [*] will apply); provided, that if SanDisk or Toshiba elect to [*] the [*] from [*] to [*],

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

13



 

CDP Product Fees and Non-CDP Product Fees already due or paid to Intermolecular prior to the election to convert to [*] are non-refundable, even if such CDP Product Fees or Non-CDP Product Fees exceed the [*] or [*], as applicable; and (3) if an election is made by Toshiba and/or SanDisk from [*] to [*], the resulting [*] license shall be made subject to any licenses made by Intermolecular to a Third Party prior to such election.

 

4.2.4         Third Party Licensees .  Licenses to Third Party Licensees shall be governed in accordance with Section 5.10 below.

 

4.2.5         No Limitation to SanDisk/Toshiba Technology .  Nothing in this Section 4 shall limit in any manner the rights of Toshiba or SanDisk to use, transfer and otherwise exploit [*] patents and patent applications, [*],[*] Design IP, Non [*] Foreground IP and any other Intellectual Property Rights and Technology of either Toshiba or SanDisk, as applicable; provided, however, that this Section 4.2.5 shall not be deemed a license, either express or implied, to any Intermolecular Technology or Intellectual Property Rights.

 

4.2.6         [*] License .  If Toshiba and SanDisk either (i) do not elect [*] license under Section 4.2.2 or (ii) elect to terminate the license in accordance with Section 4.2.2(B), Toshiba and SanDisk each acknowledge that Intermolecular may exercise its rights in any Joint IP, subject to payment of a mutually-agreed pass-through payment to Toshiba and SanDisk.

 

4.2.7         No Sublicense Right of [*] to [*] .  [*]not granted any sublicensing rights with respect to [*] under this Agreement.

 

4.3            Reservation of Rights .  Except for the rights expressly granted by each party to the other under this Agreement, all other rights are reserved.

 

4.4            Other Engagements .  The parties each agree that nothing in this Agreement, except for the exclusivity provisions of this Section 4, restrict any party from engaging in development or commercialization projects with Third Parties.

 

4.5            Favorable per-CDP Product Terms .  If [*] grants a license to the Licensed IP to any Third Party for use in competing [*] applications and/or products with any program fees (including but not limited to fees associated with the CDP), product fees and/or per-chip royalties or their equivalent and/or other licensing fees and/or [*] on terms that are more favorable to the licensee than the terms contained in this Agreement, [*] shall immediately provide written notice to [*] setting forth the details of such more favorable terms, and shall offer to [*] to incorporate those terms in this Agreement on a going-forward basis into this Agreement effective as of such notification date.  [*].

 

4.6            Bankruptcy .  Intermolecular acknowledges that the Intermolecular Intellectual Property Rights licensed pursuant to this Agreement constitute “intellectual property” to the extent provided under the United States Bankruptcy Code (the “ Bankruptcy Code ”) or similar foreign laws, and it is the express intent of the parties to this Agreement that if Intermolecular is subject to a proceeding under the Bankruptcy Code or similar foreign laws and rejects this Agreement or any portion thereof, then SanDisk and Toshiba may elect to retain their respective rights to such Intermolecular Intellectual Property Rights under this Agreement to the maximum extent provided under Section 365(n) and other provisions of the Bankruptcy Code, other

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

14



 

applicable U.S. and state laws and applicable foreign laws.  If Toshiba and/or SanDisk seek to register the licenses to be granted by Intermolecular under this Agreement with the Japan Patent Office, any foreign patent offices, governing agencies or authorities, Intermolecular shall cooperate with the party requesting such registration.  Such cooperation expenses shall be borne (a) by Intermolecular for any such U.S.  or Japanese registration, and (b) by Toshiba and/or SanDisk for any other such registrations.

 

5.              SUBSCRIPTION, SERVICE, LICENSE AND PRODUCT FEES

 

5.1            Service Fees .  Toshiba and SanDisk each will fund for the CDP under the Development Plan and agrees to pay Intermolecular [*] US Dollars (US$[*]) for a cumulative total of [*] US Dollars (US$[*]) for Intermolecular’s performance of the services described in the Development Plan.  Subject to Section 5.7, these amounts shall be paid by each of Toshiba and SanDisk in equal monthly payments of [*]  US Dollars (US$[*]) over the Initial Term starting upon the Effective Date.  Intermolecular shall ensure that these service fees fully cover and support the Development Plan to build an infrastructure and workflow as set forth in Exhibit E.  These service fees also include any expenses that Intermolecular incurs for a transfer of the process or technology to the development and production facilities of Toshiba and SanDisk (including associated travel and lodging costs except for extended stays in Japan over [*]  days).  In addition to the amounts set forth above, Toshiba and SanDisk agree to provide or pay, each on an equal basis with the other, for all of the following that is pre-approved by SanDisk and Toshiba in writing:  out-of-pocket expenses for consumables (e.g., wafers and mask sets), outsourced metrology (to the extent not part of the regular work flow), analytical services and characterization not supported internally by Intermolecular, and other mutually agreed out-of-pocket costs to support the CDP.  For costs associated with targets and materials required during the duration of the CDP, Intermolecular shall make commercially reasonable efforts to procure and/or obtain such targets and/or materials at costs which are as inexpensive as possible and shall bear [*] as part of the service fees under this Section 5.1, the first US$[*] per [*] (the first [*] being pro-rated), of such costs when verified.  Upon such verification, SanDisk and Toshiba shall bear in equal amounts, such costs arising during the [*] in question in excess of such US$[*] threshold.

 

5.2            Workflow Infrastructure Subscription Fee .  Toshiba and SanDisk will fund for the CDP under the Development Plan and each agrees to pay Intermolecular [*] US Dollars (US$[*]) for a cumulative total of [*] US Dollars (US$[*]) for all access necessary for performing under the Development Plan to and Intermolecular’s use of the Workflow Infrastructure as part of the Collaborative Development Program as set forth below.  Subject to Section 5.7, these amounts shall be paid by each of Toshiba and SanDisk in equal [*] payments of [*] US Dollars (US$[*]) over the Initial Term starting upon the Effective Date.  These subscription fees also include all costs associated with or related to Workflow Infrastructure, including but not limited to any rent, storage, utility and like costs relating to the Workflow Infrastructure that Intermolecular incurs.  Notwithstanding anything to the contrary in this Agreement in the event that the CDP is renewed after the Initial Term and/or Toshiba and SanDisk maintain [*] license to Licensed IP under Section 4.2.1, SanDisk and Toshiba will have [*] for use of the [*] after the Initial Term if Toshiba and SanDisk have extended the CDP, or entered into a new collaborative development program with Intermolecular.  During the Term and subject to the full, timely payment of the above subscription fee by both Toshiba and

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

15



 

SanDisk, Intermolecular will provide (i) access at all times to the Workflow Infrastructure to perform the activities contemplated by the Development Plan, (ii) [*], non-transferable license without right of sublicense for Toshiba and SanDisk to use at all times the HPC Technology and HPC Derivatives as incorporated in the Workflow Infrastructure in Intermolecular’s to carry out any of their activities pursuant to the Development Plan, and (iii) [*], non-transferable license, without right of sublicense, to access and use the Informatics Software via an Intermolecular-established secure portal solely for the purposes of performing activities pursuant to the Development Plan.  Intermolecular covenants that Intermolecular will not use the [*] dedicated specifically to the CDP for any purpose outside of the Development Plan and it will not allow any Third Party to use the dedicated [*] during the term of this Agreement without Toshiba and SanDisk’s prior written consent.  If Toshiba and SanDisk provide such consent for use during the Initial Term, the fees set forth in this Section 5.2 shall be reduced on a pro rata basis according to the number of days (or part thereof) that such Third Party uses the [*].  This license does not confer any ownership rights in the Workflow Infrastructure and Tempus AP-30.

 

5.3            Initial License Fees .  In addition to any other license fees payable by Toshiba and SanDisk under Section 5.4 of this Agreement, Toshiba and SanDisk each agree to pay Intermolecular [*] US Dollars (US$[*]) for a cumulative total of [*] US Dollars (US$[*]) for the Intermolecular Background IP license rights set forth in Section 4.1.1 as follows:  Intermolecular shall invoice each of Toshiba and SanDisk in the amount of [*] US Dollars (US$[*]) on (a) [*] days following the [*], and (b) [*] days following the [*] anniversary of the [*].  Toshiba and SanDisk each will pay Intermolecular based on such invoices, within [*] days from their respective receipt of such invoices.

 

5.4            CDP Product Fees; [*].

 

5.4.1         Toshiba and SanDisk each acknowledges and agrees that in addition to Section 5.3 above,

 

A.     Toshiba will pay Intermolecular a per-CDP Product fee (a “ CDP Product Fee ”) based on Table 1 below on the sale of CDP Products by Toshiba or Toshiba Affiliates to third parties unrelated to either Toshiba, SanDisk or the joint ventures between Toshiba and SanDisk (“Unrelated Third Party”) except for any payment by an Unrelated Third Party to Intermolecular under another applicable provision of this Agreement, and

 

B.     SanDisk will pay Intermolecular a CDP Product Fee based on Table 1 below on the sale of CDP Products by SanDisk or SanDisk Affiliates to Unrelated Third Parties, except for any payment by an Unrelated Third Party to Intermolecular under another applicable provision of this Agreement.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

16



 

CDP Product Fee Rate Table (Table 1)

 

[*] Toshiba or SanDisk CDP
Products Sold

 

CDP Product

containing [*]

 

CDP Product
containing [*]

 

CDP Product
containing [*]

 

[*]

 

US $

[*]

 

$

[*]

 

$

[*]

 

[*]

 

$

[*]

 

$

[*]

 

$

[*]

 

[*]

 

$

[*]

 

$

[*]

 

$

[*]

 

 

C.     Toshiba and SanDisk acknowledge that if a CDP Product incorporates different categories of Technology or Intellectual Property Rights that are subject to different [*], then in each such instance the highest [*] applicable to such CDP Product shall apply as the sole [*], as applicable.  For the avoidance of doubt, the [*] totals in the first column in Table 1 above represent the [*] total of CDP Products sold by Toshiba or SanDisk respectively.  Toshiba and SanDisk further acknowledge that if a Non-CDP Product incorporates different categories of Technology or Intellectual Property Rights that are subject to different [*], then in each such instance the highest [*] applicable to such Non-CDP Product shall apply as the sole [*], as applicable.  For the avoidance of doubt, for purposes of calculating the amounts due for Non-CDP Products, the [*] totals in the first column in Table 1 above represent the [*] total of Non-CDP Products sold by Toshiba or SanDisk respectively (however, the [*] are [*] as per Section 4.2.1(B)).

 

D.     In the event that SanDisk and Toshiba elect [*] or [*] license under Section 4.2.2(A), 4.2.2(C) or 4.2.2(D), then each of them shall pay Intermolecular US$[*] as non-refundable prepaid CDP Product Fees, which shall be paid in [*] equal installment payments of US$[*]over a [*] period, with each such installment payment being due and payable [*] after receipt of invoice (the first invoice of which can be issued upon the [*], the second invoice of which can be issued [*] after such [*] election, and each subsequent invoice of which can be issued [*] thereafter).  Each of SanDisk and Toshiba [*] due and owing by SanDisk or Toshiba to Intermolecular respectively, under any provision of Section 5.4 (including under Table 1 above).  Further, such [*] shall be [*] (i) the [*] (whether SanDisk and Toshiba elect [*] or [*] under Section 4.2.2(A), 4.2.2(C) or 4.2.2(D)) described in Section 5.4.2 below, and (ii) [*] as described in Section 5.4.2 below.

 

5.4.2         If Toshiba and SanDisk elect [*] license under Section 4.2.2(C) or 4.2.2(D), then the CDP Product Fee, [*] and [*] structure for each of Toshiba and SanDisk are set forth in Table 2 below [*].  If the [*] is [*] according to Section 2.1, then the [*] referenced below would reset to the [*] of the [*].

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

17



 

[*]
(Table 2A)

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]CDP Product
Fee [*]

 

US$[*]

 

US$ [*]

 

US$ [*]

 

US$ [*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

US$

[*]

 

US$

[*]

 

US$

[*]

 

US$

[*]

 

 

Provided, that:

 

A.     Toshiba and SanDisk each have a [*] of (i) [*] US Dollars (US$[*]) if Toshiba and SanDisk make an election under Section 4.2.2(C) above; or (ii) [*] US Dollars (US$[*]) if Toshiba and SanDisk make an election under Section 4.2.2(D).

 

B.     SanDisk’s and/or Toshiba’s [*] and [*] displayed in Table 2A and Table 2B above, and the applicable [*] shall be [*] such amounts for that party if Toshiba or SanDisk [*] CDP Products [*] (all additional [*] constituting [*] and [*] shall be referred to as the “[*]”); provided, that such [*] shall be triggered solely and exclusively by the [*] by SanDisk and/or Toshiba as the case may be.

 

C.     Payments for the sale of CDP Products by Affiliates are included in, and not in addition to, the [*] and amounts described in this Section 5.4.2.

 

5.4.3         If Toshiba and SanDisk elect [*] license pursuant to Section 4.2.2(A) above, then the CDP Product Fee set forth in this Section 5.4 will be the rate set forth in Table 1 above.  For [*] license, each of Toshiba and SanDisk shall have a separate [*] of [*] US Dollars (US$[*]).  The [*] shall be [*] for each of Toshiba and SanDisk (i.e., US$[*]) if Toshiba and/or SanDisk, respectively, [*]; provided, that any resulting [*] shall be triggered solely and exclusively by the [*] of [*] Technology by SanDisk and/or Toshiba as the case may be.  Payments for the sale of CDP Products of Affiliates are included in, and are not in addition to, the [*]and amounts described in this Section 5.4.3.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

18


 

5.4.4         [*] and [*] arising from SanDisk’s and/or Toshiba’s exercise of the license outside the CDP Field under Section 4.2.1(B) shall be [*] of the [*] and [*] set forth above.

 

5.4.5         Payments for CDP Product Fee obligations under this Section 5.4 shall be made as follows.  Within [*]  days after [*], SanDisk and Toshiba each shall notify Intermolecular in writing of CDP Product Fee amounts due and payable under this Section 5.4 (taking into account the credit described in subsection 5.4.1(d) above).  Following receipt of such written notification, Intermolecular shall provide SanDisk and Toshiba each with a written invoice matching and identifying such written notification.  SanDisk and Toshiba shall pay Intermolecular the amount stated in such invoice within [*] days from the date of invoice receipt.

 

5.4.6         Nothing in this Agreement, including the payment or nonpayment of royalties and/or fees by Toshiba or SanDisk, shall affect any obligations by or on behalf of Toshiba or SanDisk under their respective existing agreements with third parties and each other.

 

5.5            IP Buy-Out .  If Toshiba and SanDisk make the election to obtain [*] set forth in Section 4.2, then they will have the option (either jointly, or by mutual written agreement, one of them) to pay Intermolecular [*] US Dollars (US$[*]) for the assignment of [*]owned by [*] in the [*] (an “ IP Buy Out ”).  This option may be exercised [*] during the period SanDisk and/or Toshiba [*].  If Toshiba and SanDisk elect the IP Buy-Out, the parties acknowledge and agree that Toshiba and SanDisk shall not [*] under [*], including the [*] of [*] (including [*]), regardless of the change in ownership of [*].  Further, if this election is made, then the option to SanDisk and Toshiba to [*] from [*] to [*] shall [*].

 

5.6            Third Party Royalties .  Each party shall be responsible for all of its own costs of commercializing CDP Products and Non-CDP Products or sub-licensing Intellectual Property Rights, including any payments to Third Parties for work done by such Third Parties or for licenses necessary for the manufacture, sale, or use of CDP Products or Non-CDP Products by a party or its Affiliates or sub-licensees.

 

5.7            Payments . For the payments under Sections 5.1 and 5.2, at the conclusion of each calendar month, the Project Managers for SanDisk and Toshiba shall have up to [*] business days or otherwise mutually agreed upon period of time to review whether Intermolecular performed the work assigned by the Operating Committee in accordance with the Development Plan for such month .  Upon confirmation by SanDisk and Toshiba that such work has been performed (or upon the conclusion of the above-mentioned [*] business day period if neither Project Manager has issued a written notice of non-compliance), Intermolecular will invoice SanDisk and Toshiba.  If neither Project Manager has issued a written notice of non-compliance by the conclusion of such [*] business day period, the applicable work shall be deemed performed for purposes of this Section 5.7.  Disputes, if any, shall be referred to the dispute resolution process.  SanDisk and Toshiba shall pay Intermolecular the amount stated in such invoice within [*] days from the date of invoice receipt.  All payments hereunder shall be made in U.S.  dollars by Toshiba, SanDisk, or one of their U.S.  or Japanese Affiliates and are non-refundable.  All payments due to Intermolecular under this Agreement shall be made by bank wire transfer as follows:

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

19



 

Japan International Wire Transfer

 

U.S. Domestic Wire Transfer

 

 

 

To:  [*]

 

To:  [*]

 

 

 

 

 

Routing & Transit #:

[*]

 

 

 

Swift Code:

[*]

 

Routing & Transit #:

[*]

For credit of:

Intermolecular, Inc.

 

For credit of:

Intermolecular, Inc.

Credit account #:

[*]

 

Credit account #:

[*]

By order of:    [Name of Sender]

 

By order of:    [Name of Sender]

 

or another U.S.  bank account designated by Intermolecular in writing and provided to Toshiba and SanDisk.

 

5.8            Taxes .  The fees and license rates specified in this Agreement are exclusive of any sales, use, excise, value-added or similar taxes, and of any export and import duties, which may be levied upon or collectible by Intermolecular as a result of Intermolecular’s performance of its service activities or the grant of licenses under this Agreement.  Toshiba and SanDisk agree to pay and otherwise be fully responsible for any such taxes and duties.  In the case of Toshiba, Intermolecular shall provide Toshiba with necessary documents duly signed by Intermolecular or issued by U.S.  tax authorities, and otherwise fully cooperate with Toshiba in applying for exemption of withholding income tax under the tax convention between the U.S.  and Japan.  Should application for an exemption of withholding income tax be rejected by Japanese tax authorities in case of Toshiba, or should an applicable similar situation occur in the case of SanDisk, Toshiba and SanDisk shall withhold from amounts otherwise payable to Intermolecular, and pay on Intermolecular’s behalf, withholding taxes that may be required by applicable law to be withheld by Toshiba and SanDisk.  Toshiba and SanDisk, as applicable, shall provide Intermolecular with tax receipts to establish that all such taxes have been paid and are otherwise available to Intermolecular for credit for U.S.  income tax purposes or as otherwise available to Intermolecular.

 

5.9            Records; Inspection .  Toshiba and SanDisk shall keep complete, true and accurate books of account and records on its own behalf and on behalf of the Toshiba and SanDisk Affiliates for the purpose of determining the CDP Product Fee amounts, Non-CDP Product Fee amounts, and any amounts payable by Toshiba or SanDisk as applicable pursuant to Section 5.10, under this Agreement.  Such books and records shall be kept at Toshiba and SanDisk for at least [*] years following the end of the calendar quarter to which they pertain.  Such records will be open for inspection during such [*] year period by an independent auditor who is reasonably acceptable to the parties and agrees to be bound to confidentiality protections of similar scope to those set out in Section 8 hereof, solely for the purpose of verifying statements related to amounts payable hereunder.  Such auditor shall be instructed to report only as to whether there is a discrepancy, and if so, the amount of such discrepancy.  With reasonable prior notice in writing, such inspections may be made no more than once each calendar year

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

20



 

during regular business hours (other than during quarter-end or year-end financial closing periods), to the extent not unreasonably hindering any operations of Toshiba and SanDisk.  Inspections conducted under this Section shall be at the expense of Intermolecular, unless a variation or error producing an increase exceeding [*] percent ([*]%) of the royalties payable for any period covered by the inspection is established and confirmed in the course of any such inspection, whereupon all reasonable and documented costs relating to the inspection for such period and any unpaid amounts that are discovered will be paid promptly by Toshiba and/or SanDisk, as applicable.  Further, if the foregoing inspection indicates a need for a follow-up inspection, Intermolecular will have the right thereafter to conduct additional inspections from time to time within one year (in such case, the scope of the inspection shall be limited to those issues which Intermolecular needs to confirm the implementation of any corrective action therefor).  Each party agrees to hold in confidence pursuant to Section 8 all information concerning payments and associated reports, and all information learned in the course of any audit or inspection, except to the extent necessary for that party to reveal such information in order to enforce its rights under this Agreement or if disclosure is required by law.

 

5.10          Third Party Licensees .

 

5.10.1       Licenses of [*] and [*] to Third Parties .

 

A.     Subject to [*] compliance with the obligations in this Section 5.10.1, [*] shall be [*] authorized party to grant licenses to [*] and [*] to Third Party Licensees. [*] shall have [*] to the [*] to [*].

 

B.     In the event [*] will have the right but not the obligation to request [*] to license [*] and/or [*] to Third Parties.  [*] when so requesting [*] is hereby referred to as the [*] each Third Party requested to be so licensed by the [*]shall be referred to as a [*].

 

i.               Following receipt of a written request from a [*] shall promptly enter into a written license agreement with [*] in form and substance approved in writing by the [*], provided such request is [*] (or with [*] than) Table 1 above and in accordance with the provisions of Section 5.10 (each, a “Third Party Agreement”).  In the event that [*] unable for any reason to enter into and have fully executed such Third Party Agreement within [*] of the initial request from a [*] would allow the [*]to participate in an active role in the negotiations in order to ensure that such negotiations are concluded in a Third Party Agreement consistent with the relevant provisions of this Agreement.  [*] that [*] shall enter into such Third Party Agreement if the terms are [*] the applicable terms of this Agreement (subject to modifications as required under applicable laws and regulations of the relevant jurisdiction(s)).  The following provisions of this Agreement are not applicable to be included in Third Party Agreements:  Sections [*] (other than Sections [*] and [*]),[*] (other than the [*] under Section [*]),[*] (other than [*], Sections [*], and the applicable provisions of Section [*] (other than the applicable provisions of Sections [*].  In addition, for each Third Party Agreement entered into, the

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

21



 

language governing [*] under Section [*] (including but not limited to the [*]expressly set forth in Section [*]) shall apply, except that subject to such [*],[*]shall be [*] U.S.  dollars (US$[*]).

 

ii.              [*] shall have the right but not the obligation upon request by a [*], to enter into a written license agreement with a [*] in the event the [*] are [*] than [*] above.

 

C.     In the event [*], then [*] shall not [*].  For the avoidance of doubt, a designation made under subsection B above shall not be deemed a waiver of the [*]election.

 

D.     In the event [*], each of the provisions of subsection B above shall apply.  In addition, [*]the right but not the obligation [*] the [*]and/or the [*] to Third Parties [*] (each such party, a [*].

 

5.10.2       Licenses which include [*].

 

A.     If [*] and [*]:  (i) which includes [*], (ii) the scope of which primarily covers [*] (or other identified scope(s) specified in the [*] license, if any, taken outside the CDP Field under Section 4.2.1(B)); and (iii) where [*] actually receives a payment from such Third Party Licensee in partial consideration of any licenses thereunder, then [*] has the right, but not the duty or obligation, to license the patents from [*] to such Third Party Licensee, subject to payment of the [*] or [*], as applicable to [*] by [*] (x) [*], or (y) the Third Party Licensee directly under written agreement with [*] (which establishes contractual privity between [*] and such Third Party Licensee).

 

B.     Notwithstanding anything to the contrary in this Agreement, (I) no license grant by [*] entered into prior to the Effective Date shall give rise to any financial obligations on [*] to [*] under this Agreement, and (II) if [*] to grant subsequent to the Effective Date a license with a Third Party wherein a substantial number of the patents and patent applications licensed are in a related field and are not [*], then such license shall not give rise to any financial obligation on [*] to [*] under this Agreement.

 

C.     If [*], and if any [*] is licensed [*] or [*] to a Third Party Licensee that has already been validly licensed as a [*] under Section 5.10.1 (either prior to or subsequent to the licensing of such [*]), then the additional license of such [*] to [*] shall [*] on [*] to [*].

 

D.     If [*] or a [*], any party may license [*] in which it [*] without consent of or [*] to other [*] and

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

22



 

without incurring any obligations to any other party to this Agreement.

 

5.10.3       Payments .

 

A.     For purposes of Section 5.10.1, [*] shall pay to the [*], all revenues received from [*] under all Third Party Agreements (“Third Party 5.10.1 Revenue”), that [*] the [*] set forth above in Table 1 (the “[*]”), subject to the provisions for [*] set forth in Section 5.10.4.  Revenue arising from a Third Party License outside the CDP Field shall be [*] of the fees set forth above in Table 1, subject to the provisions for [*] set forth in Section 5.10.4.  [*] shall have no obligation to make any [*] or [*] to [*] under Section 5.10.1.

 

B.     For purposes of Section 5.10.2, “[*]” means [*] of the amount set forth in Table 1 applicable to CDP Product Fees, and “[*]” means [*] of a [*].  [*] and [*] are each subject to the provisions for [*] set forth in Section 5.10.4, but are not subject to the [*] set forth in Section 5.4.

 

C.     [*] may audit [*] as well as payment records associated with Third Party Agreements using Section 5.9’s procedures above (except that the rights and obligations for [*] and [*] in Section 5.9 are reversed).  Any accounting disputes arising from such audits shall be escalated to senior management of the parties for resolution.

 

5.10.4       [*].

 

Notwithstanding any provisions to the contrary in this Agreement:

 

A.     [*] in the CDP Field under Section 5.10.1 and [*] (or directly by a Third Party Licensee) to [*] under Section 5.10.2, shall be [*]as follows:

 

If aggregate revenue collected [*] by [*] under Section
5.10.1 and 5.10.2 within the CDP Field exceeds:

 

Then, Table 1 Fee Rates used to calculate [*]
by [*] under Section 5.10.1, and [*] CDP
Product Fees payable by [*] (or directly by a
Third Party Licensee) to [*] under Section
5.10.2, shall be [*] as follows:

[*] US dollars (US$[*] )

 

[*]

[*] US dollars (US$[*])

 

[*]

[*] US dollars (US$[*])

 

[*]

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

23



 

B.     For each field licensed out of the CDP Field under Section 4.2.1B above, [*] under Section 5.10.1 in that field and [*] by [*] (or directly by a Third Party Licensee) to [*] under Section 5.10.2 in that field shall be [*] as follows:

 

If aggregate revenue collected [*] by [*] under Section
5.10.1 and 5.10.2 in each field outside the CDP Field
exceeds:

 

Then, Table 1 Fee Rates used to calculate [*]
by [*] in that field under Section 5.10.1, and
[*] (or directly by a Third Party Licensee) to
[*] in that field under Section 5.10.2, shall be
[*] as follows:

[*] US dollars (US$[*])

 

[*]

[*] US dollars (US$[*])

 

[*]

[*] US dollars (US$[*])

 

[*]

 

C.     [*] an affirmative duty to inform [*] in writing when each of the thresholds under this Section 5.10.3 has been reached.  Such [*] shall be [*] based on the [*] (including other [*] or [*] where applicable under this Agreement).

 

5.10.5       Acknowledgement .  In no event shall [*] be required to [*] to any third party under this Agreement.

 

5.10.6       Payment Terms .  [*] shall make payments to a [*] under Section 5.10.1, and [*] shall make payments to [*] under Section 5.10.2 as follows:  Within [*] days after each [*] close, the remitting party shall notify the receiving party in writing of their respective obligations to make payments if any, accompanied by a reporting record adequately supporting such obligation, to the other under this Section 5.10 (taking into account, when [*] the paying party, the credit described in subsection 5.4.1(D) above).  Following receipt of such written notification, the receiving party shall provide the remitting party as the case may be, with a written invoice matching and identifying such written notification.  The remitting party shall pay the receiving party the amount stated in such invoice within [*] days after receipt of such invoice.

 

6.              COVENANTS

 

6.1            Covenant Regarding [*] Obtained by [*].  Subject to the terms and conditions of this Agreement, [*] covenants [*] against [*] and [*] respective subsidiaries, customers and distributors (collectively [*]) any [*] if such [*] is based on [*] obtained by [*], or [*] to which [*] exposed, directly or indirectly, from [*] during the duration of or as a result of the CDP.  In addition, and subject to any pre-existing contractual obligations of [*] (and [*] hereby warrants that there are no such pre-existing contractual obligations of Intermolecular related to the CDP Field), and, except as otherwise required by law or by court or government order, [*] covenants

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

24



 

not to [*] any Third Party to [*] any [*] against the [*] to the extent that such [*] is based on [*] obtained by [*] or [*] to which [*] exposed, directly or indirectly, from [*] during the duration of or as a result of the CDP.  Except as otherwise required by law or by court or by government order, should [*] or [*], against the [*] shall prove that such [*] is not based on and is independent of [*] obtained by [*] or [*] to which [*] exposed, directly or indirectly, from [*] during the duration of or as a result of the CDP.  Notwithstanding the foregoing, [*]  acknowledge and agree that the covenant set forth in this Section 6.1 does not apply to [*], any [*] to [*], or to any material breach of the license grant or confidentiality provisions of this Agreement.

 

6.2            [*] Covenant .

 

6.2.1         For the period of time ending [*] from the date of [*] including regarding the [*] and/or [*] of the [*] (hereinafter “[*]”), and subject to the terms and conditions of this Agreement, [*] by [*] (or [*] before or during the [*]) shall be subject to the limitations set forth hereinafter.  Subject to the terms and conditions of this Agreement, [*] covenants [*] not to [*] against [*] any of [*] by [*] before or during the [*] (or [*] by [*] before or during the [*] [*]), but excluding [*] (and [*] where covenants [*]) that are covered under the below-defined “[*]” regarding [*]; provided, however, that if there is any specific field regarding the [*] that needs to be excluded from the covenant [*] hereunder due to potential breach by [*] of [*] contracts with any third party existing as of the Effective Date of the Agreement, [*] shall schedule such in Exhibit F hereto and such field will be excluded from the covenant [*] hereunder.  Further, [*] not to [*] any [*] to [*] any [*] by [*] (or [*] by [*]), regarding the [*].

 

6.2.2         For the avoidance of doubt, and subject to the [*] set forth in Section [*] of the Agreement, nothing in this Section 6.2 prohibits [*] from [*] in the future under [*] to any Third Party after the Effective Date of the Agreement (collectively with [*] which are [*]  as of the Effective Date and the [*] that [*] may transfer ownership of in accordance with this Section 6.2.2, “[*]”), or prohibits [*] in the future from [*] to [*] of any [*] relating to or resulting from a [*] in the normal course of business for [*] to the extent where [*] such [*] the opportunity to acquire [*] that [*] to such [*] as part of the [*].  If [*] such [*] or [*] in such [*], then [*]  that the covenants [*] under this Section 6.2 shall not apply to such [*] for the [*] and [*] will receive a [*] to such [*]; provided that [*] that [*] will not [*] such Third Party in [*] under the [*]  against the [*].  Notwithstanding the immediately preceding sentences, [*] may be [*] in any [*] as required by being an [*] to a [*] involving the [*] for [*] purposes, solely as required by law and further [*] may be [*], as required by law, provided that [*] commercially reasonable efforts to limit the amount of [*] and/or [*] requested.  Notwithstanding the foregoing[*] and [*]:  (a) that any covenants granted by [*] regarding the [*] or [*] of [*] pursuant to this Section 6.2 apply only to [*] by [*] and [*] or [*] of by [*] or [*]; and (b) that the covenants do not apply to [*], any [*] to [*], or to any [*] or [*] of this Agreement.  [*] that the foregoing covenant shall not apply to any [*] resulting from the [*] or [*] of [*], or any [*].  Notwithstanding anything above, if [*], then the [*] shall solely in such case mean the period of time terminating [*] from the date of such election.  Further, if [*] or [*] as [*] as provided in Section [*], this covenant [*] shall not apply to [*] listed in Section [*] nor to such [*] not included in [*] as provided in Section [*], as applicable.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

25



 

6.3            Enforcement .  If [*] any claim against the [*] in violation of Sections 6.1 or 6.2 above, then [*] may seek injunctive relief to stop or enjoin [*] from undertaking such activities in addition to any and all remedies available at law and the [*] shall be fully reimbursed by [*] for their reasonable expenses and direct damages arising from such assertion.  [*] may [*] such expenses and damages [*] to be paid to [*].

 

6.4            Assignment .  Subject to the terms and conditions of this Agreement, the covenant in Section 6.1 shall be binding on any successors-in-interest, assigns, mergers, reorganizations, or any other change of control of [*], but only as to [*] obtained by [*] or knowledge to which [*] exposed, directly or indirectly, from [*] during the duration of or as a result of the CDP.  In addition, subject to the terms and conditions of this Agreement, the covenant in Section [*] shall be binding on any successors-in-interest, assigns, mergers, reorganizations, or any other change of control of [*], but only as applicable to the [*] owned by [*] on the day immediately prior to such change of control and not to any other [*] owned by the successor in interest or assignee.

 

6.5            Patent Sales .  Subject to the terms and conditions of this Agreement, if [*] or otherwise [*] or [*] any [*] or [*] under any of the [*] covered by the covenant [*] in Section [*] above (“[*]” or “[*]” as the case may be), unless such rights are specifically excluded therein, at any time during the period of time that such [*] would have been subject to the covenant set forth in Section [*] above but for such [*], to any Third Party [*] of [*], then [*]:  (i) retroactively [*], as of immediately prior to such [*], a [*] with respect to any [*] of by [*] prior to such [*]; and (ii) shall make such [*] subject to the covenant set forth in Section [*] above.

 

6.6            Application to Affiliates .  For purposes of this Section 6, Intermolecular shall mean Intermolecular and/or its Affiliates as appropriate.  Toshiba shall mean Toshiba Corporation and/or its Affiliates as appropriate.  SanDisk shall mean SanDisk Corporation and/or its Affiliates as appropriate.

 

6.7            Termination of Covenants .  If, at any time before [*] assertion of claims of [*] subject to covenants set forth in this Section 6 against a particular Protected Entity, such particular Protected Entity asserts claims of [*] against [*], or seek to [*] of [*] other than enforcement of or disagreement concerning the [*] provisions set forth in this agreement [*], the covenants set forth in this Section 6 shall immediately terminate with respect to such particular Protected Entity.  In addition, in the event of a change of control, merger, acquisition or sale of all or substantially all of the assets of [*], or of the sale of an Affiliate, subsidiary or product line of [*] the covenants granted in this Section 6 shall apply only to the products, processes, Technologies or services of [*], as of the date of such change of control, and shall not apply to any of the products, processes, Technologies, or services of the acquiring entity.

 

7.              WARRANT

 

7.1            Warrant .

 

7.1.1         Upon execution of the Agreement, Intermolecular will issue to each of Toshiba and SanDisk a warrant (each a “ Warrant ” and together the “ Warrants ”) to purchase a number of shares equal to the Warrant Amount (as defined below).  Each Warrant shall have an

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

26



 

exercise price of $3.04144 per share (the “ Exercise Price ”) and be exercisable only during the Exercise Period (as defined below).  Each of Toshiba and SanDisk must deliver an election notice of its intention to exercise the Warrant and the number of shares of Intermolecular common stock it wishes to purchase pursuant to the Warrant (an “ Election Notice ”) not later than the expiration of the Exercise Period.  The closing of the issuance of the shares to be issued pursuant to the Warrants shall occur not more than 30 days after the expiration of the Exercise Period.  At the closing Intermolecular shall at its sole expense issue all necessary and appropriate documents evidencing the issuance of the Shares.  Intermolecular represents that the Exercise Price is the lowest price at which shares were purchased by investors in Intermolecular’s Series D financing round in December 2008.  Intermolecular agrees to provide SanDisk and Toshiba upon request at the time of the License Election an investor information packet containing information which is no less than the information provided by Intermolecular or on Intermolecular’s behalf to investors in any investment round preceding the conclusion of the Exercise Period to purchasers of common stock and, in addition, shall also include a written summary of (i) the then-current capitalization table stating shares by class (including shares reserved for issuance under outstanding instruments (e.g., options, other convertible securities)) and (ii) the then-total dollar amount of outstanding liquidation preferences.

 

7.1.2         Exercise Date ” shall mean the date SanDisk and/or Toshiba makes an effective election under Section 4.2.2(A), Section 4.2.2(C) or Section 4.2.2(D) (a “ License Election ”).

 

7.1.3         The “ Exercise Period ” shall be a period from and after the Exercise Date and ending upon the date one hundred and twenty (120) days from the end of the CDP.

 

7.1.4         The “ Warrant Amount ” with respect to each Warrant shall be an amount equal to (1) 1,644,736 less (2) the number of shares of Common Stock elected to be purchased in the Notice of Exercise with respect to the other Warrant being issued on the date hereof; provided, however, that (a) if both Toshiba and SanDisk elect to purchase more than 822,368 shares of Common Stock, then the Warrant Amount shall be an amount equal to 822,368; and (b) if either Toshiba or San Disk elects to purchase less than 822,368 shares then the Warrant Amount, in which case such lesser amount shall be the Warrant Amount for such party and the other party shall have the right but not the obligation to purchase the balance up to an aggregate of 1,644,736 shares.  In no event shall the aggregate Warrant Amount purchasable by SanDisk and Toshiba collectively hereunder exceed 1,644,736.

 

7.1.5         The form of warrant is attached hereto as Exhibit G.

 

8.              CONFIDENTIALITY

 

8.1            Confidentiality .  Except as otherwise expressly provided in this Agreement, the parties agree that each receiving party of another party’s Confidential Information shall not, except as expressly provided in this Section 8, disclose to any Third Party, or use for any purpose, any such Confidential Information furnished to it by a disclosing party pursuant to this Agreement, except in each case to the extent that it can be established by the receiving party by competent proof that such information:

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

27


 

(a)            was already known to the receiving party, other than under an obligation of confidentiality, at the time of disclosure;

 

(b)            was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving party;

 

(c)            became generally available to the public or otherwise part of the public domain after disclosure and other than through any act or omission of the receiving party in breach of this agreement;

 

(d)            was independently developed by the receiving party without use of, or reference to, the other party’s confidential information, as demonstrated by documented evidence prepared contemporaneously with such independent development; or

 

(e)            was disclosed to the receiving party, other than under an obligation of confidentiality, by a Third Party authorized and entitled to disclose such information to others.

 

8.2            Permitted Use and Disclosures .  Notwithstanding the restrictions of Section 8.1, each party hereto may (a) use Confidential Information disclosed to it by another party to the extent necessary for that party to perform its obligations or undertake the activities set forth in the Development Plan and (b) use or disclose Confidential Information disclosed to it by such other party to the extent such use or disclosure is reasonably necessary in (i) exercising the rights and licenses granted hereunder, (ii) prosecuting or defending litigation, (iii) complying with applicable laws, governmental regulations or court orders or submitting information to tax or other governmental authorities (including the Securities and Exchange Commission), or (iv) preparing, filing and prosecuting patent applications; in each case, provided that if a party is required to make any such disclosure, other than pursuant to a confidentiality agreement, it will give reasonable advance notice to the disclosing party of such disclosure and will use reasonable efforts to secure confidential treatment of such information (whether through protective order or otherwise), except to the extent inappropriate with respect to patent applications.  It is understood that any party may also disclose the Confidential Information of a disclosing party upon receipt of the written consent to such disclosure by a duly authorized representative of the disclosing party.  For purposes of this Section 8, SanDisk and Toshiba may (subject to the limitations of use applicable to employees of SanDisk, Toshiba or their Affiliates) use third party contractors retained by SanDisk, Toshiba or their Affiliates as applicable, that have entered into appropriate non-disclosure agreements with SanDisk, Toshiba or their Affiliates, as applicable, and with Intermolecular where such third party contractors have direct access to the CDP or have been provided to the Intermolecular Confidential Information.  SanDisk and Toshiba shall be responsible for their respective breaches of this Section 8 by such third party contractors to the same extent as for SanDisk, Toshiba and their Affiliates respective employees.

 

8.3            Nondisclosure of Terms .  Each of the parties hereto agrees not to disclose the terms of this Agreement to any Third Party without the prior written consent of the other party hereto, except to such party’s attorneys, accountants, advisors, investors and financing sources and their advisors and others on a need to know basis under circumstances that reasonably ensure the confidentiality thereof, to the extent required by law, in connection with the enforcement of

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

28



 

this Agreement or rights under this Agreement or in connection with a merger, acquisition, financing transaction or proposed merger, acquisition or financing transaction.

 

9.              LIMITED REPRESENTATIONS AND WARRANTIES AND INDEMNIFICATION

 

9.1            By Intermolecular .  Intermolecular represents and warrants that:  (a) it has the right and authority to enter into this Agreement, and to fully perform its obligations hereunder; (b) this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms; (c) Intermolecular owns, or possesses a valid and enforceable license to use, and has full power and authority to license or sublicense, as the case may be, all Intermolecular’s Intellectual Property Rights licensed or sublicensed to Toshiba and SanDisk pursuant to this Agreement; (d) Intermolecular’s compliance with its obligations under this Agreement will not violate third party agreements nor give rise to financial obligations on the part of Toshiba, Toshiba Affiliates, SanDisk or SanDisk Affiliates under any Third Party agreements; and (e) it will perform the services contemplated by this Agreement in a professional and workmanlike manner and in accordance with relevant industry standards applicable to the services.

 

9.2            By Toshiba and SanDisk .  Toshiba and SanDisk each individually represent and warrant that:  (a) it has the right and authority to enter into this Agreement, and to fully perform its obligations hereunder; (b) this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms; and (c) each owns, or possesses a valid and enforceable license to use, and has full power and authority to license or sublicense, as the case may be, all Intellectual Property Rights which are or may be licensed to Intermolecular under this Agreement.

 

9.3            Disclaimer .  Toshiba and SanDisk each acknowledge that the CDP is by its nature a technology development project and there is no guarantee that the project will be successful, in whole or in part or will meet Toshiba’s or SanDisk’s anticipated needs.  Each party further acknowledges that the failure of the parties to successfully develop and commercialize [*] Technology, CDP Products or Non-CDP Products as the result of the CDP shall not constitute a breach of any representation or warranty or other obligation under this Agreement.  EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, TOSHIBA, SANDISK, AND INTERMOLECULAR MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, AND EXPRESSLY DISCLAIM ALL OTHER REPRESENTATIONS, WARRANTIES AND CONDITIONS, WHETHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO BACKGROUND IP, FOREGROUND IP, HPC TECHNOLOGY OR ANY INFORMATION OR TECHNOLOGY DISCLOSED OR PROVIDED UNDER THIS AGREEMENT, INCLUDING ANY DELIVERABLES PROVIDED HEREUNDER.  WITHOUT LIMITING THE FOREGOING, EACH PARTY HEREBY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF TITLE, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE, OR VALIDITY OF ANY BACKGROUND IP, FOREGROUND IP, OR HPC TECHNOLOGY, PATENTED OR UNPATENTED, OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

29



 

9.4            Indemnification .  Intermolecular shall indemnify, defend and hold harmless Toshiba, Toshiba Affiliates, SanDisk and SanDisk Affiliates against any Third Party suits, actions, claims or proceedings alleging that (a) the HPC Technology, HPC Derivatives, or any Licensed IP provided or licensed by Intermolecular under this Agreement infringes or misappropriates such Third Party’s Intellectual Property Rights and/or (b) Intermolecular has caused property damage to a Toshiba or SanDisk facility, and Intermolecular agrees to reimburse Toshiba, Toshiba Affiliates, SanDisk and SanDisk Affiliates for all damages, liabilities, costs and expenses, including reasonable attorneys’ fees, finally awarded against Toshiba, Toshiba Affiliates, SanDisk and SanDisk Affiliates by a court of competent jurisdiction that may result from any such Third Party claim or property damage or any settlement amount, as applicable; provided that (i) SanDisk and/or Toshiba (as applicable) notifies Intermolecular promptly in writing of the claim; and (ii) SanDisk and/or Toshiba (as applicable) assist and cooperates reasonably with Intermolecular, at Intermolecular’s expense, in defending and settling such claim.  Intermolecular shall have sole control of the defense and all related potential settlement negotiations, provided that Intermolecular shall not enter into any settlement which would adversely affect Toshiba, Toshiba Affiliates, SanDisk or SanDisk Affiliates without such party’s prior written consent.  In addition, each of SanDisk and Toshiba shall be entitled to be represented by its own respective counsel at its own respective expense.  Intermolecular shall maintain appropriate insurance to permit Intermolecular to reasonably carry out its indemnity obligations under this Agreement.

 

10.           LIMITATION OF LIABILITY

 

10.1          Intermolecular .

 

TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, EXCEPT FOR INTERMOLECULAR’S OBLIGATIONS UNDER SECTIONS 6 AND 9.4 OF THIS AGREEMENT, A BREACH BY INTERMOLECULAR OF ITS CONFIDENTIALITY OBLIGATIONS UNDER SECTION 8, OR A BREACH OF ANY LICENSE RESTRICTIONS APPLICABLE TO INTERMOLECULAR:  (I) UNDER NO CIRCUMSTANCES WILL INTERMOLECULAR BE LIABLE TO ANY PARTY UNDER ANY LEGAL OR EQUITABLE THEORY, INCLUDING UNDER CONTRACT, STRICT LIABILITY OR OTHERWISE, FOR ANY LOST PROFITS, LOST DATA, LOST BUSINESS OPPORTUNITY, INJURY TO BUSINESS REPUTATION OR EQUIPMENT DOWNTIME, OR FOR ANY CONSEQUENTIAL, PUNITIVE INCIDENTAL, INDIRECT OR SPECIAL DAMAGES OF ANY KIND IN CONNECTION WITH THE SUBJECT MATTER OF THIS AGREEMENT, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND (II) IN NO EVENT WILL INTERMOLECULAR’S AGGREGATE LIABILITY TO ANY PARTY EXCEED THE GREATER OF (A) US$[*], AND (B) CUMULATIVE AMOUNTS PAID OR PAYABLE BY TOSHIBA AND SANDISK (OR BY THIRD PARTIES BASED ON LICENSES MADE PURSUANT TO THIS AGREEMENT) TO INTERMOLECULAR IN THE [*] MONTHS PRECEDING THE CLAIM.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

30



 

10.2          SanDisk and Toshiba .

 

TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, EXCEPT FOR A BREACH BY SANDISK OR TOSHIBA OF THEIR RESPECTIVE CONFIDENTIALITY OBLIGATIONS UNDER SECTION 8, OR A BREACH OF ANY LICENSE RESTRICTIONS:  (I) UNDER NO CIRCUMSTANCES WILL SANDISK AND/OR TOSHIBA BE LIABLE TO ANY PARTY UNDER ANY LEGAL OR EQUITABLE THEORY, INCLUDING UNDER CONTRACT, STRICT LIABILITY OR OTHERWISE, FOR ANY LOST PROFITS, LOST DATA, LOST BUSINESS OPPORTUNITY, INJURY TO BUSINESS REPUTATION OR EQUIPMENT DOWNTIME, OR FOR ANY CONSEQUENTIAL, PUNITIVE, INCIDENTAL, INDIRECT OR SPECIAL DAMAGES OF ANY KIND IN CONNECTION WITH THE SUBJECT MATTER OF THIS AGREEMENT, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND (II) IN NO EVENT WILL SANDISK’S OR TOSHIBA’S AGGREGATE LIABILITY TO ANY PARTY EXCEED THE AMOUNTS DUE AND PAYABLE BY SANDISK AND TOSHIBA TO INTERMOLECULAR.

 

10.3          Basis of Agreement .  EACH PARTY ACKNOWLEDGES AND AGREES THAT THE FOREGOING LIMITATIONS OF LIABILITY ARE AN ESSENTIAL ELEMENT OF THE BASIS OF THE BARGAIN AMONG THE PARTIES AND THAT IN THE ABSENCE OF SUCH LIMITATIONS, THE ECONOMIC AND OTHER TERMS OF THIS AGREEMENT WOULD BE SUBSTANTIALLY DIFFERENT.

 

11.           TERM; TERMINATION

 

11.1          Term of Agreement .  The Agreement, unless terminated or canceled as provided in this Section 11, shall remain in full force and effect for the full Initial Term, and may be extended for up to two (2) additional one (1) year periods by Toshiba and SanDisk providing notice to Intermolecular of their intention to renew the Agreement providing thirty (30) days advance written notice to Intermolecular before the expiration of the Initial Term or any extension thereof.  SanDisk and Toshiba shall receive at least as favorable commercial terms from Intermolecular if they elect to extend the Term beyond the Initial Term, as those commercial terms governing the Initial Term.  If SanDisk and/or Toshiba request to extend the Term for less than one (1) year and/or wish to have lower rates in return for extending the Term, the parties shall discuss and work together in good faith to agree to such request (Intermolecular shall not unreasonably withhold agreement to a request to extend the duration of the Term).

 

11.2          Termination for Convenience .  Either Toshiba or SanDisk may terminate this Agreement for convenience without penalties of any kind, in the event of an acquisition, merger, assignment, reorganization or other change of control of Intermolecular, by providing [*] days advance written notice to Intermolecular.  “Change of control” under this Section 11.2 excludes (a) an IPO by Intermolecular, and (b) the acquisition of Intermolecular by either a financial entity, a semiconductor equipment manufacturer or a semiconductor materials manufacturer, provided that any of these entities referred to in this (b) are not affiliated with an entity that designs and/or manufactures semiconductor integrated circuits, and that any party in (b) within [*] days notifies and confirms in writing to SanDisk and Toshiba that such party shall assume all of Intermolecular’s obligations under this Agreement and SanDisk and Toshiba shall have the right to terminate this Agreement unless such party meets requirements in (b).

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

31



 

11.3          Termination for Breach .  Either Toshiba or SanDisk may terminate this Agreement in the event that Intermolecular has materially breached or defaulted in the performance of any of its material obligations hereunder, and such default has continued for [*]days after written notice thereof was provided to Intermolecular by a non-breaching party; or in the event of insolvency or bankruptcy.  Intermolecular may terminate this Agreement in the event that either Toshiba or SanDisk has materially breached or defaulted in the performance of its material obligations hereunder, and such default has continued for [*]days after written notice thereof was provided to the breaching party by Intermolecular.  Any termination shall become effective at the end of such [*]day period unless the breaching party (or any other party on its behalf) has cured any such breach or default prior to the expiration of the [*] day period.

 

11.4          Effect of Termination .

 

11.4.1       Accrued Rights and Obligations .  Termination of this Agreement for any reason shall not release any party hereto from any liability or obligation that, at the time of such termination, has already accrued to the other parties or that is attributable to a period prior to such termination, nor shall it preclude any party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement.

 

11.4.2       Return of Confidential Information .  Upon any termination of this Agreement, Toshiba, SanDisk and Intermolecular, as applicable, shall promptly destroy or return to the other all Confidential Information received from any other party other than as required to enforce or defend any continuing or surviving rights and pursuant to this Agreement obligations under this Agreement.

 

11.5          Survival .  If this Agreement terminates for any reason or expires, then Sections [*] and [*] of this Agreement shall survive such termination or expiration.

 

12.           MISCELLANEOUS

 

12.1          Governing Laws and Dispute Resolution .  This Agreement shall be governed by and construed in accordance with the laws of the state of California in the United States, without regard to its choice of law rules.  All disputes between the parties in connection with or arising out of this Agreement shall first be discussed in good faith between the parties in order to try to find an amicable solution.  If no solution can be found to settle the dispute, then such dispute shall be finally settled by arbitration in accordance with the default rules and procedures of American Arbitration Association sitting in Hawaii and conducted in English.  Within [*] days of notice that a party wants to submit a dispute to arbitration, the parties will attempt to mutually agree upon an independent arbitrator with expertise in the semiconductor industry.  If the parties are unable to agree on an independent arbitrator within [*] days, AAA will select an arbitrator within [*] days.  The arbitrator shall determine what discovery will be permitted consistent with the goal of limiting the costs and time for such a proceeding.  The parties and arbitrator shall use all reasonable efforts to complete any arbitration subject to this Section 12.1 within [*] from the selection of the arbitrator.  The parties agree that any award of damages shall not include punitive, special, consequential, or indirect damages except as specifically allowed in this Agreement and shall comply with the limitation of liability provisions set forth herein.  The

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

32



 

arbitrator’s decision shall be in a detailed writing setting forth the reasons for their decision and shall be provided concurrently to each party.  The arbitration award shall be final and binding on the parties.  Unless otherwise agreed to by the parties, each party shall pay one-third of the arbitration fees and expenses and shall bear all of its own expenses in connection with the arbitration.  Notwithstanding any of the foregoing, any party shall have the right to seek, at its own cost and expenses, preliminary and temporary injunctive relief pending resolution of the dispute via arbitration.  The parties expressly disclaim the application of the United Nations Convention on the International Sale of Goods to this Agreement.

 

12.2          Assignment .  No party may assign or transfer this Agreement either voluntarily or by operation of law, in whole or in part, without the prior written consent of the other parties, such consent not to be unreasonably conditioned, delayed or withheld, and any attempt to do so will be null and void.  Notwithstanding the foregoing, any party may assign this Agreement without such consent to a parent, subsidiary, or Affiliate, or assign this Agreement without consent to a successor in interest to its business (whether by merger, acquisition, consolidation, change of control, reorganization or sale of substantially all of its assets), provided that if Intermolecular assigns this Agreement to a successor in interest, such successor in interest within [*] days notifies and confirms in writing to SanDisk and Toshiba that such successor in interest shall assume all of Intermolecular’s obligations under this Agreement and SanDisk and Toshiba shall have the right to defer any payment under this Agreement until SanDisk and Toshiba have confirmed, in writing, such purported assignment.  The parties acknowledge and agree that if this Agreement is assigned by Toshiba or SanDisk to a successor in interest as a result of a merger, acquisition, consolidation, change of control, reorganization or sale of substantially all of their assets, then (a) the caps set forth in Section 5.4.2 shall terminate and the Fees payable shall be uncapped thereafter; and (b) the covenants set forth in Section [*] shall not apply to the successor in interest or to any products or services of such successor in interest other than the specific, then-current version of the CDP Products and Non-CDP Products in commercial production at the closing of the transaction resulting in the change of control.  The parties further acknowledge and agree that if this Agreement is assigned by Intermolecular to a successor in interest as a result of a merger, acquisition, consolidation, change of control, reorganization or sale of substantially all of its assets, then the covenants set forth in Section [*]shall not apply to [*]independently owned or controlled by the successor in interest on the date immediately prior to the closing of the transaction resulting in the change of control, nor shall the covenants set forth in Section [*] apply to any [*]created or acquired by such successor in interest after the closing of the transaction resulting in the change of control unless the identity of the former Intermolecular as a functional unit remains identifiable in which case the covenants shall continue to apply but only as to [*]created by the said identifiable functional unit during the [*].  Notwithstanding the foregoing, the covenants set forth in Section [*] still apply to any [*] filed by such successor and claiming priority to any earlier [*]obtained or developed by [*]before or during the [*].  Subject to the foregoing provisions, this Agreement will be binding on and inure to the benefit of the parties and their respective successors and permitted assigns.

 

12.3          Drafting .  In interpreting and applying the terms and provisions of this Agreement, the parties agree that no presumption shall exist or be implied against the party that drafted such terms and provisions.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

33



 

12.4          Waiver .  It is agreed that no waiver by any party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed a waiver or an expectation of non-enforcement as to any subsequent and/or similar breach or default.

 

12.5          Non-Solicitation .  During the Initial Term of this Agreement no party may individually, or in concert with or through any other person, actively recruit or solicit employment of any scientific or technical personnel of any other party.  The foregoing restriction shall not apply to, or be breached by:  (i) advertising open positions, participating in job fairs, and conducting comparable activities to recruit skilled or unskilled help from the general public, or responding to individuals contacted through such methods, (ii) responding to unsolicited inquiries about employment opportunities or possibilities from job placement agencies or other agents acting for unidentified principals, or (iii) responding to unsolicited inquiries about employment opportunities from any individual.

 

12.6          Severability .  In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect to the fullest extent permitted by law without said provision, and the parties shall amend the Agreement to the extent feasible to lawfully include the substance of the excluded term to as fully as possible realize the intent of the parties and their commercial bargain.

 

12.7          Independent Contractors .  The relationship of the parties hereto is that of independent contractors.  Each party shall not be deemed to be an agent, partner, joint venture or legal representative of the other for any purpose as a result of this Agreement or the transactions contemplated thereby.

 

12.8          Press Releases or Public Statements .  No Party shall issue any press release, publicity statement, communication with stockholders, public notice or other public disclosure relating directly to this Agreement or the transactions contemplated hereby without prior notice to, consultation with and the prior written consent of the other parties.

 

12.9          Compliance with Law .  In exercising their rights and undertaking their obligations under the Agreement, each party shall fully comply in all material respects with the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this Agreement.  Without limiting the foregoing, each party agrees to comply with all applicable export and re-export control laws and regulations maintained by the United States or Japanese governments.

 

12.10        Notices .  All notices, requests and other communications hereunder shall be in writing and shall be hand delivered, or sent by express delivery service with confirmation of receipt, or sent by registered or certified mail, return receipt requested, postage prepaid, or by electronic transmission (with written confirmation copy by registered first-class mail), in each case to the attention of the chief legal officer at the respective address indicated above.  Any such notice shall be deemed to have been given when received.  Any party may change its address by giving the other party written notice, delivered in accordance with this Section.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

34



 

12.11        Force Majeure .  No party shall lose any rights hereunder or be liable to any other party for damages or losses (except for payment obligations then owing) on account of failure of performance by the defaulting party if the failure is occasioned by war, strike, fire, earthquake, flood, lockout, embargo, act of terrorism, governmental acts, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence, intentional conduct or misconduct of the non-performing party and such party has exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a party be required to settle any labor dispute or disturbance.

 

12.12        Headings; Construction .  The captions to the several Sections hereof are not part of this Agreement, but are included merely for convenience of reference and shall not affect its meaning or interpretation.  As used in this Agreement, the word “including” means “including without limitation.”

 

12.13        Counterparts .  This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.

 

12.14        Complete Agreement .  This Agreement, together with its Exhibits and their attachments, constitutes the entire agreement, both written and oral, among the parties with respect to the subject matter hereof, and all prior agreements respecting the subject matter hereof, either written or oral, express or implied, shall be superseded by this Agreement.  Without limitation to the foregoing, except as provided in Section 4.2.2(B), the 2006 Agreement is hereby superseded and replaced by this Agreement, except for Intermolecular’s and SanDisk’s surviving confidentiality obligations set forth in the 2006 Agreement.  If there is any conflict between the confidentiality provisions in this Agreement and in the 2006 Agreement, the confidentiality provisions in this Agreement shall control.  No amendment or change hereof or addition hereto shall be effective or binding on either of the parties hereto unless reduced to writing and executed by the respective duly authorized representatives of Toshiba, SanDisk and Intermolecular.  The parties further agree that any additional or inconsistent terms and conditions of any purchase order, invoice or like document issued in connection with this Agreement shall be superseded in full by the terms and conditions of this Agreement and any Exhibit hereunder, and any such additional or inconsistent terms, unless specifically agreed to in writing by the parties at the time, are hereby rejected.

 

12.15        Third Party Beneficiaries .  Except as expressly provided in this Agreement, there are no Third Party beneficiaries expressly or impliedly intended under this Agreement.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

35



 

In Witness Whereof, the parties hereto have executed this document as the Effective Date above, or if no date is set forth, the last date set forth below.

 

Toshiba Corporation

 

SanDisk Corporation

 

 

 

 

 

 

 

 

By:

/s/ Hiroto Nakai

 

By:

/s/ Ben Tessone

Name:

Hiroto Nakai

 

Name:

Ben Tessone

Title:

SM, Flash Business Strategy Development

 

Title:

VP, Worldwide Procurement

 

 

 

 

 

 

Intermolecular, Inc.

 

 

 

 

 

 

 

 

 

By:

/s/ David Lazovsky

 

 

Name:

David Lazovsky

 

 

Title:

President & CEO

 

 

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

36



 

Exhibit A—[*]IP (Non-Exhaustive List of Patents as of Effective Date)
Exhibit B—Development Plan
Exhibit C—IM [*]Developed Technology
Exhibit D—Original CDP Developed Technology
Exhibit E—Workflow Infrastructure
Exhibit F—Exclusions from Section 6.2
Exhibit G—Form of Warrant
Exhibit H—Intermolecular Background IP for the CDP

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

37


 

EXHIBIT A

 

CATEGORY ONE IP

 

(Non-Exhaustive List of Patents as of Effective Date)

 

[Intermolecular to provide non-confidential summary to SanDisk and Toshiba prior to
Effective Date, and final version to be provided immediately after Effective Date]

 

Non-confidential summary:

 

US Applications:

 

#

 

Title

 

Short Description

 

App. No.

 

IM Ref. No.

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

PCT Applications:

 

#

 

Title

 

Short Description

 

Application
Number

 

IM Ref. No.

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

Foreign Applications:

 

#

 

Title

 

Short Description

 

Country

 

Application
Number

 

IM Ref. No.

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

Intermolecular Confidential

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

EXHIBIT B

 

DEVELOPMENT PLAN - PHASE I

 

(Version [*])

 

[*]

 

Common criteria for all [*]:

 

[*]

 

[*]

 

Stage

 

Task

 

Goal

 

Timeline

 

Metric/Output

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

Intermolecular Confidential

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

Intermolecular Confidential

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

EXHIBIT C

 

IM [*] Developed Technology

 

US Applications:

 

#

 

Title

 

Short Description

 

App. No.

 

IM Ref. No.

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

Intermolecular Confidential

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

EXHIBIT D

 

Original CDP Developed Technology

 

[*] (“[*]”) and

[*] (“[*]”) DOCUMENTATION

 

[*]

 

Exhibit A—[*]

 

Exhibit B—[*] Pivot Table

 

Exhibit C—Invention Disclosures

 

Intermolecular Confidential

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 


 

EXHIBIT A (1 OF 2)

 

 [*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

[*]

[*]

 

Intermolecular Confidential

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

EXHIBIT A (2 OF 2)

 

BKM Condition

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

[*]

[*]

 

Intermolecular Confidential

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

[*]

[*]

 

Intermolecular Confidential

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 


 

Exhibit B — [*] Pivot Table

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

Exhibit B - TFS Pivot Table

 

[*]

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Confidential

 



 

Exhibit B - TFS Pivot Table

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Confidential

 



 

Exhibit B - TFS Pivot Table

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Confidential

 


 

EXHIBIT C—Invention Disclosures

 

Docket
#

 

Title

 

Short Description

 

Exemplary Claim

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

Intermolecular and SanDisk

Confidential Information

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

Exhibit C-1

 

FILE NO. [*]

 

INTERMOLECULAR, INC. - CONFIDENTIAL

 

INTERMOLECULAR, INC.
INVENTION DOCUMENTATION FORM

 

1. [*]

 

2. [*]

3. [*]

 

4. [*]

 

4(a) [*]

4(b) [*]

 

4(c) [*]

 

5. [*]

 

5(a) [*]

5(b) [*]

 

6.

 

7. [*]

 

7(a) [*]

7(b) [*]

 

8.

 

Contains Intermolecular Confidential and

Attorney Client Privileged Information

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

1



 

FILE NO. [*]

 

INTERMOLECULAR, INC. -CONFIDENTIAL

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

Contains Intermolecular Confidential and

Attorney Client Privileged Information

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2



 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

[*]

 

[*].

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

 

 

[*]

 

 

 

 

 

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 


 

INTERMOLECULAR, INC.
INVENTION DOCUMENTATION FORM

 

1. [*]

 

2. [*]

3. [*]

 

4. [*]

 

4(a) [*]

4(b) [*]

 

4(c) [*]

 

5. [*]

 

5(a) [*]

5(b) [*]

 

6.

 

7. [*]

 

7(a) [*]

7(b) [*]

 

8.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

Exhibit C-3

 

FILE NO. [*]

 

INTERMOLECULAR, INC. — CONFIDENTIAL

 

INTERMOLECULAR, INC.
INVENTION DOCUMENTATION FORM

 

1. [*]

 

2. [*]

3. [*]

 

4. [*]

 

4(a) [*]

4(b) [*]

 

4(c) [*]

 

5. [*]

 

5(a) [*]

5(b) [*]

 

6.

 

7. [*]

 

7(a) [*]

7(b) [*]

 

8.

 

Contains Intermolecular Confidential and
Attorney Client Privileged Information

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

1



 

FILE NO. [*]

 

INTERMOLECULAR, INC. — CONFIDENTIAL

 

[*]

 

[*]

 

Contains Intermolecular Confidential and
Attorney Client Privileged Information

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2



 

 

 

 

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

3


 

 

 

 

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

4



 

 

 

 

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

5



 

 

 

 

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

6



 

 

 

 

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

7



 

 

 

 

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

8



 

 

 

 

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

9



 

 

 

 

 

Exhibit C-4

 

Lead Inventor:

 

[*]

 

Supervisor:

 

[*]

Docket No.:

 

[*]

 

 

 

 

TITLE OF INVENTION:

 

[*]

 

 

 

 

 

Problem Addressed by Invention:

[*]

 

Previous Approaches to Solving Problem:

[*]

 

Brief Description of Invention:  (Attach all relevant drawings, specs, flowcharts, design review or notebook entries)

[*]

 

Enabling and Best Mode disclosure:

[*]

 

 

[*]

 

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

10



 

 

 

 

 

[*]

 

 

[*]

 

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

11



 

 

 

 

 

Alternative structures/steps:

 

 

Key Words:

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

12


 

 

 

EXHIBIT E

 

Workflow Infrastructure

 

Dedicated
Equipment

 

Description

 

[*]

 

[*]

 

 

Other
Equipment

 

Description

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

Physical Metrology & E-Test Tools

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

13



 

 

 

EXHIBIT F

 

Exclusions from Section 6.2

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

14



 

 

 

EXHIBIT G

 

Form of Warrant

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

15



 

 

 

EXHIBIT H

 

Exhibit H as of May 10, 2010

 

Items
#

 

Docket
#

 

Title

 

Serial No.

 

Filing Date

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

[*]

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

16




Exhibit 10.4

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

ALLIANCE AGREEMENT
ADVANCED TECHNOLOGY MATERIALS, INC. AND INTERMOLECULAR, INC.

 

This ALLIANCE AGREEMENT (the “ Agreement ”), effective as of November 17, 2006 (the “ Effective Date ”), is made by and between Advanced Technology Materials, Inc. , with a principal place of business at 7 Commerce Drive, Danbury, CT 06810 (“ ATMI ”), and Intermolecular, Inc. , with a principal place of business at 2865 Zanker Road, San Jose, California 95134 (“ IM ”).  ATMI and IM are sometimes referred to herein individually as a “party” and collectively as the “parties.”

 

BACKGROUND

 

A.                                    ATMI is developing and commercializing semiconductor materials products and technologies, and possesses certain novel, proprietary materials, processes and technologies, in the Field (as defined below);

 

B.                                      IM possesses certain novel, proprietary materials, methods, processes, and technologies for the combinatorial preparation and screening of novel materials, novel process integration, and novel device integration;

 

C.                                      IM and ATMI desire to enter into a definitive agreement to collaborate on the application and commercialization of certain products, methods, technologies and expertise of both parties in the Field, including all products, methods and technologies for specific applications in the Field developed pursuant to this Agreement, on the terms and conditions set forth below.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

 

ARTICLE 1
DEFINITIONS

 

1.1          “Active Component” means a component whose functional characteristics are determined by the modulation of one or more [*], or [*] inputs. Examples of Active Components include: [*], including [*] components, including [*] and [*] components, including [*] devices; and [*] components, including [*] devices.

 

1.2          “Agreement Compound” means any Lead Compound or Derivative Compound.

 

1.3          “ Affiliate means any entity directly or indirectly controlling, controlled by or under common control with, a party to this Agreement.  For purposes of this Agreement, only the direct or indirect ownership of fifty percent (50%) or more of the voting securities of an entity shall be deemed to constitute control.

 

1



 

1.4          “Alliance Patents” means: (i) all patent applications prepared or filed by ATMI or IM in the course of and in connection with the Alliance Plan, (ii) all divisions, substitutions, continuations, continuations-in-part, reissues, re-examinations, and extensions of (i) above, (iii) all foreign counterparts of any of the preceding, and (iv) all patents issuing on any of the preceding.

 

1.5          “Alliance Know-How” means any unpatented information, trade secrets, data, or materials developed in connection with the Alliance Plan; provided, however, that Alliance Know-How shall not include Alliance Patents.

 

1.6          “Alliance Technology” means any and all technology, materials, compounds, sequences of compounds, processes, documentation and all related Intellectual Property Rights, including Alliance Patents and Alliance Know-How, developed pursuant to the Alliance Plan, including the Products, Agreement Compounds, Materials Manufacturing Technology, and any HPC Technology and HPC-Derived Technology that is developed during the course of a CDP.

 

1.7          “ATMI Independent Technology” means technology, patents and patent applications (other than Alliance Patents), know-how, trade secrets, and technical information (other than Alliance Technology) that is (i) owned, licensed or otherwise controlled by ATMI on or prior to the Effective Date; or (ii) created, conceived or reduced to practice by ATMI employees, contractors or agents without reliance, use or benefit of (a) the HPC Technology, (b) the HPC-Derived Technology licensed or developed hereunder, (c) IM Independent IP, or (d) any technology, know-how or technical information provided by or obtained from an IM employee, contractor or agent, directly and or indirectly.  The ATMI Independent Technology expected to be used in connection with any CDP may be listed in such CDP.

 

1.8          “CDP” or “Collaborative Development Program” means a specific development project agreed upon in writing by ATMI and IM that describes a defined set of activities conducted collaboratively by the parties for defined development and commercialization purposes in a defined CDP Field, pursuant to the terms of this Alliance Agreement.  Each CDP defines a unique set of technical and business objectives, development and commercialization plans, and economic, Intellectual Property Rights ownership and licensing terms between the parties, and when executed will be deemed incorporated into Exhibit A of this Agreement.  The written plan for a CDP may also be referred to as a CDP or “CDP Plan” under this Agreement.

 

1.9          “CDP Field” means a unique field defined in a CDP included in Exhibit A of this Agreement.

 

1.10        “Confidential Information” means any information disclosed by one party to the other in connection with this Agreement, whether in electronic, written, graphic, oral, machine readable or other tangible or intangible form, that is (i) marked or identified at the time of disclosure as “Confidential” or “Proprietary” or in some other manner so as to clearly indicate its confidential nature, or (ii) if disclosed orally should reasonably be considered confidential by the receiving party given the nature of the information or the circumstances of its disclosure.

 

1.11        “Critical Parameter Set” or “CPS” means a specified technology development deliverable for a CDP, consisting of a defined combination of unique elements, which, when so

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2



 

applied, (a) define or identify a Product or are useful for the synthesis and manufacture of a Product or (b) describe the use of a Product for a specifically identified purpose in a specific CDP Field, and which may include by way of example any of the following: compounds, sequences of compounds, materials, unique processes,  unique processing parameters, conditions and sequences,  unique process integration conditions and sequences, or unique device integration conditions and sequences.  The CPS for each CDP will be specifically enumerated in the Development Plan for each CDP.

 

1.12        “Derivative Compound” means any compound or mixture for application in the CDP Field that is made or derived from a Lead Compound and that is within the parameters or specifications defined in a specific Technology Firewall Set by the parties pursuant to their respective development efforts under a CDP, or as permitted to be made or derived by ATMI or under authority of ATMI or its Affiliates or Sublicensees in accordance with the licenses granted to ATMI under that CDP.  As used in this Agreement, a compound or mixture shall be deemed to have been “derived from” a Lead Compound if it results from a CDP based on a Lead Compound or from the use of HPC Technology, Alliance Technology, or IM Independent IP, or is otherwise related to a Lead Compound.  For the purpose of this definition, “otherwise related” shall mean any further modifications to a Lead Compound or Derivative Compound outside of this Agreement, but not modifications to ATMI Independent Technology created independently of any use of HPC Technology, Alliance Technology or IM Independent IP, including any compound based on structure and/or performance data relating to one or more Lead Compounds. Derivative Compounds shall also include a compound that is synthesized, based on, or derived from another Derivative Compound pursuant to a CDP as described above.  “Derivative Compound” shall not include any compound or mixture developed independently by ATMI or its Affiliates or sublicensees without reliance on Alliance Technology or IM Independent IP, and that does not infringe or misappropriate the Alliance Technology or IM Independent IP.

 

1.13        “Field” means the “Field” defined in that certain Alliance Agreement, effective as of December 19, 2005, between IM and Symyx Technologies, Inc., as such definition in such agreement may be expanded from time to time.  The CDP Field for each CDP will be defined in the applicable CDP document.

 

1.14        “FTE” means a full-time employee or contractor dedicated to the conduct of an Alliance CDP or, in the case of less than full-time dedication, a full-time equivalent person-year, based on approximately [*] hours per year of work on or related to a CDP.

 

1.15        “HPC Technology” means all techniques, methodologies, processes, test vehicles, synthetic procedures, technology, systems, or combination thereof (collectively, “Techniques”) (a) subject to or covered by any Intellectual Property Right owned by IM or licensed to IM, (b) used by IM in performance of a CDP or provided by IM to ATMI pursuant to a CDP, and (c) used for the simultaneous parallel or rapid serial: (i) design, (ii) synthesis, (iii) processing, (iv) process sequencing, (v) process integration, (vi) device integration, (vii) analysis, or (viii) characterization of more than two (2) compounds, compositions, mixtures, processes, or synthesis conditions, or the structures derived from such. HPC Technology does not include any of the foregoing Techniques to the extent they were (A) used by ATMI prior to the Effective Date, (B) created, conceived or reduced to practice by ATMI independent of this Agreement without reliance on or use or benefit of Alliance Technology, IM Independent IP, or

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

3



 

any technology, know-how or information provided by or obtained from an IM employee, contractor or agent, directly and or indirectly.  It is understood that test vehicles include physical and or electrical characterization devices such as test structures or chips, used in the design, process development, manufacturing process qualification, and manufacturing process control of Integrated Circuit devices. It is also understood that HPC Technology does not include the use of commercially available equipment in commercial manufacturing for nominally uniform processing of one or more identical Integrated Circuits on a single substrate, or the use of such equipment in research and development for nominally uniform processing of one or more Integrated Circuits on a single substrate.

 

1.16        “HPC-Derived Technology” means any data, know-how, materials, compounds, sequences of compounds, methods, processes, or other technology derived through the use of HPC Technology, including but not limited to unit processes, process integration, processing equipment, Critical Parameter Sets, Technology Firewall Sets, device architecture and device integration in the Field.

 

1.17        “IM HPC Systems” means any IM tool, hardware, or associated technology, including software provided for use therewith, that enables a user to practice HPC Technology.

 

1.18        “IM Independent IP” means all Intellectual Property Rights that are (i) owned, licensed or otherwise solely controlled by IM as of the Effective Date; or (ii) created, conceived or reduced to practice by IM employees, contractors or agents without reliance, use or benefit of (a) ATMI Independent Technology or (b) technology, know-how or technical information provided by or obtained from an ATMI employee, contractor or agent, directly and or indirectly; and including the HPC Technology.  The IM Independent IP expected to be used in connection with any CDP may be listed in such CDP.

 

1.19        “Integrated Circuit” means any miniaturized structure integrated within a single body containing a number of circuit components, including at least one Active Component and at least one Passive Component, which circuit components are arranged and constructed through a sequence of compatible processes and material interfaces (including such for the substrate and for the packaging of the structure) so as to allow (i) upon the application of power, the performance within the miniaturized structure of a function similar to the function performed by an equivalent number of separate circuit components; and (ii) component density within the miniaturized structure that is at least one order of magnitude larger than the assembly of an equivalent number of separate circuit components. The term “Integrated Circuit” includes any devices described in the paragraph immediately above that are based on technologies in commercial practice as of the Effective Date that contain more than [*] Active Components, and any such devices based on technologies not in commercial practice as of the Effective Date (“ Novel Technologies ”) that contain more than one (1) Active Component, provided it is intended that such device, after commercial adoption, will contain more than [*] Active Components. The term Integrated Circuit does not include primary batteries, secondary batteries, fuel cells, solar cells, chemical or physical property sensors, or MEMs devices where the output of such MEMs devices is mechanical. Examples of Integrated Circuits include: (i) microprocessor chips and  memory chips, including volatile and nonvolatile memory chips (examples of digital Integrated Circuits); (ii) RF chips (an example of an Integrated Circuit with digital and analog components); (iii) thin film transistors and flat panel displays (examples of

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

4



 

Integrated Circuits with digital, analog and photonic components); and (iv) data storage devices (an example of an Integrated Circuit with digital, analog and magnetic components).  Examples of Integrated Circuits based on Novel Technologies include molecular electronics products or plastic electronics products, and products derived from a combination of molecular electronics and other Active Components or Passive Components.

 

1.20        “Intellectual Property Rights” means rights in and to any and all (i) U.S. and foreign patents and patent applications claiming any inventions or discoveries made, developed, conceived, or reduced to practice, including all divisions, substitutions, continuations, continuation-in-part applications, and reissues, re-examinations and extensions thereof, (ii) copyrights, (iii) unpatented information, trade secrets, data, or materials, (iv) trademarks, service marks, trade names, trade dress, domain names and similar rights, (v) mask work rights, and (vi) any other intellectual or other proprietary rights of any kind now known or hereafter recognized in any jurisdiction.

 

1.21        “Lead Compound” means a compound or material identified, synthesized or discovered pursuant to a CDP that meets agreed upon performance criteria set forth in a Critical Parameter Set for that CDP.

 

1.22        “Material” means a specific compound or composition of materials.

 

1.23        “Materials Manufacturing Technology” means any data, know-how, techniques, methods, processes, or other technologies for the synthesis, production, packaging, shipping or distribution of commercial quantities of one or more Products, excluding HPC Technology, and that may be specifically listed as “Materials Manufacturing Technology” in the applicable CDP.

 

1.24        “Passive Component” means a component whose functional characteristics are not determined by the modulation of one or more [*], or [*] inputs, but which are instead determined uniquely by the element’s properties (e.g. materials, size, configuration). Examples of Passive Components include [*] and [*].

 

1.25        “Product” means a Material that is based on a CPS or incorporates an Agreement Compound or utilizes an Agreement Compound in its manufacture and/or otherwise incorporates Alliance Technology in its method of use or its method of manufacture and is authorized to be manufactured and sold pursuant to a CDP or is otherwise identified in a CDP.

 

1.26        Technology Firewall Set ” or “ TFS ” shall mean a defined set of Agreement Compounds and process integration sequences identified within a CDP that are minor variations on a specific CPS that accomplish the same application in the CDP Field as that specific CPS in substantially the same manner. The set of specific CPS(s) and associated TFS(s) are to be mutually agreed and documented at completion of the initial development phase of the CDP, together with supporting data setting forth the feasibility of each TFS instance for use in high volume Integrated Circuit manufacturing of the application in the CDP Field, all as further described in the Development Plan for each CDP.

 

1.27        “Third Party” shall mean any person or entity other than ATMI and its Affiliates, IM and its Affiliates, and their permitted assigns.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

5



 

1.28        “Workflow” means any combination of IM HPC Systems and other systems for use in a specific application, e.g. for use in a CDP.

 

ARTICLE 2
ALLIANCE ACTIVITIES

 

2.1          Alliance Term .   The parties will engage in development and commercialization activities pursuant to this Agreement, commencing on the Effective Date and, unless earlier terminated as set forth in Article 11, continuing for a period of ten (10) years thereafter (the “ Initial Term ”).  The parties will agree to extensions and/or expansions of this Agreement, if any, no later than [*] prior to the end of the Initial Term.  The Initial Term and any extensions thereof are defined as the “ Alliance Term .”

 

2.2          Alliance Scope .   The scope of development and commercialization activities to be undertaken together by the parties will be defined solely by the scope of the individual CDPs agreed upon in writing by the parties and incorporated into the Agreement.

 

2.2.1       Scope Description .  For each such CDP, the parties will mutually agree in advance regarding any particular applications within the Field that the parties will address collaboratively in connection with that CDP (the “ CDP Field ”), the elements of the CPS for that CDP (including the target Lead Compounds and potential Derivative Compounds), the TFS for the CDP Field, each party’s respective technology contributions to the CDP and ownership of Intellectual Property Rights in such contributions, the license terms applicable to each party’s respective Intellectual Property Rights necessary to engage in the activities specified in the CDP, any other research and development requirements for the CDP, any cost sharing for research and development activities undertaken as part of the CDP, the schedule and term for the CDP, and the commercialization plans (including whether commercialization will be exclusive or non-exclusive, in what respects and on what terms) and revenue sharing or royalties for any results of each CDP.

 

2.2.2       Initial Scope .  At the start of this Agreement the parties intend to collaborate on and incorporate into this Agreement one CDP:  [*].  Additional CDPs may be incorporated later on the basis of decisions made by the Operating Committee.

 

2.2.3       Term .  Each CDP shall have a minimum term of twelve (12) months.

 

2.3          Alliance Activities .   During the Alliance Term, the parties shall conduct CDPs solely in accordance with the terms of each CDP Plan.  The collection of all CDP Plans shall constitute the “ Alliance Plan ”, as initially documented in Exhibit A . New mutually-agreed CDP Plans, or CDP Plans revised pursuant to a Change Order, shall be incorporated into a revised Alliance Plan.  Such revised Alliance Plan shall be incorporated into this Agreement and shall supersede or supplement the previous Alliance Plan.

 

2.4          Alliance HPC Systems .   For the purpose of executing certain phases of certain CDPs in the Alliance Plan, the parties may agree from time to time that certain mutually-agreed IM HPC Systems may be transferred to ATMI facilities under the terms of a mutually-agreed subscription agreement.  Under such agreement, for certain IM HPC Systems, ATMI would pay IM a monthly subscription fee to be determined based on a mutually agreed definition of the

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

6



 

transferred Workflow.  Operating labor and consumables for the transferred Workflow will be provided by ATMI.  Ongoing program management labor, and training for ATMI, on the transferred Workflow will be provided by IM.  If ATMI terminates the Agreement, or any applicable CDP, then ATMI will pay any shipping costs to return to IM any IM HPC Systems or components previously provided to ATMI.  All shipping of IM HPC Systems will be done in accordance with IM policies.

 

2.5          Preferred Suppliers .   During the term of this Agreement, ATMI will be the preferred supplier of Materials solutions related to the CDP Fields, and IM will be the preferred supplier of all HPC Technology solutions related to the CDP Fields, in each instance unless a customer of either party specifically requests a different partner.  If a customer requests a different partner, the Operating Committee will determine an appropriate course of action, pursuant to Section 3.1, provided, however, that neither party shall be required to forego a business opportunity because the other party has not been included in the project, so long as the party not included participates in any revenue share or royalty arrangements agreed upon by the parties and set forth in the Alliance Plan.

 

2.6          Resources .   ATMI and IM will each provide the number of FTEs set forth in the Alliance Plan to conduct their respective obligations, such FTEs to be allocated over the course of the Alliance Term as set forth for each CDP in the Alliance Plan.  The parties may, from time to time and by mutual written agreement, allocate certain resources to more than one CDP concurrently, for a defined period of time. Notwithstanding any other provision of this Agreement, neither party will be required to perform development activities other than in accordance with the Alliance Plan, or utilize a total number of FTEs in excess of the number of FTEs described in the Alliance Plan or this Agreement, without its prior written consent.

 

2.7          Change Order Process .   If, during the course of the Alliance Plan, either party wishes to change the Alliance Plan, it shall give the other party written notice of such request.  The other party will respond to such request within a reasonable period of time and the parties will negotiate in good faith for a written change to the Alliance Plan incorporating the changes required by such request and which are approved and accepted in writing by each party (“ Change Order ”).  In no event will IM or ATMI be bound by any proposed change unless and until it has agreed in writing to a Change Order for such change, and the then-current Alliance Plan will remain in full force and effect, without modification, until such Change Order has been mutually agreed in writing. Once a Change Order has been mutually agreed to in writing, such Change Order will become part of the Alliance Plan.

 

2.8          Development Records .   ATMI and IM will maintain records of activities for all CDPs (or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved in the performance of all CDPs (including information sufficient to establish dates of conception and reduction to practice of inventions). The parties will maintain copies of such records for five (5) years after the term of this Agreement.

 

2.9          Employees .   IM agrees to inform ATMI of any proposal to involve any [*] employees or any non-IM employees in the performance of any activities under any CDP or in development of any Alliance Technology.  Unless otherwise expressly agreed to in writing by

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

7



 

ATMI, IM agrees that no [*] employees or any non-IM employees are to be involved in the performance of any activities under any CDP or in development of any Alliance Technology.  ATMI agrees to inform IM of any proposal to involve any non-ATMI employees in the performance of any activities under any CDP or in development of any Alliance Technology.  Unless otherwise expressly agreed to in writing by IM, ATMI agrees that no such non-ATMI employees are to be involved in the performance of any activities under any CDP or in development of any Alliance Technology.

 

ARTICLE 3
MANAGEMENT

 

3.1          Alliance Operating Committee

 

3.1.1       Establishment of Operating Committee .  ATMI and IM will establish a committee (the “ Operating Committee ”) to oversee the conduct of the Alliance Plan, monitor progress, resolve any disputes or disagreements between the Project Managers (as defined below) on any particular CDP, and ensure free and open communications between the parties.

 

3.1.2       Membership of Operating Committee .  The Operating Committee will initially be comprised of [*] representatives from each party, or such other equal number of representatives as the parties may from time to time agree in writing, with each party’s representatives selected by that party.  Either party may replace any of the Operating Committee members it has appointed at any time, upon written notice to the other party.

 

3.1.3       Meetings . During the Alliance Term, the Operating Committee will meet at least on a quarterly basis or as otherwise agreed by the parties, at locations agreed by the parties.  Upon consent of the parties, other representatives of ATMI or IM may attend Operating Committee meetings as nonvoting observers.  Operating Committee members may participate in any meeting in person, by telephone, teleconference or any other means of two-way communication mutually acceptable to the parties.  IM will prepare minutes of each Operating Committee meeting, which minutes will be reviewed, approved and signed by Operating Committee representatives of each party.

 

3.1.4       Decision Making .  At least one representative of each party must be present to establish a quorum for each Operating Committee meeting.  All decisions of the Operating Committee must be made by a majority vote of the representatives of each party present, with each party’s representatives voting as a separate class.  In the event the Operating Committee is unable to resolve an issue, it may be referred by either party to the chief executive officers of ATMI and IM, who shall discuss the matter within thirty (30) days of the referral.  Matters that are not resolved by the chief executive officers of ATMI and IM within sixty (60) days of the referral may be submitted to binding arbitration by either party as set forth in Section 11.16.

 

3.2          CDP Project Management

 

3.2.1       Establishment of Project Managers .  Each party will appoint a principal point of contact to be its project manager (“ Project Manager ”) for each CDP.  The Project Managers will coordinate activities between the parties and act as a liaison with the other party

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

8



 

with respect to such CDP.  Either party may change its Project Manager from time to time upon written notice to the other party.  Each Project Manager will also oversee and supervise its party’s fulfillment of its obligations under the CDP, discuss the progress of the CDP, and identify barriers to success, key issues and issues-resolution options with the other party’s Project Manager.

 

3.2.2       Project Manager Meetings . During the Alliance Term, the Project Managers will meet regularly, as needed, but no less than [*] times per [*] at locations and times mutually agreed upon by the parties.  Project Managers may participate in any such meeting in person, by telephone, or by teleconference.  IM will prepare minutes of each Project Management meeting, which minutes will be reviewed, approved and signed by the Project Manager of each party. In the event the Project Managers are unable to resolve an issue, such issue may be referred by either party to the Operating Committee.

 

ARTICLE 4
OWNERSHIP; LICENSES

 

4.1          Ownership .   As between the parties, ATMI shall own all right, title and interest in and to the ATMI Independent Technology.  As between the parties, IM shall own all right, title and interest in and to any IM Independent IP and, except as otherwise set forth in the applicable CDP, shall also own all right, title and interest in and to Alliance Technology and the HPC Technology.  ATMI agrees to assign to IM in the future all of its right, title and interest in and to any Alliance Technology except as otherwise set forth in the applicable CDP.  All rights not expressly granted pursuant to this Agreement and the applicable CDP Plan are reserved.

 

4.2          License to ATMI .   Specific license and sublicense grants regarding use of IM Independent IP and Alliance Technology will be set forth in the applicable CDP Plan.  Nothing herein grants ATMI a license to use Alliance Technology or IM Independent IP for any purpose except pursuant to a specific CDP Plan agreed upon in writing by the parties.

 

4.3          License to IM .   Specific license and sublicense grants regarding use of ATMI Independent Technology will be set forth in the applicable CDP Plan. Nothing herein grants IM a license to use Products or ATMI Independent Technology for any purpose except pursuant to a specific CDP Plan agreed upon in writing by the parties.

 

4.4          Additional or Independent Development Activities.

 

4.4.1       IM Third Party Activities .  ATMI acknowledges and agrees that nothing in this Agreement restricts IM from engaging in development or commercialization projects with Third Parties outside a CDP Field, except as may be set forth in each CDP Plan.  IM has no right to use any ATMI Independent Technology for any project with any Third Party absent separate written agreement with ATMI, except as may be set forth in each CDP Plan.

 

4.4.2       New Applications Resulting from CDP Activities.   Unless a different procedure is specified in a CDP, should one or both parties determine that a Product developed pursuant to a CDP may have application to another commercialization opportunity in the Field, the parties agree to promptly notify each other and work together either to execute a mutually agreed Change Order to that existing CDP or to execute a new mutually agreed CDP to

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

9



 

commercialize the new application.  The parties agree to negotiate in good faith and that ATMI shall have the right of first offer for [*] to conduct the commercialization of that Product for the new application.

 

4.5          Limited Use .  Except as the parties may otherwise expressly agree in writing, neither party shall use or sell, or authorize the use or sale of, any Agreement Compound or Product in the applicable CDP Field except in relation to the development, manufacture, use, or sale of Agreement Compounds or Products or the licensing of Intellectual Property Rights in accordance with the licenses granted pursuant to Sections 4.2 and 4.3 and the applicable CDP.

 

ARTICLE 5
REVENUE SHARE OR ROYALTIES AND OTHER COMPENSATION

 

5.1          Payments . ATMI will pay certain IM development fees and other fees as will be set forth in each CDP.  Such payments shall be made on the [*] day of each month (or the next business day after the [*] if the [*] falls on a weekend or holiday) and shall be nonrefundable and non-creditable.

 

5.2          Revenue Share or Royalties .   Each party will pay the other party any revenue share payments or royalties due, as set forth in each CDP, on a calendar [*] basis for any agreed upon commercialization licenses.  The revenue share calculations or royalties will be set forth in the applicable CDP.

 

5.3          Third Party Royalties .   Each party shall be responsible for all of its own costs of commercializing Products or licensing Intellectual Property Rights, including any payments to third parties for work done by such third parties or for licenses necessary for the manufacture, sale, or use of Products by a party or its Affiliates or Sublicensees.

 

5.4          Payment Method .   All payments due under this Agreement shall be made by bank wire transfer or ACH transaction in immediately available funds to a bank account designated by each party.  All payments hereunder shall be from a U.S. entity and made in U.S. dollars.  Any payments that are not paid within [*] days of the date such payments are due under this Agreement shall bear interest at the lesser of (i) [*] per month or (ii) the maximum rate permitted by law.  Nothing in this Section 5.4 shall prejudice any other rights or remedies available to either party hereunder or at law or equity.

 

5.5          Reports and Payments .   After the first commercial sale of a Product or licensing of Alliance Technology on which royalties are payable by either party to the other, each party shall make [*] written reports to the other party within [*] after the end of each calendar [*], stating in each such report, separately for itself and each Affiliate and each Sublicensee, the number, description, and total sales of each Product sold, and a calculation of the revenue share or royalties due as a result of license grants to customers pursuant to this Agreement and the applicable CDP, the manner of calculation of each to be specified in the applicable CDP, during the calendar [*] upon which an amount is payable under Section 5.2.  Concurrently with the making of such reports, each party shall pay the other party all amounts due as set forth in the report.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

10


 

5.6                                Currency Conversions .   If any currency conversion shall be required in connection with the calculation of royalties hereunder, such conversion shall be made using the selling exchange rate for conversion of the foreign currency into U.S. Dollars, quoted for current transactions reported in The Wall Street Journal for the last business day of the calendar [*] to which such payment pertains.

 

5.7                                Records; Inspection .   Each party and its Affiliates shall keep complete, true and accurate books of account and records for the purpose of determining the royalty amounts payable under this Agreement.  Such books and records shall be kept at the principal place of business of such party, as the case may be, for at least [*] years following the end of the calendar [*] to which they pertain. Such records will be open for inspection during such [*] year period by an independent auditor reasonably acceptable to the audited party, solely for the purpose of verifying royalty statements hereunder.  Such inspections may be made no more than once each calendar year, at reasonable times and on reasonable notice.  Inspections conducted under this Section 5.7 shall be at the expense of the auditing party, unless a variation or error producing an increase of at least [*] Dollars ($[*]) and exceeding [*] percent ([*]%) of the amount stated for any period covered by the inspection is established in the course of any such inspection, whereupon all reasonable costs relating to the inspection for such period and any unpaid amounts that are discovered will be paid promptly by the audited party together with interest thereon for late payments as set forth above.  Each party agrees to hold in confidence all information concerning royalty payments and reports, and all information learned in the course of any audit or inspection, except to the extent necessary for each party to reveal such information in order to enforce its rights under this Agreement or if disclosure is required by law.

 

5.8                                Tax Matters .   Unless otherwise required under applicable law binding upon a payor party, all royalty amounts and other payments required to be paid by each party pursuant to this Agreement shall be paid without deduction for withholding for or on account of any taxes (other than taxes imposed on or measured by net income) or similar governmental charge imposed by a jurisdiction other than the United States.

 

ARTICLE 6
INTELLECTUAL PROPERTY PROCUREMENT AND ENFORCEMENT

 

6.1                                Procurement.  It is recognized and agreed that both Parties have an interest in ensuring that the Alliance Technology is properly and adequately protected through the procurement of Intellectual Property Rights.  To facilitate this goal and to give each Party the opportunity to have input into the process of obtaining Intellectual Property Rights, Intermolecular agrees to use commercially reasonable efforts to consult with ATMI on matters relating to Intellectual Property Rights procurement strategy for the Alliance Technology owned by IM, including but not limited to (a) providing ATMI with the opportunity to participate in the preparation and prosecution of patent applications and (b) selecting jurisdictions in which to pursue Intellectual Property Rights protection, which will ultimately be determined by IM in its sole discretion.

 

6.1.1                      For any patent application prepared and filed on behalf of IM relating to Agreement Compounds, the manufacture of Agreement Compounds, or the use of Agreement Compounds in Products in a CDP Field in accordance with a CDP, in the event that IM decides

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

11



 

not to extend the patent application into a different jurisdiction where ATMI believes in its reasonable, good faith judgment a foreign counterpart should be filed, ATMI shall have the opportunity, at its own expense, to take appropriate actions to extend the patent application into such additional jurisdiction (including filing and prosecuting patent applications in the jurisdiction and maintaining any resulting patents).  All patent applications and patents, resulting from ATMI’s election pursuant to this section in that jurisdiction shall be solely owned by ATMI as ATMI Independent Technology, subject to a non-exclusive, royalty-free, perpetual and irrevocable grant-back license to IM under the resulting patent(s) to make, have made, use, offer to sell, sell and import products; provided, however, that any such grant back license shall be subject to any applicable exclusivity, revenue share and royalty provisions agreed upon by the parties for that CDP Field (i.e., if ATMI has an exclusive commercialization license in the CDP Field pursuant to the applicable CDP, then IM shall have no commercialization rights under the ATMI patent(s) obtained pursuant to this subsection in the CDP Field during the exclusivity period).  IM agrees to promptly provide notice to ATMI of any decision not to extend a patent application into a particular jurisdiction and in any event not less than [*] before any deadline by which such applications must be filed to avoid loss of Intellectual Property Rights, provided, however, that a failure to do so shall not be deemed a material breach of this Agreement.

 

6.1.2                      In the event that IM decides not to pursue patent protection or trade secret protection relating to Products or features of Products, and notifies ATMI via the Operating Committee that it will not seek patent protection or trade secret protection for a particular Product, ATMI shall have the opportunity, at its own expense, to pursue and maintain patent protection, including the right to file and prosecute patent applications covering such Products or features of Products, and to maintain any patents resulting therefrom.  All patent applications, patents, and Intellectual Property Rights resulting from ATMI’s election under this provision shall be solely owned by ATMI as ATMI Independent Technology, subject to a non-exclusive, royalty-free, perpetual and irrevocable grant-back license to IM, without right of sublicense, to IM under the resulting patent(s) to make, have made, use, offer to sell, sell and import Products; provided, however, that any such grant back license shall be subject to any exclusivity, revenue share and royalty provisions agreed upon by the parties for that CDP Field.  IM agrees to promptly provide notice to ATMI of any decision not to pursue trade secret protection or patent protection relating to Products or features of Products or as required under Section 7.4.  ATMI agrees that, before proceeding with filing or prosecuting patents for any such inventions, at the next possible Operating Committee meeting the parties shall discuss and use all reasonable efforts to agree on a course of action for protection of the inventions.

 

6.2                                Enforcement.

 

6.2.1                      Notice .  Each party shall promptly notify the other of its knowledge of any actual or potential commercially material infringement of the Alliance Technology by a third party.

 

6.2.2                      Products in the CDP Field .  Where ATMI has been granted and maintains an exclusive license, or where ATMI owns the Alliance Technology, ATMI shall have the initial right, but not the obligation, to take reasonable legal action to enforce rights contained that license against commercially material infringements that involve the manufacture, use, sale, offer for sale or import of Products in the CDP Field for such CDP.  If ATMI does not take reasonable

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

12



 

action to halt such infringement within one year following its discovery of infringement or receipt of notice of such infringement from IM, IM shall, in its sole discretion, have the right, but not the obligation to take action to stop such infringement at its sole expense.

 

6.2.3                      Outside of the Field . IM shall have the right, but not the obligation, to take reasonable legal action to enforce rights contained in any portion of the Field where ATMI does not have exclusivity.

 

6.2.4                      HPC Technology and HPC-Derived Technology . IM shall have the right, but not the obligation, to take reasonable legal action to enforce rights contained in the HPC Technology and HPC-Derived Technology, excluding Products to the extent covered by Section 6.2.2 above.

 

6.2.5                      Cooperation; Costs and Recoveries .  Each party agrees to render such reasonable assistance in connection with enforcement activities described in this Section 6.2 as the enforcing party may request.  Costs of maintaining any such action shall be paid by and belong to the party bringing the action. Any damages recovered from any such action (after the deduction of the costs of the action) shall be allocated as agreed upon in advance in writing by the parties.

 

6.2.6                      Third Party Claims of Infringement .  If the manufacture, use or sale of any Product, or the licensing of Intellectual Property Rights, pursuant to this Agreement, because of the practice of the Alliance Technology results in any claim, suit or proceeding alleging patent infringement against IM or ATMI (or their Affiliates or Sublicensees), such party shall promptly notify the other party hereto in writing setting forth the facts of such claims in reasonable detail.  The defendant shall have the exclusive right and obligation to defend and control the defense of any such claim, at its own expense, using counsel of its own choice; provided, however, it shall not enter into any settlement which admits or concedes that any aspect of the Alliance Technology is invalid or unenforceable, without the prior written consent of the other party. The defendant shall keep the other party hereto reasonably informed of all material developments in connection with any such claim, suit or proceeding.

 

ARTICLE 7
CONFIDENTIALITY

 

7.1                                Confidentiality.   Except as otherwise expressly provided in the Mutual Non-Disclosure Agreement signed by the parties on December 6, 2005 for Confidential Information exchanged between the parties prior to the Effective Date, or as otherwise expressly provided herein, the parties agree that the receiving party shall not, except as expressly provided in this Article 7, disclose to any third party, or use for any purpose, any Confidential Information furnished to it by the disclosing party pursuant to this Agreement, except in each case to the extent that it can be established by the receiving party by competent proof that such information:

 

(a)                                   was already known to the receiving party, other than under an obligation of confidentiality to the disclosing party, at the time of disclosure;

 

(b)                                  was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving party;

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

13



 

(c)                                   became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving party in breach of this agreement;

 

(d)                                  was independently developed by the receiving party without use of, or reference to, the other party’s confidential information, as demonstrated by documented evidence prepared contemporaneously with such independent development; or

 

(e)                                   was disclosed to the receiving party, other than under an obligation of confidentiality to the disclosing party, by a Third Party authorized and entitled to disclose such information to others.

 

Confidential Information shall not be considered within the above exceptions merely because the Confidential Information is embraced by more general information within the exceptions.  Any combination of features of Confidential Information shall not be considered within the above exceptions merely because individual features, as opposed to the combination itself and its principles of operation, are within the exception.

 

7.2                                Permitted Use and Disclosures.   Notwithstanding the restrictions of Section 7.1, each party hereto may (a) use Confidential Information disclosed to it by the other to the extent necessary for that party to perform its obligations set forth in the Alliance Plan and (b) use or disclose Confidential Information disclosed to it by the other party to the extent such use or disclosure is reasonably necessary in (i) exercising the rights and licenses granted hereunder, (ii) prosecuting or defending litigation pursuant to Section 6.2, (iii) complying with applicable laws, governmental regulations or court orders or submitting information to tax or other governmental authorities (including the Securities and Exchange Commission), (iv) preparing, filing and prosecuting patent applications pursuant to this Agreement, or (v) making a permitted sublicense or otherwise exercising license rights expressly granted pursuant to this Agreement; in each case, provided that if a party is required to make any such disclosure, other than pursuant to a confidentiality agreement, it will give reasonable advance notice to the other party of such disclosure and will use reasonable efforts to secure confidential treatment of such information (whether through protective order or otherwise), except to the extent inappropriate with respect to patent applications.  It is understood that either party may also disclose the Confidential Information of the other party upon receipt of the written consent to such disclosure by a duly authorized representative of the other party.  It is also understood that notwithstanding other provisions of this paragraph, neither party shall disclose trade secrets of the other party without first obtaining the written consent of the party owning such trade secrets and securing an agreement with the party to whom such disclosure will be made that such trade secrets will be treated as confidential for as long as such trade secrets qualify for protection as trade secrets.  It is further understood that such trade secrets are not to be included in any patent, patent application, or other document that is accessible by individuals not subject to an agreement requiring that the individuals maintain such document in confidence.

 

7.3                                Nondisclosure of Terms.   Subject to Section 7.5, each of the parties hereto agrees not to disclose the terms of this Agreement to any third party without the prior written consent of the other party hereto, which consent shall not be unreasonably withheld, except to such party’s attorneys, accountants, advisors, investors and financing sources and their advisors

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

14



 

and others on a need to know basis under circumstances that reasonably ensure the confidentiality thereof, to the extent required by law, in connection with the enforcement of this Agreement or rights under this Agreement or in connection with a merger, acquisition, financing transaction or proposed merger, acquisition or financing transaction, or the like.

 

7.4                                Publication of Results.   Any manuscript or other public disclosure by ATMI or IM describing the scientific results of the Alliance to be published within the term of the Alliance Term, or within eighteen (18) months after the end of the Alliance Term, shall be provided to the other party for review at least ninety (90) calendar days prior to its submission.  Further, to avoid the loss of patent rights as a result of premature public disclosure of patentable information, the reviewing party may, within thirty (30) calendar days of receiving such a proposed disclosure, notify the publishing party in writing that the reviewing party desires to file a patent application on any invention disclosed in such scientific results, in which case the publishing party shall withhold publication or disclosure of such scientific results until the earlier of (i) the time the patent application is filed thereon, (ii) the time the parties both determine, after consultation, that no patentable invention exists, or (iii) ninety (90) calendar days after the publishing party received notice of the reviewing party’s desire to file such patent application.  Further, if such scientific results contain Confidential Information of the reviewing party that is subject to the use and nondisclosure restrictions under this Article 7, the publishing party agrees to remove such Confidential Information from the proposed publication or disclosure or obtain the reviewing party’s prior consent for such disclosure.  The provisions of this section are subject to Section 7.5.

 

7.5                                Compliance with Public Company Disclosure Obligations.   Notwithstanding the provisions of Sections 7.3 and 7.4, if a party is a Public Company (as defined below), such party may disclose from time to time such information regarding the terms of this Agreement and the scientific and other results of the Alliance as such party may reasonably deem to be necessary to comply with its disclosure obligations under applicable U.S. securities law or applicable stock market or NASDAQ Stock Market listing rules; provided, however, that each party shall use commercially reasonable efforts to (i) nevertheless comply with its obligations as set forth in Sections 7.3 and 7.4, or in the event such compliance is not possible, (ii) provide the other party with a draft of the disclosure intended to be made not less than twenty-four (24) hours prior to the intended first public release or filing of such disclosure.  For purposes of this section, “ Public Company ” shall mean a company that is subject to the reporting requirements of either Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended.

 

ARTICLE 8
REPRESENTATIONS AND WARRANTIES

 

8.1                                By ATMI.   ATMI represents and warrants that: (i) it has the right and authority to enter into this Agreement, and to fully perform its obligations hereunder; and (ii) this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms.

 

8.2                                By IM.   IM hereby makes the following representations and warranties:

 

8.2.1                      Authority .  IM has the right and authority to enter into this Agreement, and to fully perform its obligations hereunder.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

15



 

8.2.2                      Legal, Valid and Binding Obligation .  This Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms.

 

8.2.3                      Intellectual Property Rights .  IM owns, or possesses a valid and enforceable license to use, all Intellectual Property Rights licensed to ATMI pursuant to this Agreement (excluding Alliance Technology other than HPC Technology) (for purposes of this Section 8.2.3, “ IM Licensed IP ”).  IM has full power and authority to license or sublicense, as the case may be, such Intellectual Property Rights to ATMI upon the terms set forth herein, and to IM’s knowledge, the use and practice of such Intellectual Property Rights by the parties in the Field pursuant to and in accordance with the terms of this Agreement will not infringe the Intellectual Property Rights of any Third Party.  IM agrees to defend and hold ATMI harmless from and against all claims, losses, damages, judgments, awards, settlements, costs and expenses (including reasonable attorneys’ fees)  of, arising out of or resulting from  any litigation or proceeding brought by a Third Party alleging infringement of a Third Party’s Intellectual Property Rights relating to the HPC Technology or HPC-Derived Technology; provided that (i) ATMI notifies IM promptly in writing of the claim (provided, however, that the failure to promptly provide notice to IM will not affect IM’s duties or obligations under this Article 8 except to the extent IM is prejudiced thereby); and (ii) ATMI assists and cooperates reasonably with IM, at IM expense, in defending or settling such claim.  IM shall have sole control of the defense and all related potential settlement negotiations, provided that IM shall not enter into any settlement which would materially adversely affect the rights granted to ATMI under this Agreement without ATMI’s express prior written consent.  Notwithstanding the foregoing, IM shall have no liability for any claim of infringement based on or arising from the Alliance Technology, the Agreement Compounds or the use, sale, offer for sale, import or manufacture of Products.  In addition, ATMI shall be entitled to be represented by ATMI’s own counsel at ATMI’s expense.  In the event the IM Licensed IP is held to, or IM believes is likely to be held to, infringe or misappropriate any Intellectual Property Rights of a Third Party, IM shall have the right at its sole option and expense to (i) modify the IM Licensed IP so that it is non-infringing and meets the criteria pre-approved by ATMI; and/or (ii) obtain a license to continue to use IM Licensed IP as licensed hereunder without additional charge to ATMI. The foregoing indemnity states the sole obligations and exclusive liability of IM, and ATMI’s sole recourse and exclusive remedy for any Third Party claim of infringement or misappropriation of an Intellectual Property Right by IM under this Agreement.

 

8.3                                Disclaimer.   ATMI and IM specifically disclaim any representation, warranty or guarantee that the Alliance Plan or individual CDPs therein, will be successful, in whole or in part.  It is understood that the failure of the parties to successfully develop and commercialize the any technology related to this Agreement shall not constitute a breach of any representation or warranty or other obligation under this Agreement.  EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, IM AND ATMI MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE TECHNOLOGIES DESCRIBED HEREIN OR INFORMATION DISCLOSED HEREUNDER, AND HEREBY EXPRESSLY DISCLAIM ANY WARRANTIES OF MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE, OR VALIDITY OF ANY TECHNOLOGY, PATENTED OR UNPATENTED, OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

16



 

ARTICLE 9
LIMITATION OF LIABILITY

 

EXCEPT FOR A BREACH BY EITHER PARTY OF ITS CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 7 AND EXCEPT FOR BREACHES OF ANY LICENSE RESTRICTIONS, OR ANY PAYMENT OBLIGATIONS RESULTING FROM AN INDEMNIFICATION OBLIGATION HEREUNDER, UNDER NO CIRCUMSTANCES WILL EITHER PARTY BE LIABLE TO THE OTHER, UNDER CONTRACT, STRICT LIABILITY, NEGLIGENCE OR OTHER LEGAL OR EQUITABLE THEORY, FOR ANY LOST REVENUE, LOST PROFITS, EQUIPMENT DOWN-TIME, OR FOR ANY INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND IN CONNECTION WITH THE SUBJECT MATTER OF THIS AGREEMENT, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.  EXCEPT FOR A BREACH BY EITHER PARTY OF ITS CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 7 AND EXCEPT FOR BREACHES OF ANY LICENSE RESTRICTIONS, OR ANY PAYMENT OBLIGATIONS RESULTING FROM AN INDEMNIFICATION OBLIGATION HEREUNDER, IN NO EVENT WILL EITHER PARTY’S LIABILITY TO THE OTHER UNDER THIS AGREEMENT EXCEED THE GREATER OF [*] DOLLARS ($[*]) OR THE AMOUNTS PAID OR PAYABLE BY SUCH PARTY TO THE OTHER PARTY IN THE TWELVE (12) MONTHS PRECEDING THE CLAIM.

 

ARTICLE 10
TERMINATION

 

10.1                         Term of Agreement.   The term of this Agreement shall commence on the Effective Date, and, unless terminated earlier as provided in this Article 10, shall continue in full force and effect for the Alliance Term, or until the completion of the last active CDP in the Alliance Plan, whichever is latest.

 

10.2                         Termination for Breach.   Either party to this Agreement may terminate this Agreement or a specific CDP in the event the other party shall have breached or defaulted in the performance of any of its material obligations hereunder, including a CDP, and such default shall have continued for [*] after written notice thereof was provided to the breaching party by the non-breaching party. Any termination shall become effective at the end of such [*] period unless the breaching party (or any other party on its behalf) has cured any such breach or default prior to the expiration of such [*] period.

 

10.3                         Effect of Termination.   Except as provided in a CDP, upon any termination of this Agreement or a specific CDP, all licenses under the Agreement or the terminated CDP, as applicable, shall terminate, and IM and ATMI shall promptly return to the other all Confidential Information received from the other party related to this Agreement or the terminated CDP except (i) one copy of which may be retained for archival purposes, or (ii) to the extent that such Confidential Information is necessary to practice a continuing license or to which the other party obtained an ownership interest pursuant to Article 4; provided, however that the applicable party  may, at its option, destroy any Confidential Information it is otherwise obligated to return and certify such destruction to the other party.  Except as expressly provided herein, Articles 5, 7, 8, 9 and 11 and Sections 2.8, 4.1, 6.2, and 10.3, shall survive the expiration or termination of this

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

17



 

Agreement for any reason.  Upon any termination or expiration of this Agreement, the parties, through the Operating Committee, shall meet within one month following determination and finally determine what, if any, potentially patentable inventions may be pursued by ATMI resulting from development then being conducted under an active CDP pursuant to Section 6.1 above.

 

ARTICLE 11
MISCELLANEOUS

 

11.1                         Governing Laws.   This Agreement and any dispute arising from the construction, performance or breach hereof shall be governed by and construed and enforced in accordance with the laws of the State of New York without regard to conflict-of-law principles that would result in the application of the law of any other jurisdiction.

 

11.2                         Assignment.   Neither party shall assign this Agreement, in whole or in part, without the prior written consent of the other party, which consent shall not be unreasonably conditioned, delayed or withheld; provided, however, that either party may assign this Agreement without such consent, to an Affiliate, or to a successor in interest to its business (whether by merger, acquisition, consolidation, change of control, reorganization or sale of substantially all of its assets) and the terms of the Agreement shall continue in effect without modification after such assignment, including without limitation the royalty provisions herein which shall be binding upon any permitted assignee. Any purported assignment without such consent shall be void and of no effect.  Subject to the foregoing sentence, this Agreement will be binding on and inure to the benefit of the parties and their respective successors and permitted assigns.

 

11.3                         No Implied Licenses.   Only the licenses granted pursuant to the express terms of this Agreement shall be of any legal force or effect.  No other license rights shall be created by implication, estoppel or otherwise.  Each party reserves all rights not expressly granted to the other party under this Agreement.

 

11.4                         Representation by Legal Counsel.   Each party hereto represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof.  In interpreting and applying the terms and provisions of this Agreement, the parties agree that no presumption shall exist or be implied against the party that drafted such terms and provisions.

 

11.5                         Waiver.   It is agreed that no waiver by either party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed a waiver as to any subsequent and/or similar breach or default.

 

11.6                         Non-Solicitation.   During the Alliance Term and for [*] thereafter, neither IM nor ATMI will individually, or in concert with or through any other person, actively recruit or solicit employment of any scientific or technical personnel of the other party. The foregoing restriction shall not apply to, or be breached by: (i) advertising open positions, participating in job fairs, and conducting comparable activities to recruit skilled or unskilled help from the general public, or responding to individuals contacted through such methods, (ii) responding to unsolicited

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

18



 

inquiries about employment opportunities or possibilities from job placement agencies or other agents acting for unidentified principals, or (iii) responding to unsolicited inquiries about employment opportunities from any individual.

 

11.7                         Severability.   In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect to the fullest extent permitted by law without said provision, and the parties shall amend the Agreement to the extent feasible to lawfully include the substance of the excluded term to as fully as possible realize the intent of the parties and their commercial bargain.

 

11.8                         Independent Contractors.   The relationship of the parties hereto is that of independent contractors.  The parties hereto are not deemed to be agents, partners or joint ventures of the others for any purpose as a result of this Agreement or the transactions contemplated thereby.

 

11.9                         Compliance with Laws.   In exercising its rights under the licenses granted hereunder, and in undertaking the activities outlined in this Agreement, each party shall fully comply in all material respects with the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this Agreement including those applicable to the discovery, development, manufacture, distribution, import and export and sale of products based on technology developed pursuant to this Agreement.

 

11.10                  Export Control Regulations.   Without limiting the parties’ obligations under Section 11.9 above, the rights and obligations of the parties under this Agreement, shall be subject in all respects to United States laws and regulations as shall from time to time govern the license and delivery of technology abroad.  Without in any way limiting the provisions of this Agreement, IM and ATMI agree that each will not export, reexport, or transship, directly or indirectly, to any country, any of the technical data disclosed to it by the other party hereto if such export would violate the laws of the United States or the regulations of any department or agency of the United States Government.

 

11.11                  Patent Marking.   Each party agrees to mark and have their Affiliates and licensees mark all products sold or licensed pursuant to this Agreement in accordance with the applicable statute or regulations relating to patent marking in the country or countries of manufacture and sale thereof, and to notify the other party if it becomes aware that the marking of any such product is required.

 

11.12                  Notices.   All notices, requests and other communications hereunder shall be in writing and shall be hand delivered, or sent by express delivery service with confirmation of receipt, or sent by registered or certified mail, return receipt requested, postage prepaid, or by facsimile transmission (with written confirmation copy by registered first-class mail), in each case to the respective address or facsimile number indicated below.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

19



 

 

IM:
2865 Zanker Road
San Jose, CA 95134

  ATMI:
  7 Commerce Drive
  Danbury, CT 06810

 

Attn:

Chief Executive Officer

  Attn:

Chief Legal Officer

 

Fax:

(408) 416-2301

  Fax:

(203) 797-2544

 

 

 

 

with copy to:
Anthony Klein
Latham and Watkins, LLP
140 Scott Drive
Menlo Park, CA 94025

with copy to:

 

Any such notice shall be deemed to have been given when received.  Either party may change its address or facsimile number by giving the other party written notice, delivered in accordance with this section.

 

11.13                  Force Majeure.   Neither party shall lose any rights hereunder or be liable to the other party for damages or losses (except for payment obligations) on account of failure of performance by the defaulting party if the failure is occasioned by war, strike, fire, act of God, earthquake, flood, lockout, embargo, act of terrorism, governmental acts or orders or restrictions, failure of suppliers, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence, intentional conduct or misconduct of the non-performing party and such party has exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a party be required to settle any labor dispute or disturbance.

 

11.14                  Headings; Construction.   The captions to the several articles and sections hereof are not part of this Agreement, but are included merely for convenience of reference and shall not affect its meaning or interpretation.  As used in this Agreement, the word “including” means “including without limitation.”

 

11.15                  Counterparts.   This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.

 

11.16                  Dispute Resolution.   Unless otherwise specified in a CDP, if a dispute arises between the parties relating to the interpretation or performance of this Agreement, representatives of the parties with decision-making authority shall meet to attempt in good faith to negotiate a resolution of the dispute prior to pursuing other available remedies.  If such a meeting is requested, it must be held, unless the parties otherwise agree, within [*] calendar days from receipt of such request (the “Request”). If within [*] calendar days after such meeting the parties have not resolved such dispute, the Chief Executive Officers of both parties shall meet within [*] calendar days after the end of such [*] day period to discuss and attempt to resolve the dispute. If the parties have not resolved the dispute within [*] calendar days after the Request, either party may submit such dispute to final and binding arbitration, before a single, mutually-acceptable arbitrator, conducted in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”).  If the parties are unable to select a mutually

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

20


 

acceptable arbitrator, AAA shall appoint an arbitrator or provide a method for selection.  Any arbitration proceedings shall be conducted in San Jose, California.  The arbitrator shall determine what discovery will be permitted, consistent with the goal of limiting the cost and time that the parties must expend for discovery.  Each party shall bear its own expenses, including attorneys’ fees, and the parties will share equally the costs and fees of the arbitrator.  The parties shall use all reasonable efforts to complete any arbitration subject to this section within [*] months from the filing of notice of a request for such arbitration.  The parties agree that any award shall not include punitive damages and shall be consistent with the limitation of liability provisions set forth in this Agreement.  The arbitrator shall not have the power to add terms not contained in this Agreement or to refuse to enforce any term.  Judgment upon any decision rendered by the arbitrator may be entered by any court having jurisdiction. The parties undertake and agree that all arbitral proceedings and all information, documentation, materials in whatever form disclosed in the course of such arbitral proceeding shall be deemed Confidential Information hereunder.  Notwithstandin g any of the foregoing, either party shall have the right to seek, at its own cost and expense, preliminary and temporary injunctive relief pending resolution of the dispute.

 

11.17                  Complete Agreement.   This Agreement with its Exhibits, and the Mutual Non-Disclosure Agreement dated as of December 6, 2005 as set forth in Section 7.1, constitute the entire agreement, both written and oral, between the parties with respect to the subject matter hereof, and all prior agreements respecting the subject matter hereof, either written or oral, express or implied, shall be abrogated, canceled, and are null and void and of no effect.  No amendment or change hereof or addition hereto shall be effective or binding on either of the parties hereto unless reduced to writing and executed by the respective duly authorized representatives of ATMI and IM.

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their authorized representatives and delivered in duplicate originals as of the Effective Date.

 

INTERMOLECULAR, INC.

 

ADVANCED TECHNOLOGY MATERIALS, INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/

 

By:

/s/

 

 

 

 

 

 

 

 

 

 

Title:

President & CEO

 

Title:

President & C.E.O.

 

 

 

 

 

 

 

 

 

 

Date:

11/17/06

 

Date:

November 20, 2006

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

21



 

EXHIBIT A
ALLIANCE PLAN

 

The Alliance Plan includes the following attached CDPs:

 

Exhibit A1                   [*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

22



 

EXHIBIT A1
[*]

 

This Collaborative Development Plan  is made as of this 17th day of November, 2006, (“Effective Date”) by and between Advanced Technology Materials, Inc. (“ATMI”) and Intermolecular, Inc. (“IM”) and is subject to and hereby incorporated in the Alliance Agreement between ATMI and IM dated November 17, 2006 (the “Agreement”).  All capitalized terms not expressly defined in this document shall have the meaning set forth in the Agreement.  ATMI and IM are sometimes referred to herein individually as a “party” and collectively as the “parties.”

 

1.               CDP Field

 

[*] of semiconductor Integrated Circuits.

 

2.                                       Business purpose

 

To collaborate using the HPC Technology, the HPC-Derived Technology, the IM Independent IP and the ATMI Independent Technology to develop specific materials and methods of using such materials, and systems and methods for rapid qualification of materials, as will be further specified in the Development Plan, to increase ATMI’s market share in [*].

 

The parties intend to perform a comprehensive assessment of the performance of existing ATMI [*] technologies, and up to [*] competing technologies, against [*] requirements for current and future high volume manufacturing of semiconductor Integrated Circuits. As a result of such assessment the parties may identify new or improved means of using or manufacturing the existing ATMI [*] technologies, or develop new [*] Agreement Compounds, Products and or Critical Parameter Sets.

 

The parties intend that as a result of the above collaboration, IM will license ATMI to make, sell and otherwise commercialize certain Products that ATMI may offer for sale to semiconductor Integrated Circuit Manufacturers (“IC Manufacturers”); that said incremental sales may provide ATMI improved market position, and financial returns; and that ATMI will provide IM a revenue share or royalty on said incremental sales.

 

The parties also intend that IM may sell services to and license Original Equipment Manufacturers (“OEMs”) or IC Manufacturers to enable either or both to modify or implement systems or methods to use the Products solely as licensed by IM to ATMI pursuant to this CDP; and that IM will provide ATMI either a share of revenue, or a royalty on, any royalties that may be obtained by IM on said licenses.

 

3.               Objectives

 

Develop [*] Workflow (“Workflow”) in CDP Phase I, and use the Workflow in Phases I and II for the purposes described in Section 2.  The parties intend that the Workflow may also be used in an approximately concurrent [*] CDP to be agreed upon separately in writing by the parties, provided however that neither party shall have an obligation to

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Annex 1 to Exhibit A1 Page 1



 

pursue a [*] CDP if the parties do not execute such a CDP within 60 days of the Effective Date.

 

The specific deliverables resulting from this CDP, including the CPS, TFS and the specifications for any Products, will be listed in the Development Plan.  The Development Plan will also list the anticipated Lead Compounds and any related potential Derivative Compounds that will be commercialized pursuant to this CDP.

 

4.                                       Estimated CDP Duration

 

 

Total Duration:

24 months

 

 

 

 

CDP Phase I:

6 to 9 months

 

 

 

 

CDP Phase II:

The remainder of the 24 month period, extendable by mutual agreement, subject to Section 13 below.

 

5.                                       Activities

 

5.1.                               Research & Development .

 

 

CDP Phase I:

Develop and harden a Workflow for application in CDP Field

 

 

 

 

CDP Phase II:

Use Workflow in the CDP Field to meet commercial objectives.

 

5.2.                               Sales & Marketing .

 

 

CDP Phase I:

Market Share growth study and plan

 

 

 

 

CDP Phase II:

Execute Market Share growth plan

 

6.                                       Collaborative Development Program

 

Subject to the terms and conditions set forth herein, ATMI and IM will conduct the Collaborative Development Program in accordance with an agreed upon written plan describing the development activities to be conducted by each party and the anticipated characteristics and properties of the developed technologies (the “Development Plan”).  A draft version of the Development Plan is attached hereto as Annex 2; the ATMI and IM Project Managers shall collaboratively and by mutual agreement develop and document the complete initial Development Plan within [*] of the Effective Date of this CDP. The Development Plan may be updated from time to time, subject to mutual written agreement of the parties and when agreed upon will be incorporated into this CDP, superseding or supplementing the previous Development Plan.  For clarity, IM HPC Systems will only be used per the Development Plan pursuant to this CDP, or as may otherwise be agreed by the parties in subsequent revisions of the Development Plan, or by written agreement, e.g. subsequent CDPs in other Fields.  Each party will commit the necessary resources in equipment, facilities and personnel to complete its respective tasks in accordance with the Development Plan, including the resources listed in Annex 2.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Annex 1 to Exhibit A1 Page 2



 

Except as stated in Annex 2 and as set forth below, IM and ATMI will each bear their respective costs associated with the Collaborative Development Program.  The parties are committed to Phase I of the Collaborative Development Program without right of termination, except for breach as consistent with Section 10.2 of the Agreement.

 

7.                                       Management

 

ATMI Project Manager:          [*]

 

IM Project Manager:               [*]

 

Either Party may change its project manager with prior notice to the other Party.

 

8.                                       CDP Fees

 

8.1.                               FTEs .

 

ATMI will pay IM for each IM FTE to perform work on the Collaborative Development Program.  The minimum dedicated FTE unit will equal one month, at a rate of [*] dollars ($[*]) per month.

 

.

 

8.2.                               Workflow Infrastructure Development Costs .

 

IM will bear [*]% of the Direct Program Cost incurred in developing a Workflow pursuant to the CDP.  ATMI will bear [*]% of such costs, which will not exceed $[*] for this CDP.  For the purposes of this CDP “Direct Program Cost” shall mean all non-labor costs incurred in the execution of this CDP, including but not limited to engineering materials, Workflow components such as IM HPC Systems and subsystems (including but not limited to processing, characterization and informatics components), and outsourced or contracted services (including but not limited to third party metrology or characterization services).  In addition, ATMI will supply all materials at no cost to IM that are required for execution of the CDP, including but not limited to ATMI Products, Agreement Compounds and other materials and wafers.

 

8.3.                               Workflow Fees .

 

Annex 1 contains a preliminary description of the proposed Workflow, which will be developed or integrated for the purposes of this CDP and which may also be used for an approximately concurrent [*] CDP, per Section 3.  Within [*] of the conclusion of Phase I, the parties shall discuss the need, timing and terms of use for the transfer of certain IM primary and secondary HPC screening subsystems to an ATMI facility, under a subscription agreement. Under such a mutually agreed subscription agreement (i) the Workflow at ATMI may include existing ATMI equipment, as may be determined by mutual agreement of the parties; (ii) the cost of manufacturing the IM primary and secondary HPC screening subsystems that would be transferred to ATMI would be paid solely by IM; (iii) the fee payable by ATMI to IM for both IM primary and secondary

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Annex 1 to Exhibit A1 Page 3



 

HPC screening subsystems, as proposed, would not exceed $[*] for the [*] of the subscription agreement; (iv) said monthly fee does not include a fee for IM FTEs, which would be charged separately, at least two of which would be required to be on-site at ATMI for the duration of the subscription agreement, as a condition of that subscription agreement; (v) the subscription agreement would be extendable by mutual agreement after the [*].

 

8.4.                               Estimated CDP Phase I Cost .

 

 

IM FTEs required:

[*] FTEs, which FTEs may also be applied to an approximately concurrent [*] CDP per Section 3; FTEs to be located at IM

 

 

 

 

ATMI FTEs required:

[*] FTEs; to be located primarily at ATMI.

 

 

 

 

Duration:

Between [*] and [*]

 

 

 

 

IM FTE Fee:

Between $[*] and $[*]

 

 

 

 

Direct Program Cost:

Not to exceed $[*], which amount may also be applied to an approximately concurrent [*] CDP, per Section 3.

 

 

 

 

Total Phase I Cost:

Between $[*] and $[*]

 

8.5.                               Estimated CDP Phase II Cost .

 

 

IM FTEs required:

[*] FTEs, which FTEs may also be applied to an approximately concurrent [*] CDP per Section 3; FTEs to be located primarily at IM, and or at ATMI if the parties agree to the transfer of certain IM primary and secondary HPC screening subsystems under the terms of a subscription agreement.

 

 

 

 

ATMI FTEs required:

[*] FTEs; to be located primarily at ATMI, if the parties agree to the transfer of certain IM primary and secondary HPC screening subsystems under the terms of a subscription agreement, or if the parties agree, at IM.

 

 

 

 

Duration:

Remainder of the [*] term; extendable by mutual agreement

 

 

 

 

IM FTE Fee:

Between $[*] and $[*]

 

 

 

 

Subscription Fee:

If the parties agree to the transfer of certain IM primary and secondary HPC screening subsystems under the terms of a subscription agreement, the fee for the Workflow HPC subsystems as proposed would be between $[*] and $[*]. Such subscription fee may also be applied to and approximately concurrent [*] CDP, per Section 3.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Annex 1 to Exhibit A1 Page 4



 

 

Total Phase II Cost:

Between $[*] and $[*]

 

 

 

 

Following CDP Phase II, and if the parties have previously agreed to the transfer of certain IM primary and secondary HPC screening subsystems under the terms of a subscription agreement, the parties will discuss whether ATMI will need continued use of IM HPC Systems for continued commercialization purposes pursuant to this CDP; and if so, the parties may extend Phase II pursuant to Section 3 above.

 

9.                                       Workflow Description

 

See Annex 1

 

10.                                Technology Provided

 

10.1.                         By ATMI .

 

ATMI Independent Technology and Intellectual Property Rights related to ATMI’s products in the CDP Field, as further set forth in the Development Plan.  ATMI shall provide, for example, Products, base components of the existing [*] products, methods for the use of those products or their base components, and any other technology background necessary for someone skilled in the art to understand and assess the formulations and their use by IC manufacturers for [*].  ATMI may also provide certain existing ATMI metrology capabilities in support of the CDP including, for example, inspection of CDP wafers using AIT inspection systems at ATMI’s [*] facility.

 

10.2.                         By IM .

 

IM Independent IP related to HPC Technology and HPC-Derived Technology, as well as to Integrated Circuit materials, processes, equipment and device technology, as further set forth in the Development Plan.  IM shall provide, for example, an HPC Workflow consisting of processing, characterization and informatics elements suitable for the purposes of this CDP; license to certain combinatorial technologies pursuant to the agreement between IM and [*]; and license to test plans and algorithms provided by [*], for use with the test wafers sold by [*].  For clarity, the parties agree that test wafers obtained from [*] shall be the only commercial test wafers to be used for development in this CDP, and that the electrical tests to be done with such wafers in the course of the CDP shall be limited to [*] and [*].

 

11.                                Ownership and Licenses

 

11.1.                         Ownership

 

As between the parties, ATMI shall own all right, title and interest in and to the ATMI Independent Technology provided for the purposes of this CDP, and to any Materials Manufacturing Technology developed in this CDP.  IM agrees to assign to ATMI in the future all of its right, title and interest in and to any Materials Manufacturing Technology developed in this CDP. As between the parties, IM shall own all right, title and interest in and to any IM Independent IP provided for the purposes of this CDP, and shall also own

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Annex 1 to Exhibit A1 Page 5



 

all right, title and interest in and to Alliance Technology, excluding any Materials Manufacturing Technology developed in this CDP.  ATMI agrees to assign to IM in the future all of its right, title and interest in and to any Alliance Technology, excluding Materials Manufacturing Technology.  All rights not expressly granted pursuant to this CDP are reserved.

 

11.2.                         License Grants to ATMI

 

Subject to the terms and conditions of the Agreement and this CDP, IM grants ATMI a worldwide, non-transferable, royalty-bearing, exclusive license, with right of sublicense as set forth below, in the CDP Field set forth herein, under and to the applicable Alliance Technology, but excluding HPC Technology, necessary to develop, make, have made, import, export, sell, offer for sale, and/or otherwise commercialize the [*] Products that result from execution of the Development Plan of Section 6 of this CDP or developed pursuant to Section 18 of this CDP.  Subject to the terms and conditions of the Agreement and this CDP, ATMI may grant and authorize sublicenses under the rights granted above to Third Parties and to its Affiliates.

 

11.3.                         Sublicensing

 

Notwithstanding the exclusivity of the license granted above, IM may continue to engage in any activities required to achieve the intent of this CDP.  In addition, as a further exception to exclusivity, IM may grant and authorize sublicenses in the CDP Field to Alliance Technology, excluding Materials Manufacturing Technology, to IC Manufacturers and OEMs solely for the purpose of enabling either or both to use ATMI [*] Products licensed by IM to ATMI in the CDP Field for purposes of achieving the commercialization objectives for IM set forth in this CDP; provided that the terms of each such sublicense shall be consistent with the terms of this CDP.  Any sublicenses granted by IM pursuant to this Section 11.3 shall be subject to the revenue sharing and royalty provisions set forth in this CDP.  Each party shall remain responsible to the other party for all applicable financial and other obligations under this Agreement and the applicable CDP for each such sublicensee, including without limitation royalty payments due to the other party hereunder with respect to sales of Products, or the licensing of Intellectual Property, by any such sublicensee.

 

11.4.                         Respective Rights .

 

For clarity, the parties intend that as between the parties, IM will be the sole licensor to any IC Manufacturers and OEMs of any Alliance Technology other than Products and or Materials Manufacturing Technology developed pursuant to this CDP, and ATMI will be the sole licensor in the CDP Field to any IC Manufacturers, OEMS or to any stand-alone third-party materials manufacturers, of any Products developed and licensed by IM to ATMI pursuant to this CDP and or Materials Manufacturing Technology.

 

11.5.                         License Grants to IM

 

Subject to the terms and conditions of the Agreement and this CDP, ATMI grants IM (a) a worldwide, non-exclusive, non-transferable, royalty-free license under and to the ATMI

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Annex 1 to Exhibit A1 Page 6



 

Independent Technology solely to the extent necessary for IM to carry out its obligations under all phases of this CDP, and (b), to the extent that the Alliance Technology infringes any Intellectual Property Rights retained by ATMI in the ATMI Independent Technology or in the Materials Manufacturing Technology, a worldwide, non-exclusive, non-transferable, perpetual, irrevocable license to license and provide Alliance Technology (excluding Products and or Materials Manufacturing Technology) to any IC Manufacturers and OEMs solely to the extent necessary for IM to carry out its commercialization objectives as set forth in this CDP.  This license will be royalty free for use of the infringing Alliance Technology outside the CDP Field for continued internal research and development purposes by IM, and fee-bearing at rates or revenue share percentages to be agreed for commercialization licenses of infringing Alliance Technology outside the CDP Field.

 

12.                                Products and Commercialization Rights

 

Pursuant to this CDP and in this CDP Field only, ATMI may sell licensed [*] Products to IC Manufacturers, or sublicense semiconductor IC Manufacturers to make and use licensed [*] Products and or use Materials Manufacturing Technology, or license third parties to make and or distribute licensed ATMI [*] Products and or use Materials Manufacturing Technology.

 

Pursuant to this CDP, IM may sell services and or licenses to OEMs and IC Manufacturers for the purpose of enabling either or both to use ATMI [*] Products licensed by IM to ATMI.  In the case that an IC Manufacturer does not wish to procure from ATMI the [*] Products licensed by IM to ATMI, then the parties may elect to follow the procedure in Section 2.5 of the Agreement.  IM agrees that it would only license the [*] Products directly to any such IC Manufacturer with ATMI’s prior approval.

 

13.                                Exclusivity

 

13.1.                         Minimum Volumes .

 

There will be no requirement for Minimum Volume under this CDP to maintain exclusivity.

 

13.2.                         IM Activities outside of this CDP .

 

13.2.1. Exclusivity within CDP Field

 

During the time that ATMI has exclusivity pursuant to this CDP, IM shall not contract with an ATMI direct materials competitor in the CDP Field, absent separate written agreement with ATMI.

 

13.2.2. Third Party Activities

 

IM, in a development program with a Third Party  outside of the CDP Field, may determine that a specific Product, or an Agreement Compound within a TFS, created

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Annex 1 to Exhibit A1 Page 7



 

pursuant to this CDP may have efficacy for an application outside the CDP Field (“Third Party Opportunity”).  IM will promptly notify ATMI and the Operating Committee of any such Third Party Opportunity and, if ATMI so chooses, IM will use all reasonable efforts to engage ATMI as the materials vendor for that program.  IM agrees that it will not use the said Product or Agreement Compound outside the CDP Field with a materials vendor who is a direct competitor of ATMI, or otherwise, without agreeing to pay ATMI reasonable compensation for IM’s use of the Product and or Agreement Compound outside the CDP Field.  The Operating Committee shall meet promptly after notification by IM to determine, for the specific IM development program with a Third Party, reasonable compensation by IM to ATMI.  Disagreement of the Operating Committee regarding such compensation may be submitted for escalation to the chief executive officers of the parties pursuant to the Agreement.  If such escalation does not result in a mutually agreed compensation plan, then the revenue share or royalty amounts may be decided by an arbitrator as expressly set forth in this CDP.

 

14.                                Revenue Share or Royalties

 

14.1.                         Royalties on ATMI Product Sales .

 

ATMI, ATMI Affiliates and ATMI Licensees will Pay IM royalties or a revenue share for all ATMI Product sales and or royalties or a revenue share from ATMI licenses for the making, using and selling of Products within the CDP Field, as authorized by this CDP, according to ATMI’s royalty rate defined in Section 14.3.  For clarification, ATMI licenses shall exclude service fees, equipment sales, software sales, and other non-royalty fees from licenses, paid by third parties to ATMI in the CDP Field.  In addition, grants or development fees from government agencies will also be excluded from royalties on ATMI licenses.

 

14.2.                         Royalties on IM Licenses .

 

IM will pay ATMI royalties for all IM Licenses within the CDP Field which incorporate Alliance Technology developed pursuant to this CDP, according to IM’s royalty rate defined in Section 14.3.  For clarification, IM Licenses shall exclude CDP fees, HPC subscription fees, equipment sales, software sales, and other non-royalty fees from licenses, paid by third parties to IM in the applicable CDP Field(s).  In addition, grants or development fees from government agencies will also be excluded from royalties on IM Licenses.

 

14.3.                         Royalty rates .

 

Each party agrees to pay the other party [*] percent ([*]%) of the CDP Direct Gross Margin it receives from the sale or license of Products under this CDP in accordance with the provisions of Section 5 of the Agreement.  This amount may be recalculated on an annual basis pursuant to Annex 3 of this CDP.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Annex 1 to Exhibit A1 Page 8


 

14.4.                      Reporting of monthly activities .

 

Within four days of the end of each month, both parties will report Direct Revenue recognized during the prior month, multiplied by the agreed upon royalty rate defined in Section 14.3, and the resulting payment due.  On a [*] basis, the cumulative amounts due will be netted, and the resulting balance due will be paid from one party to the other within 30 days of the end of the [*].

 

14.5.                      Pricing .

 

Each party will have sole discretion to set the price of its own products.

 

14.6.                      Royalty obligations limited .

 

Termination of either the Agreement or a CDP for confirmed material breach by either party shall result in immediate termination of the licenses and subsequent royalty obligations defined in this CDP.

 

15.                                Sales & Marketing

 

The parties agree to develop and maintain a jointly defined and mutually agreed Sales & Marketing Plan which will guide how parties will collaborate to develop a Sales & Marketing Strategy for the developed technology, and how parties will collaborate to perform certain Sales and Marketing activities.

 

15.1.                      Existing Customers .

 

ATMI will define, develop and maintain the Product Sales & Marketing Plan for the sale or licensing of Products to ATMI’s existing [*] customers, after reviewing and consulting on such a plan with IM on a mutually agreeable schedule.

 

15.2.                      New Customers .

 

ATMI and IM shall jointly define, develop and maintain the Product Sales & Marketing Plan for the sale of Products and the licensing of Alliance Technology, excluding HPC Technology and Materials Manufacturing Technology, to each new [*] customer, on a case by case basis. The parties understand and acknowledge that careful and timely development and execution of such a Plan for new customers is critical to the commercial success of both parties under this CDP.

 

16.                                Payment

 

ATMI will pay the specific costs for the work set forth in Annex 2, Development Plan. Additional specific costs may be set forth in the Development Plan for any successive phases of the CDP prior to the completion of the previous phase.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Annex 1 to Exhibit A1 Page 9



 

17.                                Third Party Intellectual Property.

 

If either party intends to use third party technology or sublicense third-party Intellectual Property Rights, then it will list such third party technology or Intellectual Property Rights below or in the Development Plan.

 

ATMI:  Some of the [*] technology and [*] technology may include technology that is proprietary to and licensed from [*].

 

IM:  Some of the HPC Technology is proprietary to and licensed from [*].  Some of the electrical test technology is proprietary to and licensed from [*].

 

18.                                New Developments.

 

18.1.                     Opportunities in a New Field .

 

Each party affirms and commits that the first priority for investigation and development under this CDP shall be to meet its obligations described above.  However, the parties acknowledge that during Phase I or Phase II, but not to exceed [*] after the completion of Phase I development under this CDP, the parties may become aware of one or more development possibilities relating to the proposed Products, Agreement Compounds or Alliance Technology, excluding HPC Technology and or Materials Manufacturing Technology, for application in a field outside the CDP Field (“ New Field ”).  To best take advantage of these potential technology development or commercialization opportunities (“ Opportunities ”), the parties agree to adopt the following process for analyzing and dispositioning these Opportunities:

 

18.1.1.            Proposals .

 

In addition to the Change Order process set forth in the Agreement, during and up to the end of Phase I or during and up to the end of Phase II, but not to exceed [*] after the completion of Phase I, either or both parties may propose to the Operating Committee new or additional Opportunities conceived during the initial phase of this CDP that may be used for additional applications in a New Field (“ Proposal ”).  Any proposals for additional applications in the existing CDP Field will be determined pursuant to the Change Order process set forth in Section 2.7 of the Agreement.  Each Proposal must be in writing and must include at least the following: (i) the proposed Critical Parameter Set for the Agreement Compounds or Products and the use of such Agreement Compounds or Products in a specific field or application, (ii) objective data to quantify the feasibility of development and commercialization of the Agreement Compounds or Products underlying the proposed CPS in the application field, (iii) a quantifiable, objective preliminary assessment of the market opportunity for the proposed development or commercialization effort outlined in the proposed CPS in the proposed application field; and (iv) a preliminary cost and time estimate for development and commercialization.  For purposes of clarity, the specific cut-off date for the submission of proposals pursuant to this Section 18 shall be [*] after the end of Phase I or Phase II, but not to exceed [*] after the completion of Phase I, and after such date neither party may make new Section 18.1 proposals; nevertheless, in the course of the review process provided for in Section 

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Annex 1 to Exhibit A1 Page 10



 

18.1.1, the terms of any Proposal (as defined below) may be modified or supplemented and any such modified or supplemented proposal shall be considered to be timely delivered hereunder.

 

18.1.2.            Review Process .

 

The Operating Committee will meet and review all such Proposals within [*] after the end of Phase I or Phase II, but not to exceed [*] after the completion of Phase I development under this CDP.  Proposals which by mutual agreement meet the criteria defined in Section 18.1.1 will be identified as “Valid Proposals.”

 

(a)                                  Valid Proposals shall be reviewed, discussed and decided upon as a whole by the Operating Committee within [*] after the end of Phase I, or of Phase II, but not to exceed [*] after the completion of Phase I development under this CDP.  Determination by the Operating Committee and by the parties of whether a proposal constitutes a Valid Proposal will be made in good faith based on the technical and commercial feasibility of the proposal.  An affirmative decision of the Operating Committee regarding specific Valid Proposals may result in an extension of the existing CDP, the creation of additional CDPs, or the agreement that a party may proceed independently of the alliance to develop the application; with new CDP Field definitions, development resource and timeline commitments, subscriptions for use of IM HPC Systems (if applicable), CDP fees, revenue sharing terms or royalties, and other terms to be agreed upon in writing by the parties. Disagreements of the Operating Committee regarding Valid Proposals may be submitted for escalation to the chief executive officers of the parties pursuant to the Agreement.  If after escalation from the Operating Committee to senior management of the parties pursuant to the Agreement, the parties cannot in good faith agree on whether a specific proposal constitutes a Valid Proposal, either party may submit the determination of whether a proposal constitutes a Valid Proposal to arbitration as set forth in the Agreement.  If the parties agree that a Valid Proposal has been presented, but do not agree on cooperating for that Valid Proposal and do not agree on royalty or revenue share terms for one party to proceed independently, then a determination of the revenue share or royalty amounts may be decided by an arbitrator as expressly set forth in the arbitration provision set forth in Section 21 below.

 

(b)                                  proposal that is not a Valid Proposal, once so identified, shall not be further considered in the Review Process for this CDP, and no default licenses will be granted and no default revenue sharing or royalty terms will apply for such Proposals.

 

18.1.3.            Agreement Compounds or Products in a New Field .

 

For Valid Proposals for the application of Agreement Compounds or Products in a New Field, the parties agree to use all reasonable efforts to negotiate an agreement for the development and commercialization of those Opportunities.  If the parties cannot agree on a particular Valid Proposal, then the provisions of Section 18.1.5 shall apply.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Annex 1 to Exhibit A1 Page 11



 

18.1.4.            Agreement Compounds or Products inseparably tied to other Alliance Technology .

 

For Valid Proposals which consist of Agreement Compounds or Products inseparably tied to other Alliance Technology, excluding HPC Technology and or Materials Manufacturing Technology, for application in a New Field, IM shall propose to ATMI one or more CDPs to develop and commercialize those Opportunities.  If the parties cannot agree on the terms of the one or more new CDPs following reasonable, good faith negotiations, then the provisions of Section 18.1.5 shall apply.

 

18.1.5.            Provisions on Disagreement between the Parties Regarding Valid Proposals .

 

If the parties cannot agree on a particular Valid Proposal and the terms associated with that proposal pursuant to the review process set forth above, the following terms shall apply to such Valid Proposals:

 

(a)                                  ownership of any inventions, discoveries, data, know-how, materials, compounds, sequences of compounds, methods, processes, or technology shall be determined as set forth in this CDP;

 

(b)                                  ATMI shall have a non-exclusive, non-transferable, fee-bearing license to commercialize any Agreement Compounds or Products specified in an ATMI Valid Proposal, limited to the New Field specified in the applicable proposal, and for such an ATMI Valid Proposal (i) IM shall not actively and intentionally seek to sell CDP agreements to ATMI’s direct materials competitors for the same applications in the same New Field, and (ii) ATMI may at a later time purchase exclusivity for this license from IM as set forth in Section 18.2.2 below;

 

(c)                                   no use of HPC Technology, IM Independent IP or Alliance Technology (other than any Alliance Technology, excluding HPC Technology, specified in the Valid Proposal and or specific Alliance  Technology mutually agreed upon by the parties at a later date necessary to commercialize the licensed Agreement Compounds or Products in a manner consistent with the Valid Proposal) may be made by ATMI to develop or commercialize the Valid Proposal without the prior written approval of IM and payment of any applicable subscription or other fees; ATMI will receive no right to use IM’s HPC Systems for any development or commercialization of a Valid Proposal absent separate written agreement with IM;

 

(d)                                  royalties shall be as described in Section 14 of this CDP;

 

(e)                                   ATMI shall offer IM a limited right of first negotiation for no more than [*] days following receipt of a customer opportunity to provide process or materials integration or HPC Technology services to potential customers of the Products developed by ATMI regarding the Materials specified in the Valid Proposal;

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Annex 1 to Exhibit A1 Page 12



 

(f)                                    IM shall offer ATMI a limited right of first negotiation for no more than [*] following receipt of a customer opportunity to provide Materials to potential IM customers regarding the processes or other Alliance Technology specified in the Valid Proposal; and

 

(g)                                   Unless IM grants ATMI rights pursuant to subsection (b) and (c) above, IM shall have exclusive rights to commercialize any Alliance Technology, excluding Materials Manufacturing Technology , that is specified in the Valid Proposal, limited to the field specified in the applicable proposal.

 

18.2.                     Exclusivity for New Developments

 

18.2.1.            General .

 

If ATMI makes a Valid Proposal for additional development and commercialization pursuant to this Section 18, and the parties do not agree on a development and commercialization plan based on that proposal, and ATMI elects to pursue the development and commercialization independently as set forth herein, then ATMI may elect to purchase exclusivity for the license and use of Agreement Compounds or Products for that Valid Proposal.  The price for exclusivity will be agreed upon by the parties on a case-by-case basis depending, among other considerations, on the duration of exclusivity desired by ATMI, proposed application, and ATMI’s independent development and commercialization efforts.

 

18.2.2.            Subsequent purchase of exclusivity for a new CDP field .

 

If in the case described by 18.1.5(b), and through no active and intentional effort of IM, a direct materials competitor of ATMI requests IM to collaborate on a CDP which conflicts with an ATMI Valid Proposal, IM shall promptly notify ATMI in writing of such request.  ATMI shall then, within [*] days following receipt of the notice, have the right but not the obligation to negotiate with IM to convert the non-exclusive license to an exclusive license for a new CDP field.  The price for exclusivity will be agreed upon by the parties on a case-by-case basis depending, among other considerations, on the duration of exclusivity desired by ATMI, proposed application, and ATMI’s independent development and commercialization efforts.  If the parties cannot agree on the terms for such a conversion, and if IM subsequently engages in that CDP with ATMI’s direct materials competitor, then the parties agree as follows:

 

(a)                                  ATMI shall continue to have a non-exclusive, non-transferable, fee-bearing license to commercialize any Products and or Agreement Compounds, or derivatives specified in the applicable ATMI Valid Proposal, limited as before to the New Field specified in the applicable proposal;

 

(b)                                  IM shall have no right to use the Products and or Agreement Compounds, or derivatives, specified in the applicable ATMI Valid Proposal, in that CDP with ATMI’s direct materials competitor, absent separate written agreement with ATMI;

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Annex 1 to Exhibit A1 Page 13



 

(c)                                   the royalty rates in Section 18.1.5 (d) will cease to apply to the applicable Valid Proposal;  absent agreement on the terms for such an exclusivity conversion [*] days following notification by IM to ATMI, the parties agree as follows:

 

The royalty rate paid by ATMI to IM henceforth will be [*]% of ATMI’s associated Direct Revenues.

 

The royalty rate paid by IM to ATMI henceforth will be [*]% of IM’s associated Direct Revenues.

 

For the purposes of this CDP, the following definitions will apply:

 

“Direct Revenues” means revenue directly resulting from the Sale of Products, as defined under US GAAP for shipped goods, or licensing rights related to the use of Products developed under this CDP.

 

“Sale of Products” means Product sales or license revenues from sublicenses of Products developed under this CDP resulting from use of Alliance Technology developed under this CDP and as defined under US GAAP for revenue recognition.

 

18.3.                      Additional Development Proposals .

 

Either party may at any time make proposals for additional development and commercialization opportunities outside of the process described in this Section 18, but if the parties do not agree, then no default licenses will be granted and no default revenue sharing or royalty terms will apply.

 

18.4.                      Additional Commercialization Proposals .

 

Either party may at any time make proposals for additional commercialization of opportunities which use an Agreement Compound or Product developed pursuant to this CDP, but which do not require further development using HPC Technology, outside of the process described above in this Section 18.  If the parties do not agree, then (i) IM shall grant ATMI a worldwide, non-transferable, royalty-bearing, non-exclusive license, with right of sublicense as set forth below, in any field within the Field described in the Agreement, under and to the applicable Alliance Technology, but excluding HPC Technology, necessary to develop, make, have made, import, export, sell, offer for sale, and/or otherwise commercialize the Agreement Compounds or Products developed in this CDP, (ii) ATMI shall grant IM a worldwide, non-transferable, royalty-bearing, non-exclusive license, with right of sublicense as set forth below, in any field within the Field, under and to the applicable ATMI Independent IP and  Materials Manufacturing Technology developed during the course of this CDP and necessary to license and provide Alliance Technology (excluding Agreement Compounds or  Products, and in the CDP Field, Materials Manufacturing Technology) to any IC Manufacturers and OEMs and (iii) each party agrees to pay the other party [*] percent ([*]%) of the Direct Revenues it receives from the sale or license of such Agreement Compounds or Products. 

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Annex 1 to Exhibit A1 Page 14



 

Subject to the terms and conditions of the Agreement and this CDP, ATMI may grant and authorize sublicenses under the rights granted above to Third Parties and to its Affiliates.

 

19.                                Intellectual Property Procurement and Enforcement

 

Notwithstanding Section 6.1.2 of the Agreement, in the event that IM decides not to pursue patent protection for Products or features of Products, and notifies ATMI via the Operating Committee that it will not seek patent protection for a particular Product, ATMI shall have the opportunity, at its own expense, to pursue and maintain such patent protection based on detailed written submissions to the Operating Committee, including the right to file and prosecute patent applications covering such Products or features of Products, and to maintain any patents resulting therefrom.  All patent applications, patents, and Intellectual Property Rights resulting from ATMI’s election under this provision shall be solely owned by ATMI as ATMI Independent Technology, subject to a non-exclusive, royalty-free, perpetual and irrevocable grant-back license to IM, without right of sublicense, to IM under the resulting patent(s) to make, have made, use, offer to sell, sell and import products; provided, however, that any such grant back license shall be subject to any exclusivity, revenue share and royalty provisions agreed upon by the parties for that CDP Field.  IM agrees to promptly provide notice to ATMI of any decision not to pursue patent protection for Products or features of Products or as required under Section 7.4 of the Agreement.  ATMI agrees that, before proceeding with filing or prosecuting patents for any such inventions, at the next possible Operating Committee meeting the parties shall discuss and use all reasonable efforts to agree on a course of action for protection of the inventions, including trade secret protection.

 

20.                                Effect of Termination

 

Pursuant to Section 10.3 of the Agreement, Section 11.1 and any existing payment obligations shall survive the expiration or termination of this CDP for any reason.  The licenses granted under the Agreement applicable to this CDP and granted in this CDP, including limited use restrictions pursuant to Section 4.5 of the Agreement, will be extended past the expiration of this CDP and the Agreement on the same royalty and revenue share terms, provided that there has been no material breach of this CDP or the Agreement resulting in the termination of this CDP or the Agreement.

 

21.                                “Baseball” Arbitration

 

Notwithstanding Section 11.16 of the Agreement, in the event that the parties cannot agree after escalation to their respective chief executive officers to a default royalty or revenue share amount for a Section 18.1 proposal within the ranges specified in this CDP, then the dispute shall promptly be submitted to final and binding arbitration, before a single, mutually-acceptable arbitrator, conducted in accordance with the Commercial Arbitration Rules of AAA, solely for determination of the default royalty or revenue share amount.  If the parties are unable to select a mutually acceptable arbitrator, AAA shall appoint an arbitrator or provide a method for selection.  Any arbitration proceedings shall be conducted in San Jose, California. Each party shall bear its own expenses, including attorneys’ fees, and the parties will share equally the costs and fees of the

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Annex 1 to Exhibit A1 Page 15



 

arbitrator.  Prior to the actual arbitration hearing, each party shall provide the arbitrator a written proposal of a revenue share or royalty percentage, whether within the range set forth in this CDP or otherwise, that such party believes to be fair to both parties in the circumstances.  The arbitrator must render a written decision within ten (10) days of the hearing in favor of one party’s proposal or the other, without modification.  The arbitrator must determine the prevailing party by assessing the proposal, its conformance with the requirements of Section 18, and its fairness in light of the relevant Intellectual Property Rights, technology contributions, and development and commercialization costs and expenses of each party, as well as the potential markets for the proposed application and whether third party Intellectual Property Rights, development efforts, commercialization efforts or investment is required to commercialize the proposed application.  The parties shall use all reasonable efforts to complete any arbitration subject to this section within three (3) months from the filing of notice of a request for such arbitration. Judgment upon any decision rendered by the arbitrators may be entered by any court having jurisdiction. The parties undertake and agree that all arbitral proceedings shall be kept confidential, and all information, documentation, materials in whatever form disclosed in the course of such arbitral proceeding shall be used solely for the purpose of those proceedings.

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their authorized representatives and delivered in duplicate originals as of the Effective Date.

 

 

INTERMOLECULAR, INC.

 

ADVANCED TECHNOLOGY MATERIALS, INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/

 

By:

/s/

 

 

 

 

 

 

 

 

 

 

Title:

President & CEO

 

Title:

President & C.E.O.

 

 

 

 

 

 

 

 

 

 

Date:

11/17/06

 

Date:

November 20, 2006

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Annex 1 to Exhibit A1 Page 16


 

ANNEX 1 TO EXHIBIT A1

 

DESCRIPTION OF PROPOSED WORKFLOW

[*] Collaborative Development Program (and Optional [*] CDP)

 

Screening
Tier

 

Workflow Element (WFE) Req’d.

 

Type

 

CDP as Defined
(By & Location)

 

If Subscription Agreement
Executed
(By & Location)

 

Comment

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Annex 1 to Exhibit A1 Page 1



 

ANNEX 2 TO EXHIBIT A1
DEVELOPMENT PLAN

 

(To be finalized by Parties)

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

ANNEX 3 TO EXHIBIT A1
CALCULATION OF CDP DIRECT GROSS MARGINS

 

On [*] basis, but no less than [*] prior to the end of the calendar [*], the parties agree to (a) jointly forecast, for the remainder of the Alliance Term (or other term as the parties may mutually agree, but in no case less than [*]) CDP Direct Gross Margin and any other CDP-related revenues described below; (b) use the joint forecast to calculate and mutually agree on royalty percentages for the subsequent calendar [*] to achieve an equal share of the CDP Direct Gross Margin; (c) apply such royalty percentages during the subsequent year as calculated by the agreed upon CDP Direct Gross Margin and stated as a percentage of direct revenues.

 

For purposes of this CDP, the following terms will have the meanings set forth below:

 

CDP Direct Gross Margin — The CDP Direct Gross Margin will be the result of the Direct Revenues less Direct Costs derived from Alliance Technology, excluding HPC Technology and Materials Manufacturing Technology, pursuant to a CDP.

 

Direct Revenues - Revenue directly resulting from Alliance Technology, excluding HPC Technology and Materials Manufacturing Technology, developed under a CDP and as defined under US GAAP for shipped goods.

 

Sale of Products — Product sales resulting from use of Alliance Technology, excluding HPC Technology and Materials Manufacturing Technology, developed under a CDP and as defined under US GAAP for revenue recognition.

 

Licensing of Alliance Technology — License revenue resulting from Alliance Technology, excluding HPC Technology and Materials Manufacturing Technology, developed under a CDP and as defined under US GAAP for revenue recognition.

 

Direct Costs

 

Direct costs to produce products sold — the variable and incremental cost of the product sold, reported in cost of goods sold, as defined under US GAAP (ATMI Comment:  the parties should do whatever is within US GAAP.  This could include material cost, variable manufacturing cost, and third-party contract manufacturing cost.  Any allocation of variable costs will be determined on a reasonable basis and agreed to by both parties in writing.  In general, indirect or fixed costs, including general overhead, provisions and reserves will be excluded from direct costs, unless agreed to by both parties in writing.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

Direct distribution costs of products sold — the cost of the distribution of product sold, reported in costs of goods sold, as defined under US GAAP.  This may include shipping, shipping material, duty, and other direct logistics costs.  Any allocation of variable costs will be determined on a reasonable basis and agreed to by both parties in writing.  In general, indirect or fixed costs, including general overhead, provisions and reserves will be excluded from direct costs, unless agreed to by both parties in writing.

 

Direct third party royalty / license costs - the variable cost of amounts due to a third party for licensed technology or intellectual property included in or infringed by the Alliance Technology and / or related to products sold, as defined under US GAAP.  In general, indirect or fixed costs, including general overhead, provisions and reserves will be excluded from direct costs, unless agreed to by both parties in writing.

 

Other direct costs - other direct costs as the parties may mutually agree.

 

All other costs are excluded.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 




Exhibit 10.5

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Wets Workflow Purchase Agreement

 

This Wets Workflow Purchase Agreement (the “Agreement”), effective as of July 13, 2007, or, if left blank, the last date of signature by a party hereto (the “ Effective Date ”), is made by and between Advanced Technology Materials, Inc., with a principal place of business at 7 Commerce Drive, Danbury, CT 06810 (“ ATMI ”), and Intermolecular, Inc., with a principal place of business at 2865 Zanker Road, San Jose, California 95134 (“ IM ”).  ATMI and IM are sometimes referred to herein individually as a “party” and collectively as the “parties.”

 

BACKGROUND

 

IM and ATMI entered into the Alliance Agreement (defined below) and began working on a collaborative development program directed at a [*] application in November 2006.  The parties entered into discussions in March 2007 and signed an LOI in May 2007 to align their interests with respect to the development and sale by IM of a workflow for Wets Processing as contemplated in this Agreement.  IM and ATMI now wish to define the terms and conditions under which IM may sell to ATMI and install on its premises one or more workflows for Wets Processing.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as set forth below.

 

The following exhibits are hereby incorporated into the Agreement:

 

Exhibit A:  Purchase Documentation for Initial Purchase

Exhibit B:  Symyx End User License Agreement

Exhibit C:  IM Maintenance and Support Services

Exhibit D:  Supplemental Workflow Use Acceptance Criteria

 

Capitalized terms in the Exhibits have the meaning assigned to them in the body of the Agreement, unless otherwise separately defined in the relevant Exhibit.

 

ARTICLE 1
DEFINITIONS

 

1.1                                  Adobe Software ” means machine readable, object code versions of software provided by IM to ATMI  pursuant to this Agreement (if identified in Purchase Documentation), and licensed by Adobe Systems Incorporated to ATMI in accordance with the terms and conditions of ATMl’ s end user license agreement with Adobe.

 

1.2                                  Affiliate ” means any entity directly or indirectly controlling, controlled by or under common control with, a party to this Agreement.  For purposes of this Agreement, only the direct or indirect ownership of fifty percent (50%) or more of the voting securities of an entity shall be deemed to constitute control.

 

1



 

1.3                                  Alliance Agreement ” means the agreement between the Parties with that title executed with an effective date of November 17, 2006.

 

1.4                                  Agreement WF Compound ” means any Lead WF Compound or Derivative WF Compound.

 

1.5                                  Alliance Technology ” has the meaning assigned to it in the Alliance Agreement.

 

1.6                                  ATMI Independent Technology ” means all Intellectual Property Rights (other than Alliance Technology) that is (i) owned, licensed or otherwise controlled by ATMI on or prior to the Alliance Agreement Effective Date; or (ii) created, conceived or reduced to practice by ATMI employees, contractors or agents without reliance upon, use of or benefit of (a) the HPC Technology, (b) the HPC-Derived Technology licensed or developed hereunder, (c) IM Independent IP, or (d) any technology, know-how or technical information provided by or obtained from an IM employee, contractor or agent, directly and or indirectly.

 

1.7                                  Competitor ” means a direct Materials competitor of ATMI, as listed by ATMI in writing at the time of any Formal Disclosure, but in any event shall include the following companies (which list may be updated from time to time by mutual agreement of the parties, which agreement shall not be unreasonably withheld):  [*], and [*].

 

1.8                                  Confidential Information ” means any information disclosed by one party to the other in connection with this Agreement, whether in electronic, written, graphic, oral, machine readable or other tangible or intangible form, that is (i) marked or identified at the time of disclosure as “Confidential” or “Proprietary” or in some other manner so as to clearly indicate its confidential nature, or (ii) if disclosed orally should reasonably be considered confidential by the receiving party given the nature of the information or the circumstances of its disclosure.

 

1.9                                  Derivative WF Compound ” means any compound or mixture that is made or derived from a Lead WF Compound pursuant to this Agreement.  As used in this Agreement, a compound or mixture shall be deemed to have been “derived from” a Lead WF Compound if it results from the use of HPC Technology, Alliance Technology, or IM Independent IP, or is otherwise related to a Lead WF Compound.  For the purpose of this definition, “otherwise related” shall mean any further modifications to a Lead WF Compound or Derivative WF Compound outside of this Agreement, including any compound based on structure and/or performance data relating to one or more Lead WF Compounds.  Derivative WF Compounds shall also include a compound that is synthesized, based on, or

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2



 

derived from another Derivative WF Compound pursuant to this Agreement.  “Derivative WF Compound” shall not include any compound or mixture developed independently by ATMI or its Affiliates or sublicensees without reliance on Alliance Technology or IM Independent IP, and that does not infringe or misappropriate the Alliance Technology or IM Independent IP.

 

1.10                            Equipment ” means Wets Workflow hardware tools (excluding Informatics Hardware) that may be sold pursuant to this Agreement, conforming to the Specifications set forth in the Purchase Documentation.

 

1.11                            Excluded Company ” means any of the following three (3) companies or their Affiliates who compete with ATMI in the Wets Processing markets:  [*], and [*].

 

1.12                            Field ” means the “Field” defined in that certain agreement, effective as of December 19, 2005, forming an alliance between IM and Symyx Technologies, Inc. (also termed an Alliance Agreement), as such definition in such agreement may be expanded from time to time.

 

1.13                            HPC Technology ” means all techniques, methodologies, processes, test vehicles, synthetic procedures, technology, systems, or combination thereof (collectively, “Techniques”) (a) subject to or covered by any Intellectual Property Right owned by IM or licensed to IM, (b) provided by IM to ATMI and (c) used for the simultaneous parallel or rapid serial:  (i) design, (ii) synthesis, (iii) processing, (iv) process sequencing, (v) process integration, (vi) device integration, (vii) analysis, or (viii) characterization of more than two (2) compounds, compositions, mixtures, processes, or synthesis conditions, or the structures derived from such. HPC Technology does not include any of the foregoing Techniques to the extent they were (A) used by ATMI prior to [*], (B) created, conceived or reduced to practice by ATMI independent of both this Agreement and the Alliance Agreement, without reliance on or use or benefit of Alliance Technology, IM Independent IP, or any technology, know-how or information provided by or obtained from an IM employee, contractor or agent, directly and or indirectly.  It is understood that test vehicles include physical and or electrical characterization devices such as test structures or chips, used in the design, process development, manufacturing process qualification, and manufacturing process control of Integrated Circuit devices.  It is also understood that HPC Technology does not include the use of equipment that is commercially available (from parties other than IM) in commercial manufacturing for nominally uniform processing of one or more identical Integrated Circuits on a single substrate, or the use of such equipment in research and development for nominally uniform processing of one or more Integrated Circuits on a single substrate.

 

1.14                            HPC-Enabled Informatics Software ” means software that enables Equipment to use HPC Technology.  “ Non-HPC-Enabled Informatics Software ” means

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

3



 

software that operates Equipment without enabling it to utilize HPC Technology.  Use of HPC-Enabled Informatics Software at a Site requires an HPC Site License, in addition to a license to use the software.

 

1.15                            HPC Site License ” means a license to use HPC Technology at a specific Site, for the term specified in the Purchase Documentation.

 

1.16                            Informatics Hardware ” means the information technology hardware manufactured by Third Parties, conforming to the specifications therefor as described in Purchase Documentation.

 

1.17                            Informatics Software ” means machine readable, object code versions of the software licensed to be used with the Informatics Hardware, and related documentation, together with the Updates, if any that may be provided by IM to ATMI during its license term.  Informatics Software may consist of either HPC-Enabled Informatics Software or Non-HPC-Enabled Informatics Software.  Informatics Software does not include Third Party Software.

 

1.18                            IM Independent IP ” means all Intellectual Property Rights that are (i) owned, licensed or otherwise solely controlled by IM as of the Effective Date; or (ii) created, conceived or reduced to practice by IM employees, contractors or agents without reliance, use or benefit of (a) ATMI Independent Technology or (b) technology, know-how or technical information provided by or obtained from an ATMI employee, contractor or agent, directly and or indirectly and including the HPC Technology.

 

1.19                            Intellectual Property Rights ” means rights in and to any and all (i) U.S. and foreign patents and patent applications claiming any inventions or discoveries made, developed, conceived, or reduced to practice, including all divisions, substitutions, continuations, continuation-in-part applications, and reissues, reexaminations and extensions thereof, (ii) copyrights, (iii) unpatented information, trade secrets, data, or materials, (iv) trademarks, service marks, trade names, trade dress, domain names and similar rights, (v) mask work rights, and (vi) any other intellectual or other proprietary rights of any kind now known or hereafter recognized in any jurisdiction.

 

1.20                            Lead WF Compound ” means a compound or material identified, first synthesized, or discovered in whole or in part through use of any Wets Workflow provided through this Agreement.

 

1.21                            Material ” means a specific compound or composition of materials.

 

1.22                            Materials Manufacturing Technology ” means any data, know-how, techniques, methods, processes, or other technologies for the synthesis, production, packaging, shipping or distribution of commercial quantities of one or more Products, excluding HPC Technology, that is developed, directly or indirectly,

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

4



 

through the use of the Wets Workflow that is provided in connection with this Agreement.

 

1.23                            Metrology/Characterization Technology ” means technology relating to measurements, systems, methods, techniques, test vehicles, synthetic procedures or combination thereof, used to measure Materials or  processing characteristics or parameters of wafers, wafer samples or other substrates.

 

1.24                            Microsoft Software ” means machine readable, object code versions of software provided by IM to ATMI pursuant to this Agreement (if identified in Purchase Documentation), and licensed by Microsoft Corporation to ATMI in accordance with the terms and conditions of ATMI’s end user license agreement with Microsoft.

 

1.25                            Named User ” means an ATMI employee or subcontractor, or other party with the prior written consent of IM, who has signed a nondisclosure agreement as restrictive as the confidentiality terms set forth herein and who uses the Informatics Software, or any part of the Informatics Software.  Named Users may be changed or replaced according to reasonable and ordinary business practices such as termination of employment or changes in job function.

 

1.26                            Oracle Software ” means machine readable, object code versions of software provided by IM to ATMI pursuant to this Agreement (if identified in Purchase Documentation), and licensed by Oracle Corporation to ATMI in accordance with the terms and conditions of ATMI’s agreement with Oracle.

 

1.27                            Product ” means a Material that incorporates an Agreement WF Compound or utilizes an Agreement WF Compound in its manufacture and/or methods of using the same.

 

1.28                            Purchase Order ” means a valid purchase order issued by ATMI to IM in response to a Quote, and that incorporates by reference the terms and conditions of this Agreement and the applicable Quote.

 

1.29                            Purchase Documentation ” has the meaning set forth in Section 2.2.

 

1.30                            Quote ” means the applicable IM sales quotation document issued to ATMI that incorporates by reference the terms and conditions of this Agreement, and that includes an offer for sale of one or more of the following:  the combination described in the applicable quotation of (a) Equipment, (b) Informatics Hardware, (c) licenses to use HPC-Enabled or Non-HPC-Enabled Informatics Software, (d) licenses to use Symyx Software, Oracle Software and/or Microsoft Software; (e) Services in connection with the configuration, and installation of Equipment and/or Informatics Hardware, and/or (f) other Services in connection therewith.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

5



 

1.31                            Services ” means services that IM performs for ATMI as described in any Purchase Documentation.

 

1.32                            Site ” means a building specifically identified in the applicable Purchase Documentation, or a replacement site as subsequently agreed by the parties in writing, which agreement shall not be unreasonably withheld.  Notwithstanding the foregoing, in the case of a Wets Workflow sale to ATMI, the HPC Site License for the original licensed Site shall be deemed to apply to any Wets Workflow at any site that is, now or in the future, owned or leased or rented or otherwise controlled by ATMI or an Affiliate, so long as ATMI is not in breach of this Agreement.

 

1.33                            Software FX, Inc. Software ” means machine readable, object code versions of software provided by IM to ATMI pursuant to this Agreement (if identified in Purchase Documentation), and licensed by Software FX, Inc. to ATMI in accordance with the terms and conditions of ATMI’s end user license agreement with Software FX.

 

1.34                            Specifications ” means specifications of and requirements for (a) any of the Equipment or Informatics Hardware sold in connection therewith, or (b) HPC-Enabled Software or Non-HPC-Enabled Informatics Software licensed in connection therewith.

 

1.35                            Symyx Software ” means machine readable, object code versions of software licensed by Symyx Technologies, Inc., and, if identified in the Purchase Documentation, sublicensed by IM to ATMI in accordance with the terms and conditions set forth in Exhibit B.

 

1.36                            Support ” means the maintenance and support Services as described in Exhibit C, for the term specified in the applicable Quote.

 

1.37                            Third Party ” shall mean any person or entity other than ATMI and its Affiliates, IM and its Affiliates, and their permitted assigns.

 

1.38                            Third Party Software ” is software that may be provided as part of a Wets Workflow that is published by a third party (e.g. Symyx Technologies, Inc., Oracle Corporation, Adobe Systems Incorporated, Software FX Inc., or Microsoft Corporation).

 

1.39                            Wets Processing ” means a set of operations for the development or application of liquid or fluid-based Materials, which Materials are used in semiconductor manufacturing for cleaning, etching, or electro less deposition

 

1.40                            Wets Workflow ” means the combination of one or more of the following as described in the applicable Quote:  Equipment; Informatics Hardware; Third Party Software and/or Informatics Software; an HPC Site License.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

6



 

ARTICLE 2
QUOTES; PURCHASE ORDERS

 

2.1                                  Purchases .  This Agreement sets forth terms and conditions under which IM may sell to ATMI one or more Wets Workflows, and the terms and conditions under which IM may provide related Services.

 

2.2                                  Purchase Documentation .  Each Purchase Order that IM accepts, together with the accompanying Quote, the Specifications, any acceptance criteria in connection with the sale and purchase (“ Acceptance Criteria ”) and any Statement of Work for additional Services to be provided in connection therewith, shall constitute “ Purchase Documentation ”.  Notwithstanding the foregoing, additional provisions regarding Specifications and Acceptance Criteria for the first Wets Workflow are set forth in Exhibit D, which shall be deemed part of the Purchase Documentation.  The Purchase Documentation for the initial purchase is set forth in Exhibit A. Exhibit A-1 is a Quote for a second Wets Workflow for installation in an ATMI facility, with acceptance in 2008.  If ATMI places a second purchase order with IM by the end of March, 2008, IM shall provide a volume discount for that second Wets Workflow, as shown in Exhibit A-1; if IM accepts said purchase order, it shall be deemed to have been incorporated into Exhibit A-1 as Purchase Documentation (it being understood and agreed that IM will accept said purchase order if it is consistent with the terms of the Quote incorporated into Exhibit A-1, subject to mutual agreement concerning delivery date and shipping instructions). Each subsequent set of Purchase Documentation shall be deemed to be incorporated herein as Exhibit A-2, Exhibit A-3, et seq ., and together with the terms and conditions of this Agreement, shall constitute the complete agreement regarding that purchase and sale.  Notwithstanding the foregoing, nothing contained in any Purchase Order, Purchase Order acknowledgment, or invoice shall in any way modify the terms and conditions of this Agreement, or add any additional terms or conditions; provided, however, that such standard variable terms as price, quantity, delivery date, shipping instructions and the like, as well as tax exempt status, if applicable, shall be specified on each purchase order or acknowledgment.  Any purchase order ATMI issues will include the fees and payment terms as set forth in the applicable Quote.  IM will accept each said purchase order if it is consistent with the terms of the offer set forth in the applicable Quote, subject to mutual agreement concerning delivery date and shipping instructions.  ATMI’s issuance of a Purchase Order referencing a Quote will constitute its agreement to pay IM the fees, plus applicable taxes as set forth below, in accordance with and subject to the terms of this Agreement (including, without limitation, ATMI’s acceptance rights hereunder).  Any software provided hereunder is licensed, not sold, to ATMI and any reference to the “sale” or “purchase” of software shall be deemed to mean “license.”

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

7



 

ARTICLE 3
DELIVERY; ACCEPTANCE; TRAINING, SUPPORT, AND OTHER SERVICES

 

3.1                                  Wets Workflow Assembly and Target Deliver Date .  IM shall use commercially reasonable efforts to complete assembly and configuration of each part of a Wets Workflow identified in Purchase Documentation and deliver same on or before the applicable target delivery date specified therein for that part (“ Target Delivery Date(s) ”).  ATMI acknowledges that the Target Delivery Date(s) are in fact targets; provided, however, that if IM misses a Target Delivery Date, ATMI may terminate the applicable Purchase Documentation in accordance with the provisions of Section 11.2(i).

 

3.2                                  Factory Acceptance .  IM shall provide ATMI with written notice that it has completed the assembly and configuration of any Wets Workflow item that ATMI is purchasing hereunder, which is to be completed on-site at IM’s facilities, and that it is accordingly ready to arrange for delivery.  Prior to such delivery, IM shall demonstrate to ATMI that any Wets Workflow item sold pursuant to the Purchase Documentation satisfies the Acceptance Criteria set forth therein and shall allow ATMI to conduct tests to ensure compliance with said Acceptance Criteria at IM’s facilities.  This demonstration and testing shall take place at IM’s facilities (ATMI will pay its own expenses to attend), and shall commence no later than ten (10) business days following said written notice.  Upon completion of said demonstration and testing, ATMI will either (i) confirm in writing that factory acceptance of the Wets Workflow item has occurred, and ATMI shall make the payment associated therewith as set forth in the Purchase Documentation, or (ii) identify with reasonable detail any deficiencies, in which case IM will promptly remedy the same and the foregoing demonstration and testing will be repeated.  If IM is unable to remedy the deficiency, ATMI may terminate the applicable Purchase Documentation in accordance with the provisions of Section 11.2(i).

 

3.3                                  Delivery and Final Acceptance .  Upon factory acceptance of a Wets Workflow item, IM will prepare the Wets Workflow item for shipment.  ATMI shall bear all expenses of insurance, packaging and transportation.  Title to the Equipment and Informatics Hardware and/or software licenses sold in connection therewith shall pass to ATMI at IM’s site upon delivery to the shipper, on the date so delivered (the “ Delivery Date ”).  ATMI shall prepare the site for installation of the Wets Workflow item in accordance with the Site preparation specification set forth in the Purchase Documentation prior to the Delivery Date.  IM will assist ATMI with the process of unpacking the Equipment and Informatics Hardware at the Site designated in the Purchase Documentation, and with its installation at the Site.  Upon completion of the installation, IM and ATMI will repeat the demonstration and testing, respectively, in order to ensure that the Wets Workflow item meets the Acceptance Criteria that occurred in connection with factory acceptance.  Upon completion of said demonstration and testing, ATMI will either (i) confirm in writing that final acceptance of the Wets Workflow item has occurred, and

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

8



 

ATMI shall make the payment associated therewith as set forth in the Purchase Documentation, or (ii) identify with reasonable detail any deficiencies, in which case IM will promptly remedy the same and the foregoing demonstration and testing will be repeated.  If IM is unable to remedy the deficiency, ATMI may terminate the applicable Purchase Documentation in accordance with the provisions of Section 11.2(i).  Notwithstanding the foregoing, if said demonstration cannot take place in a timely fashion because the Site has not been prepared in accordance with the Site preparation specification set forth in the Purchase Documentation as of the Delivery Date, final acceptance shall be deemed to have occurred thirty (30) days following the Delivery Date.

 

3.4                                  Support; Training; Services .  IM will provide ATMI with the Support and the training specified in Exhibit C.  For any future purchases, the Support to be provided will be subject to any modifications set forth in the Purchase Documentation.  Any additional Services to be provided by IM will be provided on a time and materials basis at its then-current rates (plus reasonable travel expenses, if any) pursuant to a mutually executed statement of work.

 

ARTICLE 4
PROPRIETARY RIGHTS; LICENSES; UPDATES; EXCLUDED COMPANIES; SOURCE CODE ESCROW

 

4.1                                  Alliance Agreement .  Nothing in this Agreement is intended to modify the respective rights and obligations of the Parties as set forth in the Alliance Agreement.  Moreover, for the avoidance of doubt, the parties affirm that they do not intend for this Agreement to supersede the terms of any CDP the parties have executed pursuant to the Alliance Agreement, or that the parties subsequently execute.

 

4.2                                  Proprietary Rights .  As between ATMI and IM, ATMI shall be the sole owner of all right, title, and interest in and to (i) the ATMI Independent Technology, (ii) Intellectual Property Rights relating to Materials or Products and methods of using Materials or Products, (iii) Metrology/Characterization Technology that is not HPC Technology, and (iv) Materials Manufacturing Technology, and improvements to any of the foregoing (“ ATMI Technology ”) derived through ATMI’s use of the Wets Workflow purchased herein.  IM will grant and hereby grants to ATMI all right, title, and interest in and to said ATMI Technology.  All rights to ATMI Technology and any improvements thereto not expressly granted in the Agreement shall be reserved to ATMI.  As between ATMI and IM, IM shall be the sole owner of the IM Independent IP, Metrology/Characterization Technology that is HPC Technology, HPC Technology, and any improvements to any of the foregoing (“ IM Technology ”).  All rights to IM Technology and any improvements thereto shall be reserved to IM.  ATMI will grant and hereby grants to IM all right, title, and interest in and to said IM Technology.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

9



 

4.3                                  Licensed Software .  ATMI shall not be an owner of any copies of the Informatics Software, Third Party Software or any documentation delivered to ATMI, but is rather licensed pursuant to this Agreement to use any of the Informatics Software or documentation specified in Purchase Documentation, or licensed pursuant to the applicable license agreement for Third Party Software.  ATMI acknowledges and agrees that the features or the graphical user interface of the Informatics Software (the “User Interface”), including, without limitation, icons, menus and screen designs, screen layouts, and command and screen sequence, are proprietary to IM and/or its licensors, and are disclosed to ATMI under a condition of confidentiality.  ATMI agrees that it will not create software programs incorporating any proprietary part of the User Interface.  Nevertheless, if ATMI creates one or more data loaders for metrology and/or testing equipment that it wishes to integrate into the Wets Workflow, IM will work with ATMI on a time and materials basis (subject to the mutual prior written agreement of the parties and at IM’s then-current IM monthly FTE rate (the rate in the most recent Quote, as set forth in Exhibit A, shall be valid for a period of 1 year) to facilitate the use of said data loader(s) with the User Interface.  ATMI further acknowledges that the User Interface is a copyrighted work of IM and/or its licensors.

 

4.4                                  License Grant for Informatics Software; HPC Site License .  Subject to the terms and conditions of this Agreement, IM hereby grants to ATMI a nonexclusive, non-transferable, license, without the right to sublicense, to use the Equipment and install and execute the Informatics Software identified in the Purchase Documentation on the Equipment and/or Informatics Hardware for which it was purchased and upon which it was installed, for use by Named Users, for the term specified in the Purchase Documentation, solely at the Site, and solely for the purpose of developing and commercializing Materials, Wets Processing, Products, and Materials Manufacturing Technologies in the Field. ATMI shall have no right to use HPC Technology under this Agreement unless it purchases HPC-Enabled Informatics Software and purchases an HPC Site License for any Site where it will use HPC Technology (subject to the exception noted in Section 1.29).  Moreover, ATMI’s license to use HPC Technology shall only be for operation of the Equipment for which it has purchased HPC-Enabled Informatics Software, and only for the license term for such software and the HPC Site License, and solely on the Site.  The scope of the HPC Site license and the HPC-Enabled Informatics Software license granted by IM to ATMI  hereunder does not include the right to use the Wets Workflow on behalf of Third Parties, except where the intended purpose of such activities is (a) the qualification or sale by ATMI of a resulting Material or Product, or (b) the licensing by ATMI to one or more of its Materials partners or customers to make, use or sell such resulting Material or Product, or from a combination of (a) and (b).  IM shall continue to be the preferred supplier of all HPC Technology solutions for such research and development activities, as set forth in the Alliance Agreement.  The licenses granted hereunder shall be subject to the payment of all fees set forth in the Purchase Documentation, including but not limited to the royalties defined therein.  IM commits that through [*], ATMI will have the right to renew its

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

10


 

HPC Site License and license for Informatics Software on the same terms and conditions included in this Agreement, including pricing terms.

 

4.5            Third Party Software .  ATMI’s use of Symyx Software shall be governed by the terms and conditions set forth in Exhibit B. ATMI’s use of Oracle Software shall be governed by the terms and conditions set forth in ATMI’s end user license agreement with Oracle.  ATMI’s use of Microsoft Software shall be governed by the terms and conditions set forth in ATMI’s end user license agreement with Microsoft.  ATMI’s use of Adobe Software shall be governed by the terms and conditions set forth in ATMI’s end user license agreement with Adobe.  ATMI’s use of Software FX Software shall be governed by the terms and conditions set forth in ATMI’s end user license agreement with Software FX.  All such end user license agreements for Third Party Software shall be perpetual use licenses.

 

4.6            Improvements Defined .  As used in this Section 4, “ Improvements ” means improvements, additions, or modifications to the Equipment or to the use or application of Equipment that IM or ATMI, as applicable, conceives, reduces to practice or otherwise develops, other than Updates (as defined in Section 4.12), after the Delivery Date.  “ ATMI Improvements ” means Improvements wholly conceived, reduced to practice, or otherwise developed by ATMI that were not known to IM prior to Formal Disclosure by ATMI to IM (as defined in Section 4.8.2), or that were not generally available to the public or otherwise part of the public domain at the time of Formal Disclosure.  “ ATMI Use Improvements ” means ATMI Improvements that are new methods of use or modifications to existing methods of use of Equipment in Wets Processing that can be implemented without any improvements, additions or modifications to the Equipment.  ATMI Improvements shall not include improvements to the Equipment manufactured by Symyx Technologies, Inc. that is identified as item 3 in Annex 1 to the Purchase Documentation in Exhibit A, or improvements to Informatics Software.  “ IM Improvements ” means Improvements wholly conceived or reduced to practice by IM.

 

4.7            IM Improvements .  IM Improvements are not included within the scope of rights granted hereunder.  IM may periodically offer IM Improvements for sale or license to ATMI and will negotiate in good faith with ATMI terms in connection therewith; provided, that IM will offer to ATMI any IM Improvements that it makes generally available to its other customers, except as limited by any Third Party agreement.  Any such sale or license shall require the mutual execution of Purchase Documentation explicitly describing the sale or license to ATMI of IM Improvements.

 

4.8            ATMI Improvements .  All improvements to the HPC Technology derived from, based on, or invented in whole or in part through ATMI’s use of the Wets Workflow pursuant to this Agreement or using the Wets Workflow purchased herein, whether an ATMI Improvement or not, and all Intellectual Property Rights therein, shall be owned by IM and if initially conceived, reduced to practice or

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

11



 

developed by ATMI (whether or not implemented by IM as set forth in Section 4.8.1), shall be assigned to IM as set forth in Section 4.2.  IM hereby grants a non-exclusive, royalty-free license (i.e., IM shall not increase the HPC Site License or HPC Enabled Software License due to the implementation or use of such Improvement) to ATMI to use any Improvement (other than an IM Improvement) on or with any Wets Workflow for which ATMI continues to pay the HPC Site License fee and continues to license the HPC-Enabled Informatics Software.  Notwithstanding the foregoing, no license to ATMI to use HPC Technology beyond the term or beyond the scope of any license granted to ATMI to use HPC Technology is intended or granted by the preceding sentence.  Any notification of a proposed ATMI Improvement shall comply with the procedure set forth in Section 4.8.2, below.  Notwithstanding the foregoing, if IM wishes to commercialize any non-obvious ATMI Improvement for sale to third parties, IM shall first negotiate with ATMI in good faith to agree upon reasonable compensation to ATMI in view of the contribution of the ATMI Improvement to the value of the Wets Workflow or a component thereof.  If the Parties cannot agree on such compensation then they shall follow the provisions of Section 4.8.3.

 

4.8.1         Any implementation by IM of ATMI Improvements on ATMI’s behalf shall be the subject of a separately executed statement of work between the parties that shall specify the commercial and other terms.

 

4.8.2         ATMI may disclose ATMI Improvements to IM pursuant to this paragraph.  Before fully disclosing any Confidential Information with respect to an ATMI Improvement to IM, ATMI shall first send a written non-Confidential summary of the proposed ATMI Improvement to the attention of the IM Legal Department.  Within [*] days of the non-confidential disclosure, IM shall inform ATMI that IM either does or does not wish to receive a more detailed description of the proposed ATMI Improvement that ATMI may label as Confidential Information (“ Formal Disclosure ”).  If IM does not wish to receive the more detailed description of the ATMI Improvement, ATMI may maintain such ATMI Improvement as a trade secret.  For the avoidance of doubt, the preceding sentence shall not change the provisions of this Agreement concerning ownership of Improvements.  Furthermore, IM’s ability to sell, license and sub-license HPC Technology shall not be limited by (i) the non-Confidential disclosure above or (ii) any disclosure by ATMI to IM employees separate from any Formal Disclosure (other than disclosures to IM employees that are subject to the IP firewall described in Section 7.5(a) hereof) of an ATMI Improvement that ATMI decides to maintain as a trade secret.  Within a reasonable time after its receipt of the Formal Disclosure, IM shall provide notice to ATMI that either (a) IM does not wish to implement the proposed ATMI Improvement, and that it is returning the Confidential Information (except as required for archival purposes), or (b) IM wishes to further study the feasibility of implementing or commercializing the ATMI Improvement including a

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

12



 

proposal on how to proceed.  Notwithstanding the foregoing, during the one-year period following final acceptance of the first Wets Workflow sold under this Agreement, ATMI shall disclose no more than two (2) potential ATMI Improvements during anyone of the four three-month periods immediately following said final acceptance for consideration by IM above.  The restrictions set forth in Section 4.13.1 only shall apply to ATMI Improvements for which there has been a Formal Disclosure (provided that the foregoing shall in no way change or reduce IM’s obligations pursuant to Section 7.5(a) hereof).  References to obligations and disclosures Section 7.5 in this Section specifically exclude disclosures by ATMI to IM employees related to improvements, changes or modifications to the Equipment and IM shall be free to sell, license and sub-license HPC Technology relating to Equipment disclosed outside of the Formal Disclosure process.  If ATMI proposes an ATMI Improvement following said one-year period, the parties will negotiate in good faith on a case by case basis any special terms and conditions that will be applicable to the sale to Third Parties of Equipment into which such future ATMI Improvements may be implemented.

 

4.8.3         Notwithstanding Section 12.16 of this Agreement, in the event that the parties cannot agree for a period of [*] after escalation to their respective chief executive officers to a reasonable compensation for a Section 4.8 proposal, then either party may submit the issue of the amount of compensation due to ATMI if IM implements the ATMI Improvement to final and binding arbitration, before a single, mutually-acceptable arbitrator, conducted in accordance with the Commercial Arbitration Rules of AAA, solely for determination of the reasonable compensation. If the parties are unable to select a mutually acceptable arbitrator, AAA shall appoint an arbitrator or provide a method for selection.  Any arbitration proceedings shall be conducted in Phoenix, Arizona.  Each party shall bear its own expenses, including attorneys’ fees, and the parties will share equally the costs and fees of the arbitrator.  Prior to the actual arbitration hearing, each party shall provide the arbitrator a written proposal for a reasonable compensation that such party believes to be fair to both parties in the circumstances.  The arbitrator must render a written decision within ten (10) days of the hearing in favor of one party’s proposal or the other, without modification.  The arbitrator must determine the prevailing party by assessing the proposal, and its fairness in light of the relevant Intellectual Property Rights, technology contributions, and development and commercialization costs and expenses of each party, as well as the potential markets for the proposed application and whether third party Intellectual Property Rights, development efforts, commercialization efforts or investment is required to commercialize the proposed application.  The parties shall use all reasonable efforts to complete any arbitration subject to this section within three (3) months from the filing of notice of a request for such arbitration.  The parties

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

13



 

undertake and agree that all arbitral proceedings shall be kept confidential, and all information, documentation, materials in whatever form disclosed in the course of such arbitral proceeding shall be used solely for the purpose of those proceedings.  Nothing in this section shall require IM to implement the ATMI Improvement following the decision of the arbitrator.

 

4.9            Restrictions .  Except as expressly permitted by this Agreement, ATMI agrees that it will not itself, and will not through any parent, subsidiary, Affiliate, agent, or other Third Party, directly or indirectly, do any of the following:  (i) reproduce, distribute, copy, sell, create derivative works of, lease, license, or sublicense the Informatics Software or any component of either, or any documentation delivered to it pursuant to this Agreement; (ii) use the Informatics Software in connection with any equipment other than the Equipment and the Informatics Hardware; (iii) attempt, or permit any Third Party, to reverse engineer, disassemble, decrypt, decompile, or otherwise attempt to derive source code from the Informatics Software; or (iv) use any Informatics Software that may be licensed hereunder in connection with any time-sharing or other multi-user network or service bureau. ATMI agrees that access to any Equipment, Informatics Hardware, and/or Informatics Software shall be limited to Named Users who are employees of ATMI (and independent contractors approved by IM in writing, which approval shall not be unreasonably withheld) working directly with ATMI.

 

4.10          Named Users .  ATMI agrees to establish and maintain records of the identities of Named Users and changes thereto, and to make such records available to IM upon request.

 

4.11          Legend .  All copies of the Informatics Software shall include IM’s copyright, trademarks, patent numbers, and other proprietary notices in the manner in which such notices were placed by IM on such Informatics Software.  Further, IM may label the Equipment with a permanent non-erasable identification label including but not limited to IM’s name, IM’s model number, a sequential serial number in IM’s standard format, date of manufacture, location manufactured, and specification version to which the Equipment was manufactured.  ATMI shall not remove, obscure, or alter IM’s copyright notices, trademarks, patent numbers, or other proprietary rights notices affixed to or contained within the Informatics Software or the Equipment.

 

4.12          Updates .  Subject to payment by ATMI of the amounts set forth in the applicable Purchase Documentation, throughout the term specified in Purchase Documentation that IM has agreed to provide support Informatics Software (the “ Support Term ”), IM will provide ATMI with error corrections, bug fixes or workarounds (“ Updates ”) to the Informatics Software that is developed by IM solely to ensure that the Informatics Software performs in accordance with its Specifications, as IM makes those Updates generally available to its customers. Updates will also include improvements to the Informatics Software developed by

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

14



 

IM that may be released by IM from time to time, other than upgrades of the Informatics Software that are offered to IM’s customers for a separate fee.

 

4.13          Excluded Companies.

 

4.13.1      Subject to Section 4.8, IM agrees that it will not, except with the written consent of ATMI, either:

 

(a)            disclose or license to any Competitor any ATMI Use Improvements for a period of [*] after Formal Disclosure, except that IM shall have the right to provide licenses of a broad or general scope that do not specifically mention or otherwise disclose the ATMI Use Improvement, or

 

(b)            disclose, license or sell any ATMI Improvement, other than an ATMI Use Improvement, that ATMI implements on its Equipment to any Excluded Company until [*] after such implementation.  Notwithstanding the foregoing, if ATMI decides not to implement such ATMI  Improvement within [*] of IM’s notice that it is available, IM shall be free to license or sell such ATMI Improvement without restriction.

 

4.13.2      IM agrees that it will not ship any Element to an Excluded Company prior to the Exclusivity Expiration Date for that Element.  (An “ Element ” shall mean either the Integration Screening & Scale-up (I&S) System, Wets, or the Material & Device Screening (M&D) System, Wets.)  The “Exclusivity Expiration Date” for that Element shall initially be the date [*] after the date of final acceptance for that Element, and shall be extended by an additional [*] for each accepted order that ATMI places for that Element before the Exclusivity Expiration Date.  ATMI may also extend by [*] the Exclusivity Expiration Date for each Element that has not reached its Exclusivity Expiration Date by successfully brokering the sale of a complete Wets Workflow by IM to any materials company with which ATMI has a then-established working relationship (an “ATMI Materials Partner”).  ATMI shall only be deemed to have successfully brokered the sale prior to the occurrence of the Exclusivity Expiration Date if the ATMI Materials Partner, in IM’s sole discretion, (a) is deemed credit-worthy by IM, (b) issues a purchase order acceptable to IM, and (c) signs an agreement for the purchase of the Equipment, Informatics Hardware, and the licenses to Informatics Software, Third Party Software, and/or HPC Site License that constitute a Wets Workflow, under terms and conditions that are substantially identical to those set forth in this Agreement (except for terms relating to exclusivity and volume discounts, and terms relating to the Alliance Agreement). Notwithstanding anything to the contrary herein, no Exclusivity Expiration Date shall be extended beyond [*].

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

15



 

4.13.3       Nothing in this Agreement shall preclude IM from (a) shipping a Wets Workflow in whole or in part to a company that is not an Excluded Company at any time, or (b) shipping a Wets Workflow in whole or in part to an Excluded Company on or after the end of the Exclusivity Expiration Date or [*], whichever occurs earlier.

 

4.14          Beta Site .  IM will offer ATMI to be a beta site for future HPC product offerings, under terms to be mutually agreed on a case by case basis in future beta site agreements.  The provisions of this Agreement with respect to compensation for ATMI Improvements, as well as the restrictions set forth in Section 4.12.1 shall be inapplicable to beta sites for IM product offerings.

 

4.15          Source Code Escrow .  In the event that (i) IM becomes insolvent or bankrupt, (ii) IM makes an assignment for the benefit of creditors, (iii) IM consents to a trustee or receiver appointment, (iv) a trustee or receiver is appointed for IM or for a substantial part of its property without its consent, (v) IM voluntarily initiates bankruptcy, insolvency, or reorganization proceedings, or is the subject of involuntary bankruptcy, insolvency, or reorganization proceedings, or (vi) IM announces that it has entered into an agreement to be acquired by a then named Competitor, then IM and ATMI will negotiate in good faith to enter into a source code escrow agreement with Iron Mountain Incorporated in a form provided by Iron Mountain Incorporated (or if Iron Mountain Incorporated is no longer engaging in the source code escrow business, a mutually agreed source code escrow company) setting forth source code escrow deposit procedures and source code release procedures relating to Informatics Software. Notwithstanding the foregoing, the escrow instructions shall provide for a release of the source code to ATMI of the Informatics Software only upon the occurrence of (a) the filing of a Chapter 7 bankruptcy petition by IM, or a petition by IM to convert a Chapter 11 filing to a Chapter 7 filing; (b) the cessation of business operations by IM; or (c) the failure on the part of IM to comply with its contractual obligations to ATMI to comply with its maintenance and support obligations for a period of more than [*] after it has received written notice of said breach. Any dispute between the parties over whether an event has occurred that would trigger a release of source code to ATMI pursuant to the source code escrow instructions shall be resolved pursuant to Section 12.16.  In the event of a release of Informatics Software source code pursuant to this section, said source code shall continue to be the Confidential Information of IM or its successor in interest In the event of a release of source code to ATMI from escrow, ATMI may only use, copy and/or modify the source code consistent with the purposes of this agreement (or have a contractor who has agreed in writing to confidentiality provisions as restrictive as those set forth in this Agreement do so on its behalf).

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

16



 

ARTICLE 5
PAYMENTS AND TAXES

 

5.1            Invoicing and Payment .  Unless otherwise stated in the Purchase Documentation, after delivery of goods or performance of services, IM shall promptly render to ATMI correct and complete invoices, which shall specify at least the following information:  purchase order number, item number, description of goods, quantities, unit prices, extended totals and applicable taxes.  ATMI shall pay to IM the fees and taxes set forth in the applicable Purchase Documentation within [*] of receiving IM’s valid invoice.

 

5.2            Transaction Taxes .  Fees payable to IM under this Agreement are exclusive of any transaction taxes (including sales, use, consumption, value-added and similar transaction based taxes, or withholding taxes) which may be imposed, in accordance with applicable laws, as a result of the licenses granted by IM to ATMI, and the sale of one or more Wets Workflows hereunder.  ATMI agrees to bear or reimburse IM for all such transaction taxes.  IM assumes responsibility to timely remit tax payments that it collects from ATMI to the appropriate governmental authority after receipt from ATMI, in each respective jurisdiction.

 

ARTICLE 6
REVENUE SHARE OR ROYALTIES

 

6.1            Compensation, Revenue Share or Royalties .  Each party will pay the other party any compensation, revenue share payments or royalties due as agreed between the parties.  Any revenue share or royalty due from a party shall be paid on a calendar quarter basis following shipment of the products that trigger the payment as set forth in Section 6.4.  The licenses granted by IM to ATMI shall be subject to payment of all fees set forth in any quotation for which ATMI issues IM a purchase order, including a royalty to IM of [*]% of gross sales proceeds on Products (less the following when separately itemized on or included and identifiable in invoices related to the sale of the Product:  (i) allowances, discounts, including cash discounts, rebates and returns all to the extent actually given in the trade by ATMI or its affiliates; (ii) sales, excise and similar taxes (including but not limited to any value added tax) or duties; (iii) insurance, packaging (except packaging that directly encloses the Products), and handling, shipping, transportation or similar; and (iv) credits or repayment for rejection or return of Products). If ATMI has suitable written records that reflect actually incurred direct costs (including but not limited to freight out, customs, duty, distribution and warehousing), ATMI may deduct such direct costs (up to an additional aggregate amount not to exceed [*]% of the gross sales proceeds for all Products during any reporting period) prior to computing the royalty on gross sales proceeds, even if such direct costs are not separately itemized to the customer.  In the case that ATMI enables a Materials partner or a customer to make or sell a Product under license in exchange for a royalty to ATMI, the royalty payable by ATMI to IM for such use shall be calculated on the value of

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

17



 

the Product used to calculate the royalty paid to ATMI (“ Product Value ”).  For business arrangements between ATMI and Third Parties related to (i) Products for which the Product Value cannot be derived, or (ii) other ATMI monetization of technology derived through use of the Wets Workflow or HPC Technology not otherwise described herein, IM and ATMI agree to negotiate in good faith to set the compensation, if any, due to IM.  Notwithstanding Section 12.16 of this Agreement, in the event that the parties cannot agree for a period of [*] after escalation to their respective chief executive officers to a reasonable compensation, the parties will use the procedure of Section 4.8.3 to determine compensation due to IM.

 

6.2            Third Party Royalties .  Each party shall be responsible for all of its own costs of commercializing Products or licensing Intellectual Property Rights, including any payments to Third Parties for work done by such Third Parties or for licenses necessary for the manufacture, sale, or use of Products by a party or its Affiliates or sublicensees.

 

6.3            Payment Method .  All payments due under this Agreement shall be made by bank wire transfer or ACH transaction in immediately available funds to a bank account designated by each party.  All payments hereunder shall be from a U.S. entity and made in U.S. dollars.  Any payments that are not paid within [*] of the date such payments are due under this Agreement shall bear interest at the lesser of (i) [*] percent [*] per month or (ii) the maximum rate permitted by law.  Nothing in this Section 6.4 shall prejudice any other rights or remedies available to either party hereunder or at law or equity.

 

6.4            Reports and Payments .  After the first commercial sale of a Product on which revenue share and royalties are payable by ATMI, ATMI shall make [*] written reports to the other party within [*] after the end of each calendar [*], stating in each such report, separately for itself and each Affiliate and each sublicensee, the number, description, and total sales of each Product sold, and a calculation of the revenue share or royalties due as a result of license grants to customers, the manner of calculation of each to be specified in Section 6.1 Concurrently with the making of such reports, ATMI shall pay IM all amounts due as set forth in the report.

 

6.5            Currency Conversions .  If any currency conversion shall be required in connection with the calculation of royalties hereunder, such conversion shall be made using the selling exchange rate for conversion of the foreign currency into U.S. Dollars, quoted for current transactions reported in The Wall Street Journal for the last business day of the calendar [*] to which such payment pertains.

 

6.6            Records; Inspection .  Each party and its Affiliates shall keep complete, true and accurate books of account and records for the purpose of determining the royalty amounts payable under this Agreement.  Such books and records shall be kept at the principal place of business of such party, as the case may be, for at least [*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

18



 

following the end of the calendar [*] to which they pertain.  Such records will be open for inspection during such [*] period by an independent auditor reasonably acceptable to the audited party, solely for the purpose of verifying royalty statements hereunder.  Such inspections may be made no more than once each calendar year, at reasonable times and on reasonable notice.  Inspections conducted under this Section 6.6 shall be at the expense of the auditing party, unless a variation or error producing an increase of at least [*] Dollars ($[*]) and exceeding [*] percent ([*]%) of the amount stated for any period covered by the inspection is established in the course of any such inspection, whereupon all reasonable costs relating to the inspection for such period and any unpaid amounts that are discovered will be paid promptly by the audited party together with interest thereon for late payments as set forth above. Each party agrees to hold in confidence all information concerning royalty payments and reports, and all information learned in the course of any audit or inspection, except to the extent necessary for each party to reveal such information in order to enforce its rights under this Agreement or if disclosure is required by law.

 

ARTICLE 7
CONFIDENTIALITY

 

7.1            Confidentiality .  Except as otherwise expressly provided in the Mutual Non-Disclosure Agreement signed by the parties on December 6, 2005 for Confidential Information exchanged between the parties prior to the Effective Date, or as expressly provided in the Alliance Agreement, or as otherwise expressly provided herein, the parties agree that the receiving party shall not, except as expressly provided in this Article 7 disclose to any Third Party, or use for any purpose, any Confidential Information furnished to it by the disclosing party pursuant to this Agreement, except in each case to the extent that it can be established by the receiving party by competent proof that such information:

 

(a)            was already known to the receiving party, other than under an obligation of confidentiality to the disclosing party, at the time of disclosure;

 

(b)            was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving party;

 

(c)            became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving party in breach of this agreement;

 

(d)            was independently developed by the receiving party without use of, or reference to, the other party’s confidential information, as demonstrated by documented evidence prepared contemporaneously with such independent development; or

 

(e)            was disclosed to the receiving party, other than under an obligation of confidentiality to the disclosing party, by a Third Party authorized and entitled to disclose such information to others.

 

Confidential Information shall not be considered within the above exceptions merely because the Confidential Information is embraced by more general

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

19



 

information within the exceptions.  Any combination of features of Confidential Information shall not be considered within the above exceptions merely because individual features, as opposed to the combination itself and its principles of operation, are within the exception.

 

7.2            Permitted Use and Disclosures .  Notwithstanding the restrictions of Section 7.1, each party hereto may (a) use Confidential Information disclosed to it by the other to the extent necessary for that party to perform its obligations set forth in this Agreement and (b) use or disclose Confidential Information disclosed to it by the other party to the extent such use or disclosure is reasonably necessary in (i) exercising the rights and licenses granted hereunder, (ii) prosecuting or defending litigation pursuant to Article 8 (iii) complying with applicable laws, governmental regulations or court orders or submitting information to tax or other governmental authorities (including the Securities and Exchange Commission), (iv) preparing, filing and prosecuting patent applications pursuant to this Agreement, or (v) making a permitted sublicense or otherwise exercising license rights expressly granted pursuant to this Agreement; in each case, provided that if a party is required to make any such disclosure, other than pursuant to a confidentiality agreement, it will give reasonable advance notice to the other party of such disclosure and will use reasonable efforts to secure confidential treatment of such information (whether through protective order or otherwise), except to the extent inappropriate with respect to patent applications. It is understood that either party may also disclose the Confidential Information of the other party upon receipt of the written consent to such disclosure by a duly authorized representative of the other party.  It is also understood that notwithstanding other provisions of this paragraph, neither party shall disclose trade secrets of the other party without first obtaining the written consent of the party owning such trade secrets and securing an agreement with the party to whom such disclosure will be made that such trade secrets will be treated as confidential for as long as such trade secrets qualify for protection as trade secrets.  It is further understood that such trade secrets are not to be included in any patent, patent application, or other document that is accessible by individuals not subject to an agreement requiring that the individuals maintain such document in confidence.  It is also understood that unless expressly required in this Agreement, neither party is obligated to disclose Confidential Information to the other.

 

7.3            Nondisclosure of Terms .  Subject to Section 7.4, each of the parties hereto agrees not to disclose the terms of this Agreement to any Third Party without the prior written consent of the other party hereto, which consent shall not be unreasonably withheld, except to such party’s attorneys, accountants, advisors, investors and financing sources and their advisors and others on a need to know basis under circumstances that reasonably ensure the confidentiality thereof, to the extent required by law, in connection with the enforcement of this Agreement or rights under this Agreement or in connection with a merger, acquisition, financing transaction or proposed merger, acquisition or financing transaction, or the like.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

20


 

7.4            Compliance with Public Company Disclosure Obligations .  Notwithstanding the provisions of Section 7.3, if a party is a Public Company (as defined below), such party may disclose from time to time such information regarding the terms of this Agreement and the scientific and other results of the Alliance as such party may reasonably deem to be necessary to comply with its disclosure obligations under applicable U.S. securities law or applicable stock market or NASDAQ Stock Market listing rules; provided, however, that each party shall use commercially reasonable efforts to (i) nevertheless comply with its obligations as set forth in Section 7.3, or in the event such compliance is not possible, (ii) provide the other party with a draft of the disclosure intended to be made not less than twenty-four (24) hours prior to the intended first public release or filing of such disclosure. For purposes of this section, “Public Company” shall mean a company that is subject to the reporting requirements of either Section 13(a) or Section l5(d) of the Securities Exchange Act of 1934, as amended.

 

7.5            Firewall Protection .  In addition to conforming to the confidentiality provisions in this Article 7, the following shall apply:

 

(a)            IM will construct an IP firewall as described below in this Section around IM employees providing Services to ATMI in connection with any Wets Workflow described in the Purchase Documentation.  Only such employees of IM will be allowed to have access to such ATMI confidential and proprietary information and information distribution will be based strictly on a need-to-know basis.  Such employees of IM shall solely use such ATMI confidential and proprietary information in providing Services to ATMI.  Physical copies of ATMI confidential and proprietary information shall be securely locked when not in use such that only those IM employees providing such Services shall have access to such information.  The procedure set forth in this Section is not intended to supersede in whole or in part the terms of Section 4.8; specifically, IM shall have the right, without obligation to ATMI, to sell, license and sublicense any improvements, changes, or modifications to Equipment disclosed by ATMI to IM outside of the Formal Disclosure process.

 

(b)            ATMI will construct an IP firewall as described below in this Section around ATMI employees who have access at IM’s facilities to HPC Technology outside of the Wets Workflow described in the Purchase Documentation.  Only such employees of ATMI will be allowed to have access to such IM confidential and proprietary information and such information shall not be shared with other ATMI employees or Third Parties without the prior written consent of IM.  Copies or samples of IM confidential and proprietary information shall not be removed or transmitted from any IM facility by ATMI employees.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

21



 

ARTICLE 8
REPRESENTATIONS, WARRANTIES, AND INDEMNIFICATION

 

8.1            By ATMI .  ATMI represents and warrants that:  (i) it has the right and authority to enter into this Agreement, and to fully perform its obligations hereunder; and (ii) this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms.

 

8.2            By IM .  IM hereby makes the following representations and warranties:

 

8.2.1         Authority.  IM has the right and authority to enter into this Agreement, and to fully perform its obligations hereunder.

 

8.2.2         Legal, Valid and Binding Obligation.  This Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms.

 

8.2.3         Intellectual Property Rights.  IM owns, or possesses a valid and enforceable license to use (with ability to sublicense), all Intellectual Property Rights licensed or sublicensed to ATMI pursuant to this Agreement (for purposes of this Section 8.2.3, “IM Licensed IP”).  IM has full power and authority to license or sublicense, as the case may be, all such Intellectual Property Rights licensed to ATMI upon the terms set forth herein, and to IM’s knowledge the use and practice of such Wets Workflow by ATMI in the Field pursuant to and in accordance with the terms of this Agreement (“Use”) will not infringe the Intellectual Property Rights of any Third Party.  IM agrees to defend and hold ATMI harmless from and against all claims, losses, damages, judgments, awards, settlements, costs and expenses (including reasonable attorneys’ fees) of, arising out of or resulting from any litigation or proceeding brought by a Third Party alleging infringement by the Wets Workflow (including any IM Licensed IP) or Use thereof, of a Third Party’s Intellectual Property Rights, provided that (i) ATMI notifies IM promptly in writing of the claim (provided, however, that the failure to promptly provide notice to IM will not affect IM’s duties or obligations under this Article 8 except to the extent IM is prejudiced thereby); and (ii) ATMI assists and cooperates reasonably with IM, at IM expense, in defending or settling such claim. IM shall have sole control of the defense and all related potential settlement negotiations, provided that IM shall not enter into any settlement which would materially adversely affect the rights granted to ATMI  under this Agreement without ATMI’s express prior written consent.  Notwithstanding the foregoing, IM shall have no liability for any claim of infringement based on or arising from the Alliance Technology, the Agreement WF Compounds or the use, sale, offer for sale, import license, or manufacture of Products or other technology sold or licensed by ATMI that is derived from the Wets Workflow.  In addition, ATMI shall be entitled to be represented by ATMI’s own counsel at ATMI’s

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

22



 

expense.  In the event the Wets Workflow (including any IM Licensed IP) or Use thereof is held, or IM, in good faith and in its sole discretion, believes may be held, to infringe or misappropriate any Intellectual Property Rights of a Third Party, IM shall, at its sole expense, exercise whichever of the following two options it selects:  (i) obtain a license to continue to use the Wets Workflow or IM Improvements without additional charge to ATMI; or (ii) modify the Wets Workflow or IM Improvements, or Use thereof, so they are non-infringing and meet the applicable Acceptance Criteria (“ Non-Infringing Modification ”).  IM’s indemnification obligations shall cease if ATMI fails or refuses to implement any Non-Infringing Modification or if the Use is other than an intended Use set forth in Exhibit D. Notwithstanding anything to the contrary in this Agreement, IM provides no indemnification of claims that Third Party Software, other than Symyx Software, infringes Third Party Intellectual Property Rights if said claims do not allege that the infringement was caused by use of the Third Party Software in combination with other elements of the Wets Workflow. ATMI’s right to indemnification, if any, in connection with such claims shall be governed by its applicable Third Party end user license agreement.  Moreover, claims alleging that the Symyx Software infringes Third Party Intellectual Property Rights shall be handled in accordance with Exhibit B rather than in accordance with this Section 8.2.3, except that IM’s liability for damages based on infringement by the Symyx Software shall be governed by Article 9 of this Agreement, which supersedes such limitations in Exhibit B (specifically i ) paragraph 9 and ii) the last sentence of paragraph 8(b)).  The foregoing indemnity states the sole obligations and exclusive liability of IM, and ATMI’s sole recourse and exclusive remedy for any Third Party claim of infringement or misappropriation of an Intellectual Property Right by IM under this Agreement.

 

8.3            Limited Warranty on Equipment .  IM warrants to ATMI  that for a period commencing on [*] and extending for [*] from final acceptance of the Equipment, the Equipment is free from defects in materials and workmanship and shall conform in all material respects to its Specifications.  The warranty set forth in the prior sentence shall apply only to the IM- supplied components of the Equipment and specifically excludes those components supplied by ATMI.  IM does not otherwise warrant the Equipment and does not warrant that operation of the Equipment will be uninterrupted or error free.  If the Equipment does not meet the warranty specified above during the warranty period, IM shall, at its option, repair or replace at no cost to ATMI any defective or nonconforming Equipment component.  Procedures and response times in connection with warranty claims under this Section 8.3, as well as IM’s obligations with respect to maintenance and support of Equipment, are set forth in Exhibit C.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

23



 

8.4            Limited Warranty on Informatics Hardware .  IM warrants to ATMI that for a period commencing on [*] and extending for [*] from final acceptance of the Informatics Hardware, the Informatics Hardware shall be free from defects in materials and workmanship and shall conform in all material respects to its Specifications.  The warranty set forth in the prior sentence shall apply only to the IM- supplied components of the Equipment and specifically excludes those components supplied by ATMI.  IM does not otherwise warrant the Informatics Hardware and does not warrant that operation of the Informatics Hardware will be uninterrupted or error free.  If the Informatics Hardware does not meet the warranty specified above during the warranty period, IM shall, at its option, repair or replace at no cost to ATMI any defective or nonconforming Informatics Hardware component.  Procedures and response times in connection with warranty claims under this Section 8.4, as well as IM’s obligations with respect to maintenance and support of Informatics Hardware, are set forth in Exhibit C.

 

8.5            Limited Warranty on Informatics Software .  IM warrants for a period of [*] from [*] of the Informatics Software to Licensee (and extending for each year that ATMI renews its license for the Informatics Software) that such Informatics Software as delivered, will function in conformity with its Specifications and the documentation supplied therewith.  IM will use commercially reasonable efforts to correct any nonconformities reported to IM in writing or in electronic form during the warranty period.  Procedures and response times in connection with claims under this Section 8.5, as well as IM’s obligations with respect to maintenance and support of Informatics Software, are set forth in Exhibit C.

 

8.6            System Warranty .  IM warrants for a period of [*] from [*] of any Wets Workflow sold hereunder, and during any additional period during which ATMI renews, under the terms of this Agreement, its HPC Site License and HPC-Enabled Informatics Software license and Maintenance and Support for each Wets Workflow item, the Informatics Software for each Wets Workflow item, and the Informatics Hardware (such additional renewal periods must be continuous from the initial [*] term), that (i) the Wets Workflow items are compatible and will operate with one another as set forth in the Purchase Documentation, and (ii) the Wets Workflow will support the applications as set forth in Exhibit D. This warranty is in addition to IM’s other applicable warranties.  IM does not otherwise warrant the Wets Workflow and does not warrant that its operation will be uninterrupted or error free.  If the Wets Workflow does not meet the warranty specified above during the warranty period, IM shall, at its option, repair or replace at no cost to ATMI the nonconformity.  Procedures and response times in connection with warranty claims under this Section 8.6, as well as IM’s obligations with respect to maintenance and support, are set forth in Exhibit C for the Equipment, Informatics Hardware and Informatics Software, provided that IM will promptly remedy any such nonconformity in 8.6(ii) above.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

24



 

8.7            Warranty for Services .  IM will provide Services in a professional manner using reasonable care and skill and in accordance with standard industry practice and all applicable federal, state and local laws and regulations.

 

8.8            Exclusions .  The warranties and remedies set forth in Sections 8.4, 8.5, 8.6, and 8.7 will be void as to (i) any Wets Workflow that has been damaged, modified, or altered (other than by IM or as authorized in writing by an officer of IM) unless ATMI can demonstrate by clear and convincing evidence that the alteration or modification did not cause the non-conformity in whole or in part, or (ii) non-conformities, in whole or in part, arising from use of the Wets Workflow with any other hardware, software, firmware, devices, or other products not provided by IM. IM shall provide no warranty with respect to any Wets Workflow to which IM has implemented ATMI Improvements and such ATMI Improvements caused such non-conformity unless the parties separately agree to such a warranty in writing.

 

8.9            Disclaimer .  ATMI and IM specifically disclaim any representation, warranty or guarantee that the use of the Equipment, Informatics Software, Third Party Software, or Informatics Hardware, will be successful, in whole or in part.  It is understood that the failure to successfully develop and commercialize any technology related to this Agreement shall not constitute a breach of any representation or warranty or other obligation under this Agreement.  EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, IM AND ATMI MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE TECHNOLOGIES DESCRIBED HEREIN OR INFORMATION DISCLOSED HEREUNDER, AND HEREBY EXPRESSLY DISCLAIM ANY WARRANTIES OF MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE, OR VALIDITY OF ANY TECHNOLOGY, PATENTED OR UNPATENTED, OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

 

ARTICLE 9
LIMITATION OF LIABILITY

 

EXCEPT FOR A BREACH BY EITHER PARTY OF ITS CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 7 AND EXCEPT FOR BREACHES OF ANY LICENSE RESTRICTIONS, OR ANY PAYMENT OBLIGATIONS RESULTING FROM AN INDEMNIFICATION OBLIGATION HEREUNDER (INCLUDING EXHIBIT B), UNDER NO CIRCUMSTANCES WILL EITHER PARTY BE LIABLE TO THE OTHER, UNDER CONTRACT, STRICT LIABILITY, NEGLIGENCE OR OTHER LEGAL OR EQUITABLE THEORY, FOR ANY LOST REVENUE, LOST PROFITS, EQUIPMENT DOWN-TIME, OR FOR ANY INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND IN CONNECTION WITH THE SUBJECT MATTER OF THIS AGREEMENT, EVEN IF ADVISED OF THE

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

25



 

POSSIBILITY OF SUCH DAMAGES. EXCEPT FOR A BREACH BY EITHER PARTY OF ITS CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 7 AND EXCEPT FOR BREACHES OF ANY LICENSE RESTRICTIONS, OR ANY PAYMENT OBLIGATIONS RESULTING FROM AN INDEMNIFICATION OBLIGATION HEREUNDER(INCLUDING EXHIBIT B), IN NO EVENT WILL EITHER PARTY’S LIABILITY TO THE OTHER UNDER THIS AGREEMENT EXCEED THE GREATER OF (A) [*], (B) THE [*] FOR THE [*] THAT IS THE SUBJECT OF THE CLAIM, AT THE TIME THE CLAIM IS MADE, AND (C) THE AMOUNTS PAID OR PAYABLE BY SUCH PARTY TO THE OTHER PARTY IN THE [*] MONTHS PRECEDING THE CLAIM.

 

ARTICLE 10
INSURANCE

 

IM shall at all times maintain the following types of insurance in the following minimum amounts with respect to its employees who are temporarily assigned to work on ATMI’s premises (other than the insurance in clause (ii), which IM will maintain in any event):  (i) workers compensation in accordance with statutory limits; (ii) comprehensive general liability, including coverage for premises/operations, products/completed operations and contractual liability:  $[*] per occurrence (aggregate, bodily injury and property damage combined); and (iii) automobile liability:  bodily injury and property damage:  $[*] per occurrence. Upon request, IM shall deliver to ATMI a certificate of insurance evidencing that IM has the above insurance in full force and effect, naming ATMI as additional insured and containing a clause which provides that such policies will not be materially changed or cancelled without 30-days’ prior written notice to ATMI.

 

ARTICLE 11
TERMINATION

 

11.1          Term of Agreement .  The term of this Agreement shall commence on the Effective Date, and, unless terminated earlier as provided in this Article 10, shall continue in full force and effect until the termination of all HPC Site Licenses and HPC-Enabled Informatics Software Licenses granted under this Agreement.

 

11.2          Termination .  (i) Either party to this Agreement may terminate this Agreement or a specific set of Purchase Documentation under this Agreement, in whole or in part, in the event the other party shall have materially breached or defaulted in the performance of any of its material obligations under that Purchase Documentation, and such default shall have continued for [*] after written notice thereof was provided to the breaching party by the non-breaching party.  Any termination shall become effective at the end of such [*] period unless the breaching party (or any other party on its behalf) has

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

26



 

cured any such breach or default prior to the expiration of such [*] period.  In the event ATMI terminates a set of Purchase Documentation due to a material breach that is not cured per the above term prior to factory acceptance of a Wets Workflow (demonstrating compliance with the Acceptance Criteria, including the Supplemental Workflow Use Acceptance Criteria set forth in Exhibit D), IM shall promptly refund to ATMI any amounts paid pursuant to such Purchase Documentation (or in the event of a termination in part, the amounts paid for the item(s) that is the subject of the termination). (ii) Either party may terminate this Agreement without cause when there is no outstanding Purchase Documentation.

 

11.3          Effect of Termination .  Except as provided in a specific set of Purchase Documentation hereunder all licenses under the Agreement or the terminated set of Purchase Documentation, as applicable, shall terminate, and IM and ATMI shall promptly return to the other all Confidential Information received from the other party related to this Agreement or the terminated set of Purchase Documentation, except (i) one copy of which may be retained for archival purposes, or (ii) to the extent that such Confidential Information is necessary to practice a continuing license or to which the other party obtained an ownership interest pursuant to Article 4; provided, however that the applicable party may, at its option, destroy any Confidential Information it is otherwise obligated to return and certify such destruction to the other party. Except as expressly provided herein, Section 4.15, and Articles 5, 6, 7,9 and 12, shall survive the expiration or termination of this Agreement for any reason.

 

ARTICLE 12
MISCELLANEOUS

 

12.1          Governing Laws .  This Agreement and any dispute arising from the construction, performance or breach hereof shall be governed by and construed and enforced in accordance with the laws of the State of New York without regard to conflict-of-law principles that would result in the application of the law of any other jurisdiction.

 

12.2          Assignment .  Neither party shall assign this Agreement, in whole or in part, without the prior written consent of the other party, which consent shall not be unreasonably conditioned, delayed or withheld; provided, however, that either party may assign this Agreement without such consent, to an Affiliate, or to a successor in interest to its business (whether by merger, acquisition, consolidation, change of control, reorganization or sale of substantially all of its assets) and the terms of the Agreement shall continue in effect without modification after such assignment, including without limitation the royalty provisions herein which shall be binding upon any permitted assignee. Any purported assignment without such consent shall be void and of no effect.  Subject to the foregoing sentence, this Agreement will be binding on and inure to the benefit of the parties and their respective successors and permitted assigns.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

27



 

12.3          No Implied License .  Only the licenses granted pursuant to the express terms of this Agreement shall be of any legal force or effect.  No other license rights shall be created by implication, estoppel or otherwise.  Each party reserves all rights not expressly granted to the other party under this Agreement.

 

12.4          Representation by Legal Counsel .  Each party hereto represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof.  In interpreting and applying the terms and provisions of this Agreement, the parties agree that no presumption shall exist or be implied against the party that drafted such terms and provisions.

 

12.5          Waiver .  It is agreed that no waiver by either party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed a waiver as to any subsequent and/or similar breach or default.

 

12.6          Non-Solicitation .  During the Term and for [*] thereafter, neither IM nor ATMI will individually, or in concert with or through any other person, actively recruit or solicit employment of any scientific or technical personnel of the other party.  The foregoing restriction shall not apply to, or be breached by:  (i) advertising open positions, participating in job fairs, and conducting comparable activities to recruit skilled or unskilled help from the general public, or responding to individuals contacted through such methods, (ii) responding to unsolicited inquiries about employment opportunities or possibilities from job placement agencies or other agents acting for unidentified principals, or (iii) responding to unsolicited inquiries about employment opportunities from any individual.

 

12.7          Severability .  In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect to the fullest extent permitted by law without said provision, and the parties shall amend the Agreement to the extent feasible to lawfully include the substance of the excluded term to as fully as possible realize the intent of the parties and their commercial bargain.

 

12.8          Independent Contractors .  The relationship of the parties hereto is that of independent contractors.  The parties hereto are not deemed to be agents, partners or joint ventures of the others for any purpose as a result of this Agreement or the transactions contemplated thereby.

 

12.9          Compliance with Laws .  In exercising its rights under the licenses granted hereunder, and in undertaking the activities outlined in this Agreement, each party shall fully comply in all material respects with the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

28



 

jurisdiction over the exercise of rights under this Agreement including those applicable to the discovery, development, manufacture, distribution, import and export and sale of products based on technology developed pursuant to this Agreement.

 

12.10       Export Control Regulations .  Without limiting the parties’ obligations under Section 12.9 above, the rights and obligations of the parties under this Agreement, shall be subject in all respects to United States laws and regulations as shall from time to time govern the license and delivery of technology abroad.  Without in any way limiting the provisions of this Agreement, IM and ATMI agree that each will not export, reexport, or transship, directly or indirectly, to any country, any of the technical data disclosed to it by the other party hereto if such export would violate the laws of the United States or the regulations of any department or agency of the United States Government.  IM will notify ATMI if any Wets Workflow item is classified for export restriction.

 

12.11       Patent Marking .  Each party agrees to mark and have their Affiliates and licensees mark all products sold or licensed pursuant to this Agreement in accordance with the applicable statute or regulations relating to patent marking in the country or countries of manufacture and sale thereof, and to notify the other party if it becomes aware that the marking of any such product is required.

 

12.12       Notices .  All notices, requests and other communications hereunder shall be in writing and shall be hand delivered, or sent by express delivery service with confirmation of receipt, or sent by registered or certified mail, return receipt requested, postage prepaid, or by facsimile transmission (with written confirmation copy by registered first-class mail), in each case to the respective address or facsimile number indicated below.

 

IM:

ATMI:

2865 Zanker Road

7 Commerce Drive

San Jose, CA 95134

Danbury, CT 06810

Attn: Chief Legal Officer

Attn: Chief Legal Officer

Fax: (408) 416-2301

Fax: (203) 797-2544

 

Any such notice shall be deemed to have been given when received.  Either party may change its address or facsimile number by giving the other party written notice, delivered in accordance with this section.

 

12.13       Force Majeure .  Neither party shall lose any rights hereunder or be liable to the other party for damages or losses (except for payment obligations) on account of failure of performance by the defaulting party if the failure is occasioned by war, strike, fire, act of God, earthquake, flood, lockout, embargo, act of terrorism, governmental acts or orders or restrictions, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence, intentional conduct or misconduct of the non-performing party and such party has

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

29



 

exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a party be required to settle any labor dispute or disturbance.

 

12.14        Headings; Construction .  The captions to the several articles and sections hereof are not part of this Agreement, but are included merely for convenience of reference and shall not affect its meaning or interpretation.  As used in this Agreement, the word “including” means “including without limitation.”

 

12.15        Counterparts .  This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.

 

12.16        Dispute Resolution .  If a dispute arises between the parties relating to the interpretation or performance of this Agreement, representatives of the parties with decision-making authority shall meet to attempt in good faith to negotiate a resolution of the dispute prior to pursuing other available remedies.  If such a meeting is requested, it must be held, unless the parties otherwise agree, within [*] calendar days from receipt of such request (the “Request”).  If within [*] calendar days after such meeting the parties have not resolved such dispute, the Chief Executive Officers of both parties shall meet within [*] calendar days after the end of such [*] day period to discuss and attempt to resolve the dispute.  If the parties have not resolved the dispute within [*] calendar days after the Request, either party may submit such dispute to final and binding arbitration, before a single, mutually-acceptable arbitrator, conducted in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”).  If the parties are unable to select a mutually acceptable arbitrator, AAA shall appoint an arbitrator or provide a method for selection.  Any arbitration proceedings shall be conducted in Phoenix, Arizona.  The arbitrator shall determine what discovery will be permitted, consistent with the goal of limiting the cost and time that the parties must expend for discovery.  Each party shall bear its own expenses, including attorneys’ fees, and the parties will share equally the costs and fees of the arbitrator.  The parties shall use all reasonable efforts to complete any arbitration subject to this section within [*] months from the filing of notice of a request for such arbitration.  The parties agree that any award shall not include punitive damages and shall be consistent with the limitation of liability provisions set forth in this Agreement.  The arbitrator shall not have the power to add terms not contained in this Agreement or to refuse to enforce any term.  Judgment upon any decision rendered by the arbitrator may be entered by any court having jurisdiction.  The parties undertake and agree that all arbitral proceedings and all information, documentation, materials in whatever form disclosed in the course of such arbitral proceeding shall be deemed Confidential Information hereunder.  Notwithstanding any of the foregoing, either party shall have the right to seek, at its own cost and expense, pre1iminary and temporary injunctive relief pending resolution of the dispute.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

30



 

12.17        Entire Agreement .  This Agreement, together with all Exhibits hereto, constitutes the entire agreement and understanding of the parties relating to the subject matter hereof and supersedes all prior negotiations and understandings between the parties, both oral and written, regarding such subject matter.

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

 

Intermolecular, Inc.

 

Advanced Technology Materials, Inc.

 

 

 

By:

/s/ David Lazovsky

 

By:

/s/ Doug Neugood

 

 

 

Name: David Lazovsky

 

Name: Doug Neugood

 

 

 

Title: President & CEO

 

Title: CEO & President

 

 

 

Date: 7/13/07

 

Date: 7/13/07

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

31


 

EXHIBIT B

 

SYMYX SOFTWARE LICENSE AGREEMENT

Intermolecular, Inc. (“Licensor,” or “we”)               Advanced Technology Materials, Inc. (“Licensee” or “you”)

 

This Symyx Software License Agreement (this “SLA”) between Licensor and Licensee is effective as of

the Effective Date. For good and valuable consideration, the receipt and sufficiency of which we hereby

acknowledge, we agree to the license terms below.

 

(1)            License.

 

(a)    We are duly authorized to sublicense to you the Symyx Software described in the Purchase Documentation (“Programs”) in object code form only, and any operating instructions (“Documentation”) delivered with the Programs, under our agreements with Symyx Technologies, Inc. and its subsidiaries (“Symyx”). We refer to the Programs and Documentation and any and all copies or modifications thereto collectively as the “Software.” For the license term defined in the Quote (incorporated into this SLA by reference and incorporated herein by reference), we grant you a personal, non-exclusive and nontransferable right to install and use the Software.

 

(b)    You may not edit, modify, change, reproduce (except as necessary to install and use) or create derivative works of the Software.

 

(c)    This License is limited to the Site. Only your Named Users may use the Software at these facility(ies).

 

(d)    We may add licenses to this SLA by issuing a Quote and receiving a Purchase Order.

 

(2)            Other License Limitations.

 

(a)    You may use the Software only for your sole and exclusive benefit as licensed hereunder, and agree not to use the Software to provide time-sharing or other similar services on behalf of third parties.

 

(b)    You will not try to reverse engineer, decompile or disassemble any portion of the Software nor use any mechanical, electronic or other method to trace, decompile, disassemble, derive or identify the Software’s source code, or permit others to do so. You may make one copy of the Software for archival and back-up purposes only.

 

(c)    You will not transfer, distribute, sell, lease, license or sublicense the Software to others (other than to Named Users as necessary to permit them to use the Software as this SLA permits).

 

(3)            Term and Termination.

 

(a)    This SLA begins on the Effective Date and continues until it is terminated. The initial license term is defined in the Purchase Documentation.

 

(b)    Either party may terminate this SLA if the other party materially breaches this SLA and does not cure the breach as set forth in Section 11.2 of the Agreement.

 

(c)    Any obligations, including payment obligations, which accrued prior to a termination or expiration will survive and must be met. All of your rights under this SLA end upon termination or expiration of this SLA. At termination or expiration of this SLA, or at termination or expiration of any particular licenses granted, you will immediately discontinue using the relevant Software, remove the relevant Programs from your equipment, and return to us all tangible copies of the relevant Software and any of our proprietary materials that you may have. Sections 1(b), 2, 3, 4, 6(b) and 6(d), 7, 8, 9, 10 and 11 survive termination or expiration of this SLA and/or your licenses.

 

(4)            Payment.

 

(a)    You agree to make all payments in accordance with the Agreement

 

(5)            [Omit]

 

(6)            Limited Warranty.

 

(a)    We represent and warrant to you that:

 

(i)     the Software contains no malicious code, program or other internal component (e.g., computer virus, worm, time bomb, or similar component) designed to disable, deinstall, deactivate, damage or destroy the Software or other computer programs or

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

1



 

data or information the Software accesses or processes;

 

(ii)    the computer diskettes or other media we use to deliver the Software to you will have no materials or workmanship defects under normal use; and

 

(iii)   the Software will function in accordance with its specifications.

 

 

(b)    If we breach Section 6(a), we will use commercially reasonable efforts to correct the error(s) or replace the affected Software at our expense. However, if the Software fails to meet the warranties in Section 6(a) because you have altered or modified it or used it in an unauthorized way, we will not be obligated to correct or replace the Software.

 

(c)    Except as provided in Section 6(a), WE MAKE NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. CERTAIN VERSIONS OF OUR SOFTWARE MAY INCLUDE BETA CODE AND MAY BE CHANGED SUBSTANTIALLY BEFORE COMMERCIAL RELEASE. WE DO NOT WARRANT THAT THE SOFTWARE WILL MEET YOUR REQUIREMENTS OR PERFORM UNINTERRUPTED OR ERROR FREE.

 

(7)            Proprietary Rights.

 

(a)    We and our licensors own all rights to and in (i) the Software, including copyright, patent, trademark and trade secret rights, (ii) each copy of the Software, and (iii) all customizations, enhancements, modifications and new code we deliver to you pursuant to this SLA. We reserve all rights to the Software we have not specifically granted to you under this SLA.

 

(b)    You agree not to remove, obscure or alter our copyright notices, trademarks, patent numbers or other proprietary rights notices affixed to or contained within the Software.

 

(8)            Indemnification.

 

(a)    If someone takes legal action against you claiming the Software infringes their patent, copyright or trade secret rights in a jurisdiction where you are licensed to use the Software pursuant to the Agreement, we will defend on that claim at our expense, and will pay any costs, damages and reasonable attorneys’ fees finally awarded as a result of a settlement or judgment against you, but only if you give us prompt and timely written notice of the claim and relevant proceedings. If you do not give us prompt written notice, and your failure to be prompt materially and negatively affects our defense, then we will not have to defend or indemnify you to the extent we are actually and materially prejudiced by the delay. We will control the defense and settlement, if any, of the claim, and you agree to cooperate with us at our expense by providing prompt and necessary authority, information and reasonable assistance to enable us, at our option, to settle or defend such claim. You may, however, participate in defending the claim using your own attorneys and at your own expense.

 

(b)    If (i) the rights owner described in Section 8(a) obtains an injunction against you and you thus cannot use the Software as licensed, or (ii) we believe an injunction may occur, we will, at our sole option, exercise the first of the following that is practicable (A) modify the Software so it does not infringe while maintaining substantial functional equivalence, or (B) obtain a license that permits you to continue using the Software at no additional cost to you. If we notify you Symyx has informed us that it has not found a commercially reasonable way to do either (A) or (B)any continued use you make of the Software shall be at your sole risk.

 

(c)    We do not have to defend or indemnify you under this Section 8 if and to the extent: (i) the alleged infringement arises because you are using the Software in combination with any other software, data products, processes or materials we did not provide or approve in writing; (ii) you continue allegedly infringing activity after we provide modifications at no charge to you that would have avoided the infringement and that do not materially impact  the functionality of the Software; (iii) the alleged infringement arises because you use the Software other than in accordance with our license grant; (iv) the alleged infringement  arises because you have modified the Software in a way we did not expressly authorize in writing; or (v) we have delivered a newer version of the Software that would not infringe,

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

2



 

and you choose to continue using an earlier, infringing version.

 

(d)    Licensee shall defend, indemnify, and hold Licensor harmless against any claim against Licensor by a third party to the extent resulting from Licensee’s use of Software in the manner described in any of Section 8(c)(i)-(v) above, and pay any costs, damages and reasonable attorneys’ fees finally awarded against Licensor or included in a settlement approved by Licensee in connection therewith.

 

(9)            Liability Limitations. You are responsible for: (a) the accuracy and adequacy of information and data furnished for processing; and (b) any use you make of or reliance you or others place on the Software’s output. You are also responsible for your own computer equipment and third-party software used with the Software, and should follow all of the respective licensors’, vendors’ and manufacturers’ operational, environmental and maintenance guidelines. WE WILL NOT IN ANY EVENT BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY OR PUNITIVE DAMAGES UNDER THIS SLA, INCLUDING LOST BUSINESS, WORK DELAYS, LOSS OF USE, RESULTS OF USE OR DATA INACCURACY, OR COST OF PROCUREMENT OF SUBSTITUTE GOODS, SERVICES OR TECHNOLOGY, LOST PROFITS, WHETHER FORESEEABLE OR NOT, REGARDLESS OF WHETHER WE HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IN NO EVENT SHALL OUR ENTIRE LIABILITY ARISING OUT OF THIS SLA EXCEED THE SUMS YOU HAVE PAID FOR THE PROGRAMS.

 

(10)          Confidentiality . The exchange of any Confidential Information shall be in accordance with the Agreement.

 

(11)         Miscellaneous.

 

(a)    The Software, any media on which it is delivered, and any other technical assistance and data we deliver under this SLA are subject to U.S. export control laws and may be subject to export or import regulations in other countries. The parties shall each comply strictly with all such laws and regulations. We represent that the Software has been classified as ECCN5D002.

 

(b)    This SLA and the Purchase Documentation are entire, final and exclusive agreement between us and supersedes all other prior or contemporaneous oral or written representations, agreements or other communications between us relating to the subject matter of this SLA. We can only amend or modify this SLA in an amendment we both sign.

 

(c)    If either of us fails to exercise any right in this SLA, that right is not waived or forfeited.

 

(d)    New York law governs this SLA, without regard to its choice of law provisions.

 

(e)    This SLA supersedes any provisions of the Uniform Computer Information Transactions Act which may otherwise apply to the maximum extent applicable laws allow.

 

(f)     If the parties cannot settle a dispute under this SLA amicably, it shall be handled in accordance with Section 12.16 of the Agreement.

 

(g)    Each party is excused from performance prevented by, and are not liable for any delay caused by, contingencies beyond its reasonable control or its supplier’s reasonable control. These contingencies include war, sabotage, terrorism, insurrection, riot or other act of civil disobedience, act of public enemy, act of any government affecting the terms hereof, accident, fire, explosion, flood, severe weather or other acts of God.

 

(h)    Neither party is the agent, employee, legal representative, partner or joint venturer of the other for any purpose whatsoever, and neither party can act for or on behalf of the other.

 

(i)     You may not assign, transfer or hypothecate this SLA and the rights, interests, benefits, duties and obligations hereunder without our prior written consent, and any attempt to do so is void. This SLA binds and benefits each party and its respective heirs, executors, administrators, successors and permitted assigns.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

3



 

SCHEDULE 1 to Exhibit B

Symyx Software Maintenance Terms

 

1.     SUPPORT SERVICES .

 

We will use commercially reasonable efforts during the term to provide the maintenance and support services described in this Schedule for the Symyx Software you have under annual licenses from us or on which you have paid maintenance fees. IM’s response times as set forth in Exhibit C shall apply for 1st Tier Support for the Software. (As used in this Schedule, 1st Tier Support means providing support based on information available in the user manual, and determining that the issue the customer is having relates to a supported feature of the product and that it cannot be resolved by following the procedures set forth in the documentation.) Sections 2, 3, and 4, below, state the commitments Symyx has made to IM regarding support beyond 1st Tier Support, and we will use reasonable efforts to enforce such commitments. Under appropriate circumstances, IM will request and use good faith efforts to obtain more urgent support from Symyx.

 

2.     SUPPORT RESPONSIBILITY .

 

a)        Error Reporting. We will provide you telephone support during our normal business hours of 9:00 am to 5:00 p.m. Pacific time, Monday through Friday, excluding our holidays.

 

You should include in each error report sufficient information to enable us to reproduce and verify the suspected error. If you do not supply this information, it will delay our response. We will acknowledge each reported error via telephone, facsimile transmission or electronic mail to your Support Contact within twenty-four (24) hours of its original report, and will use commercially reasonable efforts consistent with the severity of the error to reproduce and verify reported errors and provide Updates (including workarounds) in accordance with the terms set forth herein. You agree to use commercially reasonable efforts to assist us in our efforts to find corrections to confirmed errors you report. We will use our best judgment to determine the priority level of each reported error according to the following criteria:

 

i)            Priority 1 Error : Critical problem with significant business impact to you. No viable workaround, but you need an immediate fix or workaround to get up and running again.

 

ii)           Priority 2 Error : Critical problem with significant business impact to you. A viable workaround exists, you need a fix other than a workaround, but can wait until next scheduled Update.

 

iii)          Priority 3 Error : Problem identified with moderate business impact to you, but you can wait until a future Upgrade for a fix.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

4



 

b)        Response Times .

 

i)            Priority 1 Error. We will use commercially reasonable efforts to promptly resolve the error with an Update. We will give you periodic reports on the status of relevant Updates.

 

ii)           Priority 2 Error. We will use commercially reasonable efforts to include an error correction in the next Update, if any, of the Software.

 

iii)          Priority 3 Error. We will use commercially reasonable efforts to include an error correction in the next Upgrade, if any, of the Software.

 

c)        Support Obligation. We are not required to support or maintain any version of the Software except its then-current, commercially released version, and the version released immediately before that version.

 

3.     UPDATES, UPGRADES .

 

Update ” means a subsequent version of the Software we release generally to our end user customers that includes error corrections, bug fixes or workarounds to ensure that the Software performs according to its specifications. “ Upgrade ” means a revision of the Software we release generally to our end user customers receiving maintenance and support services that adds new and different functions or enhancements. Updates and Upgrades we provide to you are deemed “Software” under the SLA.

 

We will provide you Updates and Upgrades if, as and when we make any such Updates and/or Upgrades generally available to our end user customers receiving maintenance and support services. You agree that, except as expressly provided in Sections 2(a) and 2(b) above, we are not obligated to issue Updates and/or Upgrades and that we must provide you Updates and/or Upgrades only when we have commercially released them to our customers generally. We provide installation and training for Updates and Upgrades on a time and materials basis.

 

4.     SOFTWARE NOT COVERED BY THIS SCHEDULE .

 

 

A.

Altered or modified Software.

 

B.

Any combination of Software with other software not covered by this Maintenance Agreement.

 

C.

Errors caused by your negligence or fault.

 

D.

Errors resulting from hardware malfunction.

 

E.

Software used on a computer or operating system other than systems we specify.

 

5.     ADDITIONAL SERVICES AND CHARGES .

 

We may charge for services outside of the range of normal support services, such as (1) debugging application coding errors in your applications, (2) debugging problems in non-Licensor-supported products, or in combinations of supported and non-supported products where the problem occurs in the non-Licensor product, and (3) other cases where we judge it highly likely that the suspected problem is not our responsibility. We will advise you in advance when we believe services are likely to fall outside of the range of supported services, and give you our

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

5



 

estimates of the likely charges. IF we find that the problem is, indeed, caused by a supported product, you will incur no additional charges. However, if the problem is not our responsibility, we will charge you at the rates specified in the estimate/service agreement.

 

6.     TERM AND TERMINATION .

 

This Maintenance Schedule covers any licensed Programs as long as you continue to purchase the Maintenance and Support for the Symyx Software.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

6



 

Exhibit C: IM Maintenance and Support Services

 

I.        General Terms

 

A.       Services Provided During First Year and During Any Renewal Term

 

Section II of this Exhibit C describes maintenance and support services that IM shall provide with respect to any Wets Workflow sold pursuant to this Agreement. IM shall provide maintenance and support services throughout the initial term for maintenance and support, which shall commence upon delivery to ATMI of the Wets Workflow and continue until the first anniversary of final acceptance of the Workflow (the “Initial Maintenance and Support Term”).

 

IM shall continue to provide said services during any additional term during which IM provides maintenance and support services (each one a “Renewal Maintenance and Support Term”) in accordance with the procedure set forth in Section I B., below. Each Renewal Maintenance and Support Term for a Wets Workflow shall consist of a one-year period; the first Renewal Maintenance and Support Term shall commence the day following the last day of the Initial Maintenance and Support Term; any subsequent Renewal Maintenance and Support Terms shall commence on the anniversary of the first day of the first Renewal Maintenance and Support Term.

 

Nothing in this Exhibit C shall reduce IM’s warranty obligations set forth in the Agreement.

 

B.       Term of Maintenance and Support; Renewal

 

IM shall provide the maintenance and support services set forth in Section II of this Exhibit C throughout the Initial Maintenance and Support Term. Not less than ninety (90) days prior to the conclusion of the Initial Maintenance and Support Term, IM shall send ATMI written notice of the date that the Initial Term is scheduled to expire, together with a Quote for maintenance and support services for the first Renewal Term.

 

If ATMI thereupon provides IM with an acceptable Purchase Order in connection with the Quote, IM shall invoice ATMI in accordance with Section 5.1 of the Agreement, and provide maintenance and support services as set forth in Section II, below, for the first Renewal Term. Not less than ninety (90) days prior to the end of any Renewal Period, IM shall provide ATMI with notice specifying whether IM intends to continue to offer maintenance and support services for the Wets Workflow in question; if so, IM shall specify the price for maintenance and support for the next Renewal Term.

 

Notwithstanding the foregoing, the price for maintenance and support services for June 26, 2007 the first and second Renewal Terms are set forth in Exhibit A to the

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 



 

Agreement. The price for maintenance and support services for any subsequent Renewal Term shall be as mutually agreed by IM and ATMI.

 

C.       Special Services Provided Only During First Year

 

In addition to the maintenance and support services described above, during the one-year period following Final Acceptance of the first Wets Workflow sold hereunder, IM shall also make available one (1) product support engineer who will provide services, including but not limited to training, support or maintenance, to ATMI in the operation of the Wets Workflow.

 

D.       Modified or Altered Wets Workflow

 

The obligation to provide maintenance and support services hereunder will be void as to (i) any Wets Workflow that has been damaged, modified, or altered (other than by IM or as authorized in writing by an officer of IM), unless ATMI can demonstrate by clear and convincing evidence that the modification or alteration did not cause the non-conformity, in whole or in part, (ii) nonconformities, in whole or in part, arising from use of the Wets Workflow with any other hardware, software, firmware, devices, or other products not provided by IM, or (iii) Equipment or Informatics Hardware that has been subjected to unusual physical, chemical or electrical stress, or that has been operated without regard to any limitations defined in the Equipment Specifications.

 

E. Error Classification and Response Times

 

The following terms shall apply with respect to support for Equipment, Informatics Hardware, and/or Informatics Software:

 

(i)     Error Classification

 

(a)  Priority 1 Error : System down with critical business impact to ATMI. No viable workaround, but ATMI needs an immediate fix or workaround to get up and running again.

 

(b)  Priority 2 Error : Critical problem with significant business impact to ATMI. A viable workaround exists, but ATMI needs a fix other than a workaround.

 

(c)  Priority 3 Error : Problem identified with moderate business impact to ATMI for which a workaround may be adequate.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 



 

(ii) Response Times.

 

(a)  Priority 1 Error . IM shall provide and maintain for ATMI contact and escalation procedures for ATMI personnel to reach an appropriate IM employee as follows:

 

i.       From 8 a.m. to 12 midnight Eastern time, IM shall acknowledge the ATMI call within three (3) hours of ATMI initiating the process of contacting IM;

 

ii.      From 12 midnight to 8 a.m. Eastern time, IM shall acknowledge the ATMI call by 8 a.m. Eastern time, or within three (3) hours of ATMI initiating the process of contacting IM, whichever is later;

 

iii.     If ATMI requires faster response during a defined time period, e.g. during a critical demo, IM shall make a best effort to put in place a shorter response time, if ATMI has provided reasonable notice prior to that defined time period.

 

Upon acknowledging a Priority 1 Error, IM shall provide ATMI an initial assessment within twelve (12) hours and an error resolution plan within eighteen (18) hours. IM will use best commercial efforts to promptly resolve the error through an Update, or through the implementation of a viable workaround, or through any other means that provides the fastest time for ATMI to be up and running again. IM will give ATMI periodic reports, or immediately upon ATMI’s request, on the status of relevant error resolution plans and activities.

 

(b)  Priority 2 Error . Upon acknowledging a Priority 2 Error, IM shall provide ATMI an initial assessment within 2 business days and an error resolution plan within 3 business days. IM will use best commercial efforts to (i) include an error correction in the next Update, if any, of the Software and/or (ii) to schedule and execute in a timely fashion error resolution activities for Informatics Hardware or Equipment.

 

(c)  Priority 3 Error . Upon acknowledging a Priority 3 Error, IM shall provide ATMI an initial assessment within 3 business days and an error resolution plan within 5 business days. IM will use best commercial efforts to (i) include an error correction in the next Update, if any of the Software, and/or (ii) to implement in a timely fashion a workaround and/or schedule and execute error correction activities for Informatics Hardware or Equipment.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 


 

II. Maintenance and Support Services

 

A.                  Informatics Hardware and Equipment Support

 

IM shall use best commercial efforts to do the following during the Initial Maintenance Support Term, and during any Renewal Maintenance and Support Term:

 

(a)                                   IM shall maintain the Equipment and Informatics Hardware in the Wets Workflow in accordance with the warranty set forth in the Agreement. Service may also include scheduled preventative maintenance, as determined by IM. Remedial maintenance will be provided by IM during normal working hours when notified by ATMI that the Wets Workflow is inoperable. IM customer service may be initiated by calling 408-416-2300 (or such other number or email provided to ATMI for that purpose) between the hours of 9:00 a.m. and 5:00 p.m., Pacific time, Monday through Friday, excluding IM holidays (or such other hours and days as may be mutually agreed to by the parties, from time to time, or for Priority 1 Errors, as specified in I.E., above).

 

(b)                                  Maintenance will include replacement of parts deemed necessary by IM. ATMI must inform IM if any replaced parts may be contaminated with hazardous or toxic materials. All parts may be furnished on an exchange basis and will be new or equivalent to new. Replaced parts removed from the Equipment or Informatics Hardware shall, at IM’s sole option, become the property of IM. All customer consumable items, including but not limited to wafers, vials, chemicals, are excluded from coverage hereunder.

 

(c)                                   Exclusions: Maintenance service is contingent upon the proper use of all Equipment and Informatics Hardware, and does not cover Equipment or Informatics Hardware that has been damaged, modified, or altered as described in I.D. above. IM shall be under no obligation to furnish maintenance service if (i) adjustment, repair or parts replacement is required because of operator-caused error or repeated misuse of Equipment or Informatics Hardware; (ii) the Equipment or Informatics Hardware is repaired or if attempts to repair or service the equipment are made by other than authorized IM personnel, without the prior written approval of IM; (iii) a non-conformity arising from or after relocation of the Equipment or Informatics Hardware without prior written approval of IM, which shall not be unreasonably withheld, unless ATMI can demonstrate by clear and convincing evidence that the relocation did not cause the non-conformity, in whole or in part; (iv) the Equipment or Informatics Hardware is damaged through the use of hardware consumables that IM has not previously recommended or approved, unless ATMI can demonstrate by clear and convincing evidence that the use of such consumables did not cause the damage, in whole or in part. Maintenance service does not include damage from acts of God, such as fire, flood, or earthquakes. All repairs required by such excluded

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 



 

damage will be subject to an additional charge, as agreed in advance in writing by IM and ATMI.

 

(d)                                  ATMI shall provide full and free access to the Equipment and Informatics Hardware as needed to perform any services to be provided hereunder, subject to ATMI’s reasonable policies and procedures. ATMI acknowledges that employees or contractors of Symyx Technologies, Inc., may be providing services hereunder with respect to Equipment manufactured by Symyx.

 

B.                  Informatics Software Support

 

1.                            IM shall use best commercial efforts to do the following during the Initial Maintenance and Support Term and during any Renewal Maintenance and Support Term:

 

(a) IM shall maintain the Informatics Software in accordance with the warranty set forth in the Agreement. ATMI shall provide VPN site to site Internet access to the data network located at 6 Commerce Drive, Danbury, CT. ATMI will fund the data circuits located in the ATMI data center and IM will fund the data circuits located in its data center. ATMI shall institute and document, prior to installation of the Informatics Hardware, and maintain thereafter, a reasonable firewall management policy to enable appropriate access and block unneeded access to the Informatics Software and Third Party Software installed on Informatics Hardware as needed to diagnose any problem or perform any services to be provided hereunder, subject to the provisions of Section 7.5 (IP Firewall) of the Agreement. The response times and procedures set forth above shall not apply for any error or problem if limits on IM’s access to the Informatics Software inhibit IM’s ability to conduct an initial assessment, make a diagnosis, provide an error resolution plan, and/or perform any services related to resolution of that error or problem.

 

(b) ATMI may request services by calling 408-416-2300 (or such other number or email provided to ATMI for that purpose) between the hours of 9:00 a.m. and 5:00 p.m., Pacific time, Monday through Friday, excluding IM holidays, (or such other hours and days as may be mutually agreed to by the parties, from time to time, or for Priority 1 Errors., as specified in I.E., above).

 

(c) ATMI should include in each error report sufficient information to enable IM to reproduce and verify the suspected error. Failure to supply this information may delay IM’s response. IM will acknowledge each reported error via telephone, facsimile transmission or electronic mail to the Named User reporting the error within twenty-four (24) hours of its original report, and will use commercially reasonable efforts consistent with the severity of the error to reproduce and verify reported errors and provide Updates

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 



 

(including workarounds) in accordance with the terms set forth herein. ATMI agrees to use commercially reasonable efforts to assist IM in its efforts to find corrections to confirmed errors ATMI reports. IM will use its best judgment to determine the priority level of each reported error according criteria set forth in Section I.E.

 

(d) Support Obligation. IM is not required to support or maintain any version of the Software except its then-current, commercially released version, and the version that immediately preceded that version. For such immediately preceding software version, IM shall use commercially reasonable efforts to provide error-fixing updates, but shall have no obligation to provide upgrades that improve the functionality of that software version.

 

2.                            The following software is not covered by this schedule:

 

A.            Altered or modified Informatics Software

B.              Any combination of Informatics Software with other software or hardware not supplied pursuant to the Agreement

C.              Errors caused by ATMI’s negligence or fault

D.             Software used with hardware other than Equipment or Informatics Hardware

E.               Errors in Third Party Software

 

3. IM is not obligated to provide free of charge services outside of the range of normal support services, such as (1) debugging problems in non-IM-supported software or products, or in combinations of supported and non-supported software or products where the problem occurs in products or software not supplied by IM, and (2) other cases where IM reasonably judges it highly likely that the suspected problem is not its responsibility. IM will advise ATMI in advance when IM believes services are likely to fall outside of the range of supported services, and may give ATMI an estimate of the likely charges. If IM finds that the problem is, indeed, caused by a supported product, ATMI will incur no additional charges. However, if the problem is not IM’s responsibility, IM will charge ATMI at the rates specified in the estimate/service agreement.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 



 

Schedule D — Supplemental Specifications For Factory Acceptance

 

Application

 

Chemistry

 

Process

 

Objective

 

Description

[*]

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

[*]

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

1



 

Supplemental Tool
Specifications

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

2



 

Supplemental Tool
Specifications

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

3


 

Addendum to Wets Workflow Purchase Agreement

 

This Addendum (the “Addendum”) to the Wets Workflow Purchase Agreement (the “Agreement”), effective as of December 21, 2007, or, if left blank, the last date of signature by a party hereto (the “ Addendum Effective Date ”), is made by and between Advanced Technology Materials, Inc., with a principal place of business at 7 Commerce Drive, Danbury, CT 06810 (“ ATMI ”), and Intermolecular, Inc., with a principal place of business at 2865 Zanker Road, San Jose, California 95134 (“ IM ”).  ATMI and IM are sometimes referred to herein individually as a “party” and collectively as the “parties.”  Capitalized terms in this Addendum have the meaning assigned to them in the Agreement, unless otherwise separately defined herein.

 

BACKGROUND

 

IM and ATMI entered into the Agreement effective July 13, 2007.  The parties now wish to engage in a strategic alliance between the parties, define terms and conditions that will be applicable to the sale of three additional Wets Workflows, and define further the parties’ respective rights and obligations with respect to certain Strategic Accounts in certain Strategic Fields.  IM will issue warrants to ATMI as set forth below in this Addendum.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as set forth below.

 

ARTICLE 1
ADDITIONAL DEFINITIONS

 

1.1                                  Strategic FTE ” means a full-time employee or contractor dedicated to supporting the use of Wets Workflow(s) purchased pursuant to the Agreement and/or this Addendum, or a Wets Workflow to which access has been granted pursuant to Section 3.2 of this Addendum, or, in the case of less than full-time dedication, a full-time equivalent person-year, based on approximately [*] hours per year of work, on or related to a Strategic Account in a Strategic Field.

 

1.2                                  Strategic Accounts ” shall mean the following:  [*] and [*].  The parties may mutually agree in writing to modify the Strategic Accounts at a later date; however, such agreement can be withheld in the sole discretion of either party.

 

1.3                                  Strategic Fields ” shall mean the [*] Wets Processing applications defined in Appendix A to this Addendum.  The parties may mutually agree in writing to modify the Strategic Fields at a later date; however, such agreement can be withheld by either party in its sole discretion.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

1



 

ARTICLE 2
WETS WORKFLOW PURCHASES

 

2.1                                  Second Wets Workflow Purchase .  Upon the mutual execution of this Addendum, ATMI shall execute a separate Purchase Order for the Wets Workflow identified in Quote #2 attached to the Agreement as Exhibit A-1, modified as shown in Appendix B attached hereto, and incorporated herein by reference (“ Modified Quote #2 ”).  Said Purchase Order shall be consistent with the terms of Modified Quote #2.  Said Purchase Order and Modified Quote #2 shall be deemed to be incorporated into the Agreement as Exhibit A-1.  The Acceptance Criteria for said Wets Workflow identified in Appendix B shall be the same as set forth in the Purchase Documentation in Exhibits A and D to the Agreement; said Acceptance Criteria shall also hereby be deemed to be incorporated into the Exhibit A-1 Purchase Documentation.  IM shall deliver said Workflow to ATMI as set forth in Modified Quote #2.

 

2.2                                  Third Wets Workflow Purchase .  Upon the mutual execution of this Addendum, ATMI shall execute a separate Purchase Order for the Wets Workflow identified in Quote #3, attached to this Addendum as Appendix C, and incorporated herein by this reference.  Said Purchase Order shall be consistent with the terms of Quote #3.  Said Purchase Order and Quote #3 shall be deemed to be incorporated into the Agreement as Exhibit A-2.  The Acceptance Criteria for said Wets Workflow identified in Quote #3 shall be the same as set forth in the Purchase Documentation in Exhibits A and D of the Agreement; said Acceptance Criteria shall also hereby be deemed to be incorporated into the Exhibit A-2 Purchase Documentation.  IM shall deliver said Workflow to ATMI as set forth in Quote #3.

 

2.3                                  Fourth Wets Workflow Purchase .  Upon the mutual execution of this Addendum, ATMI shall execute a separate Purchase Order for the Wets Workflow identified in Quote #4, attached to this Addendum as Appendix D, and incorporated herein by this reference.  Said Purchase Order shall be consistent with the terms of Quote #4.  Said Purchase Order, and Quote #4, shall be deemed to be incorporated into the Agreement as Exhibit A-3.  The Acceptance Criteria for said Wets Workflow identified in Quote #4 shall be the same as the Acceptance Criteria set forth in the Purchase Documentation in Exhibits A and D of the Agreement; said Acceptance Criteria shall also hereby be deemed to be incorporated into the Exhibit A-3 Purchase Documentation.  IM shall deliver said Workflow to ATMI as set forth in Quote #4.

 

2.4                                  Third Party Workflow Placement .  If any of the above Wets Workflows are placed at a location of and/or operated by a Third Party, then either (i) the Third Party shall sign an agreement with IM containing licensing and royalty terms consistent with the existing Agreement between IM and ATMI, or (ii) ATMI and IM will determine at that time how to proceed, provided that the license and royalty terms will be the same as those set forth in the Agreement with ATMI.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 



 

2.5                                  Warranty .  NO ADDITIONAL REPRESENTATION, WARRANTY, OR INDEMNIFICATION IS HEREBY PROVIDED BY IM OR ATMI OTHER THAN AS EXPLICITLY SET FORTH IN THE AGREEMENT.

 

ARTICLE 3
STRATEGIC FTEs, PLAN AND WORKFLOW ACCESS

 

3.1                                  Dedicated Personnel :   IM shall provide [*] Strategic FTEs to provide services to ATMI, the nature of the services to be mutually agreed by the parties, to support the Strategic Accounts in connection with the Strategic Fields on the schedule set forth in this Section 3.1 (“Addendum Services”).  The parties may mutually agree in writing to increase the number of Strategic FTEs provided by IM and paid for by ATMI if the number of Strategic Fields increases or the expected workload increases at a later date; however, such agreement can be withheld by either party in its sole discretion.  Addendum Services will be provided in the manner consistent with Section 8.7 of the Agreement with the same rights and remedies set forth therein.

 

IM shall invoice and ATMI shall pay for [*] Strategic FTEs starting on January 1, 2008 and [*] additional Strategic FTEs starting upon Factory Acceptance of the first Element of each of the Second through Fourth Wets Workflows.  If ATMI elects to terminate the Purchase Documentation for the Fourth Wets Workflow as set forth in Quote #4, then IM may invoice for and ATMI shall pay the [*] Strategic FTEs associated with the Fourth Wets Workflow as of the Target Delivery Date for that Wets Workflow.

 

Table I.  Projected Starts Per Quarter for IM Strategic FTE’s

Period

 

Ql 2008

 

Q2 2008

 

Q3 2008

 

Q4 2008

 

Total
Strategic
FTEs

Strategic FTE’s

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

The Strategic FTEs shall continue to provide Addendum Services under this Addendum to ATMI in connection with the Strategic Accounts until [*].  ATMI shall pay IM for said FTEs at the rate of [*] US dollars (US$[*]) per FTE per month.  IM will invoice monthly for the Addendum Services and payment terms shall be as set forth in the Agreement.  Upon the mutual execution of this Addendum, AMTI shall issue a purchase order to IM for the total fees for Addendum Services scheduled to be rendered under this Section 3.1.

 

3.2                                  Access to IM Workflow .  IM shall be responsible for providing the IM resources described in Section 3.1 with access to a Wets Workflow that is substantially equivalent to the Wets Workflow described in Modified Quote #2 in IM’s clean

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 



 

room in San Jose, California to support activities in the Strategic Fields for the Strategic Accounts pursuant to this Addendum until [*].  This support shall include access to IM’s metrology and characterization infrastructure (i.e., physical and electrical test equipment) for that period.

 

3.3                                  Strategic Plan .  It is the intent of the parties through this Addendum to work together to drive adoption of ATMI Products for each Strategic Field in each Strategic Account through the use of HPC Technology, specifically the Wets Workflows.  To further that intent, the parties agree to develop a materials, process and process integration development and qualification plan for each Strategic Account in each Strategic Field (each a “ Strategic Plan ”).  The Strategic Plans will (a) define the priority of the Strategic Fields at each Strategic Account, (b) define a joint sales and marketing strategy for each Strategic Account, and (c) define the IM and ATMI resources, equipment, and other development resources necessary to execute on each Strategic Plan.  The Strategic Plans will be created on the following schedule:  [*] and [*] within [*] of the Addendum Effective Date, [*] and [*] no later than the Target Ship Date for the Second, Third and Fourth Wets Workflow, respectively, irrespective of ATMI’s decision to substitute a Dry Workflow for the Fourth Wets Workflow as set forth in Quote #4.  A Strategic Plan may be modified based on the mutual written consent of the parties.  In addition, each party agrees to discuss, as permitted, circumstances external to this Addendum that may have an effect on each Strategic Plan, provided, however, that the decision whether a party may or does discuss such business opportunities shall be made in its sole discretion.  Nothing in this Section 3.3 changes the right, restrictions and obligations, including Wets Workflow sales and Strategic FTE resources, set forth elsewhere in this Addendum.

 

ARTICLE 4
RESTRICTIONS AND RIGHTS

 

4.1                                  Services Restrictions on IM .  Commencing with the Addendum Effective Date, and continuing until [*], IM shall refrain from entering into any agreements defining joint marketing, sales or development obligations with a Competitor to address any Strategic Field with any Strategic Account.  For the avoidance of doubt, this provision does not and is not intended to restrict IM from (i) selling one or more Wets Workflows in whole or in part to any Strategic Account, subject to the restrictions in Section 4.2, or for performing services for a Competitor in the Strategic Fields, except as set forth above, or (ii) licensing its IM Independent IP to any Strategic Accounts or other Third Parties.

 

In the event that (i) Actual Royalties (as hereinafter defined) paid by ATMI to IM are equal to or greater than [*] US dollars (US$[*]) by [*], and (ii) ATMI elects to extend its commitment to pay for the IM Strategic FTEs in Section 3.1 for [*] through [*],

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 



 

then IM’s obligations set forth in this Section 4.1 shall be extended until [*] (“ First Extension ”).

 

If ATMI has elected to exercise the First Extension and met the requirements therein, then ATMI may elect to extend IM’s obligations set forth in this Section 4.1 until [*] if (i) Actual Royalties (as hereinafter defined) paid by ATMI to IM from [*] to [*] are equal to or greater than [*] US dollars (US$[*]), and (ii) ATMI elects to extend its commitment to pay for the IM Strategic FTEs in Section 3.1 for [*] through [*] (“ Second Extension ”).

 

If ATMI has elected to exercise the Second Extension and met the requirements therein, then ATMI may elect to extend IM’s obligations set forth in this Section 4.1 until [*] if (i) Actual Royalties (as hereinafter defined) paid by ATMI to IM from [*] to [*] are equal to or greater than [*] US dollars (US$[*]), and (ii) ATMI elects to extend its commitment to pay for the IM Strategic FTEs in Section 3.1 for [*] through [*].

 

4.2                                  Wets Workflow Restrictions on IM .  Commencing with the Addendum Effective Date, and continuing until [*], IM agrees not to ship (a) more than [*] of each Element of a Wets Workflow to a Competitor and/or (b) a [*] system(s) to a Strategic Account for use in the Strategic Fields without a written agreement that provides (i) ATMI, (ii) ATMI and IM or (iii) IM, subject to Section 2.5 of the Alliance Agreement between the parties dated November 17, 2006 (the “Alliance Agreement”), the right to source materials developed through the use of the [*] system(s) to that Strategic Account (absent mutual written consent of the parties to ship said system(s) without such sourcing rights).  For the purposes of the preceding sentence, Section 2.5 of the Alliance Agreement shall be amended so that (x) references to “CDP Fields” shall include the Strategic Fields, and (y) references to “Materials” shall mean materials developed through the use of the [*] system(s) by the applicable Strategic Account.  Nothing in this Addendum shall preclude IM from (a) shipping a Wets Workflow in whole or in part to a company that is not a Competitor or Strategic Account, (b) shipping two or more Elements of a Wets Workflow in whole or in part to a Competitor on or after [*], or (c) shipping a [*] system(s) to a Strategic Account for use in the Strategic Fields without rights to source the materials discovered through the use of the [*] systems on or after [*].  The foregoing shall in no way reduce IM’s obligations pursuant to Section 4.13 of the Agreement.

 

4.3                                  Dry Workflow Rights for ATMI .  Commencing with the Addendum Effective Date, and continuing until [*], IM agrees to provide ATMI a Right of First Negotiation (“ ROFN ”) before selling or licensing its [*] based Workflow (“ Dry Workflow ”) to a Competitor.  Under this ROFN, IM

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 



 

agrees to offer its Dry Workflow to ATMI no earlier than [*] from its initial availability and negotiate in good faith with ATMI for [*] to come to terms on the sale and licensing of IM’s Dry Workflow to ATMI.  During this [*] period, IM shall not negotiate, or enter into an agreement, to sell or license its Dry Workflow to a Competitor.  Nothing in this Addendum shall A) preclude IM from (i) shipping a Dry Workflow in whole or in part to a company that is not a Competitor, or (ii) selling or licensing a Dry Workflow in whole or in part to a Competitor on or after the [*] of the ROFN negotiation period or after [*], whichever occurs first; or B) require IM to provide ATMI a ROFN if IM does not sell or license its Dry Workflow in whole or in part to a Competitor prior to [*].

 

4.4                                  Access to Independent IP .  No license right shall be created by implication, estoppel or otherwise, by this Addendum, to the other Party’s Independent IP, except as explicitly set forth in the Agreement.

 

ARTICLE 5
ROYALTIES

 

5.1                                  Royalty Payments to ATMI :   IM shall pay royalties to ATMI of [*] percent [*] of the gross sales proceeds arising from ATMI’s successful brokering the sale of an element of the Wets Workflow to a Strategic Account, after the Addendum Effective Date, and on or before [*].  ATMI shall only be deemed to have successfully brokered the sale if the Strategic Account (a) issues a purchase order acceptable to IM, and (b) signs an agreement for the purchase of an element of the Wets Workflow, under terms and conditions that are substantially identical to those set forth in the Agreement (except for terms relating to exclusivity and volume discounts, and terms relating to the Alliance Agreement).  No royalties under this Section 5.1 shall be payable except in connection with the sale of an element of a Wets Workflow to a Strategic Account through the efforts of ATMI.  Moreover, in no event shall any royalty be payable to ATMI in connection with any sale by IM of a Wets Workflow element to IBM Corporation, except by mutual agreement of the parties; however, such agreement can be withheld by either party in its sole discretion.  Furthermore, as used in this Section, “gross sales proceeds” shall consist of the sale price of the Wets Workflow element, excluding royalties payable by the Strategic Account to IM, and excluding the price of annual warranties and licenses after the first year, and less the following:  (i) Third Party sales commissions, allowances, discounts, including cash discounts, rebates and returns all to the extent actually given in the trade by IM or its affiliates; (ii) sales, excise and similar taxes (including but not limited to any value added tax or withholding taxes) or duties; and (iii) insurance and freight.

 

5.2                                  Royalty Payments to IM :   ATMI’s obligation to pay IM royalties as set forth in Section 6.1 of the Agreement for Products, Product licenses, or other business arrangements shall apply to (a) the use of any Wets Workflow sold to ATMI

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 



 

pursuant to this Addendum, or (b) the use of the Wets Workflow access provided under Section 3.2 to this Addendum (“ Actual Royalties ”).  Actual Royalties shall include royalties payable by ATMI pursuant to Section 14 of [*] CDP agreement dated November 16, 2007 as amended by the parties in the October 11, 2007 letter addendum.

 

5.3                                  Prepaid Guaranteed Minimum Royalties :   ATMI will pay Guaranteed Minimum Royalties to IM as set forth in this Section 5.3.  Within [*] days of the Addendum Effective Date, ATMI shall pre-pay Guaranteed Minimum Royalties to IM in the amount of [*]US dollars (US$[*]) (“ Pre-paid Royalty ”).  Said payment shall be made as set forth in the Agreement and shall be applied to the Guaranteed Minimum Royalties for the Royalty Periods defined as follows:

 

“Royalty Period One”, consisting of the period from [*] through [*]:  Guaranteed Minimum Royalties in the amount of [*] US dollars (US$[*]).

 

“Royalty Period Two”, consisting of the period from [*] through [*]:  Guaranteed Minimum Royalties of [*] US dollars (US$[*]).

 

“Royalty Period Three”, consisting of the period from [*] through [*]:  Guaranteed Minimum Royalties of [*] US dollars (US$[*]).

 

In the event that Actual Royalties due to IM are greater than the Guaranteed Minimum Royalty for a given Royalty Period, the excess royalties due for that Royalty Period shall be paid from the Pre-paid Royalty.  Any excess royalty amount for a particular Royalty Period that is paid from the Pre-paid Royalty shall not reduce the Guaranteed Minimum Royalty set forth above for later Royalty Periods.  No refunds shall be due in the event that the Actual Royalties for a Royalty Period are less than its Guaranteed Minimum Royalties.  In the event that Actual Royalties due from ATMI to IM are in excess of the Pre-paid Royalty, the remaining royalties due shall be paid as set forth in the Agreement.  Royalties shall continue to be payable after the end of Royalty Period Three in accordance with the terms of the Agreement and this Addendum.

 

If ATMI terminates the Purchase Documentation, pursuant to Section 11.2 of the Agreement, of any of the Second, Third or Fourth Wets Workflows (as set forth in Section 2.1-3 of this Addendum), then IM shall promptly refund [*] of the Pre-paid Royalty for each such set of Wets Workflow Purchase Documentation so terminated.  However, if ATMI elects not to receive the Fourth Wets Workflow as set forth in Quote #4, then ATMI shall not be eligible for a refund on the Pre-paid Royalties for that Wets Workflow as set forth in this Section.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 



 

ARTICLE 6
WARRANT

 

6.1                                  Issuance .  Upon execution of this Addendum IM shall issue to ATMI a warrant in the form attached as Appendix E (the “Warrant”), to purchase common shares of IM on the terms and conditions set forth in the Warrant.

 

Except as modified by this Addendum, the terms of the Agreement shall remain in full force and effect.  The Agreement, together with all Exhibits thereto, and together with this Addendum, and all Appendices hereto, constitutes the entire agreement and understanding of the parties relating to the subject matter hereof, and supersedes all prior negotiations and understandings between the parties, both oral and written, regarding such subject matter.

 

IN WITNESS WHEREOF, the parties hereto have executed this Addendum as of the day and year first written above.

 

Intermolecular, Inc.

Advanced Technology Materials, Inc.

 

 

By:

/s/ David Lazovsky

 

By:

/s/ Daniel P. Sharkey

 

 

 

 

Name:

David Lazovsky

Name:

Daniel P. Sharkey

 

 

 

 

Title:

President & CEO

Title:

EVP — Business Development

 

 

 

 

Date:

12/20/07

Date:

 12-21-07

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 


 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

APPENDIX A

 

 

 

Opportunity (Near-term through  [*] )

 

No. of 
[*]

 

Product
Type

 

Priority

 

 

 

All (Centered around Wets workflow)

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 



 

 

Appendix B
[Modified Quote #2 Agreement Exhibit A-1]
Revised December 19, 2007

 

Description

 

Qty.

 

List Price

 

Ext. List

 

Disc. %

 

Price

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1                     [*]
[*]

Target Ship Date: [*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

2                     [*]

[*]

Target Ship Date: [*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

3                     [*]

[*]

Target Ship Date: [*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

4                     [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*] -

 

 

 

 

 

 

 

 

 

 

 

 

 

5                     [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

6                     [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

7                     [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

8                     [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

Subtotal ATMI Alliance HPC-Enabled Workflow Price

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

Volume Discount

 

 

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

Total ATMI Alliance HPC-Enabled Workflow Price

 

 

 

 

 

$

[*]

 

 

Payment terms :

[*]
[*]
[*]

 

[*]
[*]
[*]

[*]
[*]
[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

1



 

 

 

 

Description

 

Qty.

 

List Price

 

Ext. List

 

Disc. %

 

Price

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

9                     [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

10              [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*] -

 

 

 

 

 

 

 

 

 

 

 

 

 

11              [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

12              [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

13              [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

14              [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

Total ATMI Alliance HPC Use Licenses, Maintenance & Support, Annual Renewal

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

Volume Discount, Annual Renewal

 

 

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

Total ATMI Alliance HPC-Enabled Workflow Annual Renewal Price

 

 

 

 

 

$

[*]

 

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2



 

 

 

 

Description

 

Qty.

 

List Price

 

Ext. List

 

Disc. %

 

Price

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Extended Descriptions

 

[*]

 

[*]:

 

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

 

[*]

 

[*]:

 

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

 

[*]

 

[*]:

 

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

 

[*]

 

[*]:

[*]

[*]:

 

 ( End of Quote )

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

3



 

 

Appendix C
[Agreement Exhibit A-2]
Single Workflow #3 Quote — December 19, 2007

 

Description

 

Qty.

 

List Price

 

Ext. List

 

Disc. %

 

Price

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1                     [*]

[*]

Target Ship Date: [*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

2                     [*]

[*]

Target Ship Date: [*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*] -

 

 

 

 

 

 

 

 

 

 

 

 

 

3                     [*]

[*]

Target Ship Date: [*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

4                     [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

5                     [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

6                     [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*] -

 

 

 

 

 

 

 

 

 

 

 

 

 

7                     [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

8                     [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

Subtotal ATMI Alliance HPC-Enabled Workflow Price

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

Volume Discount

 

 

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

Total ATMI Alliance HPC-Enabled Workflow Price

 

 

 

 

 

$

[*]

 

 

Payment terms :

[*]
[*]
[*]

 

[*]
[*]
[*]

[*]
[*]
[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

4



 

 

 

 

Description

 

Qty.

 

List Price

 

Ext. List

 

Disc. %

 

Price

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

9                     [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

10              [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

11              [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

12              [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*] -

 

 

 

 

 

 

 

 

 

 

 

 

 

13              [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

14              [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

Total ATMI Alliance HPC Use Licenses, Maintenance & Support, Annual Renewal

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

Volume Discount, Annual Renewal

 

 

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

Total ATMI Alliance HPC-Enabled Workflow Annual Renewal Price

 

 

 

 

 

$

[*]

 

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

5



 

 

 

 

 

 

Description

 

Qty.

 

List Price

 

Ext. List

 

Disc. %

 

Price

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Extended Descriptions

 

[*]

 

[*]:

 

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

 

[*]

 

[*]:

 

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

 

[*]

 

[*]:

 

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

 

[*]

 

[*]:

 

[*]

 

[*]:

 

 ( End of Quote )

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

Appendix D
[Agreement Exhibit A-3]
Single Workflow #4 Quote — December 19, 2007

 

Description

 

Qty.

 

List Price

 

Ext. List

 

Disc. %

 

Price

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1                     [*]

[*]

Target Ship Date: [*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

2                     [*]

[*]

Target Ship Date: [*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

3                     [*]

[*]

Target Ship Date: [*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

4                     [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*] -

 

 

 

 

 

 

 

 

 

 

 

 

 

5                     [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

6                     [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

7                     [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

8                     [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

Subtotal ATMI Alliance HPC-Enabled Workflow Price

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

Volume Discount

 

 

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

Total ATMI Alliance HPC-Enabled Workflow Price

 

 

 

 

 

$

[*]

 

 

Payment terms :

[*]

[*]

[*]

 

[*]

[*]

[*]

[*]

[*]

[*]

 

[*]

[*]

[*]

[*]

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

 

 

 

 

 

Description

 

Qty.

 

List Price

 

Ext. List

 

Disc. %

 

Price

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

9                     [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

10              [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

11              [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*] -

 

 

 

 

 

 

 

 

 

 

 

 

 

12              [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

13              [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

14              [*]

[*]

 

[*]

 

$

[*]

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

Total ATMI Alliance HPC Use Licenses, Maintenance & Support, Annual Renewal

 

$

[*]

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

Volume Discount, Annual Renewal

 

 

 

[*]

%

$

[*]

 

 

 

 

 

 

 

 

 

Total ATMI Alliance HPC-Enabled Workflow Annual Renewal Price

 

 

 

 

 

$

[*]

 

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

 

 

 

 

 

 

 

Description

 

Qty.

 

List Price

 

Ext. List

 

Disc. %

 

Price

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Extended Descriptions

 

[*]

 

[*]:

 

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

 

[*]

 

[*]:

 

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

 

[*]

 

[*]:

 

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

- [*]

 

[*]

 

[*]:

 

[*]

 

[*]:

 

 ( End of Quote )

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 


 

APPENDIX E

 

COMMON STOCK WARRANT

 

THIS WARRANT AND THE SHARES OF COMMON STOCK PURCHASABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION AND MAY NOT BE SOLD, OFFERED FOR SALE OR OTHERWISE TRANSFERRED UNLESS REGISTERED OR QUALIFIED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT REGISTRATION, QUALIFICATION OR OTHER SUCH ACTIONS ARE NOT REQUIRED UNDER SAID ACT.

 

INTERMOLECULAR, INC.

 

WARRANT TO PURCHASE SHARES OF COMMON STOCK

 

WARRANT NO.

 

NUMBER OF SHARES: Up To 1,470,000

 

 

 

 

 

Issue Date:           December 21, 2007

 

VOID AFTER DECEMBER 21, 2012.

 

THIS CERTIFIES THAT, for value received, Advanced Technology Materials, Inc. (“ Holder ”) shall be, subject to the provisions and upon the terms and conditions hereinafter set forth, at any time on or after the Issue Date and on or prior to the close of business on the fifth anniversary of the Issue Date (or such earlier date as provided herein) but not thereafter (the “ Exercise Period ”), entitled to purchase up to 1,470,000 shares (the “ Warrant Shares ”) of common stock, par value $0.001 per share (the “ Common Stock ”) of Intermolecular, Inc., a Delaware corporation (the “ Company ”), at the Warrant Price (as hereinafter defined).

 

1.                                        Warrant Price .  The Warrant Price shall be one dollar and eighty-eight cents ($1.88) per share, subject to adjustment as provided in Section 6 below (the “ Warrant Price ”).

 

2.                                        Exercise; Issuance of Stock; Treatment of Warrant in Certain Events .

 

(a)                                   Cash Exercise .  The purchase right represented by this Warrant may be exercised during the Exercise Period by the Holder, in whole or in part, by the surrender of this Warrant (with a duly executed Notice of Exercise in the form attached hereto) at the principal executive offices of the Company (as set forth in Section 15 below) and by payment to the Company, by check, of an amount equal to the then applicable Warrant Price per share multiplied by the number of shares of Common Stock then being purchased.  In the event of any exercise of the rights represented by this Warrant, certificates for the shares of Common Stock so purchased shall be in the name of, and delivered to, the Holder, or as such Holder may direct (subject to the terms of transfer contained herein and upon payment by such Holder of any applicable transfer taxes). Such delivery shall be made within ten (10) days after exercise of the

 



 

Warrant and at the Company’s expense and, unless this Warrant has been fully exercised or expired, a new Warrant having terms and conditions substantially identical to this Warrant and representing the portion of the shares of Common Stock, if any, with respect to which this Warrant shall not have been exercised, shall also be issued to the Holder within ten (10) days after exercise of the Warrant.

 

(b)                                  Net-Issue Exercise .  If this Warrant has not been either fully exercised or has not otherwise expired, then, immediately after the expiration of the Lockup Period (defined in Section 8 below), in lieu of exercising this Warrant pursuant to Section 2(a) above, the Holder may elect to exercise this Warrant, in whole or in part, on a net-issue basis by electing to surrender a number of Warrant Shares equal in value to the Warrant Price for the number of Warrant Shares in respect of which the Warrant is then being exercised, by surrender of this Warrant (with a duly executed Notice of Exercise designating the Holder’s election to exercise on a net-issue basis), at the principal executive offices of the Company.  The Exercise Notice shall be properly marked to indicate (i) the number of Warrant Shares to be delivered to the Holder in connection with such net-issue exercise, (ii) the number of Warrant Shares being surrendered in payment of the Exercise Price for the number of Warrant Shares in respect of which this Warrant is then being exercised in connection with such net-issue exercise, calculated as of the Determination Date (as defined below) and (iii) the number of Warrant Shares which remain subject to this Warrant after such net-issue exercise, if any (each as determined in accordance with this Section 2(b)).  In the event that the Holder elects to exercise this Warrant in whole or in part on a net-issue basis pursuant to this Section 2(b), the Company will issue to the Holder the number of Warrant Shares determined in accordance with the following formula:

 

X = Y (A-B) / A

 

where:

 

·                   X ” is the number of Warrant Shares to be issued to the holder in connection with such net-issue exercise;

 

·                   Y ” is the number of Warrant Shares to be exercised, up to the number of Warrant Shares subject to this Warrant;

 

·                   A ” is the Fair Market Value of one share of Common Stock; and

 

·                   B ” is the Exercise Price in effect as of the date of such net-issue exercise.

 

For purposes of this Section 2(b), the “ Fair Market Value ” of one share of Common Stock will have the following meanings:  (i) if the Common Stock is listed for trading on a national securities exchange or admitted for trading on a national market or other quotation system, then the Fair Market Value of Common Stock will be deemed to be the average Closing Sales Price for the ten (10) Trading Days immediately preceding, but not including the Determination Date or (ii) if the Common Stock is not listed for trading on a

 



 

national securities exchange or admitted for trading on a national market or other quotation system, then the Fair Market Value of Common Stock will be deemed to be the fair market value of Common Stock as determined in good faith from time to time by the Company’s board of directors or a committee thereof (the “ Board of Directors ”) as of the Determination Date, and receipt and acknowledgment of this Warrant by the holder will be deemed to be an acknowledgment and acceptance of any such determination by the Board of Directors as the final and binding determination of such Fair Market Value for purposes of this Section 2(b).  “ Closing Sales Price ” means the closing sales price of the Common Stock, as quoted on the principal securities exchange on which the Common Stock is listed for trading, or if not so listed, the average of the closing bid and asked prices for Common Stock quoted on the national market or other quotation system on which Common Stock is admitted for trading, each as published in The Wall Street Journal (Western edition) or, if such prices are not published in The Wall Street Journal (Western edition), as reported by the applicable authority or association governing trading of the Common Stock.  The “ Determination Date ” of Fair Market Value will be the date indicated on the Exercise Notice; provided, however , that if the Company does not receive the Exercise Notice within five (5) business days of the date indicated thereon, the Determination Date will be the date the Company receives such Exercise Notice. “ Trading Day ” means, as applied to any class of stock, any day on which the exchange or market which is the primary market for the stock, is open for the trading of securities generally and with respect to which information regarding the sale of securities included therein, or with respect to which sales information is reported, is generally available.

 

(c)                                   Fractional Interests .  No fractional shares shall be issued upon the exercise of this Warrant, but in lieu thereof the Company shall pay therefor in cash an amount equal to the product obtained by multiplying the Closing Sales Price of the Common Stock (or if the Common Stock is not listed for trading on a national securities exchange or admitted for trading on a national market or other quotation system, then the Fair Market Value of the Common Stock as determined by the Board of Directors in the manner set forth in clause (ii) of the last paragraph of Section 2(b) above) on the Trading Day immediately preceding the date of exercise of this Warrant times such fraction (rounded to the nearest cent).

 

(d)                                  Deemed Issuance .  Upon such surrender of this Warrant, delivery of the Exercise Notice and, in the case of a cash exercise pursuant to Section 2(a) above, payment of the Exercise Price, the Company shall, issue and cause to be delivered with all reasonable dispatch to the holder a certificate or certificates for the number of full Warrant Shares so purchased upon the exercise of this Warrant, together with a check or cash in respect of any fractional shares otherwise deliverable upon such exercise, as provided in Section 2(c) above.  Such certificate or certificates shall be deemed to have been issued as of the date of the surrender of this Warrant and payment of the Exercise Price (payment of such exercise price shall be deemed satisfied by use of the net-issue exercise procedures in Section 2(b) above).

 

(e)                                   Warrant Exercisable in Whole or in Part .  The rights of purchase represented by this Warrant shall be exercisable, at the election of the holder, either in

 



 

full or from time to time in part.  If this Warrant is exercised in respect of less than all of the Warrant Shares purchasable on such exercise at any time prior to the Expiration Date, a new Warrant of like tenor exercisable for the remaining Warrant Shares may be issued and delivered to the holder by the Company.  This Warrant or any part thereof surrendered in the exercise of the rights thereby evidenced shall thereupon be cancelled by the Company and retired.

 

(f)                                     Treatment of Warrant upon a Change of Control . In the event of a Change of Control during the Exercise Period, either (x) the Holder shall exercise its purchase right under this Warrant, such exercise to be deemed effective immediately prior to the effectiveness of such Change of Control or (y) the Warrant shall expire upon the effectiveness of such Change of Control. The Company shall provide the Holder with written notice of the contemplated Change of Control, which is to be delivered to Holder not less than ten (10) days prior to the effectiveness of such Change of Control. In the event that the Company shall have given notice of a Change of Control, but such Change of Control does not become effective within 60 days of the effectiveness date specified by the Company, unless otherwise elected by the Holder, any exercise of the Warrant subsequent to the giving of such notice shall be rescinded and the Warrant shall again be exercisable until later exercised or expired.  For purposes of this Warrant, “ Change of Control ” shall mean (i) the acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation, any reorganization, merger or consolidation) unless the Company’s stockholders of record as constituted immediately prior to such transaction or series of related transactions will, immediately after such transaction or series of related transactions (by virtue of securities retained or issued as consideration in such transaction or series of related transactions) hold at least a majority of the voting power of the surviving or acquiring entity (or parent thereof) in the same relative percentages after such transaction or series of related transactions as immediately prior to such transaction or series of related transactions; (ii) a sale of all or substantially all of the assets of the Company; (iii) the closing of the transfer, in one transaction or a series of related transactions, to a person or group of affiliated persons (other than an underwriter of the Company’s securities or a transaction for the sale of Preferred Stock for capital raising purposes), of the Company’s securities if, after such closing, such person or group of affiliated persons would hold fifty percent (50%) or more of the outstanding voting stock of the Company; or (iv) an exclusive license of all or substantially all of the Company’s intellectual property.

 

(g)                                  Treatment of Warrant upon an IPO .  In the event of the underwritten initial public offering of the Common Stock (the “ IPO ”) during the Exercise Period, the Company may, in its sole discretion, elect to require the Holder to exercise its purchase right under this Warrant prior to the consummation of the IPO (a “ IPO Exercise Election ”), and the Warrant shall expire upon consummation of the IPO.  The Company shall provide the Holder with written notice of the IPO and, if applicable, the IPO Exercise Election, which shall be delivered to Holder not less than ten (10) days prior to the closing of the IPO.  In the event the IPO is not consummated within 60 days of the closing date specified by the Company in such IPO Exercise Election notice,

 



 

unless otherwise elected by the Holder, any exercise of the Warrant subsequent to the giving of such notice shall be rescinded and the Warrant shall again be exercisable until later exercised or expired.  If an IPO Exercise Election is not made by the Company, the Warrant will continue to be exercisable until later expired.

 

3.                                        Representations and Warranties of Holder and Restrictions on Transfer Imposed by the Securities Act of 1933 .

 

(a)                                   Representations and Warranties by Holder . The Holder represents and warrants to the Company with respect to this purchase as follows:

 

(i)                      The Holder has substantial experience in evaluating and investing in private placement transactions of securities of companies similar to the Company so that the Holder is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its interests.

 

(ii)                   The Holder is acquiring the Warrant and the shares of Common Stock issuable upon exercise of the Warrant (collectively the “ Securities ”) for investment for its own account and not with a view to, or for resale in connection with, any distribution thereof.  The Holder understands that the Securities have not been registered under the Act by reason of a specific exemption from the registration provisions of the Act, which depends upon, among other things, the bona fide nature of the investment intent as expressed herein.  In this connection, the Holder understands that, in the view of the Securities and Exchange Commission (the “ SEC ”), the statutory basis for such exemption may be unavailable if this representation was predicated solely upon a present intention to hold the Securities for the minimum capital gains period specified under tax statutes, for a deferred sale, for or until an increase or decrease in the market price of the Securities or for a period of one year or any other fixed period in the future.

 

(iii)                The Holder acknowledges that the Securities must be held indefinitely unless subsequently registered under the Act or an exemption from such registration is available.  The Holder is aware of the provisions of Rule 144 promulgated under the Act (“ Rule 144 ”) which permits limited resale of securities purchased in a private placement subject to the satisfaction of certain conditions.

 

(iv)               The Holder further understands that at the time the Holder wishes to sell the Securities there may be no public market upon which such a sale may be effected, and that even if such a public market exists, the Company may not be satisfying the current public information requirements of Rule 144, and that in such event, the Holder may be precluded from selling the Securities under Rule 144.

 

(v)                  The Holder has had an opportunity to discuss the Company’s business, management and financial affairs with its management and an opportunity to review the Company’s facilities. The Holder understands

 



 

that such discussions, as well as the written information issued by the Company, were intended to describe the aspects of the Company’s business and prospects which it believes to be material but were not necessarily a thorough or exhaustive description.

 

(b)                                  Legends .  Each certificate representing the Securities shall be endorsed with the following legend:

 

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION AND MAY NOT BE SOLD, OFFERED FOR SALE OR OTHERWISE TRANSFERRED UNLESS REGISTERED OR QUALIFIED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT REGISTRATION, QUALIFICATION OR OTHER SUCH ACTIONS ARE NOT REQUIRED UNDER SAID ACT.

 

The Company need not enter into its stock register a transfer of Securities and may also instruct its transfer agent not to register the transfer of any Securities, unless the conditions specified in the foregoing legend and the applicable conditions set forth in Section 4 below are satisfied.

 

(c)                                   Removal of Legend and Transfer Restrictions .  The legend relating to the Act endorsed on a certificate pursuant to Section 3(b) above and the stop transfer instructions with respect to the Securities represented by such certificate shall be removed and the Company shall issue a certificate without such legend to the Holder of the Securities if (i) the Securities are registered under the Act and a prospectus meeting the requirements of Section 10 of the Act is available or (ii) the Holder provides to the Company an opinion of counsel for the Holder reasonably satisfactory to the Company to the effect that public sale, transfer or assignment of the Securities may be made without registration and without compliance with any restriction such as Rule 144.

 

4.                                        Condition of Transfer or Exercise of Warrant; Transfer .  It shall be a condition to any transfer or exercise of this Warrant that at the time of such transfer or exercise, the Holder shall provide the Company with a representation in writing that the Holder or transferee is acquiring this Warrant and the shares of Common Stock to be issued upon exercise, for investment purposes only and not with a view to any sale or distribution, and shall provide the Company with a statement of pertinent facts covering any proposed distribution.  As a further condition to any transfer of this Warrant or any or all of the shares of Common Stock issuable upon exercise of this Warrant, other than a transfer registered under the Act, the Company must have received a legal opinion, in form and substance satisfactory to the Company and its counsel, reciting the pertinent circumstances surrounding the proposed transfer and stating that such transfer is exempt from the registration and prospectus delivery requirements of the Act.  This Warrant is transferable on the books of the Company at its principal office by the registered Holder upon surrender of this Warrant properly endorsed, subject to compliance with this Section 4 and applicable federal

 



 

and state securities laws.  The Company shall issue and deliver to the transferee a new Warrant representing the Warrant so transferred.  Upon any partial transfer, the Company shall issue and deliver to Holder a new Warrant with respect to the Warrant not so transferred.  Holder shall not have any right to transfer any portion of this Warrant to any competitor of the Company, as reasonably determined by the Company’s Board of Directors.

 

5.                                        Stock Fully Paid; Reservation of Shares .   All shares of Common Stock issuable upon the exercise of this Warrant, shall, upon issuance, be fully paid and non-assessable. During the period within which the rights represented by this Warrant may be exercised, the Company shall at all times have authorized, and reserved for issuance upon exercise of the purchase rights evidenced by this Warrant, a sufficient number of shares of Common Stock to provide for the exercise of the rights represented by this Warrant.

 

6.                                        Warrant Price Adjustments .  In the event of changes in the outstanding Common Stock by reason of stock dividends, split-ups, recapitalizations, reclassifications, mergers, consolidations, combinations or exchanges of shares, separations, reorganizations, liquidations, or the like, the number and class of shares available under the Warrant in the aggregate and the Warrant Price shall be correspondingly adjusted, as appropriate, by the Board of Directors of the Company.  The adjustment shall be such as to give the Holder of this Warrant upon exercise for the same aggregate Warrant Price the total number, class and kind of shares as it would have owned had the Warrant been exercised prior to the event and had it continued to hold such shares until after the event requiring adjustment.

 

7.                                        Notice of Adjustments .   Whenever any Warrant Price shall be adjusted pursuant to Section 6 above, the Company shall prepare a certificate signed by its chief financial officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the Warrant Price and number of shares issuable upon exercise of the Warrant after giving effect to such adjustment, and shall cause copies of such certificate to be mailed (by certified or registered mail, return receipt required, postage prepaid) within thirty (30) days of such adjustment to the Holder of this Warrant as set forth in Section 15 below.

 

8.                                        “Market Stand-Off” Agreement .  Holder hereby agrees that for a period of up to 180 days following the effective date of the registration statement of the Company covering Common Stock (or other securities) to be sold in the IPO (the “ Lockup Period ”), it shall not, to the extent requested by the Company and any underwriter, sell or otherwise transfer or dispose of (other than to designees or transferees who agree to be similarly bound) any of the shares of Common Stock at any time during such period except shares of Common Stock included in the IPO; provided, however, that all officers and directors of the Company who hold securities of the Company or options to acquire securities of the Company and all other persons with registration rights enter into similar agreements.

 

9.                                        Charges, Taxes and Expenses .  Issuance of certificates for shares of Common Stock upon the exercise of this Warrant shall be made without charge to the Holder for any United States or state of the United States documentary stamp tax or other incidental expense with respect to the issuance of such certificate, all of which taxes and

 



 

expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder.

 

10.                                  No Shareholder Rights Until Exercise .  This Warrant does not entitle the Holder to any voting rights or other rights as a shareholder of the Company prior to the exercise of this Warrant.

 

11.                                  Registry of Warrant .  The Company shall maintain a registry showing the name and address of the registered Holder of this Warrant.  This Warrant may be surrendered for exchange or exercise, in accordance with its terms, at such office or agency of the Company, and the Company and Holder shall be entitled to rely in all respects, prior to written notice to the contrary, upon such registry.

 

12.                                  Loss, Theft, Destruction or Mutilation of Warrant . Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and, in the case of loss, theft, or destruction, of indemnity reasonably satisfactory to it, and, if mutilated, upon surrender and cancellation of this Warrant, the Company shall execute and deliver a new Warrant, having terms and conditions substantially identical to this Warrant, in lieu hereof.

 

13.                                  Miscellaneous .

 

(a)                                   Issue Date .   The provisions of this Warrant shall be construed and shall be given effect in all respect as if it had been issued and delivered by the Company on the date hereof (the “ Issue Date ”).

 

(b)                                  Successors .   This Warrant shall be binding upon any successors or assigns of the Company.

 

(c)                                   Governing Law .   This Warrant shall be governed by and construed in accordance with the laws of the State of California.

 

(d)                                  Headings .   The headings used in this Warrant are used for convenience only and are not to be considered in construing or interpreting this Warrant.

 

(e)                                   Saturdays, Sundays, Holidays .   If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall be a Saturday or a Sunday or shall be a legal holiday in the State of California, then such action may be taken or such right may be exercised on the next succeeding day not a legal holiday.

 

(f)                                     Counterparts .  This Warrant may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

14.                                  No Impairment .  The Company shall not by any action including, without limitation, amending its certificate of incorporation or by-laws, any reorganization, transfer of assets, consolidation, merger, share exchange dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of the Warrant or impair the ability of the Holder(s) to realize upon the intended economic value hereof, but shall at all times in good faith assist in

 



 

the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate to protect the rights of the Holder(s) of this Warrant against impairment.  Without limiting the generality of the foregoing, the Company shall (a) not increase the par value of any shares of Common Stock issuable upon the exercise of the Warrant above the amount payable therefor upon such exercise, (b) take all such action as may be necessary or appropriate in order that the Company may validly issue fully paid and non-assessable shares of Common Stock upon the exercise of the Warrant, or (c) obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under the Warrant.

 

15.                                  Addresses .  Any notice required or permitted hereunder shall be in writing and shall be mailed by overnight courier, registered or certified mail, return receipt required, and postage pre-paid, or otherwise delivered by hand or by messenger, addressed as set forth below, or at such other address as the Company or the Holder shall have furnished to the other party.

 

 

If to the Company:

Intermolecular, Inc.

 

 

 

 

 

2865 Zanker Road

 

 

San Jose, CA 95134

 

 

Attn: Chief Financial Officer

 

 

 

 

If to the Holder:

Advanced Technology Materials, Inc.

 

 

7 Commerce Drive

 

 

Danbury, CT 06810

 

 

Attn: Chief Financial Officer

 

[SIGNATURE PAGE FOLLOWS]

 



 

IN WITNESS WHEREOF, the Company and the Holder have caused this Warrant to be executed by its officers thereunto duly authorized.

 

 

Dated as of December 21, 2007.

 

 

 

INTERMOLECULAR, INC.

 

 

 

 

 

 

By:

 

 

Name:

David E. Lazovsky

 

Title:

Chief Executive Officer

 

 

Acknowledged and Agreed :

 

ADVANCED TECHNOLOGY MATERIALS, INC.

 

 

By:

 

 

Name:

 

Title:

 

 



 

FORM OF
NOTICE OF EXERCISE

 

TO:                             Intermolecular, Inc.

2865 Zanker Road

San Jose, CA 95134

Attention:  Chief Financial Officer

 

1.                                        The undersigned, Advanced Technology Materials, Inc. (“ Holder ”) elects to acquire shares of the Common Stock of Intermolecular, Inc. (the “ Company ”), pursuant to the terms of the Warrant dated December 21, 2007,  (the “ Warrant ”).

 

2.                                        The undersigned hereby irrevocably elects to purchase                                              shares of Common Stock of TheStreet.com, Inc. pursuant to the terms of this Warrant.

 

a.                If Cash Exercise , check this box ¨ :  The undersigned tenders herewith full payment of the aggregate cash exercise price equal to $                           U.S. Dollars for such shares in accordance with the terms of this Warrant.

 

b.               If Net-Issue Exercise , check this box ¨ :  The undersigned exercises this Warrant on a net-issue basis pursuant to the terms set forth in this Warrant.  Net-Issue Information:

 

(i)                                                              Number of Shares of Common Stock to be Delivered:

 

(ii)                                                           Number of Shares of Common Stock Surrendered:

 

(iii)                                                        Number of Shares Remaining Subject to Warrant, if any:

 

3.                                        The Holder surrenders the Warrant with this Notice of Exercise.

 

4.                                        The Holder represents that it is acquiring the aforesaid shares of Common Stock for investment and not with a view to or for resale in connection with, distribution and that the Holder has no present intention of distributing or reselling the shares.

 

5.                                        Please issue a certificate representing the shares of Common Stock in the name of the Holder or in such other name as is specified below:

 

 

Name:

 

 

 

Address:

 

 

 

 

 

 

 

Taxpayer I.D.:

 

 

 

 

Advanced Technology Materials, Inc.

 

 

 

By:

 

 

Name:

 

 

Title:

 

 

Date:

 

 

 


 

AMENDMENT TO ADDENDUM TO WETS WORKFLOW PURCHASE AGREEMENT

 

This Amendment (“Amendment”) to the Addendum to Wets Workflow Purchase Agreement (“Addendum”) having an effective date of December 21, 2007, shall be effective as of December 16, 2008 (“ Amendment Effective Date ”), is made by and between Advanced Technology Materials, Inc., with a principal place of business at 7 Commerce Drive, Danbury, CT 06810 (“ ATMI ”) and Intermolecular, Inc., with a principal place of business at 2865 Zanker Road, San Jose, California 95134 (“ IM ”).  ATMI and IM are sometimes referred to herein individually as a “party” and collectively as the “parties.”  Capitalized terms in this Amendment have the meaning assigned to them in the Addendum or the underlying Wets Workflow Purchase Agreement (“Agreement”), unless otherwise separately defined herein.

 

BACKGROUND

 

IM and ATMI entered into the Agreement effective July 13, 2007 and subsequently entered into the Addendum.  The parties now wish to (i) amend certain terms contained in the Addendum and the Agreement, and (ii) modify their strategic alliance related to the sale of a Dry Workflow and the use thereof by the parties for their mutual benefit.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as set forth below.

 

ARTICLE 1
ADDITIONAL DEFINITIONS:  MODIFIED DEFINITION

 

1.1                                  Dry Workflow ” means the [*] workflow sold to ATMI by separate agreement of same date as the Amendment Effective Date, which agreement shall be termed the “ Dry Workflow Purchase Agreement .”

 

1.2                                 Strategic FTE ” shall be modified to include an IM full-time employee or contractor dedicated to supporting the use of or programs using the Wet and/or Dry Workflow purchased pursuant to the Agreement, the Addendum and the Dry Workflow Purchase Agreement, but shall otherwise remain as defined in the Addendum.  Any modification of the allocation from wet to dry programs shall be mutually agreed by the parties.

 

ARTICLE 2
WETS WORKFLOW PURCHASES

 

2.1                                  Dry Workflow Purchase .  Pursuant to the terms of the December 21, 2007 Addendum, on August 7, 2008 ATMI elected to apply its payment for the Wets Workflow in Appendix D of the Addendum to the purchase of a Dry Workflow.  In conjunction with the mutual execution of this Amendment, the parties shall execute the Dry Workflow Purchase Agreement governing the sale, license and use of the Dry Workflow, related software, and Intellectual Property rights.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 



 

2.2                                  Warranty .  NO ADDITIONAL REPRESENTATION, WARRANTY, OR INDEMNIFICATION IS HEREBY PROVIDED BY IM OR ATMI OTHER THAN AS EXPLICITLY SET FORTH IN THE AGREEMENT OR THE DRY WORKFLOW PURCHASE AGREEMENT.

 

ARTICLE 3
STRATEGIC FTEs, PLAN AND WORKFLOW ACCESS

 

3.1                                  Dedicated Personnel:  The parties agree that the final [*] Strategic FTEs referenced in Section 3.1 of the Addendum shall start on [*] providing services to ATMI to support the wet and/or dry processing activities as mutually agreed by the parties.  ATMI shall pay IM for said FTEs at the rate of [*] US dollars (US$[*]) per FTE per month.  IM will invoice ATMI monthly and payment terms shall be as set forth in the Agreement.  Upon the mutual execution of this Amendment, ATMI shall issue or have in place a purchase order to IM to cover the [*] Strategic FTE Services through [*].

 

3.2                                  Access to IM Workflow .  The Strategic FTEs shall have access to the dry workflow capabilities at IM, subject to other commitments to those tools (provided that IM shall use best commercial efforts to ensure reasonable access) until the [*] Dry Workflow tool purchased in the Dry Workflow Purchase Agreement is available to ATMI.   In addition, IM agrees to extend the Wets Workflow access provided in Section 3.2 of the Addendum until [*].  This support shall include access to IM’s metrology and characterization infrastructure (i.e., physical and electrical test equipment) for that period.  ATMI agrees to pay for consumables (such as wafers, mask sets, materials, and targets), outsourced metrology and characterization not supported internally by one of the parties, and other mutually agreed out-of-pocket costs to support the joint programs being performed by the parties using workflows at IM’s facility.

 

3.3                                  Joint Marketing and Development Efforts .  The parties agree to develop joint marketing and development plans for projects utilizing the ATMI Dry Workflow (“ Joint Plan ”).  The Joint Plan may be modified based on the mutual written consent of the parties from time to time and shall have the same term as the service restrictions in Section 4.1 below, including any extensions thereto.

 

ARTICLE 4
RESTRICTIONS AND RIGHTS

 

4.1                                  Services Restrictions on IM .  Section 4.1 of the Addendum shall be replaced with the following:

 

“Commencing with the Addendum Effective Date, and continuing until [*], IM shall refrain from entering into any agreements defining joint

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 



 

marketing (including, without limitation, joint technical presentations), sales or development obligations with a Competitor to address any Strategic Field with any Strategic Account.  For the avoidance of doubt, this provision does not and is not intended to restrict IM from (i) selling one or more Wets Workflows in whole or in part to any Strategic Account, subject to the restrictions in Section 4.2 of the Addendum, or for performing services for a Competitor in the Strategic Fields, except as set forth above, or (ii) licensing its IM Independent IP to any Strategic Accounts or other Third Parties. At any time prior to [*] ATMI may elect in writing to extend its commitment to pay for the [*] Strategic FTEs in Section 3.1 of the Addendum and this Amendment for [*] through [*].  If ATMI makes such election to extend the FTEs, then IM’s obligations set forth in this Section 4.1 shall be extended until [*] (“ First Extension ”). If ATMI has elected to exercise the First Extension and met the requirements therein, then IM’s obligations set forth in this Section 4.1 shall be extended until [*] if (i) Actual Royalties (as hereinafter defined) paid by ATMI to IM from [*] are equal to or greater than [*] US dollars (US$[*]), and (ii) ATMI elects in writing to extend its commitment to pay for the [*] Strategic FTEs in Section 3.1 of the Addendum and this Amendment for [*] additional [*] through [*] (“ Second Extension ”). If ATMI has elected to exercise the Second Extension and met the requirements therein, then IM’s obligations set forth in this Section 4.1 shall be extended until [*] if (i) Actual Royalties (as hereinafter defined) paid by ATMI to IM from [*] are equal to or greater than [*]US dollars (US$[*]), and (ii) ATMI elects in writing to extend its commitment to pay for the [*] Strategic FTEs in Section 3.1 of the Addendum and this Amendment for [*] additional [*]through December 31, 2012.

 

4.2                                  Workflow Restrictions on IM .  In addition to the restrictions set forth in Section 4.2 of the Addendum, the parties agree that commencing with the Addendum Effective Date , and continuing until [*], IM agrees not to ship (a) more than [*] of each Element of a Wets Workflow or (b) a [*] system to a Competitor.  Nothing in this Amendment shall preclude IM from (a) shipping any Element of a Wets Workflow or a [*] system, in whole or in part, to a company that is not a Competitor, or (b) shipping a workflow, in whole or in part, to a Competitor after [*].  This provision shall in no way reduce IM’s obligations pursuant to Section 4.2 of the Addendum.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 



 

4.3            Preferred Material Supplier .  IM agrees that it will evaluate available ATMI materials for any collaborative development program between IM and an integrated device manufacturer for an integrated circuit (“ IC ”) or a [*] application that starts from the Amendment Effective Date until the later of [*] or the last extension period elected by ATMI pursuant to Section 4.1 of this Amendment (“ Collaboration ”).  IM will make best commercial efforts to introduce new material opportunities to ATMI and qualify ATMI materials in such Collaborations.  IM agrees to recommend ATMI materials to IM customers in Collaborations if the ATMI materials are timely available, meet the customer’s technical requirements; and are cost competitive.  IM further agrees to provide written feedback to ATMI on any technical gaps and customer cost requirements.  The Parties understand and agree that the selection of material provider is at the sole discretion of the IM customer.  The Parties agree to review the progress under this Section at the Operating Committee meetings and work to address any issues through that process.  Subject to the foregoing obligations, nothing in this Section shall limit IM from engaging Third Parties in IC or solar applications without ATMI or using materials from a Competitor as part of any such Collaboration.

 

4.4            Access to Independent IP and IM Programs .  No license right shall be created by implication, estoppel or otherwise, by this Amendment, to the other Party’s Independent IP, except as explicitly set forth in the Agreement.  No right shall be created by implication, estoppel or otherwise, by this Amendment, for ATMI to participate in any programs IM has or may have in IC or solar applications.

 

ARTICLE 5

ROYALTIES

 

5.1            Royalty Payments to ATMI :  In addition to IM’s obligation to pay ATMI royalties for brokered sales of Wets Workflows to Strategic Accounts as set forth in Section 5.1 of the Addendum, the parties agree that IM’s royalty obligations shall apply to any Wets Workflow sale brokered by ATMI to one of its strategic material company partners.  The second sentence of Section 5.1 of the Addendum is hereby amended to read as follows:

 

“ATMI shall only be deemed to have successfully brokered the sale if the Strategic Account or ATMI strategic material company partner (a) issues a purchase order acceptable to IM in its reasonable discretion, and (b) signs an agreement for the purchase of an element of the Wets Workflow, under terms and conditions generally consistent with those set forth in the Agreement (except for terms relating to exclusivity and volume discounts, and terms relating to the Alliance Agreement).”

 

This Section does not change any of the other terms of Section 5.1 of the Addendum which shall remain in full force and effect.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 



 

5.2            Royalty Payments to IM :  ATMI’s obligation to pay IM royalties as set forth in the Dry Workflow Purchase Agreement shall apply to the use of any dry workflow to which IM provides ATMI and/or Strategic FTEs access under this Amendment and the foregoing shall be included in the definition of Actual Royalties.  Actual Royalties shall include royalties payable by ATMI hereunder or under the Dry Workflow Purchase Agreement.

 

5.3            Prepaid Guaranteed Minimum Royalties :  The royalty periods and associated royalties for the Guaranteed Minimum Royalties in Section 5.3 of the Addendum shall be amended as follows; otherwise, the terms of Section 5.3 of the Addendum remain in full force and effect:

 

“Royalty Period One”, consisting of the period from [*] through [*]:  Guaranteed Minimum Royalties in the amount of [*] US dollars (US$[*]).

 

“Royalty Period Two”, consisting of the period from [*] through [*]:  Guaranteed Minimum Royalties of [*] US dollars (US$[*]).

 

“Royalty Period Three”, consisting of the period from [*] through [*]:  Guaranteed Minimum Royalties of [*] US dollars (US$[*]).

 

“Royalty Period Four”, consisting of the period from [*] through [*]:  Guaranteed Minimum Royalties of [*] US dollars (US$[*]).

 

Except as explicitly set forth in this Amendment, the terms of the Agreement and the Addendum shall remain in full force and effect.  The Agreement, together with all Exhibits thereto, the Addendum, together with all Appendices thereto, the Dry Workflow Purchase Agreement, together will all Exhibits thereto, and together with this Amendment, constitutes the entire agreement and understanding of the parties relating to the subject matter hereof, and supersedes all prior negotiations and understandings between the parties, both oral and written, regarding such subject matter.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 



 

IN WITNESS WHEREOF, the parties hereto have executed this Addendum as of the day and year first written above.

 

 

Intermolecular, Inc.

 

Advanced Technology Materials, Inc.

 

 

 

By

/s/ David Lazousky

 

By

/s/ Daniel P. Sharkey

 

 

 

 

 

Name:

David Lazousky

 

Name:

Daniel P. Sharkey

 

 

 

 

 

Title

President & CEO

 

Title

EVP, Business Development

 

 

 

 

 

Date:

12/12/08

 

Date:

12/12/08

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 



 

Supplement for Modification of 2009 Strategic FTEs

and Addition of 2010 Process Integration Support

 

This Supplemental Agreement (“ Supplement ”) to the Amendment to the Addendum to Wets Workflow Purchase Agreement (“ Amendment ”) having an effective date of March         , 2009 (“ Supplement Effective Date ”), is made by and between Advanced Technology Materials, Inc., with a principal place of business at 7 Commerce Drive, Danbury, CT 06810 (“ ATMI ”), and Intermolecular, Inc., with a principal place of business at 2865 Zanker Road, San Jose, California 95134 (“ IM ”).  ATMI and IM are sometimes referred to herein individually as a “party” and collectively as the “parties.”  Capitalized terms in this Supplement shall have the meaning assigned to them in the Amendment or other agreements between the parties, unless otherwise separately defined herein.

 

IM and ATMI entered into the Addendum to the Wets Workflow Purchase Agreement effective December 21, 2007, and subsequently entered into the Amendment effective on December 16, 2008.  The parties now wish to (i) amend certain terms contained in the Amendment and Addendum, and (ii) modify their strategic alliance by revising certain services related to IM Strategic FTEs and adding Process Integration Support in April 2010 for their mutual benefit of the parties and their strategic alliance,

 

Process Integration Support includes access and utilization of Intermolecular’s clean room facilities, HPC systems, metrology, and other available infrastructure and expert technical support as mutually agreed to support paid programs.

 

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as set forth below.

 

1.0       Strategic FTC Modification and Process Integration Support.  The parties agree to revise the contracted Strategic FTE support for the period from [*] through [*], from [*] Strategic FTEs to [*] Strategic FTEs and these Strategic FTEs shall continue to provide services to ATMI as mutually agreed by the parties.  The parties agree that IM shall provide [*] Strategic FTEs to support the wet and/or dry processing activities from [*] through [*] and that IM will provide Process Integration Support during this period.  ATMI shall pay IM for said Strategic FTEs at the rate of [*] US dollars (US$[*]) per Strategic FTE per month.  ATMI shall pay IM for said [*] at a rate of [*] dollars (US $[*]) per month.

 

1.1        ATMI shall modify purchase order # 893103 to reflect the above Strategic FTE cancellation and reduced amount owed within one (1) week of the execution of this Supplement, such purchase order shall indicate it is non- cancellable.  This modified non-cancellable purchase order shall reflect the [*] Strategic FTE’s for the period [*] through [*] in the total amount of [*] US dollars ($[*]), and [*] Strategic FTE’s for the period [*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

1



 

thru [*]in the total amount of [*] US dollars ($[*]), plus out of pocket costs.

 

1.2        ATMI shall issue a non-cancellable purchase order for the [*] Strategic FTE’s at the above rate for a total of [*] US dollars ($[*]) and [*] at the above rate for a total of [*] US dollars ($[*]) for the period [*] thru [*] plus out of pocket costs within one (1) week of execution of this Supplement.

 

l.3         ATMI agrees to pay IM [*] US dollars ($[*]) by [*] as a [*]% advance payment of the [*] through [*] Strategic FTE and [*] — the remaining amount shall be invoiced by IM and paid by ATMI monthly over the period of service.

 

2.0        HPC and Annual License Booking.  ATMI shall issue non-cancellable purchase orders to support the HPC Site License, HPC Informatics Support and related warranties for the [*] Wet Workflows in the following amounts: [*] US dollars ($[*]), plus tax for Site #1, [*] US dollars ($[*]) for Site #2, and [*] US dollars ($[*]) for Site #3 as set forth in the attached quotes.  IM shall invoice ATMI upon execution of this Supplement and ATMI shall pay the above amounts within ten (10) days of such invoice.

 

3.0        Services Restrictions on IM.  The service restrictions, workflow restrictions and preferred material supplier language from Article 4 of the Amendment shall continue through [*] only if ATMI issues the non cancellable purchase orders in Sections 1.0 and 2.0 above and makes the associated payments in a timely manner.  Any extensions of these obligations beyond [*] shall be governed by the requirements set forth in Article 4 of the Amendment.

 

If ATMI does not issue the non-cancellable purchase orders and make the payments as set forth herein, the terms of this Supplement shall be null and void and the Amendment, Addendum and other agreements between the parties shall govern the relationship between ATMI and IM.

 

Except as explicitly set forth in this Supplement, the terms of the Amendment, Addendum, and other agreements between the parties shall remain in full force and effect.  The Supplement constitutes the entire agreement and understanding of the parties relating to the subject matter set forth herein, and supersedes all negotiations and understandings between the parties, both oral and written, regarding such subject matter.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

2



 

IN WITNESS WHEREOF, the parties hereto have executed this Supplement as of the day and year first written above.

 

Intermolecular, Inc.

 

Advanced Technology Materials, Inc.

 

 

 

By:

/s/ David Lazovsky

 

By:

/s/ Daniel P. Sharkey

 

 

 

 

 

Name:

David Lazovsky

 

Name:

Daniel P. Sharkey

 

 

 

 

 

Title:

President & CEO

 

Title:

EVP — Bus. Dev.

 

 

 

 

 

Date:

3/16/09

 

Date:

3-16-09

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

3


 

Customer:     ATMI

Dale:   3/12/2009

Quote#:   200901001-2

 

Description

 

Qty

 

List Price

 

Ext. List

 

Disc. %

 

Price

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

Total ATMI Alliance HPC Use Licenses, Maintenance & Support, Annual Renewal

 

[*]

 

[*]

 

[*]

 

CT Sales Tax

 

 

 

[*]

 

[*]

 

Total

 

 

 

 

 

[*]

 

 

Payment terms:

 

[*]

 

[*]

 

[*]

 

2895 Zanker Road

San Jose, CA 95134

www.intermolecular.com

phone (408) 416-2300

fax (408) 416-2301

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

Customer:     ATMI

Dale:   3/12/2009

Quote#:   200902002-2

 

Description

 

Qty

 

List Price

 

Ext. List

 

Disc. %

 

Price

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

Subtotal ATMI Alliance HPC Use Licenses, Maintenance & Support, Annual Renewal

 

[*]

 

[*]

 

[*]

 

Volume Discount

 

 

 

[*]

 

[*]

 

Total ATMI Alliance HPC Use Licenses, Maintenance & Support, Annual Renewal

 

 

 

 

 

[*]

 

 

Payment terms:

 

[*]

 

[*]

 

[*]

 

[*]

 

2895 Zanker Road

San Jose, CA 95134

www.intermolecular.com

phone (408) 416-2300

fax (408) 416-2301

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

Customer:     ATMI

Dale:   3/12/2009

Quote#:   200903001

 

Description

 

Qty

 

List Price

 

Ext. List

 

Disc. %

 

Price

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

Subtotal ATMI Alliance HPC Use Licenses, Maintenance & Support, Annual Renewal

 

[*]

 

[*]

 

[*]

 

Volume Discount

 

 

 

[*]

 

[*]

 

Total ATMI Alliance HPC Use Licenses, Maintenance & Support, Annual Renewal

 

 

 

 

 

[*]

 

 

Payment terms:

 

[*]

 

[*]

 

[*]

 

[*]

 

2895 Zanker Road

San Jose, CA 95134

www.intermolecular.com

phone (408) 416-2300

fax (408) 416-2301

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 




Exhibit 10.6

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

12/11/2008

 

Dry Workflow Purchase Agreement

 

This Dry Workflow Purchase Agreement (“Agreement”), effective as of December 16, 2008, or, if 1eft blank, the last date of signature by a party hereto (“Effective Date”), is made by and between Advance Technology Materials. Inc., with a principal place of business at 7 Commerce Drive, Danbury, CT 06810 (“ Customer ”), and Intermolecular, Inc., with a principal place of business at 2865 Zanker Road, San Jose, CA 95134 (“ IM ”). Customer and IM are sometimes referred to herein individually as a ‘‘party” and collectively as the “parties.”

 

RECITALS

 

Whereas, IM has developed proprietary tools to enable high productivity combinatorial experimentation and is in the business of selling, leasing and/or licensing such technology; and

 

Whereas, Customer desires to purchase from IM a dry workflow and its related licenses as contemplated in this Agreement and IM agrees to install the workflow for use at its site, and to ship to and install the workflow at Customer Site(s) as specified herein.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as set forth below.

 

The following exhibits are hereby incorporated into the Agreement:

 

Exhibit A: Quote
Exhibit B: Specifications
Exhibit C: Acceptance Criteria
Exhibit D: IM Maintenance and Support Services

 

Capitalized terms in the Exhibits have the meaning assigned to them in the body of the Agreement, unless otherwise separately defined in the relevant Exhibit.

 

ARTICLE 1
DEFINITIONS

 

1.1                                  “Affiliate” means any entity directly or indirectly controlling, controlled by or under common control with, a party to this Agreement. For purposes of this Agreement, only the direct or indirect ownership of fifty percent (50%) or more of the voting securities of an entity shall be deemed to constitute control.

 

1.2                                  Alliance Agreement ” means the agreement between the Parties with that title executed with an effective date of November 17, 2006 (“Alliance Agreement Effective Date”).

 

1.3                                  Alliance Technology ” has the meaning assigned to it in the Alliance Agreement.

 

1.4                                  Confidential Information” means any information disclosed by one party to the other in connection with this Agreement, whether in electronic, written, graphic, oral, machine readable or other tangible or intangible form, that is (i) marked or identified at the time of disclosure as “Confidential” or “Proprietary” or in some other manner so as to clearly indicate its confidential nature, or (ii) if disclosed orally should reasonably be considered confidential by the receiving party given the nature of the information or the circumstances of its disclosure.

 

1.5                                  Customer Independent Technology” means all Intellectual Property Rights that is (i) owned, licensed or otherwise controlled by Customer on or prior to the Effective Date; or (ii) created, conceived or reduced to practice by Customer employees, contractors or agents without reliance upon, use of or benefit of (a) the Dry HPC Technology, (b) Dry HPC Technology derivatives, (c) IM independent IP, or (d) any technology, know-how or technical information provided by or obtained from an IM employee, contractor or agent, directly and or indirectly.

 

1



 

1.6                                  Equipment ” means Dry Workflow hardware tools (excluding Informatics Hardware) that may be sold pursuant to this Agreement, conforming to the Specifications.

 

1.7                                  Field ” means technologies, methods and embodiments for materials, processes, apparatus, process integration, and device integration, or any combination thereof, used for the research, development, commercialization or manufacturing of integrated circuits and photovoltaic cells.

 

1.8                                  Dry HPC Technology ” means all techniques, methodologies, processes, test vehicles, synthetic procedures, technology, systems, or combination thereof (collectively, “Techniques”) (a) subject to or covered by any Intellectual Property Right owned by IM or licensed to IM, (b) provided by IM to Customer and (c) used for the simultaneous parallel or rapid serial: (i) design, (ii) synthesis, (iii) processing, (iv) process sequencing, (v) process integration, (vi) device integration, (vii) analysis, or (viii) characterization of more than two (2) compounds, compositions, mixtures, processes, or synthesis conditions, or the structures derived from such. Dry HPC Technology does not include any of the foregoing Techniques to the extent they were (A) used by Customer prior to the Effective Date, (B) created, conceived or reduced to practice by Customer independent of this Agreement, without reliance on or use or benefit of Alliance Technology, IM Independent IP, or any technology, know-how or information provided by or obtained from an IM employee, contractor or agent, directly and or indirectly. It is understood that test vehicles include physical and or electrical characterization devices such as test structures or chips, used in the design, process development, manufacturing process qualification, and manufacturing process control of integrated circuit devices. It is also understood that Dry HPC Technology does not include the use of equipment that is commercially available (from parties other than IM) for nominally uniform processing of one or more single substrate in commercial manufacturing and/or research and development.

 

1.9                                  HPC-Enabled Informatics Software ” means Informatics Software and Equipment control software that enables Equipment to use Dry HPC Technology. “Non-HPC-Enabled Informatics Software” means Informatics Software and Equipment control software that operates Equipment without enabling it to utilize Dry HPC Technology. Use of HPC-Enabled Informatics Software at a Site requires an HPC Site License, in addition to a license to use the software.

 

1.10                            HPC Site License ” means a license to use Dry HPC Technology at a specific Site as set forth in this Agreement, for the initial term and applicable renewal terms. The Dry Workflow HPC Site License is waived in this Agreement as long as Customer pays the HPC Site License for the Wets Workflows set forth in the Wets Workflow Purchase Agreement. If Customer stops making such payment, Customer agrees to pay the HPC Site License fee set forth in the Quote or subsequent documentation.

 

1.11                            IM Independent IP ” means all Intellectual Property Rights that are (i) owned, licensed or otherwise solely controlled by IM as of the Effective Date; or (ii) created, conceived or reduced to practice by IM employees, contractors or agents without reliance, use or benefit of (a) Customer Independent Technology or (b) technology, know-how or technical information provided by or obtained from a Customer employee, contractor or agent, directly and or indirectly and including the Dry HPC Technology.

 

1.12                            Informatics Hardware ” means the information technology hardware manufactured by Third Parties, conforming to the Specifications therefor.

 

1.13                            Informatics Software ” means machine readable object code versions of the software licensed to be used with the Informatics Hardware, and related documentation, together with any Informatics Updates, if any, that may be provided by IM to Customer during its license term. Informatics Software may consist of either HPC-Enabled Informatics Software or Non-HPC-Enabled Informatics Software. Informatics Software does not include Third Party Software.

 

1.14                            Informatics Improvements ” means improvements , additions, or modifications to the Informatics Software to add features, support additional Equipment or support new uses or applications of the Equipment developed and released by IM. IM may periodically offer Informatics Improvements for sale or license to Customer and will negotiate in good faith with Customer terms in connection therewith.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2



 

1.15                            Informatics Updates ” means error corrections, bug fixes or workarounds to the Informatics Software that are developed and released by IM solely to ensure that the Informatics Software performs in accordance with its Specifications, along with any improvements to the Informatics Software that may be developed and release by IM from time to time and which it makes available to customers for no separate charge. IM shall make Informatics Updates available to Customer at no charge. Informatics Updates do not include Informatics Improvements.

 

1.16                            Intellectual Property Rights ” means rights in and to any and all (i) U.S. and foreign patents and patent applications claiming any inventions or discoveries made, developed, conceived, or reduced to practice, including all divisions, substitutions, continuations, continuation-in-part applications, and reissues, re-examinations and extensions thereof, (ii) copyrights, (iii) unpatented information, trade secrets, data, or materials, (iv) mask work rights, and (v) any other intellectual or other proprietary rights of any kind now known or hereafter recognized in any jurisdiction.

 

1.17                            Materials Manufacturing Technology ” means any data, know-how, techniques, methods, processes, or other technologies for the synthesis, production, packaging, shipping or distribution of commercial quantities of one or more Products, excluding Dry HPC Technology, that is developed, directly or indirectly, through the use of the Dry Workflow that is provided in connection with this Agreement.

 

1.18                            Metrology/Characterization Technology ” means technology relating to measurements, systems, methods, techniques, test vehicles, synthetic procedures or combination thereof, used to measure materials or processing characteristics or parameters of wafers, wafer samples or other substrates.

 

1.19                            Named User ” means a Customer employee or subcontractor, or other party with the prior written consent of IM, who has signed a nondisclosure agreement as restrictive as the confidentiality terms set forth herein and who uses the Informatics Software, or any part of the Informatics Software. Named Users may be changed or replaced according to reasonable and ordinary business practices such as termination of employment or changes in job function.

 

1.20                            Product ” means a compound or material (or composition of compounds and materials) identified, first synthesized, or discovered in whole or in part through use of the Equipment and/or Informatics Software provided through this Agreement and any derivative thereof whether or not the derivative is identified, first synthesized, modified or discovered in whole or in part through use of any Dry Workflow, but does not include materials or compounds developed independent of use of the Dry Workflow and/or methods of using the same.

 

1.21                            Purchase Order means a valid purchase order issued by Customer to IM in response to the Quote, and that incorporates by reference the terms and conditions of this Agreement and the Quote.

 

1.22                            Quote ” means the IM sales quotation document issued to Customer that incorporates by reference the terms and conditions of this Agreement, and that includes an offer for sale (or license for software) of one or more of the following: the combination described in the applicable quotation of (a) Equipment, (b) Informatics Hardware, (c) licenses to use HPC-Enabled or Non-HPC-Enabled Informatics Software, (d) licenses to use Third Party Software; and/or (e) Services in connection with the configuration, and installation of Equipment and/or Informatics Hardware. The Quote is set forth in Exhibit A.

 

1.23                            Services ” means services that IM performs for Customer.

 

1.24                            Site ” means a location identified in the applicable purchase documentation, or a replacement location subsequently agreed to by the parties in writing, which agreement shall not be unreasonably withheld. Notwithstanding the foregoing, the HPC Site License for the original licensed Site shall be deemed to apply to any Customer-owned Dry Workflow or Wets Workflow (as defined in the Wets Workflow Purchase Agreement) at any site that is, now or in the future, owned or leased or rented or otherwise controlled by Customer or an Affiliate, so long as Customer is not in breach of this Agreement.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

3



 

1.25                            Specifications ” means specifications of and requirements for (a) any of the Equipment or Informatics Hardware sold in Connection therewith, or (b) HPC-Enabled Software or Non-HPC-Enabled Informatics Software licensed in connection therewith, as set forth in Exhibit B. The Specification attached hereto as Exhibit B is preliminary and shall be updated by mutual agreement of the parties prior to September 15, 2009.

 

1.26                            Support ” means the maintenance and support Services as described in Exhibit D, for the term specified in the applicable Quote.

 

1.27                            Third Party ” shall mean any person or entity other than Customer and its Affiliates, IM and its Affiliates, and their permitted assigns.

 

1.28                            Third Party Software ” is machine readable, object code versions of software provided by IM to Customer pursuant to this Agreement (if identified in the Quote), and licensed by the third party to Customer in accordance with the terms and conditions of Customer’s end user license agreement with the third party (e.g. Oracle Corporation, Adobe Systems Incorporated, Software FX Inc., or Microsoft Corporation).

 

1.29                            Wets Workflow Purchase Agreement ” means that certain Wets Workflow Purchase Agreement effective as of July 13, 2007, by and between the Parties (including any addenda and amendments thereto).

 

1.30                            Dry Workflow ” means the combination of one or more of the following as described in the applicable Quote: Equipment; Informatics Hardware; Third Party Software and/or Informatics Software; an HPC Site License.

 

ARTICLE 2
PURCHASE DOCUMENTATION

 

2.1                                  Purchases . This Agreement sets forth terms and conditions under which IM will sell to Customer a Dry Workflow, and the terms and conditions under which IM may provide related Services. The sale of Dry Workflow Equipment hereunder is conditional and subject to the terms and and conditions of this Agreement, specifically the use of Equipment to support the application or use of Dry HPC Technology (“ HPC Mode ”) shall be subject to the licenses set forth in Section 4.3 below, the Royalties payable hereunder, and the payments in the applicable Purchase Documentation associated with the Dry Workflow Equipment.

 

2.2                                  Purchase Documentation. The Quoteis hereby incorporated by reference into this Agreement. Customer will issue a Purchase Order matching the terms of the Quote within one (1) week of execution of this Agreement. The Quote together with this Agreement shall constitute the complete agreement regarding that purchase and sale of the Dry Workflow and license of the related software and documentation. Notwithstanding the foregoing, nothing contained in any Purchase Order, Purchase Order acknowledgment, or invoice shall in any way modify the terms and conditions of this Agreement, or add any additional terms or conditions. Any software provided hereunder is licensed, not sold, to Customer and any reference to the “sale” or “purchase” of software shall be deemed to mean “license.”

 

ARTICLE 3
ACCEPTANCE AND SUPPORT SERVICES

 

3.1                                  Dry Workflow Assembly . IM shall use commercially reasonable efforts to complete assembly and configuration of the Dry Workflow identified in the Quote and make it available at IM’s facility in San Jose, CA on or before [*], at which time IM will demonstrate to Customer wafer transfer and combinatorial dry process deposition (“ Platform Assembly ”) applicable to one of [*], or [*] applications. Upon completion of said Platform Assembly demonstration, Customer will either (i) confirm in writing that Platform Assembly has occurred, or (ii) identify with reasonable detail any deficiencies, in which case IM will promptly remedy the same and the foregoing demonstration will be repeated. If IM is unable to complete Platform. Assembly by [*] or to remedy the deficiency, Customer may terminate its Purchase Order and this Agreement in accordance with the provisions of Section 11.2 hereof. From Platform Assembly confirmation from Customer until Customer Acceptance, IM will use its best commercial efforts to prioritize equipment up-time over maintenance and updates.

 

3.2                                  Customer Acceptance . In the [*] calendar quarter of [*], IM shall provide Customer with written notice that it the Dry

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

4



 

Workflow that Customer is purchasing hereunder is available for acceptance testing. IM shall demonstrate to Customer that the Dry Workflow satisfies the acceptance criteria set forth in Exhibit C (“ Acceptance Criteria ”), and allow Customer to conduct tests to ensure compliance with said Acceptance Criteria. The Acceptance Criteria attached hereto as Exhibit C is preliminary and shall be updated by mutual agreement of the parties prior to [*]. This demonstration and testing shall take place at IM’s facilities (Customer agrees to attend at its own expense) and shall commence no later than ten (10) business days following said written notice. Upon completion of said demonstration and testing, Customer will either (i) confirm in writing that acceptance of the Dry Workflow has occurred, and Customer shall make the payment associated therewith as set forth in the Quote (“Customer Acceptance”), or (ii) identify with reasonable detail any deficiencies, in which case IM will promptly remedy the same and the foregoing demonstration and testing will be repeated. If IM is unable to remedy the deficiency, Customer may terminate its Purchase Order and this Agreement in accordance with the provisions of Section 11.2 hereof. If Customer does not attend, Customer Acceptance shall be deemed completed upon written notice from IM that the Dry Workflow met the Acceptance Criteria. Title and risk of loss pass to Customer upon Customer Acceptance.

 

3.3                                  Delivery . At any time from [*] until [*], Customer may request shipment of the Dry Workflow to the Customer Site. Upon such request, Customer and IM shall agree upon a target delivery date, which shall be at least [*] from the request date, when the Dry Workflow will be available for shipment to Customer’s Site (“Target Delivery Date”). If Customer does not make the request before [*], the request shall be deemed made on that date absent mutual written agreement of the parties. Delivery shall be deemed to have occurred at the IM shipping dock when notice is provided by IM to Customer (“Delivery Date”). Customer shall bear all expenses of insurance, packaging and transportation. Customer is solely responsible for and shall prepare the Site for installation of the Dry Workflow item in accordance with the Site preparation specification and that all necessary infrastructure is available prior to the Target Delivery Date (unless otherwise agreed to by the parties in writing). IM will assist Customer with the process of unpacking and installing the Equipment and Informatics Hardware at the Site.

 

3.4                                  Support, Training, and Services . IM will provide Customer with the Support and the training specified in Exhibit D, which is hereby incorporated by reference into this Agreement. Any additional Services to be provided by IM, including Services not covered by a warranty or pursuant to pre-paid maintenance, will be provided at IM’s then-current rates (plus reasonable travel expenses and other out-of-pocket expenses, if any) pursuant to a statement of work signed by the Parties.

 

ARTICLE 4
INTELLECTUAL PROPERTY
RIGHTS AND LICENSES

 

4.1                                  Prior Agreements . Nothing in this Agreement is intended to modify the respective rights and obligations of the Parties as set forth in the Alliance Agreement or Wets Workflow Purchase Agreement.

 

4.2                                  Intellectual Property Rights . As between Customer and IM, Customer shall be the sole owner of all right, title, and interest in and to (i) the Customer Independent Technology, (ii) Intellectual Property Rights relating to materials or Products and methods of using materials or Products, (iii) Metrology/Characterization Technology that is not Dry HPC Technology, and (iv) Materials Manufacturing Technology, and improvements to any of the foregoing (“ Customer Technology ”) derived through Customer’s use of the Dry Workflow purchased herein. IM will grant and hereby grants to Customer all right, title, and interest in and to said Customer Technology, unless otherwise set forth in a separate agreement related to the use of the Dry Workflow purchased hereunder for a customer program that is signed by Customer, IM and such customer. All rights to Customer Technology and any improvements thereto not expressly granted in the Agreement shall be reserved to Customer. As between Customer and IM, IM shall be the sole owner of the IM Independent IP, Metrology/Characterization Technology that is Dry HPC Technology, Dry HPC Technology, and any improvements to any of the foregoing (“ IM Technology ”). All rights to IM Technology and any improvements thereto

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

5



 

shall be reserved to IM. Customer will grant and hereby grants to IM all right, title, and interest in and to said IM Technology.

 

4.3                                  License Grant for Informatics Software and HPC Site License . Subject to the terms and conditions of this Agreement, IM hereby grants to Customer a non-exclusive, non-transferable, license, without the right to sublicense, to use the Equipment and to use the Informatics Software (subject to Section 4.4) identified in the Quote on the Equipment and/or Informatics Hardware for which it was purchased and upon which it was installed, for use by Named Users solely for the purpose of developing and commercializing Products in the Field.

 

4.3.1                         Customer shall have no right to use Dry HPC Technology under this Agreement unless it purchases HPC-Enabled Informatics Software and purchases an HPC Site License for any Site where it will use Dry HPC Technology. Moreover, Customer’s license to use Dry HPC Technology shall only be for operation of the Equipment for which it has purchased HPC-Enabled Informatics Software, and only for the license term for such software and the HPC Site License, and solely on the Site. The scope of the HPC Site license and the HPC-Enabled Informatics Software license granted by IM to Customer hereunder does not include the right to use the Dry Workflow on behalf of Third Parties, except where the intended purpose of such activities is (a) the qualification or sale by Customer of a resulting Product, or (b) the licensing by Customer to one or more of its partners or customers to make, use or sell such resulting Product, or from a combination of (a) and (b).

 

4.3.2                         The licenses granted hereunder shall be subject to the payment of all payments set forth in this Agreement and the Quote, including but not limited to Royalties. Customer agrees that access to any Equipment, Informatics Hardware, and/or Informatics Software shall be limited to Named Users who are employees or contractors working directly for Customer. Customer agrees not to sell, lease, or otherwise dispose of (“ Transfer ”) the Equipment sold hereunder, or allow access for any Third Party to use the Equipment in HPC Mode (“Access”) without explicit written approval by IM, which IM may grant in its discretion and subject to IM entering to a license agreement, if necessary under the circumstances, with such Third Party. Customer can Transfer the Equipment for non-HPC Mode use and agrees to inform any such Third Party purchaser that the Equipment cannot be used to perform Dry HPC Technology without appropriate licenses from IM.

 

4.4                                  Licensed Software . Customer shall not be an owner of any copies of the Informatics Software, Third Party Software or any documentation delivered to Customer, but Customer is rather licensed pursuant to this Agreement to use any of the Informatics Software, Third Party Software and documentation specified in Quote, or licensed pursuant to the applicable license agreement for Third Party Software.

 

4.4.1                         Customer acknowledges and agrees that the features and the graphical user interface of the Informatics Software (“ User Interface ”), including, without limitation, icons, menus and screen designs, screen layouts, and command and screen sequence, are proprietary to IM and/or its licensors, and are disclosed to Customer under a condition of confidentiality. Customer agrees that it will not create software programs incorporating any proprietary part of the User Interface. Nevertheless, if Customer creates one or more data loaders for metrology and/or testing equipment that it wishes to integrate into the Dry Workflow, IM will work with Customer on a time and materials basis (subject to the mutual prior written agreement of the parties) to facilitate the use of said data loader(s) with the User Interface. Customer further acknowledges that the User Interface is a copyrighted work of IM and/or its licensors.

 

4.4.2                         Customer agrees that it will not itself, and will not through any parent, subsidiary, Affiliate, agent, or other Third Party, directly or indirectly, do any of the following: (i) reproduce, distribute, copy, sell, create derivative works of, lease, license, or sublicense the Informatics Software or any component of either, or any documentation delivered to it pursuant to

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

6



 

this Agreement; (ii) use the Informatics Software in connection with any equipment other than the Equipment and the Informatics Hardware; (iii) attempt, or permit any Third Party, to reverse engineer, disassemble, decrypt, decompile, or otherwise attempt to derive source code from the Informatics Software; or (iv) use any Informatics Software that may be licensed hereunder in connection with any time-sharing or other multi-user network or service bureau.

 

4.4.3                         Customer agrees to establish and maintain records of the identities of Named Users and changes thereto and to make such records available to IM in connection with any audit conducted pursuant to Section 6.6.

 

4.4.4                         Subject to payment by Customer of the amounts set forth in the applicable Quote and during any period in which Customer pays for the Informatics Maintenance and Support, IM will provide support for the Informatics Software in accordance with Exhibt B and IM will provide Informatics Updates at no additional charge.

 

4.4.5                         IM commits that through [*], Customer will have the right to renew its HPC Site License and [*] HPC Informatics and Maintenance and Support Informatics Software license on the same terms and conditions included in this Agreement, including pricing terms.

 

4.5                                  Legend . All copies of the Informatics Software shall include IM’s copyright, trademarks, patent numbers, and other proprietary notices in the manner in which such notices were placed by IM on such Informatics Software. Further, IM may label the Equipment with a permanent non-erasable identification label including hut not limited to IM’s name, IM’s model number, a sequential serial number in IM’s standard format, date of manufacture, location manufactured, and specification version to which the Equipment was manufactured. Customer shall not remove, obscure, or alter IM’s copyright notices, trademarks, patent numbers, or other proprietary rights notices affixed to or contained within the Informatics Software or the Equipment.

 

4.6                                  Source Code Escrow . In the event that (i) IM becomes insolvent or bankrupt, (ii) IM makes an assignment for the benefit of creditors, (iii) IM consents to a trustee or receiver appointment, (iv) a trustee or receiver is appointed for IM or for a substantial part of its property without its consent, (v) IM voluntarily initiates bankruptcy, insolvency, or reorganization proceedings, or is the subject of involuntary bankruptcy, insolvency, or reorganization proceedings, or (vi) IM announces that it has entered into an agreement to be acquired by a then named Competitor (as defined in the Wets Workflow Purchase Agreement), then IM and Customer will negotiate in good faith to enter into a source code escrow agreement with Iron Mountain Incorporated in a form provided by Iron Mountain Incorporated (or if Iron Mountain Incorporated is no longer engaging in the source code escrow business, a mutually agreed source code escrow company) setting forth source code escrow deposit procedures and source code release procedures relating to Informatics Software. Notwithstanding the foregoing, the escrow instructions shall provide for a release of the source code to Customer of the Informatics Software only upon the occurrence of (a) the filing of a Chapter 7 bankruptcy petition by IM, or a petition by IM to convert a Chapter 11 filing to a Chapter 7 filing; (b) the cessation of business operations by IM; or (c) the failure on the part of IM to comply with its contractual obligations to Customer to comply with its maintenance and support obligations for a period of more than ninety (90) days after it has received written. notice of said breach. Any dispute between the parties over whether an event has occurred that would trigger a release of source code to Customer pursuant to the source code escrow instructions shall be resolved pursuant to Section 12.16. In the event of a release of Informatics Software source code pursuant to this section, said source code shall continue to be the Confidential Information of IM or its successor in interest. In the event of a release of source code to Customer from escrow, Customer may only use, copy and/or modify the source code consistent with the purposes of this Agreement (or have a contractor who has agreed in writing to confidentiality provisions as restrictive as those set forth in this Agreement do so on its behalf).

 

4.7                                  “Improvements” Defined . As used in this Section 4, “ Improvements ” means

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

7



 

improvements, additions, or modifications to the Equipment or to the use or application of Equipment that IM or Customer, as applicable, conceives, reduces to practice or otherwise develops, other than Informatics Updates, after the confirmation of Platform Assembly by Customer (“ Platform Assembly Confirmation ”). “ Customer Improvements ” means Improvements wholly conceived, reduced to practice, or otherwise developed by Customer that were not known to IM prior to Formal Disclosure by Customer to IM (as defined in Section 4.9.2), or that were not generally available to the public or otherwise part of the public domain at the time of Formal Disclosure. “Customer Use Improvements” means Customer Improvements that are new methods of use or modifications to existing methods of use of Equipment in dry processingthat can be implemented without any improvements, additions or modifications to the Equipment. “IM Improvements ” means Improvements wholly conceived or reduced to practice by IM.

 

4.8                                  IM Improvements. IM Improvements are not included within the scope of rights granted hereunder. IM may periodically offer IM Improvements for sale or license to Customer and will negotiate in good faith with Customer terms in connection therewith; provided, that IM will offer to Customer any IM Improvements that it makes generally available to its other customers, except as limited by any Third Party agreement. Any such sale or license shall require the mutual execution of Purchase Documentation explicitly describing the sale or license to Customer of IM Improvements.

 

4.9                                  Customer Improvements. All improvements to the Dry HPC Technology derived from, based on, or invented in whole or in part through Customer’s use of the Dry Workflow pursuant to this Agreement or using the Dry Workflow purchased herein, whether a Customer Improvement or not. and all Intellectual Property Rights therein, shall be owned by IM and if initially conceived, reduced to practice or developed by Customer (whether or not implemented by IM as set forth in Section 4.9.1), shall be assigned to IM as set forth in Section 4.2. IM hereby grants a non-exclusive. royalty-free license (i.e., IM shall not increase the HPC Site License or HPC Enabled Software License due to the implementation or use of such Improvement) to Customer to use any Improvement (other than an IM Improvement) on or with any Dry Workflow for which Customer continues to pay the HPC Site License fee and continues to license the HPC-Enabled Informatics Software. Notwithstanding the foregoing, no license to Customer to use Dry HPC Technology beyond the term or beyond the scope of any license granted to Customer to use Dry HPC Technology is intended or granted by the preceding sentence. Any notification of a proposed Customer Improvement shall comply with the procedure set forth in Section 4.9.2, below. Notwithstanding the foregoing, if IM wishes to commercialize any non-obvious Customer Improvement for sale to third parties, IM shall first negotiate with Customer in good faith to agree upon reasonable compensation to Customer in view of the contribution of the Customer Improvement to the value of the Dry Workflow or a component thereof. If the Parties cannot agree on such compensation then they shall follow the provisions of Section 4.9.3.

 

4.9.1                         Any implementation by IM of Customer Improvements on Customer’s behalf shall be the subject of a separately executed statement of work between the parties that shall specify the commercial and other terms.

 

4.9.2                         Customer may disclose Customer Improvements to IM pursuant to this paragraph. Before fully disclosing any Confidential Information with respect to a Customer Improvement to IM, Customer shall first send a written non-Confidential summary of the proposed Customer Improvement to the attention of the IM Legal Department. Within thirty (30) days of the non-confidential disclosure, IM shall inform Customer that IM either does or does not wish to receive a more detailed description of the proposed Customer Improvement that Customer may label as Confidential Information (“ Formal Disclosure ”). If IM does not wish to receive the more detailed’ description of the Customer Improvement, Customer may maintain such Customer Improvement as a trade secret. For the avoidance of doubt, the preceding sentence shall not change the provisions of this Agreement concerning ownership of Improvements. Furthermore, IM’s ability to sell, license and sub-license

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

8



 

Dry HPC Technology shall not be limited by (i) the non-Confidential disclosure above or (ii) any disclosure by Customer to IM employees separate from any Formal Disclosure (other than disclosures to IM employees that are subject to the IP firewall described in Section 7.5.1 hereof) of a Customer Improvement that Customer decides to maintain as a trade secret. Within a reasonable time after its receipt of the Formal Disclosure, IM shall provide notice to Customer that either (a) IM does not wish to implement the proposed Customer Improvement, and that it is returning the Confidential Information (except as required for archival purposes), or (b) IM wishes to further study the feasibility of implementing or commercializing the Customer Improvement including a proposal on how to proceed. Notwithstanding the foregoing, during the one-year period following the Platform Assembly Confirmation of the Dry Workflow sold under this Agreement, Customer shall disclose no more than [*] potential Customer Improvements during any one of the [*] periods immediately following said Platform Assembly Confirmation for consideration by IM above. The restrictions set forth in Section 4.11 only shall apply to Customer Improvements for which there has been a Formal Disclosure (provided that the foregoing shall in no way change or reduce IM’s obligations pursuant to Section 7.5.1 hereof). References to obligations and disclosures Section 7.5 in this Section specifically exclude disclosures by Customer to IM employees related to improvements, changes or modifications to the Equipment and IM shall be free to sell, license and sub-license Dry HPC Technology relating to Equipment disclosed outside of the Formal Disclosure process. If Customer proposes an Customer Improvement following said [*] period, the parties will negotiate in good faith on a case by case basis any special terms and conditions that will be applicable to the sale to Third Parties of Equipment into which such future Customer Improvements may be implemented.

 

4.9.3                         Notwithstanding Section 12.16 of this Agreement, in the event that the parties cannot agree for a period of [*] days after escalation to their respective chief executive officers to a reasonable compensation for a Section 4.9 proposal, then either party may submit the issue of the amount of compensation due to Customer if IM implements the Customer Improvement to final and binding arbitration, before a single, mutually-acceptable arbitrator, conducted in accordance with the Commercial Arbitration Rules of AAA, solely for determination of the reasonable compensation. If the parties are unable to select a mutually acceptable arbitrator, AAA shall appoint an arbitrator or provide a method for selection. Any arbitration proceedings shall be conducted in Phoenix, Arizona. Each party shall bear its own expenses, including attorneys’ fees, and the parties will share equally the costs and fees of the arbitrator. Prior to the actual arbitration hearing, each party shall provide the arbitrator a written proposal for a reasonable compensation that such party believes to be fair to both parties in the circumstances. The arbitrator must render a written decision within [*] days of the hearing in favor of one party’s proposal or the other, without modification. The arbitrator must determine the prevailing party by assessing the proposal, and its fairness in light of the relevant Intellectual Property Rights, technology contributions, and development and commercialization costs and expenses of each party, as well as the potential markets for the proposed application and whether third party Intellectual Property .  Rights, development efforts, commercialization efforts or investment is required to commercialize the proposed application. The parties shall use all reasonable efforts to complete any arbitration subject to this section within [*] months from the filing of notice of a request for such arbitration. The parties undertake and

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

9



 

agree that all arbitral proceedings shall be kept confidential, and all information, documentation, materials in whatever form disclosed in the course of such arbitral proceeding shall be used solely for the purpose of those proceedings. Nothing in this section shall require IM to implement the Customer Improvement following the decision of the arbitrator.

 

4.10                            Impact on Customer Acceptance . The parties agree that any implementation, as set forth herein, of Customer Improvements will not delay the Customer Acceptance date, and such implementation may start prior to Customer Acceptance upon mutual agreement of the parties (with IM’s agreement not to be unreasonably withheld as long as the Customer Acceptance date will not be delayed). Furthermore, the parties agree that any Customer Improvements will not be added to the Acceptance Criteria.

 

4.11                            Excluded Companies . Subject to Section 4.9, IM agrees that it will not, except with the written consent of Customer, either: disclose or license to any Competitor (as defined in the Wets Workflow Purchase Agreement) any Customer Use Improvements for a period of nine (9) months after Formal Disclosure, except that IM shall have the right to provide licenses of a broad or general scope that do not specifically mention or otherwise disclose the Customer Use Improvement, or disclose, license or sell any Customer Improvement, other than an Customer Use Improvement, that Customer implements on its Equipment to any Excluded Company (as defined in the Wets Worlkflow Purchase Agreement) until [*] after such implementation. Notwithstanding the foregoing, if Customer decides not to implement such Customer Improvement within [*] days of IM’s notice that it is available. IM shall be free to license or sell such Customer Improvement without restriction.

 

ARTICLE 5
PAYMENTS

 

5.1                                  Invoicing and Payment. Unless otherwise stated in the Quote, IM shall promptly render to Customer correct and complete invoices in accordance with the terms in the Quote. which shall specify at least the following information: Purchase Order number, item number, description of goods, quantities, unit prices, extended totals and applicable taxes. Customer shall pay to IM the fees and taxes within fifteen (15) days of receiving IM’s valid invoice.

 

5.2                                  Transaction Taxes . Fees payable to IM under this Agreement are exclusive of any transaction taxes (including sales, use, consumption, value-added and similar transaction based taxes, or withholding taxes) which may be imposed, in accordance with applicable laws, as a result of the licenses granted by IM to Customer, and the sale of one or more Dry Workflows hereunder. Customer agrees to bear or reimburse IM for all such transaction taxes. IM assumes responsibility to timely remit tax payments that it collects from Customer to the appropriate governmental authority after receipt from Customer, in each respective jurisdiction.

 

ARTICLE 6
ROYALTIES; REVENUE SHARE

 

6.1                                  Compensation, Revenue Share or Royalties . Each party will pay the other party any compensation, revenue share payments or royalties due as agreed between the parties. Any revenue share or royalty due from a party shall be paid on a calendar quarter basis following shipment of the products that trigger the payment. Customer agrees to pay IM a royalty on any sale of Products by Customer, Customer Affiliate or Third Party licensee of Customer (“Royalty”) and provide reports and payments as set forth in Section 6.4. The operation of the Equipment in HPC Mode and the licenses granted by IM to Customer are subject to the payment of all applicable fees in the Quote and a Royalty on Products as set forth below. Customer shall pay a Royalty to IM equal to [*] percent ([*]%) on gross sales proceeds of Products, less the following when separately itemized on or included and identifiable in invoices related to the sale of the Product: (i) allowances, discounts, including cash discounts, rebates and returns all to the extent actually given in the trade by Customer or its affiliates; (ii) sales, excise and similar taxes (including but not limited to any value added tax) or duties; (iii) insurance, packaging (except packaging that directly encloses the Products), and handling, shipping, transportation or similar; and (iv) credits or repayment for rejection or return of Products. If Customer has suitable written

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

10


 

records that reflect actually incurred direct costs (including but not limited to freight out, customs, duty, distribution and warehousing). Customer may deduct such direct costs (up to an additional aggregate amount not to exceed [*]% of the gross sales proceeds for all Products during any reporting period) prior to computing the royalty on gross sales proceeds, even if such direct costs are not separately itemized to the customer. In the case that Customer enables a Third Party to make or sell a Product under license in. exchange for a royalty to Customer, the Royalty payable by Customer to IM for such use shall be calculated on the value of the Product used to calculate the royalty paid to Customer (“Product Value”). For business arrangements between Customer and Third Parties related to (i) Products for which the Product Value cannot be derived, or (ii) other Customer monetization derived through use of the Dry Workflow or Dry HPC Technology not otherwise described herein, IM and Customer agree to negotiate in good faith to set the compensation, if any, due to IM. Notwithstanding Section 12.16 of this Agreement, in the event that the parties cannot agree for a period of [*] days after escalation to their respective chief executive officers to a reasonable compensation, the parties will use the procedure of Section 4.9.3 to determine compensation due to IM.

 

6.2                                  Third Party Royalties . Each party shall be responsible for all of its own costs of commercializing Products or licensing Intellectual Property Rights, including any payments to Third Parties for work done by such Third Parties or for licenses necessary for the manufacture, sale, or use of Products by a party or its Affiliates or sublicensees.

 

6.3                                  Payment Method . All payments due under this Agreement shall be made by bank wire transfer or ACH transaction in immediately available funds to a bank account designated by the payee. Where IM is the payee, payments shall be made to the bank account below or as otherwise designated by IM. All payments hereunder shall be from a U.S. entity and made in U.S. dollars.

 

U.S. Domestic Wire Transfer

 

 

To:                         [*]

 

 

Routing & Transit #:

 

[*]

For credit of:

 

Intermolecular, Inc.

Credit account # :

 

[*]

By order of:

 

[Name of Sender]

 

Any payments that are not paid within thirty (30) days of the date such payments are due under this Agreement shall bear interest at the lesser of (i) [*] percent ([*]%) per month or (ii) the maximum rate permitted by law. Nothing in this Section 6.3 shall prejudice any other rights or remedies available to either party hereunder or at law or equity.

 

6.4                                  Reports and Payments. After the first sale of a Product on which Royalties are payable by Customer, Customer shall make [*] written reports to IM within [*] days after the end of each calendar [*], stating in each such report, separately for itself and each Affiliate and each sublicense, the number, description, and total sales of each Product sold, and a calculation of the Royalties due as a result of license grants to Third Parties, the manner of calculation of each as specified in Section 6.1. Concurrently with the making of such reports, Customer shall pay IM all amounts due as set forth in the report. In the event payment are due from IM to Customer hereunder, IM shall follow the same procedure.

 

6.5                                  Currency Conversions . If any currency conversion shall be required in connection with the calculation of royalties hereunder, such conversion shall be made using the selling exchange rate for conversion of the foreign currency into U.S. Dollars, quoted for current transactions reported in The Wall Street Journal for the last business day of the quarter to which such payment pertains.

 

6.6                                  Records; Inspection. Each party and its Affiliates shall keep complete, true and accurate books of account and records for the purpose of determining the royalty amounts payable under this Agreement. Such books and records shall be kept at the principal place of business of such party, as the case may be, for at least [*] years following the end of the calendar [*] to which they pertain. Such records will be open for inspection during such [*] year period by an independent auditor reasonably acceptable to the audited party, solely for the purpose of verifying royalty statements

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

11



 

hereunder. Such inspections may be made no more than once each calendar year, at reasonable times and on reasonable notice. Inspections conducted under this Section 6.6 shall be at the expense of the auditing party, unless a variation or error producing an increase of at least [*] Dollars ($[*]) and exceeding [*]percent ([*]%) of the amount stated for any period covered by the inspection is established in the course of any such inspection, whereupon all reasonable costs relating to the inspection for such period and any unpaid amounts that are discovered will be paid promptly by the audited party together with interest thereon for late payments as set forth above. Each party agrees to hold in confidence all information concerning royalty payments and reports, and  all information learned in the course of any audit or inspection, except to the extent necessary to enforce its rights under this Agreement or to the extent disclosure is required by law.

 

ARTICLE 7
CONFIDENTIALITY

 

7.1                                  Confidentiality. The parties agree that the receiving party shall not, except as expressly provided in this Article 7 disclose to any Third Party, or use for any purpose, any Confidential Information furnished to it by the disclosing party pursuant to this Agreement, except in each case to the extent that it can be established by the receiving party by competent proof that such information: (a) was already known to the receiving party. other than under an obligation of confidentiality to the disclosing party, at the time of disclosure; (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving party; (c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving party in breach of this agreement; (d) was independently developed by the receiving party without use of, or reference to, the other party’s confidential information, as demonstrated by documented evidence prepared contemporaneously with such independent development; or (e) was disclosed to the receiving party, other than under an obligation of confidentiality to the disclosing party, by a Third Party authorized and entitled to disclose such information to others. Confidential Information shall not be considered within the above exceptions merely because the Confidential Information is embraced by more general information within the exceptions. Any combination of features of Confidential Information shall not be considered within the above exceptions merely because individual features, as opposed to the combination itself and its principles of operation, are within the exception.

 

7.2                                  Permitted Use and Disclosures . Notwithstanding the restrictions of Section 7.1, each party hereto may (a) use Confidential Information disclosed to it by the other to the extent necessary for that party to perform its obligations or exercise its rights and licenses set forth in this Agreement and (b) use or disclose Confidential Information disclosed to it by the other party to the extent such use or disclosure is reasonably necessary in (i) prosecuting or defending litigation pursuant to Article 8, (ii) complying with applicable laws, governmental regulations or court orders or submitting information to tax or other governmental authorities (including the Securities and Exchange Commission), or (iii) preparing, filing and prosecuting patent applications pursuant to this Agreement; in each case, provided that if a party is required to make any such disclosure, other than pursuant  to a confidentiality agreement, it will give reasonable advance notice to the other party of such disclosure and will use reasonable efforts to secure confidential treatment of such information (whether through protective order or otherwise), except to the extent inappropriate with respect to patent applications. It is understood that either party may also disclose the Confidential Information of the other party upon receipt of the written consent to such disclosure by a duly authorized representative of the other party. It is also understood that notwithstanding other provisions of this paragraph, neither party shall disclose trade secrets of the other party without first obtaining the written consent of the party owning such trade secrets and securing an agreement with the party to whom such disclosure will be made that such trade secrets will be treated as confidential for as long as such trade secrets qualify for protection as trade secrets. It is further understood that such trade secrets are not to be included in any patent, patent application, or other document that is accessible by individuals not subject to an agreement requiring that the individuals maintain such document in confidence. It is also understood that unless expressly required in this Agreement, neither

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

12



 

party is obligated to disclose Confidential Information to the other.

 

7.3                                  Nondisclosure of Terms . Subject to Section 7.4, each of the parties hereto agrees not to disclose the terms of this Agreement to any Third Party without the prior written consent of the other party hereto, which consent shall not be unreasonably withheld, except to such party’s attorneys, accountants, advisors, investors and financing sources and their advisors and others on a need to know basis under circumstances that reasonably ensure the confidentiality thereof, to the- extent required by law, in connection with the enforcement of this Agreement or rights under this Agreement or in connection with a merger, acquisition, financing transaction, or proposed merger, acquisition or financing transaction, or the like.

 

7.4                                  Compliance with Public Company Disclosure Obligations. Notwithstanding the provisions of Section 7.3, if a party is a Public Company (as defined below), such party may disclose from time to time such information regarding the terms of this Agreement as such party may reasonably deem to be necessary to comply with its disclosure obligations under applicable U.S. securities law or applicable stock market or NASDAQ Stock Market listing rules; provided, however, that each party shall use commercially reasonable efforts to (i) nevertheless comply with its obligations as set forth in Section 7.3, or in the event such compliance is not possible, (ii) provide the other party with a draft of the disclosure intended to be made not less than twenty-four (24) hours prior to the intended first public release or filing of such disclosure. For purposes of this section, “ Public Company ” shall mean a company that is subject to the reporting requirements of either Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended.

 

7.5                                  Firewall Protection. In addition to conforming to the confidentiality provisions in this Article 7, the following shall apply:

 

7.5.1                         IM will construct an IP firewall as described below in this Section around IM employees providing Services to Customer in connection with the Dry Workflow purchased herein. Only such employees of IM will be allowed to have access to such Customer confidential and proprietary information and information distribution will be based strictly on a need-to-know basis. Such employees of IM shall solely use such Customer confidential and proprietary information in providing Services to Customer. Physical copies of Customer confidential and proprietary information shall be securely locked when not in use such that only those IM employees providing such Services shall have access to such information.

 

7.5.2                         Customer will construct an IP firewall as described below in this Section around Customer employees who have access  at IM’s facilities to Dry HPC Technology outside of the Dry Workflow purchased hereunder. Only such employees of Customer will be allowed to have access to such IM confidential and proprietary information and such information shall not be shared with other Customer employees or Third Parties without the prior written consent of IM. Copies or samples of IM confidential and proprietary information shall not be removed or transmitted from any IM facility by Customer employees.

 

ARTICLE 8
REPRESENTATIONS AND WARRANTIES;
MAINTENANCE AND SUPPORT

 

8.1                                  Customer . Customer represents and warrants that: (i) it has the right and authority to enter into this Agreement and to fully perform its obligations hereunder and (ii) this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms.

 

8.2                                  IM . IM represents and warrants that: (i) it has the right and authority to enter into this Agreement, and to fully perform its obligations hereunder, (ii) this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms, (iii) it owns or possesses a valid and enforceable license to use (with ability to sublicense) all Intellectual Property Rights licensed or sublicensed to Customer pursuant to this Agreement, (iv) it has full power and authority to license or sublicense as the case may be, all Intellectual Property Rights licensed to Customer upon the terms set forth herein, and (v) to IM’s knowledge, the use and practice of the Dry Workflow pursuant to and in accordance with the terms of this Agreement will not infringe the Intellectual Property Rights of any Third Party.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

13



 

8.3                                  Limited Warranty on Equipment and Informatics Hardware . IM warrants to Customer that for a period of [*] year from Customer Acceptance that the Equipment and Informatics Hardware is free from defects in materials and workmanship and shall conform in all material respects to its Specifications. The warranty set forth in the prior sentence shall apply only to the IM supplied components of the Equipment and Informatics Hardware and specifically excludes consumables and any components supplied by Customer . IM does not otherwise warrant the Equipment and Informatics Hardware and does not warrant that operation of the Equipment and Informatics Hardware will be uninterrupted or error free. If the Equipment and Informatics Hardware does not meet the warranty specified above during the warranty period, IM shall, at its option, repair or replace at no cost to Customer any defective or nonconforming Equipment and Informatics Hardware component. Procedures and response times in connection with warranty claims under this Section 8.3 are set forth in Exhibit D.

 

8.4                                  Limited Warranty on Informatics Software. IM warrants to the Customer that for a period of [*] year from Customer Acceptance the Informatics Software will conform in all material aspects with its Specifications and the documentation supplied therewith. IM will use commercially reasonable efforts to correct any nonconformities reported to IM in writing or in electronic form during the warranty period. Procedures and response times in connection with claims under this Section 8.4 are set forth in Exhibit D.

 

8.5                                  Warranty for Services . IM will provide Services in a professional manner using reasonable care and skill and in accordance with standard industry practice and all applicable federal, state and local laws and regulations.

 

8.6                                  Maintenance and Support . If Customer has and continues to pay for maintenance and support for a DryWorkflow item, as set forth in the applicable Quote and, in the future, pursuant to procedures set forth in Exhibit D, IM will provide the maintenance and support of the applicable item as set forth in Exhibit D.

 

8.7                                  Exclusions . The warranties and remedies set forth in Sections 8.3 and 8.4 will be void as to (i) any Dry Workflow that has been damaged, modified, or altered (other than by IM or as authorized in writing by an officer of IM) (ii) any Dry Workflow that has been subjected to physical, electrical or other environmental abuse or misuse, including improper storage or conditions not in accordance with IM’s specifications, or (iii) damage or non-conformities, in whole or in part, arising from use of the Dry Workflow with any other hardware, software, firmware, devices, or other products not provided by IM or chemicals not recommended or approved for use by IM on the Dry Workflow Equipment or as otherwise set forth in Exhibit B unless Customer can demonstrate by clear and convincing evidence that the matter described in clause (i), (ii) or (iii) above, as applicable, did not cause the non-conformity in whole or in part.

 

8.8                                  Disclaimer . Customer and IM specifically disclaim any representation, warranty or guarantee that the use of the Equipment, Informatics Software, Third Party Software, or Informatics Hardware, will be successful, in whole or in part. It is understood that the failure to successfully develop and commercialize any technology related to this Agreement shall not constitute a breach of any representation or warranty or other obligation under this Agreement. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, IM AND CUSTOMER MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE TECHNOLOGIES DESCRIBED HEREIN OR INFORMATION DISCLOSED HEREUNDER, AND HEREBY EXPRESSLY DISCLAIM ANY WARRANTIES OF MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE, OR VALIDITY OF ANY TECHNOLOGY, PATENTED OR UNPATENTED, OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

 

ARTICLE 9
INDEMNIFICATION

 

9.1                                  IM agrees to defend and hold Customer harmless from and against all claims, losses, damages, judgments, awards, settlements, and costs (including reasonable attorneys’ fees), arising out of, or resulting from, any litigation or

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

14



 

proceeding brought by a Third Party alleging infringement by the Dry Workflow or the use of such Dry Workflow by Customer in the Field pursuant to and in accordance with the terms of this Agreement (“Use”) of a Third Party’s Intellectual Property Rights, provided that (i) Customer notifies IM promptly in writing of the claim (provided, however, that the failure to promptly provide notice to IM will not affect IM’s duties or obligations under this Article 9 except to the extent IM is prejudiced thereby) and (ii) Customer assists and cooperates reasonably with IM, at IM expense, in defending or settling such claim. IM shall have sole control of the defense and all related potential settlement negotiations, provided that IM shall not enter into any settlement which would materially adversely affect the Rights granted to Customer under this Agreement without Customer’s express prior written consent. Customer shall be entitled to be represented by Customer’s own counsel at Customer’s expense. Notwithstanding the foregoing, IM shall have no liability for any claim of infringement based on or arising from the use, sale, offer for sale, import license, or manufacture of Products or other related technology sold or licensed by Customer that is derived from the Dry Workflow.

 

9.2                                  In the event the Dry Workflow or Use thereof is held, or IM, in good faith and in its sole discretion, believes may be held, to infringe or misappropriate any Intellectual Property Rights of a Third Party, IM shall at its sole expense: (i) obtain a license to continue to use the Dry Workflow without additional charge to Customer; or (ii) modify the Dry Workflow or Use thereof, so they are non-infringing and meet the applicable Acceptance Criteria (“ Non-Infringing Modification ”). IM’s indemnification obligations shall cease if Customer fails or refuses to implement any Non-Infringing Modification or if the Use is other than a licensed Use.

 

9.3                                  Notwithstanding anything to the contrary in this Agreement, IM provides no indemnification of claims that Third Party Software infringes Third Party Intellectual Property Rights if said claims do not allege that the infringement was caused by use of the Third Party Software in combination with other elements of the Wets Workflow. Customer’s right to indemnification, if any, in connection with such claims shall be governed by its applicable Third Party end user license agreement.

 

9.4                                  The foregoing indemnity states the sole obligations and exclusive liability of IM, and Customer’s sole recourse and exclusive remedy for any Third Party claim of infringement or misappropriation of an Intellectual Property Right by IM under this Agreement.

 

ARTICLE 10
LIMITATION OF LIABILITY

 

EXCEPT FOR A BREACH BY EITHER PARTY OF ITS CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 7 AND EXCEPT FOR BREACHES OF ANY LICENSE RESTRICTIONS, OR ANY PAYMENT OBLIGATIONS RESULTING FROM AN INDEMNIFICATION OBLIGATION HEREUNDER, UNDER NO CIRCUMSTANCES WILL EITHER PARTY BE LIABLE TO THE OTHER, UNDER CONTRACT, STRICT LIABILITY, NEGLIGENCE OR OTHER LEGAL OR EQUITABLE THEORY, FOR ANY LOST REVENUE, LOST PROFITS, EQUIPMENT DOWN-TIME, OR FOR ANY INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND IN CONNECTION WITH THE SUBJECT MATTER OF THIS AGREEMENT, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. EXCEPT FOR A BREACH BY EITHER PARTY OF ITS CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 7 AND EXCEPT FOR BREACHES OF ANY LICENSE RESTRICTIONS, OR ANY PAYMENT OBLIGATIONS RESULTING FROM AN INDEMNIFICATION OBLIGATION HEREUNDER, IN NO EVENT WILL EITHER PARTY’S LIABILITY TO THE OTHER UNDER THIS AGREEMENT EXCEED THE GREATER OF (A) [*] DOLLARS ($[*]), (B) THE [*] FOR THE [*] THAT IS THE SUBJECT OF THE CLAIM, AT THE TIME THE CLAIM IS MADE, AND (C) THE AMOUNTS PAID OR PAYABLE BY SUCH PARTY TO THE OTHER PARTY IN THE TWELVE (12) MONTHS PRECEDING THE CLAIM.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

15



 

ARTICLE 11
TERMINATION

 

11.1                            Term of Agreement . The term of this Agreement shall commence on the Effective Date, and, unless terminated earlier as provided in this Article 11, shall continue in full force and effect until the termination of all HPC Site Licenses and HPC-Enabled Informatics Software Licenses granted under this Agreement.

 

11.2                            Termination . Either party to this Agreement may terminate this Agreement (including any associated purchase order), in whole or in part, in the event the other party shall have materially breached or defaulted in the performance of any of its material obligations under this Agreement, and such default shall have continued for [*] after written notice thereof was provided to the breaching party by the non-breaching party. Any termination shall become effective at the end of such [*] period unless the breaching party (or any other party on its behalf) has cured any such breach or default prior to the expiration of such [*] period. In the event Customer terminates this Agreement due to a material breach that is not cured per the above term prior to Customer Acceptance, IM shall promptly refund to Customer any amounts paid hereunder (or in the event of a termination in part, the amounts paid for the item(s) that is the subject of the termination).

 

11.3                            Effect of Termination . All licenses under the Agreement shall terminate, and IM and Customer shall promptly return to the other all Confidential Information received from the other party related to this Agreement, except (i) one copy of which may be retained for archival purposes, or (ii) to the extent that such Confidential Information is necessary to practice a continuing right or obligation; provided, however that the applicable party may, at its option, destroy any Confidential Information it is otherwise obligated to return and certify such destruction to the other party. Except as expressly provided herein, Section 4.2 and Articles 5 — 12, shall survive the expiration or termination of this Agreement for any reason.

 

ARTICLE 12
MISCELLANEOUS

 

12.1                            Governing Law . This Agreement and any disputes arising from the construction, performance or breach hereof shall be governed by and construed in accordance with the laws of the State of New York in the United States, without regard to its choice of law rules.

 

12.2                            Assignment . Neither party shall assign this Agreement, in whole or in part, without the prior written consent of the other party, which consent shall not be unreasonably conditioned, delayed or withheld; provided, however, that either party may assign this Agreement without such consent to an Affiliate or to a successor in interest to its business (whether by merger, acquisition, consolidation, change of control, reorganization or sale of substantially all of its assets) and the terms of the Agreement shall continue in effect without modification after such assignment, including without limitation the royalty provisions herein which shall be binding upon any permitted assignee. Any purported assignment without such consent shall be void and of no effect. Subject to the foregoing sentence, this Agreement will be binding on and inure to the benefit of the parties and their respective successors and permitted assigns.

 

12.3                            No Implied License . Only the licenses granted pursuant to the express terms of this Agreement shall be of any legal force or effect. No other license rights shall be created by implication, estoppel or otherwise. Each party reserves all rights not expressly granted to the other party under this Agreement.

 

12.4                            Representation by Legal Counsel . Each party hereto represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the parties agree that no presumption shall exist or be implied against the party that drafted such terms and provisions.

 

12.5                            Waiver . It is agreed that no waiver by either party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed a waiver as to any subsequent and/or similar breach or default.

 

12.6                            Non-Solicitation . For a period of [*] from the Effective Date, neither IM nor Customer will individually, or in concert with or through any other person, actively recruit or solicit employment of any scientific or technical

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

16



 

personnel of the other party. The foregoing restriction shall not apply to, or be breached by: (i) advertising open positions, participating in job fairs, and conducting comparable activities to recruit skilled or unskilled help from the general public, or responding to individuals contacted through such methods, (ii) responding to unsolicited inquiries about employment opportunities or possibilities from job placement agencies or other agents acting for unidentified principals, or (iii) responding to unsolicited inquiries about employment opportunities from any individual.

 

12.7                            Other Restrictions . The Parties are simultaneously entering into an Amendment to Addendum to Wets Workflow Purchase Agreement (“Amendment”), which Amendment contains certain restrictions concerning the sale by IM of Dry Workflows.

 

12.8                            Severability . In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect to the fullest extent permitted by law without said provision, and the parties shall amend the Agreement to the extent feasible to lawfully include the substance of the excluded term to as fully as possible realize the intent of the parties and their commercial bargain.

 

12.9                            Independent Contractors . The relationship of the parties hereto is that of independent contractors. The parties hereto are not deemed to be agents, partners or joint ventures of the others for any purpose as a result of this Agreement or the transactions contemplated thereby.

 

12.10                      Compliance with Laws. In exercising its rights under the licenses granted hereunder, and in undertaking the activities outlined in this Agreement, each party shall fully comply in all material respects with the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this Agreement including those applicable to the discovery, development, manufacture, distribution, import and export and sale of products based on technology developed pursuant to this Agreement.

 

12.11                      Export Control Regulations . Without limiting the parties’ obligations under Section 12.9 above, the rights and obligations of the parties under this Agreement, shall he subject in all respects to United States laws and regulations as shall from time to time govern the license and delivery of technology abroad. Without in any way limiting the provisions of this Agreement, IM and Customer agree that each will not export, reexport, or transship, directly or indirectly, to any country, any of the technical data disclosed to it by the other party hereto if such export would violate the laws of the United States or the regulations of any department or agency of the United States Government. IM will notify Customer if any Dry Workflow item is classified for export restriction.

 

12.12                      Notices . All notices, requests and other communications hereunder shall be in writing and shall be hand delivered or sent by express delivery service with confirmation of receipt to the Chief Legal Officer of the party at the address listed above. Any such notice shall be deemed to have been given when received. Either party may change its address by giving the other party written notice, delivered in accordance with this section.

 

12.13                      Force Majeure . Neither party shall lose any rights hereunder or be liable to the other party for damages or losses (except for payment obligations) on account of failure of performance by the defaulting party if the failure is occasioned by war, strike, fire, act of God, earthquake, flood, lockout, embargo, act of terrorism, governmental acts or orders or restrictions, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence, intentional conduct or misconduct of the non-performing party and such party has exerted all reasonable efforts to avoid or remedy such force majeure.

 

12.14                      Headings; Construction . The captions to the several articles and sections hereof are not part of this Agreement, but are included merely for convenience of reference and shall not affect its meaning or interpretation. As used in this Agreement, the word “including” means “including without limitation.”

 

12.15                      Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

17



 

together shall be deemed to be one and the same agreement.

 

12.16                      Dispute Resolution . If a dispute arises between the parties relating to the interpretation or performance of this Agreement, representatives of the parties with decision-making authority shall meet to attempt in good faith to negotiate a resolution of the dispute prior to pursuing other available remedies. If such a meeting is requested, it must he held, unless the parties otherwise agree, within [*] calendar days from receipt of such request (the “ Request ”). If within [*] calendar days after such meeting the parties have not resolved such dispute, the Chief Executive Officers of both parties shall meet within [*] calendar days after the end of such [*] day period to discuss and attempt to resolve the dispute. If the parties have not resolved the dispute within [*] calendar days after the Request, either party may submit such dispute to final and binding arbitration before a single, mutually acceptable arbitrator, conducted in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“ AAA ”).  If the parties are unable to select a mutually acceptable arbitrator, AAA shall appoint an arbitrator or provide a method for selection.  Any arbitration proceedings shall be conducted in Phoenix, Arizona.  The arbitrator shall determine what discovery will be permitted, consistent with the goal of limiting the cost and time that the parties must expend for discovery.  Each party shall bear its own expenses, including attorneys’ fees, and the parties will share equally the costs and fees of the arbitrator.  The parties shall use all reasonable efforts to complete any arbitration subject to this section within [*] months from the filing of notice of a request for such arbitration.  The parties agree that any award shall not include punitive damages and shall be consistent with the limitation of liability provisions set forth in this Agreement. The arbitrator shall not have the power to add terms not contained in this Agreement or to refuse to enforce any term. Judgment upon any decision rendered by the arbitrator may be entered by any court having jurisdiction. The parties undertake and agree that all arbitral proceedings and all information, documentation, materials in whatever form disclosed in the course of such arbitral proceeding shall be deemed Confidential Information hereunder. Notwithstanding any of the foregoing, either party shall have the right to seek, at its own cost and expense, preliminary and temporary injunctive relief pending resolution of the dispute.

 

12.17                      Entire Agreement . This Agreement, together with all Exhibits hereto, constitutes the entire agreement and understanding of the parties relating to the subject matter hereof and supersedes all prior negotiations and understandings between the parties, both oral and written, regarding such subject matter.

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Effective Date.

 

Intermolecular, Inc.

 

By:

/s/ David Lazovsky

 

 

 

 

Name:

David Lazovsky

 

Title:

President & CEO

 

Date:

12/12/08

 

 

 

 

Customer

 

 

 

 

By:

/s/ Daniel P. Sharkey

 

 

 

 

Name:

Daniel P. Sharkey

 

Title:

EVP, Business Development

 

Date:

12/12/08

 

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

18


 

 

Exhibit A

 

Customer: ATMI
Date: Dec 9, 2008
Quote#: 200805001-09

 

Description

 

Qty

 

List Price

 

Ext List

 

Disc. %

 

Price

 

Dry Workflow

 

 

 

 

 

 

 

 

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

Total ATM Alliance HPC-Enabled Dry Workflow Price

 

[*]

 

[*]

 

[*]

 

 

Payment terms.

 

[*]

[*]

[*]

[*]

[*]

[*]

[*]

 

HPC Use Licenses, Maintenance & Support, Annual Renewal

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

Total ATM Alliance HPC Use Licenses, Maintenance & Support, Annual Renewal

 

[*]

 

[*]

 

[*]

 

 

Quote subject to Dry Workflow Purchase Agreement

 

2895 Zanker Road

San Jose, CA 95134

www.intermolecular.com

phone (408) 416-2300

fax (408) 416-2301

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

 

Exhibit A

 

Customer: ATMI
Date: Dec 9, 2008
Quote#: 200805001-09

 

Extended Descriptions

 

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

Exhibit B
[*] Tool specifications

 

The Specification will be updated by mutual written agreement of the Parties pursuant to and in accordance with Sections 1.25 of the Agreement.

 

Tool configuration

·                                           [*]

·                                           [*]

·                                           [*]

·                                           [*]

 

Facilities Requirements

·                                           [*]

·                                           [*]

·                                           [*]

·                                           [*]

·                                           [*]

 

Tool Functionality

 

[*]

·                                           [*]

·                                           [*]

·                                           [*]

·                                           [*]

·                                           [*]

·                                           [*]

·                                           [*]

·                                           [*]

·                                           [*]

·                                           [*]

·                                           [*]

 

[*]

·                                           [*]

·                                           [*]

·                                           [*]

·                                           [*]

·                                           [*]

·                                           [*]

·                                           [*]

·                                           [*]

·                                           [*]

 

[*]

·                                           [*]

·                                           [*]

·                                           [*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

[*]

·                                           [*]

 

Recommended Spares and Consumables

 

Intermolecular will provide a list prior to Customer Acceptance.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

Exhibit C
Acceptance Criteria

 

Acceptance Criteria will be updated by mutual written agreement of the Parties pursuant to and in accordance with Section 3.2 of the Agreement.

 

[*]

 

Test

 

Metric

 

Measurement Specifics

 

Performance

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

Test

 

Metric

 

Measurement Specifics

 

Performance

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

[*]

 

Test

 

Metric

 

Measurement
Specifics

 

Performance

[*]

 

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

Test

 

Metric

 

Measurement
Specifics

 

Performance

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 


 

Exhibit D: IM Maintenance and Support Services

 

I.                                          General Terms

 

A.                                     Services and Term

 

IM shall provide maintenance and support services set forth herein for the Dry Workflow upon Customer Acceptance of the Dry Workflow and continue for a period of one (1) year (the “Initial Maintenance and Support Term”).

 

I M shall continue to provide said services during any additional term during which Customer renews maintenance and support services (“Renewal Term”) in accordance with the procedure set forth below. Each Renewal Term shall consist of a one-year period: (a) the first Renewal Term shall commence the day following the last day of the Initial Maintenance and Support Term; and (b) any subsequent Renewal Terms shall commence on the anniversary of the first day of the first Renewal Term.

 

Nothing in this Exhibit D shall reduce IM’s warranty obligations set forth in the Agreement.

 

Not less than [*] days prior to the conclusion of the Initial Maintenance and Support Term, IM shall send Customer written notice of the date that the Initial Maintenance and Support Term is scheduled to expire, together with a Quote for maintenance and support services for the first Renewal Term.

 

If Customer thereupon provides IM with an acceptable Purchase Order in connection with the Quote, IM shall invoice Customer in accordance with Section 5.1 of the Agreement, and provide maintenance and support services for the first Renewal Term. Not less than [*] days prior to the end of any Renewal Period, IM shall provide Customer with notice specifying whether IM intends to continue to offer maintenance and support services for the Dry Workflow in question; if so, IM shall specify the price for maintenance and support for the next Renewal Term subject to Section 4.4.5.

 

IM will advise Customer in advance when IM believes that maintenance and support services fall outside of the range of supported services and will provide Customer with a description of the work and any applicable charges. IM shall provide an estimate of any likely charges in advance of the services and shall notify Customer if it believes the services are not covered hereunder as soon as practical once a determination is made by IM. During the services, if IM finds that the resolution is within the maintenance and support services defined herein and in the Agreement, Customer will incur no charges. All charges by IM shall be at the rates specified in the Agreement.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

1



 

B.                                     Error Classification and Response Times

 

The following terms shall apply with respect to support for Equipment, . Informatics Hardware, and/or Informatics Software:

 

Error Classification:

 

(a)                                   Priority 1 Error: System down with critical business impact to Customer. No viable workaround, but Customer needs an immediate fix or workaround to get up and running again.

 

(b)                                  Priority 2 Error: Critical problem with significant business impact to Customer. A viable workaround exists, but Customer needs a fix other than a workaround.

 

(c)                                   Priority 3 Error: Problem identified with moderate business impact to Customer for which a workaround may be adequate.

 

Response Times. IM customer service may be initiated by calling 408 416-2300 or such other number or email provided to Customer for that purpose. IM will use its best judgment to determine the priority level of each reported error and shall inform Customer of any change and the basis thereof. IM shall provide and maintain for Customer contact and escalation procedures for Customer personnel to reach an appropriate IM employee as follows:

 

(a)                                   Acknowledgement:

 

(i)                                      Priority 1 Errors: From [*] to [*], IM shall acknowledge the Customer call within [*] of Customer initiating the process of contacting IM; From [*] to [*], IM shall acknowledge the Customer call by [*], or within [*] of Customer initiating the process of contacting IM, whichever is later; If Customer requires faster response during a defined time period, e.g. during a critical demo, IM shall make a best effort to put in place a shorter response time, if Customer has provided reasonable notice prior to that defined time period.

 

(ii)                                   Priority 2 and 3 Errors: Between the hours of [*] and[*],[*],[*] through [*], excluding [*] (or such other hours and days as may be mutually agreed to by the parties, from time to time), IM shall acknowledge the Customer call within [*] of Customer contacting IM. At all other times, IM shall acknowledge customer by [*] the [*].

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2



 

(b)                                  Resolution Plan:

 

(i)                                      Priority 1 Errors: Upon acknowledging a Priority 1 Error, IM shall provide Customer an initial assessment within [*] and an error resolution plan within [*]. IM will use best commercial efforts to promptly resolve the error through an update, through the implementation of a viable workaround, or through any other means that provides the fastest time for Customer to be up and running again. IM will give Customer periodic reports, or immediately upon Customer’s request, on the status of relevant error resolution plans and activities.

 

(ii)                                   Priority 2 Errors: Upon acknowledging a Priority 2 Error, IM shall provide Customer an initial assessment within [*] and an error resolution plan within [*]. IM will use best commercial efforts to (i) include an error correction in the next Informatics Update, if any, and/or (ii) to schedule and execute in a timely fashion error resolution activities for Informatics Hardware or Equipment.

 

(iii)                                Priority 3 Errors: Upon acknowledging a Priority 3 Error, IM shall provide Customer an initial assessment within [*] and an error resolution plan within [*]. IM will use best commercial efforts to (i) include an error correction in the next Update, if any of the Software, and/or (ii) to implement in a timely fashion a workaround and/or schedule and execute error correction activities for Informatics Hardware or Equipment.

 

II.                                      Maintenance and Support Services

 

A.                                     Informatics Hardware and Equipment Support.

 

During the Initial Maintenance and Support Term and any Renewal Term, IM shall use best commercial efforts to do the following:

 

(a)                                   IM shall maintain the Equipment and Informatics Hardware in accordance with the warranty in the Agreement. Service may also include scheduled preventative maintenance, as determined by IM. Remedial maintenance will be provided by IM during normal working hours as agreed between IM and Customer. Customer shall provide full and free access to the Equipment and Informatics Hardware as needed to perform any Services hereunder, subject to Customer’s reasonable policies and procedures.

 

(b)                                  IM shall replace parts as deemed necessary by IM. Customer must inform IM if any replaced parts may be contaminated with hazardous or toxic materials. All parts may be furnished on an exchange basis and will be new or equivalent to new. Replaced parts removed from the Equipment or

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

3



 

Informatics Hardware shall, at IM’s sole option, become the property of IM. All consumable items, including but not limited to wafers, vials, chemicals, are excluded from coverage hereunder.

 

(c)                                   IM shall not be responsible for maintenance and support services under the contract based on (i) damage caused by the Exclusions in Section 8.7 of the Agreement, (ii) adjustments, repairs or replacement parts required because of operator-caused error or repeated misuse of Equipment or Informatics Hardware; (iii) a non-conformity arising from or after relocation of the Equipment or Informatics Hardware without prior written approval of IM, which shall not be unreasonably withheld, unless Customer can demonstrate by clear and convincing evidence that the relocation did not cause the non-conformity, in whole or in part, or (iv) damages covered by Section 12.13 of the Agreement. All repairs required by such excluded damage will be subject to an additional charge, as agreed in advance in writing by IM and Customer.

 

B.                                     Informatics Software Support

 

During the Initial Maintenance and. Support Term and during any Renewal Term, IM shall use best commercial efforts to do the following:

 

(a)                                   IM shall maintain the Informatics Software in accordance with the warranty set forth in the Agreement. Customer shall provide VPN site to site Internet access to the data network located at the Site. Customer will fund the data circuits located in the Customer data center and IM will fund the data circuits located in its data center. Customer shall institute and document, prior to installation of the Informatics Hardware, and maintain thereafter, a reasonable firewall management policy to enable appropriate access and block unneeded access to the Informatics Software and Third Party Software installed on Informatics Hardware as needed to diagnose any problem or perform any services to be provided hereunder, subject to the provisions of Section 7.5 (IP Firewall) of the Agreement. The response times and procedures set forth above shall not apply for any error or problem if limits on IM’s access to the Informatics Software inhibit IM’s ability to conduct an initial assessment, make a diagnosis, provide an error resolution plan, and/or perform any services related to resolution of that error or problem.

 

(b)                                  Customer must include in each error-report information sufficient to enable IM to reproduce and verify the suspected error. Failure to supply this information may delay IM’s response. IM will acknowledge each reported error via telephone, facsimile transmission or electronic mail to the Named User reporting the ‘error within [*] of its original report, and will use commercially reasonable efforts consistent with the severity of the error to reproduce and verify reported errors and

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

4



 

provide Updates (including workarounds) in accordance with the terms set forth herein. Customer agrees to use commercially reasonable efforts to assist IM in its efforts to find corrections to confirmed errors.

 

(c)                                   IM is not required to support or maintain any version of the Software except its then-current, commercially released version. and the version that immediately preceded that version. For such immediately preceding software version, IM shall use commercially reasonable efforts to provide error-fixing updates, but shall have no obligation to provide upgrades that improve the functionality of that software version.

 

(d)                                  IM shall not be responsible for maintenance and support services under the contract based on (i) altered or modified Informatics Software, (ii) any combination of Informatics Software with other software or hardware not supplied pursuant to the Agreement, (iii) errors caused by Customer’s negligence or fault, (iv) software used with hardware other than Equipment or Informatics Hardware, and (v) errors in Third Party Software.

 

(e)                                   IM is not obligated to provide, free of charge services, additional services, outside of the range of normal support services, such as (1) debugging problems in non-IM-supported software or products, or in combinations of supported and non-supported software or products where the problem occurs in products or software not supplied by IM, and (2) other cases where IM reasonably judges it highly likely that the suspected problem is not its responsibility.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

5




Exhibit 10.7

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Modification to the Wets Workflow Purchase Agreement and Dry Workflow

Purchase Agreement

 

Advanced Technology Materials, Inc., with a principal place of business at 7 Commerce Drive, Danbury, CT 06810 (“ ATMI ”) , and Intermolecular, Inc., with a principal place of business at 2865 Zanker Road, San Jose, California 95134 (“ IM ”) entered into a Wets Workflow Purchase Agreement effective July 13, 2007, which was subsequently amended by an Addendum effective Dec. 21, 2007, then by an Amendment effective Dec. 16, 2008 and then by a Supplement effective Mar. 16, 2009 (collectively the “Wets Agreement’’). ATMI and IM also entered into a Dry Workflow Purchase Agreement effective December 16, 2008 (“Dry Agreement”).

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree to modify the terms of the Wets Agreement and the Dry Agreement (hereinafter “Modification”) as set forth below.

 

1.       Extension of exclusivity

 

1.1   In Section 4.1 of the Amendment, (i) the reference to [*] in the first paragraph is replaced with [*] and (ii) the last three paragraphs are deleted in their entirety.

1.2   The list of “Strategic Accounts” is hereby updated to include the accounts listed on Schedule A attached hereto.

1.3   The list of Strategic Fields is hereby updated to include the applications listed on Schedule B attached hereto.

1.4   In Section 4.2 of the Amendment, all instances of [*] are replaced by [*].

1.5   The following is added at the end of Section 4.2 of the Amendment- “Notwithstanding the foregoing. IM agrees not to ship a Wets Workflow or [*] to a Competitor prior to [*]”.

1.6   The following is added after the last sentence of Section 4.3 of the Amendment:

 

“If IM identifies an opportunity for IM and ATMI to work in a joint development program or if ATMI introduces IM to such an opportunity (“JDP’’) for an integrated device manufacturer (“IDM”) for which ATMI has relevant HPC resources and expertise available, IM and ATMI hereby agree to enter into good faith negotiations to agree on the revenue sharing arrangement (where such sharing shall be based on the parties’ respective resource contributions) between IM and ATMI pursuant to such JDP. Any such revenue sharing arrangement shall be detailed in a separate formal agreement (“Revenue Sharing Agreement”). It is further agreed that tor any such JDP, IM and ATMI shall, where feasible, define a joint sales and marketing plan.

 

2.       Strategic FTEs

 

2.1    In consideration for the payment identified in Section 2.2 below, IM shall commit [*] Strategic FTEs to provide services to ATMI from [*] through [*].

2.2    In consideration for the covenant in Section 2.1 above, ATMI shall pay IM at a [*] rate of [*] corresponding to each [*] in [*] and [*] (for a total payment of

 



 

[*]). ATMI shall issue a non cancellable purchase order for such payments no later than [*]. ATMI shall promptly pay IM [*] following its receipt of IM’s invoice tor such amount.

 

3.       HPC Site License Renewal

 

3.1   In consideration for the payments identified in Section 3.2 below, IM grants and ATMI accepts a 2 year extension of the HPC Site License, Informatics License and Maintenance tor the Workflow at each Site identified below. The term of extension for each Site shall start on the corresponding date identified in Column (I) below and end on the corresponding date identified in Column (2).

3.2   For each Site, in consideration for the covenants in Section 3.1 above, ATMI shall pay IM the corresponding amount identified in Column (3) below by [*] and the corresponding amount identified in Column (4) below by [*]. ATMI shall issue non-cancellable purchase orders to obtain such licenses and maintenance tor each Site as set .forth in the attached quotes:

 

Site #

 

Location

 

WF
Type

 

(1)
Start of
extension
term

 

(2)
End of
extension
term

 

(3) Amounts
payable by
[*]

 

(4) Amounts
payable by [*]

 

1

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

2

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

3

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

4

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

The Modification shall have an effective date of 8/27, 2010.                                                               (*plus tax)

 

All capitalized terms not defined herein shall have the meanings given them in the Wets Agreement or the Dry Agreement, as applicable. This Modification shall be deemed to be incorporated into each of the Wets Agreement and the Dry Agreement and made a part thereof. All references to the Wets Agreement or Dry Agreement in any other document shall be deemed to refer to the Wets Agreement or Dry Agreement, as applicable, as modified by this Modification. Except as modified by this Modification, all of the terms and conditions of the Wets Agreement and the Dry Agreement shall remain in full force and effect. In the event that the terms of this Modification conflict with the terms of the Wets Agreement and its schedules, as amended, or the Dry Agreement and its schedules, as amended, the terms of this Amendment shall control.

 

IN WITNESS WHEREOF, the parties hereto have executed this Modification as of the Effective Date.

 

Intermolecular, Inc.

 

Advanced Technology Materials, Inc.

 

 

 

 

 

By:

/s/David Lazovsky

 

By:

/s/Daniel P. Sharkey

 

 

 

 

 

Name:

David Lazovsky

 

Name:

Daniel P. Sharkey

 

 

 

 

 

Title:

President & CEO

 

Title:

EVP, Bus. Development

 

 

 

 

 

Date:

8/27/10

 

Date:

9/1/10

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2



 

SCHEDULE A

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

SCHEDULE B

 

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

4




Exhibit 10.8

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Amendment Number 5

to the

Wets Workflow Purchase Agreement and Dry Workflow Purchase Agreement

 

Advanced Technology Materials, Inc., with a principal place of business at 7 Commerce Drive, Danbury, CT 06810 (“ ATMI ”) , and Intermolecular, Inc., with a principal place of business at 3011 North First Street, San Jose, California 95134 (“IM”) entered into a Wets Workflow Purchase Agreement effective July 13, 2007, which was amended by an Addendum effective Dec. 21, 2007 (“Amendment Number 1”), and was amended by an Amendment effective Dec. 16, 2008 (“Amendment Number 2”), and was amended by a Supplement effective Mar. 16, 2009 (“Amendment Number 3”), and  was amended by a Modification effective Aug. 27, 2010 (“Amendment Number 4”) (collectively the “Wets Agreement”).

 

ATMI and IM also entered into an Alliance Agreement effective Nov. 17, 2006 (“Alliance Agreement”) and a Dry Workflow Purchase Agreement effective December 16, 2008 (“Dry Agreement”). The Wets Agreement, the Dry Agreement and the Alliance Agreement are hereinafter collectively referred to as Agreements.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree to modify the terms of the Wets Agreement and the Dry Agreement (hereinafter “Amendment Number 5”) as set forth below.

 

1.     Extension of exclusivity and Business Continuation. ATMI and IM agree as follows -

1.1     The date mentioned in Section 4.1 of Amendment Number 2 as modified by Amendment Number 4 (“Service Restrictions on IM”) will be extended by [*] to [*]. Such extension also applies to Section 4.3 (“Preferred Material Supplier”) of Amendment Number 2.

1.2     The dates mentioned in Section 4.2 of Amendment Number 2 as modified by Amendment Number 4 (“Workflow Restrictions on IM”) will be extended by [*] to [*] except for the date mentioned in Section 1.5 of Amendment Number 4 which shall be extended by [*] to [*].

1.3     ATMI and IM shall continue activities under the Agreements through the extended exclusivity terms. The elements of such business activities during the extended exclusivity terms shall be formalized no later than [*], and [*], respectively as it relates to exclusivity extension as of [*] and [*], respectively

 

This Amendment Number 5 shall have an effective date of March 3, 2011 (“Effective Date”)

 

All capitalized terms not defined herein shall have the meanings given them in the Wets Agreement or the Dry Agreement, as applicable. This Amendment Number 5 shall be deemed to be incorporated into each of the Wets Agreement and the Dry Agreement and made a part thereof. All references to the Wets Agreement or Dry Agreement in any other document shall be deemed to refer to the Wets Agreement or Dry Agreement, as applicable, as modified by this Amendment Number 5. Except as modified by this Amendment Number 5, all of the terms and conditions of the Wets Agreement and the Dry Agreement shall remain in full force and effect. In the event that the terms of this Amendment Number 5 conflict with the terms of the Wets Agreement and its

 

1



 

schedules, as amended, or the Dry Agreement and it schedules, as amended, the terms of this Amendment shall control.

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment Number 5 as of the Effective Date.

 

Intermolecular, Inc.

 

Advanced Technology Materials, Inc.

 

 

 

 

 

By:

/s/David Lazovsky

 

By:

/s/Daniel P. Sharkey

 

 

 

 

 

Name:

David Lazovsky

 

Name:

Daniel P. Sharkey

 

 

 

 

 

Title:

President & CEO

 

Title:

EVP, Business Development

 

 

 

 

 

Date:

3/4/11

 

Date:

3/3/11

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2




Exhibit 10.9

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

ADVANCED MEMORY DEVELOPMENT PROGRAM AGREEMENT

Elpida Memory, Inc. - Intermolecular, Inc.

 

This Advanced Memory Development Program Agreement (“ Agreement ”) is made as of May 22, 2008 (“ Effective Date ”) between Elpida Memory, Inc., a Japanese corporation operating at 2-1, Yaesu 2-chome, Chuo-ku, Tokyo 104-0028, Japan (“ Elpida ”), and Intermolecular, Inc., a Delaware corporation operating at 2865 Zanker Road, San Jose, California 95134 or designated Affiliate (“ Intermolecular ” or “ IM ”).  Elpida and IM are sometimes referred to herein individually as a “party” and collectively as the “parties”.

 

BACKGROUND

 

Whereas, IM and Elpida began working on a development program directed at a Dynamic Random Access Memory (“ DRAM ”) and [*] pursuant to the Demonstration Agreement executed by the parties on November 13, 2007 (“ Demonstration Agreement ”) and continued to work in these areas pursuant to the letter agreement executed by the parties on February 27, 2008 (“ Letter Agreement ”) while the parties negotiated this Agreement to define the terms and conditions for continued collaboration between the parties for the development of advanced memory solutions;

 

Whereas, the parties desire to engage in Collaborative Development Programs related to semiconductor memory products in the Field on the terms and conditions set forth below.

 

Now therefore, the parties agree as follows:

 

1.              DEFINITIONS

 

1.1           Affiliate ” shall mean any entity controlling, controlled by or under common control with, a party to this Agreement.  For purposes of this Agreement, the direct or indirect ownership of more than fifty percent (50%) of the outstanding securities of, or voting interest in, an entity shall be deemed to constitute control.

 

1.2           Background IP ” shall means all Intellectual Property Rights that are (i) owned, licensed or otherwise solely controlled by a party or its Affiliates as of November 13, 2007; or (ii) created, conceived or reduced to practice by a party’s or its Affiliates’ employees, contractors or agents without reliance upon, use of, or benefit of the other party’s or its Affiliate’s Background IP or Confidential Information.

 

1.3           CDP Developed Technology ” shall mean any Intellectual Property Rights developed pursuant to the Demonstration Agreement, Letter Agreement or an agreed upon Collaborative Development Program, including the Critical Parameter Set.

 

1.4           CDP Field ” shall mean [*] DRAM semiconductor integrated circuit memory chips.

 

1.5           Collaborative Development Program ” or “ CDP ” shall mean the Services that are conducted by Elpida and IM in accordance with a respective Development Plan.

 

1.6           Confidential Information ” shall mean any information disclosed by one party to the other in connection with this Agreement, whether in electronic, written, graphic, oral, machine readable or other tangible or intangible form, that is marked or identified at the time of disclosure as “confidential” or “proprietary” or in some other manner so as to clearly indicate its confidential nature.  The

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

1



 

deliverables provided by one party to another party under the CDP, and materials, extracts, notes, analyses, summaries or minutes between the parties from which the substance of confidential information can be inferred or otherwise understood, shall be considered Confidential Information of the disclosing party.  Except as specifically provided in Section 6 below, any terms and conditions of this Agreement shall constitute Confidential Information.

 

1.7           Critical Parameter Set ” or “ CPS ” shall mean a combination of the material, material stack, process conditions and process integration resulting from the Collaborative Development Program that meet or have the best chance to meet the specification defined by Elpida including reasonable variations and technical equivalents of the same.  The CPS shall be defined at the end of the Initial Term of the relevant CDP and supplemented at the end of any extended development periods between the parties.

 

1.8           Dry Workflow ” shall mean [*] tools using HPC Technology, including, but not limited to, [*] and [*].

 

1.9           Field ” shall mean technologies, methods and embodiments for materials, processes, apparatus, process integration, and device integration, or any combination thereof, used for the research, development, commercialization or manufacturing of integrated circuits.

 

1.10         FTE ” shall mean an employee or contractor assigned to a CDP based on approximately one hundred sixty-six hours of professional services performed by one person during a one month period, or the same number of hours in aggregate performed by two or more persons during a one month period.

 

1.11         HPC Technology ” shall mean all techniques, methodologies, processes, test vehicles, synthetic procedures, technology, systems, or combination thereof, without reference to any Elpida Confidential Information, used for the simultaneous, parallel, or rapid serial: (i) design, (ii) synthesis, (iii) processing, (iv) process sequencing, (v) process integration, (vi) device integration, (vii) analysis, or (viii) characterization of more than two (2) compounds, compositions, mixtures, processes, or synthesis conditions, or the structures derived from such on a single wafers.  It is understood that such test vehicles include physical and or electrical characterization devices such as test structures or chips, used in the design, process development, manufacturing process qualification, and manufacturing process control of integrated circuit devices, but do not include test wafers previously used in research and development using nominally uniform processing of a wafer.  It is also understood that HPC Technology does not include the use of commercially available equipment in commercial manufacturing for nominally uniform processing of one or more identical integrated circuits on a single substrate, or the use of such equipment in research and development for nominally uniform processing of one or more integrated circuits on a single substrate.  For the avoidance of doubt, HPC Technology does not include Intellectual Property Rights in and to Elpida Inventions and IM Inventions (defined in Section 3.3 below) or Background IP of Elpida.

 

1.12         Informatics Software ” shall mean the IM software platform enabling the operation of the Dry and Wet Workflows and the gathering and sharing of CDP related information through a web-based interface.

 

1.13         Initial Term ” shall mean the duration of the development program as set forth in Section 9.1.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2



 

1.14         Intellectual Property Rights ” shall mean all U.S. and foreign rights in and to all (a) patents and patent applications, including all divisions, substitutions, continuations, continuation-in-part applications, and reissues, re-examinations and extensions thereof, (b) copyrights and moral rights, (c) unpatented information, trade secrets, know-how, invention disclosures, engineering notebooks, confidential information, data, or materials, (d) mask work rights, and (e) any other intellectual or other proprietary rights of any kind now known or hereafter recognized in any jurisdiction.

 

1.15         Product ” shall mean a product containing one or more semiconductor integrated circuit memory chips manufactured by or for Elpida, an Elpida Affiliate or Third Party Licensee, including through contract manufacturers, utilizing the CDP Developed Technology, including all derivatives, modifications, improvements and enhancements thereof, or containing any device designs or architectures resulting from the CDP.  Product may be delivered to its customer in any form including without limitation, wafer form, packaged and unpackaged Products and further include any Products manufactured by Elpida or its Affiliate for providing foundry services to its customer.

 

1.16         Services ” shall mean services that IM and/or Elpida employees perform under a CDP pursuant to the mutually agreed upon Development Plan.

 

1.17         Third Party ” shall mean any person or entity other than Elpida and its Affiliates, IM and its Affiliates, and their permitted assigns.

 

1.18         Third Party Licensee ” shall mean an entity other than any Elpida Affiliate which is an integrated circuit manufacturer or designer to whom Elpida grants a license or sublicense in and to all or a portion of the CDP Developed Technology pursuant to Section 3.5.2.

 

1.19         Wet Workflows ” shall mean [*] tools using HPC Technology, including, but not limited to, [*] and [*].

 

2.              COLLABORATIVE DEVELOPMENT PROGRAM

 

2.1           Collaborative Development Program .  Subject to the terms and conditions set forth herein, Elpida and IM will conduct CDP(s) in accordance with an agreed upon written plan describing the Services to be conducted by each party and the target specification to be met through the Services (“ Development Plan ”).  The Development Plan for the DRAM CDP is attached hereto as Exhibit A-1 and is hereby incorporated into this Agreement.  The Service fees to support the FTE resources necessary to implement the Development Plan are set forth in the quote attached as Exhibit B and herein incorporated by reference.  A Development Plan may be revised from time to time by mutual written agreement of the parties.  Elpida agrees to pay the fees and royalties as set forth in Section 5 in accordance with the terms of this Agreement.

 

2.2           [*] CDP .  It is the present intent of the parties to [*] the CDP (in substantially the form set forth in Exhibit A-2) once Elpida [*] and [*] the necessary [*] related to the [*] of [*] so that [*] as between Elpida and IM can be governed by Section [*].  At the request of Elpida, Intermolecular agrees to [*] in any way consistent with the terms of this Agreement.  If Elpida is unable to [*] within [*] after the Effective Date and the parties cannot agree on [*] CDP within [*] of said [*] period, then the [*] CDP [*] to this Agreement and the work between Elpida and IM under this Agreement shall continue with respect to the DRAM CDP only and the [*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

3



 

quarterly fees beginning on [*] set forth in Exhibit B will be reduced by [*] per quarter for a total reduction of [*].  If the parties are able to [*] CDP to this Agreement, the parties will make the necessary changes to this Agreement, including, without limitation, the definition of CDP Field and [*] for [*].

 

2.3           Access to Information .  The parties acknowledge and agree that each party shall provide the other party timely and sufficient access to information necessary to carry out their obligations under all phases of the CDP.

 

2.4           Project Managers .  Each party shall by written notice to the other party appoint a principal point of contact to be its project manager for each CDP, who shall coordinate and act as a liaison with the other party with respect to the respective Development Plan (“ Project Manager ”).  A party may from time to time change its Project Manager upon written notice to the other party.

 

2.5           Elpida Engineers at IM .  IM shall provide space at IM’s facilities for up to [*] Elpida engineers.  Elpida shall notify IM at least [*] days in advance if Elpida desires to use such allotted space, such notification shall include the number of engineers and the anticipated duration of their stay at IM.

 

2.6           Development Records .  Elpida and IM shall maintain records of the CDP and related Services, or cause such records to be maintained, in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved in the performance of the Development Plan, including information sufficient to establish dates of conception and reduction to practice of inventions.

 

3.              IP OWNERSHIP AND LICENSES

 

3.1           Background IP .  Each party shall continue to own all of its own Background IP.

 

3.2           HPC Technology and Derivatives .  IM shall own all right, title and interest in and to HPC Technology and all HPC Technology improvements, derivatives and modifications developed by either party or both parties during the course of any CDP or based on IM provided tools, software or information enabling the use of HPC Technology (“HPC Derivatives”).  Elpida hereby assigns, and agrees to assign to IM in the future Intellectual Property Rights in and to HPC Derivatives when first fixed in a tangible medium or reduced to practice, as applicable.  For the avoidance of doubt, HPC Derivatives do not include Intellectual Property Rights in and to Elpida Inventions and IM Inventions (defined in Section 3.3 below).

 

3.3           CDP Developed Technology .

 

3.3.1        By Elpida .  Elpida will own all right, title and interest, including Intellectual Property Rights, in CDP Developed Technology that is a (a) [*], (b) [*] and (c) [*], and (d) [*] (collectively, “ Elpida Inventions ”), regardless of creator.  IM hereby assigns, and agrees to assign to Elpida in the future all of its right, title and interest, including Intellectual Property Rights, in and to any Elpida Inventions when any such Intellectual Property Rights are first fixed in a tangible medium or reduced to practice, as applicable.

 

3.3.2        By IM .  IM shall possess all right, title, and interest, including Intellectual Property Rights, in any CDP Developed Technology that is [*] (collectively, “ IM Inventions ”),

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

4



 

regardless of creator.  Elpida hereby assigns, and agrees to assign to IM in the future Intellectual Property Rights in and to any IM Inventions when any such Intellectual Property Rights are first fixed in a tangible medium or reduced to practice, as applicable.

 

3.3.3        Joint .  IM and Elpida shall jointly possess all right, title, and interest, including Intellectual Property Rights, in any CDP Developed Technology that is not determined in ownership through the application of Section 3.3.1 or 3.3.2.  Such CDP Developed Technology shall be [*] (collectively, “ Joint Inventions ”), regardless of creator, each party having equal ownership interest therein.

 

3.4           Cooperation .  Each party agrees to execute all papers, including patent applications and invention assignments, and otherwise agrees to assist the other party, as reasonably required and at the other party’s reasonable expense, to perfect in the other party the rights, title and other interests in their respective inventions owned by the other party under this Agreement.  In addition, each party agrees to notify the other party within a reasonable time when an invention disclosure is submitted by an employee or contractor of that party that may be owned by the other party under Sections 3.2 and/or 3.3 above.

 

3.5           Licenses to Elpida .  Subject to the terms and conditions of this Agreement, IM hereby grants Elpida, within the CDP Fields, a worldwide, exclusive (subject to any applicable provisions in Sections 3.9, 5.3 or elsewhere in this Agreement), royalty-bearing (subject to Section 5.3), nontransferable (subject to Section 10.2) license under and to IM Inventions and Joint Inventions and any Intellectual Property Rights therein and thereto (i) to use, make, have made, import, offer to sell, sell, lease and otherwise dispose of the Products, (ii) to modify or make derivatives of the CDP Developed Technology, and (iii) to exercise the limited sublicense rights as set forth in Sections 3.5.1 and 3.5.2 below.  For avoidance of doubt, this provision shall not be construed as limiting Elpida’s rights under applicable laws and regulations as the joint owner of the Joint Inventions, such as exercising any rights under patents and license them to third parties, but rather creating the exclusivity of the rights for Elpida under Joint Inventions as well as the exclusivity of the rights for Elpida under IM Inventions.

 

3.5.1        Elpida Affiliates .  Subject to the terms and conditions of this Agreement, Elpida shall have the right, but not the obligation, to grant sublicenses of part or all of IM Inventions and licenses to Elpida Inventions and any Intellectual Property Rights therein and thereto to Elpida Affiliates to use, make, have made, import, offer to sell, sell, lease and otherwise dispose of the Products subject to the same terms and obligations with respect to Elpida under this Agreement.

 

3.5.2        Elpida Third Party Licensees .  Subject to the terms and conditions of this Agreement, including the payment of royalties by Elpida on Third Party Products (in accordance with Section 5.3) and as long as Elpida maintains an exclusive license to the CDP Developed

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

5



 

Technology, Elpida shall have the right, but not the obligation, to grant sublicenses of part or all of IM Inventions and licenses to Elpida Inventions and any Intellectual Property Rights therein and thereto to Third Parties to use, make, have made, import, offer to sell, sell, lease and otherwise dispose of Third Party Products subject to the same use restrictions and confidentiality obligations with respect to Elpida under this Agreement.

 

3.5.3        Transition to Non-Exclusive License .  If Elpida does not maintain an exclusive license in accordance with Section 3.9, IM grants to Elpida, within the CDP Fields, a worldwide, non-exclusive, perpetual, non-transferable license under and to IM Inventions and any IM Intellectual Property Rights therein and thereto (i) to use, make, have made, import, offer to sell, sell, lease and otherwise dispose of the Products, (ii) to modify or make derivatives of the CDP Developed Technology, and (iii) to exercise the limited sublicense rights as set forth in Sections 3.5.1 above.  In such case, Elpida shall have the right to grant sublicenses of part or all of IM Inventions and any IM Intellectual Property Rights therein and thereto only to Third Parties who manufacture Products based on Elpida Background IP or Elpida Inventions in accordance with Section 3.5.2.  above.  In addition, if Elpida desires to grant sublicenses to all or part thereof to any other Third Party, the parties agree to discuss such arrangement, however, neither party is obligated to enter into an agreement regarding the same.

 

3.5.4        Non-Exclusive Joint IP License If Elpida does not maintain an exclusive license in accordance with Sections 3.9 or 5.3.1, Elpida and IM grants to the other a worldwide, non-exclusive, perpetual, non-transferable license, including sublicense rights, without restrictions under and to each party’s Intellectual Property Rights in Joint Inventions without any right of accounting.  If Elpida does not commercialize the CDP Developed Technology under this Agreement and Elpida sub-licenses Joint Inventions together with IM Inventions and any Intellectual Property Rights therein and thereto to a Third Party to make Products then the Royalty terms from Section 5.3 shall apply; however, the parties agree to negotiate in good faith, such agreement subject to their sole discretion, at the request of Elpida.  For avoidance of doubt, Elpida has no obligation under Section 5.3 in the case that Elpida only licenses Elpida Inventions and/or Joint Inventions and any Intellectual Property Rights therein and thereto without IM Inventions.

 

3.5.5        Limited License of Background IP .  IM agrees to grant Elpida a world-wide, non-exclusive and non-transferable license under and to IM Background IP, for which IM has the right to license without payment of a royalty to a Third Party, that is essential for Elpida, and its Affiliate and Third Party Licensees (pursuant to this Section 3.5) to exploit IM Inventions in Products in the CDP Field.

 

3.5.6        Outside the CDP Field .  If Elpida desires to apply the CDP Developed Technology outside of the CDP Field, Elpida shall notify IM in writing of its interest and the parties agree to negotiate promptly and in good faith any subsequent case-by-case agreements that enable Elpida to pursue such interests.

 

3.6           Enforcement .  IM shall promptly notify Elpida of its knowledge of any actual or potential, commercially material infringement by any Third Party of the Joint Inventions at any time, and IM Inventions while Elpida maintains an exclusive license under the Agreement.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

6



 

3.6.1        Exclusive License .  IM agrees and confirms that Elpida shall have the exclusive right, but not the obligation to enforce any Intellectual Property Rights in and to IM Inventions and Joint Inventions while Elpida maintains an exclusive license.  In this case, IM agrees not to challenge joinder of that party to the litigation.  Elpida may resolve any action or negotiation initiated by Elpida in its sole discretion, provided that any such resolution shall not include any stipulation or agreement that the applicable IM Intellectual Property Rights are invalid or non-existent except with IM’s prior express written consent, which consent may be given or withheld in IM’s sole discretion.  IM agrees to render such reasonable assistance in connection with enforcement activities described above as Elpida may request.  Unless otherwise agreed by the parties, Elpida shall be responsible for and shall pay the costs of maintaining any such action.

 

3.6.2        Non-exclusive License .  If at the time Elpida no longer maintains an exclusive license, either party, in it sole discretion may undertake an action against an infringing Third Party under Joint Inventions and the other party agrees not to challenge joinder in such an action involved Joint Inventions; provided, however, that such other party is not obligated to assist in such enforcement absent a court order.  Prior to bringing such an infringement action on Joint Invention, the parties agree to confer and determine whether a joint action or other approach is in their mutual agreement.  The preceding sentence does not limit either party’s ability to bring such an infringement action in its sole discretion.

 

3.6.3        Cost and Recovery Sharing .  Any damages and costs awarded or ongoing license revenue shall be subject to the Royalty obligations hereunder.

 

3.7           New Materials .  IM agrees to work with Elpida’s preferred materials providers to qualify and license any New Materials developed as part of the CDP.  “ New Materials ” shall mean materials developed pursuant to the Development Plan that are not available on the open market from Third Parties.

 

3.8           Reservation of Rights .  Except for the rights expressly granted by each party to the other under this Agreement, all other rights are reserved.

 

3.9           Exclusivity .

 

3.9.1        Continuing CDP Services .  As long as Elpida and IM are working together pursuant to this Agreement and any extension thereof in one of the CDP Fields, the license granted from IM to Elpida under Section 3.5 above will be exclusive for the CPS in that CDP Field for which Services are being performed.

 

3.9.2        CDP Services Terminated .  If Elpida and IM stop working together pursuant to this Agreement or any extensions thereof in one of the CDP Fields, the exclusivity under Section 3.9 for that CDP Field shall expire [*] from the termination of activity in the CDP Field (unless the program is terminated or cancelled by Elpida pursuant to Section 5.3 or Section 9.2, respectively, in which case the exclusivity shall expire immediately) unless Elpida has moved their Products into high volume  manufacturing, in which case the license will remain exclusive for the CPS in that CDP Field as long as Elpida meets the minimum quarterly volumes (“MQV”).  The MQV shall be [*] Products ([*] Products) shipped per quarter in the first full quarter following the termination of the activity in the CDP Field and shall include Elpida Products and Third Party Products for which a royalty is being paid.  If Elpida does not meet the MQV then the license under Section 3.5 above shall become a non-exclusive license pursuant to Section 3.5.3.  Notwithstanding the foregoing in this Section 3.9.2, in the event that Elpida has met MQV for at least [*] years and fails to meet MQV during a specific quarter in which case Elpida may make a

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

7



 

payment equal to the difference between Royalties owed on MQV and Royalties actually accrued (“ Gap Payment ”) during that quarter, Elpida may maintain its exclusivity during that quarter.  Elpida may exercise such rights for a period not to exceed [*].

 

3.9.3        Other Engagements .  Elpida acknowledges and agrees that nothing in this Agreement, except for the exclusivity provisions of this Section 3.9, restricts IM from engaging in development or commercialization projects with Third Parties.

 

4.              SUBSCRIPTION AND ACCESS FEE

 

4.1           HPC Workflow Subscription and Access Fee .  During the Initial Term and subject to payment by Elpida of a subscription and access fee as set forth in the quote in Exhibit B, IM will provide access, in conjunction with IM’s FTE resources and pursuant to the applicable Development Plan, to IM’s internal Dry Workflows, Wet Workflows, physical and electrical characterization capabilities, and Informatics Software (“ IM Tools and Software ”) to perform the CDP Services (“ HPC Workflow Subscription and Access Fee ”).  The HPC Workflow Subscription and Access Fee includes a non-transferable, worldwide license for Elpida to use HPC Technology and HPC Derivatives to the extent necessary for Elpida to carry out its obligations set forth in the Development Plan(s).  The HPC Workflow Subscription and Access Fee does not confer any ownership rights to Elpida in the IM Tools and Software.

 

4.2           Software License .  As part of the HPC Workflow Subscription and Access Fee, IM grants to Elpida a non-exclusive, non-transferable license to use the Informatics Software solely for the purposes of the CDP.  The Informatics Software can only be used by Elpida’s employees and is not assignable or licensable by Elpida to any Third Party.  The license granted hereunder includes all updates in content and the current functionality of the Informatics Software.  Except for the express license granted in this Section 4.2, IM reserves all rights to itself, and does not grant to Elpida any other licenses, whether express or implied, to the Informatics Software or any intellectual property rights embodied therein or related thereto.

 

4.2.1        Elpida acknowledges and agrees that the features or the graphical user interface of the Informatics Software (“ User Interface ”), including, without limitation, icons, menus and screen designs, screen layouts, and command and screen sequence, are proprietary to IM and/or its licensors, and are disclosed to Elpida under a condition of confidentiality.  Elpida agrees that it will not create software programs incorporating any proprietary part of the User Interface.  Elpida further acknowledges that the User Interface is a copyrighted work of IM and/or its licensors.

 

4.2.2        Elpida agrees (i) that no ownership rights to the Informatics Software are transferred under this Agreement; (ii) not to distribute, sublicense, assign, sell, rent or otherwise transfer the Informatics Software; (iii) not to copy, in whole or in part, the Informatics Software or any documentation related to the Informatics Software; (iv) not to modify, reverse compile or reverse assemble all or any portion of the Informatics Software; (v) not to use the Informatics Software outside the limitations of the license granted; and (vi) not to create any derivative works from or related to the Informatics Software.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

8



 

5.              PAYMENTS

 

5.1           CDP Fee Payment .  Elpida will pay IM based on the IM FTE resources allocated to the CDP in accordance with the mutually agreed upon Development Plan(s) attached as Exhibits A-1 and the quote attached as Exhibit B.  In addition to the amounts set forth in the attached quote, Elpida agrees to provide or pay for necessary travel of Elpida employees, consumables (such as wafers, mask sets, materials, and targets), outsourced metrology and characterization not supported internally by IM, and other mutually agreed out-of-pocket costs to support the CDP Services.

 

5.2           HPC Workflow Subscription and Access Fee .  Elpida will pay IM the HPC Workflow Subscription and Access Fee set forth in the quote attached as Exhibit B and described above in Section 4.1 unless Elpida cancels this Agreement by [*] pursuant to Section 9.2.

 

5.3           Royalties .  Elpida acknowledges and agrees that it will pay IM royalties for all Elpida Products and Third Party Products shipped (“ Royalties ”) except as otherwise set forth in this Section 5.3, whether those products are sold, leased or otherwise disposed of.  The parties agree to negotiate in good faith the Royalties by [*] (“ Royalty Determination Date ”) and set forth said agreed upon Royalties in Exhibit C, which shall be incorporated into this Agreement as if set forth as of the Effective Date.  If the parties reach agreement on the Royalties by the Royalty Determination Date, then the rest of this Section does not apply and Elpida does not need to make an election as set forth below.  If the parties are unable to reach agreement on the Royalties by the Royalty Determination Date, then Elpida may either i) pursue the buyout option set forth in Section 5.3.1 or ii) forfeit its license as set forth in Section 5.3.2.  Elpida shall make the decision to pursue the buyout option or forfeit its license by the Royalty Determination Date and shall inform IM pursuant to the notice provisions of this Agreement.  If Elpida does not inform IM of its decision by the Royalty Determination Date, then Elpida shall be deemed to have elected the forfeiture option under Section 5.3.2.

 

5.3.1        Buyout Option .  If Elpida and IM cannot reach agreement on the Royalties then Elpida may terminate the Agreement and maintain a perpetual, non-exclusive, royalty free license under and to IM Inventions and any IM Intellectual Property Rights therein and thereto (i) to use, make, have made, import, offer to sell, sell, lease and otherwise dispose of the Products, (ii) to modify or make derivatives of the CDP Developed Technology, and (iii) to sublicense the same to Elpida Affiliates or to Third Parties who manufacture Products based on Elpida Background IP or Elpida Inventions by paying IM the following amounts: a) the [*] and b) a one time up front, pre-paid royalty of [*] (“ Buyout Option ”).  The amounts set forth in the preceding sentence shall be paid by Elpida to IM within [*] days of the Royalty Determination Date.  If Elpida elects this Buyout Option then the IP Ownership terms of Section 3.3 shall be modified for Intellectual Property Rights conceived after the Royalty Determination Date so that as between the parties, (a) Intermolecular shall own Intellectual Property Rights first conceived after the term of the CDP by its employees or contractors, and (b) Elpida shall own Intellectual Property Rights first conceived after the term of the CDP by its employees or contractors.

 

5.3.2        Forfeit .  If the parties have not reached agreement on the Royalties and Elpida does not exercise its Buyout Option by the Royalty Determination Date, then this Agreement shall terminate and the license from IM to Elpida set forth Section 3.5 (and any other licenses set forth in this Agreement) shall terminate.  Within [*] days of such termination, Elpida shall return to IM or certify destruction of all Confidential Information provided to Elpida by IM or produced by Elpida based on CDP Developed Technology, except for Confidential Information incorporated in Elpida Inventions.  Under this option, Elpida will not receive a refund for the Service fees paid up to the Royalty Determination Date and must pay the remaining CDP Fees and the HPC Workflow Subscription and Access Fees due under this Agreement.  The full amount remaining in the CDP Fees and the HPC Workflow Subscription and Access Fees shall

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

9



 

be invoiced by IM upon such termination and Elpida shall pay the full amount to IM within [*] days of the invoice date.

 

5.4           Third Party Royalties .  Each party shall be responsible for all of its own costs of commercializing products or licensing Intellectual Property Rights, including any payments to Third Parties for work done by such Third Parties or for licenses necessary for the manufacture, sale, or use of Products by a party or its Affiliates or sub-licensees.

 

5.5           Payments .  IM shall invoice Elpida on the dates set forth in Exhibit B and Elpida shall pay IM within [*] days of such invoice unless the Agreement is terminated pursuant to Section 5.3, then the amounts shall be due as set forth in that Section.  [*]  All payments due to IM under this Agreement shall be made by bank wire transfer as follows:

 

Japan International Wire Transfer

U.S. Domestic Wire Transfer

To:

[*]

 

To:

[*]

 

 

[*]

 

 

 

 

 

[*]

 

 

 

 

Routing & Transit #:

[*]

Routing & Transit #:

[*]

Swift Code:

[*]

 

 

For credit of:

[*]

For credit of:

[*]

Credit account #:

[*]

Credit account #:

[*]

By order of:

[Name of Sender]

By order of:

[Name of Sender]

 

or another U.S. bank account designated by IM.  All payments not paid when due shall bear simple interest at a rate of [*] percent ([*]%) per month or the highest rate allowed by law, whichever is less.

 

5.6           Taxes .  The fees and royalty rates specified in this Agreement are exclusive of any sales, use, excise, value-added or similar taxes, and of any export and import duties, which may be levied upon or collectible by IM as a result of the CDP Services, or the licenses granted in this Agreement or its Exhibits.  Elpida agrees to pay and otherwise be fully responsible for any such taxes and duties, except that if necessary, Elpida shall withhold from amounts otherwise payable to IM, and pay on IM’s behalf, withholding taxes that may be required by applicable law to be withheld by Elpida and Elpida shall provide IM with tax receipts to establish that all such taxes have been paid and are otherwise available to IM for credit for U.S. income tax purposes or as otherwise available to IM.

 

5.7           Currency Conversions .  If any currency conversion shall be required in connection with the calculation of royalties hereunder, such conversion shall be made using the medium exchange rate of buying and selling exchange rates for conversion of the foreign currency into U.S. Dollars, quoted for current transactions reported in The Wall Street Journal for the last business day of the calendar quarter to which such payment pertains.

 

5.8           Records; Inspection .  Elpida shall keep complete, true and accurate books of account and records on its own behalf and on behalf of the Elpida Affiliates for the purpose of determining the royalty amounts payable under this Agreement.  Such books and records shall be kept at Elpida or its designated Affiliate for at least [*] years following the end of the calendar quarter to which they pertain.  Such records will be open for inspection during such [*] year period by an independent auditor who is reasonably acceptable to the parties and agrees to be bound to confidentiality protections of similar scope to those set out in Section 6 hereof, solely for the purpose of verifying royalty statements hereunder.  Such auditor shall be instructed to report only as to whether there is a discrepancy, and if so, the amount

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

10


 

of such discrepancy.  Such inspections may be made no more than once each calendar year, at reasonable times and on reasonable notice.  Inspections conducted under this Section shall be at the expense of IM, unless a variation or error producing an increase exceeding [*] percent ([*]%) of the royalties payable for any period covered by the inspection is established and confirmed in the course of any such inspection, whereupon all reasonable costs relating to the inspection for such period and any unpaid amounts that are discovered will be paid promptly by Elpida.  Further, IM will have the right thereafter to conduct additional inspections from time to time for reasonable cause.  Each party agrees to hold in confidence pursuant to Section 6 all information concerning royalty payments and reports, and all information learned in the course of any audit or inspection, except to the extent necessary for that party to reveal such information in order to enforce its rights under this Agreement or if disclosure is required by law.

 

6.                                       CONFIDENTIALITY

 

6.1            Confidentiality .  Except as otherwise expressly provided herein, the parties agree that the receiving party shall not, except as expressly provided in this Section 6, disclose to any Third Party, or use for any purpose, any Confidential Information furnished to it by the disclosing party pursuant to this Agreement, except in each case to the extent that it can be established by the receiving party by competent proof that such information:

(a)           was already known to the receiving party, other than under an obligation of confidentiality, at the time of disclosure;

(b)           was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving party;

(c)           became generally available to the public or otherwise part of the public domain after disclosure and other than through any act or omission of the receiving party in breach of this agreement;

(d)           was independently developed by the receiving party without use of, or reference to, the other party’s confidential information, as demonstrated by documented evidence prepared contemporaneously with such independent development; or

(e)           was disclosed to the receiving party, other than under an obligation of confidentiality, by a Third Party authorized and entitled to disclose such information to others.

 

6.2            Permitted Use and Disclosures .  Notwithstanding the restrictions of Section 6.1, each party hereto may (a) use Confidential Information disclosed to it by the other to the extent necessary for that party to perform its obligations set forth in the CDP and (b) use or disclose Confidential Information disclosed to it by the other party to the extent such use or disclosure is reasonably necessary in (i) exercising the rights and licenses granted hereunder, (ii) prosecuting or defending litigation, (iii) complying with applicable laws, governmental regulations or court orders or submitting information to tax or other governmental authorities (including the Securities and Exchange Commission), or (iv) preparing, filing and prosecuting patent applications; in each case, provided that if a party is required to make any such disclosure, other than pursuant to a confidentiality agreement, it will give reasonable advance notice to the other party of such disclosure and will use reasonable efforts to secure confidential treatment of such information (whether through protective order or otherwise), except to the extent inappropriate with respect to patent applications.  It is understood that either party may also disclose the Confidential Information of the other party upon receipt of the written consent to such disclosure by a duly authorized representative of the other party.

 

6.3            Nondisclosure of Terms .  Each of the parties hereto agrees not to disclose the terms of this Agreement to any Third Party without the prior written consent of the other party hereto, except to such party’s attorneys, accountants, advisors, investors and financing sources and their advisors and

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

11



 

others on a need to know basis under circumstances that reasonably ensure the confidentiality thereof, to the extent required by law, in connection with the enforcement of this Agreement or rights under this Agreement or in connection with a merger, acquisition, financing transaction or proposed merger, acquisition or financing transaction.

 

6.4            Firewall Protection .  In addition to conforming to the confidentiality provisions in this Section 6, the following shall apply:

 

6.4.1        IM will construct an IP firewall as described below in this Section around IM employees providing Services to Elpida in connection with CDP Services.  Only such employees of IM will be allowed to have access to such Elpida confidential and proprietary information and information distribution will be based strictly on a need-to-know basis.  Such employees of IM shall solely use such Elpida confidential and proprietary information in providing Services to Elpida.  Physical copies of Elpida confidential and proprietary information shall be securely locked when not in use such that only those IM employees providing such Services shall have access to such information.  The procedure set forth in this Section is not intended to supersede in whole or in part the terms of Section 3.2; specifically, IM shall have the right, without obligation to Elpida, to sell, license and sublicense any improvements, changes, or modifications to HPC Technology.

 

6.4.2        Elpida will construct an IP firewall as described below in this Section around Elpida employees who have access to IM’s facilities.  Elpida shall instruct its employees and agrees that they will remain in designated areas within IM’s facilities as defined by IM from time to time.  Elpida agrees that its employees will only use IM’s HPC Technology, including, the IM Tools and Software for the purpose defined in any applicable CDP.  Such employees of Elpida shall only disclose such IM confidential and proprietary information to other Elpida employees who have a need to know.

 

6.5            Residuals .  Notwithstanding anything herein to the contrary, neither party will be in breach of this Agreement or the MUTUAL NON-DISCLOSURE AGREEMENT executed between the parties as of August 15, 2007 based on the use of Residuals by employees or directors (who had authorized access) for any purpose, including without limitation use in development, manufacture, promotion, sale and maintenance of its products and services; provided that this right to Residuals does not represent a license under any valid patents, copyrights or other Intellectual Property Rights of the disclosing party.  The term “Residuals” means any information that is retained in the unaided memories of the receiving party’s employees who have had access to the disclosing party’s information pursuant to the terms of this Agreement.  An employee’s memory is unaided if the employee has not intentionally memorized the information for the purpose of retaining and subsequently using or disclosing it.  Nothing in this Section 6.5 is intended to or will modify the Royalty obligations of Elpida for Products.

 

7.                                       LIMITED REPRESENTATIONS AND WARRANTIES

 

7.1            By IM .  IM represents and warrants that: (a) it has the right and authority to enter into this Agreement, and to fully perform its obligations hereunder; (b) this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms; and (c) IM owns, or possesses a valid and enforceable license to use, and has full power and authority to license or sublicense, as the case may be, all IM’s Intellectual Property Rights licensed or sublicensed to Elpida pursuant to this Agreement, including, without limitation, HPC Technology and IM Inventions.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

12



 

7.2            By Elpida .  Elpida represents and warrants that: (a) it has the right and authority to enter into this Agreement, and to fully perform its obligations hereunder; and (b) this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms.

 

7.3            Disclaimer .  IM and Elpida specifically disclaim any representation, warranty or guarantee that the CDP or the use of HPC Technology will be successful, in whole or in part.  It is understood that the failure of the parties to successfully develop and commercialize the CDP Developed Technology in the course of the CDP or any technology developed through use of HPC Technology shall not constitute a breach of any representation or warranty or other obligation under this Agreement.  EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, ELPIDA AND INTERMOLECULAR MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO BACKGROUND IP, CDP DEVELOPED TECHNOLOGY, HPC TECHNOLOGY OR ANY INFORMATION DISCLOSED HEREUNDER, OR ANY DELIVERABLES PROVIDED HEREUNDER, AND HEREBY EXPRESSLY DISCLAIM ANY WARRANTIES OF MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE, OR VALIDITY OF ANY CDP DEVELOPED TECHNOLOGY OR HPC TECHNOLOGY, PATENTED OR UNPATENTED, OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

 

8.                                       LIMITATION OF LIABILITY

 

EXCEPT FOR A BREACH BY EITHER PARTY OF THEIR RESPECTIVE CONFIDENTIALITY OBLIGATIONS UNDER SECTION 6 OR A BREACH OF ANY LICENSE RESTRICTIONS, UNDER NO CIRCUMSTANCES WILL EITHER PARTY BE LIABLE TO THE OTHER UNDER ANY CONTRACT, STRICT LIABILITY, NEGLIGENCE OR OTHER LEGAL OR EQUITABLE THEORY, FOR ANY LOST PROFITS, LOST BUSINESS OPPORTUNITY, INJURY TO BUSINESS REPUTATION OR EQUIPMENT DOWNTIME, OR FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT OR SPECIAL DAMAGES OF ANY KIND IN CONNECTION WITH THE SUBJECT MATTER OF THIS AGREEMENT, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND IN NO EVENT WILL EITHER PARTY’S AGGREGATE LIABILITY TO THE OTHER EXCEED THE AMOUNTS PAID OR PAYABLE BY ELPIDA TO INTERMOLECULAR IN THE TWELVE (12) MONTHS PRECEDING THE CLAIM.

 

9.                                       TERMINATION

 

9.1            Term of Agreement .  The Initial Term of this Agreement shall be from the Effective Date until [*] and, unless terminated or canceled as provided in Section 5.3 or Section 9 of the Agreement, shall remain in full force and effect for the Initial Term and any extensions thereof agreed to in writing by mutual written agreement of the parties; provided that if the Agreement is not terminated prior to the end of the Initial Term, then irrespective of any expiration or termination of this CDP Agreement, other than termination by IM for cause, Elpida shall have the right to continue developing, manufacturing and having manufactured, distributing and selling current or future Elpida Products pursuant to the licenses and subject to the payment of the royalties set forth in this Agreement.  The parties agree that the terms of Section 3 (IP OWNERSHIP AND LICENSES) shall be retroactive to [*] and therefore, the terms of this Agreement shall define ownership of any Intellectual Property Rights developed pursuant to the Demonstration Agreement and the Letter Agreement.  The parties hereby agree that this Initial Term is not cancellable or terminable by either party except as set forth in Section 5.3, 9.2, 9.3 and 9.4 below.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

13



 

9.2            Elpida Cancellation Option .  Elpida may cancel this Agreement up to [*] in its sole discretion by providing notice to IM.  If Elpida does not cancel this Agreement by [*] then it shall continue according to the terms of this Agreement without right of cancellation during the Initial Term, including the full payment by Elpida of the amount set forth in Exhibit B.  If Elpida elects to cancel the Agreement pursuant to this Section then i) Elpida shall not be required to make any payment to IM including without limitation, any fee for Services performed hereunder and any HPC Workflow Subscription and Access Fee (except the amounts and obligations set forth in the Letter Agreement), and ii) the license from IM to Elpida set forth Section 3.5 (and any other licenses set forth in this Agreement) shall terminate and Elpida shall return to IM or certify destruction of all Confidential Information provided to Elpida by IM or produced by Elpida based on CDP Developed Technology, except for Confidential Information incorporated in Elpida Inventions.

 

9.3            Termination for Breach .  Either party to this Agreement may terminate this Agreement in the event the other party shall have materially breached or defaulted in the performance of any of its material obligations hereunder, and such default shall have continued for [*] days after written notice thereof was provided to the breaching party by the non-breaching party.  Any termination shall become effective at the end of such [*] day period unless the breaching party (or any other party on its behalf) has cured any such breach or default prior to the expiration of the [*] day period.

 

9.4            Termination for Insolvency .  If voluntary or involuntary proceedings by or against a party are instituted in bankruptcy under any insolvency law, or a receiver or custodian is appointed for such party, or proceedings are instituted by or against such party for corporate reorganization, dissolution, liquidation or winding-up of such party, which proceedings, if involuntary, shall not have been dismissed within [*] days after the date of filing, or if such party makes an assignment for the benefit of creditors, or substantially all of the assets of such party are seized or attached and not released within [*] days thereafter, the other party may immediately terminate this Agreement effective upon notice of such termination.

 

9.5            Effect of Termination .

 

9.5.1        Accrued Rights and Obligations .  Termination of this Agreement for any reason shall not release either party hereto from any liability or obligation that, at the time of such termination, has already accrued to the other party or that is attributable to a period prior to such termination, nor shall it preclude either party from pursuing any rights and  remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement., except as set forth in Section 9.2.

 

9.5.2        Return of Confidential Information .  Upon any termination of this Agreement, IM and Elpida shall promptly destroy or return to the other all Confidential Information received from the other party other than as required to enforce or defend any continuing or surviving rights and obligations under this Agreement.

 

9.6            Survival .  If this Agreement terminates for any reason, then Sections 2.6, 3, 5, 6, 7, 8, 9, and 10 of this Agreement shall survive, except that Section 3.5, 3.6, 3.8, and 3.9 shall not survive if the agreement is terminated according to Section 5.3 or cancelled pursuant to Section 9.2.

 

10.                                MISCELLANEOUS

 

10.1         Governing Laws and Dispute Resolution .  This Agreement shall be governed by and construed in accordance with the laws of the state of New York in the United States, without regard to its

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

14



 

choice of law rules.  All disputes between the parties in connection with or arising out of this Agreement shall first be discussed in good faith between the parties in order to try to find an amicable solution.  If no solution can be found to settle the dispute, then such dispute shall be finally settled by arbitration in accordance with the default rules and procedures of American Arbitration Association sitting in Hawaii and conducted in English.  Within [*] days of notice that a party wants to submit a dispute to arbitration, the parties shall each select one independent arbitrator and will attempt to mutually agree upon a third independent arbitrator each arbitrator will have expertise in the semiconductor industry and will not be an employee, affiliate or contractor for either party.  If the Parties are unable to agree on the third arbitrator within [*] days, the two arbitrators shall select the third arbitrator within [*] days.  If the amount in dispute is less than [*], then the parties shall agree upon a single arbitrator meeting the above conditions within [*] days of the notice of arbitration or such arbitrator shall be chosen by AAA if the parties cannot agree.  The arbitrators shall determine what discovery will be permitted consistent with the goal of limiting the costs and time for such a proceeding.  The parties and arbitrators shall use all reasonable efforts to complete any arbitration subject to this Section within [*] months from the selection of arbitrators.  The parties agree that any award of damages shall not include punitive, special, consequential, or indirect damages except as specifically allowed in this Agreement and shall comply with the limitation of liability provisions set forth herein.  The arbitrators’ decision shall be in a detailed writing setting forth the reasons for their decision and shall be provided concurrently to each party.  The arbitration award shall be final and binding on the Parties.  Unless otherwise agreed to by the parties, each party shall pay one-half of the arbitration fees and expenses and shall bear all of its own expenses in connection with the arbitration.  Notwithstanding any of the foregoing, either party shall have the right to seek, at its own cost and expenses, preliminary and temporary injunctive relief pending resolution of the dispute via arbitration.  The parties expressly disclaim the application of the United Nations Convention on the International Sale of Goods to this Agreement.

 

10.2         Assignment .  Neither party shall assign or transfer this Agreement either voluntarily or by operation of law, in whole or in part, without the prior written consent of the other party, and any attempt to do so will be null and void; provided, however, that either party may assign this Agreement without such consent, to a parent, subsidiary, or Affiliate, or to a successor in interest to its business (whether by merger, acquisition, consolidation, change of control, reorganization or sale of substantially all of its assets).  Subject to the foregoing sentence, this Agreement will be binding on and inure to the benefit of the parties and their respective successors and permitted assigns.

 

10.3         Drafting .  In interpreting and applying the terms and provisions of this Agreement, the parties agree that no presumption shall exist or be implied against the party that drafted such terms and provisions.

 

10.4         Waiver .  It is agreed that no waiver by either party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed a waiver or an expectation of non-enforcement as to any subsequent and/or similar breach or default.

 

10.5         Non-Solicitation .  During the Term of this Agreement neither IM nor Elpida will individually, or in concert with or through any other person, actively recruit or solicit employment of any scientific or technical personnel of the other party.  The foregoing restriction shall not apply to, or be breached by: (i) advertising open positions, participating in job fairs, and conducting comparable activities to recruit skilled or unskilled help from the general public, or responding to individuals contacted through such methods, (ii) responding to unsolicited inquiries about employment opportunities or possibilities from job placement agencies or other agents acting for unidentified principals, or (iii) responding to unsolicited inquiries about employment opportunities from any individual.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

15



 

10.6         Severability .  In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect to the fullest extent permitted by law without said provision, and the parties shall amend the Agreement to the extent feasible to lawfully include the substance of the excluded term to as fully as possible realize the intent of the parties and their commercial bargain.

 

10.7         Independent Contractors .  The relationship of the parties hereto is that of independent contractors.  Each party shall not be deemed to be an agent, partner, joint venture or legal representative of the other for any purpose as a result of this Agreement or the transactions contemplated thereby.

 

10.8         No Press Releases or Public Statements .  Neither party shall issue any press release or otherwise make any public statement regarding the existence or terms and conditions of this Agreement or the business between the parties, nor use the other party’s name in any advertising or promotional materials or publication or public statement of any kind, without such other party’s prior written consent given in such party’s sole and absolute discretion.

 

10.9         Compliance with Law .  In exercising their rights under the license granted hereunder, each party shall fully comply in all material respects with the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this Agreement.  Without limiting the foregoing, each party agrees to comply with all applicable export and re-export control laws and regulations maintained by the United States or Japanese governments.

 

10.10       Notices .  All notices, requests and other communications hereunder shall be in writing and shall be hand delivered, or sent by express delivery service with confirmation of receipt, or sent by registered or certified mail, return receipt requested, postage prepaid, or by electronic transmission (with written confirmation copy by registered first-class mail), in each case to the attention of the chief legal officer at the respective address indicated above.  Any such notice shall be deemed to have been given when received.  Either party may change its address by giving the other party written notice, delivered in accordance with this Section.

 

10.11       Force Majeure .  Neither party shall lose any rights hereunder or be liable to the other party for damages or losses (except for payment obligations then owing) on account of failure of performance by the defaulting party if the failure is occasioned by war, strike, fire, earthquake, flood, lockout, embargo, act of terrorism, governmental acts, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence, intentional conduct or misconduct of the non-performing party and such party has exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a party be required to settle any labor dispute or disturbance.

 

10.12       Headings; Construction .  The captions to the several Sections hereof are not part of this Agreement, but are included merely for convenience of reference and shall not affect its meaning or interpretation.  As used in this Agreement, the word “including” means “including without limitation.”

 

10.13       Counterparts .  This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to he one and the same agreement.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

16



 

10.14       Complete Agreement .  This Agreement, together with its Exhibits and their attachments, constitutes the entire agreement, both written and oral, between the parties with respect to the subject matter hereof, and all prior agreements respecting the subject matter hereof (including without limitation the Demonstration Agreement between the parties dated November 13, 2007 and the letter agreement between the parties dated February 27, 2008), either written or oral, express or implied, shall be abrogated, canceled, and are null and void and of no effect.  No amendment or change hereof or addition hereto shall be effective or binding on either of the parties hereto unless reduced to writing and executed by the respective duly authorized representatives of Elpida and IM.  The parties further agree that any additional or inconsistent terms and conditions of any purchase order, invoice or like document issued in connection with this Agreement shall be superseded in full by the terms and conditions of this Agreement and any Exhibit hereunder, and any such additional or inconsistent terms, unless specifically agreed to in writing by the parties at the time, are hereby rejected.

 

10.15       Third Party Beneficiaries .  Except as expressly provided in this Agreement, there are no third party beneficiaries expressly or impliedly intended under this Agreement.

 

In Witness Whereof, the parties hereto have executed this document as the last date set forth below.

 

Elpida Memory, Inc.

Intermolecular, Inc.

 

 

By:

/s/ Takao Adachi

 

By:

/s/ David Lazovsky

 

 

 

 

 

Name: Takao Adachi

Name: David Lazovsky

 

 

Title: Director & CTO

Title: President & CEO

 

 

Date: 22.May.2008

Date: 5/17/08

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

17



 

Exhibit A·1: [*] Project Phase 2

 

Project Manager: Imran Hashim/Sandra Malhotra

 

 

 

Step

 

Client
Deliverables

 

Activity

 

IM
Deliverables

 

Completion
Date

1

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

2

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

3

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

4

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

5

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

6

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

7

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

8

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

9

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

10

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

11

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

12

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

13

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

14

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

15

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

16

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

 

Exhibit B

INTERMOLECULAR

CDP Services Subscription Quotation

 

Description

 

Qty.

 

Price

Collaborative Development Program Service Fee

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

 

HPC Workflow Subscription and Access Fee

 

 

 

[*]

[*]

 

[*]

 

[*]

[*]

 

 

 

 

[*]

 

[*]

 

 

[*]

 

 

 

 

[*]

 

[*]

 

 

[*]

 

 

 

 

[*]

 

[*]

 

 

[*]

 

 

 

 

[*]

 

[*]

 

 

[*]

 

 

 

 

[*]

 

[*]

 

 

[*]

 

 

 

 

[*]

 

[*]

 

 

[*]

 

 

 

 

[*]

 

[*]

 

 

[*]

 

 

 

 

[*]

 

[*]

 

 

[*]

 

 

 

 

 

 

Program Total

 

[*]

 

[*]

 

Payment terms :

 

[*]

 

Payment date

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

Payment Amount

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

Exhibit C - Royalty Terms

 

Elpida will pay IM Royalties for all Elpida Products and Third Party Products shipped by or for Elpida, Elpida Affiliates or licensed Third Parties according to the following Royalty schedule:

 

Elpida DRAM Units

 

0 to X Million Units

 

X to Y Million Units

 

Y to Z Million Units

Royalty Rate ([*] Per Chip)

 

[*]A

 

[*]B

 

[*]C

 

 

[The step-down Royalty structure including units (X, Y and Z) and Royalty rate of [*] _ per chip (A, B and C above) will be mutually agreed by Elpida and IM by September 1, 2008 per the Agreement.]

 

The parties agree to include a cap that resets annually (with no cumulative life-time cap) on Royalties on Elpida and Elpida Affiliate Products (“Elpida Royalty Cap”).  The Elpida Royalty Cap amount shall be determined quarterly based on the prorated portion of the greater of a) [*] of Elpida’s combined total revenue for the previous [*], or b) [*] per year.  For example, if the combined prior [*] revenue was [*], then the pro-rated portion of [*] would be [*] compared to the pro-rated portion of [*] which would be [*], so the cap for that quarter is [*].  For avoidance of doubt, the Elpida Royalty Cap does not apply to Elpida Royalties paid to IM for Third Party Products.

 

[The terms and conditions for payment and calculation of Royalties will be discussed between Elpida and IM together with those for Royalty structure.]

 

No later than [*] days after the end of each Elpida fiscal quarter, Elpida will issue IM a written report containing the number of royalty bearing products shipped by Elpida, all applicable Elpida Affiliates, and any licensed Third Parties during such quarter and the corresponding royalty amount to be paid to IM.  Elpida will make all royalty payments within [*] days after the date of such report.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 


 

EXHIBIT C - ROYALTY TERMS

 

Elpida will pay IM Royalties for all Elpida Products and Third Party Products shipped by or for Elpida, Elpida Affiliates or licensed Third Parties according to the following Royalty schedule:

 

[*] Chips

 

[*]Units

 

[*]Units

 

[*]Units

Royalty Rate (% of Revenue)

 

[*]

 

[*]

 

[*]

 

The Royalty Rate shall be applied to Elpida, Elpida Affiliate, [*] or other Third Party “Revenue” which shall be defined as gross sales proceeds to arm’s length third party of Elpida, Elpida Affiliates, [*] (and its Affiliates) and [*] (and its Affiliates) and other Third Party (and its Affiliates) on Products (including any in-kind or other consideration), less (i) sales, excise and similar taxes (including but not limited to any value added tax) or duties; (ii) insurance, handling, shipping, and transportation; (iii) credits or repayment for rejection or return of Products when separately itemized on or included and identifiable in invoices or other documentation related to the sale of the Product; and (iv) trade or quantity discounts for sale of the Products.  IM Royalties shall only be payable once in the chain of the distribution of Products, and Elpida has no obligation to pay IM Royalty more than once on a single Product.  In this Exhibit C, “Affiliates” shall mean any entity controlling, controlled by or under common control with, Elpida, [*] and other Third Party, respectively, provided that, the direct or indirect ownership of more than [*] percent ([*]%) of the outstanding securities of, or voting interest in, an entity shall be deemed to constitute control.  Any capitalized terms in this Exhibit C shall have the meaning set forth in the Agreement unless otherwise defined herein.

 

The parties agree that the Royalty payable by Elpida to IM shall be capped at [*] per year for Elpida Products, Elpida Affiliate Products, [*] Products, and [*] Products (“ Elpida and QP Cap ”).  In this paragraph, [*] and [*] shall include their respective Affiliates.  The Elpida and QP Cap shall reset annually and shall not have any cumulative life-time cap.  The Elpida and QP Cap shall be determined annually based on the US calendar year.  Elpida shall be responsible for the payment of the Royalties for the above companies.  The Elpida and QP Cap does not apply to Royalties due from Elpida to IM for Third Party Products sold under license from Elpida other than for the companies specifically mentioned above.

 

Elpida agrees to pay IM a pre-paid Royalty in the amount of [*] (“ Pre-Paid Royalty ”) on [*].  The Pre-Paid Royalty shall be applied against the Royalties owed by Elpida to IM on a dollar for dollar basis (calculated quarterly) until the Royalties owed by Elpida exceed the Pre-Paid Royalty.  Once the Royalties due from Elpida to IM are in excess of the Pre-Paid Royalty, the remaining Royalties due shall be paid as set forth in this Exhibit C and the Agreement.  If Elpida does not put the CDP Developed Technology into production at the [*] node or other node as separately agreed by the parties (“Target Node”) and provides written notice that they do not intend to use the CDP Developed Technology at the Target Node, IM agrees to refund the entire Pre-Paid Royalty within [*] days of Elpida first shipping of the products using Target Node for which no Royalty is due.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

1



 

No later than [*] days after the end of each Elpida fiscal quarter, Elpida will issue IM a written report containing the number of Royalty bearing Products shipped by Elpida, Elpida Affiliates, [*] and any other Third Party Licensees during such quarter and the corresponding royalty amount to be paid to IM.  Elpida will make all royalty payments within [*] days after the date of such report.

 

Under the terms of Section 5.3 of the Advanced Memory Development Agreement between Elpida and IM having an effective date of May 22, 2008 (“ Agreement ”), the parties hereby incorporate this Exhibit C into the Agreement by executing this document on the last date set forth below.

 

Elpida Memory, Inc.

Intermolecular, Inc.

 

 

By:

/s/ Takao Adachi

 

By:

/s/ David Lazovsky

 

 

 

 

 

Name:

Takao Adachi

 

Name:

David Lazovsky

 

 

 

 

 

Title:

CTO

 

Title:

President and CEO

 

 

 

 

 

Date:

Aug.18.2008

 

Date:

8/18/08

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2



 

SUPPLEMENTAL JOINT DEVELOPMENT AGREEMENT
E
LPIDA MEMORY, INC. - INTERMOLECULAR, INC.

 

This Supplemental Joint Development Agreement (“ Supplemental Agreement ”) is made as of January 27, 2009 (“ Effective Date ”) between Elpida Memory, Inc., a Japanese corporation operating at 2-1, Yaesu 2-chome, Chuo-ku, Tokyo 104-0028, Japan (“ Elpida ”), and Intermolecular, Inc., a Delaware corporation operating at 2865 Zanker Road, San Jose, California 95134 or designated Affiliate (“ Intermolecular ” or “ IM ”).  Elpida and IM are sometimes referred to herein individually as a “party” and collectively as the “parties”.

BACKGROUND

 

IM and Elpida continue to work together pursuant to the Advanced Memory Development Program Agreement executed by the parties on May 22, 2008 and Exhibit C - Royalty Terms executed by the parties on August 18, 2008 (collectively the “ Advanced Memory Agreement ”) on solutions for next generation Dynamic Random Access Memory (“ DRAM ”).  IM and Elpida desire to continue working together for the development of advanced process integration solutions and wish to enter into this Supplemental Agreement to define the terms and conditions for such continued collaboration between the parties.

 

Now therefore, the parties agree as follows:

 

TERMS AND CONDITIONS

 

1.0                      Term .  This Supplemental Agreement shall extend the Initial Term from [*] until [*] (“ Supplemental Term ”).  The Supplemental Term shall be non-cancellable or terminable except for termination under Section 9.3 or 9.4 of the Advanced Memory Agreement.

 

2.0                      Operating Committee IM and Elpida shall establish an operating committee to determine the scope of work conducted by the parties during the Initial Term, Supplemental Term and any extensions thereof; the resources assigned (including the allocation of the IM FTEs); and the priority of each project if multiple projects overlap in time (“Operating Committee”).  The Operating Committee shall consist of an executive member from each party and at least one senior technical manager.  Each party will provide the other written notice of the members of the Operating Committee for that party and shall likewise notify the other party of any change in its assigned members.  The Operating Committee expects to meet at least on a quarterly basis, or as otherwise agreed by the parties, at locations agreed by the parties with the first meeting approximately one (1) month after execution of this Supplemental Agreement.  Operating Committee members may participate in any meeting in person, by telephone, teleconference or any other means of two-way communication mutually acceptable to the parties.  IM will prepare minutes of each Operating Committee meeting, which minutes will be reviewed and approved by the executive member of each party.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

1



 

3.0                      Development Plan .  For each project agreed upon by the Operating Committee, the parties will create a written Development Plan setting forth the CDP Field, target specification, and scope of work.  Each new Development plan will be signed by the parties, incorporated into this Supplemental Agreement, and attached hereto as Exhibits A-2, A-3, et seq .  Upon the conclusion of the activities in each Development Plan, the parties will set forth the CPS, if any.

 

4.0                      Fees .  The fees for the work to be performed by IM during the Supplemental Term are set forth in the supplemental Quote, attached hereto as Exhibit D and incorporated herein by reference.  These fees cover all IM FTEs and access to IM’s Tools and Software as set forth in the Advanced Memory Agreement.  Elpida agrees to pay the fees set forth in Exhibit Don the schedule set forth therein.  Nothing in this Supplemental Agreement changes the existing payment obligations in the Quote attached as Exhibit B to the Advanced Memory Agreement.

 

5.0                      Intellectual Property and Licenses The parties acknowledge and agree that the IP ownership and license terms set forth in Article 3 of the Advanced Memory Agreement shall remain unchanged.

 

6.0       Royalty The royalty terms set forth in Exhibit C to the Advanced Memory Agreement shall be amended in accordance with the following terms as provided in this Section 6.0.

 

For the calendar years [*], and [*], Elpida agrees to pay IM the Royalties according to the following Royalty schedule replacing the Royalty Rate as provided in Exhibit C, provided that no Royalty payments will be due from Elpida during any calendar year in which Elpida or a Third Party Licensee does not ship Products.  The fixed amounts for years [*] and [*]shall be due within thirty (30) days of the first quarterly report showing the shipment of the Products.

 

Calendar Year

 

Royalty per Year

[*]

 

[*]

[*]

 

[*]

[*]

 

[*]

 

The [*] Royalty due shall be either [*] or [*] (i.e., the amounts are not cumulative for [*]) depending on the date of first shipment of a Product in that year.  For the calendar years [*]and beyond, Elpida will pay IM Royalties according to the Royalty schedule set forth in Exhibit C of the Advanced Memory Agreement.

 

The Elpida and [*] Cap shall be amended so that the Royalty payable by Elpida to IM shall be capped at [*] in [*] and [*] per year in [*].  Otherwise, the Elpida and [*] Cap shall remain unchanged.

 

In addition, Elpida will be relieved from the obligation to make the Pre-Paid Royalty and the terms and conditions related thereto shall be null and void.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2



 

Except as amended hereinabove, the terms of Exhibit C shall remain in full force and effect.

 

7.0                      Definitions .  All capitalized terms not defined herein shall have the meaning set forth in the Advanced Memory Agreement.

 

8.0                      Precedence .  The terms and conditions of the Advanced Memory Agreement shall govern activities between the parties conducted under this Supplemental Agreement even if such Sections are not specifically referenced below; however, in the event of a conflict between the two agreements, the terms and conditions of this Supplemental Agreement shall govern work outside of the DRAM CDP Field set forth in the Advanced Memory Agreement.

 

In Witness Whereof, the parties hereto have executed this document as the last date set forth below.

 

Elpida Memory, Inc.

Intermolecular, Inc.

 

 

By:

/s/ Hideki Gomi

 

By:

/s/ Peter Eidelman

 

 

 

 

 

Name:

Hideki Gomi

 

Name:

Peter Eidelman

 

 

 

 

 

Title:

Director & CTO

 

Title:

CFO

 

 

 

 

 

Date:

February 6, 2009

 

Date:

January 27, 2009

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

3



 

Description

 

Qty.

 

Price

 

 

 

 

 

Collaborative Development Program Service Fee

 

 

 

 

[*]

 

[*]

 

[*]

 

 

 

 

included in program

HPC Workflow Subscription and Access Fee

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

 

 

 

 

 

 

[*]

 

[*]

 

 

 

 

 

 

 

[*]

 

[*]

 

 

 

 

 

 

 

[*]

 

[*]

 

 

 

 

 

 

 

[*]

 

[*]

 

 

 

 

 

 

 

[*]

 

[*]

 

 

 

 

 

 

 

[*]

 

[*]

 

 

 

 

 

 

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

Program Total

 

[*]

 

[*]

Payment terms :

[*]

Payment date

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

Payment Amount

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

AMENDMENT TO SUPPLEMENTAL JOINT DEVELOPMENT AGREEMENT
Elpida Memory, Inc. — Intermolecular, Inc.

 

This Amendment to Supplemental Joint Development Agreement (“ Amendment ”) is made as of May 25, 2009 (“ Effective Date ”) between Elpida Memory, Inc., a Japanese corporation operating at 2-1, Yaesu 2-chome, Chuo-ku, Tokyo 104-0028, Japan (“ Elpida ”), and Intermolecular, Inc., a Delaware corporation operating at 2865 Zanker Road, San Jose, California 95134 or designated Affiliate (“ Intermolecular ” or “ IM ”). Elpida and IM are sometimes referred to herein individually as a “party” and collectively as the “parties”.

 

BACKGROUND

 

IM and Elpida continue to work together pursuant to the Advanced Memory Development Program Agreement executed by the parties on May 22, 2008, Exhibit C — Royalty Terms executed by the parties on August 18, 2008, and the Supplemental Joint Development Agreement executed effective on January 27, 2009 (collectively the “ Advanced Memory Agreements ”) on solutions for next generation Dynamic Random Access Memory (“ DRAM ”). IM and Elpida desire to continue working together for the development of advanced process integration solutions, expand the technical scope, and engage in a more open collaboration. All capitalized terms not defined herein shall have the meaning set forth in the Advanced Memory Agreements.

 

Now therefore, the parties agree as follows:

 

AMENDED TERMS

 

1.0                                Additional Scope under CDP.   The parties acknowledge and agree to work together to improve the [*] Technology ”) by evaluating, among other things, precursor selection, process tuning, and/or stack improvements as agreed by the parties in the Development Plan as a part of CDP during the Supplemental Term.

 

2.0                                Royalty .  In place of the royalty terms set forth in the Advanced Memory Agreements, if Elpida manufactures and ships Products using [*] Technology (“[*] Products ”), Elpida will pay the fixed Royalty according to the following tables:

 

(1)                                   in the case where a [*] Product is first shipped in [*] or before:

 

Calendar Year

 

Royalty per Year

[*]

 

[*]

[*]

 

[*]

[*]

 

[*]

 

(2)                                   in the case where a [*] Product is first shipped in a year on or after [*], Elpida will pay a fixed annual Royalty of [*] for [*] years.

 

In each case of i) or ii) above, the Royalty obligation of Elpida hereunder and under the Advanced Memory Agreements shall last for [*] years from the date of first shipment of a [*] Product in which Elpida ships Products using the [*] Technology (“ Royalty Clock ”).

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2



 

The royalty terms between the parties shall remain as set forth in Section 6.0 of the Supplemental Agreement for the other collaborative development activities between the parties. For the avoidance of doubt, the fixed amounts set forth above will be included in the calculation of the annual royalty cap of Section 6.0 of the Supplemental Agreement and shall not be incremental to such cap.

 

3.0                                Future Collaboration for [*] .   Elpida and Intermolecular further agree to continue working on improving the [*] Technology for [*] and future DRAM nodes in conjunction with other applicable Development Plans (“Improved [*] Technology”). If Elpida manufactures and ships Products using such Improved [*] Technology, Elpida agrees to extend the Supplemental Term for a period of [*] months (e.g., from [*] until [*]) during which the amount of the non cancellable fees for those additional Services performed by IM is [*]. Elpida will make payment for such fees in accordance with the payment terms as separately agreed by the parties. For each node in which Elpida utilizes an Improved [*] Technology, the [*] Royalty Clock shall restart and Elpida agrees to pay Intermolecular a fixed royalty payment of [*] per year for up to [*] years in which it ships Products using the [*] Technology. In case Elpida manufactures and ships multiple nodes of the Products using any [*] Technology in the same calendar year, the fixed Royalty for each node will not be cumulative and the amount of the fixed Royalty will in no event exceed [*] for each calendar year during the [*] Royalty Clock.

 

4.0                                IP Ownership.   Section 3.3.2 of the Advanced Memory Agreement shall be modified for purposes of the [*] Technology development such that IM shall possess all right, title, and interest, including Intellectual Property Rights, in any CDP Developed Technology that is [*], and IM and Elpida shall jointly possess all right, title, and interest, including Intellectual Property Rights, in any CDP Developed Technology [*].

 

5.0                                Precedence.   Except as amended herein, the terms of Advanced Memory Agreements shall remain in full force and effect.

 

In Witness Whereof, the parties hereto, have executed this document as the last date set forth below.

 

Elpida Memory, Inc.

Intermolecular, Inc.

 

 

By:

/s/ Hideki Gomi

 

By:

/s/ David Lazovsky

 

 

 

 

 

Name:

Hideki Gomi

 

Name:

David Lazovsky

 

 

 

 

 

Title:

Director & CTO

 

Title:

President & CEO

 

 

 

 

 

Date:

6/10/09

 

Date:

6/8/09

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

3


 

AMENDMENT TO THE ADVANCED MEMORY AGREEMENTS
Elpida Memory, Inc.  - Intermolecular, Inc.

 

This AMENDMENT (“ Amendment ”) is made and entered into as of July 29, 2010

(“ Amendment Effective Date ”) between ELPIDA MEMORY, INC ., a Japanese corporation operating at 2-1, Yaesu 2-chome, Chuo-ku, Tokyo 104-0028, Japan (“ Elpida ”), and INTERMOLECULAR, INC ., a Delaware corporation operating at 2865 Zanker Road, San Jose, California 95134 or designated Affiliate (“ Intermolecular ” or “ IM ”), and amends that certain Advanced Memory Development Program Agreement entered into by the parties set forth above as of May 22, 2008 (the “ Original Agreement ”), Exhibit C - Royalty Terms entered into by the parties as of August 18,2008 (“ Amended Exhibit C ”), the Supplemental Joint Development Agreement entered into by the parties as of January 27, 2009 (the “ Supplemental Agreement ”), and the Amendment to Supplemental Joint Development Agreement entered into by the parties as of May 25, 2009 (the “ Supplemental Amendment ” and collectively with the previously listed agreements, the “ Advanced Memory Agreements ”) regarding solutions for next generation Dynamic Random Access Memory (“ DRAM ”).  All capitalized terms not defined herein shall have the meaning set forth in the Advanced Memory Agreements.

 

Whereas , Elpida and IM desire to continue working together for the further development of next generation process optimization solutions and engage in further development collaboration; and

 

Whereas , Elpida and IM now desire to extend the term of the COP and adjust the economics of the agreements between the parties with respect to COP, particularly in light of the extended COP term, regardless of the terms currently set forth in the Advanced Memory Agreements;

 

Now, Therefore , the parties agree as follows:

 

1.0                                Extended Term .  Section 1.0 of the Supplemental Agreement extended the Initial Term from [*] until [*] (“Supplemental Term”).  This Amendment shall extend the Supplemental Term from [*] for an additional [*] years to April 1, 2013 (“Amended Supplemental Term”).  This Amended Supplemental Term shall be non-cancellable or terminable except for termination under Section 9.3 or 9.4 of the Original Agreement.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

2.0                                Adjusted Economics .  Notwithstanding the royalty terms set forth in the Amended Exhibit C, Section 6.0 of the Supplemental Agreement, and Section 2.0 of the Supplemental Amendment, Elpida agrees to pay IM the following:

 

2.1                                CDP Fee Payment .  For continued CDP Services during the Amended Supplemental Term, Elpida agrees to pay IM [*] per calendar quarter, payable on the first day of each calendar quarter beginning [*].  Unless otherwise agreed between the parties, these fees will cover all IM FTEs and HPC Workflow Subscription and Access Fee including, without limitation, fees for access to IM Tools and Software as set forth in Section 4.1 of the Original Agreement.  The foregoing does not alter or affect Elpida’s continuing obligations to pay for CDP Services prior to [*].  In addition, any mutually agreed out of pocket costs for the performance of the CDP service and incurred by IM during the Amended Supplemental Term will be reimbursed.  This Section 2.1 supersedes the terms regarding Future Collaboration for [*] set forth in Section 3 of the Supplemental Amendment.

 

2.2                                Payment for Development Tasks .  For all development tasks that have been performed and completed through [*], including but not limited to tasks performed and completed relating to [*] or [*], Elpida agrees to pay an annual fixed contribution fee for work already performed and without requirement for further performance by IM in the amount of (a) [*] on [*]; and (b) then for each year thereafter for [*] years beginning on [*], [*] per year payable quarterly on the first day of each calendar quarter in payments of [*].  Notwithstanding any other provision to the contrary, these payments are due and payable on the dates specified, regardless of the timing of manufacture, shipment or sale of Products.

 

2.3                                Annual Contribution Fee Payment .  For the CDP Developed Technology resulting from IM’s provision of Services except those relating to [*] or [*] and that is utilized in any Product at any process node at the [*] process node or above (as designated by Elpida in accordance with its internal practices consistently applied), including without limitation any Product that utilize any new precursor or [*], (“ Fee Triggering Technology ”), Elpida agrees to

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

pay IM annual contribution fees of [*] per year for [*] years (the “ Annual Contribution Fee Period ”) beginning on the date that the Fee Triggering Technology is first utilized in any Product (the “ Fee Trigger Date ”), payable thirty (30) days following the Fee Trigger Date.

 

2.3.1                         For the avoidance of doubt, the Annual Contribution Fee Period will be applicable as to each Fee Triggering Technology that is utilized in any Product.  In addition, for the purposes of clarity, the Annual Contribution Fee Period shall be triggered as to each Fee Triggering Technology that is newly utilized in any Product, not as to each Product that may utilize such Fee Triggering Technology.

 

2.3.2                         The foregoing annual contribution fee would not be additive to the contribution fees payable pursuant to Section 2.2, but would rather supersede the payment obligations set forth in Section 2.2.  In addition, in case where the Fee Triggering Technology is utilized in multiple nodes of the Products in the same year, the annual contribution fees for each node will not be cumulative.  For the avoidance of doubt, the amount of the contribution fee paid by Elpida hereunder will in no event exceed [*] for each year during the Annual Contribution Fee Period.

 

2.4                                No Royalty .  Except as expressly provided in Section 2.2 and 2.3 above, Elpida shall have no obligation to make any payment, including any royalty payment under the Advanced Memory Agreements relating to the technology of [*] or [*], or the Fee Triggering Technology.

 

2.5                                Royalty Payment .  For the CDP Developed Technology resulting from IM’s provision of Services except those relating to [*] or [*], or the Fee Triggering Technology, regardless of material system, and that is utilized in any Product at any process node below the [*] process node (as designated by Elpida in accordance with its internal practices consistently applied), (“ Royalty Triggering Technology ”), Elpida agrees to pay IM royalties in accordance with the Amended Exhibit C for [*] years (the “ Royalty Period ”) beginning on the date that the Elpida ships any Products in which Royalty Triggering Technology is utilized (the “ Royalty Trigger Date ”).

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

2.5.1                         For the avoidance of doubt, a new and separate Royalty Period will be applicable as to each Royalty Triggering Technology that is utilized in any Product.  In addition, for the purposes of clarity, the Royalty Period shall be triggered as to each Royalty Triggering Technology that is newly utilized in any Product, not as to each Product that may utilize such Royalty Triggering Technology.

 

2.5.2                         Payment of royalties during the Royalty Period is in addition to the payments due under Sections 2.1, 2.2 and 2.3 above; provided however, that to the extent that the payment term for annual contribution fees overlaps with the Royalty Period, Elpida’s payment obligation will be the greater of [*] per year or the royalty amount due in accordance with the Amended Exhibit C.  In no event will Elpida be obligated to pay IM more than [*] in royalties under this Section 2.4 during any calendar quarter in [*] and beyond and more than [*] in royalties under this Section 2.4 during [*].  If additional royalties are accrued but not payable as a result, then such additional royalties will be payable in the following calendar quarter, provided, however, that in no event will Elpida be required to pay more than [*] in royalties during any calendar quarter.  In the event that IM can provide novel CDP Developed Technology (including but not limited to [*]) the definition of which will be separately determined through the good faith discussion and that such novel CDP Developed Technology is utilized in Products at the [*] node or above (as designated by Elpida in accordance with its internal practices consistently applied), then the terms and conditions with respect to the Royalties in accordance with the Amended Exhibit C will apply with the quarterly cap of the [*] mentioned above.

 

2.5.3                         After the expiration of the Royalty Period, the license for the Royalty Triggering Technology granted by IM to Elpida under the Advanced Memory Agreements shall become a worldwide, irrevocable, fully paid up license (i) to use, make, have made, import, offer to sell, sell, lease and

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 



 

otherwise dispose of to use, make, have made, import, offer to sell, sell, lease and otherwise dispose of Products utilizing Royalty Triggering Technology (ii) to modify or make derivatives of the Royalty Triggering Technology, and (iii) to exercise the limited sublicense rights as set forth in Sections 3.5.1 and 3.5.2 of the Original Agreement without prejudice to the right granted to Elpida under the Advanced Memory Agreements subject to Section 3.0 hereof.

 

3.0                                Exclusivity .  The Exclusivity terms of Section 3.9 of the Original Agreement shall continue to apply during the Royalty Period or for the duration of the CDP as set forth in Section 1 above, whichever is longer.

 

4.0                                No Other Modifications .  Other than as provided herein, no other amendments are being made to the Advanced Memory Agreements, and all other provisions of the Advanced Memory Agreements shall remain in full force and effect in accordance with the terms of the Advanced Memory Agreements.

 

IN WITNESS WHEREOF, the parties hereto have executed this document as the last date set forth below.

 

Elpida Memory, Inc.

Intermolecular, Inc.

 

 

By:

/s/ Hideki Gomi

 

By:

/s/ David Lazovsky

 

 

 

Name: Hideki Gomi

 

Name: David Lazovsky

 

 

 

Title: Director & CTO

 

Title: Presidento & CEO

 

 

 

Date: July 29, 2010

 

Date: 7/29/10

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 




Exhibit 10.10

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

COLLABORATIVE DEVELOPMENT PROGRAM AGREEMENT

GLOBALFOUNDRIES Inc. — Intermolecular, Inc.

 

This Collaborative Development Program Agreement (“ Agreement ”) is made as of June 1st, 2011 (“ Effective Date ”) between GLOBALFOUNDRIES Inc., an exempted company incorporated under the laws of the Cayman Islands, and having a registered address at PO Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Islands (“ GF” ), and Intermolecular, Inc., a Delaware corporation operating at 3011 North First Street, San Jose, California 95134 or designated Affiliate (“ Intermolecular ” or “ IM ”).  GF and IM are sometimes referred to herein individually as a “party” and collectively as the “parties .

 

Now therefore, the parties agree as follows:

 

1.                                 DEFINITIONS

 

1.1                                                  Affiliate ” shall mean any entity, controlling, controlled by, or under common control of a party to this Agreement.  For purposes of the Agreement, the direct or indirect ownership of more than fifty percent (50%) of the outstanding securities of, or voting interest in, an entity shall be deemed to constitute control.

 

1.2                                                  [*] Licensees ” shall mean the following companies: [*] and [*].

 

1.3                                                  Agreement Term ” shall mean the term of the Agreement as set forth in Section 11.1.

 

1.4                                                  AP-30 ” shall mean IM’s proprietary HPC tool, consisting of hardware and software and configured [*] on [*].

 

1.5                                                  Background IP ” of a party shall mean all Intellectual Property Rights that are (i) owned, sublicenseable without payment to any third party or otherwise solely controlled by a party or its Affiliates as of the Effective Date; or (ii) created, conceived or reduced to practice by a party ’s or its Affiliates ’ employees, contractors or agents outside the performance of this Agreement or prior to the Effective Date.

 

1.6                                                  Collaborative Development Program ” or “ CDP ” shall mean the Services that are conducted in accordance with the Development Plan.

 

1.7                                                  CDP Field ” shall mean technologies, methods and embodiments for materials, processes, apparatus, process integration, and device integration, or any combination thereof, used for the research, development, commercialization or manufacturing of [*].

 

1.8                                                  CDP IP ” shall mean any Intellectual Property Rights developed specifically under the Development Plan pursuant to the Agreement, other than Intellectual Property Rights  which are included as an HPC Derivative which may include GF CDP IP and/or Joint CDP IP after review and approval as such by the Operating Committee.

 

1.9                                                  CDP Term ” shall mean the term of the Development Plan as set forth in Section 2.11.

 

1.10                                           Confidential Information ” shall mean any information disclosed by one party to the other in connection with this Agreement, whether in electronic, written, graphic, oral, machine readable or other tangible or intangible form, that is marked or identified at the time of disclosure as “confidential” or “proprietary” or in some other manner so as to clearly indicate its confidential nature. The deliverables provided by one party to another party under the CDP, and materials, extracts, notes,

 

1



 

analyses, summaries or minutes between the parties from which the substance of confidential information can be inferred or otherwise understood, shall be considered Confidential Information of the disclosing party.  Except as specifically provided in Section 7 below, any terms and conditions of this Agreement shall constitute Confidential Information of each party.

 

1.11                                           Development Plan ” shall mean the mutually agreed upon written plan describing the CDP Services and other activities to be conducted by each party and the deliverables that are the desired outcome of the CDP Services.

 

1.12                                           Development Plan Success Factors ” shall mean the mutually agreed upon written technical specifications and timelines for completion of key milestones for each Project.

 

1.13                                           FTE ” shall mean an employee or contractor assigned to a CDP based on approximately one hundred sixty-six hours of professional services performed by one person during a one month period, or the same number of hours in aggregate performed by two or more persons during a one month period.

 

1.14                                           HPC Technology ” shall mean technology developed during the performance of this Agreement that is related to combinatorial processing of multiple regions of a substrate to produce, evaluate, analyze or characterize different materials, chemicals, processes, process and integration sequences, structures, and techniques related to semiconductor fabrication.

 

1.15                                           Informatics Software ” shall mean the IM software platform enabling the operation of the Dry and Wet Workflows and the gathering and sharing of CDP related information through a web-based interface designed and deployed by IM.

 

1.16                                           Intellectual Property Rights ” shall mean all U.S. and foreign rights in and to all (a)  patents and patent applications, including all divisions, substitutions, continuations, continuation-in-part applications, and reissues, re-examinations and extensions thereof, (b) copyrights and moral rights, (c) unpatented information, trade secrets, know-how, invention disclosures, engineering notebooks, confidential information, data, or materials, (d) mask work rights, and (e) any other intellectual or other proprietary rights of any kind now known or hereafter recognized in any jurisdiction.

 

1.17                                           Product ” shall mean a product containing one or more semiconductor [*], manufactured by or for GF, a GF Affiliate or Third Party Licensee, including through contract manufacturers, utilizing , based on or derived from the CDP IP, or containing any device designs or architectures resulting from the CDP. Product may be delivered to a customer in any form including without limitation, wafer form, packaged and unpackaged form.

 

1.18                                           CDP Services ” shall mean services and other activities that IM employees perform under the Development Plan pursuant to the Agreement.

 

1.19                                           “Third Party” shall mean any person or entity other than GF and its Affiliates, IM and its Affiliates, and their permitted assigns.

 

1.20                                           Third Party Licensee ” shall mean an entity other than a ny GF Affiliate which is an integrated circuit manufacturer or designer to whom GF grants a license or sublicense in and to all or a portion of the CDP IP pursuant to Sections 3.6.2 and 3.6.3.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2



 

1.21                                           Wet Workflows ” shall mean [*] using HPC Technology, including, but not limited to, [*] and [*] systems.

 

2.                                 COLLABORATIVE DEVELOPMENT PROGRAM

 

2.1                                                  Collaborative Development Program.   Subject to the terms and conditions set forth herein, including the payment of CDP Service Fees by GF as set forth in Section 6.1, GF and IM will conduct the CDP in accordance with the Development Plan attached hereto as Exhibit A, which is hereby incorporated into this Agreement.  The Development Plan will consist of a series of separate development activities (hereinafter “ Project(s) ”) based on the initial program applications listed in Exhibit A.  Each Project shall be assigned one of three (3) categories ( “Project Categories” ) as identified in Sections 6.3.1, 6.3.2 and 6.3.3.  The Development Plan may be revised from time to time by mutual written agreement of the parties.

 

2.2                                                  FTEs & Quality of Work.    IM will provide a quarterly average of [*] FTEs as of the Effective Date growing to a quarterly average of [*] FTEs in [*] and maintained through the CDP Term to support the development activities in the Development Plan.  IM will guarantee the quality of its CDP Development Plan work to be at or above the level of value GF engineers expect by pre-aligning the Development Plan Success Factors.  IM will deliver high quality CDP IP through evaluation of the broadest possible range of solutions and leveraging HPC enabled accelerated learning cycles.  If the parties deem that the Development Plan requires an amount of FTEs to be contributed by IM to be less or more than the aforementioned amounts during the Initial Term of this Agreement, then a proportional adjustment in the amount of CDP Service Fees will apply.

 

2.3                                                  Project Managers .  Each party shall by written notice to the other party appoint a principal point of contact to be its project manager (“ Project Manager ”) for the CDP, who shall coordinate and act as a liaison with the other party with respect to the activities in the Development Plan.  A party may from time to time change its Project Manager upon written notice to the other party.  Prior to the commencement of each Project, the Project Managers shall determine the scope of work conducted by the parties and the resources assigned (including the allocation of the FTEs) for each Project, and identify the appropriate Project Category for the Project.  Project Managers will determine the frequency of meetings on a Project by Project basis.  Project Managers will ensure that the development activities comply with planned timelines, resource usage and are meeting milestones that have been defined.  Prior to the beginning of each Project, the Project Managers will estimate out-of-pocket expenses, for each Project under the Development Plan, and establish a forecast for the total out-of-pocket expense budget for such Project.  If out-of-pocket requirements exceed initial forecast then the Project Managers will obtain approval from Operating Committee.  Upon completion of the projects, IM’s Project Manager will ensure a detailed report is provided outlining all learning associated with the Project.  Additionally, IM will support GF in the implementation of CDP IP.  IM’s Project Manager will ensure, by working collaboratively with GF’s Project Manager, that a sufficient backlog of Projects are identified and proposed Development Plan Success Factors are created to mitigate delay associated with new project start-up.

 

2.4                                                  Facilities & Workspace .  IM will provide adequate facilities and workspace for up to [*] GF employees at IM’s HPC R&D Center in San Jose, CA and additional resources as are necessary to support IM’s obligations pursuant to the Development Plan.  IM will provide badge access, landline phone connection, internet access, and cubicle or office space.  GF employees must complete IM’s standard confidentiality and safety training prior to being able to work in IM’s HPC R&D Center.  IM will provide adequate facilities space for storage of GF wafers, materials, targets and any other assets required to enable the Development Plan.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

3



 

2.5                                                  Operating Committee .  The parties will establish an operating committee (the Operating Committee ) to oversee the performance of the Collaborative Development Program, monitor progress of the CDP, resolve any disputes or disagreements between the parties and escalate any remaining disputes, as necessary, and ensure open communications among the parties.  The Operating Committee will initially be comprised of at least one (1) representative from each party (hereinafter “ CDP Manager ”) or such other equal number of representatives as the parties may from time to time agree in writing, with each party’s representatives selected by that party, provided that the CDP Manager of such party remains on the Operating Committee.  Any party may replace any of its Operating Committee members at any time, upon written notice to the other party.  The Operating Committee will meet on a quarterly basis or as otherwise agreed by the parties, at locations or in a manner agreed by the parties.  IM will assign an executive sponsor (reporting to IM’s CEO) responsible for maintaining a close alignment between Development Plan activities and IM’s overall corporate direction to facilitate project success.  IM’s executive sponsor will also serve on the Operating Committee.  The Operating Committee is responsible for approving and amending the Development Plan Success Factors for each Project.

 

2.6                                                  Intellectual Property Consulting .  IM will provide periodic intellectual property workshops to outline the legal landscapes of IM CDP IP and Joint CDP IP (collectively “CDP Patents” ).  IM shall provide actionable recommendations to the Operating Committee to enable optimal securing of CDP Patents.  Monthly landscape reports will be provided proactively to GF identifying the status and progress of invention disclosures related to the CDP Patents.  [*].  GF personnel will submit their sole and joint inventions to GF’s legal department in accordance with its standard practices.

 

2.7                                                  High Volume Manufacturing, OEM and Supply Chain Support .  CDP Services provided by IM will be compatible with High Volume Manufacturing.  IM will support activities required to achieve high volume manufacturing of Products based on CDP IP.  This entails supporting selection and qualification of equipment suppliers and other supply chain partners (including materials suppliers), as requested by GF.  IM will act in GF’s best interest to structure favorable business terms with supply chain entities when possible.  Any specific terms of such work will be part of the respective Projects in the Development Plan.

 

2.8                                                  Yield Improvement Assistance .  IM will rapidly redirect resources, at the guidance of the Operating Committee, to support yield improvement issues as necessary.  IM will leverage its HPC tools and domain expertise to accelerate the process of evaluating options enabling yield improvement.  Such work is expected to be short in duration and any specific terms of such yield improvement assistance work will be reviewed and approved by the Operating Committee prior to Project start.

 

2.9                                                  Informatics Access to Information .  IM acknowledges and agrees to provide GF timely access to CDP information from development activities by allowing a maximum of [*] concurrent Informatics software licenses during the CDP Term for GF designates.  IM will provide the necessary hosting, maintenance and support of Informatics hardware and software to ensure that high up-time, security and industry standard back-up protocols are in place.

 

2.10                                           Development Records .  GF and IM shall maintain records of the CDP Services, or cause such records to be maintained, in sufficient detail and in good scientific manner as will properly reflect the work done and results achieved in the performance of the Development Plan, including information sufficient to establish dates of conception and reduction to practice of inventions.

 

2.11                                           Period of development activities in the Development Plan .  The initial period of all development activities in the Development Plan (“Initial Period”) shall be for three (3) years starting on the Effective Date.  [*].

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

4



 

Upon expiration of the Initial Period if not previously terminated, the period of development activities shall automatically renew for successive periods of 12 months each unless either party provides written notice to the other party, given not less than [*] prior to the expiration of the then-current period (hereinafter “CDP Term”), of its intent to not continue such development activities after such expiration.  Notwithstanding the foregoing, if during said [*] period, GF elects not to extend the CDP Term, GF shall provide IM written notice of non-renewal during said period.  Such non-renewal shall be effective [*] from such notice. Such expiration shall not impact termination of the Agreement which shall be solely governed by Section 11 (“Termination”).

 

3.                                 IP OWNERSHIP AND LICENSES

 

3.1                                                  Background IP .  Each party shall continue to own all of its own Background IP.

 

3.2                                                  HPC Technology and Derivatives .  Notwithstanding anything to the contrary in this Agreement, [*] shall own all right, title and interest in and to HPC Technology and all HPC Technology improvements, derivatives and modifications developed by either party or both parties during the CDP Term and based on IM provided tools, software or information enabling the use of HPC Technology ( “HPC Derivatives” ).  [*] hereby assigns, and agrees to assign to [*] in the future Intellectual Property Rights in and to HPC Derivatives.

 

3.3                                                  CDP IP.

 

3.3.1       By GF .  GF shall own all right, title and interest, including Intellectual Property Rights, in CDP IP that is solely invented by GF’s employees, contractors or agents (“ GF CDP IP ”).

 

3.3.2       By IM .  Subject to Section 3.3.4 below, IM shall own all right, title, and interest, including Intellectual Property Rights, in CDP IP that is solely invented by IM’s employees, contractors or agents (“ IM CDP IP ”).; .

 

3.3.3       Joint.   Subject to Section 3.3.4 below, IM and GF shall jointly possess all right, title, and interest, including Intellectual Property Rights, in any CDP IP that is jointly invented by employees, contractors or agents of GF and IM (“ Joint CDP IP ”).  Subject to the terms of this Agreement, GF shall have the right to assign its interests in and/or license and/or enforce such Joint CDP IP without accounting to or further consent from IM.  In the event that IM’s cooperation is required in any enforcement action by GF, IM agrees to provide such cooperation.

 

3.3.4       GF Option . At any time prior to the filing of a priority patent application for a particular invention that qualifies as CDP Patents, GF may elect, at its sole discretion, the sole rights to obtain patent protection for such invention in its own name in any jurisdiction; provided, however, GF may not, without IM’s consent, elect more than [*] inventions that qualify as Joint CDP IP in each [*] period of the Agreement beginning on the Effective Date..  GF will be solely responsible for the costs of obtaining such patent protection.  IM hereby assigns to GF all of its right, title and interest in such elected inventions and agrees to execute any papers required to perfect such patent protection.  Notwithstanding the foregoing, such assigned CDP Patents would be counted toward the [*] patent filings defined in section 2.6.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

5



 

3.4                                                  Cooperation .  Each party agrees to execute all papers, including patent applications and invention assignments, and otherwise agrees to assist the other party, as reasonably required and at the other party’s reasonable expense, to perfect in the other party the rights, title and other interests in their respective inventions owned by the other party under this Agreement.  In addition, each party agrees to notify the other party within a reasonable time when an invention disclosure is submitted by an employee or contractor of that party that may be owned by the other party under Sections 3.2 and/or 3.3 above.

 

3.5                                                  Collaboration Licenses

 

3.5.1       IM License to GF .  Subject to the terms of the Agreement, IM grants to GF for the CDP Term, a non-exclusive, non-transferable, non-sub-licensable, worldwide, royalty-free license under and to the IM Background IP and to any other Intellectual Property Rights IM contributes to the Development Plan under the CDP, solely to engage in the CDP and perform the activities set forth in the Development Plan, and not for the benefit of a Third Party.

 

3.5.2       GF License to IM .  Subject to the terms of the Agreement, GF grants to IM for the CDP Term, a non-exclusive, non-transferable, non-sub-licensable, worldwide, royalty-free license under and to the GF Background IP and to any other Intellectual Property Rights GF contributes to the Development Plan under the CDP, solely to engage in the CDP and perform the activities set forth in the Development Plan, and not for the benefit of a Third Party.

 

3.6                                                  Licenses to GF .  Subject to the terms and conditions of this Agreement, IM hereby grants to GF, within the CDP Field, a worldwide, non-exclusive, royalty-bearing, non-transferable (subject to Section 12.3) license under and to IM CDP IP (i) to use, make, have made, import, offer to sell , sell , lease and otherwise dispose of the Products, (ii) to modify or make derivatives of the IM CDP IP, and (iii) to exercise the limited sublicense rights as set forth in Sections 3.6.1, 3.6.2  and 3.6.3 below.  Additionally, subject to the terms and conditions of this Agreement and to the extent it is necessary for GF to exercise its rights under sections (i), (ii) and (iii) (hereinafter “Licensed Rights” ) and provided IM has the right to grant such a license, IM hereby grants to GF a non-exclusive, worldwide license under IM’s rights in IM’s Background IP to exercise the Licensed Rights.  The licenses granted herein shall be perpetual and shall not be revocable by IM as long as GF makes its payments under Section 6.

 

3.6.1       GF Affiliates .  Subject to the terms and conditions of this Agreement, GF shall have the right, but not the obligation, to grant sublicenses to part or all of IM CDP IP (including IM’s rights in IM’s Background IP necessary to exercise such sublicenses) to GF Affiliates to use, make, have made, import, offer to sell , sell , lease and otherwise dispose of the Products subject to the same terms with respect to GF under this Agreement.

 

3.6.2       GF Third Party Licenses to [*] Licensees .  Subject to the terms and conditions of this Agreement, including the payment of royalties by GF (in accordance with Section 6.8) and as long as GF maintains a license to the CDP IP, GF shall have the right, but not the obligation, to grant (directly or indirectly) sublicenses to part or all of IM CDP IP (including IM’s rights in IM’s Background IP necessary to exercise such sublicenses) to [*] Licensees to use, make, have made, import, offer to sell , sell , lease and otherwise dispose of Products subject to the same terms with respect to GF under this Agreement.  The sublicense granted under this section shall not be sublicensable; except that IM

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

6



 

understands and accepts that [*] Licensees will have the rights to sublicense their subsidiaries.  The licenses granted in this subsection 3.6.2 shall only apply to Products that incorporate in whole or part a technology jointly developed by GF and one or more of the [*] Licensees.

 

3.6.3       GF Third Party Licenses to Third Parties other than [*] Licensees .  Subject to the terms and conditions of this Agreement, including the payment of royalties by GF (in accordance with Section 6.9) and as long as GF maintains a license to the CDP IP, GF shall have the right, but not the obligation, to grant sublicenses to part or all of IM CDP IP (including IM’s rights in IM’s Background IP necessary to exercise such sublicenses) to Third Parties other than [*] Licensees to use, make, have made, import, offer to sell , sell , lease and otherwise dispose of Products subject to the same terms with respect to GF under this Agreement.

 

3.6.4       Exclusive License to GF in the CDP Field . Subject to the terms and conditions of this Agreement including GF’s obligation to make payments under Section 6, IM agrees that it will not grant any licenses to Third Parties under and to IM CDP IP and Joint CDP IP in the CDP Field without prior written approval from GF.

 

3.6.5       Exclusive License to IM outside the CDP Field .  GF agrees to consider in good faith any request from IM to grant it an exclusive, worldwide, license to grant sublicenses to Third Parties outside the CDP Field under GF’s rights in CDP IP. If such request is approved, the parties will enter into good faith negotiations on all terms for such licensing including compensation, if any.

 

3.7                                                  Responsibility for and Cost of Patenting .  Each party shall be solely responsible for and shall at its own expense determine whether or not to seek patent protection, prepare, file and prosecute patent applications and maintain the patents (collectively hereinafter “Manage” ) in the CDP IP that is solely invented by the party’s employees, contractors or agents.    In good faith, both parties agree to mutually develop a process for managing Joint CDP IP and associated expenses.

 

3.8                                                  Intentionally left blank

 

3.9                                                  Reservation of Rights . Except for the rights expressly granted by each party to the other under this Agreement, all other rights are reserved.

 

4.                                                         HPC and Informatics License

 

4.1                                                  HPC Workflow Subscription and Access Fee .  During the CDP Term and subject to payment by GF of a subscription and access fee as set forth in Section 6.2, IM will provide GF and its Affiliates access, in conjunction with IM’s FTE resources and pursuant to the applicable Development Plan, to IM’s internal Wet and Dry Workflows, physical and electrical characterization capabilities, and Informatics Software (“ IM Tools and Software ”) to engage in activities under the Development Plan (“ HPC Workflow Subscription and Access Fee ”).  The HPC Workflow Subscription and Access Fee includes a non-transferable, worldwide license for GF to use HPC Technology and HPC Derivatives to the extent necessary for GF to carry out its obligations set forth in the Development Plan(s).  The HPC Workflow Subscription and Access Fee does not confer any ownership rights to GF in the IM Tools and Software.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

7



 

4.2                                                  Software License .  In consideration for the HPC Workflow Subscription and Access Fee, IM grants to GF and its Affiliates a non-exclusive, non-transferable license to use the Informatics Software solely to engage in activities under the Development Plan.  The Informatics Software can only be used by employees of GF and GF’s Affiliates and is not assignable or licensable by GF to any Third Party.  The license granted hereunder includes all updates in content and the current functionality of the Informatics Software.  Except for the express license granted in this Section 4.2, IM reserves all rights to itself, and does not grant to GF any other licenses, whether express or implied, to the Informatics Software or any intellectual property rights embodied therein or related thereto.

 

4.2.1      GF acknowledges and agrees that the features or the graphical user interface of the Informatics Software (“ User Interface ”), including, without limitation, icons, menus and screen designs, screen layouts, and command and screen sequence, are proprietary to IM and/or its licensors, and are disclosed to GF under a condition of confidentiality.  GF agrees that it will not create software programs incorporating any proprietary part of the User Interface.  GF further acknowledges that the User Interface is a copyrighted work of IM and/or its licensors.

 

4.2.2      GF agrees (i) not to distribute, sublicense, assign, sell, rent or otherwise transfer the Informatics Software; (ii) not to copy, in whole or in part, the Informatics Software or any documentation related to the Informatics Software; (iii) not to modify, reverse compile or reverse assemble all or any portion of the Informatics Software; (iv) not to use the Informatics Software outside the limitations of the license granted; and (v) not to create any derivative works from or related to the Informatics Software.

 

5.                                                         HPC Tool Purchase

 

5.1                                                  IM hereby grants to GF and GF hereby accepts from IM, a limited term right to purchase an [*] for $[*] under a mutually agreed tool purchase agreement.  In order to exercise the right, GF shall in its sole discretion, no later than [*] days from the Effective Date, inform IM of its intent to purchase and by [*] issue a purchase order pursuant to the quote in Exhibit C.  During the CDP Term, IM will provide to GF maintenance and support of the [*] free of charge.  After the CDP Term, IM will provide such maintenance and support at an annual rate of $[*] of which up to $[*] may be offset by GF from its obligations to make payments to IM under Section 6.3.

 

5.2                                                  IM hereby grants to GF and GF hereby accepts from IM, a limited term right to purchase an [*] for $[*] under a mutually agreed tool purchase agreement.  In order to exercise the right, GF shall in its sole discretion, no later than [*] days from the Effective Date, inform IM of its intent to purchase and by [*] issue a purchase order pursuant to the quote in Exhibit D.  During the CDP Term, IM will provide to GF maintenance and support of the [*] free of charge.  After the CDP Term, IM will provide such maintenance and support at an annual rate of $[*].

 

5.3                                                  IM hereby grants to GF and GF hereby accepts from IM, a limited term right to obtain subscription and access to an additional [*] in exchange for a payment of $[*] per quarter.  In order to exercise the option, GF shall, no later than [*] days from the Effective Date, inform IM of its intent to subscribe and by [*] issue a purchase order pursuant to the quote in Exhibit E.

 

6.                                                         PAYMENTS

 

6.1                                                  CDP Service Fees .    During the CDP Term, in  consideration of services rendered, IM shall invoice GF as follows:

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

8



 

(a)                                                    [*]

(b)                                                   [*]

(c)                                                    [*]

(d)                                                   [*]

(e)                                                    [*]

 

IM shall invoice GF on the first day of each quarter.  Invoices pursuant to 6.1(a), 6.1(b) and 6.1(c) above shall be payable no sooner than [*] and no later than [*].  All other invoices shall be paid no later than [*] days from the invoice date.  In addition to the amounts set forth above, GF agrees to provide or pay for mutually agreed and pre-approved (by GF) out-of-pocket expenses including consumables (such as wafers, mask sets, materials, and targets), outsourced metrology and characterization not supported internally by IM, and other expenses to support the CDP Services.  Prior to the beginning of each Project, the Project Managers will estimate out-of-pocket expenses, for each Project under the Development Plan, and establish a forecast for the total out-of-pocket expense budget for such Project.

 

6.2                                                  HPC Workflow Subscription and Access Fee .  During the CDP Term, IM shall invoice GF for subscription and access to the Wets Workflow and for subscription and access to the Dry Workflow (for purposes of this section “Dry Workflow” refers to the tools described in Exhibit F) as follows —

 

6.2.1                                           [*]:

(a)                                                    [*]

(b)                                                   [*]

(c)                                                    [*]

6.2.2                                           [*]:

(a)                                                    [*]

(b)                                                   [*]

(c)                                                    [*]

(d)                                                   [*]

6.2.3                                           [*]. [*]. [*].

 

6.3                                                  Royalties under IM licenses to GF based on CDP IP.    It is expected that GF or GF’s Affiliates will develop, manufacture, have manufactured, distribute, lease, sell or otherwise dispose of (collectively “Commercialize” ) Products that utilize, are derived from or incorporate (collectively “Based on” ) the CDP IP developed as a result of conducting each Project (hereinafter “Project Products” ).  For all CDP IP developed during a Project (hereinafter “ Project IP ”), as partial consideration for the licenses granted in Section 3.5, GF shall pay IM a royalty as a percentage of gross revenues, excluding any [*] costs, from unrelated companies for Project Products Commercialized by GF and GF’s Affiliates.  The royalty percentage to be applied will depend on the Project Category as identified in the Development Plan.  Each Project shall be associated with a Project Category prior to the commencement of such Project.  For avoidance of doubt, any IP created on [*] described in section 5.1 after the CDP Term and outside of a Project in the Development Plan, shall be royalty-free.  If the Development Plan Success Factors are not met or exceeded as agreed upon by the Operating Committee, the royalty percentage will be adjusted in accordance with the guidelines provided by the Operating Committee.  Notwithstanding the aforementioned, Annual Royalty Caps in Section 6.7 remain in effect.

 

6.3.1       Category A is related to [*]. Subject to the minimum payments identified in Section 6.6, GF shall pay IM [*] on the Commercialization of Project Products that are Based on Project IP from this Category A.

 

6.3.2       Category B is related to [*]. Subject to the minimum payments identified in Section 6.6 and the maximum payments identified in Section 6.7, GF shall pay IM [*] for Project

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

9



 

Products Commercialized by GF and GF’s Affiliates where such Project Products are Based on Project IP from this Category B.

 

6.3.3       Category C is related to [*]. Subject to the minimum payments identified in Section 6.6 and the maximum payments identified in Section 6.7, GF shall pay IM [*] for Project Products Commercialized by GF and GF’s Affiliates where such Project Products are Based on Project IP from this Category C.

 

6.4                                                  Royalty Clock. For each Project IP, GF shall be subject to the royalties identified in Section 6.3 for a period of [*] from the date of first commercial sale of the Project Product ( “Project Royalty Period” ) containing all or any portion of Project IP.  For the purpose of the aforementioned clause, a commercial sale of a Project Product is the result of a bona fide sale of a Project Product to a customer.  A commercial sale is not (i) a shipment or sale of samples of a Project Product or (ii) the receipt of any payments from customers for non-recurring engineering fees related to any Project Product.  For the avoidance of doubt, a new and separate Project Royalty Period will be applicable as to each Project IP that is utilized in any Project Product provided such Project Royalty Period does not extend beyond [*] for Project IP developed during the Initial Period.  For Project IP developed beyond the Initial Period (subject to a mutually agreed extension of the Development Plan per Section 2.11), the parties shall negotiate in good faith the duration of such Project Royalty Period.  In addition, for the purposes of clarity, the Project Royalty Period shall be triggered as to each Project IP that is newly utilized in any Project Product.

 

6.5                                                  Product Based on IP from multiple Projects.   In the event a Project Product is Based on Intellectual Property Rights from multiple Projects in multiple Project Categories, the applicable royalty percentage for such Product shall be the sum of each Project Category percentage.  For the avoidance of doubt, at no time shall the total royalties paid by GF under Section 6.3 during any calendar year exceed the annual royalty caps provided in Section 6.7.  In no event shall the total royalty percentage per Product exceed [*] of GF Product revenues.

 

6.6                                                  Minimum Royalty Payments starting in [*].  Notwithstanding the foregoing royalty calculations in Section 6.3, and beginning in [*], GF shall pay IM an annual minimum of $[*] in exchange for the licenses granted by IM to GF and GF’s Affiliates in Section 3.6.  Quarterly minimum payments of $[*] shall be due and payable by GF at the end of each calendar quarter beginning in the first quarter of [*] and ending in the last quarter of [*].  No minimum royalty payments shall be due for the first quarter of [*] and thereafter.

 

6.7                                                  Annual Royalty Caps. The royalties payable by GF to IM under Section 6.3 shall be capped for each calendar year at the maximum annual royalty payment amounts provided below -

 

[*]

 

6.8                                                  Royalties under GF sublicenses to [*] Licensees .  GF may grant royalty-free sublicenses to [*] Licensees subject to payments in Sections 6.3 and 6.6.

 

6.9                                                  Royalties under GF sublicenses to Third Parties other than [*] Licensees.   GF shall pay IM [*] received by GF from Third Party Licensees other than [*] Licensees.  If, under such sublicense to such Third Party Licensee, GF receives a license under patents owned or controlled by such Third Party Licensee, then GF shall pay IM [*] (net of GF’s direct costs) received by GF from such Third Party Licensee.  .

 

6.10                                           Royalties under IM licenses to Third Party Licensees in the CDP Field.  If an opportunity for IM to grant a license under CDP IP to Third Parties in the CDP Field were to arise, GF and IM will

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

10


 

agree in good faith to discuss whether such a license promotes the business interests of both parties.  If GF agrees that IM may grant such a license, IM shall pay GF [*] (net of IM’s direct costs) received by IM from such Third Party Licensees.

 

6.11               Third Party Royalties .  Each party shall be responsible for all of its own costs of commercializing products or licensing Intellectual Property Rights, including any payments to Third Parties for work done by such Third Parties or for licenses necessary for the manufacture, sale, or use of Products by a party or its Affiliates or sub-licensees.

 

6.12               Payments and Reporting on Royalties .  The accounting periods under this Agreement shall be on a calendar quarter basis ending on each March 31, June 30, September 30, and December 31 of each year, with the first accounting period ending on the end of the first such calendar quarter beginning in the first quarter of [*].  Within [*] days after the end of each accounting period, GF shall furnish to IM a written report, certified by a duly authorized officer of GF stating the computed royalties due, if any, and the royalty payment due shall accompany such written report.  The written report shall set forth the number of Project Products Commercialized, the associated Category in accordance with Section 6.3, the associated revenues and such other information as may be necessary to enable the calculation of royalties due under this Agreement.  If no computed royalties are due, the basis for such conclusion shall be set forth in the written report and the minimum payment in accordance with Section 6.6 shall accompany such report.

 

6.13               Processing of payments . All payments hereunder shall be made in U.S. dollars to IM .  All payments due to IM under this Agreement shall be made by bank wire transfer as follows:

 

International Wire Transfer

[*]

 

Routing & Transit #:

[*]

SWIFT CODE :

[*]

For credit of:

[*]

Credit account #:

3[*]

By order of:

[*]

 

or another U.S. bank account designated in writing by IM.  All payments not paid when due shall bear simple interest at a rate of [*] per month or the highest rate allowed by law, whichever is less.  Unless expressly stated in Section 6.1, 6.2 or 6.12, payments shall be made 45 days after invoicing.

 

6.14               Taxes .  The fees and royalty rates specified in this Agreement are exclusive of any sales, use, excise, value-added or similar taxes, and of any export and import duties, which may be levied upon or collectible by IM as a result of the CDP Services, or the licenses granted in this Agreement or its Exhibits.  GF agrees to pay and otherwise be fully responsible for any such taxes and duties (but for avoidance of doubt, excluding any tax based upon IM’s net income), except that if necessary, GF shall withhold from amounts otherwise payable to IM, and pay on IM’s behalf, withholding taxes that may be required by applicable law to be withheld by GF and GF shall provide IM with tax receipts to establish that all such taxes have been paid and are otherwise available to IM for credit for U.S. income tax purposes or as otherwise available to IM.

 

6.15               Currency Conversions .  If any currency conversion shall be required in connection with the calculation of royalties hereunder, such conversion shall be made using the medium exchange rate of buying and selling exchange rate s for conversion of the foreign currency into U.S. Dollars, quoted for current transactions reported in The Wall Street Journal for the last business day of the calendar quarter to which such payment pertains.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

11



 

6.16               Records; Inspection .  GF shall keep complete, true and accurate books of account and records on its own behalf and on behalf of the GF Affiliates for the purpose of determining the royalty amounts payable under this Agreement.  Such books and records shall be kept at GF or its designated Affiliate for at least three ( 3 ) years following the end of the calendar quarter to which they pertain.  Such records will be open for inspection during such three ( 3 ) year period by an independent auditor who is reasonably acceptable to the parties and agrees to be bound to confidentiality protections of similar scope to those set out in Section 7 hereof , solely for the purpose of verifying royalty statements hereunder. Such auditor shall be instructed to report only as to whether there is a discrepancy, and if so, the amount of such discrepancy.  Such inspections may be made no more than once each calendar year, at reasonable times and on reasonable notice.  Inspections conducted under this Section shall be at the expense of IM, unless a variation or error producing an increase exceeding [*] of the royalties payable for any period covered by the inspection is established and confirmed in the course of any such inspection, whereupon all reasonable costs relating to the inspection for such period and any unpaid amounts that are discovered will be paid promptly by GF.  Further, IM will have the right thereafter to conduct additional inspections from time to time for reasonable cause.  Each party agrees to hold in confidence pursuant to Section 7 all information concerning royalty payments and reports, and all information learned in the course of any audit or inspection, except to the extent necessary for that party to reveal such information in order to enforce its rights under this Agreement or if disclosure is required by law.

 

7.                                 CONFIDENTIALITY

 

7.1                 Confidentiality .  Except as otherwise expressly provided herein, the parties agree that the receiving party shall not, except as expressly provided in this Section 7, disclose to any T hird P arty, or use for any purpose, any Confidential Information furnished to it by the disclosing party pursuant to this Agreement, except in each case to the extent that it can be established by the receiving party by competent proof that such information:

(a) was already known to the receiving party, other than under an obligation of confidentiality, at the time of disclosure;

(b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving party;

(c) became generally available to the public or otherwise part of the public domain after disclosure and other than through any act or omission of the receiving party in breach of this agreement;

(d) was independently developed by the receiving party without use of, or reference to, the other party’s Confidential Information, as demonstrated by documented evidence prepared contemporaneously with such independent development; or

(e) was disclosed to the receiving party, other than under an obligation of confidentiality, by a T hird P arty authorized and entitled to disclose such information to others.

 

7.2                 Permitted Use and Disclosures .  Notwithstanding the restrictions of Section 7.1, each party hereto may (a) use Confidential Information disclosed to it by the other to the extent necessary for that party to perform its obligations set forth in the CDP and (b) use or disclose Confidential Information disclosed to it by the other party to the extent such use or disclosure is reasonably necessary in (i) exercising the rights and licenses granted hereunder, (ii) prosecuting or defending litigation, (iii) complying with applicable laws, governmental regulations or court orders or submitting information to tax or other governmental authorities (including the Securities and Exchange Commission), or (iv) preparing, filing and prosecuting patent applications; in each case, provided that if a party is required to make any such disclosure, other than pursuant to a confidentiality agreement, it will give reasonable advance notice to the other party of such disclosure and will use reasonable efforts to secure confidential

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

12



 

treatment of such information (whether through protective order or otherwise), except to the extent inappropriate with respect to patent applications.  It is understood that either party may also disclose the Confidential Information of the other party upon receipt of the written consent to such disclosure by a duly authorized representative of the other party.

 

7.3                 Nondisclosure of Terms .  Each of the parties hereto agrees not to disclose the terms of this Agreement to any T hird P arty without the prior written consent of the other party hereto, except to such party’s attorneys, accountants, advisors, investors and financing sources and their advisors and others on a need to know basis under circumstances that reasonably ensure the confidentiality thereof, to the extent required by law, in connection with the enforcement of this Agreement or rights under this Agreement or in connection with a merger, acquisition, financing transaction or proposed merger, acquisition or financing transaction.

 

7.4                 Firewall Protection .   In addition to conforming to the confidentiality provisions in this Section 7, the following shall apply:

 

7.4.1      IM will construct an IP firewall as described below in this Section around IM employees providing CDP Services.  Only such employees of IM will be allowed to have access to such GF Confidential Information and information distribution will be based strictly on a need-to-know basis.  Such employees of IM shall solely use such GF Confidential Information in providing CDP Services to GF.  Physical copies of GF Confidential Information shall be securely locked when not in use such that only those IM employees providing such CDP Services shall have access to such information.

 

7.4.2      GF will construct an IP firewall as described below in this Section around GF and its Affiliates’ employees who have access to IM’s facilities.  GF shall instruct its and its Affiliates’ employees and agrees that they will remain in designated areas within IM’s facilities as defined by IM from time to time.  GF agrees that, for the Initial Period, its and its Affiliates’ employees will only use IM’s HPC Technology, including, the IM Tools and Software for the purpose defined in any applicable CDP with the exception of the tools described in section 5.1 and 5.2 of this agreement which, subject to the approval of the Operating Committee, can be used for GF exclusive and sole use to the extent it does not reasonably interfere with a Project in the Development Plan.  Such employees of GF shall only disclose such IM Confidential Information to other GF employees who have a need to know.

 

7.5                 Residuals . Notwithstanding anything herein to the contrary, neither party will be in breach of this Agreement based on the use of Residuals by its or its Affiliates’ employees or directors (who had authorized access) for any purpose, including without limitation use in development, manufacture, promotion, sale and maintenance of its products and services; provided that this right to Residuals does not represent a license under any valid patents, copyrights or other Intellectual Property Rights of the disclosing party.  The term “Residuals” means any information that is retained in the unaided memories of the receiving party’s employees who have had access to the disclosing party’s Confidential Information pursuant to the terms of this Agreement.  An employee’s memory is unaided if the employee has not intentionally memorized the Confidential Information for the purpose of retaining and subsequently using or disclosing it.  Nothing in this Section is intended to or will modify the royalty obligations of GF for Products.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

13



 

8.                                 LIMITED REPRESENTATIONS AND WARRANTIES

 

8.1                 By IM .  IM represents and warrants that: (a) it has the right and authority to enter into this Agreement, and to fully perform its obligations hereunder; (b) this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms; and (c) IM owns, or possesses a valid and enforceable license to use, and has full power and authority to license or sublicense, as the case may be, all IM’s Intellectual Property Rights licensed or sublicensed to GF pursuant to this Agreement, including, without limitation, HPC Technology and IM CDP IP

 

8.2                 By GF .  GF represents and warrants that: (a) it has the right and authority to enter into this Agreement, and to fully perform its obligations hereunder; (b) this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms; and (c) GF owns, or possesses a valid and enforceable license to use, and has full power and authority to license or sublicense, as the case may be, all GF’s Intellectual Property Rights licensed or sublicensed to IM pursuant to this Agreement

 

8.3                 Disclaimer .  IM and GF specifically disclaim any representation, warranty or guarantee that the CDP or the use of HPC Technology will be successful, in whole or in part.  It is understood that the failure of the parties to successfully develop and commercialize the CDP IP in the course of the CDP or any technology developed through use of HPC Technology shall not constitute a breach of any representation or warranty or other obligation under this Agreement.  EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, GF AND INTERMOLECULAR MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO BACKGROUND IP, CDP DEVELOPED TECHNOLOGY, HPC TECHNOLOGY OR ANY INFORMATION DISCLOSED HEREUNDER, OR ANY DELIVERABLES PROVIDED HEREUNDER, AND HEREBY EXPRESSLY DISCLAIM ANY WARRANTIES OF MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE, OR VALIDITY OF ANY CDP IP OR HPC TECHNOLOGY, PATENTED OR UNPATENTED, OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

 

9.                                 INDEMNIFICATION

 

9.1                 IM agrees to defend GF from and against any Third Party action, suit or proceeding (each, a “Claim” ) against GF alleging that the HPC Technology, HPC Derivatives, IM Background IP, Joint CDP IP and IM CDP IP licensed to GF under this Agreement directly infringes upon the patents of such Third Party and to indemnify GF against any liabilities, losses, damages, costs and expenses (including reasonable attorneys’ fees) finally awarded against GF as a result of such Claims or agreed upon by IM in writing in settlement of such Claims; provided that GF provides IM (a) prompt written notice of any communication that may reasonably lead to such Claim (including assertion or demand letters), (b) sole control of the defense or settlement of such Claims, and (c) reasonable assistance in the defense or settlement of such Claims at IM’s request and IM’s reasonable expense.

 

9.2                 Notwithstanding the foregoing, IM will not be obligated to defend or indemnify GF to the extent that a Claim is based upon IM’s literal compliance with GF’s requirements, designs, specifications, or instructions; use of the Products by GF in combination with other products not supplied by IM or in a manner not specified by IM, if such infringement would not have occurred but for such combined use; or modification of the Products by anyone other than IM, if such infringement would not have occurred but for such modification.

 

10.                          LIMITATION OF LIABILITY

 

EXCEPT FOR A BREACH BY EITHER PARTY OF THEIR RESPECTIVE CONFIDENTIALITY OBLIGATIONS UNDER SECTION 7, OR INDEMNIFICATION UNDER SECTION 9, OR A BREACH OF ANY LICENSE RESTRICTIONS, UNDER NO CIRCUMSTANCES WILL EITHER PARTY BE LIABLE TO THE OTHER UNDER ANY CONTRACT, STRICT LIABILITY,

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

14



 

NEGLIGENCE OR OTHER LEGAL OR EQUITABLE THEORY, FOR ANY LOST PROFITS, LOST BUSINESS OPPORTUNITY, INJURY TO BUSINESS REPUTATION OR EQUIPMENT DOWNTIME, OR FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT OR SPECIAL DAMAGES OF ANY KIND IN CONNECTION WITH THE SUBJECT MATTER OF THIS AGREEMENT, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND IN NO EVENT WILL EITHER PARTY’S AGGREGATE LIABILITY TO THE OTHER EXCEED THE AMOUNTS PAID OR PAYABLE BY GF TO INTERMOLECULAR IN THE TWELVE (12) MONTHS PRECEDING THE CLAIM.

 

11.                          TERMINATION

 

11.1               Term of Agreement .  The Agreement shall be from the Effective Date and, unless terminated or canceled as provided in this Section 11 of the Agreement, shall remain in full force and effect until 5 years from the date of the last sale of a product.  Notwithstanding any expiration or termination of the Agreement, other than termination by IM for cause, GF shall have the right to continue developing, manufacturing and having manufactured, distributing and selling current or future Products pursuant to the licenses and subject to the payment of the royalties set forth in this Agreement.

 

11.2               Termination for Breach .  Either party to this Agreement may terminate this Agreement in the event the other party shall have materially breached or defaulted in the performance of any of its material obligations hereunder, and such default shall have continued for [*] after written notice thereof was provided to the breaching party by the non-breaching party.  Any termination shall become effective at the end of such [*] period unless the breaching party (or any other party on its behalf) has cured any such breach or default prior to the expiration of the [*] period.

 

11.3               Effect of Termination .

 

11.3.1       Accrued Rights and Obligations .  Termination of this Agreement for any reason shall not release either party hereto from any liability or obligation that, at the time of such termination, has already accrued to the other party or that is attributable to a period prior to such termination, nor shall it preclude either party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement, except as set forth in Section 9.2.

 

11.3.2       Return of Confidential Information .  Upon any termination of this Agreement, IM and GF shall promptly destroy or return to the other all Confidential Information received from the other party other than as required to enforce, exercise or defend any continuing or surviving rights and obligations under this Agreement.

 

11.4               Survival .  If th is Agreement terminates for any reason, then Sections 1, 3, 6.3 - 6.5, 6.7- 6.16, 7, 8, 9, 10, 11 and 12 of this Agreement shall survive.  [*].

 

12.                          MISCELLANEOUS

 

12.1               Governing Laws and Dispute Resolution . This Agreement shall be governed by and construed in accordance with the laws of the state of California in the United States, without regard to its choice of law rules . All disputes between the parties in connection with or arising out of this Agreement shall first be discussed in good faith between the parties in order to try to find an amicable solution in accordance with Section 12.2.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

15



 

12.2               Escalation. The parties shall make a good faith attempt to resolve any dispute or claim arising out of or related to this Agreement through negotiation.  Within thirty (30) days after notice of a dispute or claim is given by either party to the other party, the Operating Committee shall meet and make a good faith attempt to resolve such dispute or claim and shall continue to negotiate in good faith in an effort to resolve the dispute or claim or renegotiate the applicable section or provision without the necessity of any formal proceedings.  If the Operating Committee is unable to agree within thirty (30) days of their first meeting, then the matter will be referred to the parties’ designated executives (Vice President or above), who shall meet to attempt to resolve the dispute by good faith negotiations within thirty (30) days.  In the event the executives are unable to resolve such dispute either party may proceed with any other dispute resolution procedure available under this Agreement in Section 12.1 or under law.  During the course of negotiations all reasonable requests made by one party to the other party for information, including requests for copies of relevant documents, will be honored.  The specific format for such negotiations will be left to the discretion of the designated negotiating teams but may include the preparation of agreed upon statements of fact or written statements of position furnished to the other party. In order to foster the free exchange of information and points of view to resolve a dispute, the parties shall be free to discuss the dispute frankly in the nature of settlement discussions. The observations or statements of neither party shall be used in evidence against that party in any dispute resolution that may ensue.

 

12.3               Assignment .  Neither party shall assign or transfer this Agreement either voluntarily or by operation of law, in whole or in part, without the prior written consent of the other party, and any attempt to do so will be null and void; provided, however, that either party may assign this Agreement without such consent, to a parent, subsidiary, or Affiliate, or to a successor in interest to its business (whether by merger, acquisition, consolidation, change of control, reorganization or sale of substantially all of its assets).  Notwithstanding the foregoing, IM shall not be able to assign this Agreement to an entity that is a logic foundry competitor to GF without the prior written consent of GF.  Subject to the foregoing sentence, this Agreement will be binding on and inure to the benefit of the parties and their respective successors and permitted assigns.

 

12.4               Drafting .  In interpreting and applying the terms and provisions of this Agreement, the parties agree that no presumption shall exist or be implied against the party that drafted such terms and provisions.

 

12.5               Waiver .  It is agreed that no waiver by either party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed a waiver or an expectation of non-enforcement as to any subsequent and/or similar breach or default.

 

12.6               Non-Solicitation .  During the Term of this Agreement neither IM nor GF will individually, or in concert with or through any other person, actively recruit any scientific or technical personnel of the other party.  The foregoing restriction shall not apply to, or be breached by: (i) advertising open positions, participating in job fairs, and conducting comparable activities to recruit skilled or unskilled help from the general public, or responding to individuals contacted through such methods, (ii) responding to unsolicited inquiries about employment opportunities or possibilities from job placement agencies or other agents acting for unidentified principals, or (iii) responding to unsolicited inquiries about employment opportunities from any individual.

 

12.7               Severability .  In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect to the fullest extent permitted by law without said provision, and the parties shall amend the Agreement to the extent feasible to lawfully include the substance of the excluded term to as fully as possible realize the intent of the parties and their commercial bargain.

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

16



 

12.8               Independent Contractors .  The relationship of the parties hereto is that of independent contractors.  Each party shall not be deemed to be an agent, partner, joint venture or legal representative of the other for any purpose as a result of this Agreement or the transactions contemplated thereby.

 

12.9               Press Releases or Public Statements .  Neither party shall issue any press release or otherwise make any public statement regarding the existence or terms and conditions of this Agreement or the business between the parties, nor use the other party’s name in any advertising or promotional materials or publication or public statement of any kind, without such other party’s prior written consent given in such party’s sole and absolute discretion.

 

12.10             Compliance with Law .  In exercising their rights under the license granted hereunder, each party shall fully comply in all material respects with the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this Agreement.  Without limiting the foregoing, each party agrees to comply with all applicable export and re-export control laws and regulations maintained by the United States governments.

 

12.11             Notices .  All notices, requests and other communications hereunder shall be in writing and shall be hand delivered, or sent by express delivery service with confirmation of receipt, or sent by registered or certified mail, return receipt requested, postage prepaid, or by electronic transmission (with written confirmation copy by registered first-class mail), in each case to the attention of the chief legal officer at the respective address indicated above and when to GF with a copy to Law Department, GLOBALFOUNDRIES, 840 N. McCarthy Boulevard Milpitas, CA  95035 (Facsimile:  (408) 462-4299) (e-mail:  Legal.Notices@globalfoundries.com).  Any such notice shall be deemed to have been given when received.  Either party may change its address by giving the other party written notice, delivered in accordance with this Section.

 

12.12             Force Majeure .  Neither party shall lose any rights hereunder or be liable to the other party for damages or losses (except for payment obligations then owing) on account of failure of performance by the defaulting party if the failure is occasioned by war, strike, fire, earthquake, flood, lockout, embargo, act of terrorism, governmental acts, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence, intentional conduct or misconduct of the non-performing party and such party has exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a party be required to settle any labor dispute or disturbance.

 

12.13             Headings; Construction .  The captions to the several Sections hereof are not part of this Agreement, but are included merely for convenience of reference and shall not affect its meaning or interpretation.  As used in this Agreement, the word “including” means “including without limitation.”

 

12.14             Counterparts .  This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.

 

12.15             Complete Agreement .  This Agreement, together with its Exhibits and their attachments, constitutes the entire agreement, both written and oral, between the parties with respect to the subject matter hereof, and all prior agreements respecting the subject matter hereof, either written or oral, express or implied, shall be abrogated, canceled, and are null and void and of no effect.  No amendment or change hereof or addition hereto shall be effective or binding on either of the parties hereto unless reduced to writing and executed by the respective duly authorized representatives of GF and IM.  The parties further agree that any additional or inconsistent terms and conditions of any purchase order,

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

17



 

invoice or like document issued in connection with this Agreement shall be superseded in full by the terms and conditions of this Agreement and any Exhibit hereunder, and any such additional or inconsistent terms, unless specifically agreed to in writing by the parties at the time, are hereby rejected.

 

12.16             Third Party Beneficiaries .  Except as expressly provided in this Agreement, there are no third party beneficiaries expressly or impliedly intended under this Agreement.

 

In Witness Whereof, the parties hereto have executed this document as the last date set forth below.

 

GLOBALFOUNDRIES Inc.

Intermolecular, Inc.

 

 

 

 

 

By:

/s/ Chia Song Hwee

 

By:

/s/ David Lazovsky

 

 

 

 

 

Name:

Chia Song Hwee

 

Name:

David Lazovsky

 

 

 

 

 

Title:

Chief Operating Officer

 

Title:

President & CEO

 

 

 

 

 

Date:

5/27/2011

 

Date:

5/24/2011

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

18



 

EXHIBIT A — [*]

 

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

19



 

EXHIBIT F

[*]

 


[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

20




QuickLinks -- Click here to rapidly navigate through this document


Exhibit 23.1


Consent of Independent Registered Public Accounting Firm

The Board of Directors
Intermolecular, Inc.:

        We consent to the use of our report dated June 30, 2011, except as related to note 6(a) to the consolidated financial statements which is as of July 28, 2011, included herein and to the reference to our firm under the heading "Experts" in the prospectus. Our report refers to the change in the manner in which the Company accounted for convertible preferred stock.

/s/ KPMG LLP
Mountain View, California
September 30, 2011




QuickLinks

Consent of Independent Registered Public Accounting Firm